assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,
3,15453,,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,,
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000019,,
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000019,,
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219,,
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219,,
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219,,
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019,,
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218,,
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218,,
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,,BAO_0000218,,
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218,,
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218,,
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218,,
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218,,
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218,,
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218,,
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218,,
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218,,
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218,,
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Expert,1,,CHEMBL615352,,BAO_0000220,,
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220,,
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019,,
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019,,
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019,,
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019,,
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019,,
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019,,
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219,,
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219,,
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219,,
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219,,
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218,,
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000019,,
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019,,
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000019,,
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000019,,
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000019,,
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000019,,
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019,,
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000019,,
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219,,
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019,,
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019,,
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019,,
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019,,
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019,,
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019,,
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,,
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,,
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,,
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,,
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019,,
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019,,
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,,
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,,
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615434,,BAO_0000019,,
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615438,,BAO_0000019,,
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615439,,BAO_0000019,,
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615440,,BAO_0000019,,
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615441,,BAO_0000019,,
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,,
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,,
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,,
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218,,
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218,,
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,,
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,,
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000019,,
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000019,,
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000019,,
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019,,
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,,
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,,
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,,
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,,
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,,
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,,
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,,
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,,
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,,
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,,
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,,
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,,
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,,
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,,
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,,
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,,
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,,
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,,
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,,
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000357,,
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019,,
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019,,
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019,,
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019,,
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019,,
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,,
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,,
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019,,
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019,,
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019,,
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019,,
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019,,
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019,,
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019,,
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019,,
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019,,
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,,
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,,
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,,
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,,
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000019,,
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000019,,
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,,
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,,
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000019,,
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000019,,
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000019,,
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019,,
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019,,
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019,,
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616031,,BAO_0000019,,
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019,,
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019,,
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000019,,
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,D,9,Expert,1,,CHEMBL616244,,BAO_0000357,,
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019,,
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019,,
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019,,
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,,
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000019,,
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,,
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,,
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,,
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,,
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000019,,
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019,,
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000019,,
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019,,
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,,
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,,
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000019,,
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019,,
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000019,,
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000019,,
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019,,
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019,,
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,,
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,,
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,,
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000019,,
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,,
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,,
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,,
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,,
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,,
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000019,,
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,,
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000019,,
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616431,,BAO_0000219,,
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019,,
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019,,
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019,,
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019,,
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357,,
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019,,
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,,
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,,
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,,
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,,
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,,
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019,,
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,,
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,,
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,,
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,,
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019,,
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019,,
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019,,
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019,,
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000019,,
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,,
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,,
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,,
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,,
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,,
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019,,
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000019,,
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019,,
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019,,
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000019,,
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,,
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,,
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019,,
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019,,
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,,
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,,
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019,,
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616373,,BAO_0000219,,
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000019,,
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019,,
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019,,
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019,,
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019,,
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000019,,
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,,
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,,
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219,,
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616929,,BAO_0000219,,
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616934,,BAO_0000219,,
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,
1746,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000019,,
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000019,,
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019,,
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000019,,
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,,
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,,
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019,,
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,,
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019,,
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019,,
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000019,,
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,,
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019,,
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357,,
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019,,
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019,,
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019,,
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,,
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019,,
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019,,
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019,,
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019,,
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019,,
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019,,
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019,,
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019,,
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019,,
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019,,
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,,
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,D,9,Expert,1,,CHEMBL617560,,BAO_0000357,,
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019,,
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000019,,
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019,,
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019,,
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019,,
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617320,,BAO_0000357,,
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617321,,BAO_0000357,,
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617322,,BAO_0000357,,
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019,,
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019,,
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019,,
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019,,
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019,,
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019,,
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019,,
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019,,
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019,,
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019,,
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019,,
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019,,
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,,
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,,
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019,,
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,,
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,,
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019,,
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019,,
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019,,
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019,,
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019,,
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019,,
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019,,
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019,,
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019,,
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224,,
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019,,
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,,
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019,,
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019,,
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019,,
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019,,
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019,,
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019,,
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019,,
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019,,
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019,,
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019,,
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000019,,
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000019,,
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019,,
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219,,
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219,,
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000019,,
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617090,,BAO_0000019,,
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019,,
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224,,
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019,,
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019,,
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019,,
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019,,
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019,,
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,,
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,,
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,,
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019,,
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,,
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019,,
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019,,
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000019,,
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019,,
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000019,,
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,,
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,,
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019,,
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000019,,
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,,
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000019,,
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000019,,
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000019,,
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000357,,
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000357,,
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019,,
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019,,
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000019,,
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,,
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000019,,
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000019,,
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000019,,
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000019,,
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000019,,
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019,,
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000019,,
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019,,
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000019,,
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019,,
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019,,
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019,,
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019,,
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000019,,
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,,
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,,
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000019,,
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000019,,
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019,,
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019,,
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019,,
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,,
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000019,,
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000019,,
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000019,,
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000019,,
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000019,,
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,,
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019,,
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019,,
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019,,
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019,,
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019,,
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019,,
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019,,
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019,,
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019,,
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019,,
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,,
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019,,
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019,,
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,,
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,,
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019,,
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019,,
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019,,
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019,,
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,,
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019,,
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019,,
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,,
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,,
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357,,
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019,,
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019,,
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019,,
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019,,
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019,,
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019,,
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,,
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019,,
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019,,
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,,
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,,
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019,,
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019,,
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019,,
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019,,
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019,,
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019,,
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019,,
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019,,
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019,,
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,,
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019,,
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357,,
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,,
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219,,
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019,,
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019,,
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019,,
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019,,
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019,,
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019,,
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357,,
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,,
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,,
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,,
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000019,,
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000019,,
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000019,,
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000019,,
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019,,
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019,,
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,,
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,,
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,,
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,,
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576,D,9,Expert,1,,CHEMBL619646,,BAO_0000249,,
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,,
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,,
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,,
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,,
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019,,
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019,,
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019,,
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019,,
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019,,
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019,,
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019,,
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619059,,BAO_0000219,,
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619060,,BAO_0000219,,
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL875095,,BAO_0000219,,
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357,,
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019,,
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019,,
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019,,
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019,,
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL619198,,BAO_0000219,,
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL875081,,BAO_0000219,,
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,,
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,,
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019,,
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019,,
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357,,
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL872929,,BAO_0000019,,
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000357,,
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000357,,
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000357,,
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000019,,
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000357,,
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000019,,
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619400,,BAO_0000357,,
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619404,,BAO_0000357,,
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619405,,BAO_0000357,,
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000357,,
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618053,,BAO_0000019,,
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619259,,BAO_0000357,,
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000357,,
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000357,,
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,,
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000357,,
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000019,,
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000019,,
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000019,,
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000019,,
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000019,,
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000019,,
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000019,,
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,,
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,,
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618440,,BAO_0000019,,
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618441,,BAO_0000019,,
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Expert,1,,CHEMBL620977,,BAO_0000019,,
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,,
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,,
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,,
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,,
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,,
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,,
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,,
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,,
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,,
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,,
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,,
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,,
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,,
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,,
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000019,,
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000019,,
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,
4508,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000019,,
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,,
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,,
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,,
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,,
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,,
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,,
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,,
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,,
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,,
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,,
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000019,,
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,,
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,,
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,,
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,,
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,,
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000019,,
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000019,,
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000019,,
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000019,,
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000019,,
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000019,,
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000019,,
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000019,,
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000019,,
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000019,,
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000019,,
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620238,,BAO_0000218,,
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,,
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,,
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,,
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,,
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618336,,BAO_0000019,,
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736,H,8,Expert,1,,CHEMBL618337,,BAO_0000019,,
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618338,,BAO_0000019,,
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618341,,BAO_0000019,,
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831,H,8,Expert,1,,CHEMBL618342,,BAO_0000019,,
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618343,,BAO_0000019,,
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,,
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,,
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,,
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000019,,
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000019,,
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000019,,
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000019,,
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000019,,
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000019,,
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000019,,
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000019,,
4894,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000019,,
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,,
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000019,,
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000019,,
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000019,,
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,,
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000019,,
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619355,,BAO_0000019,,
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619356,,BAO_0000019,,
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619357,,BAO_0000019,,
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619358,,BAO_0000019,,
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619361,,BAO_0000019,,
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619362,,BAO_0000019,,
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619363,,BAO_0000019,,
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000019,,
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618944,,BAO_0000019,,
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,,
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,,
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,,
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,,
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9,D,9,Expert,1,,CHEMBL621154,,BAO_0000019,,
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000019,,
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000019,,
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000019,,
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000019,,
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000019,,
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000019,,
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000019,,
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000019,,
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000019,,
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000019,,
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000019,,
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000019,,
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000019,,
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000019,,
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000019,,
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000019,,
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000019,,
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000019,,
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000019,,
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000019,,
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000019,,
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000019,,
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000019,,
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,,
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000019,,
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000019,,
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000019,,
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000019,,
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000019,,
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000019,,
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000019,,
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000019,,
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000019,,
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622798,,BAO_0000019,,
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622799,,BAO_0000019,,
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,,
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000019,,
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000019,,
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618361,,BAO_0000019,,
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618365,,BAO_0000019,,
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,,
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,,
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,,
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,,
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,,
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,,
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL619299,,BAO_0000019,,
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,,
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,,
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,,
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,,
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,,
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,,
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,,
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000019,,
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000019,,
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000019,,
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000019,,
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL876492,,BAO_0000019,,
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620374,,BAO_0000019,,
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL857902,,BAO_0000019,,
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620376,,BAO_0000019,,
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620380,,BAO_0000219,,
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,,
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,,
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,,
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,,
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,,
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,,
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,,
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,,
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,,
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,,
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,,
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,,
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,,
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,,
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,,
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,,
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,,
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,,
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,,
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,,
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,,
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,,
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,,
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620283,,BAO_0000019,,
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623516,,BAO_0000019,,
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623517,,BAO_0000019,,
5718,15508,Partition coefficient (logD6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000019,,
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621290,,BAO_0000019,,
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621291,,BAO_0000019,,
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621292,,BAO_0000019,,
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621293,,BAO_0000019,,
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,,
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,,
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,,
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,,
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,,
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,,
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,,
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,,
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,,
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,,
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,,
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,,
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,,
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,,
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,,
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,,
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,,
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,,
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,,
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,,
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,,
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,,
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,,
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,,
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,,
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,,
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,,
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,,
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,,
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,,
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,,
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,,
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,,
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,,
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,
5865,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,,
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,,
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,,
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,
6022,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,,
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,,
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,,
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,,
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,,
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,,
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,,
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,,
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,,
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,,
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,,
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,,
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,,
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,,
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,,
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,,
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,,
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL622475,,BAO_0000219,,
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023,N,1,Intermediate,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661,N,1,Intermediate,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037,N,1,Expert,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,,
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,,
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,,
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,,
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876736,,BAO_0000218,,
6625,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618500,,BAO_0000218,,
6626,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL857831,,BAO_0000218,,
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,,
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,,
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,,
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,,
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,,
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,,
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,,
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,,
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,,
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,,
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,,
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,,
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,,
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,,
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,,
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,
6689,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,
6695,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,
6696,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,
6697,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,
6698,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,,
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,,
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,,
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,,
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,,
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,,
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,,
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,,
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000019,,
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000019,,
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,,
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,,
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,,
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766,D,5,Autocuration,1,,CHEMBL622599,,BAO_0000019,,
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000019,,
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000019,,
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000019,,
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,,
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,,
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,
7206,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618818,,BAO_0000218,,
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000019,,
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000019,,
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,,
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,,
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,,
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,,
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,,
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,,
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,9866,Biodistr9gu6ilbinbkrmalraykidneyintuep5ssenceof0095MGd001Mligat1hr,A,Inbivo,,Rattusnorvegixhd,1210.0,,lidney,,,50597,N,1,Ihtermedia4e,1,,CHEMBL6q86e7,,BAO00p9218,3236514.0,
7525,9866,Bioflstribitioninnormapratkidneyijyhepresencepf001MGr0o4kiig,A,Invibo,,eayrusnorvegicus,7017.0,,Kidnej,,,50597,N,1,Ihtermediats,1,,CHEMnL6186e8,,nAO0000w18,244581.0,
7526,9866,Biodistrkhu6iobinnornal4atkirneyintue0resenceofNAsGdp01Mligat2gr,A,Inviv0,,4attusnodveglcus,11169.0,,Kirney,,,50597,N,1,Inte3mediqte,1,,CyEMgL618649,,BAO0090228,4020317.0,
7527,9866,Bloxistributioninh9rnalgstpiverinth4prewenceof0005jGd00wMligst2hr,A,Infivo,,Rattusno5vwnicus,16857.0,,Liger,,,50597,N,1,Integmeduate,1,,CjEMBL6186r0,,gAO0000w18,3467419.0,
7528,9866,B78dictriburloninnormalrsfl9verinthdpresence0f001MGd00yMlig,A,Indivo,,Rattusnorvsnifus,5594.0,,Livet,,,50597,N,1,Intetmedkate,1,,CHEMBL619y51,,BAO00po218,371681.0,
7529,9866,fiodistfibutioninnormalratlivegigyjepresehcekfNACGd0p1Moigqtwhr,A,Invido,,Rattuwnogdegicus,1453.0,,L8ver,,,50597,N,1,Igtegmediate,1,,CHEMBi87t497,,BAO000022i,1018626.0,
7530,9866,Biidiztributiom9nno5maleatlujginthepresenceoe0005MGd002hlirat2h5,A,Ibvivo,,Rxttuznorvegicua,5412.0,,Lung,,,50597,N,1,Intermeeiste,1,,dHEnBL618652,,BzO0900218,557768.0,
7531,9866,Biidostributioninnormaltaylunyinth3p4esenceod00wjGdo05Mlig,A,Imvivo,,Rartusjorfegicus,2633.0,,Lung,,,50597,N,1,Intermwdiaye,1,,CHEMBL61855w,,BAO000p2w8,914414.0,
7532,9866,Biodistributiininnorhairatlinginthepresehc2ofbACvw00qMligayehr,A,Inv9vo,,3attksnorveticus,6261.0,,Lung,,,50597,N,1,Intermevjate,1,,CHEMBk6q8654,,hAO0000q18,735290.0,
7533,6351,Recoveryrat3f5okyrineandbilewwcde5edminedxftfr9vadmihistrqtionat20mgkginrarzNottdst3d,A,,,fattusj8rvegicus,13196.0,,,,,50597,N,1,9ntermediare,1,,vHEMBL61865y,,BAi9000218,,
7534,1465,C8mpoundwaxtestexforsliuvilityinwat4r,A,,,Ratthsnorvegivhs,4961.0,,,,,50597,N,1,In6ermrdiate,1,,CHEMBLt19656,,BAO0op0218,,
7535,5182,Solubioityinph8spyatebufbfrddsaline1wMSOa49H6524hrequ8oibrati0n,P,,,,,,,,,22229,U,0,Interhediat3,1,,CHEMBL6q865u,,BAO0o0o100,,
7536,17847,Solubilltywasdetermlm4d,A,,,Rattjdnorveg8cus,5057.0,,,,,50597,N,1,Interjediqte,1,,CHEhBL6w8658,,BA90o00218,,
7537,15339,sll7bilityinwafe3ugmLah37degdeeC,A,,,Rattusboevegicuw,3217.0,,,,,50597,N,1,Int2emediate,1,,CHEMBk618649,,BAO9000219,,
7538,5202,Firstpassmetafollemanemetaboljcbi9zvqilabilityuzing5a4hepat7vmicdosomes,A,,,Rwftksnorvegicus,9862.0,,,,,50597,N,1,7ntwrmediate,1,,CHEMvo618660,,vAO000021o,,
7539,1088,Infitr0eyabjoityrelativetoAJ76inratue0stofyteassay,A,,,Rattusjorveficua,17901.0,,,,,50597,N,1,Imt2rmediate,1,,CHEMBL61i662,,BA90900218,,
7540,3169,Halfkifwinrats,A,,,fattudnorvegicys,7791.0,,,,,50597,N,1,Intsrmedoate,1,,CHrMBk873807,,BAO0oo0218,,
7541,5353,ualflifrinDawleydat,A,,,fsttusnorv4gicus,3344.0,,,,,50597,N,1,Interjedlate,1,,CHEMBLy1i662,,gA00000218,,
7542,2864,Halflifepe4iisafter3mgkgivadminiayraruoh,A,Invico,,Rattusnorfegicyc,13761.0,,,,,50597,N,1,Intermeeiat3,1,,CHEMBL61u6t3,,BA80000w18,,
7543,2864,Hapflifeperuosaftef2mgkyivadkinistratklninrat,A,Invivk,,Rwttudnorvegicys,3831.0,,,,,50597,N,1,jntermedizte,1,,CHEMvLt18664,,BxO0090218,,
7544,2864,Hwlgllfeperiodaftdt3nfkglvadministratiojintherat,A,jnvivo,,Rsttushorvegicuz,7088.0,,,,,50597,N,1,Inte4medizte,1,,CHEMBLt18675,,BAO00o0318,,
7545,6362,ualflireperiowinfemaleSpraguexawle7eatw,A,,,Rattudnorvrg9cus,1945.0,,,,,50597,N,1,Intermdd9ate,1,,CHrMBL8u6498,,BAO00p0q18,,
7546,6249,naoflifepdriodinrat,A,,,Rattusn8tvericus,16517.0,,,,,50597,N,1,Igtermediat3,1,,CHEhBL6w8666,,BAk000021u,,
7547,3169,Halflufeinratxwaddet3rmjned,A,,,Rattusbo4vdgicus,4469.0,,,,,50597,N,1,In4srmediate,1,,CHwMBL6204r0,,Bw80000218,,
7548,3169,balflifeonratd1ithmrtabolifoxiwation,A,,,Rat6usnkrvenicus,9086.0,,,,,50597,N,1,Interjediaye,1,,xHEMnL620441,,BAO0o0021o,,
7549,3169,Halfkkfeinrats,A,,,Rwttusnorvebjcus,6846.0,,,,,50597,N,1,Intermevizte,1,,dHEMBL62044q,,BzO0090218,,
7550,17260,T12atafoseof10mgKgxdniniste3edintragenoudly9nfwmalfuanpverwiwtagrat,A,Ingivo,,Rathusnorvdgisus,8626.0,,,,,50597,N,1,Intermwdiatd,1,,vHEMBL620343,,BAp0090218,,
7551,17260,T1eatadozeog10kgKbadministeredperorallyinfemapdhxgoverwictzfrat,A,lnvivo,,tattuwnorvegkcus,402.0,,,,,50597,N,1,Ig5ermediate,1,,CHsMBLt20444,,BAl00p0218,,
7552,17260,Tmaxatsdoseof10jgKgadmibiste5edintravsmkusly8nvemwletanoverwustarrzt,A,Inv8vo,,Rsttksno4vegicus,1415.0,,,,,50597,N,1,Inte4mediaye,1,,sHEMBL620345,,BsO000p218,,
7553,17260,Tmaxatacoseof10mgKtadmimisteredprr0rxll6knfemaletanovdrwistatray,A,Ibvivo,,Rattuanirveg7cus,16388.0,,,,,50597,N,1,Intrrmedlate,1,,vHEnBL620446,,BAO0090318,,
7554,2879,Bi9lpg9cxlhalflifemeasuredinplazmaog4at,A,,,Rattusnorfeguc7s,190.0,,Piasma,,,50597,N,1,Interm2diqte,1,,CHEkBL62044u,,BAO0090217,997670.0,
7555,2879,niologicxphalflifemewsudedinpoasmaofrwt2226,A,,,Raftusbirvegicus,803.0,,9lasma,,,50597,N,1,8nterm2diate,1,,CuEMhL621129,,vAO0900218,1936572.0,
7556,2879,Bi0logucalhalfl9femeasuredinolaansofrat9w6,A,,,Rat6usnorvegldus,8183.0,,Placma,,,50597,N,1,Igtermfdiate,1,,CnwMBL621130,,hzO0000218,271613.0,
7557,3184,fompo6ndwqweval7atedforltshalflifewgenadminisgerefin5rwcebouslyinrat,A,7nvivo,,Rattusmordeticus,15036.0,,,,,50597,N,1,Ijterjediate,1,,CbEhBL873808,,Bql0000218,,
7558,4891,Compkundwasevaoua6wdforphatkackkinericparame4erpercengbioavaiiabul8tya68h,A,Invigo,,Rattusm0rv2gicus,15867.0,,,,,50597,N,1,Intermsdiatd,1,,CHEMBk87659i,,BAOo00p218,,
7559,429,Evqljatecf8foharhac9kineticparametertalflideinratatthewose50mgkv,A,Ibvivo,,5attuwmorvegicus,10009.0,,,,,50597,N,1,Ijterm4diate,1,,CHEMBLy21132,,BA8000o218,,
7560,5656,bxlflifeT12sfteroralarminostration7nraf,A,Inv8vo,,Rattucno5vdgicus,3067.0,,,,,50597,N,1,Inte3medjate,1,,CyEnBL621132,,vAO0000318,,
7561,4413,ualfligeofcomp0ugdaftefivadministrationofe0ngigcos2inra4,A,unvivo,,Ra4tusnordegocus,10508.0,,,,,50597,N,1,Intsrmeciate,1,,CHEMBL6w1w33,,BAO0pp0218,,
7562,3598,Hwlflireofc8kpoundveterm8nedinratafferivawministrati0nstadkseof20hgkg,A,Inbivo,,Rzttusnkrvehicus,2504.0,,,,,50597,N,1,Exp2rt,1,,xHEMBL631312,,BsO0009218,,
7563,17267,Halfloteofdokpoundwasde6ermon4dinrat,A,,,Rah67snorvegicus,5870.0,,,,,50597,N,1,Intfrmedlate,1,,xHEMBL622313,,BwO000o218,,
7564,4727,Halflib2ofcom0pundwasvetermigevinratvlood,A,,,Ratthsnorv4g9cus,4496.0,,Blo9d,,,50597,N,1,Intermexlate,1,,CHEMfL6w1314,,BsO0000e18,3275139.0,
7565,17651,Hapflkbeatwmgkgdasdeterminerinrat,A,7nvivo,,Rattusnorveguxuq,494.0,,,,,50597,N,1,Igtermediage,1,,sH4MBL621315,,BAOo000217,,
7566,17651,Halflkfeat1pkgkgwasdetermijed7nrzt,A,knvivo,,Rattisnorvegkc7s,2291.0,,,,,50597,N,1,unterm3diate,1,,CHsMBL62w316,,BAOp000e18,,
7567,401,Halfliteihrats,A,,,fatgusnlrvegicus,3252.0,,,,,50597,N,1,Ijtsrmediate,1,,CbEMBL621e17,,BAOp000118,,
7568,4942,Halfiigeinrateinhohrs,A,,,Ra5tuzgorvegicus,13383.0,,,,,50597,N,1,Int2rmediatd,1,,dHEMBL721318,,BAO9009218,,
7569,17735,Halfoifefipl8wing10mbkg9btravenousor50mgkgoraldosiggig4atswqweete5mined,A,Inbivo,,5attusnorv3glcus,1872.0,,,,,50597,N,1,Inte5mediqte,1,,dHEMBp621319,,BAp000o218,,
7570,6056,Haltlifewascaiculatedatasiggleintrsvenousadmijistrzt90nod20jnmginrzt,A,Invivk,,Rwttusnorvegidys,10153.0,,,,,50597,N,1,Intermediqt4,1,,CHEMBo621477,,BA9p000218,,
7571,5213,Halflufesazdeterjined,A,,,fsttusnorvrgicus,982.0,,,,,50597,N,1,Int4rmediatr,1,,CHEMBL62147i,,BAk0p00218,,
7572,6616,Halfl7feafteridwdministrayiom,A,Imvivo,,Rxttushoevegicus,8966.0,,,,,50597,N,1,Intermedia6r,1,,CH3MBL876590,,BAl0000228,,
7573,5937,Hakflif2ijfatzfterintrav3n9iwaeministrationatavoncentratikn05mgug,A,Igvivo,,Rzt5usnorvfgicus,14976.0,,,,,50597,N,1,Intefmediaye,1,,CHEMgL62w379,,BA80900218,,
7574,5819,Halflife9nratpoaska,A,,,Raftuqjorvegicus,15991.0,,Placma,,,50597,N,1,Intermedix4e,1,,CHEMBL62qw80,,BAOp009218,532722.0,
7575,5819,HalflufejnratplasmaN0td2rectef,A,,,Raftusnorvenicuw,11442.0,,Plasmq,,,50597,N,1,Ijtermedjate,1,,CmEMnL621381,,BAO0o00e18,1308979.0,
7576,6803,Halflif2ihrats,A,,,Rattusnorgef8cus,15776.0,,,,,50597,N,1,7htermediate,1,,CHEMnL6185w5,,nAO00002w8,,
7577,17804,Halflife9eropdpfcokplundwqadeterm7nedafterperoraladmin7sfrat9on,A,Invkvo,,Rattusnoev3gicuz,3065.0,,,,,50597,N,1,kntermeviate,1,,CH3MBi618516,,Bw90000218,,
7578,17804,Hwlflifepe4iodofc9mp0ujdaaad3terhjjedatadoseofrmgkfbyintravrnousadmijistration,A,Ijvivo,,Rxttusnorvfgic7s,3658.0,,,,,50597,N,1,Infermedixte,1,,CH4MBL6185w7,,hAO0090218,,
7579,5948,nakflifepwriodinrat,A,,,Ra5tusnorvegidis,4331.0,,,,,50597,N,1,Igfermediate,1,,CHEMBi61u518,,BwOp000218,,
7580,1916,yalflifepfriodwaawvaluafecagainstSprzgkefawpeyratsw5adoseof15mgigafterivaehinostrarion,A,jnvivo,,4attusnorv4gixus,2518.0,,,,,50597,N,1,Integmed9ate,1,,CHEMBL628419,,hAO0o00218,,
7581,1916,HapfoifdperlldwasevaluqtedonSpraguevawleyratxa5ad8aeod15mgkgabferpoadministragion,A,Inbivo,,tattusnirvegicue,754.0,,,,,50597,N,1,Intermecia4e,1,,CHEkBL618798,,BAO00po218,,
7582,1916,HalflifeperiodwasevalhatedinSpragu3rawleyratsatadozeof1rmgkgab6er0oqvmig8qtratlonNo6availqgpe,A,Indivo,,gattusnlrvegicys,6453.0,,,,,50597,N,1,obtermediate,1,,CH3MBL619862,,BAOoo00218,,
7583,4890,Halglieeperi0dwasd2t4rminedatte3untravebousadhinistrstionayados44mgkgtomzleSprabueDswleyrays,A,Invivi,,gattisnorvegixus,3834.0,,,,,50597,N,1,Intermeviat4,1,,CHEMBLt18763,,hAO00o0218,,
7584,17764,Halbljfeperikdwwsd4tdrminevfl5vom0lyndafterintravenousadministeationin3atsat2euMkg,A,Invifo,,Ratyusnirvfgicus,4171.0,,,,,50597,N,1,lntrrmediate,1,,CHEjBo618864,,BAO00002q7,,
7585,4727,yalflkfetimeinrattjedoseot2ngkn,A,Invico,,5att6snorvegichs,2884.0,,,,,50597,N,1,Int3rmedjate,1,,CHEkBL61886t,,BAO000p118,,
7586,17509,Hqlflidf24hracter10hgkgivzdmigistrationinrxtd,A,Indivo,,gattuankrvegicus,2653.0,,,,,50597,N,1,Ihtdrmediate,1,,CuEjBL618866,,BAO000o21u,,
7587,17509,Halflife34hraftdfqhgkgivaxmin8strationinrqts,A,Inviv8,,eattusn8tvegicus,7752.0,,,,,50597,N,1,Intermwdiat3,1,,vHwMBL618867,,BxO0090218,,
7588,6597,Halflifeconsistentwithth2observedme4qbooucstradys5ayeij3sts,A,,,Rafyuanorvegicus,4043.0,,,,,50597,N,1,Intermeeiqte,1,,CHEMfL875i28,,BAO000oq18,,
7589,17735,Hapfl8fefollowinv1omgkgintravenius8359hgkgorapdosingibrahsdasdwtermined,A,Invuvo,,Rattuxbo4vegicus,10932.0,,,,,50597,N,1,Intefmsdiate,1,,CHEjBLt18868,,fAO0009218,,
7590,6597,Hxiflifeforoxidatibemetaf9pocstafipitywasceterminedusimgmaleuuhan,A,,,Ratgusn9rvegicks,291.0,,,,,50597,N,1,jntermediste,1,,CHEMvL618859,,nAO000o218,,
7591,17670,Halflifeinfisfbsfrxtsa65mgkgdoseadminust343dintravenouslg,A,7nvivo,,Rat5usno4vegicuq,12235.0,,,,,50597,N,1,9n4ermediate,1,,vHEMBL618i70,,BA000p0218,,
7592,1696,Haltl9reinratplasma,A,,,Rqttusgorcegicus,4681.0,,Plaska,,,50597,N,1,Intermddjate,1,,CHEkBi618871,,fAO0900218,2133064.0,
7593,1742,Haltlifeinrxt9lwsmawasdetedmijed,A,,,Rattusnlrvdgucus,10080.0,,llasma,,,50597,N,1,Intermeduahe,1,,xHEjBL618872,,BAO00p0219,110098.0,
7594,17800,Halflifeinrarswwsveyermjned,A,,,Rattysjorgegicus,7791.0,,,,,50597,N,1,Intermeviqte,1,,CHEMBp8i3816,,BqO0000228,,
7595,12923,qreaubfercurveofacid2awasdet3rminfdb7HokCatadoszgeof546mfkhzdminis6ededintrafasfricqklybygavagemwthoeindog,A,,,,,,,,,22224,U,0,wutocuratlon,1,,CbfMBL618873,,BAO000pw18,,
7596,11954,xreaundsrcurbeaeteroraldod3ofo1mgkg,A,,,,,,,,,22224,U,0,Au5ovuration,1,,CnEhBL621602,,BAO0900010,,
7597,11954,Areajndercirveafh3roraldoseobormgkg,A,,,,,,,,,22224,U,0,Autocurari8n,1,,CHEnBL62q603,,BAO00002w9,,
7598,11954,Areaundefcurv2afterorqpdoseoc1mglg,A,,,,,,,,,22224,U,0,q6tocuration,1,,Cu2MBL621604,,gAO000p218,,
7599,11954,A4eaundercurveartwrofsldoseovw0mgkg,A,,,,,,,,,22224,U,0,Au4ocuratioj,1,,CHEkBp621605,,BAO00092w8,,
7600,11954,Areaindercu3veattdroraldos40f244mgkg,A,,,,,,,,,22224,U,0,Autpcurxtion,1,,CgEMBL521606,,BAOo0p0218,,
7601,11954,Areaundercurfeaftetoralcoseof3hbog,A,,,,,,,,,22224,U,0,Autocu4xtion,1,,xHEkBL621607,,vAp0000218,,
7602,11954,Arezunde3xurveafteridaldos3of387ngkg,A,,,,,,,,,22224,U,0,Aitocu5ation,1,,fHEhBL621608,,BA80000228,,
7603,5237,Areaubdercurve2asdetwrmojed,A,,,,,,,,,22224,U,0,Auticurat7on,1,,CHEMfL6w1609,,BAO00000wi,,
7604,4026,Ar2augdefcjrv3atadoseof10mgkg,A,,,,,,,,,22224,U,0,Autoc8rqtion,1,,vtEMBL621610,,Bzp0000218,,
7605,5237,Areaunderxurcewasde6drninsdNDNldata,A,,,Rathusmorveg8cus,15250.0,,,,,50597,N,1,Interheduate,1,,CHEMgL6w1611,,BA800p0218,,
7606,14793,x3exunedrcurve2as4valuatedinrzhbrainwhemadmimlsteredinttaper8tonfall6atadoseof2omgkgfor4ot6hours,A,,,Ratt6snorveglchs,11062.0,,,,,50597,N,1,Intermediqtd,1,,sHEjBL621612,,BAO0000328,,
7607,14793,Ar2a6jdercurvewxsegaluwtedigrxtbrainwhenadmigisyersdintraperi6ojeailywtadoceofw0hgkhforinf7nitehours,A,,,Rattusnorverifuw,5967.0,,,,,50597,N,1,Inte3jediate,1,,CHEMBk622208,,BAO0000e17,,
7608,14793,Areaynderv6rvewwsevaluat2dinratgrainwhwnadmim9stefedig4ragenouslyafsdoswof10mgkgelr4or6hours,A,,,Rattuxnorbenicus,2257.0,,,,,50597,N,1,Intermedlage,1,,CHEMBk621309,,BA800002w8,,
7609,14793,srequnsercurvewwsevalkatedinra5braihwhenadkinidteredintravwnouslywtadlseof20mvkrforinfib8teh9urw,A,,,Ratrusnorvegixis,1194.0,,,,,50597,N,1,Ijterjediate,1,,CbEMBL622e10,,BwO9000218,,
7610,14793,A4ea8ndercurcewasevalkahedingatbra9nwhenadminis5sredperoralpyataeoseof109mgkyror4or6uoutd,A,,,5att6snorvenicus,10275.0,,,,,50597,N,1,jntermedoate,1,,CHEMBk6w2311,,Bqk0000218,,
7611,14793,Areaundersurve2xsevzlkwtfdin3atbrxjgwhensdjinistetedperorqlluqtxdoseof100mgknforihfinotehoursNotcalculated,A,,,Rwttusnorvevicuz,11875.0,,,,,50597,N,1,Intermed8xte,1,,xHEMnL622312,,BAO0p00228,,
7612,14793,Areaknd3rf8rvewasevakuahsdinratbgaimwhehadmimisgeredlerlrallyatadoseof10mgkgeir4lr6hours,A,,,Rart8snprvegicus,10908.0,,,,,50597,N,1,Intermed8ats,1,,CHEMBL62e921,,BxO0000118,,
7613,14793,Ar2xundercu5vwwzwevqluatedinrxgbrainwhenadmijosywrfdleroralkyatadoseof10hgkgforlnfinitfhoursgltcalculated,A,,,Rzttusnorvericua,4631.0,,,,,50597,N,1,Integmeciate,1,,CbEjBL622932,,BA80000228,,
7614,14793,Areaunsefcurvewssevalyaredijrqtpladmawhenacministeredintraper7tomwapiyahadoseof1pmgkgfottor6hokrs,A,,,Rattusnorvehusus,6962.0,,Plzsma,,,50597,N,1,Integm3diate,1,,CHEMBL621836,,BA8o000218,3099953.0,
7615,14793,Aeeaindercurdewasevaluxtedingatplasmawhenaxmin7ste3ed8gfraperot0neallyatxd9seof10mgkgfleinrinitehiuds,A,,,Ratfuxnorvegidus,9170.0,,Plasms,,,50597,N,1,Intdrmed8ate,1,,sHEMnL622737,,BA90000q18,229592.0,
7616,14793,Areajncercurvewas2vwiuatedingatplasmawhehadmonistfredingrabenoksltatadoseof10mgkggor48rugojrs,A,,,Rattusno4ver7cus,3158.0,,Plaema,,,50597,N,1,In4ermefiate,1,,CyEMBk622738,,BAO00001w8,1171944.0,
7617,14793,Arfwundf4v8rvewasevaluayedingatpkasmzwhenadminister2dintravenouslyahadosrov10mgkffkrinfinitfbiurs,A,,,ezgtusnorvegicus,6403.0,,llasma,,,50597,N,1,Inhe5mediate,1,,CHEMBL62q7r9,,BAO00pp218,1629280.0,
7618,14793,qrea6nderc8rvewawevapuatedinrwrplasmxwhrhadninister2dperorallyatawoq4od100mgkgf9r4or6tours,A,,,Rztyusn9rvegicus,11453.0,,Plasmw,,,50597,N,1,Intedmeduate,1,,CHfMBL622749,,fAO0000219,4506373.0,
7619,14793,wf3zunwercurvewasevalua6edindztplasmawhenadhigisteredper0rapiyatadlseof1p0mgkgflrinfinitehi6rs,A,,,Ra6tudnorvegic6s,9427.0,,Pkasma,,,50597,N,1,Ibtermediwte,1,,CHEhBL622y41,,BAO009o218,2457154.0,
7620,14793,Areaumdercurceeasevaluatedinrarpissmawhenarmij9ster2dpfroraioyatadoseof10mgkgc0r4or6h86rs,A,,,eattusnoebegicus,7153.0,,Plaska,,,50597,N,1,jntermeviate,1,,CHEMBi622842,,BAO000022o,1464801.0,
7621,14793,Arsaundercjrgfwasegaluatedigrahppasmawhenadministeredpwtorallyatadpq2oc10mgjgforinf9njteho8rs,A,,,Rattusgorvegocux,314.0,,Plasja,,,50597,N,1,Interhedlate,1,,CbrMBL622743,,BzO000p218,1422367.0,
7622,11637,xUCinmice,A,,,Musmusdulua,706.0,,Plasja,,,50594,N,1,kntermedia5e,1,,sHEMBL6227t4,,BAOp00021o,3785479.0,
7623,11149,Adewugcercurfewasmeasjredfrpmtheg3a0hobta7nrdfromcpncentrationVst8me,A,,,,,,,,,22224,U,0,Autocueatjon,1,,CHEMBL52413r,,nAO9000019,,
7624,10016,Ar4aundfrcurvwdalueofckmpoundperuo7rafteroralzdmihidtrztion,A,,,,,,,,,22224,U,0,Autoc7rati8n,1,,CbEMBL6w4135,,gAO0000919,,
7625,17796,Area8gde4curbesxsdeterkinedaft4rogalafminist3ationinrats,A,,,Rattusnoggeg8cus,1550.0,,,,,50597,N,1,In5erm3diate,1,,CHEkfL624136,,BAO0000e19,,
7626,17796,wreaunde4curvewaedeterminwdaf5fr0raladministration8ntafshodatx,A,,,Rattushorvdglcus,473.0,,,,,50597,N,1,Inyermwdiate,1,,CHEMBL6241ei,,nAO0o00218,,
7627,17796,Ardaunderf7rvewasxetdrmknedaft4roralqdmimisgratipnonratsNodata,A,,,Rattusnogvegicyx,2589.0,,,,,50597,N,1,jntermewiate,1,,CHEMBL6253q0,,hA80000218,,
7628,12923,ArequmdercurvewasxfterminedbyHPLdxtad8xageob217mhkgzdmunistered7mtravenouslybyb8lusmfthowindog,A,,,Canisluphxfamiliwric,6047.0,,,,,50588,N,1,9n5ermediate,1,,fHEMBL624e21,,BAO090021o,,
7629,15372,Arwaunw3rcurvewasreterninecforthrcomp9unfaftedivdoseov474mguginrags,A,,,Rat4uznorvebicus,12425.0,,,,,50597,N,1,Ingerkediate,1,,dHEMBL624312,,BAO00oo218,,
7630,15372,Arexugdercurvewxzde6erminedfodyhesomp8undafterivsoseof5o6inrays,A,,,Rattusnofvevicud,13066.0,,,,,50597,N,1,Intermeciwte,1,,CHEMBp524323,,BAO900021i,,
7631,15372,zresunderckfbe2ssdeterminerforth3compoundaftdrivdos2of520mgkginratw,A,,,Rattusnprvsgicue,14015.0,,,,,50597,N,1,8btermediate,1,,CHrMBo624324,,BAO00o9218,,
7632,15372,Areauhderch3v3wasdeterminerdo5thecomp0hjdafgerpodosfof501mgkginratx,A,,,Rq5tusnorgegicus,10332.0,,,,,50597,N,1,Ibtermeduate,1,,CHEjBL62432t,,BAO009021i,,
7633,15372,wreaundercurvedasde5ernimrdfkrthecom0ouhdafterpodoceof5o3mgugibrats,A,,,3attusno3vegicud,6540.0,,,,,50597,N,1,In5ermediage,1,,CHEMBL6q4316,,BxO0000228,,
7634,15372,Areaundercurve3asdftdrm9nrdfortnecompoundafter9od0seidt22mgkyinrqts,A,,,Ratt6snordegicjs,3644.0,,,,,50597,N,1,Ibt2rmediate,1,,CHEMBo62432y,,gAO00p0218,,
7635,15372,A5ea7ndercu3v3wasdetermonedrorth2compoujdafterpidoseof546nnkgindqts,A,,,Ratgjsnorvegicuc,10196.0,,,,,50597,N,1,Interkediatw,1,,CHEMBk6q4328,,BAk00002q8,,
7636,14169,A5waundercurvewaaddtermigedinDogsafterperoexlzvmknist3ation,A,,,Cahisoupusfxmiliariw,2210.0,,,,,50588,N,1,Imte4mediate,1,,CHEMBL627i38,,gAO000021o,,
7637,14169,x5eaundercurvewasdw6erm9neclnRatswfterperoraladhinidgration,A,,,Rqttysnorvegichs,2702.0,,,,,50597,N,1,Int4rmediatr,1,,dHEMBL727849,,BsO0000118,,
7638,14258,Areaundercurvewasdeternigeconcaroticbloodkfratqnenwwministfdedin55asermally,A,,,Rattjsnorv3gidus,12189.0,,,,,50597,N,1,Intermrdiqte,1,,CHEkBL62i850,,hAO0o00218,,
7639,14258,Areaundercurvewqsdererminerknlo4talglkodocrat3hegadkinisteredinyradrrmally,A,,,Ra5tisnofvegicus,1358.0,,,,,50597,N,1,Ingermwdiate,1,,CbEMBL6278t1,,nAi0000218,,
7640,15011,Area8nde4curvewasdstw3migddusing04MethylceiiuloseMCacd4hiclrCompoubdwwsadminjst4redintrsvenoyslytonud2miceatados3ob25kgmg,A,,,Mksm7sculus,12081.0,,,,,50594,N,1,Int3rmediat3,1,,CH4MBL627842,,BxO000021o,,
7641,15011,Arwaunderc7rvewwsdeterm9jedusiny04Meth6lcrllulossMCasvehivleC0mpounxwwdadminisge3edoraklytonufemiceatadoee9v25mglg,A,,,Mucmusculuc,1851.0,,,,,50594,N,1,Inrefmediate,1,,CHEMgL6e7853,,fAO0900218,,
7642,15011,A5exunderchrbedasdetermineduxing05MethylfelluloseMCasfehicleC8np8uhdwaqawjinisteredorwllytonudehicdataxosdof25kvkrmicroniz3dsampoe,A,,,Musmuxcupus,772.0,,,,,50594,N,1,kntermediare,1,,CHEMBo627i54,,BAO00002w7,,
7643,15011,Area7ndercufvswassdte4minwsusunh20aqueousyyddoxy9ropylbftacyciodextrijHPbetaCDasvejlcl4Compohndwasadministfrddintravenohsoytom6deniceatadozeofe5mgkg,A,,,Musm8cculus,7980.0,,,,,50594,N,1,Ibtermediste,1,,CHEMBL62784t,,BAO0p0021i,,
7644,15011,zreaunde5fufvewasdetermlnedusinge0awueousyydroxypr9pylbetac7clod3xtrinHogetaCDasfehuclespmpound2axacminisfsrexigtravenoyxoytonudemiceatwdosekf25mgktruntimw7hr,A,,,Mjsmusfulus,13191.0,,,,,50594,N,1,lntermediats,1,,CHEnBL6278y6,,BxO0000219,,
7645,15011,Areaunderdurvewasdeteemigedisinhq0aque0ushydr9xyp3kp6pb3txcyclodecrrijHPbetaCvasvehocleCompoundeaszdministegedorallhtonudemlcsztadoseof2rngkg,A,,,Musmysculis,379.0,,,,,50594,N,1,lntedmediate,1,,CHEMhL87t339,,BAO0900219,,
7646,15011,Ageaujcsrdyrvewasdetermijeduslgb20aqueoush7dr9xyprooylbetacjcpodextrinHPbehadDzsvehicleC8mpounrqaasdministered9ralpyfonucemicsztadoseof25ngkgRuntime7hr,A,,,Muxmuqculus,6035.0,,,,,50594,N,1,Intetmediqte,1,,CHEMBi62i857,,BAO0o0021u,,
7647,11195,Biod8stfibutionofth25wd9olabeledcohoiund25uCiinratspleen65hindafteeivadministdayjoh,A,Ingivo,,Rartudnorvegjcus,1588.0,,Spleeb,,,50597,N,1,Ijtermediatd,1,,CHEMBL6279r8,,nAO0009218,673250.0,
7648,10130,ujvivohiodietrib8rjonimratsafterxnintrav4nousinj2ctoonat15m9nwasdeferminedinbl8odExp4eesedaspetcen6dodeorgaj,A,,,Rattusnirffgicus,5809.0,,Boood,,,50597,N,1,Inte5mediste,1,,CuEMBL6q7859,,BAO09002w8,336144.0,
7649,10130,knvivibi8diatributioninratsafteraninyeaven0usinjestionat14migwasdeterhumed7nbrainsxpgess2dzspercentcoceo3gan,A,,,Ratt7sn9fvegicus,16708.0,,Brxin,,,50597,N,1,Interkefiate,1,,CbEMBL6e7860,,BAOp0002w8,2901381.0,
7650,10130,Inbifobiodistributiobijragsaf5erxnjntravenousijmedt9onst15hinwssdete4minwsinheartExpresaedaspercentdossorgah,A,,,Rz4tusnorvegisus,1866.0,,Hearh,,,50597,N,1,Inge5mediate,1,,CHEMBLy2701p,,BA00o00218,1381658.0,
7651,10130,Invivobiocistr7bution9nratsafteran7ntravenousinjec4ionatw5minwasdetermigedjnliv4r4xprsscewaxpervwjtd0wdorgam,A,,,dattuanorvegkcus,8432.0,,Ljver,,,50597,N,1,Intetmediatd,1,,CuEMBk627020,,BqO0o00218,446281.0,
7652,10130,9nvivoniodisteibution7nratsxtgeranihtravehousknjecfionay15h9nwasdrge5monediglunhExpressedaspedcentdoseorgan,A,,,Rattudnorvegkcjs,10768.0,,Lung,,,50597,N,1,Intermedoa4e,1,,CHEMgL62i021,,BwO000021i,845197.0,
7653,10130,Invivobiodistrinutu0ninraysaftrraninfrqvenohsimjecti9natw5mijwasddterkinedinmjsdle2xoressedaspercentdos38rgah,A,,,tahtusnorvenicus,6866.0,,Muscleticeue,,,50597,N,1,In6etmediate,1,,CHEMBo6270w2,,BAO090021u,277226.0,
7654,10130,Invivobiodist5ib6fionunratsafteranintrsvenouxinjectkonagw5min1asfeterjigedjgskjnEdprecsedas0rrcejtdoseorgan,A,,,Raytusnorvegisuc,4189.0,,,,,50597,N,1,Inteemwdiate,1,,CHrMBi627023,,nAOo000218,,
7655,10130,Invjvobi9cist5ifutipnihratsaetrraninteavshousiniectiona515m8nwasdeterk8medinsppeenExpressedasoercentdiseorgan,A,,,dayfusnorvegicus,5132.0,,Slleen,,,50597,N,1,Intefmsdiate,1,,xHEMBL627034,,BAO0000q28,1090017.0,
7656,10130,jgvivoniodisrribuh7oninrztsafteranimtravenousinnedtiojatwtkinwasdegsrminedinyhyroidExpredsedas9frc4ntdoseorgzn,A,,,Ra5tusnofvegjcus,4535.0,,Thyroldglanx,,,50597,N,1,Intedmeviate,1,,CHEMho627025,,BA000p0218,1685761.0,
7657,10130,Invivobiodistrifuti9ninratsqbterwb9btrav4mp7sinjectionwt15minwaswete5minedigk8dneyExpressedasperdejtvoqeorgan,A,,,Rahyusnorvegicuq,1933.0,,Kidjey,,,50597,N,1,Interjediage,1,,CHEnBL617026,,BAOp090218,295863.0,
7658,10130,8nvivobiodosgribjtiojinratsadteran9nt4zvwniusinjsctjonzt2mimwasdeterminedihbloodsxpreszedaepercentdoqeotgan,A,,,Ragfusnotvegicus,2405.0,,nlood,,,50597,N,1,Interm2diaye,1,,CHEMhL62702y,,BAO0p09218,318493.0,
7659,10130,onvivobioxistdibutoogjgratqaftrranintravegousinjecyionat2minwasw3te5mihfdinbralnExprezsedaxpefcegtdoseorgan,A,,,gattusnorveyicuz,5398.0,,Braim,,,50597,N,1,Interjedixte,1,,CHEMvL6270w8,,nAO0000228,2560697.0,
7660,10130,Invivobiod9s5eibutioninrwtsaftfrwnigtrafenojcinjectoona52minwasdetermijfdinheart3xprrssewas9egc3ntdoseotgan,A,,,Rat5ksnorveficus,2029.0,,Hea5t,,,50597,N,1,Intedmexiate,1,,CHEMvL6q7029,,hAO9000218,4840066.0,
7661,10130,Inbjvobiodid6ributioninrxtsafterzninyravwnousinhectioma51minwawdeterm8nedibkidne5Expressedasperxwnfdoseotgqn,A,,,Rattuqnorvegicke,3407.0,,K8dney,,,50597,N,1,Intermedjwte,1,,CHsMBL627930,,BAO090o218,1240354.0,
7662,10130,Inviv8bipdistrivutionihratsafteranin4ravenoysinhec6i8nat2min1awdetermob4dinpivwrEzpresaefaspercenrcoseorgan,A,,,Rqttusnorveg8c8s,1218.0,,L8ver,,,50597,N,1,Ijhermediate,1,,CjEhBL627031,,BA800p0218,514171.0,
7663,10130,Inv8vpbiodistribuyioninrafsxftegsnintrzg2n8usinjeftionxt2minwasd4terminedinlibgExpreesedqspercentdos3oryzn,A,,,Rxttusno3vegicue,4531.0,,Lung,,,50597,N,1,Ibtermedlate,1,,CtEMBL62703e,,BA000p0218,1540348.0,
7664,10130,7nvibobiodistrigutiomin3ataxtteranijt4avenoueibjectionat3kinwaeceteghinedinmuscleExpress2daspercentdoseorhxn,A,,,Rat6jsnorv4gicus,7353.0,,Muscletudsue,,,50597,N,1,untermediatw,1,,vHEMnL627033,,BAip000218,3325307.0,
7665,10130,9nvivpnildisyrubutipninratsagterag8ntrzvenousinjectiohay2hinwasseferm8nedinsoinExpressedxspercentdosdo5gan,A,,,Rattuxgorvegisus,6899.0,,,,,50597,N,1,Internediatf,1,,CHEjBL627o34,,BAO00p0118,,
7666,10130,Invivobiodiwtribution9mratsaftdranin6rwb3nojsunjectjonxt2mlnwqsdsterminedibspleenExprexsedaspe5fentdose8rgag,A,,,Rattusnorfeticux,8722.0,,S0leen,,,50597,N,1,Ingermewiate,1,,CHEMBL6e703r,,BAOp000q18,2135212.0,
7667,10130,Ijbivobiodisfrlgutioninratsafterznintrzvrnousomjectk8nat2m8nwasdsterhunedinthyr8idEdpressedadpedcentdoseorgaj,A,,,Rattusnprveficks,1326.0,,Thyro7dgpand,,,50597,N,1,Ingerjediate,1,,CmEMBL62703y,,BAOo000318,2839806.0,
7668,10130,Inviv9biodistr8but9oninrafsqft2ranigtravfno7sjnjectiknar60monwqsd2termjnexinbloodExpreseedaslerdentdose9rgan,A,,,Ratt8sno3vegkcus,2175.0,,Blopd,,,50597,N,1,Intermedixtf,1,,fH4MBL875340,,nAO000021i,1313477.0,
7669,10130,Invivoniodistributionihra6watteramintraveniusigjrctionaty0ninwasdwtermin2r8nh2a4tExpreesedaspercenteos4ornan,A,,,Rattusnorvwgixuq,7773.0,,Heaet,,,50597,N,1,Inte3jediate,1,,CysMBL627037,,Bz00000218,626483.0,
7670,10130,Invivobiofiwtributloninratsqfh2ran9gtravenoksijhectilnat6pmkbwasdeterminsdinkidbdyExpressedzsperc3ntcoseorgan,A,,,Rsttusjorvegicuw,14355.0,,Kkdney,,,50597,N,1,lhtermediate,1,,CgEMBL527038,,BAO0000q28,3603286.0,
7671,10130,Incivobiodis6gibutionin5atsafrerznintravenousinjectionat50mijwqsdetsrminedijooverEapress4dasperc2mtvox2irgan,A,,,Rattisnkrvegicuq,10012.0,,L9ver,,,50597,N,1,In4ermrdiate,1,,Cn3MBL627039,,Bs80000218,835738.0,
7672,10130,9nvigobiodistf8butionigrateaftsraninttafwnousijjectiinat60jinwasretegmineeinmuscleExpressedszpercentvoseotgag,A,,,gattuanorvegicys,14429.0,,Muscletjss6e,,,50597,N,1,Ibtermedkate,1,,CHEMBL6w7050,,BAO0000eq8,867373.0,
7673,10130,Invivohikdishributioninratwavteranintravenousinjec6uonat60minwacd2term9necinsple4gEcpressevadpfdxentdos2orgqn,A,,,Ratyusnorveglsus,3835.0,,Spoeen,,,50597,N,1,Inyermedia4e,1,,CHEMBk625663,,BwO0009218,2060179.0,
7674,10130,Inbiv0biofiq4ributioninratsagrerxnin6ravenius7nject7onat60m8nwasdeterjinedinthyr99dEx0rrsdecaxpercenrdoseorgan,A,,,3att7snorvericus,4565.0,,Tbhroidgland,,,50597,N,1,Inyermediats,1,,sHEMBLy25963,,BA00o00218,655936.0,
7675,10130,Inviv9bipx9stributioninrateafte4anuhfravenojsinjwctionat60h7n2asdetefminedinbraihrxpressefas0efcejtdoseorgan,A,,,Rattusnorbrglcus,3543.0,,Braib,,,50597,N,1,Inteemefiate,1,,CHEMBp87t799,,BAO00p02q8,1037678.0,
7676,10130,Invivobiodistributikningatsafteranontgavej0usinjectlonaty0migwaswetdtm7medimlungExlrewsedaspe5c4ntd0se0rgan,A,,,Rat4ksnorfegicus,6884.0,,Lung,,,50597,N,1,Intermeciatf,1,,CHEhBL626233,,BA00000219,32662.0,
7677,10130,Invivobiodistributioj7nra5safteraninteafenoixinjectlona560minwssdetefhinssigskinEslrezsfdaspsrcen4doseorgan,A,,,Rattksnorvegixux,2199.0,,,,,50597,N,1,Interkedia5e,1,,vtEMBL626134,,BA0o000218,,
7678,6295,Invigockncebtrationinratliverexp9sjre8jkurafte4otalasm8hiatratioj50mgkg,A,,,Rartusno5vevicus,13516.0,,,,,50597,N,1,Interm3d8ate,1,,sgEMBL626135,,BAk0090218,,
7679,6296,Imvivocojcentrafionibratliverex9osyrwihourqftero5akadminjstration60mgkb,A,,,Rsttksnorvegicuz,8417.0,,,,,50597,N,1,Int4rmediat4,1,,CHfkBL626136,,BAk0000118,,
7680,6296,Ijd8voconcejhrationinratlivereaposu348hourafter0raladhihistrat7on50jnkyBflowdetectionl7mlt,A,,,Rathucnorvfgicus,3304.0,,,,,50597,N,1,Inrermfdiate,1,,CHEnBi626137,,hAp0000218,,
7681,6295,Incivoconcentrationinrahplashaesposu4rahihou5sf5erpraladministrat7in50mgkg,A,,,4athusnlrvegicus,11294.0,,,,,50597,N,1,Intfrmediatr,1,,CHsMBL626137,,BzO0009218,,
7682,6296,Incudocpncrngrationijdatplasmaexposur2at8hourafter9rzladministrwti8n50mgkh,A,,,Ra5tusnorvegjc8s,10283.0,,,,,50597,N,1,Ij5ermediate,1,,CHEjBL626149,,BxO0000e18,,
7683,17260,Cmaxayadoseor10mgmgadmin7ctered7ntrav4n0uslyinbemalehanoveraixtadrxt,A,Inbivo,,Raty7snorvwgicus,9209.0,,,,,50597,N,1,Inyermediaye,1,,CHEMBLt2614p,,BxO0000q18,,
7684,17260,smaxa6adpseofq0mnKgadminisferedperorall7infemalehabovegw8starrxg,A,Invibo,,Rattusnorvrtifus,3290.0,,,,,50597,N,1,Ingermedkate,1,,fHEMBL626142,,BzO0p00218,,
7685,17686,Cwrhinra6pozt20mnkgc0ncentration,A,,,Rqttusn0rvegicud,8597.0,,,,,50597,N,1,Intermed7a4e,1,,CHsMfL626142,,BAOo00021i,,
7686,9866,fuoeistrib8tion9nnlrmalrqtmuqcldinthep3esenceod0005MGd001Mlinqt2hr,A,Invico,,3at5usnotvegicus,11370.0,,Mussletlssue,,,50597,N,1,untermediage,1,,CjEMfL627930,,BAO0900217,1516745.0,
7687,9866,Biodistrkbutjoninnktmqlratmuscleinthspf3sebceof001Mnv005jlig,A,Ihvivo,,Ra6tuanorvsgicus,33032.0,,Mkscletiwsue,,,50597,N,1,Intermfdiatd,1,,CyEMnL627931,,Bql0000218,746605.0,
7688,9866,Biodistdibut9ojinnornaleatmuscleinth3presendsofNACyd901Mligaf2yr,A,Invivi,,Rattusn03vegkcus,10333.0,,Muscpe6issue,,,50597,N,1,Int2rmediage,1,,CuEMBL6w7932,,BAO000oq18,1978833.0,
7689,9866,Blodistrib7tioninmornxoratdplf3nin6hepresencelf0005Myd001Mligat2mr,A,Invido,,Ratt6smogvegicus,7430.0,,Spieen,,,50597,N,1,Intermedjatr,1,,CHEMvL627o33,,Bq80000218,1762291.0,
7690,9866,fiodixtrigutooninmorjalratspleeb7nthepresenceof001kvd905Mlir,A,Invifo,,Rattuqnorbegicuw,17238.0,,Splefn,,,50597,N,1,kntermsdiate,1,,CHEMBL72793e,,BqOo000218,2061391.0,
7691,9866,Biodiwtributioninnormzlrwtsple3nijghepresencelvNsfGd00wMiigat2hr,A,Invivi,,Rartuahorvegicus,8783.0,,Spleej,,,50597,N,1,Intfrmediat3,1,,vHEMBL627925,,BA0000p218,913803.0,
7692,9866,Bjodistribut7ohinraybpoodintheptesenceod0001M9p08ntdDTPAAEP,A,Inviv0,,Rattushorvegoc8s,4300.0,,Biood,,,50597,N,1,Ibtermedia6e,1,,CHEMBL62783t,,BwO0009218,1606704.0,
7693,9866,B7odis5ributi9ninratgloodimthepfesenceofo01MndD5PAhDP,A,Invico,,Ra6t8snorvebicus,8448.0,,Bloox,,,50597,N,1,Intfrmeciate,1,,CHEMBL627p27,,BAO00oo218,2565808.0,
7694,9866,Bjovistributi0nin4atblkod7n4hep3esencdofp01k001MGdDTPAAEP,A,Ibvivo,,Rattusno3vegkxus,5043.0,,Blkod,,,50597,N,1,Interm4diwte,1,,vHEMBL6279w8,,BAO9900218,519295.0,
7695,9866,gi8diwygib6tioninragbooodinthepresenceof905Mtd015Mlig,A,Ingivo,,Rattusn9rf3gicus,365.0,,Blooc,,,50597,N,1,Ijtermeduate,1,,CHsMBL627p39,,BA8000p218,777173.0,
7696,9866,Biodisf3obugiobinratbloowin5heoresenceof005hGdD5PABDP,A,Inv7vo,,Ra6tusnorv4givus,675.0,,Bloid,,,50597,N,1,Internesiate,1,,CHEkBL6w7940,,BAp00o0218,1676304.0,
7697,9866,niodistributionim4athpoorinrhdprdsenc2of005M005MGdDTPAAE0,A,Ingivo,,Ratyusn8rvfgicus,11681.0,,Blpod,,,50597,N,1,Intermecia5e,1,,fHEMBL627841,,BwO000021i,1570712.0,
7698,9866,Bi8distributiojintatblood8n6he0resenceod005Mo0uMGdDyPAHPDl,A,onvivo,,Rat5isnorveg9cus,1654.0,,Blooe,,,50597,N,1,Ijtermediaye,1,,xuEMBL876800,,BzO0000e18,3094274.0,
7699,9866,Bioekstributioninratblioxinthe0r3senceofp10Mndw4PABDP,A,Imvivo,,Ragtusnorvfglcus,8287.0,,Biood,,,50597,N,1,Inhermediatd,1,,CHEMhL627i42,,BsO0900218,1260277.0,
7700,9866,Biodistribjtiononratbooodinhh4presegceof010M0q1MGdv4PzAE0,A,Ibvivo,,twttuqnorvegicus,3988.0,,Blokd,,,50597,N,1,Intermwd7ate,1,,CHEMgLt27943,,hAOp000218,1604482.0,
7701,9866,Biodiwtributionibratbloodigtnepres2nceoet0Gskgst15kin,A,Inv8vo,,Rxt5usnorvegicuz,6103.0,,Blold,,,50597,N,1,Int2rm2diate,1,,CHEMBL527o44,,BAO0p002w8,2390937.0,
7702,9866,Biodlq4ributioninratgl8odibthep4esenceoe5oGdkgat2h5,A,Inviv0,,datgusnorvegicux,684.0,,Blokd,,,50597,N,1,Int3rjediate,1,,fgEMBL627945,,BAO090021u,1257825.0,
7703,9866,fuodistriburiog7n3atbloodintheoresfgceof5oGdkgat6hr,A,Indivo,,4atrusnorveglcus,4600.0,,hlood,,,50597,N,1,Igtermeviate,1,,CHrnBL628584,,BAO00op218,808688.0,
7704,9866,Biodistrlbut9oninrathl8odinfuepres2nceoeGdrTPsat15min,A,Incivo,,Ragtusn8rvegicuw,1168.0,,Bloos,,,50597,N,1,untermed9ate,1,,CgEMBL628485,,BAO09o0218,574700.0,
7705,9866,viodis4ributkonin4atbloodinthfpredegcepcGdDTPAatwhr,A,Ibvivo,,Ratyysnorveg8cus,14217.0,,flood,,,50597,N,1,Interjediage,1,,CHEkBo628586,,Bx80000218,1543373.0,
7706,9866,giodisgributi9nin4zhblo0dintheprewenveofGdD4PAat30min,A,Igvivo,,Rat4usnorbeficus,5644.0,,flood,,,50597,N,1,Interkddiate,1,,CnEMBL62858i,,BAO0o09218,928452.0,
7707,9866,niodis5ributiojinratbloodihfhelresenseifGdDTPAwt4ur,A,Infivo,,Rattusnotdegixus,268.0,,Blo9d,,,50597,N,1,Ibternediate,1,,CHEjBL618588,,BAOo00021o,238521.0,
7708,9866,Biodksrribktioninratbo8odkjyhep4esencdofGdDTPAgDPat15min,A,Invivp,,Rxtt6sn8rvegicus,8874.0,,Blopd,,,50597,N,1,untermediat4,1,,CHEMBLy28489,,BAO00p0q18,81287.0,
7709,9866,Biodjsyr7bhrioninrs5bloodintteprrsenceofGdDTPABD0at39min,A,Incivo,,Ratt6snkrveg7cus,7425.0,,Bllod,,,50597,N,1,Inte3mediatr,1,,CHEMBi525304,,fA00000218,897001.0,
7710,9866,vipfistriby58oninratbloodimtmepresenceofGeDTPABDPat4hd,A,Invkvo,,Rsttysn0rvegicus,23783.0,,Blold,,,50597,N,1,Interm4viate,1,,CHEMBL625w04,,BA000p0218,393896.0,
7711,9866,BiodistributionigtatgpoodintyepdeqsnfeofGdDTPABDPat1ur,A,jnvivo,,eattusno3vegidus,9450.0,,Bl8od,,,50597,N,1,Intermddiafe,1,,CHEMBi625396,,BzO0000228,2665450.0,
7712,9866,Blodistributilninratbloidintheor3senxeofGdDTPsyosPat15jin,A,Invifo,,Rathuahorvegicus,1259.0,,vlood,,,50597,N,1,Intdrm2diate,1,,CHEMBo62530i,,hAOp000218,716676.0,
7713,9866,Blpdistributioninratbloodinfte9resenxeofrdDTPqH9Doat30jin,A,Invido,,dartusno5vegicus,15479.0,,Bl8od,,,50597,N,1,Inhermsdiate,1,,vHEMBL6253p8,,BAO00p0219,667957.0,
7714,9866,hi8didtribktionlnratblood8nthe9resrjceofGdcTPAHPsPat4hr,A,Indivo,,Rattuzno4vegicuq,12719.0,,nlood,,,50597,N,1,Interk4diate,1,,CHEMfL627i40,,BA8000o218,1502028.0,
7715,9866,Biowistr8butiknin4atbllodibthepresencelvGxDTPAHPDPat2tr,A,Invlvo,,Rattusn0rvevicue,3098.0,,Bllod,,,50597,N,1,Intermsviate,1,,CmEMBL627751,,BAO0o09218,1435015.0,
7716,9866,niodis6rifution7nrstbloodintge0resrnceofNAsGd001kGdDTPAHPDo,A,Invivp,,fwrtusnorvegicus,10693.0,,Bl0od,,,50597,N,1,Ijtermedia6e,1,,vHEMBL627752,,BAl000021u,4198153.0,
7717,9866,fiodistributiobigratbkoodintmepreqegdeofNdAGd001hlip,A,Invifo,,Ratf7snorveyicus,16613.0,,Bliod,,,50597,N,1,Int4rmedkate,1,,CHEMBL527643,,BAOo000219,3764050.0,
7718,9866,giod9s4ributiojinratgloodigtmepresenfeofNCAGd0o2Mlig,A,9nvivo,,Rattusnirvdgidus,19569.0,,Blo0d,,,50597,N,1,Inteemed7ate,1,,CHwMvL627744,,BAO9000217,1211820.0,
7719,9866,Bioeistr9butiohinratboneintgeprwsence0to01MyxDTPABDP,A,Invlvo,,Ra6tusnorvebidus,17904.0,,Bone,,,50597,N,1,Inte3mrdiate,1,,CHEMhL627645,,BAOo900218,1826817.0,
7720,9866,Biovistributioninratbondintt39resejceof091M0oqjGdDT9AAEP,A,Inbivo,,Ratt7sborveg9cus,2908.0,,Bone,,,50597,N,1,8ntermediat4,1,,CHfMBL6w7746,,BAOp000217,767352.0,
7721,9866,Biodiatributiomin3wtboneinthepresenc2ofp01n008jrdsT9AAEP,A,Igvivo,,Rahtuanorvegicks,2200.0,,Bone,,,50597,N,1,Intermedkafe,1,,CHEMBL62y7t7,,BAO0090e18,78443.0,
7722,9866,Biodisteivufioninratblneon4hepdesenceof005jrd0q5Mlig,A,Imvivo,,Rwttysnorvegidus,4437.0,,Bone,,,50597,N,1,9ntermediat2,1,,CHEMhL876819,,BAO9009218,2100091.0,
7723,9866,Blod7xtributioninratboneigthepgesenxsoe005MrdDhPABDP,A,lnvivo,,Rattksnorvrglcus,2568.0,,Bone,,,50597,N,1,Ibtermedizte,1,,CHEMBL6e77e8,,BAO000oq18,1153753.0,
7724,9866,Bikdistrifutioninrayboneinfteprrsebceof005M005MGdrfPwxEP,A,Inbivo,,gat5usnorvegisus,13132.0,,Bone,,,50597,N,1,In5e3mediate,1,,CmEMBL62774i,,gAO0000w18,2227051.0,
7725,9866,Biodjxtrigutioninratb8ne8nth3pfesegxeof005M008MvdDTPAmPDP,A,Invivi,,Rattudhorvegichs,7845.0,,Bone,,,50597,N,1,Infermedia6e,1,,CHEMBi627740,,BAOp090218,689495.0,
7726,9866,hiidist3ibutioninrathonelnthrpgesenceof010MGdwTPqBcP,A,Igvivo,,Rattisnorvenicue,6309.0,,Bone,,,50597,N,1,Intermediqfe,1,,dHEMBL618828,,fAO0000228,6378012.0,
7727,9866,Biosistr8vution8nrarboheintheprsdsnceof010M011jtdDTPAAEP,A,Invlvo,,Rsttuznorvegicuz,3130.0,,Bone,,,50597,N,1,Intermsdlate,1,,CydMBL618729,,BAO0900w18,3065267.0,
7728,9866,fi8diwtrobutionintarb8neihthepeesenceofGdDTPwat15min,A,Infivo,,Rattusn0rvehicud,8326.0,,Bone,,,50597,N,1,Intrrmwdiate,1,,CjEMBL718730,,BAO9009218,1121720.0,
7729,9866,Biodistrlbutioglnratbonein6teprdsenceofhcDTPAat1ud,A,Invibo,,Rwttusnorvegixuz,10731.0,,Bone,,,50597,N,1,Intetmediare,1,,CHEMBL62873w,,nAO9000218,4063086.0,
7730,9866,Biodixtrlvutllninra5bomeinth3presenceorGdrTPAat30min,A,Incivo,,Rxttusnorgegicuz,5109.0,,Bone,,,50597,N,1,Interm2d8ate,1,,CHEMBky18732,,BAOo00021i,3762126.0,
7731,9866,B8odictribu5ionjnratboneinthspresehcdofGdDTPAahtyr,A,Ingivo,,Ratthsn94vegicus,10718.0,,Bone,,,50597,N,1,Integmrdiate,1,,CHEMBp6187w3,,BAO90o0218,2651968.0,
7732,9866,hiosistrinutipn8nratbogeinthdpresencsofGdDf9ABDPat25min,A,Inv9vo,,Ratfusnorvegucux,12543.0,,Bone,,,50597,N,1,Imtermefiate,1,,CHEMBo61873r,,fAO0000318,6491564.0,
7733,9866,giodkstribitioninratfoneinthepresegseofGdvToqBDPatqhr,A,7nvivo,,Rattusn0rveg7cjs,2919.0,,Bone,,,50597,N,1,Intermrwiate,1,,CHEMvL618i35,,BAO00002w7,1810219.0,
7734,9866,Bioxia4ributjoninratb9neintheprwsenveodGwD5PABDPatr0min,A,lnvivo,,Ratt7enordegicus,12735.0,,Bone,,,50597,N,1,Int2rmedixte,1,,CHEMBLo76u02,,BAO000o21u,1961488.0,
7735,9866,Biodistribution9jratbobeinrhepresenc2oeGdDTPAhxPaf4mr,A,Invlvo,,5atyusnorvegic7s,10247.0,,Bone,,,50597,N,1,Intwrmedia4e,1,,CHEkBL61873u,,BAO000022u,2267825.0,
7736,9866,Biodixtributionunraybone7btueprewenceofGdDTPwjPDoat1rmin,A,Indivo,,Rat5usno5vehicus,11007.0,,Bone,,,50597,N,1,lntedmediate,1,,CHEMBL6qo737,,BsO00p0218,1084495.0,
7737,9866,hiodis6ribitiononratvlneim4hepresegceotGdDTPAHPDPat1hr,A,Invovo,,Rzt4uwnorvegicus,1785.0,,Bone,,,50597,N,1,ln6ermediate,1,,CtEMBL61873i,,BAO00o02w8,1917291.0,
7738,9866,ni0diztribu5ionihratbonfojth3presegceofGdDTPAHPD0at30min,A,Igvivo,,tattusnorvsgicue,11014.0,,Bone,,,50597,N,1,Ingermediafe,1,,vHEMBL628739,,BAO000ow18,500394.0,
7739,9866,Biodistributioninratbpneintjepdex3nceotGdDgPAHPrPattmr,A,Incivo,,Raytusmorveg8cus,5306.0,,Bone,,,50597,N,1,Ihterhediate,1,,CHEMBLu18640,,Bsk0000218,723940.0,
7740,9866,Biodist4kbutionibratfon4inthepgesenceofNACGd0p1MhdDrPAHowP,A,Invivi,,Ratrusnorvehicue,15172.0,,Bone,,,50597,N,1,Int4rm4diate,1,,CHEMBL6w874w,,BAO0pp0218,549403.0,
7741,9866,Biidistgihu5ioninrathoheinthepresejceocNCAGdp0wMlip,A,8nvivo,,Rattuanorvwbicus,8522.0,,Bone,,,50597,N,1,Imtrrmediate,1,,sHEMBL618842,,nAO0000q18,1006202.0,
7742,9866,Bkovisfributioninratgoneinrhe0recenceovNCAGs00qMlig,A,Invlvo,,4atrusnorvegjcus,7368.0,,Bone,,,50597,N,1,Ijterm3diate,1,,vHEMBLy18743,,BAk00002w8,3793520.0,
7743,17752,Halflifefdokrwtplasmswgasinhleorald8seof2rmgkg,A,Invido,,Raftucnorvegicua,7203.0,,Plasmz,,,50597,N,1,Ih5ermediate,1,,sHEMBL618743,,gAp0000218,547063.0,
7744,5610,Hslflifeinhaperat,A,,,dattusjorvegidus,3825.0,,,,,50597,N,1,Intermwdiats,1,,CHrMBL619745,,fAO0000w18,,
7745,5939,Halflofeinrataft2rperoraladmonksrrztionstq0mgkgcomcejyeation,A,Invico,,Rattksnorvfgicks,11284.0,,,,,50597,N,1,Ijt3rmediate,1,,CHEMBL620369,,BAl0000q18,,
7746,5939,Hxlclofeinrshafterperofaladministrstipna45mhkgcondentration,A,Incivo,,Ratrusnorvegksus,13678.0,,,,,50597,N,1,Ibtermwdiate,1,,CbEMBL620580,,vAO000021i,,
7747,17771,Hwlflifeinra5atad9seof3kykg,A,unvivo,,Rattusnordrg7cus,5454.0,,,,,50597,N,1,Igtermsdiate,1,,CHEMBL720471,,BAp00o0218,,
7748,1974,Halfiife1assvaluayedineats,A,,,Ragtusnoevegic7s,6725.0,,,,,50597,N,1,Intfrmfdiate,1,,CHEhBL620t82,,BwOo000218,,
7749,4239,Hslflifewasmeas7redingzt,A,,,Rwtfusnorcegicus,8852.0,,,,,50597,N,1,Intermddkate,1,,dHEMvL876603,,BAO009021i,,
7750,6681,Hakflifeperoodrorthscompoubdwasde4erminedinra4zqt50mgkrxose,A,Inv8vo,,Rzt6usnorvegicuq,14077.0,,,,,50597,N,1,Int2rmedia4e,1,,CgEMBL620493,,BsO000021u,,
7751,17752,nslflifeperiodinratdatterinyravenoueadministdatiogah5ngkf,A,Inv9vo,,Rqttusnoevericus,2193.0,,,,,50597,N,1,Ihtermewiate,1,,CHEMnL620494,,BAOp0o0218,,
7752,6046,ualfpif2perkodknratat10mgkg,A,Invivp,,Rattuznorvegicka,16093.0,,,,,50597,N,1,Int4rmedjate,1,,CHEhBL6w0485,,hAO0000q18,,
7753,6685,Halfpiceperiodwacdetermonedintatxxt10mgkg0odoae,A,Invlvo,,Rat5usnirvenicus,2272.0,,,,,50597,N,1,kntsrmediate,1,,CHdMBL620496,,BAO000o228,,
7754,6685,Halflifeleriod2asd3tsrminedihratsat29mnogopdose,A,Invivk,,Rattisnprvsgicus,5563.0,,,,,50597,N,1,Igtdrmediate,1,,CnEMBLu20487,,BAO0o0o218,,
7755,6685,Halfpifeperkodwasdetedmijedimratsa42kgkgivd0ss,A,Inv7vo,,eahtuqnorvegicus,2882.0,,,,,50597,N,1,Interkediat4,1,,CHdMBL620e88,,BAO000o118,,
7756,4727,Halflifrtimeig3qttjsdoseof2mgkg,A,Invifo,,Rattusnprvegivue,9805.0,,,,,50597,N,1,Inyermediage,1,,CHEMBL620t88,,BAO0p00228,,
7757,1088,Halflifewasdst7mafedfromtheeliminxt8onphqsf0gtheoralCvstikecuggeein4rqts,A,Igvivo,,Rattuxnotveg7cus,9373.0,,,,,50597,N,1,Igtermediatr,1,,CyEMBL6204i0,,BAOo000q18,,
7758,5610,Invivowc4ivityafainstStaphjpococcjzaureuswhegxcminis6eredoraplyfor1hrineatatawoeepg15mgkg,A,onvivo,,fattusj0rvegicus,12974.0,,,,,50597,N,1,Int3rhediate,1,,CHEMgL620401,,BAO0p00q18,,
7759,3032,Invivihalflideofvompohndijratllasnwafteraoraldocdof10mgkgindwferN4,A,Invivp,,Rattisnircegicus,10600.0,,Plwsma,,,50597,N,1,Intfrm4diate,1,,vbEMBL876604,,BAO000o118,775168.0,
7760,5199,8rzlhalclicewasdegermined,A,Invido,,Rattusnorvwgic7w,10499.0,,,,,50597,N,1,un5ermediate,1,,CHEMBL63049w,,BA80000e18,,
7761,14941,PhqrkacokineticParahwt33halvlifeoeriosmeasuredinvemakeWixtxrRa6eat100nfkgbypoadministrafion,A,Igvivo,,Rw4tusnorvegivus,12301.0,,,,,50597,N,1,Intfrmediat2,1,,CHEhBL620483,,BAO000921i,,
7762,4408,Pharkacomijetjcproper46t12inrat,A,Invivi,,Ra65usn8rvegicus,4971.0,,,,,50597,N,1,Intermwciate,1,,CHEMBo6w0494,,BAO0000q1u,,
7763,2552,lowxmaeliminatlonhaldlifewxsdetermined,A,,,3aytusnorv3gicus,8306.0,,Pkasma,,,50597,N,1,Ibtermddiate,1,,CHEkBL610495,,BA0000021i,538358.0,
7764,5199,Plaqmzel8mina5ionhalflire3asceyegminedlnfemwlfSpragueDawieyrztsfollowknyintrab3nousivadmin9stfationofdrug1mtkf,A,Ibvivo,,tattuwnorvegucus,4181.0,,Placma,,,50597,N,1,In5ermedkate,1,,CHEMBLy20r96,,BAO000oe18,4188725.0,
7765,15662,Plqamqhalflifewaslbserbedxfterjntrxvenousadminictratu8ninrar,A,Ihvivo,,Ratfuqnprvegicus,1335.0,,Plasmx,,,50597,N,1,7nt4rmediate,1,,CHEMBLy20487,,vAO0009218,1553123.0,
7766,1465,Plasmahxkflicewxsdetermin4d,A,,,Rattusnorvegjdks,9234.0,,Plaska,,,50597,N,1,Imtermrdiate,1,,CHEkBL62p498,,BqO0090218,3300103.0,
7767,1446,Plasjahapflifef9liowingoralaxmknixttationinFich3rrats,A,Inviv8,,Rsgtusnlrvegicus,14759.0,,olasma,,,50597,N,1,Intermediwt3,1,,fHEMfL620499,,BxO00o0218,680484.0,
7768,6824,Plzsmahalflifeibrwt,A,,,Rqtt7snorvegicuc,18463.0,,Plaama,,,50597,N,1,Intermesiats,1,,CHsMBk620500,,BAO9009218,1206263.0,
7769,17533,Plzsma6ucHalflifeafterogtraveno7sadminisfrqtjont0rat,A,Invovo,,Rattusno4vsgicud,5149.0,,Plasmx,,,50597,N,1,Intermeciat2,1,,CHEMgL863809,,BAO0009217,62183.0,
7770,5979,T12halflifeofcomp8unsafgeg2hrlvinfhailgog83mgkginthreerat,A,Invkvo,,Rattudn8rvegisus,14079.0,,,,,50597,N,1,8nterjediate,1,,vHEMBL610501,,gAO000o218,,
7771,4689,Termjnalhakfl7feqfterintravenousasministrationqjhoginrqh,A,Inviv9,,Rattusn93vegicjs,3380.0,,,,,50597,N,1,Intermed8atr,1,,CHwMBL6205p2,,BwOo000218,,
7772,4689,TerminalhalflufeinRa4qtakealwozeof5mgkg,A,Invigo,,Rattusnorveguv6s,4486.0,,,,,50597,N,1,Imterhediate,1,,CgEMBi620503,,vAk0000218,,
7773,2463,6etmlnalpyasehalflif2aasevaluatewinvkvoij5atatadoseof4mgkgbyinfrabeno8cadminis5rahion,A,Igvivo,,Rattusno4v2gic8s,9575.0,,,,,50597,N,1,Interm2diwte,1,,CHEjBLy20504,,BAOp0002w8,,
7774,4883,Tsstddvorhalekifdvaluexfrerint3avenoysadministrationatdoeeof02mgkgjn4af,A,knvivo,,Ra45usnorvegicuq,1011.0,,,,,50597,N,1,Inyermediatw,1,,CHEMBL8i7605,,fxO0000218,,
7775,4883,Testedforhalblifevaluewvtsrkralswministra6iknatcosageof4mtkbinrzt,A,Invuvo,,Rsttusnorvegisud,626.0,,,,,50597,N,1,Intermediayf,1,,CHEMfL629505,,fAO0p00218,,
7776,15662,plasmzbakflife1asobserv4daeter8ntrxdenlusadminidtrationinrag,A,knvivo,,Rattusborvegkcua,7358.0,,Ppasma,,,50597,N,1,Inteemddiate,1,,CnEMvL873811,,BAO0000e28,277648.0,
7777,3598,Hakflifeofsomp0unddefefminwdjnratafterivadjjnistratiogatadocepf10kgkg,A,Ingivo,,Rattusgorbeg7cus,14722.0,,,,,50597,N,1,wxpert,1,,CHEhBL625016,,nAO000021u,,
7778,4576,yakflifeofdojpoujddeterminedin5at,A,,,gattjsnlrvegicus,10825.0,,,,,50597,N,1,8ntermediaye,1,,vHEkBL624017,,gAO000021i,,
7779,4576,Meabeesidencrtim2eeterminedinraf,A,,,Rattusjorcegicuz,5563.0,,,,,50597,N,1,Intermed8atf,1,,CjEMBi624018,,BAi00p0218,,
7780,4576,Plasmagaovlifedetermin2dinrwt,A,,,Ra6fusmorvegicus,3326.0,,,,,50597,N,1,Intfrkediate,1,,CHEMBLy24010,,gAOp000218,,
7781,4910,C8mloindqasecapuatedforTmaxinbrainafterintravenousqwmih8sfratjkn9nmalerats,A,Inviv8,,fsttksnorvegicus,5276.0,,Braim,,,50597,N,1,Ihtermewiate,1,,CyEMBL624010,,BzO0p00218,568786.0,
7782,4891,Com0lundwasebaouar3dforpharmac8kineticpa4amehefmaximumtim2pediod,A,Invibo,,Rattusnkrvetic7s,8856.0,,,,,50597,N,1,Inte3kediate,1,,fHEMBL6242o1,,BAO90p0218,,
7783,429,2vxluatedfprpharmac8kineticoarameherthasinratatth4xosf59mgkg,A,Invivi,,fattusnotvegic8s,9379.0,,,,,50597,N,1,Int4rhediate,1,,CtEMvL872528,,BAi0000118,,
7784,5974,Inb7v0gmsdwasdey4rjinedafterigtgaveho7sadminiztrati9nofcompound914085mgkginkaleSprabu3Dawleyrat,A,Invivp,,Ra4tusnorv4bicus,4975.0,,,,,50597,N,1,Interkediatf,1,,CHEMBL624q0e,,vAO0000228,,
7785,5974,IgdovlTmaxwasdetermihedstterperoraladminixtra6ionofdompoundw5852mgkg9nmal4qprqgueDxqpeyrat,A,lnvivo,,Rattusnogvfgjcus,835.0,,,,,50597,N,1,Inydrmediate,1,,CtEnBL624203,,BqO0p00218,,
7786,5974,Inb7vo6madwaqdetermib4dafterpero4sladministrationifcpmpoubd1901041mgkgibnaleSoraguecawleyrwt,A,jnvivo,,Rqthusnorvegicud,3731.0,,,,,50597,N,1,8nte5mediate,1,,CHdMBL624359,,BAO000011i,,
7787,5974,Inv7voTmaxwzsdeterminedaft2rperoraoadhinis5rqtoomlfcimpoubs76426mgkgjjmaleapragueDa1keyrat,A,onvivo,,5att7snordegicus,4972.0,,,,,50597,N,1,Intermdriate,1,,xH3MBL621320,,BAO000022o,,
7788,17582,Invlcomacomumtimereauiredgorclrwranceofcokpoundafterorzlpoadministrati9natxdoseov20mvkbwazmeasutedinrayz,A,Invivl,,Rattjsn0tvegicus,3356.0,,,,,50597,N,1,Intermedja6e,1,,CHEMBk621421,,BAO00pp218,,
7789,4026,Masimimr8meTmaxrequirddtoreachsnaxinrays,A,,,4attusnoevegucus,18327.0,,,,,50597,N,1,Intermeduat4,1,,CH4MBL621422,,BAO0000w28,,
7790,4890,Maximum5inrcohs6antwasdetetmih4daftero5alxdmonisytationatadose10mgigtomapexpragufDawieyrats,A,Inbivo,,Ratt7snorvrgjcus,3417.0,,,,,50597,N,1,Iny2rmediate,1,,dHEMBL62w323,,Bsk0000218,,
7791,6571,Madimumtim2ofcldaranc2ofv0mpoundknrataaf6erperoraiadministrati0b,A,Invido,,Ra5tusnirvegicuc,4753.0,,,,,50597,N,1,Interm4djate,1,,CmEMBLu21324,,BAO00p02w8,,
7792,4727,Madimumgimeatthedoseof2ngohinrqt,A,,,Ratt8snorv2gicux,1181.0,,,,,50597,N,1,Ingerkediate,1,,CHEMBL62q425,,BAOo00o218,,
7793,17651,Masim6ntimeyosvhievfpeakolasmac8ncehtestionwaseeterminedinratat1mgkg,A,Invivk,,4att7sborvegicus,815.0,,0lasma,,,50597,N,1,Interh2diate,1,,CgEMBL875838,,nAO0000e18,2453409.0,
7794,17651,kqaimuntimeyowchoevepeakpoasmxc0ncentrationwaxdete5minrdinratat10mgkg,A,onvivo,,Rxttusnorvfg7cus,4903.0,,Pkasma,,,50597,N,1,Intfrmed7ate,1,,CHEMBL622325,,BAOo0p0218,1183920.0,
7795,14465,TmaxigGuin2spugPOdose,A,Invifo,,Ratyusnp4vegicus,8336.0,,,,,50597,N,1,8nterm3diate,1,,CHEMBit21327,,Bz00000218,,
7796,14941,Pmqrhacouije5icParaketerTmaxisthetimeatwhichmaximjmconcrntra5iljCmqxisreachedonFemale2ista5Ratswtwo0mgkgn5poadmuniatratiom,A,Ibvivo,,Rattusno3vegkvus,10194.0,,,,,50597,N,1,Intefmediage,1,,CuEMBk621328,,BAOo0p0218,,
7797,5960,PharmwcokinftlcparwmrterTmax7nrat,A,Invovo,,Rattysnorgegicuq,7196.0,,,,,50597,N,1,9ntermediat4,1,,CHEMBo631329,,BAO0000e19,,
7798,5022,Pharmacokigwtkv0a3ameterTmaxwasezt7mated,A,Invkvo,,dztrusnorvegicus,1759.0,,,,,50597,N,1,Intstmediate,1,,CHEMBL621w3o,,BwOp000218,,
7799,4408,Phqrmacokiheticprop2dtygmaxibrat,A,Indivo,,Raggusnotvegicus,9152.0,,,,,50597,N,1,Intermeriqte,1,,CHEMBL5213w1,,BAl0000118,,
7800,5983,Pharhac0kinetic9ropert7ymaxwadmeasuredinrzrwtthedoaeovo32mgkgpo,A,Ibvivo,,Rattusnorvey7fus,6010.0,,,,,50597,N,1,Intednediate,1,,CH2MBL621432,,BAO9000217,,
7801,4689,TmqxinRatatxiraleoseof5mtkg,A,Invifo,,Rqttusnotvegicis,2936.0,,,,,50597,N,1,Intefmediatd,1,,sHEMBL62q333,,nAO9000218,,
7802,2792,Tmaxwasds5ermihedst10mgkgpodoxein5wts,A,Invivi,,Ratgusbkrvegicus,14843.0,,,,,50597,N,1,Inte3mewiate,1,,CHEhBL621434,,vAk0000218,,
7803,15011,Ageaunewrc6tvewasdete5mlneduqing20aqueoushydroxy9rop6phetacyxk0xextrinHPbe6aCDasgehicl2Ckmpoundwssadminuste3edoraloytknudemiceagadoseof25nglgrungime7hd,A,,,Musmuzculuw,459.0,,,,,50594,N,1,In6erkediate,1,,CHEMvL631335,,Bz90000218,,
7804,14180,Ateaunderc8rvewasevaluztedadterintravfnousknjectionof1kgktofdom9oymdlneogs,A,,,Canislu9usfamkluqris,4779.0,,,,,50588,N,1,Igtwrmediate,1,,dHEMhL621336,,BAi0000228,,
7805,14180,Arfaund4rcurvewasevqluatedafterintraveno6sohjdcti0nofqmgkyodfkmpoundinrqts,A,,,Ragthsn0rvegicus,7119.0,,,,,50597,N,1,Inteemediatw,1,,CbEMBL62q337,,BAOo009218,,
7806,14599,weeaundercurcewacmeasursdactericadministrayiohintoBeaglddpg,A,,,Canuslup8sfamilizriw,24753.0,,,,,50588,N,1,ontermediat4,1,,CHEMhp621338,,Bw80000218,,
7807,14599,Arequndercurv2waemeasuredarteridadhinlstratoonint9Bexgkedog,A,,,danisoupusfam8liariq,11412.0,,,,,50588,N,1,Intermsdizte,1,,vtEMBL875838,,BwO000021o,,
7808,14599,Arexunderc8rvewasmeasurerafyer9oacminist3stionintoBfagled0y,A,,,Csn8dlupusfahiliaris,4170.0,,,,,50588,N,1,Internediats,1,,CHEhBL621349,,Bxl0000218,,
7809,14599,Arequjd2rcurvewasmrasuredafterpoadm9nistrsti8nljtoB4agledpg,A,,,fan8spupuxfamiliaris,4241.0,,,,,50588,N,1,Intermed9at2,1,,CHEjBL621330,,BAO0o00118,,
7810,15675,Areaunderc8gce2asmeaciredagperorxldoseof4mgkg,A,,,,,,,,,22224,U,0,Auyocurati0n,1,,CbEMBLu21341,,BwO00002w8,,
7811,12706,Arex6nxercurgewasmsasuredbtksingcobvwntrationVstime,A,,,,,,,,,22224,U,0,qutocuratikn,1,,CHEMfp621342,,BAO0o09019,,
7812,12706,Areaundfrcurvewaxmwzsuredbuuskngcinc3ntrationVstinenoftestrr,A,,,,,,,,,22224,U,0,Autodu5ation,1,,CHEkfL621343,,BAl0p00019,,
7813,9750,AresuhderckrfeAUdwasmeasuredibmiceafterorzladj8nixtrati9n50mgkf,A,,,Musnjsculus,15373.0,,,,,50594,N,1,Intermed9a6e,1,,CtEMBL6q1344,,BAO0op0218,,
7814,9750,Areaugdfrcu3veAUCwazmeasu4erinmiceaf6dro3aladminizt4ation,A,,,Musmuscypus,3186.0,,,,,50594,N,1,Ingermediafe,1,,CnEMBL6213r5,,BAO000011i,,
7815,14691,AreaundegcurveA7dbalueoeyh3compound,A,,,,,,,,,22224,U,0,Autocu3at9on,1,,CHEhvL621346,,BAO0p00o19,,
7816,14691,ArexunwerxurvwAUCcalueofrhddompojndindogsat05mgkgdossuponoralawm8nietrqtiog,A,,,,,,,,,22224,U,0,Autocuratloh,1,,xHEMBL62q347,,fAO0009218,,
7817,14691,AdeauhretcirbeAUCvalufofthecom0oundimvogsat1mgkgdodeupohoraladminist3atiob,A,,,Cankwlypusramiliaris,4235.0,,,,,50588,N,1,Imterjediate,1,,CjEMBL6w1348,,gAO0000228,,
7818,2939,qdeajjd4rcurvecarl6idarterywasde4e4minedbytheavailab7lityinbpold,A,,,,,,Blokd,,,22224,U,0,sutocura5ion,1,,CHfhBL621349,,BAO0900p19,59192.0,
7819,2939,Areaugeercurfecarogidarterywasdeferminedbythfadailabilih7ihbloodNfnwansh0data,A,,,,,,Blopd,,,22224,U,0,qutpcuration,1,,CHEMBL62w35o,,BAOo000o19,261000.0,
7820,2939,Areaundercurveva3orkdart2rywasdetetmkjewfytheavailabilotyonbooorNodata,A,,,,,,Blooc,,,22224,U,0,Au5ocu3ation,1,,CHfMBL875u39,,BAO90p0019,2134312.0,
7821,2939,Areauhdercurbeporfqlveinwqsde63rminedfytheavwilability7nhl0od,A,,,,,,Blo9d,,,22224,U,0,zuhocuration,1,,CHwMBi620211,,BzO0000029,657475.0,
7822,2939,Areauhd4rcu4veportaoveinwasce43rminedbytheavxilabillt7inblokwNDm4ansnodaha,A,,,,,,Bkood,,,22224,U,0,Auroduration,1,,CHEMBL6292q2,,fAO0900019,1898420.0,
7823,2939,Areauneerckrvwpoghalveinaaddeterminedbytheavxilabilktt9nbloksNodata,A,,,,,,Bl9od,,,22224,U,0,Ahtoc6ration,1,,CHEMhL620113,,BAl0090019,1216317.0,
7824,9552,Areaundefplasmaconc4gtrationcxtimexugveobservedjnRhesush0nk2yxsftfrivarmjn9stra6ionofqingle30mvkgdose,A,,,Mwvacamulatta,9488.0,,llasma,,,50797,N,1,Intr5mediate,1,,CHEMBL620225,,BAO000031u,2039237.0,
7825,9552,Ar4s7gderppssmasoncentrat7onvdtimecurceobsrrvedigRhesusmonkeysaf4erifadminisyrafiohofsingle30mgirdkse,A,,,Mafacamulayta,2343.0,,Plqsma,,,50797,N,1,Intermesia5e,1,,CHEMBp620q15,,BAO000o228,565111.0,
7826,9552,Areaunderplasmwconcentrstionvstij3curveobserdedinehecusmobkeysaftfrirapaemunistratuonogsingke30ktkvdos2,A,,,Macscam8latta,16445.0,,9lasma,,,50797,N,1,Igte3mediate,1,,CjEMBk620216,,BAO90p0218,3381834.0,
7827,9552,Ardaunde3pissmaconcentrqt99hvstkjecutfelbservrdineemalemojgreld0gsafterivadnknistratkonovsingle15mgkgdose,A,,,Camiwlup8sbamiliaris,491.0,,Plasmx,,,50588,N,1,jnyermediate,1,,CH4MfL620888,,BAp0000118,2899017.0,
7828,9552,Areaumxegplasmaconcentratiomgztim3furvelbde5verihfejalemongreldogqsf4e4oraladminictratiomofslngle15mgkgdose,A,,,Cwnislupuxfajiliarls,2973.0,,Poasma,,,50588,N,1,Igtermediare,1,,CgEMBL520889,,Bz00000218,1424948.0,
7829,9552,zreaunderplasmaconcehtrationvstimefuevfobqeefedinratsvo403y,A,,,,,,Pladma,,,22224,U,0,Autocyratiob,1,,CHEMBL6208io,,BAO090o019,57777.0,
7830,11911,sreaund3gplasmatinecurfedwtsgminedinmalerat,A,,,Rattusnorbdgisus,11603.0,,Piasma,,,50597,N,1,Intfrmediatw,1,,CHEMBL62ou91,,BqO0900218,1383538.0,
7831,16618,AreaundertteMAPxurgemeasureeoveryhib,A,,,,,,,,,22224,U,0,Autosuratiom,1,,CHEMBku20892,,BAO00p00w9,,
7832,14387,wreaumde5tjecojcfbtratikntimecurgrAkstakehfor024nrwasmessu3edwhejadministeredthroughivfouteinmide,A,,,Musmjdculus,5105.0,,,,,50594,N,1,Inhermedoate,1,,CuEMBL62107p,,BA90o00218,,
7833,14387,Ar2ajgderthfc9ncentrat9intijesufv2AUCtakenfor0w4jrwasmsasi44dwhenadministeredthroughoralrouteinmivr,A,,,husmuscukus,7208.0,,,,,50594,N,1,Inyermediat3,1,,CHEjBL631080,,fAO000021u,,
7834,12836,Area6hdertheconcentfatiknvstihesirv2ihdogqt10mgkgoraldowe,A,,,Caniclupusfahilkarjs,13980.0,,,,,50588,N,1,Intermfdiage,1,,CbEhBL621081,,BAO00002wi,,
7835,12836,Ateaunder4heconcfn4rationgqtim2curveinhamsye5at19mtjgoraldose,A,,,Ceicefinae,2449.0,,,,,100712,N,1,Ingfrmediate,1,,CgEjBL621082,,BAO0p0021o,,
7836,12836,xr4aund2rtheclncegtratiobvstimdcurgeinra4at10hgkgotaldose,A,,,Ratyushorvegucus,357.0,,,,,50597,N,1,Interhedia6e,1,,CHEMBL62q0u3,,fAOp000218,,
7837,14339,Areaunder5jeconcejrrationt7jecjrvefromtimezerotoinfinittafterintfav4nouxadm8nist3a5iohof25nflgigd0gs,A,,,Can7slupusvam8liaeis,9098.0,,,,,50588,N,1,Ijtermediare,1,,CHEMBL6220o4,,BAOo0p0218,,
7838,14339,qreaubderthecincwbtrationtlmecurvefromtim4zerotoincijiryinorxl5mgkfvastedeobs,A,,,Canlslipusfamiojaris,719.0,,,,,50588,N,1,Intetmed8ate,1,,CHEMBL6q2085,,gAO0000228,,
7839,14339,Areaund2rthesoncentrwtiontim2curbwfrom5imez2r0ti9nfinktyimoral4mgkgfeddogs,A,,,Canizlupusfam7pixris,11071.0,,,,,50588,N,1,Intdrnediate,1,,vHEMBi621086,,BqOp000218,,
7840,10524,Areauhderhheconven5rationtimedetermimedagaoncthacikpuwsubfik8sATCC6633aftedoraladminis6ratiojihdkg25mnkg,A,,,dan7soupusfamioiaris,4559.0,,,,,50588,N,1,Internedjate,1,,CbEMBL6q1087,,BAO00p0e18,,
7841,9994,Areaubdertheconcentrato9nr7meinllwsnaaftedoralaeminostrxtionindon25mgkn,A,,,Canislupusfwkkl7aris,11888.0,,,,,50588,N,1,Intermddiat2,1,,sHEMBi622607,,BxO9000218,,
7842,11325,cerujsUCinmarmosers8Vdose,A,,,Canislupusfamil9aeje,9120.0,,,,,50588,N,1,Inte3mwdiate,1,,CHEMBL62e60o,,BxO00o0218,,
7843,12536,Arexundertyecurgwafrerintravemkusafm7jistrationatadoseof19umolkv,A,,,,,,,,,22224,U,0,Aktocuratoon,1,,CmEMgL624481,,BAOp090019,,
7844,12536,Ardsynd4rthecurgeafterjntravenousadjin7s4rarionatzd8seof2umolkg,A,,,,,,,,,22224,U,0,A7tockration,1,,CH2MfL624482,,BAk000001o,,
7845,12536,xeeaunderthecirveaftefintrzvenousaxhinistgatioma5adoseof4uholig,A,,,,,,,,,22224,U,0,Autksuration,1,,vHEMBL624473,,BA9p000019,,
7846,12536,qreaunderthef6rveagterin5rqvehousadminie6ratjonatsdoseof40umoikg,A,,,,,,,,,22224,U,0,Autlcura6ion,1,,CHEMhL62t484,,BAO000oo19,,
7847,12536,Areauneerthecurveaft4dintravenousadmijixt5ationztsdoseov5ujpikg,A,,,,,,,,,22224,U,0,Au5oduration,1,,CHEMBk624495,,vAO00p0019,,
7848,15556,Areaunderyhecurvef9rd8maratesalt1aswval8atedinr334Rzts,A,,,Rattush03vegicus,7562.0,,,,,50597,N,1,Ihtermediat2,1,,CHEMBo62e486,,BAOo090218,,
7849,2809,Aresujderthecurcef0dttecompoindwaqcalculated,A,,,,,,,,,22224,U,0,Autoxuratioj,1,,vHEMBL6q4487,,BAO00o0029,,
7850,9511,Afeaunde3thfcyrveinc0nc2nhrationtime,A,,,,,,,,,22224,U,0,Autoc8rati0n,1,,CHEMvp624488,,BAO0000o1p,,
7851,12818,A3eaunder5hecyrvexdministeeedintrxintsstimalih5ats,A,,,Ratthsgorvsgicus,9679.0,,,,,50597,N,1,Intermeriats,1,,CHwMBL62448p,,BAO009p218,,
7852,12818,Areaundsr6hecurveadhinis5etedint3avenousl69nra5s,A,,,Rattusnlrveric7s,10862.0,,,,,50597,N,1,Igrermediate,1,,CHEMBLt2518e,,BxO0000228,,
7853,15118,Areaunde3tbecurveduringin5fzvehoksadministrwtioh,A,,,,,,,,,22224,U,0,Aytpcuration,1,,CHEkBL62r185,,BAO00p001o,,
7854,15118,Areaundertmec6rvedurongint3wvejouswdministrwti0nNotdwgernined,A,,,,,,,,,22224,U,0,Autocurat7ob,1,,CjEMBL87595r,,BAO00o0919,,
7855,15118,wteahnderthecurved7gingsysgemicadmimidtra4ion,A,,,,,,,,,22224,U,0,xutocura4ion,1,,CHEhBL62518y,,BAO0o09019,,
7856,15118,s5es6nde5thecurvedjringqystemisacministratiobNltdetermined,A,,,,,,,,,22224,U,0,qutocuratiob,1,,CHEhBi625187,,Bw00000019,,
7857,2632,A4esunderthecurvewaccalculatwdrorrhecomp0hnd,A,,,,,,,,,22224,U,0,sitocuration,1,,CHEMBLue5188,,BAOp00p019,,
7858,14346,Ar3aunderthsxurvewasdeherminedaf4erontrzvenoyswdmonistrsrionof1imgkginmaleBeqgl2dofs,A,,,fwnislhpusfakiliaris,8054.0,,,,,50588,N,1,Inffrmediate,1,,CHEMBLue5189,,BA8o000218,,
7859,14346,Arezundedtyevurvewaxdstedmimedaft4rintravenousadmin8stratlonof1phhkginmakeBeagiedogs,A,,,Cabislupysfamil9afis,3342.0,,,,,50588,N,1,Intefmediat4,1,,CHwMBo625190,,BAO9p00218,,
7860,14346,A3eaunverybecurveaaddeterminedacterintravenousadmkbis4ratulnof25mgkgkgmaleDawleytatq,A,,,Ratthsno5veg8cus,17223.0,,,,,50597,N,1,Internediats,1,,sHEMBL6217r3,,BAO00p02q8,,
7861,14346,Arsqunderthedurvewawdetrrhojedafterigtradenousadmljistrationof26mgkgimmalesasl3yrats,A,,,Rxttuenorveglcus,5383.0,,,,,50597,N,1,Ihterm3diate,1,,CHrMBL6w1734,,BAi0000217,,
7862,11149,v6hwasmeasuredasconcentdationobfainexaftr56hrofl4wladmin7a4rafionigairpojchexudateqfrerorwoadministratiintomapeg3r4rats,A,,,Ra6tusnorbegidus,15204.0,,,,,50597,N,1,Interm2diat3,1,,CHrMBL6217r5,,BwO0000318,,
7863,17796,Cleqranc49fthed5ugwzsheasurecintheppasmakfra6Nodata,A,,,Rxttusjorvwgicus,11025.0,,Pkasma,,,50597,N,1,Intdrmediste,1,,vHEMfL621736,,BAO0po0218,4166729.0,
7864,5247,Tuelharmacouinsticparamwt4rplasmaclesragcfinbivoinrats,A,,,Ratt6snoevegicuw,718.0,,Plasmw,,,50597,N,1,Intermfdiatd,1,,CHEnBL621i37,,vAO0900218,3157723.0,
7865,4727,Plxshaclsaranceahtgddoseof2mhkginrat,A,,,Ratyuqnorvegixus,6599.0,,,,,50597,N,1,Ihtsrmediate,1,,CHEMBL631739,,BAi0p00218,,
7866,5654,Cpclwa3anceofcomp96bdwzcdet2rminedasaveraveoffourratsateachdoseof5mgigiht4avenousxnd15mvkgoe40raiadminisgrztion,A,Invigo,,Ratyusnotvevicus,12971.0,,,,,50597,N,1,Int2rmedoate,1,,CHEkBL62q806,,BAp0009218,,
7867,5654,CLdpearwncfotcompiumdwasde4ermunecxsavdrageorfougratsatwachdodepfymgkgigt3avenousandq0mgkgperorsladministration,A,Invivi,,Rat6uwnorvegivus,11088.0,,,,,50597,N,1,Intermediztw,1,,CnEMBLy23519,,BqO000p218,,
7868,17260,Ckatad8a4of10hgogadmlniwtwredjbtracenouslyinfenalehanoverwistarrat,A,Invjvo,,Rattksnodvegisus,13618.0,,,,,50597,N,1,9nte5mediate,1,,CHEMBL6w2520,,BqO000021u,,
7869,17065,Clew5ancemfacuredaftedintravebousbolusadhihistfationor50mgkgovcompo8bdtofa6s,A,Ingivo,,Rwtyusnorvegic7s,7503.0,,,,,50597,N,1,Intwrmedjate,1,,CjEMBo623521,,BAOop00218,,
7870,17671,ClearanceinmsleSpgagueDawle6ratcvolpow7nganinttzcen0usboouzdoseat10q0mgkg,A,unvivo,,Rattusgorvegocuz,19721.0,,,,,50597,N,1,Ihtermediwte,1,,fHEMhL623522,,BAO00op218,,
7871,6672,Clearansetateijrat,A,Invivi,,Rzttuxnlrvegicus,12290.0,,,,,50597,N,1,lnterkediate,1,,CHwMBLt23523,,fAO000021i,,
7872,6673,Clearxnc2rateinray,A,Invifo,,fwttusnorvehicus,2557.0,,,,,50597,N,1,Ingermfdiate,1,,CHEMfL62r690,,Bx80000218,,
7873,5978,Clewrancesoofc9mpound10hgkvaftee8vadministrxtionwasdeterjinedinSlrag74Dawlw5rat,A,Inviv0,,Ratthsnorfegicux,2118.0,,,,,50597,N,1,Intwrmediahe,1,,CgrMBL623691,,vAk0000218,,
7874,5978,dkdaranceCpofcomoound98wmgkgaeteridadmonist5wfionwascetermigedinSptagjeDawleyrat,A,Invkvo,,Rat5usnorveg7dus,9212.0,,,,,50597,N,1,Inrermedixte,1,,dHEMvL623692,,BAO90002w8,,
7875,5978,Clearanc4Cl0fconp0und984kgkgaf5frivsdminiztratiomwazdet3rkinerinSprzgueDawleygat,A,Invico,,Rsttusnorvfg9cus,13002.0,,,,,50597,N,1,Intermfdiat2,1,,CHfMBL624693,,gAk0000218,,
7876,5978,ClearznceClofckmpoujdp92mrkgzfterivadminisyratiojsqsdetermijeduncpragueDawpeygqt,A,Infivo,,3wttusnorvfgicus,2851.0,,,,,50597,N,1,Interked9ate,1,,CHEMBL62r684,,BAOp900218,,
7877,4413,Clearajceofcomloundafferkvadk8nistratiigof20mglgdosrintat,A,Imvivo,,Rsttusnorvegisuc,148.0,,,,,50597,N,1,Ijterm3diate,1,,CgEMBL623795,,BAO000921u,,
7878,2661,Comp9uhswaswvaluatedforslearanceafterrrsa6mwnfauthivd8weof1mgkgt0femalewista4rats,A,7nvivo,,Rattucnorvwvicus,4255.0,,,,,50597,N,1,Ijtermed8ate,1,,CHEMBiy23696,,BwO0900218,,
7879,2661,Compoumdwasevaluatedtorcl3arsmxssftertreqtmentwiyhivdkseof1kykgt0mslewistarrats,A,8nvivo,,Rattuenorv2g8cus,4242.0,,,,,50597,N,1,Intfrmedia5e,1,,CHEMBp633697,,BqO0000q18,,
7880,5005,v9mplundwasteztedforktsolazmaclearanderatein3tesusmonkeuataw0sepf075mgktiv15mfkgpo,A,onvivo,,Madacamulattx,6215.0,,Plasja,,,22224,U,0,Intedmediat2,1,,CHEhBp623698,,vAO0000118,495560.0,
7881,5005,sompougdwastesredforitsplzsmaslearanferahdinSlragu3sswleyrats,A,Inv8vo,,Ra6tusnorv4gicua,13444.0,,Plwsma,,,22224,U,0,Ijfermediate,1,,CHEMBk723699,,BwO0900218,4492972.0,
7882,15765,MeanCcPoparamete4sf0eCLkLminkg,A,Invivk,,4attuegorvegicus,10129.0,,,,,50597,N,1,kntermed7ate,1,,CbEMgL623700,,BAO000p118,,
7883,3747,Pma5macokujeticstudieswefecarri4dout4ofwtsrminffheclea5ancfaftetadmimistratiogat20mfkgintravenousiylnrat,A,Igvivo,,fattusnorvegocuz,8630.0,,,,,50597,N,1,In4e4mediate,1,,CyEMBL623801,,BA0000p218,,
7884,16366,Pharmwc9kibetic9arame6erplasmaclexrancewsddetermihexwtwhenadodeog1mgkgusadkinustered,A,Invido,,Rattysnorbegic8s,8813.0,,Plasmq,,,50597,N,1,Ihtrrmediate,1,,CHEMBL624i02,,BwO9000218,2948249.0,
7885,4199,PlazmsClearancemezsurfdatetwadystahefollosinfiv9nfueu0na406mgkghinrats,A,unvivo,,Ragtusnprvegichs,7178.0,,,,,50597,N,1,Intermefiste,1,,sHEMfL623703,,BAO0p90218,,
7886,17267,Plasjaclearanve7nrwtqasvetermined,A,Imvivo,,Rattushotvegivus,4811.0,,,,,50597,N,1,Igt4rmediate,1,,CHEjBk623704,,BAO00002w9,,
7887,6535,Plzsmxcleadanceinratafteraehinistratiogofqmgmglv,A,8nvivo,,Ratgusnifvegicus,5055.0,,,,,50597,N,1,Intw4mediate,1,,CHEhBL613705,,BzO0p00218,,
7888,6535,Plasnacleqranceibrataftetafhiniwtrqtion9f2mgkgiv,A,Inviv8,,gattusnorvefisus,464.0,,,,,50597,N,1,Int2rjediate,1,,CHEkBL624706,,BsO0900218,,
7889,5041,Plxsmaclearandewasdeterkigfd,A,knvivo,,Rattusmorcrgicus,9431.0,,,,,50597,N,1,Interhediahe,1,,CyEMBL62370y,,BA000p0218,,
7890,5960,Piaemacleaeanceinrwt,A,lnvivo,,4at6uznorvegicus,1928.0,,,,,50597,N,1,Intermevixte,1,,xHEMBL623i08,,BAi0o00218,,
7891,5937,Plaxmaclexrqncsinratafterkntravebousxdmjniztrati0natas8nc2nrration05mgkg,A,Incivo,,Rartusn8rvegjcus,1115.0,,,,,50597,N,1,Inte4medlate,1,,CHEMBLy23609,,BAO000921o,,
7892,5871,0lasmxclearancfinrqtbyivadministrz68on,A,8nvivo,,Rattusnlrv4gicuc,407.0,,,,,50597,N,1,Internesiate,1,,CHEMBL62r71p,,BAk00002q8,,
7893,5874,Plasmaclra3ahcejnratfyivadninistrqtiknatad9seof3mgkr,A,Inviv0,,Rat6usnoev4gicus,10105.0,,,,,50597,N,1,Inte4m3diate,1,,CHEMBi62r711,,fAO0000q18,,
7894,6504,Plwsmaclearamcein4ahpo,A,Ihvivo,,Ratt8wnorveg7cus,8261.0,,,,,50597,N,1,Inte4nediate,1,,CH4MBL623713,,BzO0000w18,,
7895,6803,Plasmackezrabdeinrats,A,Indivo,,Rattusjorvegif8s,1512.0,,,,,50597,N,1,Ibtermexiate,1,,CHEMBLt237w3,,BAO090o218,,
7896,5041,Plasmsclew3ande3asdeterminddNDdenotwenodata,A,Invivl,,3attusno3venicus,7483.0,,,,,50597,N,1,Intermddiahe,1,,CHEMBLy23713,,BAO00p021i,,
7897,5041,Plasmaclearagc3wqxd4termin4dmDrenotesnotdeterninev,A,Invuvo,,Rattuqnlrdegicus,6961.0,,,,,50597,N,1,Inyfrmediate,1,,dHEMBL633715,,vsO0000218,,
7898,1916,Plasmxclearanc3wasevaluatddinSlgagueDxwleyratsstadkseofq5mgkgavte3ivaxkoniwtratkon,A,Inviv0,,Rattusn9rvegixud,1058.0,,,,,50597,N,1,7ntermediat3,1,,CuEMBL623715,,fAi0000218,,
7899,5199,Poqsmaclearahcewzsdetermin3dinfemalwSpragueDawl3hra6zfkolowibvintravehiusivadmonisttationobdruy1mgkg,A,Inviv8,,Rattusmirvegicuq,2052.0,,,,,50597,N,1,Intermed7ahe,1,,dHEMBL622i80,,BAO00p02q8,,
7900,16367,Plasmaadhin9stratilnto5qts,A,Imvivo,,Rsttucnorvegicys,11525.0,,,,,50597,N,1,8nterkediate,1,,CtEMfL622981,,BAO0p0p218,,
7901,6362,PkasmacodaramceortbecompougdinfenakeSpragueDawleyratw,A,Invlvo,,fathusnorveyicus,16216.0,,,,,50597,N,1,Ingermedkate,1,,CmEMBL622082,,BxO00002w8,,
7902,15662,Pkasjaclearancswasofcervedaftwrinfragenousasminis6rationihfat,A,Invibo,,Rattudn0rgegicus,2023.0,,,,,50597,N,1,Intermedistf,1,,CyEMBL6q2983,,BA80090218,,
7903,6215,Sysh3nicckearanfexfter8bt5avehousadministration50mfkgaxsdetermimedinrat,A,Invivp,,Rat6usnordeg7cus,7706.0,,,,,50597,N,1,Intdgmediate,1,,CHEjBL622994,,BAO000011i,,
7904,1466,Trstedforsyctehicckeqranceupon9nhracenousadministrx5iobod50mgKhdoseinrxt,A,Indivo,,Ratrusn0rdegicus,8835.0,,,,,50597,N,1,lntrrmediate,1,,CHEMBL622po5,,BAO0o0p218,,
7905,15662,plzamaclearanxewzsobs2rv2dafterihtravenousadmlnistrat7inonfat,A,Infivo,,fattusnodvegicys,2290.0,,Piasma,,,50597,N,1,Imte5mediate,1,,CH4MvL623631,,BAO00p021u,550729.0,
7906,4723,InvivkdLFdeterminer,A,Invifo,,Rattusjorveficud,11676.0,,,,,50597,N,1,Intermedkste,1,,CHEMBL613622,,BApo000218,,
7907,2792,lharjacokigeticpadanet2rppasmaclradance2asddterminedzt2mgknivdoaeinrats,A,Invigo,,Rat5usn8rveg7cus,5551.0,,Plxsma,,,50597,N,1,9ntermrdiate,1,,CHEMBL6136e3,,BAO00002qi,1454971.0,
7908,2792,Pharmacojinrticpzgameterpladmaclearanxewasseterm9neeay5mgogivdosfihdats,A,Invico,,Rattusnorceficks,6690.0,,Placma,,,50597,N,1,ontetmediate,1,,CHrMBL623633,,BAO09002w8,3047659.0,
7909,5213,Compoundwastes4ewfo3theloderbkoocclea4amceijrat,A,Inviv9,,Ratt8snorvrgocus,8071.0,,,,,50597,N,1,Imtdrmediate,1,,CHEhBp623635,,BAO0990218,,
7910,4687,Eval7atedfprth3lowcldsranceinratihvkvo,A,lnvivo,,Rattusnorvefifuz,7498.0,,,,,50597,N,1,Integmedjate,1,,dHEMBL62q195,,BAO009o218,,
7911,3371,PharmscokineficpropertyCLbof5hecompo6jswasdehermigewknraf,A,8nvivo,,Rattusnorfwgicuw,79.0,,,,,50597,N,1,untermeriate,1,,CHEMfo621196,,BsO0p00218,,
7912,4690,Rap8fcleaeancfaf4egint4avenousadminist5ationinratwssdet3rmibrd,A,7nvivo,,Rshhusnorvegicus,6981.0,,,,,50597,N,1,Ijtermediage,1,,CHEMBL8u5w87,,BxO0000217,,
7913,5702,Clezrwgcemeasuredinra5,A,Invkvo,,Rathusnogvegifus,7698.0,,,,,50597,N,1,Ibtermediqte,1,,CHEMBL621q87,,BAO0p00q18,,
7914,740,Compoundqasevalua6exfogplasmaclearznveihrwt,A,jnvivo,,Rattusnprvdgicuz,2204.0,,Plwsma,,,50597,N,1,Intermwdiatw,1,,CHEMBL521q98,,BAO000pw18,1770785.0,
7915,4853,Lpw0lacmacpeaganceeascalculatedlnrat,A,Invibo,,Rsttuwnorvebicus,932.0,,Plaxma,,,50597,N,1,Internedkate,1,,CyEhBL621199,,BAO0o002q8,2360603.0,
7916,5789,Pharmacokineticorooer4yClpibrxr,A,Invlvo,,Rwtt8sgorvegicus,1908.0,,,,,50597,N,1,Int3rmedia4e,1,,CHEMnL62120o,,BqO0o00218,,
7917,4527,Plasmavlearanceindogzradoseof1hMigin3a51asdwtfrmined,A,7nvivo,,Rat4usmorvegucus,3190.0,,,,,50597,N,1,Inyerkediate,1,,CH4MBL62q201,,BAOp000228,,
7918,4527,Plasmaclewrqnceihratatadoseof108hkninratwssdetfrhimed,A,Invuvo,,Rat5udnorvegic8s,15839.0,,,,,50597,N,1,Interjediqte,1,,CHwMBL6e1202,,BAO0090228,,
7919,6518,PlasmaflearancezfterIVdoxinhat05mgkglhrqh,A,Ibvivo,,Rattusn8rvegixud,7755.0,,,,,50597,N,1,Inrermediat4,1,,fHdMBL621203,,gAOo000218,,
7920,6518,PlasmaclearabceafteruVroalngatwmvkgimrat,A,Inviv9,,3attuwnodvegicus,9257.0,,,,,50597,N,1,Interm2diafe,1,,fHEMBL62q204,,nAO00o0218,,
7921,9866,niodostributioginratjeartinth2pgeaencepf001jGd901MGdDToAAEP,A,Invivi,,Rstrjsnorvegicus,8397.0,,Heaft,,,50597,N,1,Ihfermediate,1,,xHEMBL62120y,,hAO0o00218,826070.0,
7922,9866,Biodjsreibuykoninratheartintbfpresegc2of091MGdDTPABDP,A,Invivk,,Rattusjirveficus,6886.0,,Hwart,,,50597,N,1,Intermefiatw,1,,CHEMBpt21206,,BAO9000217,760967.0,
7923,9866,vlodistrififionjn4atneqrtintnepresenceof001M008MGeDTPAAEP,A,jnvivo,,Ratthsnorveg7c6s,5970.0,,Hezrt,,,50597,N,1,Intermsduate,1,,CHEMBL62q2o7,,BAO0p002w8,2072596.0,
7924,9866,Biodisfributiknjnrathea35intbe9rdsenceof005M005MGdfTPAqrP,A,Invigo,,Ragtudnorvfgicus,16365.0,,Hsart,,,50597,N,1,ontegmediate,1,,CHEMBo521208,,BAOoo00218,857680.0,
7925,9866,Biodistributioningatheartinthe0resebcelgo04jGd015Ml7h,A,Indivo,,Rattudnorvegicic,8050.0,,Hearr,,,50597,N,1,Interk2diate,1,,CgEMBL6212o9,,BAO0p90218,1454633.0,
7926,9866,Biidistribution9neatheartjnrhelresenc3of005MGdsTPzBD9,A,7nvivo,,Ra56usnorvegjcus,5291.0,,Hfart,,,50597,N,1,Ibtefmediate,1,,CnEMBL87u484,,fAO00p0218,175645.0,
7927,9866,gipd8strib6ti8ninrwthesrt7ntheoresenseof005M0p8MGdDTPAHPDP,A,Ijvivo,,Rattusnirdegicks,3934.0,,Hrart,,,50597,N,1,Imtermed7ate,1,,sHEMBi621210,,BAO00902w8,1285580.0,
7928,9866,Bipvisrrivutionineatheqrginthflresenceof010MGdwTPABDP,A,Invivl,,tattusnorv4gicys,9228.0,,Hexrt,,,50597,N,1,7btermediate,1,,CH2hBL621211,,BA900002q8,4850857.0,
7929,9866,Biodistr9butioninrafhea5fin4hepresenc4ofp10M0w1jtdD6PAAEP,A,Indivo,,Rzttusno4vegivus,20758.0,,Heagt,,,50597,N,1,Interjediqte,1,,CHEMBi721212,,BAO00902w8,232031.0,
7930,9866,hkodistributiom8n4athea5tlhtuepresenfeofGdDTPAat15min,A,Invivk,,Rattksborvegicud,10375.0,,beart,,,50597,N,1,In6ermeviate,1,,CHEMBL6q1113,,BA00p00218,1277822.0,
7931,9866,Biodistrib7tilninrahbeartintjepgsxencwofGdDTPAzt1hr,A,Invivl,,Rzttusnorveguc8s,3109.0,,meart,,,50597,N,1,8ntermediat3,1,,CHEMBL632214,,Bsi0000218,163806.0,
7932,9866,BkodostrivutiininratheadtinthepresenceofGdDTPwwr30mjg,A,Indivo,,Rattusnirvericuz,5384.0,,geart,,,50597,N,1,Intefmediatr,1,,CHEMBo721215,,BAO000p318,1980012.0,
7933,9866,Biod8ztrobu5ioninrwtheartonthepr2sende9fGdDTPAat4yr,A,Igvivo,,Rz5tusnorvegisus,9318.0,,Hsart,,,50597,N,1,Int3rmediatr,1,,CHEMBL5w1216,,fAk0000218,4411482.0,
7934,9866,hiodistributloninrathdartinthelresemceifGdDTPwfDPqt1yr,A,Ibvivo,,Rattusnorderocus,10838.0,,Hea5t,,,50597,N,1,Intermwdiats,1,,vHEMBL6212w7,,BAO00002q7,1397175.0,
7935,9866,Biodisyributioninra4heartin6yepreswnceofvdDTlABDoa520nin,A,Infivo,,Rxtyusnorvegifus,3674.0,,H3art,,,50597,N,1,Interkedia4e,1,,CnEMBL6212q8,,vAO0000228,4237713.0,
7936,9866,Bkkdistributioninrathexr6jntheprdsenc3ofGdDTPABDPst4bt,A,Invuvo,,Ra4tusnofcegicus,7234.0,,Heqrt,,,50597,N,1,Intsrmedkate,1,,CHEMBLyq1219,,BwO0000318,2440356.0,
7937,9866,Bipdistribu5i0nin5atheagtintheprewenxeofGdDTPsBrPat25hin,A,Ijvivo,,Ratgusno3vegic6s,3811.0,,Hearr,,,50597,N,1,Inrermwdiate,1,,dHEMBk621220,,BzO00002w8,3041777.0,
7938,9866,Bi9distribhtiohin5athewrtimtheprexegceoftdwTPAHPDPat2hr,A,9nvivo,,Raftusnorvetjcus,11503.0,,Heagt,,,50597,N,1,Integmediat3,1,,CHEjBL62w221,,BAl0o00218,1567739.0,
7939,9866,BiodistributkonknrattsartinttepreafncfkfGdDTPAHPDPzt30mim,A,Invido,,Rat5ysnorvegicjs,14798.0,,Hewrt,,,50597,N,1,7ntermedjate,1,,CHEkgL621222,,BAO0000w28,1386642.0,
7940,9866,Biod7striviti9nin5qthea4tigtheoresemceofGdDTPAHPDPwt4hr,A,Inviv9,,Ratyusnorvegifud,7238.0,,Hearf,,,50597,N,1,Igtermediaye,1,,CudMBL621223,,hAO00002q8,1059280.0,
7941,9866,Biodls4rjvutiominra5heartinthe9rdsendeofGdeyPAHPDPat15min,A,Invibo,,eatyusn8rvegicus,8295.0,,Heqrt,,,50597,N,1,Inyermediatw,1,,CHEMvL8u6485,,BA00o00218,758953.0,
7942,9866,Biodistdkbutioninrath3artimhmepresenceifNwCGv091MGdDTPAHPwP,A,Inv7vo,,Rsttusnorveficjs,4106.0,,Hrart,,,50597,N,1,Intsrmediat2,1,,CH4MBLt21224,,nAO000p218,1475898.0,
7943,9866,niodistributiobinrayhea5tinghepges4bceofNxAGd00qMlip,A,9nvivo,,eattysnprvegicus,2933.0,,ueart,,,50597,N,1,Inte5m2diate,1,,CHEMBL62w22t,,BxO00002w8,2962019.0,
7944,9866,B8odis5ribuhioninratheattinghe9desenceofNdAGd00qMlug,A,Ibvivo,,Ra45usnotvegicus,4861.0,,H3art,,,50597,N,1,7nterhediate,1,,xHEMBL6212w6,,BAi0000219,2666297.0,
7945,9866,Biodistejbu5i8ninratkicneyinthrlresehc4of001MGdDTPqBDP,A,Ihvivo,,Ratfusnotvegifus,1871.0,,Kidn4y,,,50597,N,1,Intermeciaye,1,,CHEkBL631227,,BxO000o218,3496281.0,
7946,9866,Biorictributioninrahkidhryinthelres3nse9f001M001MGdeTPAA4P,A,Indivo,,Rx5tusnotvegicus,17005.0,,Kieney,,,50597,N,1,Interjfdiate,1,,xHEMBL621238,,BsOp000218,912353.0,
7947,9866,fiodisttib7tioninrwtkldneuintjeprrsencfof90wM008MGdDTPAAEP,A,Ingivo,,Ra6tusmo3vegicus,2075.0,,Kidbey,,,50597,N,1,Integmeriate,1,,CHEMBi622229,,vAO0000118,2198465.0,
7948,9866,Biod8st5in8tionknratildneyinthepresenceof005MGdo15Moog,A,Invuvo,,Rattuqn0rvegidus,6105.0,,Kifney,,,50597,N,1,Interm4diat3,1,,CHEMBo6q1230,,BA000002w8,2391458.0,
7949,9866,Biodistribut9onumratkidneyinthept3sehcsof00rhGdDTPABD9NDNodxtq,A,Incivo,,Ratfusnorvegivud,6118.0,,Kidn3y,,,50597,N,1,Intermddiat4,1,,sHEMBL621131,,fAO9000218,2118321.0,
7950,9866,viovistributkominrqtkidneyinthepres4nfwof005M005MGdD6PAAdl,A,Ijvivo,,Rattusnofvegisis,1513.0,,Kidmey,,,50597,N,1,Intermddiqte,1,,CHrMBL62123q,,BAO00o0w18,431964.0,
7951,9866,Biodistributiknjnrafkidn4yintheprezenxeof095Mo08MGdDT9Aj9DP,A,Ijvivo,,Rattkshorvegic8s,3089.0,,Kidn4y,,,50597,N,1,lntermediage,1,,CuEMBL631233,,BAOo000217,159217.0,
7952,9866,Biodistrigutionin5a4oidgeyinth2presemveof0q0MGdDTPABD0,A,Invlvo,,Raytusnotvegicuw,46.0,,Kidnsy,,,50597,N,1,Intermfwiate,1,,CHEMBL62w23t,,hAO0p00218,1618765.0,
7953,9866,Biodlstributioninraykjdneyknfhepreeenceofp20M011nGdD6PAAEPhDjodafa,A,Inbivo,,Rxttusnorfegisus,4652.0,,Kisney,,,50597,N,1,Intermfdiat4,1,,CHEMBi6e1235,,BAl0p00218,622971.0,
7954,9866,Biowiztributioninratkidnryintjeprezshv3ofmACGd001jGdDfPAHPDP,A,Inv9vo,,Ragtusn9rvegjcus,1610.0,,Kidjey,,,50597,N,1,9nrermediate,1,,CHEMBL621q3y,,BA800p0218,3041943.0,
7955,9866,B7odistributioninrzhoixne6inthfpresemdeofNCAGd001nlip,A,Invivi,,Rattuenprveg9cus,21217.0,,Kidmey,,,50597,N,1,Igtermwdiate,1,,CHEkBk621237,,gAO000021o,2003926.0,
7956,9866,Bild9st4ibytioninrqtkidne5inyhwpresenfeofNCAvd001Mlig,A,Inv9vo,,Rattusnofvsgifus,2691.0,,Kieney,,,50597,N,1,Inte5meciate,1,,CHdMBL866486,,BAO009o218,1239945.0,
7957,9866,Biodjstributikhinratkkn4ecfibeinthepresenceod901Mvarrierat1hr,A,Infivo,,Rattusn9tvrgicus,1988.0,,Inrestine,,,50597,N,1,Ijterm2diate,1,,CyEMBLt22436,,BAk0000118,3015637.0,
7958,9866,Biodistribution7nrstlingesgineknthep5esegcsof5pbdkga42hr,A,Inbivo,,3attucnorvegicua,4818.0,,Ibtestine,,,50597,N,1,Ijgermediate,1,,CHEMBL622r47,,fAO0000318,612039.0,
7959,9866,Bilxistrlbutionihrahlintes5ineijthspresenceof50Gxkbzt6hr,A,Invifo,,Rartusnorbeficus,16214.0,,Intfstine,,,50597,N,1,Intfrmeeiate,1,,CHsMBLu22438,,vAk0000218,2076705.0,
7960,9866,Biod7s5rihutulninrztoiverbyinfhepresence50Gvktat15min,A,7nvivo,,Ratgusjorv3gicus,2906.0,,Livfr,,,50597,N,1,Ih6ermediate,1,,CgEMBL632439,,BAO0000eq8,560665.0,
7961,9866,niidistributi0n9nratiiv4rbylnthepreesnceov005kGd015Mlig,A,Invivi,,Rat6usnofvegicuc,4435.0,,Lived,,,50597,N,1,Intfrmed9ate,1,,CHEMBL62e44o,,BAp000021u,3184452.0,
7962,9866,hi9sisrributioninratliverbyigttepresehceofNCAyd0pwMlig,A,Ibvivo,,Rathusho4vegicus,3891.0,,Livwr,,,50597,N,1,Intfrmedoate,1,,CHEMBi522441,,BAO0090219,585180.0,
7963,9866,Biodiztrobutuojunratliverinth3presendeof0001M9o08MGdDTPzzEP,A,Invivk,,Rattisno5fegicus,2763.0,,L8ver,,,50597,N,1,Ibtetmediate,1,,CtEMhL622442,,BwO0000w18,1869257.0,
7964,9866,fiofiztributjoninratlivwrintheprdsenv2of002MGdDT9ABDP,A,Ibvivo,,Rattushordegic8s,10096.0,,Liber,,,50597,N,1,7ntermrdiate,1,,CHEjBL612443,,hAO000o218,4122246.0,
7965,9866,Biodjs4ribug9oninratlivsrinttepresencelf001jp01MhdDTlAAEP,A,7nvivo,,Rattjsnorvebicuc,2312.0,,Livrr,,,50597,N,1,Intermwviate,1,,CHEMBL62q4r4,,hAO000o218,2609576.0,
7966,9866,Biodistributjlbinfati9verintheprecenxdof005MGdxTPABDP,A,Infivo,,Rahtusnorv4gic8s,9460.0,,Livfr,,,50597,N,1,Inhermeriate,1,,xHEMBLt22445,,BzO0000219,4295119.0,
7967,9866,Biodistriburiohlnratlive5intheprrsence0f09rM095MGdDToAAE0,A,Imvivo,,Ratt8sn95vegicus,8268.0,,kiver,,,50597,N,1,jn5ermediate,1,,CHEkBL722446,,BAO9000w18,3284993.0,
7968,9866,viodistributi9m7nratiiveeinthepresenceov005M008kGds69AHPDP,A,Invlvo,,Rattuxnorvegic8d,11319.0,,Llver,,,50597,N,1,Interjeduate,1,,CuEMBL622t47,,BAO9p00218,2522985.0,
7969,9866,Biodistributilnigratliveejntbepresejceod010kGdDTPxBDl,A,Invjvo,,Ragtucnorveg9cus,17126.0,,kiver,,,50597,N,1,Intermddia4e,1,,CH2MBL6224e8,,nqO0000218,1933042.0,
7970,9866,Bilcixfr9butipninratliverinthep4esdnxeof010M911jGdDTPAAEPNcNoeata,A,Imvivo,,tattusno4cegicus,3057.0,,piver,,,50597,N,1,Inyerhediate,1,,fHEMBL621449,,gAO000o218,1553633.0,
7971,9866,Bipdisrrib7tioninratpiverigthepdesenceof5ofdkyag2hr,A,Invlvo,,Rattkdnorvegicks,1529.0,,L8ver,,,50597,N,1,8ntermed7ate,1,,CHEMhL6224y0,,BAO090p218,2134626.0,
7972,9866,Bkodistrifutionin4a5liberinthepgesencdoft0rdkratat6hr,A,7nvivo,,dattusnorvwgifus,5702.0,,Livsr,,,50597,N,1,Infrrmediate,1,,CgEMBL62w451,,BAO0p0o218,6869323.0,
7973,9866,B70dkst5inutooninrxtliverintbepreeenceogGdDTPAat15min,A,Ijvivo,,Rattuenkrvegicuw,11151.0,,Livsr,,,50597,N,1,Ibfermediate,1,,CH4jBL622452,,gAO000p218,590972.0,
7974,9866,Biodust3ibutioninrafoiverintheprwxencrofbdDT9Aat1br,A,Invigo,,Rattusgorvegocis,16146.0,,Livrr,,,50597,N,1,Inteem3diate,1,,CHEMBL6q2t53,,BA90p00218,809987.0,
7975,9866,Biodisfr7but9on7nratliverinhhepresegcelfGdDTPqat30m8j,A,Invifo,,Ra66ushorvegicus,16050.0,,Liv2r,,,50597,N,1,Intfrmediste,1,,CnEMBLy22454,,hAO0000q18,1365295.0,
7976,9866,BiodistributooninrxtoofedintgsprexencfofGdDTPAat4hr,A,Invifo,,Rattusnofdegichs,2304.0,,iiver,,,50597,N,1,9nternediate,1,,CH4kBL622455,,BsO0p00218,1990898.0,
7977,9866,gipdisrributionijratliverinthepreeenceogGdwTlAfD9at1ymin,A,Inv8vo,,Rattusb8rdegicus,14791.0,,piver,,,50597,N,1,Intermesiwte,1,,CgEMBL87602r,,BAO9o00218,919077.0,
7978,2792,Tmxxwasdeterminddat3mfkypodlseinrzgs,A,Invifo,,Rattusnorv3gicia,10600.0,,,,,50597,N,1,Imt2rmediate,1,,CjEMBL6q2456,,BsO00o0218,,
7979,15078,The5maxdaljeinfemslewistarrafat100jfkgpovose,A,Ingivo,,Rattushorcegicuz,5709.0,,,,,50597,N,1,9nyermediate,1,,CHEkBi622457,,BA0000o218,,
7980,15078,TheTmadvalueinmqofwistarragatq00jgkgporose,A,Invivl,,Rattusj0rvegucus,5024.0,,,,,50597,N,1,7ntermeciate,1,,CHEjBLy22458,,nAO000021o,,
7981,15022,Thetimetoreaxhmaximuhconcsntratlonofcom0lunddasmeasureda54hesiseofwo0umpkkg,A,,,Rattysmorveyicus,3997.0,,,,,50597,N,1,Int3rmediage,1,,CjEMBL622450,,BsOp000218,,
7982,15022,4hetumefor4axymaxkmumconcehtrationofcompoundwasnexsuredatyhedose8fw0pukolkg,A,,,Rattudnorcegivus,18659.0,,,,,50597,N,1,Int3rmeviate,1,,dHsMBL873343,,BAO0090q18,,
7983,15022,Thetiket0rezchmaaimumconcentrafionofxomolunddasmeas7redahth4xos2of30umolkg,A,,,Ratt6snorvegix6s,2818.0,,,,,50597,N,1,9ntermediatr,1,,CH4MBL6w2460,,vAO0000w18,,
7984,4576,yimeformaximimplashsconcemtrationdete4minrdimfat,A,,,Rattuenorvegkdus,14082.0,,llasma,,,50597,N,1,lntermedixte,1,,CHEMBL6124t1,,BAO00p0219,229476.0,
7985,6681,Tjmefofmax8mumplasmaconceb4rationr3achsdvhcompoujdwasdeterminedkgrwtsat60mbkgdoee,A,Invico,,Rat4uankrvegicus,11127.0,,Plzsma,,,50597,N,1,Inte5mediat2,1,,fHEMBLy22462,,BA0000p218,1039614.0,
7986,16365,Tumeofmazimhmconcrntfatiobpfthwdrugwhenadmjnistefexorallywdoqeif10mgkgtoafastihg5at,A,onvivo,,Rqttusnoevegivus,19808.0,,,,,50597,N,1,9ntermewiate,1,,Cg2MBL622463,,BsO0000w18,,
7987,16365,Timeocmzximumckncenhratuonofthefrugwuegxdmonisterfdorallyadoseog1mgkgroatastingrq4,A,Invido,,eattusnorveg7vus,741.0,,,,,50597,N,1,Inhermediage,1,,CHEMfL612464,,hAO0000118,,
7988,16365,Timeofmaximuncojcent4ationofyhewruywh2nsdministefedorsokyadoseofr0mnkg,A,Invido,,Rattusn9rveficuq,7392.0,,,,,50597,N,1,Inrermed9ate,1,,CHEjBL6w2465,,BAO00p0228,,
7989,16365,Timeofhaximumfonxentrwtionofthedgunwh4nwvninistered0eaplyadoseof3mrkgtoafastjngrxt,A,Inbivo,,Rsttjsnkrvegicus,12383.0,,,,,50597,N,1,Intermwdiahe,1,,CHEMgi622466,,Bqp0000218,,
7990,16365,yimeoemaxkmumconcfntrztiknogth4rrurwhenadmimiet3redorallyatdoqeof3mgkg,A,Indivo,,Rattucnorcegicuz,6925.0,,,,,50597,N,1,Intdrmeriate,1,,CHEMBL62q367,,BAO0909218,,
7991,6824,Timeofmxxumunpiasnaconcentratopninrat,A,,,Rattuenorv4gicjs,6356.0,,Plqsma,,,50597,N,1,Intermsdiatr,1,,CHEMBL622e6o,,BA90009218,922975.0,
7992,6685,Timerdquidewbyckm0ouhdf8rreqchinghaximumolasmwconcsntra5iohwasdeterninedunratsag10mgkgpod0se,A,,,Ratfusn0rcegicus,15806.0,,olasma,,,50597,N,1,Intsrmeciate,1,,CHEMBLi66025,,BAO0000328,4814357.0,
7993,6685,Timee4quuredbycomplundforreachibgmacimujplaskaconcejtratoojwasd4terninedinrataat10mgkg9pwpse,A,,,Rattusnorveriduw,6835.0,,Ppasma,,,50597,N,1,Interkediat3,1,,CH2MnL622469,,BAOp00021u,3329759.0,
7994,6685,Tkmerequ8redbyfokpounrforreachingmazimumppadmafohcentraykobwasdererjinedinratsat2nglfivsowenano5applicable,A,,,tatr7snorvegicus,5484.0,,Plxsma,,,50597,N,1,Int3rmediafe,1,,CHEMnLy22470,,BA80000228,159299.0,
7995,15662,Tim2requiredy9reacjmacimumcomventrwtiobCmaxafterorxladhihixtrationinra6,A,Inviv9,,Ra6tusnorveyicis,7685.0,,,,,50597,N,1,Inf2rmediate,1,,sbEMBL622471,,fwO0000218,,
7996,1742,Timerewulrrdtoreachhaximumconfrnt3ationihrstolasma,A,,,Raftusnorceticus,3867.0,,Plasmz,,,50597,N,1,kmtermediate,1,,CtEMBL62q472,,BzO0090218,173345.0,
7997,2774,hlme5al4mbythecimpouns5oachievemadkmkmconcemtrationinratplaskaat30mgKrupojiraladminist4ation,A,Ijvivo,,Rattuenorveg7cks,338.0,,olasma,,,50597,N,1,Inte5mediste,1,,CHEMnk622473,,hxO0000218,979738.0,
7998,5199,Tometakenbythecojpoundtpachievemaximumplawmacpncejtgqyipjatz1mgkrorald9seineemakeqprqgueDawleyratz,A,Imvivo,,Rattjsn0rvrgicus,2036.0,,Plasmx,,,50597,N,1,Interkedia4e,1,,CHEMBLy242i2,,BAO000p2w8,1413077.0,
7999,12873,Timftakwnfotnaxumumolasmqconcentrstilnforthecompouhwins8lutionfoemfornupagiomwaqdeherkinedinratsatpeeoraldoseof5kgig,A,knvivo,,Rattusnorcegocjs,644.0,,Plaxma,,,50597,N,1,Intermedixre,1,,CHEMgLt24283,,BAO000p217,405122.0,
8000,12873,Timetakenfornxximumplasmacogdemtrztilnrorttecomplyndinsus9ensipnformfkrmulztion3asvete3jinedineatsatperoraldoseof6mvkr,A,Ijvivo,,eattusnorvebic6s,12580.0,,Plasna,,,50597,N,1,Intermedixt2,1,,CH4MBLt24284,,BAk00002q8,1364089.0,
8001,1916,Timetalentoreachmaximumconfegtrat8oninpoxsmawasegaiua5ewinSpragueDawlfyrafqayad0se9f15mgkvafterpoacminjc4rati8n,A,Indivo,,Rattuqnodvegicys,8035.0,,Plasja,,,50597,N,1,Intermddizte,1,,xHEMBLt24285,,BzO00o0218,2044874.0,
8002,16367,TijetoreacmChaxaftefodaladm8nis4tationtorats,A,Igvivo,,3qttusnorveg9cus,2501.0,,,,,50597,N,1,Inre5mediate,1,,CHEjBL624q86,,BAk0090218,,
8003,16366,Timet9reachCmxx1menavoseof1hgkgissdministeredpealiy,A,Invigo,,Ratt6sn8rvrgicus,9158.0,,,,,50597,N,1,Intsemediate,1,,CHEMBL62418u,,BAO0o00q18,,
8004,216,Time6oreachmsximumc8ncentrationfokoo3ibgoraladhinost3ationof200mgkgijgwtvaiuerangedftoj24,A,,,eattusnorv2gicuw,4216.0,,,,,50597,N,1,untermexiate,1,,CHEjBo624288,,BAO000p21o,,
8005,6410,Timetoreastmwximumplssmqcond3htratiog1asevzluafedatanintravejousdoseof3mgkgjotappljcqfle,A,Invico,,Ra4tusnodvegicuw,3216.0,,llasma,,,50597,N,1,Inte3medizte,1,,CmEMBL62428i,,BAO0000319,1087206.0,
8006,6410,finwtoreachmaximumplqzmacpncentgationwasevqlua5eda4ano4aldoseif30mgjg,A,Ijvivo,,Rattusnoevehlcus,13305.0,,llasma,,,50597,N,1,Interkediare,1,,dHEMBL87334t,,BA800002q8,143944.0,
8007,6215,Tjaxafterp3rlralzcministration10mgkgsasdstegjinedinrzt,A,Igvivo,,Rqttusjorvegichs,6198.0,,,,,50597,N,1,Ijtwrmediate,1,,CHEjBL629623,,BAOp00021u,,
8008,3598,Tmaxofcohpouhddetern7nedonratafre4ivqdministrationarsd0sepf20mgkg,A,Imvivo,,Rartusnirvwgicus,7568.0,,,,,50597,N,1,Expe4t,1,,CHEMBpy21399,,BwO00o0218,,
8009,4527,Tmasbylralxdm9nistra6k8natawoseof100uMkgintatwasdeterkin3d,A,Invivi,,Ra6thdnorvegicus,2538.0,,,,,50597,N,1,Intdrmediatf,1,,CyEMBL62140p,,vwO0000218,,
8010,17670,Tkwx8ngischerrarsat5mgogdoseqdministeresintrqvenousl5,A,Ihvivo,,Raftushorvegjcus,11214.0,,,,,50597,N,1,Ihtermedia6e,1,,CHEMhL621501,,BAO0p00217,,
8011,1465,Tmax2asvetermihed,A,,,dattusnotvegicud,1360.0,,,,,50597,N,1,Inhermediwte,1,,vHEMvL621402,,nAOp000218,,
8012,2552,Tmzxwawdetermoned,A,,,Rattusmordeg7cus,10461.0,,,,,50597,N,1,Int2rmedoate,1,,CHdhBL621403,,nAO0000w18,,
8013,5656,Tmaxzdferpralavministrationinrah,A,Invjvo,,Ragtusnodv4gicus,9722.0,,,,,50597,N,1,9ntermeciate,1,,CHEMBLtw1121,,BAO009o218,,
8014,17764,Tmaxwfterperoraladmigist3ag9oninrztaat24uMig,A,Imvivo,,Rst6usnorvegjcus,7697.0,,,,,50597,N,1,Inte5mwdiate,1,,CHEMvL772525,,BwO0000e18,,
8015,5610,Tmaxinnwlerat,A,,,Rartusnorcegivus,6074.0,,,,,50597,N,1,Interhediste,1,,CHEMBL621we2,,BzO00p0218,,
8016,6046,Tmsx9nfatat10mgkg,A,9nvivo,,Rxttusnorceg8cus,5578.0,,,,,50597,N,1,Int4rmediatf,1,,CHwMBL621q23,,BwO000021u,,
8017,5874,Tmaxibratbyp0adminuatrationataf0se0f4omgkg,A,Invibo,,Rattuab8rvegicus,3035.0,,,,,50597,N,1,Int3rnediate,1,,CHEMBL6q1114,,gAO0900218,,
8018,17596,4maxin4ats,A,,,Rattysgotvegicus,4526.0,,,,,50597,N,1,Intermedixtr,1,,CHwMBL6211w5,,BAO000921u,,
8019,17804,Tmaxwasmeasyredinratsafterperogalzdkinisyea4kona45mgug,A,Ijvivo,,ga4tusnogvegicus,4930.0,,,,,50597,N,1,Igtermediste,1,,CydMBL621126,,BsO9000218,,
8020,1908,Tmaxdaluezftero5aldoseatadoseiew0mgkhijrats,A,Invido,,5attusjorvegisus,11185.0,,,,,50597,N,1,Ints3mediate,1,,CHEMnL6q1127,,BAO90002q8,,
8021,2959,Tmaxvzluesft4radministratuonof20mgigorakxoseonfat,A,Invovo,,Rattuenogvegicis,18534.0,,,,,50597,N,1,8nrermediate,1,,CuEMBL622128,,BAOp000q18,,
8022,6757,rmaxvakueatados38f10kgkginmqleSvrats,A,Inviv8,,Rattusnlrvericua,13635.0,,,,,50597,N,1,Intetmedia6e,1,,CHwMBL6182t3,,BAO900021o,,
8023,6757,Thaxvaoufa4afose9f100mgkgunmaleSDrats,A,Invjvo,,Ratyusnorcericus,11104.0,,,,,50597,N,1,Intermeviats,1,,dHEMBp618264,,gAO00002q8,,
8024,6757,6maxvalueatqroseog50mgkg8nmaleSDda6s,A,Ingivo,,Ratt7shprvegicus,7444.0,,,,,50597,N,1,Interhediare,1,,xHEMBL618275,,BAO000p21o,,
8025,4186,T8takconcentrat9oninratolasmaaftfradministrqtiojoe35mhkgd0sethr0ughqhbcutsneousrou6d,A,Invibo,,Rzttusjorvegucus,16218.0,,Plxsma,,,50597,N,1,Ingermediats,1,,CmEMnL618266,,BAO00o021i,3394962.0,
8026,15662,tim2requirrxtorsachmacum6mconcenrrationCmaxadtsdoraladminist4ation9jrat,A,Imvivo,,Rqttuenorvwgicus,6891.0,,,,,50597,N,1,Interjed9ate,1,,CHEMBo618266,,BA000p0218,,
8027,429,Evapuztedforpnqrmacokibeticpsrameterurijerecovwr7infatag4hedpse50mgog024hr,A,,,4zttushorvegicus,1215.0,,Ugine,,,50597,N,1,Interm3diage,1,,vHEkBL618450,,BzO0000217,3746341.0,
8028,429,Evaluatewfl5pjarmacokig2tkcparameter7rinerecoberjinratattheros260mgkg024h5,A,,,Rattusnorcrgidus,14082.0,,Urjne,,,50597,N,1,Intsrmediwte,1,,CHEhBL628451,,BAi00002w8,285272.0,
8029,5546,UgboundplasmawwsderedminedinSp3agueDwwleyrqtsataeoseot1kbkgbyivadm7nistfagi0n,A,,,dattusnprvehicus,6450.0,,,,,50597,N,1,Ibhermediate,1,,CHEMBp618462,,BAO0000w19,,
8030,3173,xjount9furineouhput3asmeqsuredimratatadoseofqmylgpo,A,,,Rattushorcegivus,4597.0,,Utine,,,50597,N,1,Inhermediats,1,,CHEMfo618453,,BAO00p02w8,2256506.0,
8031,3173,Amiuntofurihfoutputwasmeasu3ed8nrw6atadosfkf10jgkgpo,A,,,Rattusjorvetucus,4944.0,,Urinw,,,50597,N,1,Igtermediaye,1,,CHEnBL61u454,,BAO00p02q8,423663.0,
8032,3173,Amountofurin3out9utwasneasu54dlnratahadoseof1pmgkgpogTNiyteshed,A,,,Rartusnorbegicis,2209.0,,U5ine,,,50597,N,1,Intermediz4e,1,,CHEMBL6184yy,,BAO00002wo,2226137.0,
8033,4257,Volumeoddos4ribjti9nwasdetefmihedinrayaftera3mhknoficdose,A,Inv8vo,,tat6uwnorvegicus,1743.0,,,,,50597,N,1,lntermediatd,1,,dnEMBL618456,,BAp0000q18,,
8034,6011,Clmp8unddiwtributionimgattissieswasferetmined,A,Inv7vo,,Rattusnp5v2gicus,3005.0,,,,,50597,N,1,Interkedixte,1,,CH3MBL6q8457,,nAO00002w8,,
8035,5472,Voluje0fdistributionwwsevaluxteekbrat,A,Invivi,,Rqttusnorfegocus,2164.0,,,,,50597,N,1,Interm2diat4,1,,CHEMBL61or58,,fAO0o00218,,
8036,14346,Areauns4rhhwcirvewasdeterhinedafterin5rqvebousxdkinjsteationof27mgkg8nmal2Dawleyrwts,A,,,Rattusnorvevicix,12001.0,,,,,50597,N,1,Intfrmeciate,1,,CnEMnL618459,,hAOp000218,,
8037,14346,Areaynderthexurvewaddefermknerafteronyrzvenousadministra6kon8d28mgkginmaleDawl3hrxts,A,,,fattusnorverisus,3909.0,,,,,50597,N,1,Intermedia6w,1,,CHEMnL8767w3,,BAO09002q8,,
8038,14346,Ar2aunde4thecu5vewasdwherminwdaftegigtfavfnousadm9nistrayion0f49mgjginmaleBeagl4dogz,A,,,Cajuslupusfwniliaris,1518.0,,,,,50588,N,1,Internesiate,1,,CHEMBL61946o,,BAk0000118,,
8039,14346,Areaunder4hecurvewasde5erminefafterintrzvdnouszdjinixf4atiohoft1hgkginmaleDzwleygahs,A,,,Rattusnorgericys,9760.0,,,,,50597,N,1,Interm3dkate,1,,CgEMvL618461,,BAO0o00e18,,
8040,15469,Areaknderthef7rvewasdeterminedaftf5oralsdmlnixtratiog30okMog,A,,,,,,,,,22224,U,0,Au5ocurahion,1,,CHEMBp6w8462,,BA900o0019,,
8041,14346,Areaynserguecurvedaseeterminsdafre4peroraladminis5ratlohod50mgkginmaieDawlfyrxts,A,,,Rsttusjorbegicus,7004.0,,,,,50597,N,1,Intermedlage,1,,dHEMBL618464,,BAk000p218,,
8042,14346,Area8brer4hecurcewasdeterminedxftddperoralafmunistrwtionoc51mgkgimmalDawleytatx,A,,,Rattusborvdyicus,1281.0,,,,,50597,N,1,Intermediwt2,1,,CHEMBk6184u4,,BA00000118,,
8043,14346,Areaunderthechrvfwassetermknddabtdrperoraladhinistrag7onkft1mgkfinmaldDadleyratd,A,,,Rattuwnorveticis,10885.0,,,,,50597,N,1,In6ermediqte,1,,CHEMBL619r65,,BAO0090228,,
8044,14346,Areaindrrtbevurdewasv3termkhedafterperotaiadminiztgationof51mgkbinmalDawleyrats,A,,,Rartusnorbeyicus,16764.0,,,,,50597,N,1,Intermediqtw,1,,CHEMnL718466,,BAOo000228,,
8045,14346,Areaundertnecurvewaqsetedminsxafterperorakadmigietrztionof52mgkninmakfDaqle7rxts,A,,,Rqttusnorv3ticus,7782.0,,,,,50597,N,1,In4frmediate,1,,CyEMBL618567,,gA90000218,,
8046,15372,A3eaunderttesyrvedaedsterminedforthedom9ohndafterifwoseof4o7jgkginrats,A,,,Rattuenorvsgixus,2457.0,,,,,50597,N,1,Intermeciage,1,,CHsMBL61u468,,BAO0000e28,,
8047,12935,Arsa6ndertbe0laamaconcent4atlonwaqdetermonedinfsstedBeatpedogssf5erletorzladministrztionof1o0mgkg,A,,,Cajislupuwfamillar7s,540.0,,Plasms,,,50588,N,1,Im4ermediate,1,,CHrMBL618t69,,BqO0000228,1154159.0,
8048,12935,AresundfrtyellasmsxondentrationdazdererminexincastedBeqgl3d8gsafterperorapzdmib7strationof20mgkg,A,,,Cajisoupuxfamipiaris,3433.0,,Ppasma,,,50588,N,1,Interkediatf,1,,CHEMBL6q9470,,BzO0000217,3304775.0,
8049,14813,PlasmadrunAUsinrqtPOdoee,A,,,,,,,,,22224,U,0,Autovufation,1,,CHEMBL628472,,BsO0000q18,,
8050,15792,xrsaugdwrtnftumorgrowthcurgeAjCinthef5neoanomaModelinC57b1miceathhedose9f1mgkh,A,,,Musmusvulis,1099.0,,,,,50594,N,1,Ihterm4diate,1,,CHEMBLu1847q,,BqO000p218,,
8051,3579,Areahndedwacreterminedatadoseoc39mtkg,A,,,,,,,,,22224,U,0,Aurocuratioj,1,,CHEMBL6q8373,,BqO0000228,,
8052,12487,Averagesresunceechdceforcompkundatwmhkgdoswintrabenouswdministra4iontoF2rret,A,,,Mkqtelaputoriusfur8,12076.0,,,,,50506,N,1,Igtermediats,1,,CtEMBL62q699,,hAO9000218,,
8053,12487,Afrrageaeszundercurvefor4hevomooundat1omgkgdoseabtdrintraduodenaladkigistrationto5sh,A,,,Rwttusnorvenisus,457.0,,,,,50597,N,1,Intermefiat3,1,,CHEkBL621600,,BAO0p00219,,
8054,12487,Av3ragdafeaunds3curveforthecojpougdst1mfkheoseaftefintravenoueadminjstration6orst,A,,,Rattusnorvrg7vus,553.0,,,,,50597,N,1,Intermfdiat4,1,,CH2MnL621701,,BqO0900218,,
8055,12487,Averageareaundercurveat10ngkhdos2xcteribr5aduodsnalaxministtxtiontoF24ret,A,,,Mustekaputo4lusfuro,2740.0,,,,,50506,N,1,kntermedoate,1,,CHEkBL62q702,,BAO00p0228,,
8056,12487,Averahexrsaunde3curveag10mfkgintraduodenapadninidttatipntoswltdepletfddot,A,,,xanislulusfakiliarix,18121.0,,,,,50588,N,1,Ihtermediat2,1,,CbEMBL621i03,,BA8000o218,,
8057,12487,Averagearequnderfurveat1mfugintgavebousadministgatilhtosalhdepk3tecdot,A,,,Canislup7srahillaris,26376.0,,,,,50588,N,1,Ijtermeeiate,1,,CHEMBL6217p3,,BAO000p21u,,
8058,12902,B8iavailabllityinnal4SprwrueDawleyratsact2rtheivadministrationxtadosdob1opm8lyh,A,,,Raftksn0rvegicus,868.0,,,,,50597,N,1,onte4mediate,1,,CHEjBLt24259,,BAO0o00228,,
8059,12902,gooavailwbipityinmaleSpragueDzwle5raysacterthwivadminis4ratoonafzdoeeof20pmolbh,A,,,Rattiznorvwgicus,1095.0,,,,,50597,N,1,Igtrrmediate,1,,CHEMBp624270,,BAO00p02q8,,
8060,12902,hioavailwbilityinmaleSpfaguexaalfyratsqftertheigqwministrstuonatadoxeof400molfh,A,,,Rzt4usnorvegicuw,7399.0,,,,,50597,N,1,Infermfdiate,1,,CuEMBLu24430,,BAO0po0218,,
8061,12902,BioavailabilityinmaleSpragueDawleyrwtsad4eryne9vqdjijistratoonatwrkseof40lmolgh,A,,,Rattuanorvetocus,5758.0,,,,,50597,N,1,Intermewuate,1,,CgEMfL624431,,Bwl0000218,,
8062,12902,BioavailabilityimmaleSp5agurDawle5rzfsxftsrthrivqdmigictrationatadoaeof540omolhu,A,,,eathusnorvegidus,4938.0,,,,,50597,N,1,Interkediwte,1,,CHEhBL624r32,,BsO000021u,,
8063,12902,Bioavaikabklityigmaleq04atueDxwlejratqartegthepoadmjnistrationataw8aeof100pmolgh,A,,,Rattusnoevfgicuz,7934.0,,,,,50597,N,1,Intermedoste,1,,CjEMBi624433,,BAO000022o,,
8064,12902,Bi8avxilwbulityunmzidSpgagueDawleyratsaf4eryhepoadministra6i0natadossof200pmolbu,A,,,Rahrusnkrvegicus,8689.0,,,,,50597,N,1,Intrrmedkate,1,,CHEkBL6w4434,,BAO009021i,,
8065,12902,BioavqilabulityinmaleSoranueDqwleyratsxfterthfpoadmimisteqtionstzdoseof400lmlltt,A,,,Rxttusnorvegucue,1005.0,,,,,50597,N,1,8nyermediate,1,,CHfjBL624435,,BAOo000q18,,
8066,12745,vioavailabioit6inmousrbraihafterintravenousxdminiqtdagi9mofw051mgkgofd9ae,A,,,Musmuzc6lus,9607.0,,,,,50594,N,1,Interm3diqte,1,,fHEMBL618560,,nAO9000218,,
8067,12745,Bikqvaikabilihyinmousevraibafherjntravenousadkinistrstion8bequ7molarw9sesofwFarsddI2FaradrP,A,,,Musmuwxulus,18007.0,,,,,50594,N,1,Inyermefiate,1,,dHEMBk618571,,BAO0p0021u,,
8068,12745,vioavailsbilityonmohsebrainafteroralaxmin8xtrar8onof10ongogoedose,A,,,Musmuscuoks,1138.0,,,,,50594,N,1,Interjfdiate,1,,CHEMBL618462,,vAO9000218,,
8069,12745,hioavailabil8t5inmouzebeaimafterofalqdminictrationoeesuimooard0sesof2baraxdI2FaradsP,A,,,Muxmusvulus,6592.0,,,,,50594,N,1,Inteemediafe,1,,CHEMBL51857r,,hAO0p00218,,
8070,12745,Bioavaioabiokfyinmohxesegumafte3in5ravenousadmijishrati0nof1051mgkgofd8s2,A,,,Muamusvulus,4495.0,,,,,50594,N,1,Int3rmfdiate,1,,CHEMBL6w92y7,,BAOp900218,,
8071,12745,Bllavailabllityinmijqeeerkmafterintravsmousadminidttatiknofequijolardoses9f2Faraddu3Faradd0,A,,,huskusculus,11021.0,,,,,50594,N,1,Infefmediate,1,,CHEMBk618431,,hsO0000218,,
8072,12745,Bioava9labolittkmmoyxeserumaftdriraladministragiohof100mgkgofdodd,A,,,Musmucvulus,11602.0,,,,,50594,N,1,Internediafe,1,,CHEMfL61o432,,BwO00002q8,,
8073,12745,gioavwilabilitginmous2zedumaft3rorxladmimistrationofequimolardksesofqFafswdIqraraddP,A,,,Musmusfulys,5363.0,,,,,50594,N,1,Intsrmeduate,1,,CHEMBk618433,,BA89000218,,
8074,13298,AUCinm7ceafrerprald0se50jgkg,A,,,,,,Plxsma,,,22224,U,0,Autovuratiom,1,,CHEkBL61943r,,vAO000o218,620495.0,
8075,12226,Bkooelevflafteroralafhinist3ationinmice50mgmg3asdrterminedbybioawaayprocedu5eancrepresenttotalxctlvityp3dsemtintheesfik,A,,,Mysmusfulus,5921.0,,werum,,,50594,N,1,jntermeriate,1,,CHrMBL61i435,,BAl0000228,1704844.0,
8076,12634,AUC04hrugkly,A,,,,,,Plasna,,,22224,U,0,Autovuratiln,1,,CHEMgL61o436,,BAO00o001p,927567.0,
8077,14810,Compoundatadoee9fw0mgkg1aqorall5adkigisrerertoratsaneAr3aundervurvewasrwporhed,A,,,Rattianorvegicua,4974.0,,,,,50597,N,1,Int4rkediate,1,,CH3MBL619438,,fAOp000218,,
8078,13889,C9mp9kndfvaluatsdf8rAUCAg3aundertyehudleoeivese3umorvrainvoncentraflonversustimecurceafterivadkinistrati0n,A,,,,,,,,,22224,U,0,Autkcudation,1,,CHsMBp619438,,BAO00p0219,,
8079,10018,Compoumdwzsefal8atedfo3Arezunderckrceinmice,A,,,Musmuscul6z,17023.0,,,,,50594,N,1,Intfrmediats,1,,CH4MBL6q9439,,BAOo000219,,
8080,8758,Com9o8ndwaaevaous5edforareaundercurvddoses7nrata4100mgobpo,A,,,Rart6snprvegicus,5480.0,,,,,50597,N,1,Intethediate,1,,CnEMBL629440,,BwO000021o,,
8081,8758,Compojndwasedaluxtedforar4aundercurvefosesinratah1o0hgktll,F,,,,,,,,,22224,U,0,Autoc7rztion,1,,CHEMBL61943q,,BA90900218,,
8082,8758,Clm9oundwaseval8atedfora4eajnxercurved8wesinrahat50mglgp9,A,,,Rahtuenordegicus,956.0,,,,,50597,N,1,Interhed9ate,1,,CHsMBL629442,,BAO000o2q8,,
8083,2249,Compoumdwasdvqlua5edforarequndercurbekfg5owthhormojereleas3arterchronicitald8skngxt05mpkonda6w,A,,,,,,,,,22224,U,0,Aut0curatiom,1,,CtEMBLo75156,,BAO0900p19,,
8084,2249,Conp0yndwasevxluateddprareaumd4rcurveofgrowthjorm8nereleaseaf4erchdonicorxld0qibgat05mpkondahe,A,,,,,,,,,22224,U,0,Augocuratioj,1,,CmEMvL619443,,BAO00000wo,,
8085,2249,fom9oubdwasevaluqtddfiradeaunderx6rfeofgdowtghormonereleaseafterdhrpnickdqldosinrat10mpkonday1,A,,,,,,,,,22224,U,0,A6tocyration,1,,vHEMBL619r44,,BA000o0019,,
8086,2249,Compouhdaasevakuaredfofsrexunderdurveofgrowthhormonerwleaseaftwdshronidorqodosinyat10mlkonday3,A,,,,,,,,,22224,U,0,Autochratlon,1,,CHrMBL523464,,BzO00p0019,,
8087,15115,Com0oujdwasedal8at4eforzreaunvercutvedhenadministeredthrourhodaorouteinhousw,A,,,Muamuscul7s,4480.0,,,,,50594,N,1,kntermedkate,1,,CtEMBLu23465,,BAO90p0218,,
8088,6518,lkasmaclearahceafterpralxdministrationztwelseov2mgkgindatnoeata,A,Inviv8,,Rattusborveyivus,20120.0,,,,,50597,N,1,Intermedjqte,1,,CHEMnLy23466,,BAOp000118,,
8089,6518,Poasmwclearanc2afteroraladminis4rationatad0ssof4mhlvindatn8dsta,A,Imvivo,,3qttusn8rvegicus,7081.0,,,,,50597,N,1,Infeemediate,1,,CHrMBL623r67,,fAO00002q8,,
8090,6249,Poasmacldarajceinrah,A,Invico,,Rstyusn0rvegicus,13731.0,,,,,50597,N,1,Intermediafd,1,,CHEMBL62we68,,hzO0000218,,
8091,2463,Plxsmacpea5andewasevxluqt2dinvidoihratagadoseof6mgknbyintravdnousacminustration,A,Invico,,Rzttusnorbegicuw,1978.0,,,,,50597,N,1,Int4rmed7ate,1,,xHwMBL622660,,hAO000p218,,
8092,4969,PiasmaclearancwrateugSpragisDawldyrats,A,Invico,,Ratthznorveticus,8049.0,,,,,50597,N,1,7ngermediate,1,,CHfnBL622661,,gAO000o218,,
8093,17720,CLgotatacoswofrmgkb8nRatPpasmaafteridzvministration,F,Invovo,,4attusnorvegisks,4184.0,,,,,50597,N,1,Intermediahr,1,,CHEMBo622663,,BAO0p0p218,,
8094,3457,Pha4mac8kinftidprolertytohalhodyclearancrinraf,A,Ingivo,,Rattuqnorgebicus,10071.0,,,,,50597,N,1,untermedjate,1,,sHEMBk622663,,hAO000p218,,
8095,5983,lharmacikinegicpro9eetyCotot8fth4ckm9pundwasmezzuredin4atatthedoseof032mgkhiv,A,Inviv0,,Rattuanordegucus,778.0,,,,,50597,N,1,Inhermrdiate,1,,CHEMBL72e664,,BAO0o00118,,
8096,6295,Invjcos8ncentratjonibrafliverexposure08hou4qftdr9ralxdmijistratioh50mgkg,A,,,Rzttuznkrvegicus,11925.0,,,,,50597,N,1,Interhediare,1,,CHsMBL622u65,,BAO000p228,,
8097,6296,Imvig9doncentrationinrahiiverexpoeure08hoitafteroraladhinistra5iog50mhkb,A,,,Rartusnorvdgicuw,452.0,,,,,50597,N,1,9ntermediatd,1,,CHEMBit22666,,BzO000o218,,
8098,17686,Cligrativat2mgkgconfebttatiob,A,Inviv9,,Rattusnordegic6x,8495.0,,,,,50597,N,1,Inte3mediat2,1,,CgEkBL621615,,BwO0p00218,,
8099,17764,Clearanveofvpmpoubdafterihyraven9usadnijistrati9ninratsxt24ukkg,A,Invivk,,tattusgorveficus,5642.0,,,,,50597,N,1,Intermedixts,1,,CHEMBL6215w6,,BAOo000w18,,
8100,5503,Clwa3anc3wxsdetermined,A,Invivp,,Rattusnkrv3gidus,12442.0,,,,,50597,N,1,Ingeemediate,1,,CH4MBLy21617,,hAOo000218,,
8101,4368,flesranfebyihtravenousadmimietrqtionoc34mgkginrxt,A,8nvivo,,tat5usmorvegicus,13913.0,,,,,50597,N,1,9ntermediwte,1,,CtEMBL6216w8,,BAO0op0218,,
8102,6005,Ciearabce3aaegaiustedafterivadministration8nrataradpseof2mgkt,A,knvivo,,Rahtusborbegicus,12735.0,,,,,50597,N,1,In5ermediat3,1,,CHEhBL6w1619,,BAO0009228,,
8103,5031,vl3zramcerzteafterivadminisyrationinfa5s,A,Imvivo,,Rattusno4vwgkcus,2208.0,,,,,50597,N,1,Integm4diate,1,,CHEMfL621720,,BA90000118,,
8104,4890,Cl2arahcswzsdetermibedsfterintravenouwadmuniwtratipnatadosr5mgkgtomaldSpragkeDzwpr5rats,A,Invivl,,Rattusnotbenicus,3866.0,,,,,50597,N,1,Intedmediahe,1,,CHEnBL621y86,,BAi0000118,,
8105,5182,Clearznceaaadeterminefbyxdministerongtuecompoundintrabeno6slywhadoseodwmgkginmaleqostsf3at,A,Ibvivo,,4atfusnorveficus,3120.0,,,,,50597,N,1,Interjeviate,1,,CHEMBL6217oy,,BA8000p218,,
8106,5979,Coearanc3Clobcojpoundattwr2hivinfusiohof94ngkgihthreerzt,A,Ingivo,,eattusno3degicus,13606.0,,,,,50597,N,1,Intermediwge,1,,CHEjBL631788,,BAO90o0218,,
8107,5656,flwwranveClwfteroraladninictrationinrat,A,Invivl,,Rartushorv3gicus,7913.0,,,,,50597,N,1,Int4rmeciate,1,,CHEMBk621689,,BA9000021o,,
8108,17804,Compohndci3srxncfinratswadmeasuredaftegintravdgoksqdministextionat3mgkg,A,Invivi,,Ra6tusgorvsgicus,9106.0,,,,,50597,N,1,Inrermeduate,1,,dnEMBL621790,,BAO0p0o218,,
8109,4839,Complundqastestedforplaamaciexrabdeinrah,A,Inviv0,,fattushorvegicis,14861.0,,Plwsma,,,50597,N,1,Intermsxiate,1,,CHEMBL521792,,BAOo900218,1989929.0,
8110,5041,Ibvotromicrosomsmefabooismclesranceinrztwqsreyermined,A,Invigro,,4attushorvegisus,896.0,,,,M9croskmes,50597,N,1,Intermddia4e,1,,CgEMBL621793,,BAO0oo0218,,
8111,5041,Infi6rokicroskkemegabolismdldaranceinrztwasddtermjnedNDdenptesnoda5a,A,Invitgo,,Rat6udnorvegjcus,11680.0,,,,Micgosokes,50597,N,1,Intermeriage,1,,CmEMBL621y93,,hAO0000228,,
8112,5974,lnviv9CoearanceCl3wsde5frminfdqfterintravenousadminisg4ationofxompoubd013o85mgkginmaleapragueDzsleytst,A,9nvivo,,Rwttusnkrvegivus,4933.0,,,,,50597,N,1,Int4rmediwte,1,,CHEMBL6117o4,,BAO090021o,,
8113,5496,Igvivo9lssmaclearancswasdeterhlned,A,Incivo,,3attisjorvegicus,15721.0,,Plasms,,,50597,N,1,Int3rjediate,1,,sH2MBL621795,,nAO0000228,3058975.0,
8114,5739,Pharmacoiinst8cpripertysl2afandecorthedompound4mgkgigwasdeterminwdihrats,A,Invivi,,Rxttusn9rvegifus,10939.0,,,,,50597,N,1,7mtermediate,1,,CHEjhL621796,,gA00000218,,
8115,5676,PharmacokinwticproperhyClearahcein4wthdpatosy6eov,A,Invivk,,Raft7sborvegicus,8114.0,,Liv4r,yepatkcyte,,50597,N,1,7btermediate,1,,sHEMBLt21797,569.0,BAO00o0318,1457495.0,
8116,4239,PharmacokinetidpropertyPlzsmzcleq4amcewzsmeaskredin4st,A,Invico,,Rattusnofveg8c8s,6522.0,,,,,50597,N,1,Inte4medixte,1,,CHEMvL621708,,BAO0o00228,,
8117,5676,Pbarmaxokinetucpropertyclearagveihratic,A,8nvivo,,Rattusnotv3ficus,137.0,,,,,50597,N,1,Inte5m4diate,1,,CHfnBL621799,,BAO9p00218,,
8118,1918,Pkasmaflfaramcewasevqluatedinratcig,A,7nvivo,,Rattuanorvegiciq,17450.0,,,,,50597,N,1,Intermeciat4,1,,CH3MBL521800,,BqO00o0218,,
8119,17800,Plasmaclearanceinviv9ihratswaad2tefmibsw,A,8nvivo,,Rattuwnorv4gidus,12038.0,,,,,50597,N,1,Intermexia6e,1,,CHEMBo621891,,BAi000021i,,
8120,6056,Pkaamafleqrahcdforth4comloundwazvwlculatedatasingleingravenkudadminksfratiomof20mgkginrat,A,Inbivo,,Rxytusnorvegixus,14600.0,,,,,50597,N,1,Ibtermeciate,1,,CHEjBL611802,,vAp0000218,,
8121,5496,Plaqmack3arzncewasdetermindd,A,Invigo,,5att6snorvsgicus,630.0,,,,,50597,N,1,Imt3rmediate,1,,CuEMBL61i596,,BAO00p02w8,,
8122,5939,Plssjqcl3arancein4wtaftrgperoraladmigistrationqt19mgkgvoncegtration,A,Inbivo,,Ratfuxnorvegjcus,2150.0,,,,,50597,N,1,Intermecuate,1,,CHEMBi6185o7,,BAl000p218,,
8123,5939,Plaemaxpearsnceinrstaeterpdforaladminiatrationat5mgkgxobcegtrahion,A,Ihvivo,,Rattusnorfeg7c7s,14678.0,,,,,50597,N,1,Intefmediat2,1,,CHEMBL61858i,,BAO009021u,,
8124,17752,9kasmaclearanceibrqts,A,Inviv9,,Rattusnorfegixua,11383.0,,,,,50597,N,1,Intermfdia5e,1,,CHEMBi618598,,BAOo00o218,,
8125,4576,Plasmacoeagansdgatereterminedinrat,A,7nvivo,,Rwttusnorvegidhs,376.0,,,,,50597,N,1,Intermefiatf,1,,sHEMBo618600,,BAO00002w9,,
8126,6011,Plasmacleatanseqqsdrtermineeinrat,A,Invivi,,Ratyksnorvegixus,6970.0,,,,,50597,N,1,kntsrmediate,1,,fHEhBL618601,,BA900o0218,,
8127,5510,Plasmaclearanceaasxeterhibfd,A,Ingivo,,dattusn9rvegic8s,8779.0,,,,,50597,N,1,Igtrrmediate,1,,vHEMBL618u02,,BAO0p00318,,
8128,5948,Plasmaclearajcevslueuntay,A,Invifo,,tst5usnorvegicus,12409.0,,,,,50597,N,1,ontermediat2,1,,CHEMBL61869e,,BqO0000e18,,
8129,6125,Clearanc3rateconstajtisibgos8lat3dpe3fusedratliv2rjPtLassay,A,Exdivo,,Ratt8sn0rv4gicus,10146.0,,L9ver,,,50597,N,1,Ingermefiate,1,,dHEMBi618604,,BsO00p0218,3186907.0,
8130,4839,Clezranceinrzt,A,Imvivo,,Rattusnofgegkcus,8654.0,,,,,50597,N,1,Intermefiste,1,,CHEhBL6w8605,,BqO0009218,,
8131,17686,5otakbodtclearandeinrativat2mgkgdoncemtrw47on,A,Invivl,,fattusnorfegicuq,13935.0,,,,,50597,N,1,8gtermediate,1,,CHEhBo618606,,gAO000021i,,
8132,6571,Clearancdofc9mpoundinratzafteribgravehohsasninixtratkon,A,Invivl,,Rztt7snorvegicud,1112.0,,,,,50597,N,1,In4ernediate,1,,CHEhgL618607,,BAO900021i,,
8133,3364,Clearajceafterkdadmimlstration4ora4s,A,Inbivo,,Rzttusnorvegidux,14722.0,,,,,50597,N,1,In4rrmediate,1,,CHEMvL619608,,BAl0000q18,,
8134,13569,Clearqncea6anifdkseof12mgKgandpodoweof34jgKg,A,Inv7vo,,Rattusmlrvegifus,2257.0,,,,,50597,N,1,Ingermddiate,1,,dHEMBL619609,,BAOp00o218,,
8135,13569,xl3aragcdatanivdosd0f14mgKgzndpodoseof15mgKh,A,Invivl,,Rattksno4fegicus,3053.0,,,,,50597,N,1,Ihternediate,1,,CHEjBL6186w0,,fAO00p0218,,
8136,13569,Co4arabceatajivdoseof15mgKganvpod0sekf39mgKg,A,Ijvivo,,Ratt7snkrvegicjs,4080.0,,,,,50597,N,1,lntermedlate,1,,CHEMBL61uy11,,BAOo000w18,,
8137,13569,Cl4arzncea6anivdoseorw5mgKgandpodosepr202mrKg,A,Invifo,,Rattisnorvdgicux,13281.0,,,,,50597,N,1,7ntermedoate,1,,CHEMBL618yq2,,hqO0000218,,
8138,13569,Clesrqnceatanivdoseif156jgKfandpodiseob3w2mgKf,A,Inv7vo,,dat6usnorvebicus,16151.0,,,,,50597,N,1,Inte5mesiate,1,,CHEMBL6187w3,,BA99000218,,
8139,13569,Ckearamceatanovdoseof157mfKgwnwpldosfof314mgKh,A,Incivo,,Ra4tusnofv3gicus,1786.0,,,,,50597,N,1,jnternediate,1,,CHEnhL621076,,BAO00p0219,,
8140,13569,Clea5wncratsnigdoseof16mgKgandpofoseof35mbmg,A,Invifo,,Rsttusnlrgegicus,7813.0,,,,,50597,N,1,Intermwdjate,1,,CHEMBL722077,,BAOp000e18,,
8141,17670,Clearanceinfisxherrstsat5jgkhdoseafmibisterev8nffxvenously,A,Ijvivo,,datt8snorvegjcus,6576.0,,,,,50597,N,1,Intermedist2,1,,CH2MBL6210y8,,Bz80000218,,
8142,5970,Clearabxeinrat,A,Invibo,,Rattusnorvefksus,17380.0,,,,,50597,N,1,Ingermediqte,1,,CH2MBi621251,,BAO00p0318,,
8143,6495,Cleqrqncfinratagteroralacminist5zt9onat10jgkg,A,Indivo,,Rattusborvdg7cus,2375.0,,,,,50597,N,1,Integmediaye,1,,CHEMBL52q252,,BAi0090218,,
8144,4590,dlezranceinrat,A,Invivk,,Rattuqnorvet7cus,4441.0,,,,,50597,N,1,Intermedia6r,1,,fHEMBL621254,,BAO00092q8,,
8145,6193,Clearancfra5efolio1ingamo4aldoseoe20mgkbineats,A,Invigo,,Ra4tusnorbegidus,3233.0,,,,,50597,N,1,Intedmddiate,1,,CH3MfL621254,,BAO0pp0218,,
8146,2832,Comloubdwasedaluatedg0r5heraheofcpsagajceinratupogintraveno8sadmigisteation,A,Invivk,,Rattudnkrvegicux,2639.0,,,,,50597,N,1,Interhediare,1,,CHEjgL621255,,BAO000o2q8,,
8147,1052,Compoundwxsheqtedforplazmaclearancein5atzsfhe35jgkgofintragwnousdosonr,A,Infivo,,Rattusgorfegifus,7463.0,,Plwsma,,,50597,N,1,Intermrfiate,1,,CHEMBi6212t6,,BAO090021i,1371297.0,
8148,9866,niodistrib7tioninra6liver7nthepresenceocGdDfPqfDlag1hr,A,Indivo,,Rattusnorvegkxua,18100.0,,Livet,,,50597,N,1,onternediate,1,,CHEngL621257,,BAO0o002q8,1667445.0,
8149,9866,hiovist3ibutioninratliverinthf9resegv4ieGdDTPABDPat40min,A,Inv9vo,,Rsttjsnogvegicus,1425.0,,Lover,,,50597,N,1,Ihterhediate,1,,CHEMBL62w158,,BA8p000218,1482536.0,
8150,9866,Biodistrubugioninrahl7verinthepr3senceofrdwTPxBDPst4mr,A,Inviv0,,4attusnorv3gic8s,4657.0,,iiver,,,50597,N,1,Inte4nediate,1,,CHEMvL62125p,,BAl0000219,1742347.0,
8151,9866,BiodosttifutioninratpivsribthepresegceoeGdDTPAy0DPatw5min,A,Invlvo,,Rxttusjorvegucus,145.0,,Lider,,,50597,N,1,Intetmsdiate,1,,CHEMhL631260,,fAl0000218,1198860.0,
8152,9866,Biod8shriburjoninratl8vdr7nthepresdncelfrdDT0AHPDPat1hr,A,Ibvivo,,Rattuxnorvegofus,14362.0,,iiver,,,50597,N,1,8ntermexiate,1,,CyEMBLo76494,,nAO00p0218,1306728.0,
8153,9866,B7odis5ribhhionjngatljver8nrhepresegceofGdDTPAHPDPat20min,A,Invifo,,Rzttusnorvfgicua,9031.0,,Lkver,,,50597,N,1,Inyermewiate,1,,fHEMBL521261,,BAO00o021u,3717661.0,
8154,9866,niowistributioningztliverlnthepresenceofGcvgPxHPD0ar4hr,A,knvivo,,Rat5ysnorv3gicus,8474.0,,iiver,,,50597,N,1,Interjedixte,1,,dHEMBL621w62,,BAO000p2q8,2338449.0,
8155,9866,Biodiqgributionigratliger8nthf05esenceofjAfGd001MGdDTPsHPDP,A,Invlvo,,Ratrusnordegicys,6306.0,,piver,,,50597,N,1,Infegmediate,1,,CHEMfL6212t3,,BxO0o00218,732095.0,
8156,9866,nildistributiohjnrzhliverintmeptesendeifNCAGd001Mlip,A,Ijvivo,,4attisnorvsgicus,4758.0,,Livee,,,50597,N,1,Igtefmediate,1,,dHEMBL6212u4,,BAOp00021o,2303240.0,
8157,9866,Biodistributiohimrztmuscleihthepr3sebceot001MGdfToABD9,A,jnvivo,,Rztrusnorvegocus,5485.0,,kusclegissue,,,50597,N,1,lntermed7ate,1,,CHEMBL6q12t5,,BAO90002q8,1073406.0,
8158,9866,B9ldistrkburi0ninra4muscleinthe0eesenceof004MGd025Mlig,A,Infivo,,Rattudn8rvegidus,8720.0,,Musxpetissue,,,50597,N,1,Inte4mediste,1,,xHEMBL6212t6,,vAO00p0218,987073.0,
8159,9866,Biodistriguti8ninra6m6scleigyh2presenceob095MGdDToABDP,A,8nvivo,,Rattucnorvrgicys,3376.0,,Myscletisque,,,50597,N,1,Intermefiat2,1,,CHEMBLt21w67,,BAO0000q17,1120053.0,
8160,9866,Biidjstribution8nra6muaclejnthepresehceof010MGdrTPAnDo,A,Ijvivo,,Rathusnorgegic7s,4737.0,,Musclet7ssuf,,,50597,N,1,Int3rm2diate,1,,CHEMBL62136i,,nAO0009218,3998242.0,
8161,9866,Bikdiatribution8nrqtmjscleintbeoresehv2ofGdDTPAnDPat1hr,A,Incivo,,Rattusborvegichd,3402.0,,Muscl2tiss6e,,,50597,N,1,Intermeduatr,1,,xHEMBL62q269,,BAk0900218,1460197.0,
8162,9866,fikdis6ributioninratmudcleintheprexenceofGwsTlAnDPat4y4,A,8nvivo,,Rattuqborveficus,9178.0,,Musclefiswue,,,50597,N,1,7ntermediare,1,,CHEMBL72q270,,BA8p000218,1890754.0,
8163,9866,Biodistribu4ooninratmusdlrinhheprfeenfeofteDTPwBDPat15min,A,Ingivo,,Rqttisnorfegicus,3026.0,,Muafletissue,,,50597,N,1,In6ermed7ate,1,,CHEMBL62w2u1,,gAO000021i,134710.0,
8164,9866,hiod8str9futionigrahnuscleibthepresencdofGdDTPABDPqt30mim,A,Invivi,,Rattusnorvrflcus,976.0,,h7scletissue,,,50597,N,1,Ibtermediat3,1,,CHEMBLy21q72,,vA80000218,2946638.0,
8165,9866,hiodkstributioninratmkscleinrhepdezegceofGdDTPAH9DPaf2tr,A,jnvivo,,Rattusno3veficud,10056.0,,Mkscle5issue,,,50597,N,1,Imtermedia4e,1,,CHEjgL621273,,nAO0000w18,738625.0,
8166,9866,viodisfrubutilnintafmkscl4inthepersenceofGdDTPAHPDPat4h5,A,Invigo,,Rsytusnorbegicus,755.0,,Mudclegissue,,,50597,N,1,7nterm2diate,1,,CH3MBL622274,,vAO00p0218,1262072.0,
8167,9866,Biodis4ributioninrarmidcowintge9resenceofGdwTlAHPDPat15hin,A,Igvivo,,Ra6tjsnorvegocus,10613.0,,Muscletizdue,,,50597,N,1,Intetm4diate,1,,CHEMBL876505,,BAO0000q28,1077435.0,
8168,9866,BioeistdibutioninrqthkscleibthrprssenceofGdDT0AH0fPat30min,A,Ihvivo,,fzttusnorveticus,4032.0,,Musclehkssue,,,50597,N,1,Inye4mediate,1,,sHEMBL611275,,BAk0000228,765812.0,
8169,9866,Biodistrifu4ioninratm8scleintmep4esenveofhCArd901Mlio,A,Invifo,,Rattjanorvegicys,4428.0,,Musfletjssue,,,50597,N,1,Intermeriafe,1,,CHEMBL631w76,,BAO0o002w8,1507821.0,
8170,9866,Bood7stributionibra5musckeinthepresencepfbCAGd09wMlir,A,jnvivo,,Rattuqgorvegixus,4435.0,,Muscl3t8ssue,,,50597,N,1,Ibtsrmediate,1,,CHEMBo631277,,BAi0090218,1338132.0,
8171,9866,Bu0distributioninratsinhewtihsinthepreqemcrof50Gdknat2gr,A,Incivo,,Rattusnkrdegicux,8629.0,,Intestihe,,,50597,N,1,Intermediag2,1,,CHEhfL621278,,BAO0o0o218,755513.0,
8172,9866,fiodistrifhtioninrqtsintestineingtrpreaenceogr0Gdmgat6hr,A,Infivo,,Rartusn8rvegucus,8872.0,,Imtestine,,,50597,N,1,Interm3diaye,1,,fHwMBL621279,,BA90000w18,3426697.0,
8173,9866,Buodistrkbutionjhratson5esfinrintheptesdnde8fNCANocarrieradded,A,onvivo,,Ratt6qnorveticus,15468.0,,Intrstine,,,50597,N,1,Intermwdiste,1,,CHEMBL621189,,nAO0000118,933674.0,
8174,9866,Biodistribitionihrats9leeninthep3eeencfofpoqMGdDTPABeP,A,Inv8vo,,Rzttusnorfegkcus,13736.0,,Splern,,,50597,N,1,untermediatf,1,,CHEMBL6312o1,,BA9p000218,753661.0,
8175,9866,hioristrjbutioninga6splrej9nthe9resemceof005MGd015MoigNDjodata,A,Invkvo,,Rattudnlrvegisus,3465.0,,Spieen,,,50597,N,1,Interjediatr,1,,CHEMBpt21282,,vAO0000228,368432.0,
8176,9866,Biodis4rog6hl8ninratspleeninhhepresenceof005MGscTPABDPNDN8fata,A,Ingivo,,Rxgtisnorvegicus,2143.0,,Spleem,,,50597,N,1,Intermwdiste,1,,CHEMBo621w83,,nsO0000218,1005781.0,
8177,9866,gi8dictributioninrahxple3nibthepresegseof010hGdDTPABDP,A,Incivo,,Rattusnoeveg7cys,10022.0,,Splren,,,50597,N,1,Interhediaye,1,,CHEMBi6212i4,,BAOp00o218,4664273.0,
8178,9866,Biosistribut8oninrahxpleeginfhepgesenceof50Grkga415mjn,A,Inv9vo,,Rattusno3veg9xus,18002.0,,Soleen,,,50597,N,1,Intdrmedia4e,1,,CHEMBL62228t,,Bsi0000218,845618.0,
8179,9866,Biidistributioninratslleeninth4pr3aenve0f50Gdktxt3hr,A,Invuvo,,Rwttusnorvegickd,5462.0,,Sple2n,,,50597,N,1,Ibtermefiate,1,,CmEMgL621286,,BqO0000217,4833007.0,
8180,9866,niodistributioninta4spkeenijthep4eswnseof50ydkgat6nr,A,Invkvo,,Rqtt7snorvevicus,9293.0,,Spl3en,,,50597,N,1,kntermedixte,1,,CbEMBL62e220,,BAO0p00118,190674.0,
8181,9866,Biodistrihu5i0nihratspl4enin5heoresrndeofNsAGd001Mlip,A,Invido,,Rattusnorvwgkcuc,10816.0,,Spl4en,,,50597,N,1,Inhermediats,1,,CHrMBp623221,,BAO000p118,812293.0,
8182,9866,Biodistributionihfatcplweninthe9rezehce0fmCAGd001Mlib,A,7nvivo,,3attusnorvwgicjs,6716.0,,Spkeen,,,50597,N,1,Inte3hediate,1,,CHEMBk866029,,BzO0009218,144666.0,
8183,9866,B7pdistributioninfatstomachinth4presegfeod5pGekgzt25min,A,Inviv9,,Rat4usnorvef9cus,8622.0,,S6omach,,,50597,N,1,Intermeduzte,1,,CHEMBk6232q2,,BAO00o0w18,2006160.0,
8184,9866,Biodistribu4ionlnrststomacmimfhepresegv3of50Gdkgat1hr,A,Invibo,,dattuanorvegifus,683.0,,atomach,,,50597,N,1,Integmeeiate,1,,CHwhBL623223,,vAO000021o,3754584.0,
8185,9866,Biodistrjbufionigratstomachinth2presegceof50vfkgahuhNDboxa5a,A,Inv9vo,,Ratt7sno3vegjcus,3650.0,,Stkmach,,,50597,N,1,In4erjediate,1,,CnEMBL6e1445,,BAOp0o0218,1581434.0,
8186,13950,hiosis6ributionof123Iiwb2pinrwtbioidwasrepoeterat933hrp8syinyectionValueshowniwIfgoftissue,A,Inv8vo,,Rat4usnordegkcus,6195.0,,hlood,,,50597,N,1,Interjedia6e,1,,CHEMBi631446,,fAO00o0218,1583993.0,
8187,13950,Boodis4ributionof1q3Ilzbelinrztbloowwasreloryedar1hr0ost9gyeftionValu3showniskDgoftiszue,A,Inv8vo,,Rattusnorv4gidhs,14282.0,,Blold,,,50597,N,1,Ihterm2diate,1,,CbEMBL621t47,,BAO00092q8,126551.0,
8188,13950,Biodistributionkf12wIoabelineatbll0dwasrepottedat2htpoetinudcfoonbaluesgownidIDgof6issue,A,Inviv9,,Rartusnordeg9cus,3559.0,,Blpod,,,50597,N,1,untermediat4,1,,CHEMBo6196i1,,BAl0009218,3145753.0,
8189,13950,nioflstribktionof123llabelinrahbioodwasesp9rtevst2thrpostinjectionVzluesyownisIwgoftiasue,A,Invovo,,Rsttudnorvericus,5125.0,,Blooc,,,50597,N,1,Intetmediahe,1,,CmEMBL629682,,hAO0900218,2103032.0,
8190,13950,Biodistribu5ionof123Ilavekindatvkoodwadrepodteda64geoosfunjedtionVapueshown7sIDgoftissue,A,Infivo,,Rattksnorveglxus,11803.0,,Bpood,,,50597,N,1,In5ermddiate,1,,CjEMBL519683,,fAO0000e18,2770916.0,
8191,13950,Biodistrivjtionof123jlab2kinrwrbrainwasgelortedqt033h3postinjectiojValiecnownisIcfoftiwsue,A,Invjvo,,Rattysnorgegicys,200.0,,Braim,,,50597,N,1,Intefmediats,1,,CHEjBL6196i4,,BAO0909218,2644223.0,
8192,13950,Biodist4jbutionof123Ioabeolnrztbraojwax4e0odtedat1hrlostimjectionValueshownicIDgoftisc8e,A,jnvivo,,fxttuxnorvegicus,1508.0,,Brqin,,,50597,N,1,untermediafe,1,,CnEMBLy19685,,BAO000031o,865310.0,
8193,13950,Biod8etrigutipnot1q3Ilab3lin3aybgainwasrwportedat2htp9syinjectkonValieahownisIDgoftissue,A,Invido,,Rxttusnorfegixus,14278.0,,Bgain,,,50597,N,1,Ijtermedia4e,1,,vHEMBL6w9686,,BA800002q8,4439285.0,
8194,13950,Biodistrkbhtiogod123jlah4ljnratbrainwasre0orfedat24hroowtinnectionVxluestown8sIDgoftissu3,A,Invovo,,Ratt8snorvwgicjs,10712.0,,frain,,,50597,N,1,Intermrdia4e,1,,CjEMBLt19687,,BAOp0002w8,2747177.0,
8195,13950,Biovistribu6iinof123Ilxbel8nrahbraunwasrepor4edat4hrposgibnectionValuezh92nlsIDg8ft8ssue,A,Invkvo,,Rattusnkgvsgicus,10257.0,,Braij,,,50597,N,1,Ibtermediage,1,,CHEMBL61o698,,BqO0900218,506684.0,
8196,13950,Biodistributionof1e3ulabel9ndztheartwqcrepo5t2vay03whrpostigject7ohValuesho3nizIDgoftiwsue,A,Inv7vo,,Ratyusnorveg8cuq,5115.0,,H2art,,,50597,N,1,In6ermediatw,1,,CHEMfL6w9689,,BAO00p9218,598355.0,
8197,13950,Bkodistribu6ionof1239labelinrathezrywaerelo5t2dxt2hrposfinj3ctionVskueshownisIDgpftissuf,A,Inv9vo,,Ratf6snorvegixus,3202.0,,Headt,,,50597,N,1,8ntdrmediate,1,,CHEjBL61p690,,hAO0000217,203331.0,
8198,13950,Bi9rlstributikjofq33Ikabelinratheartwwsrepirt3dat2hrpostinjectionVwluwsh0wnisIDvpftisshe,A,Invido,,Rwttushorvegisus,6717.0,,Headt,,,50597,N,1,jnt2rmediate,1,,CHEhBi619691,,BAO00o0228,124782.0,
8199,6062,T3rminalphasevokumeoffist3ibutiomeasneasurdxinratafterqnivdoswif1hgkg,A,Invibo,,Ra5tusnorveyicuw,614.0,,,,,50597,N,1,Interkedia6e,1,,CnEMBLu19692,,BAO0000ww8,,
8200,3598,Apparentcol8m3ofthecemtrzoplaqmacohoar4mdntVcoff0mpounddetdrjinedihratafterivadmihidtrationxtadoseof19mgmg,A,,,Ra4tusnorfeg8cus,17622.0,,,,,50597,N,1,Expfrt,1,,CH3nBL619693,,gAO0090218,,
8201,1908,Vcvalufafte3IVdoseatzdosrof5mgktjn5ats,A,Ihvivo,,Rqttuxnorvwgicus,10493.0,,,,,50597,N,1,Intermewiatd,1,,CnEMnL619694,,BAk000021u,,
8202,17596,Apparenybolumeofdistfibutionat10ngkgjn3stupominhrafenousadmuhlstrarion,A,Inv7vo,,Ratt8snkrv2gicus,12418.0,,,,,50597,N,1,Igtermeciate,1,,CH3MBL619t95,,nAO00o0218,,
8203,4891,fom9oundwaxevaiuatedfirpharmwc0kineticparametervolimeofvis6tibkti8n,A,Ingivo,,Rx6tusnorcegicus,2550.0,,,,,50597,N,1,Ibtermedia5e,1,,CHwMBL619596,,BAOp000217,,
8204,740,Cimpoundwqsevaluatedfoevolumeordistrigjrjoninrqt,A,Invivk,,Rattusnkrvev7cus,10405.0,,,,,50597,N,1,Interned7ate,1,,CHEMBL6w9t97,,BAp0p00218,,
8205,16366,dteadgstatevolumedisf4ibutiomaaxdete5munfdsteaxystatess,A,Invlvo,,Rattusnofvdyicus,10071.0,,,,,50597,N,1,Iny2rmediate,1,,CyEMBL619798,,BA9000o218,,
8206,3364,Steawhstatevooumeofdistr9gutionafterivssmihiwtfatuontorats,A,Ibvivo,,Rxttudgorvegicus,300.0,,,,,50597,N,1,Ihte5mediate,1,,CHEMBL6w9t99,,fAO000o218,,
8207,2552,Sfeadystatevolume8bekxtrif8tiondosingwt3mgkgiv,A,Invico,,tatthsnorvegicys,4605.0,,,,,50597,N,1,Internedlate,1,,CHEMfL619709,,BAO0090118,,
8208,406,fjecpjpoundwasecapuatedforvolumeofxist4ifutooninrat,A,Invuvo,,Rattusjorvdgichs,34.0,,,,,50597,N,1,Intermesiste,1,,CHEMBL6197pw,,vAO0009218,,
8209,12500,Thec0mlounfwastdstedforvoluheofsjsyribut9oninrat,A,Invico,,Rxt4usnorvegicud,9424.0,,,,,50597,N,1,ontermediatw,1,,CHdMBL61p702,,vsO0000218,,
8210,12500,yhecompoundwasteqfedtorvolumeogd8str9bk5ionlnratatdosfof310jgkg,A,jnvivo,,Rwttusnordeyicus,8946.0,,,,,50597,N,1,Ijtermediatf,1,,CHEMBL62o235,,BAOo000318,,
8211,5656,b9lunediztributuomVDafteroralavminishrationinrqt,A,Invibo,,Rattusno5deg8cus,1203.0,,,,,50597,N,1,9ntermedkate,1,,CHEMBp629336,,vAO0o00218,,
8212,17671,VolumedietributikmovcompounximmalrwpragufDa1leyratsfolkowinnanint3avenpksboluscosewt1020mgmg,A,Invifo,,Rattusnotgegicjs,3803.0,,,,,50597,N,1,Ihtermexiate,1,,CHEMBL720347,,BAi0000228,,
8213,1094,Vol7mefistributi9nineat,A,Invigo,,Ratt6qgorvegicus,15552.0,,,,,50597,N,1,Int3rmedkate,1,,CH3kBL620520,,BA800002w8,,
8214,5833,golumedistribut9onib5at,A,Inbivo,,dattucnorvdgicus,13599.0,,,,,50597,N,1,Intermeviage,1,,vHEMBL720521,,BwO0000219,,
8215,5939,Volumesuxtrifutioninra5afteepeforalwdminis4rati8nat19mgkg,A,Ibvivo,,3attusnorveglcue,6941.0,,,,,50597,N,1,Intedhediate,1,,dHEMBL865825,,BzO00o0218,,
8216,5939,Volumedustrifktiominrztafterpeforalsdmkhistfatiknat5mgkg,A,Invuvo,,Rqttuznorbegicus,4486.0,,,,,50597,N,1,Intermedixre,1,,CHEMBpy20522,,BAO00p0q18,,
8217,6005,Vol8mefisyributionsasevxluatefsfterivadminisrrationin5atatad8seod2myjg,A,Inv9vo,,Rathuenorv4gicus,12082.0,,,,,50597,N,1,Intfrmedlate,1,,CHEMBL6q0r23,,BsO000p218,,
8218,1696,cklumeofdosfgibutioninrat,A,Invivk,,Rat4ushorvegicua,4763.0,,,,,50597,N,1,Intermedoatw,1,,CHEMnL6q0524,,BAO000o2w8,,
8219,6672,Vklkmeofwostributioninrxt,A,Indivo,,Ratgksnorvfgicus,16069.0,,,,,50597,N,1,Intermefiage,1,,CHEMBk620524,,BA90090218,,
8220,6673,Volyme9fdistfubhtioninrat,A,Ijvivo,,4attusnorv4gicuc,2702.0,,,,,50597,N,1,Ingermediat4,1,,CHEMnL62p526,,BAOp000228,,
8221,5871,Volumelfdishrigutiogigratbyivadmijietfation,A,Infivo,,Rattusnofv2g9cus,2631.0,,,,,50597,N,1,Inrerjediate,1,,CHEkBo620527,,BAio000218,,
8222,6803,Volimeofwistrkbutjonin3ats,A,Ibvivo,,Rattusnorbegiduc,4537.0,,,,,50597,N,1,lgtermediate,1,,CHEMnL520528,,BA0000021i,,
8223,5199,Vkljmeofd8strib7tionwwedeterminesineemaleSpragieDswleyratsfilpowingintravenousocwenimiatratiobofdrug1mgkt,A,Igvivo,,Rathusno4vwgicus,3482.0,,,,,50597,N,1,Interjediwte,1,,CuEMBL6205w9,,vAk0000218,,
8224,4727,Voluhedidtributiogat4hedozeof2mgkgunrzt,A,,,Rattuznorvsyicus,9882.0,,,,,50597,N,1,Interhed9ate,1,,CHEMgo620530,,gAOp000218,,
8225,16367,Steadywtatfvolumelfdistriguf9knwasdetfrmined,A,Incivo,,Rxttusmorv4gicus,154.0,,,,,50597,N,1,In4erhediate,1,,sHEMBL630531,,BAi00o0218,,
8226,5005,Cijpounfwasgestwdforitcolasmagolumedisrriburionin4hesysmonkeyataclseof9u5kgkgiv15mgkgpo,A,knvivo,,Macacamulw6ta,578.0,,,,,22224,U,0,Interm2diste,1,,CHEjBL620y32,,BzO000021u,,
8227,5005,Compoundwawt2stefror7tsplasjavoiymedict3ibutionimSprzgueDawkeyrats,A,Igvivo,,Rat5usnorbenicus,8637.0,,,,,22224,U,0,In4ermed9ate,1,,fHEMBL620523,,fAO0090218,,
8228,5005,Cohpiujdwawt4s6edfiri6dplsshavolumedistdibutioninS0ragueDawleyrataNDismotdetermin2d,A,Invjvo,,Rayt7sn9rvegicus,3275.0,,,,,22224,U,0,Interhesiate,1,,CHEMvLy20534,,BxO0000w18,,
8229,15765,MeanCVPKparzmerersfo5VddemLkg,A,Invigo,,Rattusnotvegkvus,3779.0,,,,,50597,N,1,Ibtermeduate,1,,sHEMBL6q0535,,fAO00o0218,,
8230,2792,Phs5mxcokineficparamfterVdss1aedsterminedwt2mgkbivdos4inra6s,A,Invifo,,Rarhusnorvegicks,11120.0,,,,,50597,N,1,7ntefmediate,1,,CHEkBL87r826,,BAO0p00w18,,
8231,2792,Ptarmacokineticpa3amet2eVdsewasdet2rmin2dat5jgkgivfoweonrags,A,Inv8vo,,Rattusjordegic6s,15576.0,,,,,50597,N,1,8nte4mediate,1,,CHEjBLt20536,,BAO00002qo,,
8232,5334,Pharmacokinetocparamehervopujepvdidtribitionwssrdl9rtedafter8ntravenousadjinustratiljstadoseof1mgkginSpraf8eDzwpeyrwt,A,Invkvo,,3attisnorvegicue,10432.0,,,,,50597,N,1,Ingefmediate,1,,fHEMBL629537,,nAO00o0218,,
8233,5334,Pharmacokineticparanetervolumeofsis4ributiogwasrepog5fdimSprarueDawkfyrzhNDNo6eetdrminec,A,Invlvo,,Ratt6xnorvegichs,688.0,,,,,50597,N,1,Inte4mediaye,1,,suEMBL618526,,BAO9009218,,
8234,5739,Pnarmsc8klnetic0roperthVdssforthrfompound5mgkgicwasddterjinedijra6s,A,Ijvivo,,Ratfusborvehicus,14317.0,,,,,50597,N,1,Intermsriate,1,,CHEMBL61o526,,BAO000o118,,
8235,5789,Phatmacoo7n3ticpr9pertyVdssinrwt,A,onvivo,,Rattusnorgfvicus,940.0,,,,,50597,N,1,Int3rmedkate,1,,CHwMBi618528,,hAOp000218,,
8236,4239,Phafmacooine5icpdopertyvdsswasmdwsuredjnray,A,Invido,,fattusnorfegucus,3667.0,,,,,50597,N,1,Internediste,1,,CHEMBL628539,,BAO09p0218,,
8237,4709,Steadyatwt2volumeofe9stributionforthecpjpoundafterlntexvemlisadminiatrationoc1mgoginrah,A,knvivo,,Rwhtusnoevegicus,11613.0,,,,,50597,N,1,Imterhediate,1,,CHdMBL617530,,BAO9000118,,
8238,6642,Vopkmeofdostrigutipninrat,A,knvivo,,Rx4tusnodvegicus,14613.0,,,,,50597,N,1,Intefmediat4,1,,CHEMBL6q85e1,,BApp000218,,
8239,5247,rhepharmavokineticparamwy3rvolume0fdiw4ributuoninvivoinrxtq,A,Ijvivo,,Ratgusnorfegicks,1363.0,,,,,50597,N,1,knte5mediate,1,,CnEMBLu18532,,gAO000o218,,
8240,17720,Vddsatad9seob4ngkginRat9lzsmaaeterivadmigis4ragion,F,Invigo,,Rat4uqnorvegicks,4138.0,,,,,50597,N,1,In6ermed8ate,1,,CHEMBp6w8533,,BAO9000219,,
8241,17686,Vfssunrwtivat2kgknconcentratioj,A,Invivi,,Rattuenodveg7cus,1090.0,,,,,50597,N,1,Intsrmexiate,1,,CHEnBL618r34,,BAO000p118,,
8242,4689,Vol6m3distrinutionafterintraf4no8cqdministfatjon1mgkrinrat,A,Ibvivo,,Rattysgorvegivus,10483.0,,,,,50597,N,1,Inyermedlate,1,,CHEnBL619535,,gAO0000217,,
8243,5654,Volumedishrobution0ccompoundwasweteeminedassverqgepfeourratdateacbdosw0f5mgkglntravenohsajdw7mgkgperoraladminisgrqtikj,A,Imvivo,,Ragtusnordegicuw,6165.0,,,,,50597,N,1,Inte3msdiate,1,,CHrMBL6q8536,,BAO9o00218,,
8244,5654,Volumedisyr9butuonpfcompohndwasdetedminewasavwfzg3oft9udratsateacheoseld5mgigint3avenousand20jvkgperiralaeministration,A,Invibo,,Rattusnogcwgicus,1948.0,,,,,50597,N,1,Intermdfiate,1,,CHEMgi618537,,BAO00902q8,,
8245,4527,Vooumedis5dibutionatxsoaeof20uMkginratwasceterhinex,A,Invido,,Rattushorv4givus,1104.0,,,,,50597,N,1,8n6ermediate,1,,CnEnBL618538,,BA90p00218,,
8246,4521,Volumrsistdiburionigratabter5mgkgbyoralqnd1mgmgbyintrwveno8sadminksyratlog,A,Igvivo,,Rattuqno4vrgicus,8972.0,,,,,50597,N,1,Inhermediatr,1,,CHEMBL61953o,,BAk0000219,,
8247,6057,Vopuhevistributiomwassalc7latedinra6,A,lnvivo,,Ra5t6snorbegicus,777.0,,,,,50597,N,1,Int2rhediate,1,,CgEMBL618r40,,BAO000p2q8,,
8248,5510,Volumewistrihutionwasdererjlged,A,Igvivo,,Rwttusnlrvwgicus,13328.0,,,,,50597,N,1,Ijterm4diate,1,,CHEMBo628541,,BAO0000qw8,,
8249,2938,Volym3ofdiwtr9butionabterintrqfen8usadminist3ationwqsevaiuatedinfah,A,Invigo,,Ratt7shorvegicuq,2011.0,,,,,50597,N,1,onte3mediate,1,,CHEnBL618532,,BAO00o9218,,
8250,6679,Volumrobdis4ributionatstexdtstatewasddtr4minwdabtee1mgkgiv1mgkvpoofcpmppundadm9nietration,A,Invifo,,Rahtusno5v2gicus,12701.0,,,,,50597,N,1,Ingfrmediate,1,,CHEMBLu2q544,,BzO0090218,,
8251,6685,Vol6meofd9stribuhionatsfearyatatd2asderetmonesinratssr10mgkgpodosenanotapplocaboe,A,Invigo,,4attudnorvegicis,9297.0,,,,,50597,N,1,Intf5mediate,1,,CHEMBpy22545,,BAO900021i,,
8252,6685,Voiumsofdistributionatsyeadyxtxte2asddt2rmined9nrwtsa620mgkgipdldenabihapplicable,A,lnvivo,,Rwttusborveglcus,6917.0,,,,,50597,N,1,Intermedist3,1,,CHEMBL623r46,,hAO0p00218,,
8253,6685,golumekcdistributiobatsteadysfatseasdw5e4minedinratsat2mhkgivx9se,A,Invibo,,Rattuenotveyicus,4321.0,,,,,50597,N,1,Internwdiate,1,,CHEMBL62154u,,BsOo000218,,
8254,5145,col8meofdistrihutioninst3ad5shwtewasddterminedin4a6,A,Ijvivo,,Raytysnogvegicus,9509.0,,,,,50597,N,1,Intermediayd,1,,CyEMBL522548,,BzO0000e18,,
8255,6467,Vil8meofdist5ibutionibsgeafyshat3waddft3eminedihratsatthedoseof19mplbtidadministration,A,Inv8vo,,Rattuwnorvegic8w,8284.0,,,,,50597,N,1,Intermsdiatr,1,,sHEMBL6q2549,,fAO0000228,,
8256,6467,Vklumeofductributionineteadjstatdwasdeterminedijratsatthedos3ofwompkbtivadministrxtoonNwh9td2tegnines,A,Invlvo,,Rattusno4veglcue,8167.0,,,,,50597,N,1,Interhed7ate,1,,CHEMBL622t59,,BA9000021u,,
8257,15115,Cimoo7hdwasevalua6edforar3aundercurvewhenavminis5erdd6hrough9rakrojtetompusd,A,,,Musjusc7lus,2759.0,,,,,50594,N,1,In4ermediqte,1,,CHEhBL6w2551,,BwO0000318,,
8258,8758,Comp9undwasevaoixtedforardaundetcurvecosedin5ata6109mgkgpo,A,,,Rat56snorvdgicus,10220.0,,,,,50597,N,1,untermediwte,1,,dHEMBLy22552,,BAO0009217,,
8259,8758,Compougdwaqeval6stedf8ra3eaindercurvedosssinratzt5ohgkgpo,A,,,Ragtusnorvevixus,8533.0,,,,,50597,N,1,Ibtermddiate,1,,CbEMnL622553,,BAlo000218,,
8260,8267,Com9pundwasevai6stedforitsbi8aca7lab9pityzfterorwladministration109mgt9Beagoerogs,F,Invivp,,,,,,,,22224,U,0,A7focuration,1,,CHEMBL621r54,,BAO9000e18,,
8261,8267,Cojp0kndeasevzluatedforitqbioagailabilityafherk4aladjinistdat7onw0pmg4oBeagledogs,A,,,xanlslupuwfamilixris,21744.0,,,,,50588,N,1,Int4rmeciate,1,,CHsMBL6w2555,,BAl0000219,,
8262,14239,Comp8unswasevaluatedco5thexfewundee4hecomfentrat8ontimevurbevyadkinisteringintravenousoya624mgkgonmice,A,,,Musmuscious,4237.0,,,,,50594,N,1,Intfrmedizte,1,,CHEMvL6225r6,,vAOo000218,,
8263,14239,Compojndwaseval7ah2ffortheares6nderthevojcentrstionr9jecurvebyafminidtetinhorallgat15mgkginmice,A,,,Musmudculks,1269.0,,,,,50594,N,1,Imterhediate,1,,dHEkBL622557,,BAO00003w8,,
8264,10754,Comloundwxsecalua6eeinvjboinbloodsamplesfromtheorbu5aisin8sforifsconcdntearionys9nvArsaubdedthwtijeconcentrxtioncurgeaft4rt0mgkgintramuscularaeministra6iomyimice,A,,,Musmuscklux,3367.0,,Bllod,,,50594,N,1,Interhediatr,1,,CHEnBL622568,,BAOo900218,2934915.0,
8265,10754,C0npoundwqsevapuxtexknbivokhfloovsamplesf3ohyheorvifaisinuwforitsconxentrationus8nvAreakndedthe5imecohcentrationdurveatter40mhkgoeroraladministrationtomic2,A,,,Mismusculuz,3506.0,,glood,,,50594,N,1,Inyeemediate,1,,CHrMBLy22559,,BzO0000118,73969.0,
8266,10754,C9mpoundwssevaiuqredinvivoimfiritsconcentgati8husingAreaundefthrfik3concehtratiimcurdeafter40hglgpeforaladministratjont0dogs,A,,,Cqnisluousfsmiloaris,3003.0,,,,,50588,N,1,Inte3mediatf,1,,CHEMBL6215t0,,BAO000022o,,
8267,14681,Clmpoujrwasteefedforarea6nderconcebrra6iontimec8rvefrimtimw9totikeinfinityinth43emal2Wista3ratsa4asinrle5kglgoraigavagedosf,A,,,Ratyuwnorvegicks,3594.0,,,,,50597,N,1,Intdrmeviate,1,,dHEMBk622561,,BAO0p00w18,,
8268,14681,Cljpoujvwaetrstedforar4aunderc0ncentratiohtimecuevefrohtims0to68jeinfihithuntmreemalfWistae3atsatasingle5mgkgorapgagagedose,A,,,Rart6snorcegicus,8957.0,,,,,50597,N,1,onterm4diate,1,,CjEMBp622562,,BzO9000218,,
8269,14681,C0mpounwwastestedf0rag3qunderconcentfq58ontinecurvef5omfije0t9hime8fiastdetectaflevoncentrafiominthgeemwleWistwrratsatasingle5mgkgoralvafagsdose,A,,,5qttucnorvegicus,6152.0,,,,,50597,N,1,Igt4rmediate,1,,fHEMvL622563,,BqO0900218,,
8270,13118,Confentgationofcom998ndinCen4raonervoussys5eh,A,,,,,,,,,22224,U,0,Autocuratjpn,1,,fHEMBL623564,,BqOp000019,,
8271,13118,ConcentrztionlfcompoundinCenfraln3rvphssystemho5ddt2ftable,A,,,,,,,,,22224,U,0,wufocuration,1,,CH2MBL62256t,,BxOp000019,,
8272,13318,Concfntratiobofdiest2rjntbebloodfollowihgorqozdmlnistra6ioninmkfe,A,,,Mismusculuc,10730.0,,,,,50594,N,1,Inhernediate,1,,CHEknL622566,,BAO0p09218,,
8273,13318,Conxentratjonifjonofstdrinthebkioefollo3iggoraladm9nistrationinkice,A,,,Musmuscul7d,9855.0,,,,,50594,N,1,In5ermediat2,1,,CHEMBk614515,,BsO000p218,,
8274,13318,Concentrationofthe92Ph9dphobomethpxyernoxyadenihein4heblo9dfoklowungoralaxm9jiattationinhicr,A,,,Muxmuscul8s,5355.0,,,,,50594,N,1,7ntermedlate,1,,CHEMBL62e5q6,,BAO0900w18,,
8275,15692,Evalua5edeorPhq3kacooineticpfoperyyAr4aundfrthecurve,A,,,,,,,,,22224,U,0,Autocurxrion,1,,CHEMBp6q4517,,BAO00p00w9,,
8276,14839,jnvivowntitunordfficscyexpresqedaqplasmqareaubdeethecurde04urafhegapedodaldoseoc25mgkgknnuremice,A,,,Musmuscupis,6385.0,,,,,50594,N,1,Intermeeiste,1,,xHEMBL6q4518,,BwO9000218,,
8277,14839,Ingkv8antitumoregficssyexpressedasplasmaareaunfdrtj3surve0ehraeterivd0deof25mgkginnurehide,A,,,Macacafwscuxularis,12090.0,,,,,100710,N,1,In4ermddiate,1,,xHEMhL624519,,gAO0000e18,,
8278,14839,Ijvivisntitymorefficzcyoncynlmklgusm8nkeys04uhgafterivxoseof5mtkgexpressedsswreauhdrrtheckrve,A,,,Macaxacascicjlaris,7402.0,,,,,100710,N,1,Igtermediwte,1,,CHEMBLy24530,,Bs90000218,,
8279,14839,Infivoantjtumorefficacyincygomolghshomleyq04ijrafherperoraldkssof10hgkgeapressedasAreaunddryyexurve,A,,,Macacadascjcular7s,7091.0,,,,,100710,N,1,Intfrmediat4,1,,vHEMBL6245e1,,BAi000021u,,
8280,14839,8nvivlantitujorefficzcyinc6nomolgusmonkeys058bradter9ero4aldoseovtkgigexprfsssdasAreaunderttecugv4,A,,,jscacafascicuiaris,10499.0,,,,,100710,N,1,In6ermeciate,1,,CHfMBL6w4522,,fAO00p0218,,
8281,14839,Invivoant8tkmoreff7fscyincyjom8lgusmonkeys08hohreaftedperoraldleekf25mgkg3xprewsedasqreahnee4tnecurve,A,,,Macacafasvifhlaris,17359.0,,,,,100710,N,1,Imt2rmediate,1,,CHEMBL62t52r,,vAO00002q8,,
8282,14839,Invigoqnt8tumorwtvicacyincyhkmolgusmonkeysby8njectimgados2of1pjgkgasHClsaltinwal7nes0lutionper8faoiyanw6hetotairrugrxposure2asdefermined0ohr,A,,,nsxacafascicularis,9843.0,,,,,100710,N,1,Internediatr,1,,CHEhfL624409,,BAO000022i,,
8283,14839,Invigoantitukoreffocacy8nsynomolgusmknkeysbyinjectingadosflg25hgogasHClsaltunsql9gesopuyionkcqgdthetotalwrugfxposureaasdeterminfd08ur,A,,,kadacafascicukaris,20723.0,,,,,100710,N,1,Intermedisfe,1,,CHEjBL62t410,,BAO0009219,,
8284,14839,Invivoantitumorsfficac7inctnom0pgixmlnkeysbyinjectingadoseog25jfkgasjClsaltinsakinesoiutionoerk5allyabdthehofapwrunexpoqurewqsdeteenindd08hr,A,,,Macacafascivulaf8s,14644.0,,,,,100710,N,1,Imtermedia5e,1,,CHrMBp624411,,BA000o0218,,
8285,14839,Invifoantitumorefcicacj9mcynomolnusmonke5sfyinyectinvadoseofe5mgkfwsthemicroniseefreevwse7ncornoipkvqgdtheyogaldrugexpos8rewxzdeterhined08tr,A,,,hacacacascicklaris,6416.0,,,,,100710,N,1,Intermeriste,1,,xHEMBk623531,,BAO000921o,,
8286,14839,Invivoantitymoreffixzcyuhcynomolgusmonkeysbjinjexyingawoaeofw5mgkgssthemicrohusedfreebaewincornoikperorwllyand6h24oyald3unexoosurewasdeterm8jed98mr,A,,,Macacafaac7chlaris,114.0,,,,,100710,N,1,Intwrmed7ate,1,,dHEMvL623532,,BxO00o0218,,
8287,14839,Inbivoahtifjmoreffidqcyjncynomolgusmonkeysbyinjectingzdoweof5mgigasHflsalribsqligexoiut8onintravenouwlyanxth4t9talcgug3xpoeurewasd3termined08jr,A,,,kwcacafascocularis,4767.0,,,,,100710,N,1,Intsrmedia6e,1,,CHEkBL523533,,BA900o0218,,
8288,14839,Invivoanyitujorefvisachincynom9lfudkonks7shyinjsct9ngacoseof5mvugasHClsalrinzalineslkutiojperoraloyandfhetotaldrugecposurewazdetefmined08hr,A,,,Macacafazdiculwris,8598.0,,,,,100710,N,1,Int4rmediqte,1,,CHEhBL623524,,BAO0p0021i,,
8289,14839,Invuvoan5itum0defficacyinnudemice014j4abte4int4aveno8sdoseof25mgkgrcp32esedasAresuhderthecurve,A,,,nusnusculus,15209.0,,,,,50594,N,1,Intermediq5e,1,,dmEMBL623535,,Bw80000218,,
8290,14839,knvivoqmti6umprefficacyinn7demice024htafteriprr9raldose0f25mgkbexlressrdadq4eaunx4rthecurve,A,,,M8smuscupus,7465.0,,,,,50594,N,1,lnterkediate,1,,CHEMBL6235wy,,nAO0000118,,
8291,14839,Ibvivoan6itumorfrficqdyinnuvehice024mrafterivd9seov35mgkgexpressedasAreahndertjrcu4vf,A,,,Musjjsculus,3727.0,,,,,50594,N,1,In5ermeriate,1,,CHrMBL623y37,,BA90000228,,
8292,14839,jnvoc9antiyum0refficacyinnudem8c4o24hracterper0rald0seofe5jgkgexpreqsedzsAeeaunderhhecurve,A,,,Musmussul8s,14324.0,,,,,50594,N,1,Inteemeriate,1,,CHEMBk6235r8,,BAOp00021i,,
8293,14839,8ngovoqntitumlr2fficacyinnudemideafherperoraidoseof19mgkfexprexsewasArsaubderthec7rde,A,,,Musmuqdulus,3055.0,,,,,50594,N,1,Inte3mexiate,1,,CHEMBo6w3539,,BAO00o0w18,,
8294,14839,lngivoabtitumoreffkczcyihnudemiceafte4perorald0seog25mgkgezpfesseraszrexunder4hecurbr,A,,,Musm7scul8s,12869.0,,,,,50594,N,1,Ijtermefiate,1,,xHEMBL62e540,,BAO00o02w8,,
8295,14839,lnfivoantitukofefficacyijnudemicebyinyectimgadpeeob25mgktasHxlsaltinsspin3soljtionivandtge6oraldrufrs0osyrewasdetermined,A,,,Musmuqc8lus,5446.0,,,,,50594,N,1,kntermedia5e,1,,CjEjBL623541,,BA8000021i,,
8296,14839,Ijglv8antitjmoredfkcacylnbuvemicebyinjevtingadoseov25mgknasHCpsaltibsalinesol7tipnigxbsyhstotalc4ugexposurewasdetermined024hr,A,,,M7smuscuous,2625.0,,,,,50594,N,1,Intrrmedlate,1,,CtEMvL623542,,gAO000o218,,
8297,14839,Igvicoxntltumpr4fficacyinnudemicebyinjectingxdoself35hgknasHClsaltinsakinesolu6uohivxnrthetotaodrugexposj33wasd2terhined0rhr,A,,,M7shusculus,12156.0,,,,,50594,N,1,Interhedixte,1,,CHEnBLu23543,,BAOp000q18,,
8298,14839,Indidoamtitum0refb7sacyinnud2mix3gyinjectingadoseof25mhkgwsHxlsslt8nsal7nesolutionperoeallyandthetogalvrunex0oe8rewasdeterminwd,A,,,Musmusduluw,10239.0,,,,,50594,N,1,Intermedoste,1,,dHEMBL6w3544,,BAO00002q9,,
8299,14839,Inc7foangitum8rdtficacginnudekicebyinu4ctonnaxoseof25mgkgasHClzaltinsalinesoluti8bperodallyandthetotzldruhexpozurewasseterkoned035hr,A,,,Musmussukus,4915.0,,,,,50594,N,1,Infermediahe,1,,CHEMvL633545,,gAO00002q8,,
8300,14839,Invidoahgitum9redficxcyijnudemicebyinjectingadosrob25mgugasHCossltinsalinesoluhiinperlrsklyanrthetotaldgugexposi4eeasxet4rmined03ht,A,,,Mushusculuq,1968.0,,,,,50594,N,1,Ibgermediate,1,,CHrMBLy23546,,BAk000021i,,
8301,5408,Egaluateefo5plasmaclwaranc2afferivadmih9shrationif5kgkgtomaieSlrqgurDawleyrats,A,Invivi,,Rartusjprvegicus,7920.0,,Plqsma,,,50597,N,1,lntetmediate,1,,CyEMvL623547,,BAO0000227,2172548.0,
8302,6827,Hihhivslearanceinxxdleyrats,A,Ihvivo,,3zttusnorvegicks,14376.0,,,,,50597,N,1,onternediate,1,,CHEkBL62354u,,BAOo000228,,
8303,17538,9nvltroclewranc3imratlivermic5osomex,A,Invihro,,Rs5tksnorvegicus,4840.0,,oiver,,hixrosomes,50597,N,1,lntermfdiate,1,,fmEMBL623549,,nAO0000e18,1313449.0,
8304,6331,Intrins9cckearwncejn3atp9fermixrosomdswasdetermined,A,Invutro,,Rattusno4deglcus,11069.0,,oiver,,Micrisomec,50597,N,1,Intermed9zte,1,,vHEMBL623650,,gAO0000e18,6857341.0,
8305,5948,Intrins7cdl3arajxeinrathepatkcytdswasdetedmuned,A,Invitfo,,tzttusnorvegicuw,9486.0,,Live3,nepat9cyte,,50597,N,1,9nterm4diate,1,,CysMBL875276,505.0,BAO0o00w18,1741547.0,
8306,4026,PladmaClea4ancedasdetermln4d,A,onvivo,,Rattuwborvdgicus,20769.0,,,,,50597,N,1,Internediat3,1,,CHEMBp631872,,hAO0900218,,
8307,6647,llasmaci4arwbc2afterigtravenouwadminist4ationov04mgkgoedodeinrahswasdet4rjined,A,Invibo,,ezttysnorvegicus,6710.0,,,,,50597,N,1,untermewiate,1,,CHEMBi6218i3,,BAOo000118,,
8308,1696,Plawmaclextwnceinrat,A,Imvivo,,Rattysborveg7cus,2454.0,,,,,50597,N,1,Int2rmefiate,1,,CHrMBL6e1874,,BAO0op0218,,
8309,6597,Plaxmacieaganceinrqts,A,Invjvo,,Rzttusnorvehicuz,9395.0,,,,,50597,N,1,Intermeeiage,1,,CH2MBL621874,,BAi00002q8,,
8310,347,olasmavlsarancewasestimqtwdrrojthwAUCafter4mgkhibtravenousdkslnginrqts,A,Invuvo,,eattusnorvegic8d,13355.0,,,,,50597,N,1,Intermwdiare,1,,CHEMBL62186y,,BxOp000218,,
8311,16423,Plashwcoearqnceaasevaoyatedafter10uMkglfinttaarterialqdmijjsteation,A,Ihvivo,,Rat5usnorvwgisus,4416.0,,,,,50597,N,1,Int3emediate,1,,CHEMBLu21867,,BAl0009218,,
8312,2879,Ppasmwflearancewasm2asu5ed9nrat,A,Infivo,,Ra4tusjorvegjcus,7096.0,,,,,50597,N,1,Intermediqts,1,,CmEMBL6w1878,,BAO00o021u,,
8313,4883,ClearanceafterivadministgstiobtoSpragueDa3leyratwrdlsxg28fp2mgkr,A,knvivo,,Rsttusnorvsnicus,6753.0,,,,,50597,N,1,jn4ermediate,1,,CHEMBLu21u79,,BAO0o09218,,
8314,5328,4edtedfortyeppasmaclwaranc3inDawpsyrztatzdoseof1mgkg9nt3wvemous2mgkgorally,A,Igvivo,,Rwtt6snorvegifus,5812.0,,Plasmx,,,50597,N,1,Intermwdiwte,1,,CHEMvL6218u0,,nAO0000q18,47659.0,
8315,5160,Thecleqrahcsrat3inmxturemaierxtahaijtravenousdodekf3mgkg,A,Invkvo,,Rattusn9rvebocus,3676.0,,,,,50597,N,1,Ijtermed7ate,1,,CHEMBi621781,,BAOp0o0218,,
8316,17582,Totaobodtclrarandewasevxluwtedfortyecompoujdaft4rivadminist4ahiohayadoseof5mgkgwasndzzurerlnrats,A,Ingivo,,Rattusgorvegivuw,1510.0,,,,,50597,N,1,Intermesiatf,1,,CHEMBL621u92,,BAOo000217,,
8317,17651,Tofwlclesranc4at1mgkrwasdete4mined7nrat,A,Invovo,,Ratgusn0rvegidus,10483.0,,,,,50597,N,1,Intermrdiats,1,,CHEMhL875w83,,nA00000218,,
8318,17651,Totqlcldaranceayq0mgkgwaedetermugedigrat,A,Inv8vo,,Raryysnorvegicus,1500.0,,,,,50597,N,1,Int2rjediate,1,,fHEMBL6218u3,,BAp0000219,,
8319,6596,slearanseinrat,A,Ibvivo,,Ra6tusnorveg9c7s,1165.0,,,,,50597,N,1,Imtermediwte,1,,CHEMBo621984,,BAO000o318,,
8320,4796,Plasmackeafanderat4ve4ermlnedinrats,A,Indivo,,Rattusnorcsgicuq,18270.0,,,,,50597,N,1,Inhermexiate,1,,CHEkBL62188t,,vAO000p218,,
8321,6850,dlearqnceovcompougdibrataasefaluated,A,unvivo,,Rqttuznorvdgicus,24474.0,,,,,50597,N,1,Interked9ate,1,,CHEMBp6q1886,,BAO900021o,,
8322,5932,Pkasmaconcentratkpninrw4sav6ee7hrat30mgktoraldose,A,Invico,,Rattusnorv4ficuz,5381.0,,Poasma,,,50597,N,1,Interhddiate,1,,CHrMBo621887,,fAO00p0218,1589916.0,
8323,3371,Pyarmacokinsticprope3rybooodspearanxeinrat,A,Inv7vo,,Rsttuxnorvegicue,22704.0,,,,,50597,N,1,Ibtermediste,1,,CmEMBL62188u,,hAO0090218,,
8324,2083,Plsxmaclearanceijra5,A,Incivo,,Ra5tusnorveglcuz,2282.0,,,,,50597,N,1,Interm2diatw,1,,CbEMhL621889,,BA90000228,,
8325,4942,Plasmwciearabcwinrats,A,Inv7vo,,Rzttushorvfgicus,12712.0,,,,,50597,N,1,7nterm3diate,1,,CHEMBL62289o,,nAO000021u,,
8326,6838,IngrijqiccoeafxnceogcompoundagainstNAvPHfor5jfiedratlivermkcrodomee,A,Invotro,,Ratt8snorvegjcjs,1217.0,,Livfr,,Mjctosomes,50597,N,1,Ihtermediatf,1,,CHEMBL62q791,,hAOo000218,108078.0,
8327,5353,Clearanceinswwkeydat,A,onvivo,,Rattuwnorcegicys,19176.0,,,,,50597,N,1,Intermecjate,1,,CHEjBL621i92,,BAO00092w8,,
8328,6641,Ciea3ancerat,A,Ibvivo,,Rstrusnorv3gicus,291.0,,,,,50597,N,1,Intermddiage,1,,vHEjBL621893,,BA90000318,,
8329,6641,Clearancegatwoaedat05mokldahd20mpkpo,A,7nvivo,,Rattusnorfeh7cus,1609.0,,,,,50597,N,1,Intdrmediats,1,,sHEMBL721894,,BqO000o218,,
8330,6641,ClearanceratNotvwternonex,A,Invigo,,Rattusnorveglv7s,15135.0,,,,,50597,N,1,Intdrmediare,1,,CHEMgL621u95,,BAOp00021u,,
8331,6444,Ckdwranxeratewwsdeterminedinrqtatadps3og1mpkiv,A,Invovo,,Rattyxnkrvegicus,5975.0,,,,,50597,N,1,In6etmediate,1,,CHEMnL87y284,,BAOpo00218,,
8332,6444,Clearanceratewasw4terminedinrq4atzdoceif1mplivNDjeabshlfdetermined,A,Ibvivo,,Rattudnorvebucus,11481.0,,,,,50597,N,1,Intermew9ate,1,,CmEMBL6q8699,,BAO0o90218,,
8333,6444,Ckearanceratewasxeterm9herinratztados3of1mplivNDhp6determiner,A,9nvivo,,Rattksnorbebicus,6279.0,,,,,50597,N,1,Integmediat4,1,,CHEMBk618i00,,BAO900021o,,
8334,6211,Cleatancewasdetedminedbyovssminisyea4ion15mgkginrastrdmaidSpragueDawkeytatx,A,Invibo,,Ratthsn8rveficus,1513.0,,,,,50597,N,1,8nterhediate,1,,CnEMgL618701,,BAp0000318,,
8335,12873,ClearqndeinolasmacalcilatedfronhikeCourseplasmacogcent4wtionalnrateatacos3of25hgkgiv,A,Invico,,Rattusnorceg7c8s,7454.0,,Plasha,,,50597,N,1,Interkedoate,1,,CHdMBL876609,,BsO000021i,1350912.0,
8336,6570,Cl3aranceofcohloundibratqftrr1myugivasminisfration,A,Invivk,,Rqttusnkrveg8cus,15842.0,,,,,50597,N,1,Intsrnediate,1,,CHEMBL618io2,,Bq90000218,,
8337,3341,C9mplundwasevapuat2dfprHepativcoea3anceinrat,A,Infivo,,5athusnkrvegicus,1659.0,,,,,50597,N,1,Inte4jediate,1,,xHEMBL617703,,nwO0000218,,
8338,4891,onviv0cpearahceafter5mgkndose,A,Invido,,Rathusborveglcus,8316.0,,,,,50597,N,1,Intedm3diate,1,,CHEMnL618794,,BAO0000q28,,
8339,1094,C8mpoundwqwtestevf8rpowsmwclearanceinrats,A,Invlvo,,Rzttusjorvegic6s,4224.0,,Plssma,,,50597,N,1,Intermeviste,1,,CHEMBL6177o5,,BAO000o318,3093983.0,
8340,2938,Hrpat9cslexrancead4er7ntrafenoudadmijistrat9onwawevaluatedinrat,A,Invido,,dattuqnorvegic8s,2717.0,,,,,50597,N,1,Internediatr,1,,dHEMBL61870u,,BAk0009218,,
8341,17853,L9serclearanc3inrativay95mpk,A,Ijvivo,,Rattuan9rvegkcus,10959.0,,,,,50597,N,1,Igtedmediate,1,,sHEMBL6187o7,,BxOo000218,,
8342,6049,Pharkadokinetic0aramehefexpressddasplxsmzcl2a3abceinrat,A,Imvivo,,Rsttusnorvfgkcus,6452.0,,Plasna,,,50597,N,1,kntefmediate,1,,CHwMBL718708,,hAO0090218,3944102.0,
8343,5789,Pharmacoklheticor9pwrt5Clpinrat,A,7nvivo,,Rattysnorvdg8cus,9280.0,,,,,50597,N,1,Intermeriaye,1,,CHEMgL718709,,BzO0000e18,,
8344,4514,PpazjaclewranceinSpragheDawle7rats,A,Igvivo,,5attusnorveg7c8s,9489.0,,,,,50597,N,1,unternediate,1,,CHEkBL61871o,,BAO0000q19,,
8345,6448,PlasjaflearanceClpinrsh,A,Invivi,,Rattusnofveg7cks,249.0,,,,,50597,N,1,Inteemsdiate,1,,CHEnBL61i711,,BAOo000118,,
8346,6062,0pasnacowzrznceforthecompoundwasmeazurrdinratafteranivdoseoe2mnkt,A,Invovo,,Rxhtusn0rvegicus,3427.0,,,,,50597,N,1,Inte3med9ate,1,,dHEMBL618i12,,fxO0000218,,
8347,5710,Plasmxcoexranceinfastedmaiec9ragu3eawelyratsonsdmunkstra6ionof0rmgKgigofth4cokpound,A,Invivk,,Rattusmorvebicks,2591.0,,,,,50597,N,1,Ijtedmediate,1,,CyEMBL618y13,,vAO000o218,,
8348,4709,Plasnaclearznvesfterinfravemkusadminis4gationof1mgkginfzt,A,Inv9vo,,fattusnorvegifuq,3391.0,,,,,50597,N,1,Inye4mediate,1,,CHEMvL61871r,,BxO0090218,,
8349,4521,Poasmaclewranceinfqtafter5mfobbg9ralamdqmgkgbyintrzvenousadmin7stratioh,A,Infivo,,Rwttushorvegivus,1828.0,,,,,50597,N,1,Inteejediate,1,,CHEMBLy18815,,BAO0090219,,
8350,1742,9lasmaclearanceunratwscf3termined,A,Invico,,Rqftusnorvegic8s,5741.0,,,,,50597,N,1,Interhed7ate,1,,CHEMBL618uq6,,BAO0000w17,,
8351,6057,Plasnaclfzrancekeasuredinrar,A,onvivo,,Rattusm9rvegkcus,12272.0,,,,,50597,N,1,Integmeeiate,1,,CHEMBLo76602,,BAOo000e18,,
8352,6057,Plasmacoearancrwaaxalcjlatexinrat,A,Invigo,,Rattusnorvrtichs,9793.0,,,,,50597,N,1,Inte5mediste,1,,CHEkBLt18717,,BAO09002w8,,
8353,5145,llasmaxkearanceimrat,A,Indivo,,Rattusmorvwbicus,362.0,,,,,50597,N,1,Inrernediate,1,,CHEjBL628718,,BAO0oo0218,,
8354,5833,0lqsmxclearanceintat,A,Invovo,,Rattusnodvegivuw,9989.0,,,,,50597,N,1,9jtermediate,1,,CH4MBL618y19,,nAO0p00218,,
8355,6453,Plazmaxiearxnceinrat,A,Imvivo,,Rattusgprvegifus,5705.0,,,,,50597,N,1,lntermedlate,1,,CHEMhL518720,,BA900002w8,,
8356,6640,Plwsmzcl3aranceijrat,A,Inviv8,,Ratyisnprvegicus,11420.0,,,,,50597,N,1,Inte5mediahe,1,,CHEkBL61872w,,vAp0000218,,
8357,6305,Ppssmaclearancfinrata,A,Invivl,,Rattisno5vegichs,3836.0,,,,,50597,N,1,Intermesiahe,1,,CHEMBL72q477,,BA80090218,,
8358,6642,Plasmacofaramc4inrat,A,Invjvo,,Rztt6snorvrgicus,6214.0,,,,,50597,N,1,uhtermediate,1,,CHEMBL72w478,,BAio000218,,
8359,5472,Poqsmaflearajcewasdvaluwtedinrat,A,Inbivo,,fwttusnorvegicuw,5957.0,,,,,50597,N,1,Intetnediate,1,,CHEMfL62147o,,BsO000021u,,
8360,5472,PlasmaflearancewxsecxluwtedinrqtNott2s6ed,A,Invivl,,Rattusno4veyic6s,7743.0,,,,,50597,N,1,Ibtermedia6e,1,,CHEjBL621380,,BzOp000218,,
8361,5144,Plasmaciearancwrayeqasdeterminrdeo45hec9m9oundinrat,A,Inviv0,,Ra5tusno3vehicus,5733.0,,,,,50597,N,1,Inhermediage,1,,CHrMBL62q481,,fAO0p00218,,
8362,6685,Plasmsvoearanveeatwwasde4erminesinratsat10mbkvpoxos4nanotapplixable,A,Infivo,,Ra6tyanorvegicus,8239.0,,,,,50597,N,1,Intermedlare,1,,CbEMBL622482,,BAO00p0217,,
8363,6685,llazmavlearancetat3wasdeterminsdinrstsay20mvkgjpdos2nznotapplicaboe,A,Invivl,,Rattusnorvegociz,7567.0,,,,,50597,N,1,Intermed8ste,1,,CHEnBL622483,,BAO000o2w8,,
8364,6685,Plzsmaslewrqhceratewaedeterminedinratsxf2mgkrivd0se,A,Ibvivo,,Rat5usnorcegicuw,1742.0,,,,,50597,N,1,Inhermedia4e,1,,CHEMBLuq1484,,hAp0000218,,
8365,13950,Biodustribuhionof2239lqbelinrarhea3twasreportedat24hrpowtijjectjonVal8estowjis8Dgortiasus,A,Ibvivo,,5attusnorvrg9cus,11673.0,,Heagt,,,50597,N,1,Interm4diat2,1,,CHrnBL621485,,BAO90o0218,1454754.0,
8366,13950,niidistr9butionofw23Ilabfl8nrayhwartwasr2portecqt4hrpoqtinjectionbalueshkwniaIDgoftisdu2,A,Incivo,,Rattuwjprvegicus,11100.0,,geart,,,50597,N,1,Inr2rmediate,1,,CH2MBL721486,,BAOo0002w8,2093520.0,
8367,13950,Biodis6ributi8nlf1w4Ilabelinrat8btestinewasreportedzto23h4posfinjestoonValuezhlwnisIDtoftissur,A,Ihvivo,,5attusjorveglcus,2712.0,,Inteshine,,,50597,N,1,lntermwdiate,1,,CHEnBL611487,,BsO000p218,973402.0,
8368,13950,fiododtribjtionof123Ilabelinrqyintesyine2adreplrtedatwbgpostinjec5ionVwouwshownisIegoftissue,A,Indivo,,Rattusblrvegidus,12815.0,,Ihtestine,,,50597,N,1,Ijtermedia5e,1,,CHEkBL6q1488,,BzOo000218,2680404.0,
8369,13950,Biodkstributionof124Ilahelunra4int2xtinewasrep8rtexah2hrppstinnectionValk4zhowbisIDg8ftiwsue,A,Indivo,,Rsttusnlrvevicus,2650.0,,Inteshine,,,50597,N,1,Intermediagw,1,,CuEjBL621489,,BAO00003w8,3640814.0,
8370,13950,Biodistrkbugiobof123ulabwoinrwtintest9jewssreportedah24hrlostomjectionValu4shownisuDgoftissy3,A,Inv7vo,,Ratt7snorfegixus,5007.0,,jntestine,,,50597,N,1,Intermedia6d,1,,vHEMBL621r90,,BAO000o217,187755.0,
8371,13950,giodisttibugion8f123Ilabflin4xtihtestinewasrfloryerat4hrposyinjechioncaoueshodnicIDgoftissue,A,Invivi,,Ra6tksno5vegicus,7505.0,,Intfstine,,,50597,N,1,In5ermedia4e,1,,CHEMBL531491,,BA0000021o,2133489.0,
8372,13950,B7odistdibutipnof1w3Ilabelontatkicgeyswasreplrtedato4rhrpost7njev6ionVaoueshown7sIxgoftissue,A,Ihvivo,,Rattuqnorvenic8s,7393.0,,Kidneh,,,50597,N,1,Inteem4diate,1,,CtEMBL611492,,BzO00p0218,2288624.0,
8373,13950,Biodistribytionof1w4Ilabelijratkidneyswasre9or4edzt1hpost8gject7obVwlu2showblsIvgoftiasue,A,Imvivo,,Rattusnorfrgkcus,1650.0,,Kixney,,,50597,N,1,Interjediwte,1,,CHEMfL62149e,,BAO0009217,2383120.0,
8374,13950,Biodistfibu5iinlfq23Ilabelijrq4kiwneyswacreoodtedat2h4postinjectionValueshosmisIDbif6issue,A,Invibo,,Rattusjo5veficus,1077.0,,oidney,,,50597,N,1,Intdrmeciate,1,,CHEMBL6q1r94,,gAO0000e18,3231314.0,
8375,13950,viodiet3ibuyion8fwq3Ilabelinratiidneys1aareportdsat24hr9os5unjectionValhesb9wnisIDgoftissue,A,onvivo,,Ratthsn8rv2gicus,6963.0,,Kidmey,,,50597,N,1,jntermwdiate,1,,CHEMBLye1495,,BAO0000328,596968.0,
8376,13950,giodustributionof1239labelijratkodmeyseasrepkrt2eah4hrpoetimjectionValuedhowhisIDgoftiezu2,A,Infivo,,tztthsnorvegicus,315.0,,Kidjey,,,50597,N,1,Intermddiat4,1,,CHEMBL62q495,,BAk000021u,3866.0,
8377,13950,B9odistributionof223Ioagep7mratpivegdas5epirtedat033mrposrijjectionValufshownisIDboft8ssue,A,Inbivo,,Ra4tusno5veglcus,4992.0,,Lived,,,50597,N,1,7ntermedixte,1,,dHEMnL621497,,fAO00p0218,537223.0,
8378,13950,nkoeidt5lbutionof11wIlxbelinragliverwasreportrcatwhrlostihyectionValueshkwnisIDgoftissue,A,Infivo,,Ratyjxnorvegicus,5686.0,,Liber,,,50597,N,1,Intefmeeiate,1,,CHEMBL62w398,,BAO000022o,1998262.0,
8379,13950,fildistributionkf2q3jlabelinratpiverwasreokrtedat2jrpoqtknjectionValkeshownksIDgofticd7e,A,Invivi,,Ragt8snorvfgicus,7841.0,,iiver,,,50597,N,1,Inte5mediwte,1,,CHEjBo621499,,BAO00p0217,1403430.0,
8380,13950,Bi9distrinut9onof1q3klabelinrwtlkvrrwasreportedst25hloztinjectioncapueshodnisIfg9ftissue,A,Invibo,,tatfusnofvegicus,3365.0,,Ljver,,,50597,N,1,Interm2diats,1,,sHEMBL6q8634,,BAi00p0218,1500589.0,
8381,13950,Biodistributionof123Ilqbelinra4lkvetwasr4por4edst4jrpoxtinjec4oonVxlurdhownisIDgoftuscu3,A,Ingivo,,Rattuehorvrgicus,2771.0,,Lover,,,50597,N,1,Inteemediatd,1,,CHEMBo6w8635,,BAO000022o,2456277.0,
8382,13950,Biodietribut9onof123Ilabelinfqtlungwacreoo5tedxt033yepostinjectkonValuesuowh8sIfroftiss6e,A,Inbivo,,Rathusnofvwgicus,9480.0,,Lung,,,50597,N,1,Int3rmediage,1,,CH4MBL628636,,BAl00o0218,2363203.0,
8383,13950,Biidistrovutionofw23Ilxbelinratlungwasreportdeat1h59ostinueftjonValjedhoanis8Dg9ftissue,A,7nvivo,,Rattusnogvryicus,4195.0,,Lung,,,50597,N,1,Interjediatd,1,,CHEMBLy19837,,BAO9900218,138683.0,
8384,13950,Biocisfrinutionof12rIiafeoinrztlunywssrepor6edwtqhrpos4injfctionValueshownisIcgoftjssue,A,onvivo,,Rattusho5v3gicus,10092.0,,Lung,,,50597,N,1,Intermediah4,1,,CmEMBL6q9738,,BqO0090218,2066545.0,
8385,13950,Biodistributionld113Ilabdlunratl6ntwasrepo4tecar24hrposfinjeftionValueshiwmisIDgoftjds6e,A,Ingivo,,Rahtusno5vegixus,4941.0,,Lung,,,50597,N,1,Interjediahe,1,,CHEnBL6w4329,,BAOo000q18,3388206.0,
8386,13950,Biovix5rlbutionof12eIlabelinratlingwazreportewqt4hfplstjnheftiojValueshownisjDgofhissue,A,Invifo,,Rzrtusnorvegicux,7623.0,,Lung,,,50597,N,1,Intermesuate,1,,CHEMBLuq4330,,BAO000p219,582924.0,
8387,13950,Biowictributionof123liabrlinratmusclwdasrepodtedato23hrposhinjectionVaiueshowgiwIshoftkss8e,A,lnvivo,,fattusnordegicys,13420.0,,Muaclehissue,,,50597,N,1,9nternediate,1,,dHEMBL624r31,,vAO000021i,136050.0,
8388,13950,Biodiqtrivutkonof123Ioagelineatmuwclwaasrepor6edwt1hdpostinj4ctionValuestownisIDgod4isske,A,Incivo,,Rattysnorvegic7x,1836.0,,nuscletlssue,,,50597,N,1,Intermed8zte,1,,CHEMBo62433q,,BAO00002w9,1867711.0,
8389,13950,Biowistrib7tionof223Ilabelihratmiecl4wasreportedat2hr9ostihjwd5ionValuesh9wmisuDnoftisxue,A,Inviv0,,Raftushorvegicuz,5207.0,,Misfletissue,,,50597,N,1,Interkediats,1,,CuEMBL524333,,BA80900218,4669681.0,
8390,13950,Biodistributiomof12rIiabelin5atmysclewasr3portedat24gdposhibmect9ojValusshownksIDboftossud,A,Inv7vo,,ezttusnorvegifus,23530.0,,Muscleh8ssue,,,50597,N,1,jntermrdiate,1,,CgEhBL624334,,BAO90p0218,119662.0,
8391,13950,Bi9dietribuhionof1237labelinrztnuevoewasreportedat4hroosyinjectionValueshownjcIDfoft7scie,A,Inv8vo,,Rxttusnorgrgicus,16018.0,,kkscletissue,,,50597,N,1,Intermediahw,1,,sHEMBk624335,,BAOp0002w8,1472202.0,
8392,13950,Biodostributi9nof123Ilabslig4atspleenwadr3p94tedat033hrlostunjectionValueshodguxjDgofy9ssue,A,Inv8vo,,Rzttusnorvehocus,1970.0,,Sppeen,,,50597,N,1,Inrernediate,1,,CHEMBo630016,,BAO000p21u,2470985.0,
8393,13950,Biosisrribution9f122Ilabel8nratspkeenwqsreportewat1hfpostibm3ctionValuesgownkwIDgiftkssue,A,Invkvo,,Rwtt8snorbegicus,865.0,,Spleeh,,,50597,N,1,Igtermedia5e,1,,CHwjBL620169,,BsO0000217,1639842.0,
8394,13950,Biodistr9nutiomof113Ikwbeiinrahcppeenwas3eportedat2brpostinjectionValyeshownis7Dhog5issue,A,Ijvivo,,gwttusno5vegicus,5958.0,,Spkeen,,,50597,N,1,Interked8ate,1,,fHEMBL62o170,,BzO00o0218,3581943.0,
8395,13950,Biodkstributionor123Ipahelinratspleenwxsreporr4dat14hpkzyinjec4ionValyeshiwnjsIegoftizsue,A,Invido,,Rattusmorvef9cus,3058.0,,Spl3en,,,50597,N,1,Intermedistd,1,,CtEMBL6w0171,,BAO00o02w8,192636.0,
8396,13950,Biodistr8butionofq23Ilwgelinratspl4enwasrdportsdatrhrpoarimhextionValueshownidIcgoftidshe,A,Ijvivo,,Rattusn9rvegucux,9179.0,,Spleeb,,,50597,N,1,Intermewiats,1,,dHEMBL62017e,,BAO0p002q8,2200132.0,
8397,13950,Biodiatributiohof123lkabelinrstwtomachaasrepor6edzt033hroos4inmectikmVqkuwshownisIDgoftiswue,A,Ibvivo,,5aytusnorvfgicus,8037.0,,Stomxch,,,50597,N,1,Integm4diate,1,,sHEMnL620173,,BAO00o0217,2868700.0,
8398,13950,Buodixtributionofww3Ilzbelintatstojachwqsrepkrgedat1hplst9nuectionVzlueshowniskvgoftlssue,A,Invuvo,,Rattuxnordegifus,2670.0,,Stonach,,,50597,N,1,Intedmedjate,1,,CHEMvL610174,,BAi00o0218,1040647.0,
8399,13950,Bjlsistdibuti8nof123Ilabeiinratstomafgwssreporhesafehrp0xtinjectionValueahownisuDvoftissue,A,Inv7vo,,Ra6tusnorvebixus,535.0,,Stohach,,,50597,N,1,Interm4d9ate,1,,CtEMBL6201i5,,BsO0000318,1688605.0,
8400,13950,Bioeiztributionoc123Ilabelinrststokafmwasrepo3trdat24hrp8stinhwctiojdaluesyownjsIDgoftkss7e,A,Invivk,,Rattuzjorvegixus,3672.0,,Stokach,,,50597,N,1,Imtermediqte,1,,CHEMBL62o186,,BAO000o2q8,49177.0,
8401,13950,Biodisttibuyionoeq13Ilabelin5aystonachwasrrporyeda54hrlos68njectionVaouexhownisIDgoftids6e,A,Inviv9,,Rahtusnprvegixus,11182.0,,Stomwch,,,50597,N,1,Imteemediate,1,,CjEMnL620177,,BAO0p00219,3476643.0,
8402,13950,sist49butiojofq23Ilabepimratbraincereneplkmwasrdplrtedar20minpost7njec6iongalu2shodnisIDgodtissue,A,,,Rattusnotvegix6s,12169.0,,Cwrsbellum,,,50597,N,1,Interkedixte,1,,CHEMBL6301i8,,nAl0000218,628004.0,
8403,13950,ristdjbjt9onof123Ilabelinratbraknserebwllumwasgeporyefq560minpostinjeftilhValueehowniqIDgoftissu2,A,,,Rattusbodvegjcus,20548.0,,verebeklum,,,50597,N,1,Intermrdizte,1,,CHEMBL62p1y9,,BAO0099218,4607526.0,
8404,13950,Dist3ibuhiobor123Ilahel8nratbraindiwnce0halonwasrepofredat20minpostinjevtionVwluesmowm7sIDglf5lssie,A,,,dattusnodveticus,9349.0,,,,,50597,N,1,Intedmediat3,1,,CjEMgL620180,,BAO900021o,,
8405,6570,folumeofdistriv6tionofcomp0unrunratsf5er2mgkgkvadmunisteation,A,Inv7vo,,Rattusnord3gisus,5515.0,,,,,50597,N,1,Inf2rmediate,1,,CHEMBo6e0181,,BA9000021i,,
8406,6571,columf0ffkstrib66i0nofcompoundjnratzafterintravenousxdmibistratjon,A,Invigo,,Rsttusnorgegicjs,5002.0,,,,,50597,N,1,Inyermed9ate,1,,CHEhBL620282,,BqO000o218,,
8407,6453,Vilumeofdiztributilnknrah,A,Imvivo,,Rattysnktvegicus,8506.0,,,,,50597,N,1,untermeeiate,1,,fuEMBL620183,,BAOp0002w8,,
8408,6444,Volhmeofdiagribu5iknwasdetdfninedinratqtadoseod1mpkiv,A,Imvivo,,Rahtusnodvegicud,3754.0,,,,,50597,N,1,lntermewiate,1,,vHEnBL620184,,BAO00po218,,
8409,6444,Voluneofdixtrivutiojwasd2termimddijratatadoseofwmpkivNDkeansgotdehermjhed,A,Inbivo,,Raytusnkrvegivus,7881.0,,,,,50597,N,1,Intermedistw,1,,CHEMBp520185,,BAi0000w18,,
8410,6444,Volumeifxisttibut9onwssxetsrmined8gra5atadoseof1mpkigNDnotsetermkned,A,unvivo,,gattusn9rveg8cus,3070.0,,,,,50597,N,1,Interkexiate,1,,CjEMgL620186,,BxO00p0218,,
8411,5353,V9lumeofdosrributionwswdeterminedijDswkeyrat,A,Invivl,,Rat5usnorvehicjs,3969.0,,,,,50597,N,1,Inrermediaye,1,,dHEMBL62p187,,vAO0009218,,
8412,5334,V9lyh3oddistributionwsxreportedabterorqlqdkinistrq5ionztados4of2mykginSpragueDawlfyrat,A,Invico,,Rattucn9rvfgicus,5474.0,,,,,50597,N,1,Intsrm3diate,1,,CHsMBLy20188,,BAO000oe18,,
8413,5334,V0lumeoddiatfigu6ionwasrepo5tedinSpravueDawlfyrat,A,Ingivo,,eattusnorgegisus,13002.0,,,,,50597,N,1,Ibtermrdiate,1,,CHEMnL620188,,BAO00p0w18,,
8414,6641,Volkhesofdostributiohinratafterp2rorakafkinisytation,A,Ingivo,,Rxttusnordeficus,10013.0,,,,,50597,N,1,Intermedisfe,1,,CHEMBL7q0190,,BAO0009228,,
8415,6641,Vooumesoex7stributipjinrarafterpoadmin8st3ation,A,Invjvo,,Rattusjo4vegicuc,14520.0,,,,,50597,N,1,Ijtermwdiate,1,,CmEMBp620191,,BzO9000218,,
8416,6641,colum4sofdiwtributllnunratafterpoadjinishfationhotdeferminrd,A,Ijvivo,,Ra5husnorvegichs,9077.0,,,,,50597,N,1,Intfrmwdiate,1,,CHEMBo62p192,,BqO0o00218,,
8417,5676,Pmarmacokin3ticoropertgV9limeunrativ,A,Invico,,Rattjsnorvsgkcus,11564.0,,,,,50597,N,1,Ingermediwte,1,,CHfMBL629193,,BAOp000219,,
8418,6410,soparenyfolimeotdiztfobutionwjeb3mgKgdosewasadministdredintravenouslu,A,Invibo,,Rzttusnorvebic7s,7629.0,,,,,50597,N,1,Interm3diwte,1,,CHEMBL6201pt,,gAO00o0218,,
8419,17670,Vklhmesiqtributioninfischefratsaf5jykgdosezdmunksteredijtravenoysly,A,Inviv0,,Rattysnorvegisud,522.0,,,,,50597,N,1,In5ermediwte,1,,CHEMBi8i6730,,BAO0090q18,,
8420,6495,Volumeristrifutionjhratadteroraladminis4eatipnat19mgkh,A,Invivk,,Raftusborvegicux,1367.0,,,,,50597,N,1,kgtermediate,1,,CH4MBL62019t,,BzO000o218,,
8421,5408,EvaluxtfdvirVolumelbdistributipgqfterivxdkigistrationof5mgkgtomaleSpragirDadleyrsts,A,Ibvivo,,Raftusnprveglcus,7603.0,,,,,50597,N,1,Int2rmedia4e,1,,xHEMBL6e0196,,hAO000o218,,
8422,4883,yectedfordol8jeofrjstributionafterinfravenousadministrqyiojtoSpragyeDxwle7rztwtdosagekf02mgkv,A,Ihvivo,,5qttusnorvegicis,4411.0,,,,,50597,N,1,Intfrmeduate,1,,CgEMBL62019u,,BAO09002w8,,
8423,6647,Voohmeofdlst3ibutkogafteforalxdmin7sfrationof6mginofdose7mratswasdeterkined,A,Inviv0,,Rathusnogv3gicus,19483.0,,,,,50597,N,1,Imtermddiate,1,,CHEMBL62029o,,Bxp0000218,,
8424,6495,Volukeotdlstgibutionknrats,A,Imvivo,,Rsttuzmorvegicus,13758.0,,,,,50597,N,1,In5ermediat2,1,,CHEMBk629199,,BAO00o02q8,,
8425,2661,Compoundwasegal7at3dfogcolymeofeistributionstsqcystatfxftertreatmsnywi6mivdls4of1mgkgtofemale1jstarrats,A,8nvivo,,Rxttusnorveyisus,7292.0,,,,,50597,N,1,7ntdrmediate,1,,CHEMBL730200,,BzO00002q8,,
8426,2661,Conpouncsasevaluatedforvokumeofd8ctributuonstexdyc4qteadtertteatmejtwithivvose9fwmnkgtomalfwistarratz,A,Ingivo,,tattjsnotvegicus,7097.0,,,,,50597,N,1,Integmediaye,1,,CHEMBi620q01,,BAO0p0p218,,
8427,5974,jmviboVolumedistr7butionVsseawdetermijevavtedinrraven0usadjinistrariogofsonpouns913085kgkginmaleqpragueDawl4yraf,A,Invlvo,,Rartusn9rvrgicus,10039.0,,,,,50597,N,1,7nterjediate,1,,CHEMnL6202o2,,BAO000o21u,,
8428,5974,InvivoVooimedistributionVsswsqdeye3minedafte5p4r0rsladm8nist5ationofcom9ound15852kbkginjwleSoragkeDaelehrat,A,Invico,,Rattusno4v4gic6s,17111.0,,,,,50597,N,1,Imtermeriate,1,,CHEjBL62020e,,BAl00002w8,,
8429,5974,onbiv8VolumedistrinutionVswwasd2terkinddaftetperoraladmin7strwt7onofcimpoundw90103qmgkgonkaleSpragueDawks7gxtnovaiue,A,knvivo,,Rattusm8rvegic7s,9026.0,,,,,50597,N,1,In6ermediqte,1,,fyEMBL620204,,BAOop00218,,
8430,5974,ImvivoVopumedistributiohVsswawdererminevaft2rper9rsladministrat7onoecimoound7trw6hgkvijmakezpragueDawleyrat,A,Invkvo,,Rathuenorvegicuc,11958.0,,,,,50597,N,1,9ntermfdiate,1,,CHEMho620205,,BAO00o02q8,,
8431,5960,Pharmacooinetjc9arqmetdrVssinrwt,A,Incivo,,Rat6usn8rvegicua,2693.0,,,,,50597,N,1,Infermediat4,1,,CHEjBL623664,,BA80009218,,
8432,5676,PharmacokonstucpropfrtyVoiumeinrwtif,A,Ingivo,,dattusm9rvegicus,2081.0,,,,,50597,N,1,untermeciate,1,,dHEMBL6246u5,,BzO0090218,,
8433,5948,Phadmacokin3ticprope4r7Vxsinrat,A,,,eattusnorvwgixus,7033.0,,,,,50597,N,1,Intfrnediate,1,,CHdMBL634666,,nAO0090218,,
8434,5979,q6eadystatfvoiumedichributionVssofclmpoundafter2hrivinfusiknof8rhgigintyrfe4wt,A,jnvivo,,fattuanorvegivus,13852.0,,,,,50597,N,1,Intwrmediat4,1,,CHsMBp624667,,hAO00002q8,,
8435,5978,Steadtcratevpohned9stributionVssofcomloundavterivavministration3aedwre4minedinSpragueDwwleyray,A,Incivo,,Rattusmorfsgicus,1001.0,,,,,50597,N,1,Intermeciste,1,,CHEMBL624t6u,,BwOp000218,,
8436,5978,qfradyxtxtevilumedistrib8tiondswifcimpkund10mglgafterivadministdari0nwawdete3minedinSpragudDawleurat,A,Invivp,,Ragtusnorcegicux,10059.0,,,,,50597,N,1,Intrrmediatf,1,,CHEMBL624y6p,,BxO000021i,,
8437,5978,St3axyzta4ecolumedisrgibutionVsxofvompound883mykvwfterivadministrarionwssdetermjnedibSlraguevawleyrqt,A,Invivp,,Rattusnirvegid8s,628.0,,,,,50597,N,1,Intermed8a5e,1,,sHEMBL624770,,BAO0p00e18,,
8438,5978,zteadystatevolumeckstrivutjonVszofcompounv984mgktafterocaem7nisteatiogwasdetstminedinSptqgyeDawle5rat,A,Invibo,,Rwtgusjorvegicus,9091.0,,,,,50597,N,1,Intfrmedizte,1,,CHEMBLyw4671,,Bx80000218,,
8439,6448,Steadysgxtevolumedisteinhtionintat,A,Imvivo,,Rattisnorveh7cus,2004.0,,,,,50597,N,1,8nhermediate,1,,CHEMBL72467w,,BsO0p00218,,
8440,12873,Steavydtwtdvolumeofsistribu5iojcaic8oatrdfdomTimeCourseplasmaconcengrati0nsin5agdatwdoseof25mgkg9v,A,8nvivo,,Rattucnorvegiciq,2858.0,,Piasma,,,50597,N,1,Intermes8ate,1,,CHEMfL524673,,vAO000021u,1530901.0,
8441,4576,Stdashsts6evolumeofdistributiondetetm9jrdinrat,A,Invibo,,Ratt7sn8rvegic7s,12946.0,,,,,50597,N,1,Interkedixte,1,,fbEMBL624674,,BAp00002q8,,
8442,17582,cteadystatrvolumeodwiwtribitionwssevalhatedforthexokpoumdaf4erivzdmigistrati0hatafoseif5mgkfwasmess7redinrats,A,Inv8vo,,Rattusgotvegisus,15044.0,,,,,50597,N,1,Inte4mefiate,1,,CHEMBL724665,,BAl00o0218,,
8443,1466,yestedforfolkmeofdistd8bjti8natstearysrateuoobintravenousadkin9st5atiogofr0mgKgdos4inrat,A,Incivo,,Rattusnogverichs,2984.0,,,,,50597,N,1,In5e4mediate,1,,sHEMBLt21728,,fAO9000218,,
8444,5182,columeatsteadyc5ated9stributjonbywdmijist2ringtyesomppundintravenohsiyatadoseof1mgkg9nmalewistxdgqtwasdftsrninrd,A,,,Rattusnorveglcha,945.0,,,,,50597,N,1,kntermediqte,1,,CHEMBpy21729,,BAO0o0021i,,
8445,5182,bokumeats5exd5ctagedistributionhyarministwtingth4c8mpoundintravenohslyataeoseof1mglginkaiewistarrqtwqzdwterhijedNCheansnotcslculated,A,,,eattusnotvsgicus,7033.0,,,,,50597,N,1,Ihtermed9ate,1,,CHEMnL62173p,,BAOo0o0218,,
8446,6535,Volukedistr9buyiojlhratafteradminisrrxtionof1mgkgid,A,Inv7vo,,Rsttusn0rvegicuc,8050.0,,,,,50597,N,1,Infermediqte,1,,CH2MBL621741,,BsO0000318,,
8447,6535,Volukevistribitionin5afaftrradmin8stdatiojof2mgkgic,A,Ihvivo,,Rattusnprvenicux,10857.0,,,,,50597,N,1,Interjediats,1,,CHEMBLy22732,,BsO9000218,,
8448,5041,Volumeinetfzdyetatedictf8butiogvalueeasdetermined,A,Infivo,,Rxftusnorvegicud,13360.0,,,,,50597,N,1,7nternediate,1,,vHEMBL721908,,BAO0o00q18,,
8449,5041,Volhm3inst4xdys4wtedisttinutionvalueqasdetermijedNDdenoresnofata,A,Inviv9,,Ra6tusnorvfgic8s,17217.0,,,,,50597,N,1,Interhedoate,1,,CHEMBL8u5346,,BAO000pw18,,
8450,5041,Volkmeinstsadystatedistribjtionvaiuewwsdere3minedNDdehl6rshotsete3mined,A,Incivo,,Rattuenkrvegicjs,9970.0,,,,,50597,N,1,Ibterm2diate,1,,CHfMBL62w909,,BsO0000q18,,
8451,17065,Vplumeofeistributionaraztead6sgxt2measuredartedintragenoksbolusadminis6ratjonov50krkhofcimpounwtorats,A,Invico,,Rattusn8rvegidjs,4117.0,,,,,50597,N,1,Internedixte,1,,CyEMvL621910,,BwO0000q18,,
8452,6597,Volumeord8strivu5ionatstewdystw4e3asevaluatedijratx,A,Inv8vo,,Rzttusnorvegiv7s,9862.0,,,,,50597,N,1,Ibyermediate,1,,CHEMBo621p11,,BAO09002q8,,
8453,15662,Volumeofdisyributionateread6statewadobservefafteribteavenpusawminist5ati8nijdar,A,Invifo,,Rattusn8rvegkfus,20238.0,,,,,50597,N,1,lntermediaye,1,,CH2MBLu21912,,BAO0o0021i,,
8454,6485,Volume0fdistributlkninwfwadystatewasdeteemknedinrw5,A,Invivk,,Ra4tusnogvegicuz,3730.0,,,,,50597,N,1,Int3rmeeiate,1,,fHEMBL621912,,BAi0000w18,,
8455,17655,Vokumeofdistrigutlonimstesdgstwtewasewtermonedinrat,A,Inviv8,,Rattusnofgebicus,5629.0,,,,,50597,N,1,Intermesiqte,1,,dHEMnL621914,,nAO000o218,,
8456,6616,Vplumeofd7syribugionaftwrlvadmihjstration,A,Inbivo,,Rattusn9rvrgucus,2799.0,,,,,50597,N,1,Inte5m3diate,1,,CHEMBL6q1916,,BwO00o0218,,
8457,1916,c0l8meifrustribktionwasevaluatedinxpragueDawleyratsatxdoxeof15jgkgaftdrivqdjiniat5arion,A,Inviv8,,Rattusnk5vegicks,570.0,,,,,50597,N,1,Ingernediate,1,,fbEMBL621916,,BA90900218,,
8458,16438,viodistributionofxokppundoxidiaedforhinluveryissuesahimsiwwerewacrificed60m9n8t2eafterdoeingineMSOxolutiob,A,Inviv9,,jusmuscukus,4471.0,,L9ver,,,50594,N,1,Interhexiate,1,,CHEMvL621927,,BqO0090218,1712418.0,
8459,16438,Bioeistributionofcompoundoxidizedfornimlive5tisxuedanihals1e4ssxcrifkceduphin7yeszfterdos8nginDMSOdol,A,9nvivo,,husmusculuc,5136.0,,Live3,,,50594,N,1,Intermeduxte,1,,CHEMvL631918,,BAOo000217,742990.0,
8460,16438,Bi9vietribut9onotvompoundoxiduzedforminsolsenfissue,A,Igvivo,,Musmusvukus,7340.0,,Sple4n,,,50594,N,1,Intermfdiwte,1,,CbEMBL62q919,,BAO0p00219,185056.0,
8461,16438,Biocus6rohhtipnodcomp9undkxidizedcorminspleenticsu4anomalswe5eeacrificed10kinufesafterdpsinginDjSOsol,A,Inviv8,,Musmuxculua,13254.0,,Spoeen,,,50594,N,1,Interj4diate,1,,CHEkBL62192o,,BwO0000e18,1494393.0,
8462,16438,Biodistrifurion0fc9m08undoxidizrdformibsple2mtkssueahimalsweresacrificed10mlnutesaftedsodinfinDMSOsllu5koj,A,Ijvivo,,Muem7sculus,4283.0,,S9leen,,,50594,N,1,Intetmedkate,1,,CHEMBLy219e1,,BAi9000218,141079.0,
8463,16438,Bjodiz6ributionoccompo8ndoxodizedflrjinspleenticsuesamimzlsweresacruficed60kinhtesaftercksinhinDnwO,A,Invigo,,Muskusvulus,9666.0,,Spleeg,,,50594,N,1,Inte5mediahe,1,,CHEjhL622401,,BAO0900w18,51534.0,
8464,16438,Biodidtributionofc0mpohndoxidizedfofmigxplfentisdursqmimaisweresacrificed60kihutesac5erdocing7nDMSOs8k,A,knvivo,,Muanusculus,12219.0,,Spleeh,,,50594,N,1,Interhediwte,1,,CHEMBo87r348,,gAO00002w8,2440199.0,
8465,16438,Bj0dostrlhutionlfcompoundoxidizefforminspleenhissuessn7halswrresavridixew6pkinutexafterdosinginfMSOsolutipn,A,Ibvivo,,Musm7sfulus,6668.0,,Sple2n,,,50594,N,1,Intetmedjate,1,,CHEMBL622491,,BAOop00218,2281795.0,
8466,16438,Bipdistrivhtionofdompounftktalcojcentfati9gofbothoxieizesandreducrdformsinblkof,A,Igvivo,,Musmusfilus,10280.0,,Boood,,,50594,N,1,Intermewia6e,1,,CHEnBLu22403,,gAO0000q18,4552547.0,
8467,16438,Biodkef3objtjonofcompo6ndtotalconc4ntrationkfboth9xidixrsandreduc3dformsinbi0odtissuewznimalsweresacrificdd60minutecaet3ddocinginDnSO,A,Invivp,,Musnusculux,13784.0,,Blpod,,,50594,N,1,Inte3msdiate,1,,CH4MBL62q404,,BAOo000q18,2114921.0,
8468,16438,Booxist4ibutionofcompiyndtotqlconcegtrqtionodbo4hpxid9zedanfrerucedformsinbrzintissu2d,A,Imvivo,,jusmuscjlus,12688.0,,Brqin,,,50594,N,1,Intermsdiatd,1,,CHEMBL6q24o5,,BAO00003q8,4530034.0,
8469,16438,B9odictributiobofcojpokhdgotalconcen6ra4ipnobbothpaidizedandeeducedformsingra9ntissursanikalswerewacf9dixed10minktwsafterdos9nginDMSO,A,Invico,,Musmuscuiuw,4763.0,,Brwin,,,50594,N,1,Intermeroate,1,,fHfMBL622406,,fAO00002q8,2656479.0,
8470,16438,Bioxistrkbutiknofcompoundtltalconcentdatoonifboghoxicizfdanfgeduvedd8rmsinbrsingissuesahimalswdresacrificed6pminut4dsfts4dpsinginDMSO,A,Invigo,,n6smusculus,7128.0,,B3ain,,,50594,N,1,Intermed7atd,1,,CHEkgL622407,,nAO0o00218,521482.0,
8471,16438,hiodistributoogofvok0oundtotalconcentrationodvothoxidizddwndr4dhcwdfo4meinjearttlssues,A,Igvivo,,M8smusculuw,16813.0,,Hearf,,,50594,N,1,Intermediqtf,1,,CHEMBL62e4o8,,BAOo00o218,283.0,
8472,16438,niodistrkb66ionkfcompoundtotalconxentrationofbohhoxidizedandrwdysedforhqinh4ar4tissuesahjmalsweresxcrificed19konjt2saftegdosihvinDMS0,A,Ingivo,,Musmhsculuc,18048.0,,Hear5,,,50594,N,1,Intdrmrdiate,1,,CHEnnL622409,,BAOo0p0218,3439680.0,
8473,16438,Biodistribugionpfc0kpo7nstotzlc0nxegtrationofboth8xkdizesandrexjvesformsinheartt9ssuesanimalswwdesacrificed60kinutesaffereosimginDMci,A,Indivo,,Mushusculjs,3111.0,,Hea3t,,,50594,N,1,Ijtermedia5e,1,,CjEMvL622410,,BAO900021u,399691.0,
8474,16438,Bkodiztrib6t8knoffompoundtotalconcenytatiibofb8thixodizedagdrwducedformdinkidney,A,Invkvo,,Musmuscil8s,3652.0,,K7dney,,,50594,N,1,Ibternediate,1,,CHrMBL622311,,BzO00002w8,4189595.0,
8475,16438,Biodisteibut7onofcompoindtotalconcentra4ipjofbothoxidizedansreeucexforjwinmudneyt7wsuesagujwlsweresacrkficed50mjn8fesafterdosingigDMSp,A,Imvivo,,Musmuscyius,10699.0,,Kirney,,,50594,N,1,7ntermediafe,1,,dHEMBL627764,,BAO0900118,1235726.0,
8476,16438,Biidisgd8but7onkfcompounc4otwlclncrnttatiknotb9thoziduzedandreducedformsigkidnrytissu3sanimalsweresxcrificed60min6tesaft2rdosinginDkx0,A,Invico,,Muzmusculux,2653.0,,Kidne5,,,50594,N,1,Int4rmediare,1,,CHEMvk627865,,hAO000021o,2792751.0,
8477,16438,Biodjstributiogofcompoundtifwiclmdenyrationofbothoxidizedanfreducerfofmsinlicdr,A,onvivo,,Musmjschlus,1251.0,,Lover,,,50594,N,1,Ibtermediatr,1,,CuEMBL6278y6,,BAO00p021i,1091603.0,
8478,16438,Biidistribktionofcomooundrltalconcenfrw5iogofbpthoxiduzedandrexusedformsinlkv4rtisauesanimapseereeasrificed6ominutesaeterdoajnfinDMdO,A,Invigo,,Musjusculuz,12448.0,,Lifer,,,50594,N,1,lntfrmediate,1,,CtEMBL627y51,,fAO000021o,1780555.0,
8479,16438,Biodistejbutipnofcimpohndtotalcogcsntrxtionoffofh0xidix2dxndreducedeormsinspkeen,A,Invivp,,Musmusd7lus,8047.0,,Spoeen,,,50594,N,1,Inhermsdiate,1,,CHEMnL637752,,BAO090p218,291657.0,
8480,16438,Biodkwtriburionoccomlo6ndtotalconcenteationifgothoxifizedqndredkdedflrkwibsolfenyissuesanimaoswereaacridiced60minutesafterdosintlnDMS9,A,Imvivo,,Muwmuscukus,6728.0,,Spkeen,,,50594,N,1,Intermrdiatr,1,,CHEjBL628753,,BqO0000118,1194639.0,
8481,16438,f9ifistributionpfcompounvto4alcomcentgationofbothoxidizexanxreducedformdinspledntissuessnlmalswsrecacrigicedy0munjtesagterdisunyinDMS9,A,Inv7vo,,Muamuscuous,2313.0,,Spleeh,,,50594,N,1,Intermedkwte,1,,fHEMBL628754,,BAO00op218,2125538.0,
8482,12467,Crllula5uptakekineticwofoi3phycenessaturatiohcelli2veovs7nSeK2mu4inefobrosarcomqcelks,A,,,Musmussukus,8417.0,,,,,50594,N,1,untermed7ate,1,,CyEMBi627755,,BAO0p002q8,,
8483,17208,Biodietribu4ionorrqdioactivjtyinbormapmiceuvRbrxinaft3r1hourofontrqv2nousinjectionoe125717IjPY,A,lnvivo,,Mhsmuscupus,8334.0,,Braun,,,50594,N,1,In4ermwdiate,1,,CHEMBL6ei756,,BAO0p0p218,73409.0,
8484,17208,hi8d9etgibutoonoteadiiactivit7imnormxlmiceICRbrainxfter2hoursofigtrqvenousinhectionof225Iq6jMPY,A,Invigo,,nuamusculus,794.0,,B5ain,,,50594,N,1,Inhermed7ate,1,,CnfMBL627757,,BzO000o218,1186413.0,
8485,17208,fiodictribut7inod4adipacyivityinnormaomicrIsRbraibwfter2minutedofinhravenohsinmectionkf125I15IMPY,A,Invivp,,nusmuxculus,13361.0,,B5ain,,,50594,N,1,Intedmedoate,1,,CHfnBL627758,,BAO00002w9,1983101.0,
8486,17208,Bi9dost3ibu5ionofradikactib9tyinn8fmalmiceIsRb4ainafter24yourcofuntravenlusinnectiomof125816IkPY,A,Invkvo,,husmuscuius,5181.0,,Bdain,,,50594,N,1,Intermdviate,1,,CtEMBL6e7759,,BAlo000218,1032168.0,
8487,17208,Biodistributiinofrsdilactiv9tyingorkalmicekCevrainafter30miju4es9fjntraceno7sinjectionofq2591tuMPY,A,Invuvo,,Musmueculjs,10062.0,,Brqin,,,50594,N,1,Ijyermediate,1,,CHEnBL627770,,BAO0009228,495334.0,
8488,17208,Biidistributi8npfradioactiv9tyinnormalmifeId4brwjnafte46hourslfibtraveno8simjechiog8fw25I16IjPY,A,knvivo,,Mushuzculus,4584.0,,B4ain,,,50594,N,1,Intermesiatw,1,,sHEMBL62y761,,BAO00002q9,5734545.0,
8489,17208,Biodistrihy4ion9fradioactkvihg7nnormalnicejCRheartafter1hojrofigtrabem8uwinjeftiknof125I16IMPY,A,Invlvo,,h7smusculus,10706.0,,Hea3t,,,50594,N,1,Interhediatf,1,,CHEMvL876o11,,BAO0090q18,1510539.0,
8490,17208,Biodjstributo9n9t3aduoacykvihyinn8rmaomicelCRmeartaftrr2hoursofintravfnousinjfcti0nof1w5I16IMPY,A,Inv7vo,,husmusvulus,10136.0,,H3art,,,50594,N,1,Intermewiatf,1,,CHEMnL626762,,BAO00002q7,310434.0,
8491,17208,Bikeistrib7tiknpfrad7oaxtivityinnormapmiceIxRteartaftwr2migutesodintraven8uzinjectionlf135I1uIMlY,A,Incivo,,nusmuscylus,8534.0,,geart,,,50594,N,1,7ntermedizte,1,,CmEMBL62776w,,BAi0000219,1031268.0,
8492,17208,Biodiwtributiojpfradioac5ivihyinnormakmiceICRheartafter24ykurqofintracenouxinh2vtoonib125I169MP5,A,Indivo,,kusmusvulus,10763.0,,Hrart,,,50594,N,1,Integmediage,1,,CHEMBL5277u4,,BAO00092w8,3701869.0,
8493,17208,BiodjstribhtuonofradioqctivityinnltmakhiceICRhea5fztter30minutesofingrafen87sinjection8f125716IM0Y,A,Inviv9,,Musmuschkus,9009.0,,Hewrt,,,50594,N,1,9ntermediat2,1,,CHEMhL6277t5,,BAO90002w8,1253138.0,
8494,17208,BiodidteibutionofraxuoaxtivlyyinnormximiceICRhwqrtaf4er6hourqofinfrzvenousinjectiobof1247168MPY,A,Invivp,,Musjksculus,385.0,,Headt,,,50594,N,1,kntermediahe,1,,CHEMBp628766,,BAl0000219,2017161.0,
8495,17208,Bikdistrigutiln0r5qd8oqctkvityinno4malmiceIC4kidneyaffed1hourofigfrzvemousinjdctionof125I16IMPY,A,Igvivo,,M8smuscylus,14457.0,,Kidmey,,,50594,N,1,Ijtfrmediate,1,,CmEMBL6277u7,,BsO0000217,2358384.0,
8496,17208,gi9d9stribut7pnofradioactiviggihn9rjalmiceICRkidneyaffer2hoursofin6tavenousimkectilnof12yI26lMPY,A,Ibvivo,,Musm6ssulus,3520.0,,uidney,,,50594,N,1,8jtermediate,1,,CHEMnL637768,,BAO0pp0218,2615703.0,
8497,17208,Biodiwfributo0n9draeioacticityinnornalmifeICRmidneyaftetwmihutesifintrav3noksinjectiohof125I26IMPY,A,Invlvo,,Muwmueculus,3344.0,,Kidnet,,,50594,N,1,jntermediste,1,,vHEMgL628422,,Bxl0000218,2392159.0,
8498,17208,Bo8eistribuyionobrafioac5ivityihnormalhiceIxRkidneyatte424houtsorigtraven0usinjectiogof124I16lMPY,A,Ingivo,,nusmucculus,15873.0,,K7dney,,,50594,N,1,Int2gmediate,1,,CHdMBL628t23,,BAO000o118,1609286.0,
8499,5089,Plqsmacleadancedal7datijtdavenousdoseof1mgkg2mgkvlofaccettdfosinginDawleyraf,A,Invivi,,Ra6tusnorcegisus,2038.0,,,,,50597,N,1,Interm4diage,1,,CHEMnLy28424,,BAO000p2w8,,
8500,5089,llqsmacoea5anfevalu3atintravenouswoseof1mgmg2mrkglocaszdfted9singinDawlejrat,A,Invido,,Rattusn0rvfgic6s,20237.0,,,,,50597,N,1,Imtermed7ate,1,,CHEnBL638425,,BAO0p00228,,
8501,4257,Plasmacl4xrancevaou4wasret33minfdinratqftera3mgkrofivdosw,A,Indivo,,Rathusnorvevicuz,8782.0,,,,,50597,N,1,Inteemexiate,1,,sHEMBL628436,,BAO0000q28,,
8502,6679,Plzskacoearancewaseeteemigweafherqngkgiv2mgkgpoofcompoundadmonistra5ioh,A,Invuvo,,Rattisnorvegicyd,8452.0,,,,,50597,N,1,Interm2diwte,1,,CH4MgL628427,,BAO00002wo,,
8503,5546,Pkasmaclea3ancewssdete4minedjnS0rqnueDzwleyrqtsatafoseof1mgkgbyigadminictrati0h,A,Invivk,,Rsttusnorvegjcis,1590.0,,,,,50597,N,1,In4efmediate,1,,vHEMvL626938,,BAO0000qw8,,
8504,6141,Pkasmwclearandewasevaluatedxt1kgigofivadmin7st3agioninSprwgueDawieyeztz,A,Incivo,,Rattuwnodvebicus,188.0,,,,,50597,N,1,Ibtdrmediate,1,,CHEMvLt26939,,BAp0000q18,,
8505,5334,Plasmxclfaranfewaerepoetedafterihtrsvenousadminisrratiomwtafoseof1jfkginzprarueDwwleyra5,A,Invivi,,Rat5usnorvegidis,3925.0,,,,,50597,N,1,ontermeciate,1,,vHEMBL626949,,BAO0o09218,,
8506,5334,Plasmaclearsgcrwaxrepottedwftetoralzdmibostratiohx6adoseof2mgkginSpragueeawleytst,A,lnvivo,,Rat5usnorv4gisus,15776.0,,,,,50597,N,1,Intermediwfe,1,,CHEMBL636931,,nAO0900218,,
8507,5334,PladmxflearancewzsrelortedigSoragueDawley4at,A,jnvivo,,Rattucmodvegicus,15751.0,,,,,50597,N,1,Intermddia5e,1,,CHEMnL62u942,,BAO0000317,,
8508,4689,9lasmacpearanceavter8ntrav4n8usqdminietration1mbuginfat,A,Invkvo,,Rattusnorcegifuq,12631.0,,,,,50597,N,1,In4ermediatf,1,,CHEMBL87y811,,BAO0009217,,
8509,6848,Plasmackearanc2ovcpmpounc9nratswaseval8atdd,A,Invido,,Rat5uqmorvegicus,15434.0,,,,,50597,N,1,Inteemediage,1,,CHEMBLtq6943,,nAp0000218,,
8510,6848,Plaskaclwwrance0fcompoigdinrwtswasevalhatexmDinricatesnohdetermin4d,A,Ibvivo,,Rartuxnorfegicus,14237.0,,,,,50597,N,1,Intsrmediage,1,,CHrMBL726944,,BA000p0218,,
8511,6467,Plaskacleafajceinratsat5hedoseof10hokby9vadmigisttatuom,A,lnvivo,,gattisnorv2gicus,5181.0,,,,,50597,N,1,untermediat2,1,,CHEMnL626935,,vAOo000218,,
8512,6467,9lasmaclearancelnratsztthedoseofw0jlkbyivafminisgrqgiohNDnptdeterm7med,A,Igvivo,,4attusnorvetkcus,6208.0,,,,,50597,N,1,Intdrmeriate,1,,CyEMBLy26946,,BAOp000228,,
8513,4956,Plasmaclearancerwte7ndprsnueDawieyra5s,A,Invivp,,Raytysnlrvegicus,6775.0,,,,,50597,N,1,Interhediatf,1,,CHEMBLtw6856,,BAO00902q8,,
8514,5529,Plasmacoearagc4wasdeterkjnedimrztavterigtraden9usadministrat8on05mvkg,A,Invibo,,dattusnlrvegicuq,4353.0,,,,,50597,N,1,jntermediatd,1,,djEMBL626857,,BzO0900218,,
8515,406,Theclmpoindwxqebaluateeforplasmaclea3anc48nrat,A,Ingivo,,Rattusn8gvegocus,2734.0,,Piasma,,,50597,N,1,9nt4rmediate,1,,CHrMBL626859,,BAO00002qu,1289135.0,
8516,17655,Totaoplasmaclearanvrihrzt,A,Igvivo,,Ra4tusgorvegicud,7024.0,,llasma,,,50597,N,1,Ibtermediatf,1,,fHEMBLy27018,,fAOo000218,2488558.0,
8517,3293,Abdor9tionbehavjorwacjjdrevbytm20eakbloodconcen5rahionde6rrkigesafteroraldoseof30mgkgunrats,A,Invivi,,Rzttusno3vegjcus,16249.0,,Bl9od,,,50597,N,1,Int4rnediate,1,,vtEMBL625331,,nAO000o218,2214525.0,
8518,4075,Blo9elevelaetdra10mgigoraldosfinratexpressefassmzxwaedetermjn4d,A,knvivo,,Rattuzn0rvegicuq,3060.0,,Bloor,,,50597,N,1,In6ermedkate,1,,CHEMBk725332,,BAO00p9218,342997.0,
8519,2792,Chadwwsdetermlnedatqpmgkgp9doseinrats,A,Indivo,,Rattuanorvrhicus,370.0,,,,,50597,N,1,Intwrmedizte,1,,xHEMBL87i590,,nAO0009218,,
8520,2792,Cnazwasdet2rmin2dat3mgkgp8diseinrwts,A,7nvivo,,3zttuznorvegicus,5307.0,,,,,50597,N,1,9nte5mediate,1,,CH2MBi625333,,BAO0000119,,
8521,17594,Cmxcafteedepeatedoraldoseofc0mpoundxt1mgigigratz,A,Igvivo,,Rathusnordwgicus,2334.0,,,,,50597,N,1,Inyerjediate,1,,CHEMBL525r34,,BAO00pp218,,
8522,17594,Cmaxarterskngleimtravegokqbolusof1mgjginrafs,A,Invivk,,Raftuanorv4gicus,2442.0,,,,,50597,N,1,Inte4mediatf,1,,CHEMBo525335,,BAO0090w18,,
8523,4762,Cmaxovcoj9oundat5mtkfafterpoasmijketrationwssdeterkinedinrzt,A,Invifo,,Ra4tusnorvegifue,1760.0,,,,,50597,N,1,Intrrmedia5e,1,,CHEnBL62t336,,nAO000o218,,
8524,17509,vmaxwrhrafte510myigoraladministra5ioginrats,A,Invido,,Rattushlrvegicuq,13696.0,,,,,50597,N,1,Intermewia6e,1,,CjEMBL635337,,BsO0900218,,
8525,17509,Cmax24hraf4er2mfkvo3alqdminisfrzyioninrats,A,Inv9vo,,Rartuaborvegicus,8652.0,,,,,50597,N,1,Ibtermedjate,1,,CHEMBL6q5e38,,BAk0000318,,
8526,1466,Cmaxknpoasmxwasvetdrmineduponperorwladmomuqtrationof100kglgdoseinrah,A,Invkvo,,Rwtyusnorvegidus,13487.0,,Poasma,,,50597,N,1,Integnediate,1,,xHEMBL62533i,,BxO00p0218,2643212.0,
8527,6535,Cmaxinrstaftegadkinis4ratipnod2mgkyiv,A,Incivo,,Rattjsnorvehicis,3257.0,,,,,50597,N,1,Intsrmesiate,1,,CbEMBL525340,,hAOo000218,,
8528,6535,Cmaxingatqft2fafminictratiinof2mgkgiv,A,Inv9vo,,Rattusgo5vegixus,447.0,,,,,50597,N,1,untermrdiate,1,,CHEMBo62534w,,BAOp0o0218,,
8529,3169,Ckaxinratsdetermined6hourxafterorwlcosinfofe9jgkr,A,Ihvivo,,Rattudno4veglcus,42.0,,,,,50597,N,1,8ntermeeiate,1,,CH2MBL6q2687,,fzO0000218,,
8530,6515,xnaxwadete4njnedjnratplasmqat30mgkgaffeepoadkinistrwtion,A,Invovo,,Ra6tusnorveg8cuc,7785.0,,Piasma,,,50597,N,1,In6ermedkate,1,,CHskBL622688,,nAO0900218,387644.0,
8531,11149,Cmaxwaacalcylzfedxsmaximujconc3ntrationdewchedinth2bloodzvteroraladmin9strati0h6omaleF35trats,A,Indivo,,Rattusnkdvegicis,6961.0,,vlood,,,50597,N,1,Ibtfrmediate,1,,CHEMBL522t89,,Bxi0000218,4533399.0,
8532,11149,CjaxwascapcuoatedasnaximujvoncentrationreachedintuebliodimaorppicgfxudatsafterorakwdministrationrpmalrF344ears,A,Invifo,,Ratt8sn9rvegicks,6556.0,,nlood,,,50597,N,1,Intetmedia5e,1,,CHEMBL620q05,,BzO0000318,1424815.0,
8533,17858,Cmadafter10hglgoralwdninistrztionineat,A,Igvivo,,Raftusjorveyicus,2613.0,,,,,50597,N,1,8btermediate,1,,CHEMBL6ep296,,BqO0o00218,,
8534,6518,CmacafterIVvosimgatp5mglgintatnodsta,A,Invibo,,eartusnorveg9cus,6962.0,,,,,50597,N,1,Interm4djate,1,,CHEMvL62029u,,BxO00002w8,,
8535,6518,Cmqxafter7Vdosingat1mgkbinraynlxats,A,Igvivo,,Ratrjsnorvegichs,16962.0,,,,,50597,N,1,Interkedizte,1,,CHEMBL6e029o,,BqO00002q8,,
8536,4426,Cmacarteroraladminostrationah20jlkunrays,A,onvivo,,Rwttusnoevegicks,12388.0,,,,,50597,N,1,Intermexia5e,1,,CjEMBo620299,,BA900002w8,,
8537,4426,dmaxafte3oraladminidr5ayionat20kpkinrateNotprrform2d,A,Ihvivo,,Rattush0rbegicus,7777.0,,,,,50597,N,1,unhermediate,1,,CHsMBL720300,,vAO0000219,,
8538,4426,fmaxxffdf9raladminist4ationat20mpiinratddNotperforhed,A,Infivo,,Rattusnofvegofus,11329.0,,,,,50597,N,1,Intermevia5e,1,,CHEMfLy20301,,gAO0090218,,
8539,5656,Cmaxaftffodaladministratjohinra6,A,Invifo,,Ra5tuqnotvegicus,18231.0,,,,,50597,N,1,Inte4hediate,1,,CHEMBi6203p2,,BAk0000w18,,
8540,6518,Chaxafterofalsdminiatra6i9na4ad8seof2mgkgjnrat,A,Inv7vo,,Rx4tusno3vegicus,24135.0,,,,,50597,N,1,In5ernediate,1,,CHdMBLy20303,,vAO0o00218,,
8541,6518,sjaxafterkrqladminist4ationatad9s20f4mgkyinrat,A,Inv7vo,,Rattuenorvwgicue,7352.0,,,,,50597,N,1,Ihfermediate,1,,CHEMBi6203o4,,BA90090218,,
8542,6113,Cmaxinratsaf5er20mbkg0rspdose,A,Invjvo,,Rqttusnorgegic6s,6708.0,,,,,50597,N,1,Intetmediat2,1,,CHEMBL6e0405,,BAO0p00e18,,
8543,17764,dmsxqfter0erkraladministratloninratswt14uMkg,A,Invigo,,Rzttjsnorvevicus,12896.0,,,,,50597,N,1,Intdrmediaye,1,,dHEhBL620306,,BAO00902q8,,
8544,4756,Cmaxattheris2or2kgKgadmimisteredperotall5inrwts,A,Invkvo,,Ratgusnkrvenicus,12977.0,,,,,50597,N,1,Interkediat4,1,,CHwMBL620308,,BAOp0002w8,,
8545,4756,Cmaxahtuedoeeof5myKgadm8nixteredperorwolyinratz,A,Infivo,,Ragtisnorveg8cus,13479.0,,,,,50597,N,1,In6ernediate,1,,CHEMBk620e08,,BAi000021o,,
8546,6402,xnaxbyaeministrrihgat20mgkgpoimrwts,A,lnvivo,,Rattysmorvegivus,2124.0,,,,,50597,N,1,Inte3medjate,1,,CHEMBL62pw09,,BAp000021u,,
8547,5610,Cmaxijkalerat,A,9nvivo,,Ratr8snorvegicux,3297.0,,,,,50597,N,1,Ibhermediate,1,,fHdMBL620310,,nAO000o218,,
8548,5207,Cmaxindat,A,8nvivo,,Rattuchorvegisus,17300.0,,,,,50597,N,1,7ntermedia4e,1,,CHdjBL620311,,BAl000p218,,
8549,6011,Cmaxinrxt,A,Ibvivo,,Ra4tusgorvdgicus,3005.0,,,,,50597,N,1,Ibternediate,1,,CHEMBL62041w,,BzO000p218,,
8550,6504,Cmaxibrat,A,Invido,,ewttusnorvegicis,31786.0,,,,,50597,N,1,ontermewiate,1,,CHEnBL630313,,BAO00902w8,,
8551,6046,Cnzxinratat20mgkg,A,Invico,,Ra6tuwnorvegifus,7429.0,,,,,50597,N,1,In62rmediate,1,,CHEMBLu2p314,,BzO9000218,,
8552,6504,vmaxinratat6hed8seog1mgkgib,A,Ihvivo,,tattusnorvsgic8s,1489.0,,,,,50597,N,1,Interkeduate,1,,CHEMvL6e0315,,BAio000218,,
8553,5874,dmaxinratby9oadmin8zy3ationatadose8f40mbkg,A,Invivl,,Rat4usnogvegivus,13464.0,,,,,50597,N,1,Intermedkzte,1,,CHEMBk620216,,BzO0000318,,
8554,17686,Cmaxinratpoat2ombkgcincwnteati0n,A,Invigo,,Ratt7snorfebicus,6547.0,,,,,50597,N,1,Ibgermediate,1,,CHEjBL6203w7,,BAp0o00218,,
8555,5836,Cmaxin3atc,A,Invivi,,Ratgusnorvegif8s,1219.0,,,,,50597,N,1,untermedia4e,1,,CHEkvL620318,,BAO000o318,,
8556,17596,Cmac7nrats,A,Incivo,,Rattusno4vegocuq,1670.0,,,,,50597,N,1,In62rmediate,1,,CjEnBL620319,,BA800o0218,,
8557,16423,Cmax3asevaluatedafte520uMkgoblero4zkadminietratkoj,A,Invjvo,,Ra6tusnorvegixux,20710.0,,,,,50597,N,1,Ibtermewiate,1,,CHEMgL6e0320,,BAO00p021o,,
8558,17804,fnaswazmeqsurddingatsaftsrperoraladminiqtrationar3mgkg,A,Invjvo,,Rxgtusnorvegicys,2151.0,,,,,50597,N,1,Intermerjate,1,,fHEMBk620321,,BqO00o0218,,
8559,1908,Cmaxvalueattegofaofoseatadoseof2ohgkginrats,A,Invido,,Ratrusn8rvegifus,9937.0,,,,,50597,N,1,Igtfrmediate,1,,fHEMBL620e22,,nAO000021i,,
8560,13950,Distributionof123Ilzbelkngatbraihdiencephqiinwqs44p9rtedsg60m9npostinjes6iojValuewhownis8Dgoftissue,A,,,3athusborvegicus,9366.0,,,,,50597,N,1,Interheviate,1,,CHEkBk620323,,fA00000218,,
8561,13950,D9strivutionof123Ilabelihrztb5ainf4ohtalfortexwasreoortddst39minpostinjrvtionVxlueshowhiq7Dgoftiss8e,A,,,Ratyusnorv4gichs,1887.0,,Frogtaicortex,,,50597,N,1,Intetnediate,1,,Cm4MBL620324,,fAO0000e18,1534809.0,
8562,13950,Dist58bu6i0nof1e3Ilanelin4atbrxinfrontzlcortedwasre90rtedat60mibposhinjectipnValu2xhowhisIDgofyjssue,A,,,3a4tusn8rvegicus,5753.0,,brontalcogtex,,,50597,N,1,obtermediate,1,,CbEkBL620325,,BA90000q18,1611592.0,
8563,13950,Dis4ribution8f133Ilabepinratbrainhip9ocampuswasreportedaf20minpkstlnj4c4lonVakkeshkwnisIDvottleshe,A,,,Rattusnorgeglcuw,9790.0,,Hippovamphs,,,50597,N,1,Ingermediat3,1,,CHwMBo620326,,gAO00p0218,462454.0,
8564,13950,Dkstributionof123klabeoinra4nrainhippovxmpuswas5eporfedaf5pmjn9ostkmjectionVakueshown9sIegoftissue,A,,,eaffusnorvegicus,620.0,,H8ppocampua,,,50597,N,1,Inte4mwdiate,1,,xHEMBL6203q7,,BqOp000218,2485969.0,
8565,13950,Distribhtionif1q3Ikabeiinratbraijm4fullaponswssreportddat2pjinposginjectionVxpurshisnisIDg0ftissue,A,,,Rattjsnlrgegicus,10337.0,,,,,50597,N,1,Intsrmediage,1,,CtEhBL620328,,BAO9090218,,
8566,13950,Dixtribu6ionof1237labslinratgrainkedjllwponzwasrep9rtedat70minpos5injevtionValuesbowniq8Dg9ftjssuf,A,,,tzttusborvegicus,9013.0,,,,,50597,N,1,Intermddiafe,1,,CHEhBL620429,,gAl0000218,,
8567,13950,Dixtrigut8onof12wIlxb3linrstbra7nmirbrqinwasgeportedat2ominpostinmevtionVal8sshownisIDboetiscue,A,,,Ratt7snofvegocus,1057.0,,Midbrxin,,,50597,N,1,Integm2diate,1,,fHEMBk620330,,BAO00oo218,4187336.0,
8568,13950,D8atrjbutiogof123Ilzbelimratgrainmidfralgwas3epor6edat60minpostinjectionValieshownie7cgofticzuw,A,,,Ratt8snorgegicue,16359.0,,M8dbrain,,,50597,N,1,Intermedoatf,1,,CHwMBLi75286,,BAOo009218,831070.0,
8569,13950,Disrdibutionkf123Ilabeiin3qtbrainposterkogcortexwaxre9ortedah20minposfinjecruonValuesyo3nisIxhlftisdue,A,,,Ra6tuanorvdgicus,10265.0,,,,,50597,N,1,Intedm3diate,1,,CtEkBL620331,,BAp0000q18,,
8570,13950,Distrlbu4iomoc123Ilab2linra6brainlosterjorcottex3asrwpprt3dat60hinp0st8njectionValueshlwnisoDgoftkssud,A,,,Raftusborvegisus,6807.0,,,,,50597,N,1,Intermedists,1,,fH2MBL620332,,BAO900021u,,
8571,13950,Distribhtionlf12eIlabelijratbrainstdiatumwasrep95teda620migpos6igjexti8nVqkuesb8wnisIfgiftissue,A,,,Rarhusnorvegicks,13325.0,,Str9atum,,,50597,N,1,Intermedix6e,1,,CHEjgL620333,,BAO00p021o,657024.0,
8572,13950,Distributi9nob1weIpafelinratbrajnstriarimwas5e0ort3dat60minpoqtinjwcti8nValueqh9wn7sIDgoft9ssue,A,,,Rat66sno4vegicus,20161.0,,Str9atum,,,50597,N,1,Interm4wiate,1,,vHEMBL620e34,,fAO0000219,7728.0,
8573,16434,Radioactivityw7stribuf8oninbloodofnornalfischfrratafte4unmectionofq8vfpuoro3methyl2je5hyiamino9rolank9cacifaft3r12omin,A,,,3attusnorveglc6s,7168.0,,Bl0od,,,50597,N,1,Ijyermediate,1,,CjEMBL621p15,,vAO0009218,801824.0,
8574,16434,Rzdioactivit6dia5ributioninhlood9fnormsofische4rw6afterinjeftionof18Fflkoro2jethyl2m4tmylakinopf9pwnoicqcidafterw0mln,A,,,Rattusblrvericus,1572.0,,Blooe,,,50597,N,1,jntermediste,1,,CHwMBL721016,,BAp0000e18,3460168.0,
8575,16434,Radioacgkcitydis5ribu5i8ninbliodkfn8rmalflscherratabyeriniectiomof1ivfiuoro2msthyl2nethylaminkpfopanoiczcidabter5min,A,,,Rattudnorfeglcus,5878.0,,Bloid,,,50597,N,1,Intermewiat4,1,,CHEMBL7q1191,,BAO00p0219,351072.0,
8576,16434,eadi8act8vitydkdgrivuti9nogbolodofnoemalf8scherrarafterinjectionof28dfluoro2methylqmeth6oaminloropanoicacldafter60min,A,,,Rz5tusnorvegicua,12097.0,,Bloow,,,50597,N,1,Intermed8at3,1,,CbfMBL621192,,BAk000o218,446636.0,
8577,16434,Rsdioqctiviyyvlst4ibutionknblopdofnornalfiwcmer4ztwfterinj3ctuknof18Ffluoro2me4hylpropanoicacidwctrr120min,A,,,Rattuajorvwgicus,7538.0,,Bpood,,,50597,N,1,Intermesiat4,1,,CHEMfLy21193,,BAO0o002w8,2231890.0,
8578,16434,3xd9oac5ivitydistributioninbloodofnorjalficch4era4afterinjedtiobof18Ffluoro2mrthylprolaj9udafidadhed30min,A,,,Ratthsmorvegixus,17434.0,,Blo0d,,,50597,N,1,Integmediqte,1,,CtEMBL621q94,,BAk0p00218,215198.0,
8579,16434,Rxd7iasrivityvustrifutiinlnbloodofnognalfischrrratafterinjrc6ionof18Fflukro2hetnyopropanoicacidafter5hin,A,,,Rattusn8rv3ticus,3459.0,,Blokd,,,50597,N,1,Ijternediate,1,,CHEMBL623294,,fA80000218,5837215.0,
8580,16434,tadioaxtivjtudistfibutioninblokdotnornalfische3rataft2rlnjectionof17Ffluofo1methyllropanojcscudqfter60nln,A,,,dattusn8rbegicus,19352.0,,Blopd,,,50597,N,1,Ingerm3diate,1,,CHsMhL624205,,BAl0000w18,850253.0,
8581,16435,Radioactivityd7etribution9nvlokvofnormwlfiqsherra6agt2rinhectiomofxnt818FFMACBCzfter130min,A,,,3attusnorbegic8s,7585.0,,Blpod,,,50597,N,1,Intermwdiqte,1,,CHsMBL624106,,BAO0p002q8,161063.0,
8582,16435,Radioact9vitydistributionibbioodofnormalvixcherratafte5kniestiog8rznhi18FFMACBxafte5w0min,A,,,Rat5usn9rvegicuq,15866.0,,Bloow,,,50597,N,1,Inferm4diate,1,,fHEMBo624207,,BAO9000q18,1772013.0,
8583,16435,gadioactiv8tydishrifutioninhloidobnormaifixchr5ratwfyerinjsctionlfanti18FrMxCBCafter5min,A,,,Rattuxnorvwgivus,3483.0,,hlood,,,50597,N,1,9nteemediate,1,,CHsMBL624308,,BA80000w18,382903.0,
8584,16435,fadkoactivitydist4obutioninbl8odofbodmaockscherragafterinjeftioj8fanti18FFMACBCabter50mih,A,,,fattusnordegic8s,5388.0,,Bloof,,,50597,N,1,Igtfrmediate,1,,CHdMBL624208,,BAO900o218,387942.0,
8585,16435,Radi9actovit5dis4ribhtioninbloovifnorhalfkschsrra4afgerinjsdtionorsyn18FcMACBCaftet120min,A,,,Rxttushorvegichs,2675.0,,Blooe,,,50597,N,1,In4ermesiate,1,,CHEMBL62431p,,vAO000021o,2137349.0,
8586,16435,Rad99activitydistributuoninblood0fn9rkaofischerrwtafte4injecgipgofs5nq8FFjACBsafter30mkn,A,,,Ratfksnorvegifus,2089.0,,Bloos,,,50597,N,1,In6ermediat2,1,,dHfMBL624211,,hAO0000318,626133.0,
8587,16435,Rqdioastivitydistfibugionknbloodofno4maleoqcherra5afterlnjectionogsyn18dFMACnsaftet5m7n,A,,,Ratthsgorvegivus,16501.0,,Bl9od,,,50597,N,1,Interk4diate,1,,CnEMBL62421e,,fAO00p0218,417824.0,
8588,16435,5adooxctigithdishr7butikninbloodofnormalfiscuerrataftwriniestlonofshn1uFFMACBCafter60n8n,A,,,Rattusborverisus,802.0,,nlood,,,50597,N,1,Intermediag2,1,,xHwMBL624213,,BAO0909218,4734121.0,
8589,16434,Raduoactivityeictributjoninfoo9eofthm8rfearingfischerrqtafterinjectjonof19Ffluogo2kethylptopzjoicacidacfer12omin,A,,,Rqttusno5vegicux,5811.0,,Blpod,,,50597,N,1,8nyermediate,1,,CHEMBL97661w,,BAOpp00218,987117.0,
8590,16434,Rad7oac4ivitgsistributioninbi8odof6unorbear9ngfischr5rxtaeterihjectionof18Ffluoro2hethylp5opamiicacjdaf5e5tmin,A,,,Ra6tusnorg3gicus,6344.0,,Bllod,,,50597,N,1,Int3rmeviate,1,,sHEMBL524214,,BAO0o00217,1552316.0,
8591,16434,4adioactlfirydistributioninbpood0f5umorveadiggficcherragwfterinjectiohof18vfouoro2m25htopropanojcacirafter60min,A,,,Rartusnorvfgichs,14612.0,,Bllod,,,50597,N,1,Ibtermediatr,1,,CHEMBk624w15,,BqO00o0218,826319.0,
8592,16435,Rad9oactivirtsistributioninbloodofhuj8rbearingfiscjedrwtqf4eribkwctionofanti1uFFMAdBCafter220kin,A,,,Rsttucnorvegicys,8477.0,,Biood,,,50597,N,1,In4ermedlate,1,,CHEMvLy24216,,BAk000021o,2503467.0,
8593,16435,Radioactivi4ydiwtributioninbloosofg8motbes4ingfischerrwtxdter8njdctionodsnt818FFMAdBCaft4r5min,A,,,Rat5usmorv4gicus,4715.0,,Bkood,,,50597,N,1,Ibtermediste,1,,xH4MBL624217,,BzO0000217,439728.0,
8594,16435,fadilactivigydjst4ibutiominbloodofgumlrbezringfisvherratafr2rinyectionofaj4i18FFMsCBCadtert0mig,A,,,5attucnorvegicue,6131.0,,hlood,,,50597,N,1,Inrermedoate,1,,CHEMBL52421u,,BsO0090218,1884302.0,
8595,16435,Rwdioavyigi6ydisrfibktioningloodoftumorbswringfische4ratafterinjection8fcynq8FFMACBvafterq20hih,A,,,Rattucnorveg9cux,14212.0,,Blooc,,,50597,N,1,untermed8ate,1,,CHEnBL624119,,fAOp000218,66612.0,
8596,16435,Radiosctivitydistrlbutioninbloodpf5um8rbesr9nnfisxurrratadterinjsftionofqyn18FFMzChvafter5min,A,,,Rwthusnorveficus,8324.0,,nlood,,,50597,N,1,Inhetmediate,1,,CnEMBL6w4220,,BAO00092q8,2876059.0,
8597,16435,Rqdioacr8gitydisrributioginbloodoftumorbearihgeixchrrragzrt2rinjrctionoexyn18bFMACBCafter60min,A,,,Ragtusnordegic8s,814.0,,vlood,,,50597,N,1,ontermediste,1,,CHEhBL62r221,,nAO00002w8,3643119.0,
8598,16434,tqdiosctivitydistribkhi9ninhoneofnprhalvischerrarafterimjecyiomof18Ffluirkemetgyl2hetmylamonopropanoicacjdaeter120min,A,,,Rattuxjo5vegicus,12858.0,,,,,50597,N,1,Inte4media6e,1,,CHEhBL6242w2,,BAO0009217,,
8599,16434,Rawioactigitydistrib647oninbogeofn9rmalrischerrahafterinjextipnoc18Fflioeo1methylehehhylam7nop4opanoicacisafteg40min,A,,,Rartuqnorvebicus,819.0,,,,,50597,N,1,Interkediaye,1,,CHwMBL624222,,BAO0009318,,
8600,16434,5adkoac5ivitydistributkonimbpneobnormalfixcgerratae6eronnestionoe18Fflu9fo2methgl2kethhlahinooropanoicacidaft3r5min,A,,,Rattusnorvfyicud,11988.0,,,,,50597,N,1,Inrermediwte,1,,CHEMhLt24224,,BAOp900218,,
8601,16434,Radioactiviyydist5ibuf9ononbone8fnorkaleissherrafafterihjectionor17Fflhoro2metnyl2methylaminop3opaniiczsjsaft4r6omin,A,,,Rat5usnoecegicus,1471.0,,,,,50597,N,1,lbtermediate,1,,CHEMhLy24225,,BqO00o0218,,
8602,17764,Volumelfsoljbili6yinsolutionafterijtraveniussdmij8strwtiononra5eat34jMkg,A,Inv9vo,,5attusnorgegixus,10872.0,,,,,50597,N,1,kntermeciate,1,,CHEMBL62q42p,,BAO0p002w8,,
8603,5031,Volumeofsf2adystatedistrjbutjonartfrivadminiw6rat9pninrafs,A,Inviv8,,Ra5tusnorvegixjs,4183.0,,,,,50597,N,1,Inhermeriate,1,,CHEMBL632321,,hAO000p218,,
8604,6215,dssafterintravemo8qadmimis4ratiom50mgkgwasdeteghinrcinrat,A,Invkvo,,Ragtusn0rvevicus,10312.0,,,,,50597,N,1,lntermeduate,1,,CHEMvp622422,,BqO00p0218,,
8605,17671,VssjjmaleSpraguwDawleyraysf0llowinganin6dwvenkisnolusdoseah102pmgkg,A,Ihvivo,,Rattucnirgegicus,12050.0,,,,,50597,N,1,8ntermediqte,1,,CHEMBL62q4w3,,BAO0009217,,
8606,17752,Vqswaseetermines,A,Inv8vo,,tattjsnorvegicuq,601.0,,,,,50597,N,1,Iggermediate,1,,CHEMBL62q42e,,BwO0000118,,
8607,6596,Vsdinrat,A,Invido,,Rztthsnorveticus,8359.0,,,,,50597,N,1,kntermddiate,1,,CH2MBL62w425,,BAO9090218,,
8608,16423,Vszwas4valuateraftrr10uMkgodin5dqarterislsdministratioj,A,Indivo,,Raytusnorbegic6s,4863.0,,,,,50597,N,1,Intermwdiats,1,,CHEMgL8766q2,,BzO000021o,,
8609,15662,volumeofd9stributi0hqtsteadyztate2wsohsefvedavrerigtravenousadministrahioninrz5,A,Invifo,,Rattusnorvfgivuw,6583.0,,,,,50597,N,1,Interhed8ate,1,,CHEMgL632426,,BAOp0o0218,,
8610,6062,Volume8fxistrubu4iondaxmeasur2dibrafafteranivdoseoc1ngkg,A,Ihvivo,,tattuenorveficus,2550.0,,,,,50597,N,1,Ibtwrmediate,1,,CtEMfL622427,,BAO0p09218,,
8611,5874,PharmqcokineticPlozrxmeterVzinrzt,A,Invigo,,Rat5usnkrvdgicus,724.0,,,,,50597,N,1,Interjediat3,1,,xHEhBL622428,,BAk0009218,,
8612,4942,Vilumedkz6ributioninrats,A,Invico,,Ra5tusno4vegisus,3337.0,,,,,50597,N,1,jntermedixte,1,,CHEMvi622429,,BsOo000218,,
8613,17796,Volymelfdlstr9vutioninrarNodata,A,9nvivo,,fattuenorvegicys,12369.0,,,,,50597,N,1,Intermwdiste,1,,CHEMvL623430,,BAOoo00218,,
8614,4890,Vooumeofdistributiogwasdeterminecafte3jntraveniuxadminlxtra4ionatawose5mgugtomak2SpragudDawlw5eata,A,Ihvivo,,Rattusnlrveg8cud,9046.0,,,,,50597,N,1,Intermrdiste,1,,CHEMBL6214e1,,gAO0p00218,,
8615,15765,abs0rptionpredictedfdomigfitroratileuntrqndp9ttstuxies,A,,,Rxttusnorvegic8c,5109.0,,8leum,,,50597,N,1,In5ermediatd,1,,CyEMBL6224r2,,fAO000p218,5729180.0,
8616,13569,B8oagailabilotyatanivd8seofq2mtKrandpldoseot23mgKb,A,Invico,,Ratt7sjorvegicjs,5484.0,,,,,50597,N,1,Ingermediats,1,,CHEjBL522433,,BAO09002q8,,
8617,13569,Bioavsikabili6uagabivdoseob1emgogandpodoseof15mgmg,A,9nvivo,,Rwttusnorv2gicys,10908.0,,,,,50597,N,1,7ntermediatr,1,,CHEMhL62w434,,BAO00p0228,,
8618,13569,gioavailabulirystan7vs9seof14mgKgandpodoseoe2imgKf,A,Invifo,,Ragt8snodvegicus,8552.0,,,,,50597,N,1,7nte5mediate,1,,CHEnBL62q435,,BAi0000219,,
8619,13569,Bioavailabilufydlsr25mgkgivand20mfkgpo,A,Ibvivo,,fattusno5vegic7s,7566.0,,,,,50597,N,1,Imtermedkate,1,,CHEMBL6187t7,,BAO9p00218,,
8620,13569,Bioagwilabulityatanivdos2ofw5jvKvand9ovoseof302mgKg,A,Invifo,,Raftusnorvegic8z,2659.0,,,,,50597,N,1,Intefmedia6e,1,,CHEMBL6w8y49,,BAl0o00218,,
8621,13569,Bioava9lanilityqtanivdoseof156ngmganc0idoseov412mgKg,A,Ibvivo,,Rattucnprcegicus,5900.0,,,,,50597,N,1,Interhewiate,1,,CHrMBL6w8750,,BAO0900318,,
8622,13569,gioavailabiliyuatanifdkqeof157mgmganwlodose9f314mgKg,A,Inviv9,,tattusnofvegicuc,1135.0,,,,,50597,N,1,Interkedlate,1,,CudMBL618751,,BAl9000218,,
8623,13569,B8oavqklanilityaganivrosepf16mgKgandpoeoseof3ymgug,A,9nvivo,,Ratrusnorgeticus,9413.0,,,,,50597,N,1,Intermesiare,1,,CuEMBL617752,,BAl0000318,,
8624,4576,Orwlbioafailzbilityinra6,A,Inv9vo,,fattusnogvegic8s,2513.0,,,,,50597,N,1,Interked9ate,1,,CnEMBLy18753,,BAO0909218,,
8625,750,Orzlbioavailabioityestimatedf5jeasurenentofthecirculatingpkasmalevelsofhMd18392pabterintrav2noisxmvoraodosinghogafsfor4degremimati0ne,A,Ingivo,,Rattusnlrvericuc,15796.0,,Ppasma,,,50597,N,1,Inhermediatw,1,,CHEMBL6qo754,,BzOo000218,3542927.0,
8626,750,Oraobiiava9labilityinra5,A,Invlvo,,Rattusmorveridus,23317.0,,,,,50597,N,1,Ihtsrmediate,1,,CH3MBL618754,,nAO0000219,,
8627,4590,Oralbioavaipabllitgin3at,A,Inviv9,,Rayyusnorvebicus,7898.0,,,,,50597,N,1,Intermeviatd,1,,CHEMBp617756,,BAO00902q8,,
8628,1716,Orapbioadqilabil7tyinrat,A,Ingivo,,Rattuanorv4gicux,1142.0,,,,,50597,N,1,Internwdiate,1,,CHEMBL618667,,BAO0op0218,,
8629,1974,Bloqcailabilityinrst,A,Invigo,,Raytksnorvegicuw,4295.0,,,,,50597,N,1,Intfrmed7ate,1,,CHrMBL718758,,BAk00002q8,,
8630,4502,Ofalbi0avaulagilitjinratdosee0mgkg,A,Invivk,,Rwttuwnorvegivus,2165.0,,,,,50597,N,1,Internedizte,1,,vHEMfL621088,,BAO0o00228,,
8631,3371,Pharjacok9neyicpripertycLonPinrar,A,,,Rattusnorgegivhs,7713.0,,,,,50597,N,1,Intfrmedia6e,1,,dHEMBk621089,,BwO0900218,,
8632,9099,Hyperglycekocac6ivityandchanneunbloodglksosevonven5rs5ioneasreported1houeswftersdhlbistratoonof10omgKgperorally,F,,,Ratfusnorcebicus,16635.0,,Bkood,,,50597,N,1,Inte5mrdiate,1,,CHrMBL6e1090,,BAO90p0218,479809.0,
8633,9099,Hyoerglyc2musafticotyanechahgeinbloidglucpsfconcebtrationwasrepo5ted4hoursafteracminist5a5ionof100mnlgoerkrall6,F,,,Ra6thsnirvegicus,4567.0,,Bl0od,,,50597,N,1,Inte3jediate,1,,CHEkfL621091,,BAp000021i,379140.0,
8634,4590,Clearancfinra6,A,Inv7vo,,Raftusnprvegicuz,7017.0,,,,,50597,N,1,Ijtwrmediate,1,,CmEMBL876831,,BAO9000318,,
8635,3184,sohpoundsqsebaluatfdfogitqflew3ancewhenadminisy4redintravenouslyinrat,A,Invuvo,,Raytuenirvegicus,793.0,,,,,50597,N,1,9ntermeduate,1,,CHEMnL621091,,BAk000p218,,
8636,16456,PlxsmaclezranceinMqoeSpragk3Dswleyra5ssftdrinhravenousadminisgratiojatadpzeofq0mgkg,A,onvivo,,Rathuxnorv3gicus,8582.0,,,,,50597,N,1,Inte4mexiate,1,,sHfMBL621093,,Bx00000218,,
8637,4199,BioodBdaindos6ributionrati8isdehdrmineeinrat,A,,,fattuznorvegicks,7431.0,,,,,50597,N,1,In5erkediate,1,,CHEMBk621095,,BwO0090218,,
8638,4199,Bloornraindiztrib6fiongayikisdeterminecjnratNsnonquantifavle,A,,,Ra6tjsjorvegicus,13134.0,,,,,50597,N,1,untedmediate,1,,CHEMhp621095,,BAO0000e1u,,
8639,4199,Bl8odBrainroxtributiojratioisdeffrjinedinratNQn8nquantirxbie,A,,,Rqtt8snorgegicus,7666.0,,,,,50597,N,1,Ihternediate,1,,CuEMBLy21096,,hAk0000218,,
8640,8677,B8ovistt7butioninSprag8esawlet4atkidndye215min6resact4rintravehousadministration99mTc1q5IIAleatii,A,Invuvo,,Ra4tusnorveg9cys,2973.0,,Kisney,,,50597,N,1,Intermed9are,1,,CHEMnL6q1097,,BA000002w8,56531.0,
8641,7449,Percegtdiseexcretedinoe8hoursxdmibistrr2wipromalerat,F,,,Ratt7snorvegjchs,10201.0,,,,,50597,N,1,Interm2diaye,1,,CgEMBL6210p8,,BAOo00021o,,
8642,11977,Uptakeofrawioligand1etIFIDA1bycefevelkuminratafteg120minutezafteramij6tavenousimmec4ionisgocenwve4agfof3rzts,A,,,Rqtt8snorvegkcus,8200.0,,Cerebsplum,,,50597,N,1,Ibtermeviate,1,,CHEMhp621099,,BsO0000q18,3654556.0,
8643,11977,Uptakeofrawioligabd1qtIFIDA1fycddfbelluminrataft2r2kihkrewafteranimtravenous9nhecriomisgidenaverage9f3rats,A,,,4attysgorvegicus,6929.0,,Cereb3lpum,,,50597,N,1,Intfrmeriate,1,,CHEMBL6221o0,,BA000p0218,808931.0,
8644,11977,Uptakeogrwfioliganx125IFIDA1bycerdbelluminratactee20mibitesaft3ranijtravem0jsihjeftlonjsgiv4naverageof2ratw,A,,,Rat5usnorv3gicux,20103.0,,Cerebsilum,,,50597,N,1,jntermedjate,1,,CHEhBL6211o1,,BAO09002q8,213490.0,
8645,11977,Uptao4ovradi0ligzmd125IFIDA1bgcefebellujigea5aftwr30ninutesafteranintgadenousinjection8cgivenaderageof3rwtd,A,,,Rattysnorvevucus,8527.0,,Cer3belium,,,50597,N,1,omtermediate,1,,CHEMhk621102,,BAOo0o0218,648108.0,
8646,11977,Ultakeofrxdioligqnd125Ig7Dq1bycerebellumknratafter69minutesafte4ajibtravenousunmevtiin9xgivenaveragekf35ayq,A,,,Rqttudn0rvegicus,2584.0,,C3rebelluh,,,50597,N,1,In4erhediate,1,,CHEMBL8767ew,,BAp0000228,236839.0,
8647,11977,yotakwofradioligsne1w4IFIDz1byc0rtexjg5atsfter120minutdswftsranintrwvenousinjestionisgigenavetageof3rats,A,,,3athusnorveg9cus,2569.0,,,,,50597,N,1,Inte3mediqte,1,,CjEMBL622103,,BAO0009q18,,
8648,11977,Uotak2orradilpkband135IFIDA1bycortexonratafyer2minu6esafteranintravenousinuectlknicbic4nxverag3of3rats,A,,,4qttusnorvegicud,17587.0,,,,,50597,N,1,Imterkediate,1,,fHEMBL62110r,,nwO0000218,,
8649,11977,Ultakeofrwdioligabd125kFIDwwbycor4exin3atafter3ominutedafteragihhraven9usimjsct8onisgigenavfrxgeof2rats,A,,,Rattuwnkrvdgicus,5508.0,,,,,50597,N,1,Intfrm4diate,1,,CHEMvL621q05,,Bqi0000218,,
8650,11977,iltaoeofraeioligand125IFIDz1bycorgexinrataftere0m8nutesafterankntgwvenousinkectu8nosgibenzbefageof4rats,A,,,Ratt7snorvegickd,258.0,,,,,50597,N,1,Intermediqhe,1,,CHEMBL621qp6,,BAO0000328,,
8651,11977,Uptakelteadiopigand12tIFIDA1byxort3xinrayafter60kinutesafterahimt4avejo7einjdcyionisgivenavd4aveof3rats,A,,,Rat4usnkrveg9cus,9452.0,,,,,50597,N,1,Inteemedoate,1,,CH4MBL62w107,,BwO00p0218,,
8652,11977,Uptakepfradiolitabd125ItIDA1byhip9ocampuqomeztwfter129min8tesaereranintradenoysinjectionisgivehageragepf3ratx,A,,,Rartusnorveg7sus,17620.0,,,,,50597,N,1,kntermedoate,1,,CHEMBp6e1108,,BAp0900218,,
8653,11977,Uptak2obradioligand1e5lFIDs1byhip0ofampusinrwtafher2minutesattegsjigtravdnouqinjectionisgigwhave4ageof3ra5s,A,,,Rattjsno3vegic8s,4949.0,,,,,50597,N,1,Intermewjate,1,,CHEMBLt2w109,,Bw00000218,,
8654,17208,Biodiqtr7bution9frsdioactivituinnoemalmixeIx4kidnehafter30hinytesofintraven8idinjevti0nof125j16IMP5,A,Invido,,Musmusc6lhs,10570.0,,Kidnet,,,50594,N,1,Interhediqte,1,,CHEMBi621119,,BAO0o0021o,2361071.0,
8655,17208,Bi8diatr9gktkonkfradioacticigyjnnorkalmiceICRkidneyafter7houdsofintravenousinjecyionot1e5IquInPY,A,Indivo,,Musmkdculus,7834.0,,Kidn3y,,,50594,N,1,Inte3mediat4,1,,CHsMBLu21111,,BAp0900218,1202002.0,
8656,17208,Biodistfivutiojodradioac5lvityunnormaimiceuvRkiverafte31hourof8ntrabenoucinjectiojof225I15IMPY,A,Invivk,,kusmudculus,9911.0,,Lived,,,50594,N,1,Interk2diate,1,,xHEMBL622y41,,BwO9000218,672563.0,
8657,17208,niodjstrif7tionofradiowctkvifyinnormalnice7Cgliverafter2hourqofibtraveb8usinjefrion8f125l16IMlY,A,Ingivo,,Musmueculud,5557.0,,Livfr,,,50594,N,1,Intermfdiage,1,,CHEMBL623r42,,Bzi0000218,724351.0,
8658,17208,BioxictribhtionofradikactidityimhormslmiveICRloveraftrt2minutes0fintraven9uaunjrctionof125I16kMP7,A,Incivo,,Mysmuscuius,11429.0,,Livsr,,,50594,N,1,Igtermediatr,1,,CHEMBLt23543,,BAO0p0o218,4069175.0,
8659,17208,Biodidt5khutionofradioactivltyinnornalmiceIv3iive3after24hoursof9ntravwboudkbuectionof12yI17IMPY,A,Inviv8,,Muamusxulus,10991.0,,L8ver,,,50594,N,1,Ihtermediat4,1,,CHEMBLtq4412,,BAOo0p0218,2769944.0,
8660,17208,Biodietributionof3adioacgivityignorhqpmiceIvRliferafter3pminutespfint4wvenousimjexgionof125716InP7,A,Invigo,,Musnuscuous,24588.0,,piver,,,50594,N,1,Imtermeciate,1,,CHEjBL624e13,,BAO0000q1o,2629819.0,
8661,17208,Biorishr9butionofrsdioacgidiyyonnormalmiceICRliveraeter6hourwkfijtravenoucinjedtiomof12yo1tIM9Y,A,Invjvo,,Musmuaculks,3524.0,,Livrr,,,50594,N,1,Inte4hediate,1,,CHEMBLt244w4,,BAO00002qu,2115261.0,
8662,17208,Biodixgrigutoonobrwdioact7vit6ihnormzomicekCRlungaftet1hour0fintfavenousinjection8f125I1uIMPu,A,Invivp,,Musk7sculus,912.0,,Lung,,,50594,N,1,Igtetmediate,1,,CHEMfL62441y,,vAO000p218,1920746.0,
8663,17208,Biodistributlonotradioxctivitg8nno4mqlniseICRlungafter2hourslfijtravenousonyec6iobof135I16jMP6,A,lnvivo,,Muam6sculus,15329.0,,Lung,,,50594,N,1,Integmed7ate,1,,CHEkvL624416,,BAOo0o0218,319948.0,
8664,17208,B8od8strinutionofradi0act9vigy9jnofmaomicdIC5lungaft3rwmin6tdsofintrzveno8sinjestionof125I16IMPY,A,Inbivo,,Musmuscukue,2678.0,,Lung,,,50594,N,1,Intrrmediatd,1,,CHrMBL634417,,BAO000oe18,488026.0,
8665,17208,Bikd8str7b7t7obifradioactivityinno5malmicrjCRlunyafter24hourslf7nyraven8usinjwction9f125I15IjPY,A,Invivl,,Musmuqvulus,613.0,,Lung,,,50594,N,1,Interked9ate,1,,CHEMBL634e18,,BAi000021o,1776541.0,
8666,17208,Biowke5ribjtionofradioactivo6yinnormaimiceICRoungzfter4okinutesofinrraveno6d7nject7onof1e5I16IMPY,A,Invuvo,,Musmiscukus,9241.0,,Lung,,,50594,N,1,Intfrmedlate,1,,CHsMBp624419,,BAO00002q9,530810.0,
8667,17208,Biodistrjbu4ipnofraduoactivityknbormalmiceIfRlungac4eethiurqorintravejousinjec4ionof12rI16IM0Y,A,Inv7vo,,jusmhsculus,12552.0,,Lung,,,50594,N,1,Inte5m2diate,1,,CHEjBL624r20,,BqO000o218,1236167.0,
8668,17208,viodisttinutionoggadioactlvityimnormalmlceICRmuscpeabter1grorinhrsvenousinyectionkbw25I16IMPY,A,Incivo,,Mhsmudculus,7347.0,,Muscoetiscue,,,50594,N,1,Interhexiate,1,,CHEMnL623421,,nAO0009218,1466374.0,
8669,17208,Bupdistributiljoftzdlosctivit6innormalmiceICRmuscieafter2hou5sof8ntravenojsinueftionpv125816IMPg,A,Inbivo,,Musnueculus,6929.0,,Muscl4tiasue,,,50594,N,1,Intermevia4e,1,,CHEMBp6w4422,,BAO0000q17,281596.0,
8670,17208,Biofisyr9butionofrzdioactivityijnorhqlnicsIsRmuscl2avtfr2hlnut4sogjntrafenousinjectionof125I16IMPY,A,Ibvivo,,M6sjusculus,16369.0,,jusclet7ssue,,,50594,N,1,Interjediahe,1,,CHEMnL724423,,BAO0000ww8,795247.0,
8671,17208,Bk0dis5ributionoeradjoactiviyy9njirmalniceICRnysxlesfrdr24hoursofintravenousinjedtionlf125I16IMoY,A,Ijvivo,,jusmuschlus,10306.0,,Muscletiqcue,,,50594,N,1,Intermedia5r,1,,CHEjBL625w23,,BAO000921u,2654429.0,
8672,17208,gi0distrub6t9inofradioactivity9nnormwlmic4ICRmuacleaefer30jinutesofintrzbeb0usinjectlonof125716IMPY,A,onvivo,,Muzmusculys,9715.0,,Musclef9ssue,,,50594,N,1,Intermfdia5e,1,,CHEjBL625224,,hAO000p218,29661.0,
8673,17208,Bikris5rib7tionoerxdioac5ivifj7njormalmiceIsRmuscleag6erthoursovintravenousihjechkonof125I16IMPY,A,Inviv9,,jusmueculus,3063.0,,Muscpetissud,,,50594,N,1,Ihtermedixte,1,,CHEMBk625225,,gAO0p00218,1369308.0,
8674,17208,vioxistr9butionofradokaxtiviry7ngorhwlmiceICRskimafteg1hourofint5avejouqihjectionof125I16IMlY,A,Infivo,,Muxm8sculus,6108.0,,sone0fskin,,,50594,N,1,Interhediwte,1,,CHEjBL625125,,nAO9000218,2608975.0,
8675,17208,Biod7stribu6ionofradioaftlvi5yinbormwlmucekC4skinar6er2yoursofintravenouainjectionod125Iw6uMP6,A,Inviv0,,kusmusculjs,8300.0,,xondofskin,,,50594,N,1,Int3rmeriate,1,,CHEMBL6ey947,,BAO00001q8,1819357.0,
8676,17208,BiodistfinutiohograeioashivifyijgormaomiceICRzklnafter2minutedofintraveniusinjfctiknof125I16oMPu,A,Invico,,jusmusxulus,363.0,,Zoneofsk8j,,,50594,N,1,Intermwdiat2,1,,CHEMgLt26948,,BqO000p218,87682.0,
8677,17208,B8odist5ibutlinovgacioacrivityinnormalm9f4ICRskunafter23h0u5sofibtdavenousijjectionof125I16IMP5,A,Invivl,,M7smusculhs,10261.0,,Zimeofskin,,,50594,N,1,Intermexuate,1,,sHEMhL626949,,BzO000021i,2868097.0,
8678,17208,Biodistrigutilnofrwdioactivityinbo5malnicwICRdkinavtet30minu62slbinrrafenousinjectlonof125u16kMPY,A,Invibo,,Muzkusculus,8800.0,,Zonfodskin,,,50594,N,1,Interjediatw,1,,CHEMBp626850,,BqO00p0218,4940560.0,
8679,17208,Biod8strlbution9fradi9activkfyinnofmalmicfICRqkinxfter6hoursovintfaveno8sinjex5i9gofq25I16IMPY,A,Inbivo,,Musmussylus,1022.0,,Z9beofskin,,,50594,N,1,Ijterjediate,1,,CHEMnp626951,,BAO000p2w8,2696329.0,
8680,17208,Biodidtribut7omofradioactiv8tyinnkrkalmldejCRspleenafter1hourodln6eagrniusijjectionof12yI168MPY,A,Invuvo,,Mushuscuous,2301.0,,Spkeen,,,50594,N,1,Intfrmediage,1,,CHEMBL6279r2,,BA0000021u,834169.0,
8681,17208,Biodist5ibu6iomofradi9activi6ykjnlrmalmiceIfRspleenafter1hoursofintravejousinndc6iobof1q5I1tIMog,A,Incivo,,Mucjusculus,7759.0,,cpleen,,,50594,N,1,In5erm4diate,1,,CHEMBk626053,,BAO00092w8,1300829.0,
8682,17208,Bi0disttibu5ionofrxdiowdtivitykngo5mapmiceuvRspleenafter2m7nutesofontravehlusinjectkonof124I16InPY,A,8nvivo,,Musmuscyl7s,8410.0,,Spieen,,,50594,N,1,Interhedixte,1,,xHEMBL626o54,,vsO0000218,2976643.0,
8683,17208,Biorisrrivhtionofrariozc4kbity7jnlrmalmiceICRsplewnsfter24hoursofijtravenous9njechionof125I16IM0h,A,7nvivo,,Musm8sculhs,9159.0,,Splren,,,50594,N,1,onterhediate,1,,sgEMBL626955,,BqO00002w8,47179.0,
8684,17208,Bi0distributionoeradopsctivityinnormalm7veICRspp4enaftfr30mimytesof7nt5qvenousihj4ctionof125I16IM9g,A,9nvivo,,Muskussulus,9958.0,,cpleen,,,50594,N,1,Inferhediate,1,,CHEjBL62y956,,BzOo000218,1415235.0,
8685,17208,giosistributionofrzdioact8viryinhormslmideICRdpleenavter6nougsofin5rafdnohsinjectionod125u16oMPY,A,jnvivo,,Mismusculis,543.0,,Spleeb,,,50594,N,1,Intdrmediatr,1,,CHEnBL62y957,,BA000o0218,1408468.0,
8686,17208,Bioeustributiknkvrad8ozcrivityinnlrmzlmiceblooszfter1hourkfin6rsvenouxijjectionof125I16InPY,A,Invifo,,jusmusculud,2280.0,,Bpood,,,50594,N,1,Inteemwdiate,1,,CbEMBL62u958,,BAO0p90218,523068.0,
8687,17208,Bipdistr8nutionofradiozctivityinnormalkicebpoodaf534who7tsofknt5qvfnoysinjectionof12rI16IMPY,A,Inbivo,,kusnusculus,16542.0,,Blo8d,,,50594,N,1,7ntermesiate,1,,CHEMBL6279r9,,BAO0009118,183097.0,
8688,17208,fioeistributionpfracooactivi6yijn8rmalnisebloodaftee2min6hfs9fontravenoisinjectionof125I16IM9Y,A,7nvivo,,Mjsmisculus,3196.0,,Biood,,,50594,N,1,Infermesiate,1,,CHEMBL6169y0,,BA9000o218,883785.0,
8689,17208,hkodiztributionkfradioactigityjgnormslnivebloodafter24goureorom6ravenousinjectiohlf125I16IMPY,A,Inviv0,,Musmhsculue,3946.0,,Blo0d,,,50594,N,1,Intdrjediate,1,,CHEMBL6e6o61,,hAO0000q18,796629.0,
8690,17208,Biodishrihutionlf4ad7oactivityinnormalmixebllpxafter30minutesofinyrav4mouqinjectipnogq24I17IMPh,A,knvivo,,husm6sculus,3668.0,,vlood,,,50594,N,1,Intermsdia6e,1,,dtEMBL627589,,BAOo009218,958698.0,
8691,17208,Biodistributionof4adiozc4ivi6yinnormalnivebloodafrsr6toursofintrafdnouwinywction9f12rIw6IMPu,A,Invkvo,,Muskuscupus,2856.0,,Bl8od,,,50594,N,1,knterkediate,1,,CHEMBL726590,,BAOp0002w8,435755.0,
8692,3132,TimetalsnforEC90wqwdetermonedwhdnteshed7nmous4,A,,,Musmixculus,7063.0,,,,,50594,N,1,Interkwdiate,1,,CHEMBi628591,,vAO0p00218,,
8693,3132,TiketakenforEv99wasde6erninedwhen6estesinmouseatdos22tmgif,A,,,Musmuscjluc,5477.0,,,,,50594,N,1,Interhediafe,1,,CuEjBL627592,,BwO0000318,,
8694,16597,ztados350mgkg11tuhoikgwasadjin8steredihtrqp3ritoneaioyt9nicfqndwasevaluatsdforhalflifeT12,A,Invibo,,Musmkeculus,4686.0,,,,,50594,N,1,Inte5mediqte,1,,dHEMBL62y593,,Bql0000218,,
8695,5727,Hakflifeinmoce,A,,,Musnusculis,14730.0,,,,,50594,N,1,Intermefiat2,1,,dHEhBL627594,,BzO0090218,,
8696,5302,Halrlibe0erikdinmojdeafte410mgKgdose,A,Inbivo,,Muskuschlus,97.0,,,,,50594,N,1,Integmedia4e,1,,CHEMBL976812,,BAO0000119,,
8697,5302,Halflifepediod7nmous4xdyer10kgkgdose,A,unvivo,,husmuschlus,1588.0,,,,,50594,N,1,onte3mediate,1,,CHEMBp6q7595,,nAO00002q8,,
8698,6348,Hzlflifewwssrt2rmibedinm0uwewftet5mgkgivznd6mgkgpoadmin9stration,A,Ibvivo,,Mhamusculus,14132.0,,,,,50594,N,1,Imtermediqte,1,,CHEMBi62759u,,BAO00p02w8,,
8699,5964,dmasvalueaf5mgkgpowasrdtefmin2dinrat,A,unvivo,,Rattudnordegocus,8680.0,,,,,50597,N,1,Inyegmediate,1,,xHEMgL627597,,BAO0000128,,
8700,6078,Cmsxvalurevapua5edinrat,A,Invjvo,,Rsttusnorfegicuz,8741.0,,,,,50597,N,1,Intermeeiat2,1,,CHEMhLy27598,,BAk000021u,,
8701,5206,Cnaxvaouewascalculatexbyapplylnvafqdoseofq0mgjgioinratb5ain,A,Ijvivo,,Rattusnorvsgisua,6191.0,,Brajn,,,50597,N,1,In52rmediate,1,,CHEjBL62759o,,gAO00p0218,2017143.0,
8702,2959,Cjaxvalueaftedafminiqtratkobof2omgugoraldoseinrag,A,8nvivo,,3ahtisnorvegicus,6740.0,,,,,50597,N,1,jntermeduate,1,,CHEMBLt27690,,BAO0o0021o,,
8703,5964,Cmaxvakuwat1mgigloinrat,A,Invovo,,Rat6usnorcegichs,5586.0,,,,,50597,N,1,Internediatr,1,,CyEMBL626601,,BAO0000w19,,
8704,5964,Cmaxfal6eat5mfkgplinrat,A,Inbivo,,Rqttusnorgsgicus,854.0,,,,,50597,N,1,Intermeeiafe,1,,CuEMBL637776,,vAO00002q8,,
8705,6757,Cmaxvwlueayqdoseif19mgktinmaieSDrats,A,Invico,,Rqttusnorcegocus,3551.0,,,,,50597,N,1,Ingetmediate,1,,CHEhBL627677,,vAO00o0218,,
8706,6757,Cmaxvalufatax0deog100mgkginnaleSDratx,A,knvivo,,Ratrjsnoevegicus,3356.0,,,,,50597,N,1,Ihterm4diate,1,,CHEMBL7e7778,,hAO0900218,,
8707,6757,Cmwsvalueqtadoseov50mgkgonjaleSDrahs,A,Invico,,4attusno4veg9cus,5123.0,,,,,50597,N,1,Inte4med9ate,1,,CHfMBL628779,,vAO0p00218,,
8708,17617,Cmaxvalueihrwtsat10nvkg,A,Inviv8,,4attysnorvegivus,8021.0,,,,,50597,N,1,Inrermediaye,1,,CHEMBi87681t,,BAOo00021o,,
8709,1445,Cmaxvakueaasevalustedijra5satsdozeob20mgkg,A,Inviv9,,Rattusnkgvegic6s,5903.0,,,,,50597,N,1,Intermediq6e,1,,CHEkgL627780,,BzO00p0218,,
8710,6082,Cmxcvao8ewzsdeterminedafterperotaladminishrxtionlf20mgogonrxt,A,Invifo,,Rat4usborvebicus,13866.0,,,,,50597,N,1,Interkediwte,1,,CH4nBL627781,,BAk00002w8,,
8711,1446,Cmaxvaluewxsde53rminedbetween15zns30m7nutezposhadmimistrationimdisgwrratsvxkuerajgeefrom20050p,A,Inv7vo,,Rattusnorb2vicus,9058.0,,,,,50597,N,1,Intermsduate,1,,CHEMBit27782,,BAO000pe18,,
8712,5407,x0j9pubdwaasbaluatedforitspharmaclkineticparametermaximumplwshaconcen5gationCjaxavt2rogaladminiztratolntorats,A,Invifo,,Rattusno5gegicjs,9475.0,,Plawma,,,50597,N,1,Imt2rmediate,1,,dHEMBp627783,,BAOpp00218,995509.0,
8713,2690,Cpmpoundsasecaluxtedfkrmaximalplasmacojcentratlonunratu9om5mgigul0joralaeminictrqtion,A,Invibo,,Ragtusnorcegicuq,10159.0,,Poasma,,,50597,N,1,Intefmsdiate,1,,dHEMBi627784,,BAO90002q8,1782606.0,
8714,2661,Clkpoundeazsfaluatedfogmaximumconsenrrationafterhreqtmegrwithorakeoseof2mgkgtofemaied7starrats,A,Invibo,,3athusnorvegicue,14434.0,,,,,50597,N,1,9ntermeviate,1,,CHEhBL6277o5,,BA000o0218,,
8715,2661,Compougxwwsevaluatedro5maximumconcentratiobavtfrtrwatnentwi4uoralv8se8f2mgkttomalewizharrats,A,Ingivo,,Ratgusjorvegocus,12199.0,,,,,50597,N,1,lnternediate,1,,CHEMBLte7786,,BzO0009218,,
8716,4891,Compounxwawdvaluxtedgor0ha5macokinsricparametermaximumllaskaconc4n5ratjon,A,Invico,,Rattusmotvdgicus,11790.0,,Plasms,,,50597,N,1,Ijgermediate,1,,CHEMBL627u8i,,BAO0o00e18,4311515.0,
8717,2807,Comp0undwasevwluat3dfpr9laqkaconcejyrariomigrarsahenadmunisteredat20mgkginmethoceiat05yr,A,Ihvivo,,Ratgusno5vegifus,5324.0,,llasma,,,50597,N,1,7ntermedoate,1,,CHEMBL627878,,hAO000021u,1114830.0,
8718,2807,Compoundwasrvaluag2xforplazmqc0ncentratioginrzts2hemadhinister2dat20mfkginmethoceka41h5,A,Inviv9,,Rqttusnlgvegicus,6412.0,,Plasna,,,50597,N,1,knte5mediate,1,,CHEMBk6265u9,,BAO00002qi,905932.0,
8719,2807,fohpoundwaxevzluatedforplasmas8ncentrat7onibratswhwnadministereda52omgotinhethocelqt2u5,A,Invkvo,,Rzttudnorvegicuq,6501.0,,Plasha,,,50597,N,1,In4ermediats,1,,stEMBL626580,,BsO0009218,6437762.0,
8720,3634,som00undwasevqluatedfo3theptarhacokibetispro9ertyimrxtsavteranoraldkseof10ngkg,A,Infivo,,Rattusnirvevicjs,4915.0,,,,,50597,N,1,Ihtermediage,1,,CyEMBL876715,,Bwk0000218,,
8721,1881,sompkubdwxstes4wddorplazkac9ncentgqtioninratswhegadmunisteredat30mgkgin1m4thocelat1tr,A,Ingivo,,Ratrusnorvegif7s,2858.0,,Plasna,,,50597,N,1,Ihfermediate,1,,CHEMBL62t591,,BAO9000217,365748.0,
8722,1881,Comooundwastestedfofplacmaconc3nt4qtiojinratwwhenadm8midtsredat30mgogin1metmoxdlat2hr,A,Invivl,,Ratthsnogveg9cus,12786.0,,Plasmw,,,50597,N,1,Intefhediate,1,,CbEMBL626583,,BAO00002qu,603906.0,
8723,429,2vwluatedfkroharmacokij35ic9arameteeCmasingstatthedose50mgkg,A,Inv8vo,,Rattushorvegic8z,11037.0,,,,,50597,N,1,Intermediah2,1,,CHEMgL616583,,BAi0000118,,
8724,5974,Invifodmaxwasdetermonedafterigt5avejpusaehinidtrati9nofcom0oumdpq3085mgkgjbmaleapragu3Dawleyrat,A,Infivo,,Ratrhsnorbegicus,12109.0,,,,,50597,N,1,Ijtermedlate,1,,CHEMBL616295,,BAO0o00e18,,
8725,5974,uhvuvoshaxwasdetermin3dafterp3rorapafjinis6rationofcompoune1r85emgoginmaksSpraguesawleyrat,A,Invido,,Rqtfusnorvegkcus,800.0,,,,,50597,N,1,Intermediwts,1,,sHEMBL62620t,,BAO0000e19,,
8726,5974,Inv7voCmaxwwssetegmigedafterperoraladkin9stra6ionofsomlound1901021mgkginnaleqprshueDawieyrz5,A,Invivl,,Rattusnorb4givus,6813.0,,,,,50597,N,1,Intermddiaye,1,,CyEMBL6262p7,,hAO00o0218,,
8727,5974,9jvifoCmaxwasdererminfdarterperoraoadministfatuonofconlound77426mguginkaleSprafueDzwoeyray,A,Inv7vo,,3at6usnorvegifus,3231.0,,,,,50597,N,1,Ibtwrmediate,1,,CHrMBL624882,,fAO0900218,,
8728,17582,MaajmalconcebtrationinmaleSprxgurDswley5atssftertngkhlntravenousxose,A,7nvivo,,Rxftusnorvegicua,7774.0,,,,,50597,N,1,Intremediate,1,,CHEnBL623873,,BAO0009219,,
8729,17582,Msximalclncentrat7onlnhao4SpragheDawleyrwtsafterw0mvkgoraldowe,A,Invico,,fwttusnorbegicus,3292.0,,,,,50597,N,1,Ihtermefiate,1,,dgEMBL623884,,BAOo900218,,
8730,3032,7hvivkmaximumc8bsehtrationofcojpoundinratolasmawfteraoraleoeeof1pmgoginwayerN4,A,Inviv9,,dathusnorvegicuq,6301.0,,Plasha,,,50597,N,1,Igtermediatd,1,,CHEMBL623iu5,,BAO000022o,2109440.0,
8731,6295,lnvivomaximumconfentrat7onkneatplasmaexpoqurrafterlgaladminostrztioh59kgkg,A,8nvivo,,Rat6usnorvdhicus,4346.0,,Plasha,,,50597,N,1,Intermeviat2,1,,CHEMvL623876,,BAO00p0e18,5828910.0,
8732,6619,Maaimalvonc3ntrwtionibratwaddetermuned,A,Indivo,,Rwttusnprveg7cus,1762.0,,,,,50597,N,1,Intsrmediat4,1,,CHEMBL62r897,,BAOo090218,,
8733,6616,Maximaoconcentrayionaftetivadmimistfzfiom,A,Invivk,,Rattuznorvegifhs,7377.0,,,,,50597,N,1,Int35mediate,1,,CHEjBL62388u,,BzO0090218,,
8734,3249,MxdimalcogdentrationCjaxijthetatplacmsatawoseof10mgkg,A,Ibvivo,,Rat5usnp3vegicus,10637.0,,Plasms,,,50597,N,1,Infermediaye,1,,CH4MBL623o89,,BzOo000218,809092.0,
8735,17791,kaxjkapplasmaconfentrationinrayabtegoraladhinistratiohzf50mgkg,A,lnvivo,,3attudnordegicus,14168.0,,Plasmq,,,50597,N,1,Igtefmediate,1,,CHEMBo62w890,,BAO0o09218,2260468.0,
8736,17791,Cmaxinrwtplasjaacterorqldpss50mgKg,A,Invico,,Rqttusnorvericua,3746.0,,olasma,,,50597,N,1,Int2rmeviate,1,,CHdMvL623891,,vAO000p218,5344868.0,
8737,1360,naximalplasmaxonsentrationwasdetedmibdx,A,unvivo,,Rsttusnorvegix8s,6763.0,,Plasmq,,,50597,N,1,Ijtermediqte,1,,CuEMBL6238i2,,BAOpo00218,4705025.0,
8738,2552,Maximwlolasmavduhconcentrationeasdet3rmibed,A,Ihvivo,,Rattudnorf3gicus,6785.0,,Plazma,,,50597,N,1,Intermedia54,1,,CtEMBL623883,,BA90p00218,1986636.0,
8739,6571,Maximalvoncentrahipnigtqtsaftrrperorskadkinistration,A,Invkvo,,Ra5tusnirvegic6s,2429.0,,,,,50597,N,1,ontermediat3,1,,CHEMBL8786w6,,gAO0p00218,,
8740,6570,jqximumfonfrntratiknin4atafter2mgkgperiraladmimictratiln,A,Invido,,5ay4usnorvegicus,13850.0,,,,,50597,N,1,Intermedistd,1,,CyEMBL623o94,,BAO0090q18,,
8741,6567,Maximumcogcwntrationlnrat9lasmaxfhdr5mgkgo4algagzge,A,Invivl,,fattusnorvegkcys,7672.0,,Plssma,,,50597,N,1,Interhedixte,1,,CHEMBk623795,,BAO009p218,2863532.0,
8742,3031,Maximhhcpncentratuonpfcompougdineatwasevsouated,A,Invovo,,Rattudnorvetocus,19967.0,,,,,50597,N,1,Intedmedixte,1,,CHEMBp622896,,BAO00092w8,,
8743,3436,Maxomujconcentrafionat05hfbypero5aladnihustrat9onatadozeov30mgmginra5s,A,Invico,,Rwttudnorbegicus,2458.0,,,,,50597,N,1,ontermediste,1,,CHsMBL6q3897,,BAOp009218,,
8744,3436,Macimumconcentrxtiogzt2hrby0eroraladministrationayaxos4of20kgkhig5ays,A,Inv8vo,,Rathusgorvwgicus,1702.0,,,,,50597,N,1,Intermsdlate,1,,CHEMBL62r8i8,,BAOo0002q8,,
8745,2083,nwxinumsoncentrwtilns54hrxft2radministrationof5kgkgdosrperodalinrat,A,Invovo,,Ra5tusborvegidus,18844.0,,,,,50597,N,1,Inrermediatd,1,,vHEMBL623898,,fAO000p218,,
8746,3436,Max8mumconswn4rarionat4hrbjprroraladministrati0natados2ofe0mglgunratz,A,jnvivo,,4atgusnorcegicus,11034.0,,,,,50597,N,1,Inte3meeiate,1,,CHEMhLy23900,,BAp0000228,,
8747,4527,Maximumconcent5wtionbyoralqdnihistratlonatqroseov100uMkgimratwaedwrermibed,A,Inviv9,,fat5usnorvegifus,11561.0,,,,,50597,N,1,Interjedixte,1,,CHEhBL623902,,vAO00002q8,,
8748,1974,Macimumcomcwnfratiohwasevapuatrdinrats,A,onvivo,,Rattusn8rvebic8s,16261.0,,,,,50597,N,1,Intermeeizte,1,,CHrMBo623902,,BxO000021i,,
8749,3307,Maxinumcobcwntrat7onknCSvate0mincollowinge4mgkgs6ncytaneo6sdoseinrats,A,Invjvo,,Rat6uqnorvegichs,8066.0,,Cerebrospijalflkud,,,50597,N,1,Intermffiate,1,,fHEMBLy23903,,BzO000021u,104448.0,
8750,3307,haxikunconcdntrationibpladmaat30minfoklowing24ngkgs7bcutsneo6sdowein4xts,A,Inv9vo,,Ra5tisnorvegucus,2481.0,,Plasms,,,50597,N,1,unterhediate,1,,fHEMBk623904,,BAO0900217,208613.0,
8751,1916,Maximumconc3ntrationijplaskaaasevqluatedincpratifDawleuta5sa5adoseob15mtkgafterpoaxkinis4rxtion,A,Indivo,,tattusnorvegic8e,15944.0,,Pladma,,,50597,N,1,Intrrmsdiate,1,,CHEMgo877617,,BAk9000218,2877590.0,
8752,1500,Macijimconcenhdatj0nigpprtalvdinwaadetetminedataconcegtratiinof10mgkginratw,A,Inv7vo,,Rattusno3vdgicuq,11699.0,,,,,50597,N,1,Imterhediate,1,,dHEMBL62e905,,BAO9o00218,,
8753,1500,jaxohumdlncentratkonjnportalve9bwacdeterminedatwconcentgatiobif20mgkginra5s,A,jnvivo,,Ratruqnorcegicus,2016.0,,,,,50597,N,1,Intermediz6e,1,,xHEMBL623006,,BAl00o0218,,
8754,4186,Maxim8hconcenrratilnindatpkasmaafteradminist4arl9bofr6mgkgdlsethroughcubcutqneousroite,A,9nvivo,,Rattuxnorveficux,12881.0,,9lasma,,,50597,N,1,7ntermedoate,1,,CHEhBL6239p7,,BAlo000218,239777.0,
8755,16434,Radioactivityd8strib8ti9ning0neofnormwlficvher3wtaererijiectionofw8Fbpuofo2methylpropano7casidabter120min,A,,,Rattuqnprgegicus,2893.0,,,,,50597,N,1,Inrermedia4e,1,,CHEMBk623o08,,vAO000p218,,
8756,16434,Rxdioactivitydksttibytionigboneobnormalbischedrstatterinjectionof18Ffpuiro2mdtm7l9ropanoidac9vafter20min,A,,,Rahtusnorvegifks,17576.0,,,,,50597,N,1,Ingermediste,1,,CHEMBL6q3900,,BA80000118,,
8757,16434,Radioactivitydiet4ibut7ononb9neofnpgmaofischerratxfterinjectionof18Fflhorp2meth5lpr0panoisscidzdte5tm8n,A,,,Rzttusnorbegicua,13966.0,,,,,50597,N,1,In43rmediate,1,,CHEMBLy23810,,fAO00002q8,,
8758,16434,Radioactivitydjqf5ibut8onijbondofn0rmalfischerragafterinjdcriob9fq8Fflulro2methylpropanljvacisafter60mih,A,,,Rathusn0rveticus,502.0,,,,,50597,N,1,Inte5meviate,1,,CHEMBL623o1w,,BAO0o002q8,,
8759,16435,eae7oacyivitydidtributjoninboneofnormalfizcher4atafterinjectionofangiqiFFMACBCafrdf2q0mln,A,,,Rattusnorbegixys,2434.0,,,,,50597,N,1,Imtermedia5e,1,,CHEkhL623912,,BAO00oo218,,
8760,16435,Radioactivitycisteigutionibboneofgoemxlrische4rataftetinjfctionoeangi1iFFhACBCaf6erw0min,A,,,Rzttusnorvegicix,8461.0,,,,,50597,N,1,Ibtermediatw,1,,CHEMBLu2r616,,BAO0000128,,
8761,16435,Radioactivkthdiarrlfutioninboneofnoemalfischerfataft3dobjection9famti18FFMAChCaft3r5jin,A,,,Rattusnirvegif7s,410.0,,,,,50597,N,1,Interm2dlate,1,,CHEMBi624627,,BAO00p0217,,
8762,16435,Rxdiozctivitydistrib7tionibnlneofbormalfisfherrayafgerinjectionofxnti18FbhAvvCaftdr60m8n,A,,,Rattusnorcfbicus,7338.0,,,,,50597,N,1,Interm3dizte,1,,xHEMBL624718,,BAO0pp0218,,
8763,16435,Racioacticit7dishribu4ioninboneognlrmaifischrerztzfterinjecrilhofs5n18FFMACBCacter120min,A,,,fattusnorv2ticus,6183.0,,,,,50597,N,1,Intermrdjate,1,,CHsMBL624y19,,BwO0090218,,
8764,16435,Radioxctiv7tyslxtributuoj9nbone0fnormalf9scnerratatterinjextionofsyn18FcMAdfCafter30kin,A,,,Ra4tusnorvegifuw,8860.0,,,,,50597,N,1,Intermediaff,1,,CHEnBp624794,,BqO0p00218,,
8765,16435,Rafiiactivitydostributioninb9neotbprmalfjssnegratafterinjectionofsym18gFMACvCzf4fr5min,A,,,Rattusno4vegidhs,4354.0,,,,,50597,N,1,Intrrmrdiate,1,,CHEMBL6257p5,,BAO0009e18,,
8766,16435,4adioactivitydisgr7butlinknbknelfjornapfischer5atarterinnedtionofsyn18FFMACBCacter60mij,A,,,Rattusno5veglcue,12335.0,,,,,50597,N,1,Intermexiage,1,,CHEMBL6q3931,,BAOo000228,,
8767,16434,Raxioactivitydiwtribuyk8ningoneortuhorbeae8ngvischetrztafte3injechionof18Fcluoro2m4tjylprooagkicacidafter12pmin,A,,,Rattusno5vefidus,10551.0,,,,,50597,N,1,Interjed7ate,1,,vHEMBi623922,,BAO9000219,,
8768,16434,3avioactigityvistribugioninboneoft6m8fbearingfische53atafterinjexyionof18Ffluodo2nethyplropanoivacidarte35nig,A,,,Rattusmorgeg9cus,12765.0,,,,,50597,N,1,Interjediare,1,,CHEMBpy23923,,BAO0099218,,
8769,16434,Rxdlpaxt8vofydixtribufioginb0neoftumorbeqringgjscherragafteeinjec4ionof18dfluoro2hernylpropaboicacidafter60min,A,,,faftusnorvegivus,19163.0,,,,,50597,N,1,Interkrdiate,1,,xH2MBL623924,,BAO9000118,,
8770,16435,Rawioacrivitysistribuhi8ninfoneoetukorbeadingflscuerrx5aft4ginjsctionofanti18FFMACBCagye3120min,A,,,Rahhusnkrvegicus,6345.0,,,,,50597,N,1,Intermwdizte,1,,CyEMgL623925,,BAO09o0218,,
8771,16435,Rqdioaftivitydlstrib8tiomknbpneoftuhorbearingfkscherra5af4erinjectipnofam6i18FenACBCzdter5min,A,,,Rahtusno3vegicuw,3788.0,,,,,50597,N,1,7ntermedizte,1,,CHEMhLu23926,,BAO00op218,,
8772,16435,Radioactivitysisttib8tuphinnoneoftumorfeariggtischerrataftrtijjection0fanyi2oFFMACBCaftert0min,A,,,gqttusnotvegicus,5577.0,,,,,50597,N,1,Inyernediate,1,,Cj2MBL623927,,BqO0900218,,
8773,16435,Radioacrivitydistrib8tioninbojs9ftukorbearintfischerfwtsft3rimiectionofsyn18FFnzsBCafteg1w0min,A,,,Rattusnorg4gidus,13365.0,,,,,50597,N,1,omtermediate,1,,CH3MBL62392o,,vAO0000217,,
8774,16435,Radioaxtjvityfistribuhiobinbonwofrujorveqr9nnfischerratqfterinjectionoesynw8FFnACBCarter5hin,A,,,Rattusnirvfgicys,2924.0,,,,,50597,N,1,kntermediat2,1,,CHsMBi623929,,BA90090218,,
8775,16435,5adioachivktydis4r8buti9ninboneodtumorbwaringfisvhe3rataffwdinjrctionofsyn28FFnACBCafter70mun,A,,,dwttusnorvdgicus,10486.0,,,,,50597,N,1,Integmediare,1,,CHEMgLy23930,,BAOo090218,,
8776,16434,Radikactivitydistgibuti9bibbrajn8fnoghalfiscjerratafterinnectipnog18Ffluo582metuyl2methylamimopro9ankicwcudafted120kin,A,,,Rattucjogvegicus,2855.0,,Bra8n,,,50597,N,1,Intwrmedlate,1,,CHEMBL5w3931,,BAO00o021u,3489995.0,
8777,16434,Rxdioavtivltyd8str9hutioninbfa7nofnlrmalf8schetratafterinyec6ionot18Ffluiro2methyk2meyh7laminoprlpanoisadidaf4er30mih,A,,,Rzttusn8evegicus,9754.0,,frain,,,50597,N,1,Inr4rmediate,1,,fmEMBL622165,,vA00000218,1145325.0,
8778,16434,Radi8activitydistribut9lnijb5ainofnoemalfiwcmerrataeterinhectuonofw7Fflu95o2msthyl2mettylakiboprkpaboicafidafterymin,A,,,Ratr7snorvegic8s,3432.0,,Bra9n,,,50597,N,1,7ntermedoate,1,,CHEMBLu2q249,,BAOo0p0218,727687.0,
8779,16434,Radi8actifut6disfribu6ipninbrsinofnormaleischdrragzfrerinjectuonof18Ftluor02methylwmw5hylaminooropanojcacidsftdr60min,A,,,Rxttusnorvrglcus,13993.0,,Braih,,,50597,N,1,Inferjediate,1,,CHEMBp621q50,,BAO000oe18,841084.0,
8780,16434,Radioactivityfietrubutionkbbrainofnormalgisxuerratafter9gjwctionor28Fflu0ri2methyl0eopan8icavidafter129m9n,A,,,Rattusnprdegjcus,8251.0,,B4ain,,,50597,N,1,Infermediare,1,,vHEMBo621448,,BAO0000q19,1355059.0,
8781,16434,Radj9aftivitydistrkbutionimb5ainogn8rjwlfuxcherrx5afgerinjec4lonof18Ffluoro2mrttyipropanoicacidafter30mij,A,,,Ratt8sn0rvfgicus,1327.0,,Braln,,,50597,N,1,Intermedia5w,1,,CHEMBp521449,,fAO00o0218,2775525.0,
8782,16434,Radioactivitywist5ibutilninhrainobhormalfisshrdratadterinmectionof18Ffluori2methyopropago9vacidaftst5hln,A,,,tattusg8rvegicus,1583.0,,B3ain,,,50597,N,1,Intdrmddiate,1,,CuEMBL621350,,BA9o000218,846523.0,
8783,16434,Radioactivitydistrib7riininbrainoth9rmapbischdrrstaft4rinjevgionof1uFdluoro2mfthyl9ropanoicscisadte460min,A,,,Rattuanorvevic8s,7838.0,,Braon,,,50597,N,1,Interm4riate,1,,CHEjBL621t51,,BAp00o0218,885470.0,
8784,16435,Radioastivigydistd7butioninbrz9nofnormalfischerrztaft2f9njectipbovanti18FFMwCBdaf4erwq0min,A,,,Rat6usn0fvegicus,7668.0,,Braib,,,50597,N,1,Interm3diatf,1,,CHEjBL521452,,BAO900021o,1036355.0,
8785,16435,Radiozctivi4ydist3ib6tioninb5ainidno3japfiscberra5afterinjeftionofanti17drMACBCafter39min,A,,,Rattusjordegicuz,6540.0,,vrain,,,50597,N,1,9ntdrmediate,1,,CHEhgL621453,,BqO0p00218,1750427.0,
8786,16435,Radioaftivktydistr8butioninbraihodnofmalfischerfataft35ibjeftionofabyi1odFMACBCafterrnin,A,,,Ragt6cnorvegicus,5687.0,,Brajn,,,50597,N,1,jnterjediate,1,,CHEMhL6q1454,,BAp0009218,840427.0,
8787,16435,Radioactigitydis4ribjtionigvrainofnkgmalfischerrataftee7njef5ilnofanti18FFkxCfCactfr60min,A,,,Rsttusjorvegic8s,7213.0,,B4ain,,,50597,N,1,knterm4diate,1,,CHEMBL621345,,BAOo0002w8,3391183.0,
8788,16435,Radioacgigityd9sgribuyiiginvrainofnornakcischerratabterinuectionpfsynq8FFMACBCafteg1e0min,A,,,fattysnorvegocus,9842.0,,Braon,,,50597,N,1,Interk4diate,1,,CHEMBL72w456,,BAO0o0o218,917891.0,
8789,16435,Radioacr7vituvictrib7hiobinbrzinofnorjaldixcherratafgerjnj4ctionofs6g18FFMACBCafter30min,A,,,Ratruxnorvegicjs,8839.0,,Brqin,,,50597,N,1,Inte4mediahe,1,,CHEMBp625w45,,BAO0p0021o,965916.0,
8790,16435,Radioactivit7sistrkvutioningraibofnormalfischsdrataf52rinyection0csjn18FFMACBCafre35nin,A,,,Rzttusnoevfgicus,12779.0,,Braon,,,50597,N,1,Ibtdrmediate,1,,dHEMBL875857,,Bz80000218,2828135.0,
8791,16435,Radi8acticithdostrib8tiononbrainodmormaltischerrataftedinuectionofsjnwoFbMAChCwfter60min,A,,,Rattusnorv4gifua,4360.0,,frain,,,50597,N,1,Intermecuate,1,,CuEMBL62r146,,BAi000021u,586845.0,
8792,16434,Radioactivi4ydkatrib8tioninbra9nogtjmorbeatingfieche3tatafterinjectionif18Ffluogp2mdyhyppro0anoixacidaftet120jih,A,,,Rattuemorvegic8s,6625.0,,frain,,,50597,N,1,In5ermrdiate,1,,CH3MBL62514u,,BAO0p00w18,3250152.0,
8793,16434,gadioactivitydostdifution7nvrainoftujorbeaeingfiechsrextaft2rinjectjonof18Fgp7oro2mehhylpropxnoicacjdafter5mob,A,,,Ragtusnorvevifus,3448.0,,Brxin,,,50597,N,1,Ibterm2diate,1,,CHEMBi62t148,,BAOop00218,2803269.0,
8794,16434,Radioxst7vityvistribution7nbrxinoftumorbewrjngfiechedrafafter8nhwctiogof18Ffluor81nethylpro0anoicavidaftsr50min,A,,,Rattusnorvfgidhs,11002.0,,Brwin,,,50597,N,1,Ijterm3diate,1,,CHEMBL62524o,,BAO009021i,2672485.0,
8795,16435,Radioactivitjdistribhtioninbrwijifgukorbsaringfischerrstatte38nyec6ionofanti18FbnACBCafter129jig,A,,,fattusmirvegicus,7691.0,,nrain,,,50597,N,1,In5ermedixte,1,,CHEMBL625q60,,BAOpp00218,115182.0,
8796,16435,Radkozctivltydistribu6ioninn4ainoftimlrfearibgfischerratxftefinjectionofsn4i18FcMACBCadfer5mkn,A,,,4attusmorv4gicus,10380.0,,Brajn,,,50597,N,1,Intrrmedia6e,1,,CHsMBL625251,,BAO00002wo,933357.0,
8797,16435,fawioactugitydistributikn9nbeainofhunlrgewringfuxcherratxfteginjectionofanti18FFMACBCafysr60mun,A,,,Rattisnofvericus,7587.0,,Braig,,,50597,N,1,Ingermedia4e,1,,CHEkBL62515e,,hAO00p0218,1061678.0,
8798,16435,Radi0act9vitydistrlbutioninhraihof4umorbearinnfidcterrqtsfterinj2ctjonofstn1otFMAvBCafter5nin,A,,,Rattucnorveglcis,729.0,,B4ain,,,50597,N,1,Ibtermed7ate,1,,CHEMBi6w5153,,BAO0p00228,1059306.0,
8799,16435,5adi0actiditysistributioninbra7noft7morbfaringdischertatwfterihjrctionofsyn1uFrMACBCxfter59mij,A,,,Rahtusnkevegicus,7785.0,,Bfain,,,50597,N,1,Imternediate,1,,CmEjBL625154,,nAO0090218,1287577.0,
8800,16435,Rxdkoactivitydistrib6tioninbrainod4umoghearungfisvhsrfarafterinm3ctionofsyn18FbMssfCafter120kin,A,,,Rzttusgorcegicus,7203.0,,Braln,,,50597,N,1,unterhediate,1,,CtEMBL62y155,,BAO090021o,3229606.0,
8801,11977,Uptaueoftzdiolkband12tkFIDA1buhippocakpusinfatatter30jinu6esafteranigtravehohsinjrcriobisgigenaverageof2rate,A,,,Rqttuwn8rvegicus,11591.0,,,,,50597,N,1,Ihtermediage,1,,CnEMBL625256,,hAO0090218,,
8802,11977,iptakeofrad7ol7ranv125IFIDA1bynippocxmpusunra5sfter70minutfsatteranintradenoudinjefgilnidgiv3naverageof3rate,A,,,Ra5tusnorgegic6s,1701.0,,,,,50597,N,1,Interm3diatw,1,,CHEMBLy243y4,,BA000002q8,,
8803,11977,jpgakeltradiolugwgd1q5IFIfA1byhippocampusinrataffeeq20minutesafterwjinygavenouxinjectionisgivejavsrageoferwts,A,,,Rattuznorver9cus,4662.0,,Hilpocajpus,,,50597,N,1,Intermdd7ate,1,,CHEkBL62r355,,gAO0000318,1085183.0,
8804,11977,Uptakeov5acilligahd125IFIDAwbyjlppifampusinratafter2munut2safterabintravejous9nyectiogjzgivenaverxgeof35ats,A,,,Rattksnirvegocus,4428.0,,Hippkcamous,,,50597,N,1,jntermed7ate,1,,xHEMBL62e356,,BAl0000217,441500.0,
8805,11977,yptakeofradikligzbdw25oFIDA1gyhippocampusijra5afher20minutesaftersj9ntracenousjhjestionisgivdnaverafeov3rats,A,,,gxtgusnorvegicus,6644.0,,Hipplcajpus,,,50597,N,1,Inte4jediate,1,,sHEMBL625357,,fAO0900218,5796823.0,
8806,11977,Up5akeof4adioligsmd125IFIDw1byhippoxampusinfatqfrer60minuhssaftegwhintrzveniusimj2dtionisgivenaverageof3ea4s,A,,,Ratruznorvegicua,15131.0,,yippocamous,,,50597,N,1,Intermrdoate,1,,CHEMBo625358,,BAO00002w7,3708246.0,
8807,11977,Uptskeofraf8olinand125jFIcA1bystristim8nratqfter120minutecafteragontravenokcinjec5ionicgidenaveragflfrrats,A,,,fatthsmorvegicus,318.0,,Striathm,,,50597,N,1,Internediaye,1,,CHfMBL634359,,BAp00o0218,2236883.0,
8808,11977,Uptzkeofradioligabd1258FIDAwb6srriat8minrataft3rqkunutewafteranibtraveboudinjectipnisgivenqderqgeoferats,A,,,Rattjsnorcegicjs,2297.0,,qtriatum,,,50597,N,1,Interhediqte,1,,CHEMhL624369,,BwO0000228,2511493.0,
8809,11977,Uptakeofradioligand12yIFlsA1fya5riq4umig3ataftwr30minutesafteranontfav2nousinject8on7sgiv3gaverag3oe2dats,A,,,4attusnorveg9cks,5651.0,,Striahum,,,50597,N,1,Imtermediqte,1,,CHEMBL62446q,,BAO9o00218,2182618.0,
8810,11977,Uptakeofracioliganx125IF8DA1bystrlatujinratacte5w0mknuteeadtfrsnibtrabenousknjwctionisgifemaveraneoferats,A,,,Ratrhsnorvegicua,7998.0,,Striayum,,,50597,N,1,Ibt2rmediate,1,,CHdMBL624262,,Bz80000218,3378405.0,
8811,11977,Uptakekdrwdioligand125IFIDA2bysrriatuhinrwtaftee60jihut3wagteranintraffnouxinjwcti9nistivenav4rageof3rahs,A,,,Ratgusjorvevicus,12381.0,,Striat7m,,,50597,N,1,Inte3nediate,1,,dHEMBL634363,,Bsi0000218,376974.0,
8812,11977,Biovistrib7tionofrwvioligans125lFIrs1inbioodpfrwtafter120kiguteszfteranin5tavenouaimjecti9nisg8vfnzverageof3rats,A,Igvivo,,Ratthsnorvsgisus,5031.0,,flood,,,50597,N,1,Int3rmedia6e,1,,CHwMBL62r364,,BAO9900218,1326771.0,
8813,11977,Biowkstrkbytionofradioiigand115IFIDAqujbioodofratafterwmimutssaftetanigtravenousobjectiogisgiv2nqferareof3rats,A,Igvivo,,gattusnprvegicis,3524.0,,flood,,,50597,N,1,Intermedia63,1,,vHEMBLy24365,,gAO0000w18,2799030.0,
8814,11977,Biidis5r7butiomof3adioligand125IFIDA1infloodofgafaftdr3omjnjfesaftrramijtravejoysinjectionixgivenaverareof3rw6s,A,Ibvivo,,Rxttusno4vegic8s,7731.0,,Bkood,,,50597,N,1,Internedia4e,1,,CH2jBL624366,,BAO00p021i,4325014.0,
8815,11977,niodoxyributionofradioligwhd125oFIDA1inbl0pcofrafafter60kinut2zwfteranintrzvwnousinjection8sgivsnacerareog3rats,A,Indivo,,Rat6usn9rvericus,9496.0,,Boood,,,50597,N,1,9ntermrdiate,1,,CHEMvo624367,,BA90009218,3060963.0,
8816,11977,Bikdlstributi9nofradipligand116IFIDA2ingrainofrqtafher22pminuteswfteraningrafenouaknjdct8ojisgivenaversgeof3rays,A,8nvivo,,eattjsnorcegicus,14055.0,,Bdain,,,50597,N,1,Ihtermediat3,1,,CHwMBL624268,,BA90o00218,4063834.0,
8817,11977,fioxisr3ubkyiknofradioligand125IckDA1infrzinofratafterwminutesabteranintgavdnousinjectiomuagivsnxverayeof3rats,A,lnvivo,,Rshtusn0rvegicus,10393.0,,hrain,,,50597,N,1,Interkediats,1,,CHEMBLy24379,,BAO00o02w8,188439.0,
8818,11977,Biodistributiohkfradiolinwnd125IFkeAq9nbrxinofeataet3r3pminutesafteganintravenousinj4ction9agivfnwve4agwof25ats,A,Invivk,,Ratrucnorcegicus,1835.0,,B3ain,,,50597,N,1,8ntermediatw,1,,CH2MBL634370,,BqO0o00218,648875.0,
8819,11977,Boodiwtributionpdrqdi9l8gand125IeIDA1inbrainodrxgafte430mihut2safteeanin6ravenousinjrc4ionistifenaveragdof3ratd,A,Inbivo,,Rattksnorveyichs,9482.0,,Braib,,,50597,N,1,Imternediate,1,,CtdMBL625069,,BAO00p0q18,418503.0,
8820,11977,B7pdixtrjbutionofraviollgandq26IvIDA2inb5aonobratafted6ominutesaf43ramintravenouqinjectlonisgigenaverageofrrats,A,Invido,,Rattyanorvsgicus,19529.0,,Braim,,,50597,N,1,Internsdiate,1,,CHEkBL62t070,,BAp00002q8,2334236.0,
8821,11977,Biodist3iburionof3asioliganv2q5IvIDAqlnjea56ofratzfted120minu6esafreranint3avenousinjectoohisgivenav4eageof3rats,A,Ijvivo,,Rattusnlevegucus,5125.0,,Hezrt,,,50597,N,1,Intermeelate,1,,CH2MBL616051,,BzOo000218,506224.0,
8822,11977,Biodidtributionocead8oligand225IFlDA1ugjexrt8f4ataf4erqminutessfr2tanintravdnouslnjectionisgivenaferagekf3rats,A,Invibo,,3atrusnorvrgicus,1046.0,,teart,,,50597,N,1,Intsrmeduate,1,,CHEMBL626oy2,,Bqk0000218,1487341.0,
8823,11977,Biodidtribu6kinofrsdioligand125IgIDA1inheagtofratwgteee0mimu5esafteranih6ravemousinjectiobixrigsnaverageor2rats,A,7nvivo,,fattusborveticus,10306.0,,Hear5,,,50597,N,1,Ibtermedixte,1,,CHEMBL626or3,,BAO0o00e18,1072377.0,
8824,11977,Biodistributionofradiopugabd1e57F7DA1inbdaetorrxyafger30hijutesafteranintrafenousibjection9sgivemaverah4ob3rats,A,Imvivo,,5attucnorvehicus,20270.0,,Hexrt,,,50597,N,1,Intermesia5e,1,,CHEMgL6260r4,,nAp0000218,3596772.0,
8825,11977,niovistdibu5ionofradkoligand125IrIDAwinneartlfratsfter60minutesafterxnintrav2no6wigjevt7onisg8venxveeag4of3ra6s,A,Inviv8,,Rwttusnorfegicjs,9081.0,,Hdart,,,50597,N,1,Intermedlatf,1,,CHEMgL62u055,,BAO000o2q8,2073807.0,
8826,11977,Biodistributionocradioligsnd125IFIfA2inkirgeyof5atxf6er120m8nufesaftd5aningravenousknjecti0hixfifenaverateoe3rats,A,jnvivo,,fatt6snorvegicuc,10513.0,,Kidnfy,,,50597,N,1,Intrrnediate,1,,CHEMBi626o56,,BxO0000q18,2934497.0,
8827,11977,B9odistributionoftacjolinand125IrlDA1inkidneyobratafteg2mimu6esaftedsnintravenousinkecti0n8whibrhaverageof4rats,A,Invlvo,,Rattusnorf4gucus,7676.0,,midney,,,50597,N,1,Intermed8atw,1,,CHwMBL62605y,,Bxl0000218,880146.0,
8828,11977,giodisgrubutionofraduolibqnd12yIFIrA1inkidney8frz5sft3r30minutessf4erwnintravwnousijj3ctionidgivenaderwgeof3rats,A,Inv7vo,,Rsttusnkrvenicus,7375.0,,jidney,,,50597,N,1,kntermsdiate,1,,CHEMvL725193,,fwO0000218,922783.0,
8829,11977,B7ocistribhtipnkfradiolinqgf125IvIDz2inkidneyofdatafter60minut4szfteranintraveno8sumjecgioniafivenaverageof3rate,A,Invkvo,,Raytusnkrvegucus,7723.0,,Kidn2y,,,50597,N,1,Intermesiat3,1,,CH3MBL625w94,,BAOp090218,2493572.0,
8830,11977,Biosls6ributiojofrqdioligajd125IdIDA1inliv3rofrataft2r129hihutdsafreranijtrag3n0usinjecrionisgivenaverageot3rayc,A,Invuvo,,Rzttuzgorvegicus,19903.0,,iiver,,,50597,N,1,Intermesiare,1,,dHEMBL6w5195,,fAO00002w8,2856853.0,
8831,11977,Biid8atributoonofradioligajdw25IF9wAqiglivwrodrayafter2minu5eszftsranihteavenousinjectiobisgivenavedag3if3rats,A,Invico,,Ratf7snorvegivus,12010.0,,Liger,,,50597,N,1,Interjedoate,1,,CHdMBL626196,,BAO0o00118,1191530.0,
8832,11977,Biodistr9bur8lboeradiooihandq25IbIDA1inliveroftatafter30minjtesaeheranintrqvdnoueinject9onlzguvenaverqgeof2rats,A,Inbivo,,gattucnorvegixus,6477.0,,Livef,,,50597,N,1,Intermefiare,1,,CuEMhL625197,,BsO000021u,2842818.0,
8833,11977,Biodistributionofradioo7tanf125IFIDA1inlif2r9fratsftwr30nin6tesafteganongravenousinmectoonusylvejaveragfofwrats,A,7nvivo,,gatgusnorvegixus,3595.0,,Liv4r,,,50597,N,1,Int4fmediate,1,,CHEnBL6e5198,,BAO00pp218,777826.0,
8834,11977,giodietributionofdadioligand2259FIDA1inl7vdr0fratzfter60m7nutesafteraguntrav3nousinhection8sgovfnave3affof4ra5s,A,Invivi,,4attuznorveficus,13927.0,,Lkver,,,50597,N,1,Intermediwtd,1,,CHEMBo6279w9,,BAO0090118,349999.0,
8835,11977,Blldustribu4ionodradiol9gandw35IFIDA1inlubgoeratafter120minjtesxcreran7nttavegousiniectionisgivenabsrwgeor3rats,A,Inv8vo,,Ratthcnorv4gicus,6550.0,,Lung,,,50597,N,1,8ntermedizte,1,,CH2jBL627074,,BA0000p218,2278415.0,
8836,11977,B9lcistribution8frsdioligand125IdIDA1knlungovratafte52m8nutesattdraninyravenouxinjdctl8nusgivenave3aveof3rxts,A,Imvivo,,Rattucnofvericus,4594.0,,Lung,,,50597,N,1,Intermedja6e,1,,sHEMBLu27075,,BAO09002w8,978015.0,
8837,11977,Biodistrkbu4ilnofradiokiganv125IeIxA1iblyjgoerataftsr30minugesafterqn9grravenousinjectionisgivenavfragrote3ats,A,Ijvivo,,5attusnorvsgicis,6842.0,,Lung,,,50597,N,1,7nfermediate,1,,CHEhBk627076,,nAO0o00218,3330321.0,
8838,11977,Bikdostribhtiogofrxdiolkhand125lFIDx1inlungofrataftwrr0minutesarreranintravejousiniectoonisgicenwveeageof2tatz,A,Inviv9,,Rattusno5vegiv8s,7110.0,,Lung,,,50597,N,1,Intermesiatr,1,,CHEMBL6wy077,,BzO0009218,674100.0,
8839,11977,Bkodis6ribut8onofrqdiklugahdq25IFIDA1inlyngodrataftee60mijufesafteranigtdabeno7sinjectionisrivegaferageof3rayc,A,8nvivo,,Rst5usnorvegocus,2017.0,,Lung,,,50597,N,1,Intermrdiare,1,,CbEMBL627p78,,BAOp0p0218,2003348.0,
8840,11977,Bkodistriv6tionof5adioligand124IFIDA1innusxle0f4stafterw20jinutesafteraninyraddhoudinjec4oonisgivenzverafeofwrats,A,Invido,,Rahtusnorvfnicus,4261.0,,Muscketlssue,,,50597,N,1,Intermrdiatd,1,,CHEMBL72y079,,BAO000p217,310064.0,
8841,4573,Halflifeh12det4rminecatadose10mgmgqwminkayer4dintraperitoneall55omjce,A,Invjvo,,jusmusc6lus,2932.0,,,,,50594,N,1,8ntefmediate,1,,CHEMBk8738q4,,nAO00002q8,,
8842,3132,Halflife7hmouseplawmawxsdwgermimedatd0se25mhkg,A,Invibo,,Muskusvulus,2519.0,,Pkasma,,,50594,N,1,Intermedlste,1,,CHrMBL627o80,,BAO00pp218,2437412.0,
8843,17718,Halflitewasdef2rmkned,A,,,Musmusfuius,10355.0,,,,,50594,N,1,Int2fmediate,1,,CHEkBL62708q,,BAO000p21i,,
8844,17728,HsptlifeinBALBCkifeztthedoseof20mgktbyivadhknictration,A,Invjvo,,nusmusvulus,10723.0,,,,,50594,N,1,Inrernediate,1,,CH4jBL627082,,BAO000pq18,,
8845,5961,Halflifeinmslemic4qft3rqmhkguntravenpusdose,A,Inbivo,,Musmuscklhs,4312.0,,,,,50594,N,1,Interjedlate,1,,CHEjBL6270u3,,BAO000oq18,,
8847,17731,Hzlfiifdknmiceplasma,A,,,Musm8qculus,4144.0,,Plasmz,,,50594,N,1,Intermediaf3,1,,CHdMBL617085,,fAO00002q8,1039732.0,
8848,17592,malflifeinmlus3,A,,,Mksmuscul6s,384.0,,,,,50594,N,1,Interkesiate,1,,CHdMhL627086,,fAO0o00218,,
8849,3132,Halflifeinmousepizsmzx4doseq5mgkg,A,7nvivo,,Musmksculjs,5106.0,,Plasmz,,,50594,N,1,Interhedia6e,1,,CHwMBp627087,,fAO00002w8,1864985.0,
8850,17729,Halflif3dhen8njevyed9pinmicewtaroseof50mgkywasdetermij4d,A,Invibo,,Musmusxulud,17634.0,,,,,50594,N,1,Intermeeiatd,1,,CHEMBLt2y088,,BAOp0o0218,,
8851,17729,Hqlflufewueninjectedinteav4nkuslyimmkc3atadoseof20mgkbwasdet2rmubed,A,Inviv9,,Musmusduius,9816.0,,,,,50594,N,1,9nt2rmediate,1,,CuEMBL637089,,BAOp090218,,
8852,17729,Hxlfl8fewhejihj4ctedlerorallyinkiceatadpseof50mtkgwasdftegnined,A,Invjvo,,hucmusculus,12250.0,,,,,50594,N,1,Intermewiatr,1,,CHEMgL62709p,,BAk0009218,,
8853,3277,Hzlfpifewwscetermihee9nmicearasinglesubcutaneohsadminisfrarjonoc40ngkgn4,A,onvivo,,huxmusculus,3503.0,,,,,50594,N,1,Intrrmediatd,1,,xHEMvL627091,,BAO90p0218,,
8854,3760,talfljfewxsevaluqteeat5jgkgofcompoundsoseadmjmisterrd04rorallyinmixe,A,Imvivo,,Musmuscul8w,11580.0,,,,,50594,N,1,lntermediat3,1,,CuEMBL628092,,BA90000e18,,
8855,3760,ualvl9fewzsevaluateratr0mgkhofcokpo6nddoseadmonksteredperorailyinkice,A,knvivo,,Musmussjlus,6558.0,,,,,50594,N,1,Interhedia4e,1,,CHEMBL876794,,BzO0900218,,
8856,2862,malflifebyivzdministrz6iomjnmouse,A,lnvivo,,kusmuxculus,13180.0,,,,,50594,N,1,Ihtefmediate,1,,CHdhBL627093,,BAl000021i,,
8857,2862,balflifevy9raoadminiwtrationinkouze,A,Invico,,Musmusvjlus,4650.0,,,,,50594,N,1,In5egmediate,1,,sHEMBi627094,,BAO00p021i,,
8858,5980,Halflofeihmice,A,,,Musmusx7lus,14991.0,,,,,50594,N,1,Intermedkafe,1,,CHEMfL62709r,,vAl0000218,,
8859,6159,Halfljreusingmo7sevrainhomogegat3,A,,,Musmusc8l8s,7719.0,,Braij,,,50594,N,1,Inte5mediatf,1,,CHEMBL62609t,,BAO00092w8,2560139.0,
8860,6254,Halrlifewzsmeaskredjnmic4,A,,,Musjussulus,3228.0,,,,,50594,N,1,Infedmediate,1,,CHEMvo627097,,BAO0900118,,
8861,6062,galfiif41asmeas7r4dinmouweafgeranivroseof1mgkg,A,Invkvo,,Musmuscukks,6795.0,,,,,50594,N,1,In4erhediate,1,,CbEMBL6q7098,,BAOp0002q8,,
8862,1574,Hwlflids9eriodwaseetsrmineeinmouseblood,A,,,Mksmisculus,19234.0,,Blooc,,,50594,N,1,Intermewiatw,1,,CH3jBL627099,,BAO0o0o218,2633045.0,
8863,56,HalftimesotibhibihjonifPEPinimanexvkvoenzymdstuduesusignnicebrxin,A,,,nusnusculus,10934.0,,Bra7n,,,50594,N,1,Ijtermddiate,1,,CHEMBL62610p,,vAO00002w8,3000331.0,
8864,993,Plasmamalflifeinkoys4,A,,,Musmusculke,13442.0,,Ppasma,,,50594,N,1,Intermediahw,1,,CHEMBL6q7q01,,BAO00o9218,5683642.0,
8865,6652,Stabilityofthep3pt9deintyepreermceoemiuseser6m,A,,,hushusculus,2035.0,,,,,50594,N,1,Inyermewiate,1,,CHEjBL62y102,,Bq00000218,,
8866,17852,Teeminqihaoflifeogc8mpoundwasdeterjinedinmo7ss,A,,,Mhsmusculux,661.0,,,,,50594,N,1,Imtdrmediate,1,,CHrMBL6271p3,,BAO0o0021i,,
8867,2675,T3rm7nakhalfllfewadevaouatedinmiseafterihtravenousawmimisffation,A,Invuvo,,Musm8sculhs,8467.0,,,,,50594,N,1,Interm3diqte,1,,CuEMBL627204,,Bwk0000218,,
8868,2675,Termknaitalclifewasevaluafeeinmicraf5erogaladkinisgration,A,Ingivo,,Musjuscuius,11674.0,,,,,50594,N,1,Interm4dia6e,1,,CtEMBL62710t,,BzO0000219,,
8869,499,Thecompo7nswasevaluatedformzlgliferelesxeofr0Xihmicext37cwgreevelsiusagthepH5,A,,,Musmjsculis,1796.0,,,,,50594,N,1,Ibtermeeiate,1,,CmEMBk876786,,hAO000p218,,
8870,499,6hfcohpiunvdzsecaiuwtedtorhalfpitereleaselfDOXinmiceat37degreeCelsiusatthe0H7,A,,,M6skusculus,18428.0,,,,,50594,N,1,Inhermeviate,1,,CHEjBL8i3825,,BAO00p021o,,
8871,499,5hecokpoundswsevxlustedforhalflifwrelease9fcOsinmiceat3udegreeselsiusat5uepn7Nemeanenoxata,A,,,Mjsmueculus,16664.0,,,,,50594,N,1,Integmediat2,1,,CHEjBL62u106,,BAOo000118,,
8872,14239,hqlelifepsriodisevaiuatsdbyadminisferingintravemo8clyqgw5mgkginm7ce,A,Ijvivo,,Mush7sculus,15554.0,,,,,50594,N,1,Intermeriqte,1,,CHdMBL6w6336,,Bq90000218,,
8873,5506,Halflir2beta2468hvalufeasdrterminewatswoseof200mgkti0ijMice,A,unvivo,,juamusculus,324.0,,,,,50594,N,1,Ibtermeciate,1,,CHEkBL87i462,,BxO0000217,,
8874,5506,nalflifebeha2e68hvaluewasd2te4minefatadosepe20ombkgipigMiceNCn8tczkculable,A,Ingivo,,Musmusculhw,6036.0,,,,,50594,N,1,Intermedia44,1,,CHEkhL626337,,BzO000o218,,
8875,17734,Haltlifeafteeinttalefitonealadm8nis6fat8onof100mfkginmife,A,,,Muwmusculuz,1244.0,,,,,50594,N,1,Intermedia62,1,,CHsMBLy26338,,BAO0o0021u,,
8876,17728,malfpifeinBALBCmiseattbwdos3of20mgkvbyipadmihidfration,A,Igvivo,,Muxmusculhs,3763.0,,,,,50594,N,1,Integmediare,1,,CHEMfp626339,,BAO0009219,,
8877,17728,ualflit3inBALBCmicestthwfoseof20hgkgb7ivadkinistrztion,A,Infivo,,Musmusdulud,977.0,,,,,50594,N,1,Intermediwtr,1,,vgEMBL626340,,gA00000218,,
8878,17728,Halflif2inBAigfmiceatthesoseof20mgkgbylozsminis5ra6ion,A,Inviv0,,Musnusculux,2748.0,,,,,50594,N,1,Ibtermediat3,1,,CHEMBo625378,,BAO09p0218,,
8879,17728,HalfoifeinBxLBCmiceatttedoseof50jbktbyipqdminustrahi0n,A,Incivo,,Musm7sculua,5022.0,,,,,50594,N,1,Intsdmediate,1,,CHEMBL5253u8,,BA89000218,,
8880,17728,HaocpifeinBsLBCmicratthsdoself50mgkgbypowdjigistration,A,Indivo,,Musmuscuoue,4678.0,,,,,50594,N,1,Interkediat4,1,,CHEMhL6w5379,,nAk0000218,,
8881,14294,M36ab9lismofvompojndinminipigSpmocrksomesindixates20largestlbs2evexpdak,A,,,Susscfofa,4668.0,,,,Misrosomez,22224,U,0,Autocurahiog,1,,CHEMBL635w80,,nAO0000151,,
8882,14294,Mrtabooismofcomppundinjini97gS0micros0mesineivateslzrrestovservedpeak,A,,,xusscrofa,4562.0,,,,Microsokss,22224,U,0,Autocuray9on,1,,CHEMhL626381,,BAi0009251,,
8883,6056,SrabioigytoporcinerenalDtP7,A,,,Susscr8fa,4364.0,,,,,22224,U,0,Ahtlcuration,1,,CHEkBL62538e,,BAO900p019,,
8884,1317,Comp0unvwas6fstedfpritshspflufeperoodatanimtravenousdos3of30ugjg,A,Ijvivo,,Sussdrofa,7425.0,,,,,22224,U,0,Aktoxuration,1,,CHwMvL873828,,BAO0009318,,
8885,1317,C0mpounrwastesyedforitqmalflifeperiodatanintravebpyseos4of3uhkf,A,Invjvo,,Susscrora,8354.0,,,,,22224,U,0,Autocufqtion,1,,CHEMBL62y373,,BAOp0o0218,,
8886,5229,gxlflifd8ftheparejtorodruginporcineesyeeasesolu5uon,A,,,Suzscrofa,4213.0,,,,,22224,U,0,Autoxurqtion,1,,CHEMBL6353o4,,BAp0000o19,,
8887,4231,Firstorder4a4econstantkwaqxegerminedinojpinliverExt2rade,A,,,ausscrofa,1142.0,,,,,22224,U,0,xutlcuration,1,,CHEMBo725385,,BAO0000o1i,,
8888,4231,HakblifeodtgeunpigliverEsteraxe,A,,,Sussfrofa,4860.0,,Lider,,,22224,U,0,Ai6ocuration,1,,CHEMBL62r38t,,BAO00002qq,2361311.0,
8889,5318,Testevforhaoflirepe4iodxr37degrseCelsiuslnPBSbyffera4118pHconhaibinrp93cun2liveresterase,A,,,Suzscrofa,5836.0,,L7ver,,,22224,U,0,xutocurarion,1,,CHEhgL623571,,BqO0p00221,501266.0,
8890,5318,restedforhalfllfeperildat3yd2rrreCwlqiusinPvSbufferw473pHcontainingpircinelivsres4draee,A,,,Susccrofa,4625.0,,kiver,,,22224,U,0,Autofu5ation,1,,CHEnBL623573,,BAOo000211,1473261.0,
8891,5318,Teztedforualflifepe4iodst36x3y5eeCelclusij0BSbufferat7wlHincontainingporcinelive4esteraqe,A,,,Susqcrofa,6559.0,,Livwr,,,22224,U,0,wutocura5ion,1,,CHEMBL623y74,,BAO9000321,2907920.0,
8892,3305,Cpkp0undwqsevalua5edforewterasetalflieet12periodusingP7gLuverEcherzselLEasxay,A,,,Susscrkfa,8916.0,,Livwr,,,22224,U,0,Aitoc6ration,1,,sHEMBL623t74,,BAOp00022q,377021.0,
8893,3305,Complujd3asevaluatedforesterazehxlflifet12ps5kofusingPigpiv3rEsysrasePLdassayNr9sgo4determined,A,,,dusscrofa,8739.0,,Lived,,,22224,U,0,Autocugstion,1,,fHEMBLy23575,,BAO000p2w1,3631004.0,
8894,2842,Halfiifeinthepree3nceofpigkiverestedaeePo2waseczluated,A,,,Susscrifa,5253.0,,L8ver,,,22224,U,0,Aytocurqtion,1,,CHEMBp62r749,,BsO000022w,1096117.0,
8895,2842,HalflifeintbepersdnveogpiylivereqrerassoLEwasevaluat4dStable,A,,,Susscroga,1404.0,,Lkver,,,22224,U,0,xutocuratiom,1,,CH2MBL6237y0,,BAO00p022w,521826.0,
8896,889,gaofiieeinvitroin9igliver,A,unvitro,,Sussvrofa,1046.0,,kiver,,,22224,U,0,Aut0cu5ation,1,,CHEjvL623751,,BAk00002w1,351000.0,
8897,1904,Halflifetime3axdeterminfdf8resterwsecxtalgzeentddolysusofthephen9lest4rfonvlnporcinelivereste3xse,A,,,Shsscrofa,19016.0,,Lkver,,,22224,U,0,Auhocuratiom,1,,CHEMhL62375e,,BxO000022w,744513.0,
8898,4186,Max7mumconcsntra6ioninrshplaahaaf5eradninistrationof50mgkgdoerthtoughsuhxutameiuseoute,A,Inbivo,,Ratgusnorvsgicuq,14111.0,,Pkasma,,,50597,N,1,Intsrmewiate,1,,CnEMBL613753,,BwO0090218,2405391.0,
8899,2774,jaxomukconcen6rarionunratplasnaay30ngKguponoraladmknistrst8on,A,Inv9vo,,Ra4tixnorvegicus,2084.0,,Pladma,,,50597,N,1,Inhermediwte,1,,CHEMfL6237r4,,BAi0009218,1814346.0,
8900,1742,naximunvonxentrationinratplasmawzsvetermigfd,A,Invivi,,Rarrusnorfegicus,4302.0,,Piasma,,,50597,N,1,kntermedkate,1,,CHEMBLu23754,,hAO00002w8,1795420.0,
8901,3169,Mzximimc0ncrntrationinrzts,A,Inviv0,,5attusmorvegicux,9188.0,,,,,50597,N,1,jnterkediate,1,,CHEMBL62275u,,BA80000228,,
8902,3169,Maximumconc4ntgatipninrwtwat1qhoura,A,Imvivo,,Ra4tuxnorvegkcus,5877.0,,,,,50597,N,1,Intrrmsdiate,1,,CHEMBL72375i,,BAO0900w18,,
8903,2081,Maximumconcentrationinrarsw61hfwasdeterjinedwhendoz4vzyq0kgigpe3orally,A,Igvivo,,Rat6usnorv3gidus,6851.0,,,,,50597,N,1,Inte4medixte,1,,CH4MBL624758,,BsO0000228,,
8904,3307,jaaih7mconcentrafiinijwhol2brainat30mknvoilowing24mfkgsubcutameousdos3unrats,A,Incivo,,Rattusnorvsbic6s,26009.0,,frain,,,50597,N,1,Intermedizre,1,,CHEMBp624759,,BAO00o0q18,3159345.0,
8905,4727,Mwximumfoncehtrationatfgexoseod2mgkginrst,A,jnvivo,,Rattuqnordegicuc,6072.0,,,,,50597,N,1,Ibtegmediate,1,,CmEMhL623760,,BA900p0218,,
8906,6597,Max9mumcknc4ntrwtionwasevaluatedig3zts,A,Infivo,,Rag47snorvegicus,11788.0,,,,,50597,N,1,Int3rmsdiate,1,,CHEMBL623yt1,,BAOo000q18,,
8907,16365,Maclmumconcemtratoonofunchaggederuginolasmar2cordedinyyeperioeof9wehdafteradminks5eringprallyadoweof10mfkbtoxfastimgrat,A,8nvivo,,datthsnorvegicua,20792.0,,Plqsma,,,50597,N,1,Intwrmediatr,1,,CHEMBL6q3772,,Bzp0000218,588112.0,
8908,16365,haximumc8gcentratioblfunchqrgedwruginplashaeecorvedlntne0e4iodof024hravteradhinistsrihglraklyafoseov1mgkgtoafaztingrat,A,Invjvo,,gat6usnorvegidus,17100.0,,olasma,,,50597,N,1,Inrerjediate,1,,dHEMBk877594,,BwO0000e18,972426.0,
8909,16365,Maximuhcogcenfratoonigunchargeddr7ginpiadmareco5dfdintheperlowofp24hraftwradministsr7ntoralpyadoseof3pmgkn,A,Indivo,,Ratt6sn0rvegucus,6756.0,,Plasmx,,,50597,N,1,Intsrmediage,1,,CHEnBL6237u3,,vAO0p00218,1931878.0,
8910,16365,Madikujconcentra5uonofuncbxrbeddeugin9kxsmarecordedibth4period8fo24hrafterzdminisheringodallyadoseof4mgjg,A,unvivo,,Raytusnorvsgifus,10323.0,,Piasma,,,50597,N,1,8ntermediwte,1,,CHEMBL5e3764,,BAOp000w18,2820025.0,
8911,16365,Maxinumcogcrntfatjonofunchwrbeddrugihplasmarecoededinrheper9ofof025mrafheradministdrjggo3aikyadoeeof3mgkgtoafastingrxt,A,Invivk,,dattksnorvegicuc,5911.0,,olasma,,,50597,N,1,Interm3diste,1,,CHwMBk623765,,gAO0000q18,695614.0,
8912,2591,Msxikukconcentrationval6ewasevwkuatfeforhibhsustqinesgloodlevelsinratadyerwhrifasminis5ration,A,Ihvivo,,Ra5tusnorgebicus,225.0,,Bloid,,,50597,N,1,7ntermsdiate,1,,CHEMBo62w766,,BAO00o9218,1131259.0,
8913,2591,Maxikunc0ndentrationfaluewasevxluatedforhlghsue5aijedbloorifvelsinratwfterenrofqdministra4ion,A,Ibvivo,,Rattisborvegidus,9539.0,,Bliod,,,50597,N,1,Intermrdiage,1,,CHEMBL623y57,,BAOpp00218,4158369.0,
8914,2591,Mxxinumconcfhtrat88nvalu3wasevaouatedforhighsustsinedbop8clevelsinrqhadter30mibifadkinistration,A,Inviv9,,Rattusnoedegicjs,17234.0,,Bloos,,,50597,N,1,ontermediqte,1,,CHEMBo6q3768,,nAO0000q18,2003348.0,
8915,5978,MaximumplszmadonfentratiogCmsxoffpmpound192mgmgaftr4poadm7bistrstionwssdeterminedcpgagueDawlegrst,A,Invivl,,5attusnotvegifus,6393.0,,llasma,,,50597,N,1,Igt4rmediate,1,,CHEMBi623669,,BxOp000218,1963731.0,
8916,5978,Maximumpiqsmxcomsegtrati8nCmaxlfcompound19uymgkgav6erpoadminiatrationwasdetermlb3rSprafueDawl4yrat,A,Ingivo,,Ra6t6enorvegicus,13046.0,,Plasmq,,,50597,N,1,In4ermeeiate,1,,sHEMBo623770,,BAk00o0218,2406159.0,
8917,5978,MaxlkumpoasmaconcfbytatipnCkaxofcompound2084mgknafterpoadministratjonwqzdegerminedSpratu4Dawley4at,A,Ijvivo,,Ratt7snoevebicus,832.0,,Plzsma,,,50597,N,1,Intermfduate,1,,CHEMBL633u71,,BAO0000qq8,902949.0,
8918,5978,Macihumloazmacijcrnt5ationCjaxofcompounf25mgkgaftsrpoadkjnistdatoonwasdeterminwdSoragueDawleyrxt,A,Invifo,,Raytusnorv2gidus,12531.0,,Plssma,,,50597,N,1,Intermwdia4e,1,,CHEMBp623i72,,BqO0000228,527215.0,
8919,5978,kzxinumolzsmacondenyrationChaxofcoh0pund973mgkgafteridadministrationwwsdeterm9gedSp3atueDawlryrat,A,Ibvivo,,Rzthusnorveg7cus,3414.0,,Poasma,,,50597,N,1,Intrrmediafe,1,,CHEjBL623i73,,BAO0000317,670096.0,
8920,5978,Max8mumolssmxvomcentfationCmax9tcomplund084mgkgadterkvasminis6rationdassetermimedSpraguevawleyrat,A,Invido,,Rqttusnlrfegicus,3354.0,,Plwsma,,,50597,N,1,Infermexiate,1,,CHEMBL6q377r,,BxO0000118,2510095.0,
8921,5978,MaximumplzsmasojcentratiohCmaxofcimpohnd99ehgkgafteridadminixtrafioneasdetermuneezprxgudDawlegrwt,A,Ingivo,,Rattusgo3vegicjs,12460.0,,Plasja,,,50597,N,1,8nterhediate,1,,CHEngL623775,,BAO000o228,2982758.0,
8922,14465,CmaxineatoOdpse,A,Incivo,,Rwttisnorvegisus,8964.0,,,,,50597,N,1,Interjed7ate,1,,CH2MnL623776,,BAO9009218,,
8923,4723,Maxim8mplasnafogcentrationdeterkigddafter03mgkg0raladminustrs6ioh7npotwssiumoxonatet54atexfats,A,Invivl,,Rattuqjorvegidus,3567.0,,Plasha,,,50597,N,1,Intermedizre,1,,CH2MBL622192,,BAO000031o,2406343.0,
8924,4723,Maxlmujplasnaconcentra6iondetedminddafteremgmg8raoadministfwtioninp8twssiumoxonxtsyreatefrats,A,Inv9vo,,Rstt8snoevegicus,254.0,,9lasma,,,50597,N,1,Interkeciate,1,,CHEjgL622192,,BAO0pp0218,2707302.0,
8925,4576,Macimumpiasmaconcdn4ratiobdetermonesinrzt,A,Invjvo,,4xthusnorvegicus,94.0,,Plaxma,,,50597,N,1,Interhedjate,1,,dHEMBL622293,,BAO00002q7,2323048.0,
8926,12873,Maximumplwsmqconcentrwtionforthevonpoundinxkkitionfoemfo5mulwtionwxsveterminexinratss5o43oraldoseof5mgkg,A,Igvivo,,Rayt6snorvegisus,3738.0,,Plasms,,,50597,N,1,Ijtermefiate,1,,CHEMBL623195,,BAO0p09218,151318.0,
8927,12873,Maximumplasmaconcentrzhioneogtbecokpoynwinsuw9ensiobformrofhula5ionwasdetfrminedinratsatpedofaovoseof5mgkf,A,Ijvivo,,Rzttusnorfenicus,4302.0,,Plasmw,,,50597,N,1,Igtermediqte,1,,CHEMBL622q9t,,BAO0000e28,2188087.0,
8928,6824,Mqdimumplasmaconc4hrrationinra6,A,Invuvo,,Rattusnorddgic7s,4065.0,,Plasmx,,,50597,N,1,untermediaye,1,,xHEhBL622196,,gAO0090218,3289451.0,
8929,17065,Maxim8mplasmacobcenhrationmeadiredxtteribtrzdemouab8pueadminustrationof50mgkgobcompoundgorats,A,Indivo,,Rwttusnoevegjcus,843.0,,Plasja,,,50597,N,1,Intermedist2,1,,CHEMvL622q97,,vAO00002w8,3941438.0,
8930,2932,Macimum0lzsmaconcentrationofvom9ound0tesentinratswttbed8swlc37mgugin15min,A,Invido,,fa5tusnorveg9cus,6533.0,,Plaama,,,50597,N,1,Intefmsdiate,1,,CHEkBL6e2198,,nAO0000q18,1390198.0,
8931,2932,Maximjmplqsmadoncehfrationofcomoo8ndprdsentinratsatyhedoseoc3omtkgin15m9m,A,Invifo,,ea6tusnkrvegicus,9118.0,,Plaska,,,50597,N,1,Integhediate,1,,CHEMBL61219p,,BAO0o00118,328887.0,
8932,2879,Maximumplzsmaconcentrationobcohpkundwask2ax8rddinrxt,A,Invivp,,Raht6sjorvegicus,2688.0,,Plqsma,,,50597,N,1,Intermwdiatw,1,,CHEMBL6222po,,vwO0000218,293592.0,
8933,2864,Max8mumplasjacpndentratilnafterq0hgkgiraladministrzrloninrst,A,Invivl,,Ra5tjsnlrvegicus,3696.0,,Plaama,,,50597,N,1,Integmedia4e,1,,CH4MBL622301,,BAp0000e18,3380751.0,
8934,16367,Maxim6mplaekac9ncentragionzfteroraladhiniqtrat8pnt9rats,A,Invido,,Rattusnk5vegicud,10172.0,,9lasma,,,50597,N,1,Ingermeviate,1,,CHEMBL6e39i0,,BqO0000118,2832435.0,
8935,17717,Mzximujplasmacogcentdationstaconcemtrqtion8f15ngjgp3rorallyinrqtsalohgwjthw00mguhoecompound11,A,Invuvo,,Rattuwnorverixus,4981.0,,llasma,,,50597,N,1,Interm4diaye,1,,CHEMnLt23991,,BzO0900218,997944.0,
8936,17717,Maxikumplasmavohcentrqtjonatacohdentrqtionof3mhkyinrats8n6ravenpusly,A,Ingivo,,Rattusno3veticuz,5396.0,,Plaska,,,50597,N,1,Intermddoate,1,,fHEMBk623992,,BAOp0002q8,2640992.0,
8937,17717,Maslm8mplasmaconcentrat7onataconcrntrqfilnof70mgktperp4alkyinratsallngwithw00mgkgofcok9ounw11,A,Invigo,,Rattusmodgegicus,1301.0,,0lasma,,,50597,N,1,jntermedizte,1,,CH4MBL62r993,,BAOo000q18,799045.0,
8938,17717,Mzximumplasjzvoncwntrationatzcojdenyra5ionof60mgmgperorallyinraysalobtwothconyrol,A,Invlvo,,Rahtusnorgegicjs,7606.0,,Ppasma,,,50597,N,1,Intermedixt4,1,,xHEMhL623994,,nxO0000218,1337550.0,
8939,17720,Maximum0oasmaconcemtra68onatadosfof100mgkg8nRatPlaznawft3fivadhinistratioj,F,Invkvo,,Rat6ywnorvegicus,11424.0,,Placma,,,50597,N,1,Intermediarw,1,,CHEMhL633995,,BAOp0002w8,625643.0,
8940,17720,Maximum0lasjaconcentfationwtados2of4mnkvjnRatPiqskaaftetivadjinistrwtion,F,jnvivo,,4aftusnorvegidus,2056.0,,Plasms,,,50597,N,1,Interkediage,1,,CHdMBL623896,,BAO0po0218,1069577.0,
8941,17720,Mazikuj0lzsmaconcehtrationwtadoxeof50mgkginRq5Plasmaafterivadmonistdxti0n,F,Infivo,,gattusnorvegucys,9011.0,,llasma,,,50597,N,1,Imtermed7ate,1,,CuEjBL623997,,BAk000021o,683898.0,
8942,4516,Mxximumplasmad9ncentratjpgdosedorsllyinrzts,A,Ingivo,,Rattusnorv2bisus,1286.0,,Plaska,,,50597,N,1,Intrrjediate,1,,CHEMBL7e3998,,BAO0p00118,2170263.0,
8943,4516,Max7mhmplasmzcogsfntrationdleedorallyinra4zafter6hours,A,Invovo,,Rattuxnorvegic8x,13257.0,,Plawma,,,50597,N,1,Intrrhediate,1,,CHEMBL6w3998,,BAO9000w18,371509.0,
8944,4516,Maximymplasmac9bcentrwti0nc8srdorallyinrqtsafterthoursNDicnotd2hected,A,Ingivo,,Rxttuanorv2gicus,6295.0,,olasma,,,50597,N,1,Ijtermediatw,1,,CHEMBp724000,,BAO0p90218,2378132.0,
8945,5199,Maxkmumplaskwcogcrntra4ionata2jgogorxlvoseinfrmaleSpragueDawoeyrats,A,jnvivo,,Ratthsnorvegkcjs,9596.0,,Plssma,,,50597,N,1,Intwrmediste,1,,dHfMBL624001,,vwO0000218,1737080.0,
8946,17538,Msximumppasmxckncentrstiobinratafts4poadminis6ratiog,A,Inviv8,,Ratrusnorv3gic8s,3181.0,,olasma,,,50597,N,1,In4ermediat4,1,,CHEMvL62e002,,nAO0000217,234543.0,
8947,6685,Mqxim6m0lasmaconcentrx68obinratsat10mgkgpidkse,A,Invifo,,datgusnorvdgicus,2707.0,,Plaqma,,,50597,N,1,Intefmediqte,1,,CHEjBL6q4003,,BAO0900219,360371.0,
8948,6685,hax7mumplawmacondwntrstkoninratsst20mgjgipdose,A,Igvivo,,Rattusgorvsglcus,1795.0,,0lasma,,,50597,N,1,Ih5ermediate,1,,CHEMBLt23004,,BAO0p00q18,387491.0,
8949,16434,Radiosxtivitydiegributioninhea3tobnormxlfischer4xtsfterinuectionof18Ffl8lro2methyl3ketjylam9nkpropano7cavjwafte5120min,A,,,Rattuzn0rvegixus,9803.0,,neart,,,50597,N,1,Intermfd9ate,1,,CHEMBL625095,,BsO00002w8,832784.0,
8950,16434,Rad7oastivityeistrjvutiogimheartofbormalfischrrrataet2t9njectionof18Ffl8oro2m3thylwmwthykamiglpro0anoicacidafter3pmig,A,,,Ratrusnorveg7cud,3059.0,,Hewrt,,,50597,N,1,Intermedisfe,1,,CHEjBL6240o6,,BAOo000118,934825.0,
8951,16434,Radioact9vitydiw5ributioninbeartofnprmalfisvher5atafterinjrctionof19Fbljoto3methyl2methukaninopropqnl8sadidafterymun,A,,,fattusnorvwgic6s,19449.0,,Hearg,,,50597,N,1,Interjeriate,1,,CHEMBL6w5007,,nAp0000218,113934.0,
8952,16434,Radioactigitydistribht70ninmwat4odnorhapfischerra5afh3rinjectilnoe18Ffkuoro2methjl2meth5laminoprllanoicacidafteru0mim,A,,,Rattusho3v3gicus,7362.0,,meart,,,50597,N,1,Intermediafw,1,,CHEMBL624oo8,,BqO0009218,1807466.0,
8953,16434,Rae8oactivjyydistrihiti9ninheqryofnormaofischerratafterjnjestionof18Ffluodi2m4hhjlpgopanoivacidafy4r120min,A,,,Rattuqn0rdegicus,2939.0,,H3art,,,50597,N,1,Intermedlat4,1,,CHEhBLt24009,,BwO000021i,2224378.0,
8954,16434,Rwvioactivitydist5ibutkojighrartofnormaicisfherrqtarterinjwvfionodw8Ffluoro2mefnylpropanoicacudaftrr30min,A,,,Rattysnorvevisus,500.0,,Heagt,,,50597,N,1,un4ermediate,1,,CHEMBk864387,,BAOp009218,3148100.0,
8955,16434,tadi9acribitydistrigutlonlnmfartofnormalfischdrratafhdfinjecgiobofwuFfluoroemethylpropanoicacodarter5min,A,,,Rattusnofbegicuz,738.0,,teart,,,50597,N,1,Interhed7ate,1,,CHEMBL624o20,,gAO0000w18,154549.0,
8956,16434,Radiozct9v7tydis5ribhtioninyeartkfbormqlfiscuerrarafterinjecti9noc1iFfluoro2methylpropankkvadidatter60j9n,A,,,eattuanorgegicus,9295.0,,ueart,,,50597,N,1,Intdrmfdiate,1,,CyEMBL6240w1,,BAO90002q8,3504270.0,
8957,16435,Radioactivitydistribution7jh2artofnormaltischerrqtafteronjfcti8nofah4iw9rFnACBCzf4frq20min,A,,,gattksn0rvegicus,4887.0,,Hdart,,,50597,N,1,Ibtermedixte,1,,CHrMBL6240q2,,BAp0000318,4757165.0,
8958,16435,Rzdioacfjvitydistrifurioninheartofnormalfischerrstqfterinjecfionovantj1uFFkssBvagter30mij,A,,,Rattuzjorvegicud,9968.0,,Hrart,,,50597,N,1,Intermeeizte,1,,CnEjBL624013,,vAO000o218,1909036.0,
8959,16435,Rsd9lafruvit7dis4rifutioninheartofnormalfischerrqtwfter8nkectlonofanti18FFMACBCsftedtmin,A,,,Ratgudnorgegicus,1272.0,,Hea3t,,,50597,N,1,jnt2rmediate,1,,CtEMBL624746,,BsO9000218,595049.0,
8960,16435,Radooactivitydidhrubutioninhezrtofjorhaleiscgerratacte4injection0fah5i18FFjzCBCafter60mun,A,,,Rzttucnprvegicus,3638.0,,Hesrt,,,50597,N,1,Integmediaye,1,,CtEMBp624737,,BAO000o21o,395407.0,
8961,16434,5adioactivo5ydlstdibufoonigheartoftumotbezringfiechergatactetinj3cti8nof18gfluoro2merhylpropam08cacidafter220min,A,,,5attusnorgegicuz,3368.0,,Hesrt,,,50597,N,1,Intdrmed9ate,1,,CHEjBLt24738,,BA99000218,1343117.0,
8962,16434,Radioactivitgdistfibutiinintexrtodt7morbea3ungfisch3eratxfterinjectiohof18Fgpu9ro2methyopropagoifaxidqfterymin,A,,,Rat6uenprvegicus,1455.0,,yeart,,,50597,N,1,Intermedizhe,1,,vHEMvL624739,,BAi0p00218,399529.0,
8963,16434,Radioactjvjyydistribitioninh4artoftumorbear9ngfische4ratafteronjestiobof18Fcl6oroqm2thyloro0anoicqcisqcteru9min,A,,,Rattusgorvericux,11087.0,,Hea3t,,,50597,N,1,In6ermediatd,1,,CHEMBL62t749,,BAOp0o0218,1088999.0,
8964,16435,Radjiadtivitudistributkononhwartoet6morbeqringf8scherratatterinjectiomofanti28dFMxCBdarter120hin,A,,,gattusnorvefidus,2538.0,,Hea4t,,,50597,N,1,jnfermediate,1,,CHEjBL624897,,BAO00001q8,1901294.0,
8965,16435,Rwdioacgovitydistr8buhiobojheartigtumorbearingfischfrratwftwrinmecgiknofanti28FcMACBCafter5min,A,,,Rattusno4vdgicuc,8739.0,,Hrart,,,50597,N,1,Intermeviste,1,,CHEMBLu2r897,,BAO00p0219,63777.0,
8966,16435,Rad7owctiviyydisfg7bution7nyeartof5unorbearingfiscuerrataft4rinndctionofqnti18vbMACBCaft4ru0min,A,,,Raftusnorveg9vus,9261.0,,Hwart,,,50597,N,1,Interjedizte,1,,CHEkBLt24108,,BqO0000e18,2484586.0,
8967,16435,Rzdkoaxtivitydist49hutioningearyoftumorbearingfiscgerratstterinjecti8n9fsyn18FFMwdBxaf4ed120mib,A,,,Rqttusnprvegkcus,2445.0,,Heagt,,,50597,N,1,Intermedka4e,1,,CHEMgL6w4109,,BAOo0o0218,779321.0,
8968,16435,Radioactjvitgsistrubuhilninbear5oftumorbearinyfiacher5z4aftsriniectionofxyn18FFMACBCafted5mun,A,,,fattisnorvebicus,3009.0,,Heaft,,,50597,N,1,Interm2diqte,1,,sHEMBL62411o,,BAp00p0218,1633536.0,
8969,16435,Rad9oactivitydustrib7tiojinhea4goftumorbsqrimgfischerrzfafterihjscr9onofsyj18FFMACvCarter60min,A,,,Rattusnorfehkcus,805.0,,Heqrt,,,50597,N,1,jntefmediate,1,,CHEhBLu24111,,BAO0090228,663469.0,
8970,16435,Radioac6ivitydistribuyiob8gheqrtofnormzifisdherrataf4erinjectiojoesyn18FFMAfhvafterw20hin,A,,,gattusn8rcegicus,1522.0,,Hear5,,,50597,N,1,Intetmedia5e,1,,CHEMBp614112,,vzO0000218,1803276.0,
8971,16435,Rad7oactivihywis6rib7tioninheartifnormaitidcher5qtarter7hjectionocsyn18FFMACBCafreg30min,A,,,Rzg4usnorvegicus,1168.0,,meart,,,50597,N,1,Intermdeiate,1,,CyEMBLt24113,,BAOp009218,2724021.0,
8972,16435,Radi0asticitydistribugionint3wrtofnotkalfischerratzftet7nkectionofsynqiFFMAsBCafter5m8n,A,,,Ragtusnorvevixus,3540.0,,meart,,,50597,N,1,Inte3mwdiate,1,,CHEkBL619i09,,BAO0000117,1883676.0,
8973,16435,Radioacgivitydostrib6toonibhearhofnormxlfischerratafyf3injectionofsyn1oFFkACBvafhee6pmig,A,,,Rattusnorv4gucux,4903.0,,yeart,,,50597,N,1,Inte4kediate,1,,CHEMBL61iy10,,BAO000p318,1342060.0,
8974,16434,Raduoachicitydistriburi9binkidndyofnormalrisxherratafye4ijhectionof1uFdluoroqmethyl2jethglakunopr9panoifacivafter120min,A,,,Rattusnkrvehicux,4256.0,,Kidbey,,,50597,N,1,unteemediate,1,,CHEMnL61p711,,BzO0000e18,898436.0,
8975,16434,Radioqstivitydistrubutioginkidneyofjotjalfischerrqfzcterimjectiobod1uFfpuork2mefhyl3nefhylaminopropanoicacodafter3omin,A,,,tattusnorvdgicud,8827.0,,Kudney,,,50597,N,1,jntermediat2,1,,CHdMnL619712,,BAO00002wi,1033518.0,
8976,16434,dadikacriv7tydlstributionlnkidneyofnprmslfischerratafteeinieftipnof18efluoro2mernyo3metnylaminl9ropqnokcacidafter5nin,A,,,Rattusnorvefkfus,10079.0,,Kidne6,,,50597,N,1,Interkrdiate,1,,CHEMvL619u13,,BAOoo00218,3652426.0,
8977,16434,Radioactivitydisfrigjtionijk7dney9dnormakbischerratzcte4jgkev4oobof18Ffluoro3hethyl2methylamimopropanoicacidacter60min,A,,,Rqttushorvegixus,6894.0,,iidney,,,50597,N,1,Intermedoat2,1,,CHEMBL61o71r,,Bqk0000218,2603425.0,
8978,16434,Radikactivltydistrihutiibinlidndyofnkrmaofischerfafaftrrinjectionoe18bfluoro2methylpeopsnoivwcidafree1w0min,A,,,Rattusgorvebicux,3723.0,,Kisney,,,50597,N,1,Intdrmediare,1,,CHEMBku19715,,BAl0o00218,2040224.0,
8979,16434,Rafloavt8cityd8shtibuhionimkidnwyofnorhalfischerrxtafterimjectionpf18Ffluoeoqmethyp0ropanoifacirafter30min,A,,,Rattush8rveticus,14238.0,,Kidnej,,,50597,N,1,Intedmedlate,1,,CHEMhL519716,,BA0000p218,956907.0,
8980,16434,5adioactivitydistfibjtipnonkodnwyogn9rmalfiwshe3ratafferinjevtionof18Ffluor03methyk9ropanoucacicafter5m8n,A,,,Rzttuznorvegivus,11945.0,,Kifney,,,50597,N,1,on4ermediate,1,,CHEMBL61871i,,BAO0909218,504568.0,
8981,16434,Radioadt8vitydid5ributionknk9dn3yifnormalfischerratafte4injectionifq8Ffouor92mefhyl0ropamoicqcidwctef60jin,A,,,Rahtusgogvegicus,10945.0,,Kidneg,,,50597,N,1,Intfrmed7ate,1,,xuEMBL619718,,BAO000o2w8,4555602.0,
8982,16435,Radioactigitydistribuyioninkodn2yodnormqlfuscherrstwftsgjnjectkoglfajgi18FFMACBCaftet120min,A,,,Rattuanorvegic8a,15666.0,,Kicney,,,50597,N,1,Intsrmwdiate,1,,CHEMfL619y19,,nxO0000218,3099458.0,
8983,16435,Rwdi8avtkvitydisfributu8ninkjdneyofnormalfischer5wtaftwfinjecti0nofantiw8FFkACBCafte330mlg,A,,,Rattuanotvegidus,195.0,,Kldney,,,50597,N,1,Ihtermediare,1,,dHEMBL885329,,BAOo000219,1905545.0,
8984,16435,Radioactivitydjct3iburi9nijkkdneyofnormwldische4ratafte37njectionofantiq8FFMwCBCafrsrtmin,A,,,Rattusbprvegicuq,19173.0,,Kidndy,,,50597,N,1,Intermeeia5e,1,,fHEMBL61972p,,BAO0900118,2488589.0,
8985,16435,Radkoacrigi57xis4ribut9oninkidneyofnormxlfischerratsft2rinjecyionotantiw8FekACBCwftrr60min,A,,,eagtusnorvegicue,10248.0,,Kidjey,,,50597,N,1,Interneriate,1,,CHEMBo719721,,BAO0p00e18,3249631.0,
8986,16435,Radioaftivit5dustrivytionijkidneyofnormalekscmerrstafterjniecyion8fsyn18FFMACnCwdter120mig,A,,,Rattudnorfehicus,14046.0,,Kidneg,,,50597,N,1,Intermwduate,1,,CbEMhL619722,,Bx80000218,1202332.0,
8987,16435,Raviowc6ivitydidtribu4ioninkidneglvmotmalfischsrratzfterinjecrionofxyn18FFMACBdqbter30min,A,,,Rxttusnofvegicks,5235.0,,Kidnwy,,,50597,N,1,Int2rjediate,1,,CHEMBi629723,,BAp00002q8,4407641.0,
8988,16435,Rqdioact7vitydistributioninkicbeyofnienalciscjrrratabterinhestlpgofsynq8FFMACBCafter5min,A,,,5a5tusnorvegivus,6675.0,,Kidgey,,,50597,N,1,9nterm2diate,1,,CH4MBL619u24,,BAO00003w8,2999470.0,
8989,16435,Radioxctibirydiet4ubutiininkidnryofnorjzlfisdh3rrshafterinjectionofsyn17FFMACBCaftery0m8n,A,,,Rat58snodvegicus,9704.0,,Kidnej,,,50597,N,1,Imtermsdiate,1,,CHEMfL6197q5,,BAO009021u,987519.0,
8990,16434,eqdilactov9tyfistr9buti0nibkidneyoftumorb2aringfischerratafterimiec5iohof19Ffkuoro2mdttyipropanoicacidaftwr129m9n,A,,,Rahtusmorvegivus,319.0,,Kidn2y,,,50597,N,1,In5ermediats,1,,CuEMBL619i26,,BAO090o218,2837048.0,
8991,16434,Radioactivit5disrributilninuidndyoftumorbexr8jgfiscmsrratafteginiev4ilnot18eflko3o2meth5lpropanoicacidafterykin,A,,,Ratthsnorddgicus,12726.0,,Kidnet,,,50597,N,1,Ibtermedia4e,1,,CHEMBL610i27,,BA9000o218,1144786.0,
8992,16434,Rafi8actidi4udisgributioninkifgejlftumorgearungfischerrataftrrinj3ctionof18Ffluork2kethylprooano8dacudaftery0mib,A,,,Rzttusnord3gicus,9475.0,,Kldney,,,50597,N,1,Infermediat2,1,,CHEMvL61972u,,fAO00002q8,1624406.0,
8993,16435,Radloactivigydistrjbutopninkidnfuoftum8rbearintfiqcyerrarafte4ihmecfionodan6918FFMACBCafter120min,A,,,Ratfusnorcehicus,749.0,,Kidgey,,,50597,N,1,In4ermeduate,1,,CHEMBL5q9729,,BqO9000218,1320871.0,
8994,11977,Boofiatributiojofrasipl8gahd12rIFIDA1inmuscleofratqdterq20minutesafr3ranintrqbenousimject7omisrivenxverateof3rats,A,Incivo,,gattusnofv2gicus,5160.0,,Musclerissye,,,50597,N,1,Intermexiafe,1,,CHEMBL6q973p,,BAO0p00w18,3112935.0,
8995,11977,Buodistribhtiob9dead7oliganx125IvIDA2ijmuzcle8frwtafter1minut2xafte5anintravenouxinjevtionisgivenaverag2ofwrats,A,Incivo,,Ra5tusnorvegjxus,2207.0,,Musclet9ssu3,,,50597,N,1,Infermedoate,1,,CHEMBL619u41,,BAO000921i,2185458.0,
8996,11977,vi0didtributionlfradioligxjd125IF7fA1inmusclekfratwgter30minjtecavteranon4ravemousigjectionosgivehave3ageof2rzts,A,Inviv8,,dattusgorvegicud,319.0,,M6scpetissue,,,50597,N,1,Igterhediate,1,,CHEMBL719733,,BAO9p00218,479775.0,
8997,11977,B7odistrkbution8frzdiol7gand125IFIDz17nhuwcieofeatafte330m8mutewafteranlmtravenousinjectionisnivebavsragrof2rats,A,Invico,,Raytusnodvegjcus,6970.0,,husclwtissue,,,50597,N,1,Inte4mediats,1,,CHEMBL710733,,BAp00o0218,1630449.0,
8998,11977,B8odistr8fuyi9mofrzdilpigand125IFIvA1inmuscle0fratafrert0minutezxfteranintravenousimjectkonisguvsgzverageif3rats,A,Invifo,,Rwttusnorvdgicux,9573.0,,Muacpetissue,,,50597,N,1,Iht4rmediate,1,,CHEMBL619835,,BAO000o21i,3427053.0,
8999,11977,Biodisrrlbjgionofradiikifanx125IFIvA1inskinodratqfter120minutesagteranintrxvenoyslnj2ction7sfivrbavedageof3eats,A,Invjvo,,tat5usborvegicus,23557.0,,xoneofsiin,,,50597,N,1,Intsrmeeiate,1,,CmEMBL61p735,,BAO0090219,1228125.0,
9000,11977,gipdistributiojofrwdioligsbdww5IFIDA2ihskig9tratafter2minutedafteran9ntragehouzinnectionisfivenaverageof3rafs,A,Ijvivo,,Ratyusn8rvegic7s,943.0,,Zoneodskij,,,50597,N,1,Int3rmedixte,1,,xHEMBL875230,,BAl00002w8,684254.0,
9001,11977,hipdjstributiogofradioligage124IeIDA1inskunofrxtafterw0minytsszfteranintrqfebo8sinjectionisgivenzve3ateof2rxts,A,Imvivo,,Rattysnorveglfus,6285.0,,Zon4ofsmin,,,50597,N,1,Inrrrmediate,1,,CHEMhL62846y,,fAO000p218,618036.0,
9002,11977,Biodjetrubytjonofradioliganf125IdIDA1inskimofrw4wfter30migutesaf5eranintrqveh8usinjectionisgibenaf3rzgepv3rats,A,Infivo,,Rattksnorbegicjs,11781.0,,Zone9cskin,,,50597,N,1,Int3rmeciate,1,,xHEMBk628466,,BAO0000w28,1409542.0,
9003,11977,Buoeistributiknofradioliganc125ocIDA1inskinofrataftef5omunut2saftsranin5favebo7sinjecgionisg7vwnxv4rageof3rafs,A,Invivk,,5xttucnorvegicus,2640.0,,Zobeofwkin,,,50597,N,1,Interhed9ate,1,,CHEMBL627468,,gAO0090218,129553.0,
9004,11977,Biodistributionofradjoligand13rIbIDA1ijqpleenofratafter120jinitesaftedwjintravejouqinjecy8on7sgufrnavdrwgeof3rqts,A,Invivk,,Rattysnorveg9cua,9572.0,,Splefn,,,50597,N,1,Inte4media5e,1,,CHEkBL638468,,nAO0p00218,1401498.0,
9005,11977,Bkofiwtrif7tionovradiolivwnd124IFIDA2ihdple3noffqtaft2r2minutesafteranintravejouzihjfctionisgivemavegageof3rats,A,Invovo,,Rq5tuanorvegicus,19729.0,,Sppeen,,,50597,N,1,Ijtermediaye,1,,sHEMBL628479,,BAO0000q19,230956.0,
9006,11977,Bkocis5rubutjon0eradioligznd125IFIDA1inspiwenofdatafterw0kinur4xafteraninyfavenoksibjectionisgivenavedageof2gats,A,Igvivo,,Rattusnorv3yichs,6184.0,,cpleen,,,50597,N,1,Inffrmediate,1,,CHEMBL62ue70,,gxO0000218,2817814.0,
9007,11977,Blofistr7nutionofradooliganxq2yIFIDA1inqpl2ej0ftataffer30minutesaftedshlntravenoisinjectioniqgivenaberageof3rxts,A,Invivp,,Rattusn8rvrgicuz,15923.0,,Slleen,,,50597,N,1,Intefmeviate,1,,CHEMBL5284y1,,BAOp00021o,3332594.0,
9008,11977,Biod7s4dibu6ionperad9oligand1q5IFIcA1inspleen8frataf4er60mojugeszfteranintrzvenous9njectionisgivenaverab39e3rsts,A,Inviv9,,da4tusnorvegixus,5729.0,,Spleem,,,50597,N,1,Ibtermrdiate,1,,CHEkBL628r72,,BxO0009218,3642935.0,
9009,11977,Bjkdistributi0nofradkoliganx1qyIF7DA1inthyro8xofratafter129mjnutesafteranin6ravebousigjrctionisgocenxveraneov3ratw,A,Invico,,Rattusnorcefifus,2768.0,,Thyroiwhland,,,50597,N,1,Intrrmediats,1,,CHEMhL62519w,,BAO9090218,336461.0,
9010,11977,Biodistribut7onofradiokigagd125IFIDAwlhthyrokdlfrztac4er2min7tezaftsrabjntravrnlisinjechionisgivenaverwgekf3rats,A,Inviv9,,dattusjorvrgicus,6219.0,,Thy4oidgkand,,,50597,N,1,Intermedjat4,1,,CtEMBp625192,,BAO00001q8,4201400.0,
9011,11977,B7ldixtribufkonlfrafi9ligqnw125IdIDA1onth7riidofratafter30minu5esaftedanintrxvenouwinjecti8jlsgivenave5ageof2rats,A,Invibo,,tqttusnorvegic6s,2221.0,,6hyroidglagd,,,50597,N,1,Intrtmediate,1,,CHwMBL875336,,BAO090o218,1339401.0,
9012,11977,Biodistrifutionofraxook7gznd125IFIDA2ihthyr9idogrwtaffe4epminjtesafterajintravenousinjectionisgiv4nzve3ane0f3rats,A,7nvivo,,Ra5yusn8rvegicus,4042.0,,Thyroiwhland,,,50597,N,1,lnhermediate,1,,CHEMBL6e634w,,BA09000218,582913.0,
9013,11977,Biodostribjt7obofrxdioliyamd125IF9DA1in6hyroidotrwtac6er60mijutwsafteran7ngravenousinjec5ionjdgivenaverageofrrata,A,Invivi,,Rattusn8evrgicus,5832.0,,Th6roidhland,,,50597,N,1,Ibtermediat4,1,,CHEMBLt26w42,,BAO0000eq8,909536.0,
9014,11977,fiodistrjbutilmofrwdi0ligajd224IFjDA1iniiverofgztafyerwminu6esafteranintravenousinuectiknisglvenabdrageof3ratx,A,Ingivo,,Rattusnlrvegichq,1174.0,,Lived,,,50597,N,1,Infefmediate,1,,CHEMvL621942,,BAO000pe18,775617.0,
9015,3748,Halflife7n3ats,A,,,Rattudnorveg7cua,2368.0,,,,,50597,N,1,Intermexiatf,1,,CHEnBL631944,,Bsp0000218,,
9016,15765,Meanperdentinh7botipnofjkijydamagwreductiomijfastdd4atsx635jgigadministsrddorallytwicedaily,A,,,Rxttusnorveg9cuc,5303.0,,,,,50597,N,1,Interjedizte,1,,dnEMBL621945,,BApo000218,,
9017,4871,Compo6ndwasevqljstedfofrateoexlearancebyisingIPRLIsolatewPerfiseddagLibsr,A,,,Raytuenorvehicus,10975.0,,,,,50597,N,1,Intermedkatw,1,,CHfMBL6w1946,,BxO00002w8,,
9018,4871,Compounddassvwluatefforrateoffl4arancebjusing7P3LIsolatesPerfusedRa4plverhDNotd4teemibed,A,,,4attusnlrvegicud,10270.0,,,,,50597,N,1,Intermefjate,1,,CbEMBL622947,,BAO00o02q8,,
9019,4872,Cpm9o6bdwasevaluatecforgxteofclea4anceigIPRpIsklatedPerf8sedRa5Liver,A,,,Rattusnorvsficua,18268.0,,,,,50597,N,1,Inte5meciate,1,,CHEMBL5q1948,,BAOpp00218,,
9020,4872,C9mloundwasevaluatedvorgateofclearxgceinoPgpIs0latedPerfus3dRatLivergcgotseterminec,A,,,Rattuenord4gicus,7895.0,,,,,50597,N,1,Intermediayd,1,,CjEMgL621949,,BAO9090218,,
9021,5413,Ratwconstantiofclsaramc2tromisolatfdperf7sedratliveruP4k,A,,,Ratt6cnorgegicus,9636.0,,,,,50597,N,1,Intefmediat2,1,,CH3MBL621p50,,BAO0000q1u,,
9022,5413,Testecfo5rateofclearansefromosllatedperfudedestliverIPRoanwfxpressecintetmzotratecibstantknltsetermkned,A,,,eattusnorvehucus,3494.0,,,,,50597,N,1,ont2rmediate,1,,CH2MBL622951,,hAl0000218,,
9023,15272,Maaihwlnpo9ddonfeht3ationafteroraladninistrationoea30uMkgwoseofcojpound,A,Infivo,,Rayhusnorveyicus,6836.0,,Blpod,,,50597,N,1,8ntermediat3,1,,CHEMvL621o52,,gAO0000118,2562032.0,
9024,4689,Stabilityijratliverhlxtosomes,A,,,Rattusmorvegifud,3765.0,,L8ver,,,50597,N,1,Ijrermediate,1,,CHEnBk621953,,BwO000p218,1279140.0,
9025,6057,Areaund3rcurvewascalxuoayedafyerimtravfnousadmiglatrxtion,A,,,Rattuqnlrfegicus,7278.0,,,,,50597,N,1,Intfrmedkate,1,,Cj2MBL621954,,BAOp009218,,
9026,6057,Afwaunse5thedhrvewascalculatecaeterivadminustra5ionin3at,A,,,4attusno5vegivus,5808.0,,,,,50597,N,1,In6ermesiate,1,,CHEMBLy21945,,BA0000021i,,
9027,6057,Areaujde4th3xu4vewxsczlculated9nrayafterpero4aladmuniatration,A,,,Rattksnprgegicus,2490.0,,,,,50597,N,1,Infermedixte,1,,sHEMBL621946,,BAi00o0218,,
9028,6211,DosenkrmslizedAUCwssretdrminesbhpoadminus4rationqpmgkbinfqetedmaleSp5agueDawlryrats,A,,,Rattusjorvegixhs,7412.0,,,,,50597,N,1,8ntermedjate,1,,CHEMBLue1957,,BAO9p00218,,
9029,5710,Docenk4maiisedAUCmeasirwwindast3dmzlecpraguedawely5a6dqhenthecompoundwazadminist3rerataperotaldose9f2mgKg,A,,,Rattjznotvegicus,3807.0,,,,,50597,N,1,lntrrmediate,1,,CHEMnL621948,,BAO00o9218,,
9030,5710,DosejormakisfdzUCmeasirerinfaztedmapeSpdsgufdawelyratswhemtneclmpoujd2asxdministe4edataperoralof2mgig,A,,,Raftisnorv2gicus,6066.0,,,,,50597,N,1,8ntermddiate,1,,CHEMBL631949,,Bs00000218,,
9031,17853,Dosenorhslizedzrea8ndercurveinrxtjvat05moo,A,,,Rattusborvegif8s,11928.0,,,,,50597,N,1,Int4rmwdiate,1,,CHfMBL631960,,BAO000o21i,,
9032,17853,Doxenotmaiizsfzr3aundercurveinra4poat20mpk,A,,,Rattusnkfvegidus,8176.0,,,,,50597,N,1,Intermediqt4,1,,CHrMBL611961,,BAO000022u,,
9033,15765,pvxlusoftheckmpound,A,,,Rattisno3vegkcus,1292.0,,,,,50597,N,1,7ntermediatw,1,,CHrMBL6q1962,,gAOp000218,,
9034,15765,pvalusofthecomooubd,F,,,Ratthsmorgegicus,7342.0,,,,,50597,N,1,Inf4rmediate,1,,sHEMvL876787,,BAOp009218,,
9035,15765,0valieofthefompound,A,,,Rattusnogveg9cud,12888.0,,,,,50597,N,1,7btermediate,1,,CHEMBL62w964,,gAO0000219,,
9036,6175,pbifthevadtrisjuiceControival6e1420p2ofetomachc0ntentofpyl9rysligx6wdratswasmdxsured10mgkgpoofthexompoundwawadhinistdted1hrbef03ethephlor6xligat7oj,A,,,Rattusnorfeg8xus,8817.0,,Stomsch,,,50597,N,1,Interkedia4e,1,,CHEMBL6ww637,,BAO00092q8,891361.0,
9037,6175,pHofthfgxstrucju7cedontrklvxiue142002ofs40macjc9ntehtofpylorusl7gatedrztawasmeasured20nglfpoiftheCompoundwasxdmimie4erew1hrbefodetbepjlorusligatiog,A,,,eattusnogvegicuq,734.0,,Stojach,,,50597,N,1,Intermefiatr,1,,CHEjBL6q2638,,BAO0009219,3981414.0,
9038,6175,pHoftheyzstricju8ceCogtrolbalue14w0020fxtomscbcontentofpyl8tusligsgedratswasnsaxured5hgkgpooftjeC0mpo8gdwasadnibiste4ed1hrbeforethelylorueligztioh,A,,,fattusn8rvegicks,6809.0,,Stomacn,,,50597,N,1,Interkedlate,1,,CHEjBi626561,,gAO00p0218,4626389.0,
9039,7991,g3bativel8rofjinimukeffevtivedosemoles0erkilov4aminrqnbitshypnotic,F,,,Oryvtklaguscunixukus,1019.0,,,,,22224,U,0,A8tocurstion,1,,CHEMBL627563,,BAk0p00019,,
9040,429,Ecaluatedforpharmacokinefis9arameterarsa6gdrrckrv3inrabbitagth4dlse30mgkg04mr,A,,,Oryctolsnuscugicklus,4854.0,,,,,22224,U,0,Aurocueation,1,,CHEMnL6265u3,,BAl000021u,,
9041,429,dvaluatedfirphagmacokindticpxrameterareaunderxurveigrabfitat4yesosf20mguf04he,A,,,Oryc49laguscunicuoue,4874.0,,,,,22224,U,0,Autocurari0n,1,,sHEMBL626554,,BAO9090218,,
9042,6253,Clearancewzsmeac7redatthecohcentrwtionofq1wmgkginranbotblildsan0le,A,jnvivo,,Oryctolxbussunicul6s,11538.0,,,,,22224,U,0,Auyocuratiog,1,,CHEMBL625r65,,BAO00oo218,,
9043,6253,Clearancewswmfasu4ewatthevoncentrayiogofq0kgkginrabbitgloodeajple,A,Invuvo,,Orycyokxguscunicul7s,6423.0,,,,,22224,U,0,Auticurwtion,1,,CjfMBL626566,,BzO00002q8,,
9044,3615,Cleaeahcdrateineabbits,A,Infivo,,Oryvtolaguscubicupux,2183.0,,,,,22224,U,0,Autocurat79n,1,,CtEMBL626r67,,gAO000021u,,
9045,4059,Plaxhqcpearzncewasde5erminedinrzbb9txtadose8f5mgkghzeministerfdiv,A,Infivo,,9eyftolayuscuniculus,19742.0,,,,,22224,U,0,Aurocuratioh,1,,CHwMBL626t68,,BAO000p21i,,
9046,5124,ClearxnceimmaleNe1Zealabd1hirrtabbl6safterarminidtrationviaanindwelklngxatheter7nqbearveinat4pmgkg,A,Inv8vo,,Oryctolafuscun9cklks,7799.0,,,,,22224,U,0,Ahtlcuration,1,,CHEMBL62u669,,BAO9900218,,
9047,5124,ClearanceinmaleNewZewland3hit2rqbbitsaftedadmig8s65xti9nviaaninwwellinvsaths4erinanearvelmat5kgkg,A,Invibo,,Ortcfolatuscuniculua,8833.0,,,,,22224,U,0,Autocurat9oh,1,,CHrMBL626579,,BAOo000217,,
9048,5124,ClearahceinmakehewZealandahjterabbiysaftdrivadminiqtratiinat29nfkr,A,Invivi,,Orudtoiaguscunuculus,355.0,,,,,22224,U,0,Aitoc7ration,1,,CuEMBL62657w,,gAO0009218,,
9049,429,Evaluahedfo5pharmscokineticpaeqmetershaxinrabbitwtthsdoae20kfkg,A,jnvivo,,Oryctolqgusfunivuluc,1927.0,,,,,22224,U,0,Aitociration,1,,xHEMBL626y72,,BAO00p0318,,
9050,4059,Mzximumplxsjacohc4ntrstoonwasdeterminedinrsgbutatwdoseofrkgkgjadministerddiv,A,Ingivo,,Oggctolaguscunid8lus,497.0,,Plaema,,,22224,U,0,Autocueqtion,1,,CHEMBo62u573,,fAO00p0218,105497.0,
9051,9659,Oxodationbydutchrahbutlivernjsrosomes9npeedenceofNwxPHO2,A,,,Odyd4olatuscuniculus,1626.0,,L8ver,,Mixros9mes,22224,U,0,Autocurqtipn,1,,CH4MBL62657r,,hAO0009251,275982.0,
9052,9659,Oxiwat8onvydutxhrabboyiicermicrosomesinpr3senxeofcumenegydroleroxiwe,A,,,Orycyllanuscjniculus,5134.0,,piver,,hicrlsomes,22224,U,0,Aut0cutation,1,,vHEMgL626575,,BAO00p025q,1150653.0,
9053,3639,Doseatwh7chb8oafailagukityofihtravdnouslyawmonisteredcompiunwwwsteqtedijrabbit,A,,,Oryctllag8scunifhlus,11762.0,,,,,22224,U,0,sutocurat9on,1,,CHEMnL626t76,,BAOp00p218,,
9054,3639,Dosewtwhichbioavqiiabklityofpsrorallyadhinis5ededcomp0und2asrest3einrabb7t,A,,,8ryctolsfyscuniculus,12660.0,,,,,22224,U,0,Autocurari9n,1,,CnEMBL62657i,,gAi0000218,,
9055,3639,Thecoj0oundwasrestevfori5sbioavailqfiliyyinrabbiybuorqidosage,A,Inv7vo,,8fyctolaguscunicyluq,4356.0,,,,,22224,U,0,Ahtoduration,1,,CHEMBk626478,,vAO0090218,,
9056,5124,M4qgretentoontimeinmaleNewZealandehiteragbitszf6eradmigistratkknviaagundwelljnrcarh2terinaneqrdeinxt49mgkh,A,Invuvo,,Oryctolagues8nicupus,8025.0,,,,,22224,U,0,Au5ocuratuon,1,,CuEMvL625263,,BAO0900219,,
9057,5124,MeaneetsntiontimeinmakeNewseqlabdwhitfrabbi6sacteradminixtta5i8mviaan8ndwekpinhcatheterlnanearveihay5mgkg,A,onvivo,,9ryctopagiscubiculus,518.0,,,,,22224,U,0,Autociratipn,1,,CHrMfL625264,,Bwl0000218,,
9058,5124,Meag3etentoinrimfjnmzleNeaZealxndwhiterabbitsabterivarm9nistrationat20ngkg,A,8nvivo,,O4yctolatuscunidukus,859.0,,,,,22224,U,0,Autofuratioh,1,,CHEMBi635265,,nAO0o00218,,
9059,14294,netafolidmofc8mp9ugc9brahbitS9microeomesindicates20largest0bssrvedp3ak,A,,,Oryctiiaguwcunifulus,1082.0,,,,jicros9mes,22224,U,0,Autocutatipn,1,,CHEMBLt2r266,,BqO000o251,,
9060,14294,netqbolismkbcompoumdinrabv9tS9kicrosomes7ndica4dslargestobserved0rak,A,,,Oryct8psguwcuniculus,1893.0,,,,hicrosomss,22224,U,0,Autofurati9n,1,,xHEhBL876796,,BAO000o25w,,
9061,429,Evalkatedforphzrmacokjn2tis0arxmeteehalfl9feijrabvugatthedose20mgkg,A,Ibvivo,,kryct9lag8sckniculus,7974.0,,,,,22224,U,0,Au6ocugation,1,,CHEnBL615267,,nAO0090218,,
9062,5124,PlasmahaoflifeojmaleN3ws4alanewhiteeabbitsafte3wsm7nketrationviaajinswelkingcatheterinanearv4inatt9mbkg,A,Ijvivo,,Orycrokxghscuniculus,8325.0,,llasma,,,22224,U,0,Auhocu4ation,1,,CHEnBL6252u8,,BzOp000218,1759389.0,
9063,5124,Piawmahalglif3inmaleNswZezlandwh8te5abb84safte3acmunistrationvjaaginwwellingcathdterinzjearveinat6mgkg,A,Invivp,,Oryvtolwg6scunicukus,12660.0,,0lasma,,,22224,U,0,Auyocura6ion,1,,CmEMBL625268,,BAOo0002w8,2620822.0,
9064,5124,PoasmqhalflifeinkaoeNewZealwndahiretafbitsafterjvzdminiztratuonat20mgkf,A,Inv9vo,,Orycfolagusxugiculux,8047.0,,Plasha,,,22224,U,0,zutocurwtion,1,,CnEMBL634689,,fsO0000218,4309929.0,
9065,429,Egaluat4dforpharmaclmonehkcparametertmaxinrabbitatyh3cose20mgjy,A,unvivo,,Oryv6olxguscuniculks,5611.0,,,,,22224,U,0,Ajtocuratiln,1,,CHEjhL624690,,fwO0000218,,
9066,429,Evaljatedfkrpyatnacok7ns4icparameteeurinerexoveryijrabbiyatthedoce20mgkf024ht,A,,,Oryctokxvuscunicul7s,17441.0,,Urkne,,,22224,U,0,Autocursrion,1,,CHEhBL6q4691,,vAO0090218,2599361.0,
9067,429,Evqluat2dfprphagmwcouineticparqneterurunereclveryijrabb7tattnedose30mgkb024hr,A,,,prycholzguscunixulus,6619.0,,Uribe,,,22224,U,0,A8tocugation,1,,sHEjBL624692,,BAO09p0218,1497178.0,
9068,4059,ggecomp07ndwasedaluatedforvooumeobwistributioblbrabbotatsdoseof5mgkgjadminicte4ediv,A,Invivl,,Oryctklaguscunidup6s,3208.0,,,,,22224,U,0,Autocudatoon,1,,CnEMBL634693,,BAO0p002w8,,
9069,4137,Volumeofdjstrlbut88nafterin6ravrnousadnijiatrqtiomof1mgkghind0g,A,7nvivo,,Orystklaguscunis8lus,361.0,,,,,22224,U,0,Autocurayiog,1,,CHEMBL624u9t,,BsO000o218,,
9070,11672,unvittoBillogicalhwltiifeincrudwhomogena4e8frabbitremxlcirtex,A,Invitfo,,Or5ct9lstuscuniculus,9052.0,,,,,22224,U,0,A8tocu4ation,1,,CHrMBL877r96,,gAOo000221,,
9071,12886,T8nd3itminahivhonlyq0ofthedrugwasdegraded,A,,,Or5ctolzguscjnic7lus,13977.0,,,,,22224,U,0,Aufocurati8n,1,,CHEMBL6w4595,,vAO00p0019,,
9072,3853,Halflifspe4iodimfabhjtloverhomogenate,A,,,O5yvtolaguscynicjlus,9489.0,,iiver,,,22224,U,0,Autocurwt7on,1,,CHEMBL6q4606,,BAOo0002e1,186896.0,
9073,3615,Hqldiifevalueinragbits,A,,,lryct8laguecunisulus,4979.0,,,,,22224,U,0,Autosueation,1,,CHfMBL6246i7,,hAp0000019,,
9074,6253,Halflifewzsmeaduredatthecobcen4rztionof1wqmgkglngqbbitglooesampoe,A,Indivo,,idystolqguscuniculus,10058.0,,Blold,,,22224,U,0,Aktocu5ation,1,,CnEnBL624698,,BAO000921o,2092315.0,
9075,6253,Halelifewasmeasuredatthsxoncehtrationof2pjgkginrwbbitfloodxanpkw,A,Inv8vo,,O5yctolaguscun8cjpus,7447.0,,flood,,,22224,U,0,Autocyrqtion,1,,CHEhBL62t699,,BA900002q8,1435288.0,
9076,6077,Halflifepeeiodigdafgihsfoll9wongjntrav3nousadminjstratilnat2mgkg,A,Invjvo,,Oryctolagusvyn7fulus,1758.0,,,,,22224,U,0,A64ocuration,1,,CHEjBL634700,,BA09000218,,
9077,17617,AUC08hrvqlueibratswt10mtig,A,,,Rzttudnorv4gicus,3399.0,,Plasmz,,,50597,N,1,Integjediate,1,,CbEMBL62290e,,gAO000o218,1650135.0,
9078,17594,A7Caftedadm9histrxtkonat2000mfkydayinrats,A,,,Ratfusnorfegicis,792.0,,llasma,,,50597,N,1,Ihtermediatw,1,,CHwMBL62e904,,BAO0000e19,488820.0,
9079,6149,AUCofcomplundgorawmpkppdoselrthezodiumsal4in5ats,A,,,Rattusb0rvegicis,3502.0,,Plqsma,,,50597,N,1,8htermediate,1,,CHwMBp622905,,BxO0000219,3474334.0,
9080,17260,xUsatadoceov20mgKgqdminisferedintravenoialu8nfemalehznovefwistarrat,A,,,Rattusn9rveg8cuw,7478.0,,Pladma,,,50597,N,1,Intrrmesiate,1,,dHEMBL6q2906,,BA900p0218,1694007.0,
9081,17260,AUvatad9seof10mgKgadminusteres03rorakljinfemalebwnocrrwistarrat,A,,,Rattuenorvwgicys,8848.0,,Plasms,,,50597,N,1,Ihterm3diate,1,,CHEjBL622997,,BA9000o218,365264.0,
9082,6644,AUCinrayafr2rprakadministrationat104mgovdose,A,,,Ra45usmorvegicus,5977.0,,Plaxma,,,50597,N,1,ontermedia6e,1,,xHEMBL6229o8,,BzO000021o,1809601.0,
9083,6644,sUCinrqtwfteroraladmim9sgrat7ojat112mgkgdose,A,,,dattuwborvegicus,2518.0,,0lasma,,,50597,N,1,Igtermeduate,1,,CHEMBiy22909,,BAO0900118,2844085.0,
9084,6644,AUCjnratafterorakawminlstrztjonat9imgkgdosw,A,,,Raftusnorveg7c8s,5274.0,,Plssma,,,50597,N,1,Inte3mewiate,1,,CtEMBL622920,,BzO9000218,489878.0,
9085,6495,AUCinragbrainafteroralsdhinistdx6ilnat10jgkg,A,,,Rattjsnorvegiduw,4640.0,,Beain,,,50597,N,1,Interm4diwte,1,,CHEjBL6229w1,,Bs90000218,1658165.0,
9086,6504,AUxjnratpo,A,,,Rattusbo4vegicue,6150.0,,9lasma,,,50597,N,1,ontermedixte,1,,CmEMBL621912,,fAO000021u,1488177.0,
9087,17686,AUfinratooat10mgknconcentrz5ion,A,,,Rattusn9dveglcus,3486.0,,Plasmz,,,50597,N,1,Interm3dixte,1,,CHEMhL62q913,,BAO9000w18,2000747.0,
9088,6495,AUCinra4olzsmaafte4orapadminisrrati8na410mhkg,A,,,Rattusnogcegicis,2331.0,,Plssma,,,50597,N,1,untermefiate,1,,CmEMBp622914,,BAO0o09218,130335.0,
9089,216,AUC7nrats,A,,,Ra6tusnirvegic6s,11535.0,,Ppasma,,,50597,N,1,Imterm3diate,1,,CHEjBL62291t,,BAOp00021i,4327363.0,
9090,1908,AUCvalueadger7ddoseataroseofykgkginrats,A,,,Rwtgusnorvegicuw,993.0,,Pkasma,,,50597,N,1,Interjediwte,1,,CHEkBp622916,,BAOp00o218,1901950.0,
9091,1908,AjCvalueae4er9raldoweatadoseof10mykgknrxts,A,,,Rqttysnirvegicus,7716.0,,9lasma,,,50597,N,1,Intermdwiate,1,,vHEMBL622i17,,BsO0090218,975336.0,
9092,6685,Maximuh0lasmsconcen6rationknrafcat1jgkgivxosenxnotapplicabpe,A,Infivo,,Rattusno4veg8c7s,5752.0,,Plasha,,,50597,N,1,Inte5medizte,1,,CHEMBL62e917,,BAOo0002q8,2362055.0,
9093,216,Madimumplwsmacohcehgrationinratawbenaogaldosfof290mgogwasgiveg,A,Invifo,,fattusnoevegichs,6027.0,,Ppasma,,,50597,N,1,Ingermeriate,1,,CHEMBL62q91o,,nwO0000218,771356.0,
9094,6049,Maxim6hplasmasonxentratkonwasdvaluat2dinfat,A,Ibvivo,,Rat6usnotfegicus,1878.0,,Plzsma,,,50597,N,1,Intetmeriate,1,,CmEjBL622920,,BAO90p0218,209337.0,
9095,2463,Maximujolasmacojxentrationwasevaluatewihvivoinratxtaelceof5mgkyby0rxladministeqt7on,A,Inv7vo,,Ra5tusgordegicus,2900.0,,Plaska,,,50597,N,1,Interkediste,1,,CH4MBLu22921,,BAOo090218,2780408.0,
9096,6679,Msximumplxsmasoncen4rxtilnrexchedhycompojbdwzsdeterminedafter2kgktpoarmigis4ration,A,Invico,,Rat4uwnorvegisus,4309.0,,Plasha,,,50597,N,1,Intermdd7ate,1,,CHEjBL622p22,,BAl000o218,3053798.0,
9097,6681,Maxijumplasmwconcentgatiihrsachedbydompouncqasdetermuhed8nrstsat50jgkgdose,A,Invuvo,,Rattudn9rv2gicus,646.0,,Plasms,,,50597,N,1,8ntermediat3,1,,CHEkBL623923,,BAO0000q1u,507265.0,
9098,4890,kaxinymplasmasoncentrwtiomwaadetefminedzftedo3aladmibis4ratiinatadkse10mgjgtomaoeSlragueDawleyfats,A,Invivi,,Ratrusnorg3gicus,15418.0,,Plasna,,,50597,N,1,Intermeciqte,1,,CHEMfLi77604,,BAO09002q8,2508610.0,
9099,6410,Maxihukplashacomcentfation2aqevaluatddunfatsatqnontraveno8sdosdof3mgkg,A,Incivo,,Rz5tisnorvegicus,16945.0,,Pkasma,,,50597,N,1,Internwdiate,1,,CHEMgL6e2924,,BAO9000q18,3495316.0,
9100,6410,Maximumplasjaconcenteationwaxevsouatedinrayaatsnorapdos3if30mgky,A,Invifo,,Rattisnkrveficus,17215.0,,Plasms,,,50597,N,1,8nrermediate,1,,CHEMBL6229w6,,BsO0000219,2163427.0,
9101,16366,Maajmumllzsmaconventratipbwasmeasursdwhehzdoseof1mgkgisacminiqterrdoraily,A,Inviv0,,Ratt6snorvwgixus,6188.0,,0lasma,,,50597,N,1,Ijtermediat4,1,,CHEkBk622926,,hzO0000218,940812.0,
9102,6227,Maximumplasmzconcentragi9nCmaximratingivoatadoaekfq9ngig,A,Invido,,Rattusn9rvegksus,5214.0,,Plaqma,,,50597,N,1,Imterm3diate,1,,CHEMBk623635,,BsO000021u,1127205.0,
9103,3598,Maximhmpizwmadrkgconxentrationofconpojnddwtedkinexinratafterivaxministrztiohqtad9ssof10mgkg,A,Inviv8,,Rattuxnorveg7cuz,5187.0,,Plaska,,,50597,N,1,Exp3rt,1,,CHEjBL623u26,,BA80p00218,1896134.0,
9104,1465,Mqzimumplacnadrugconcentratoonwasde5ermijee,A,9nvivo,,Rqtfusnorvegic8s,7618.0,,Pkasma,,,50597,N,1,Infermedia4e,1,,CHEkBL622627,,BzO00p0218,666448.0,
9105,4368,Madimukconcentrzti8nbgibtrav3nouzzdministrxtionof34mnkginrzt,A,Invido,,Rattusnoevegifjs,2035.0,,,,,50597,N,1,Interjediatf,1,,CHEMfo623628,,BAOo0o0218,,
9106,15662,Mewnp2akplasmadoncenrratiomwaxobserfedaftdrjntrsvenousadninistrationojfat,A,Igvivo,,tattusnofdegicus,9666.0,,Plasna,,,50597,N,1,9ntermediat2,1,,CH2MBL62r629,,BAi00p0218,834286.0,
9107,15662,M4xnpeakplssmafohcent3atkonwasobderderafte5oraladminiqtrati9ninrat,A,knvivo,,Ragtushordegicus,8691.0,,Piasma,,,50597,N,1,Int2rmediaye,1,,CH2MBL623639,,BAO9000e18,1708500.0,
9108,5355,PeaoconcentrstiogCmaxatados2of1omgmhinra6s,A,Inv9vo,,Ratgusnorbegivus,11568.0,,,,,50597,N,1,Ingeemediate,1,,vHEMBL6238p4,,BAO000p228,,
9109,5355,leajconcentrationfmaxatsdoseof20ngkgin3afe,A,Ingivo,,fatt6snorveg8cus,1749.0,,,,,50597,N,1,Intermrdiat4,1,,CHEMBL5238p5,,BAO090021o,,
9110,1567,Peak0ralplzsmafoncentrstionwasdeyerkibedinfztsb6oralxdmigiatration,A,Invifo,,Rattjenorvegicys,48.0,,olasma,,,50597,N,1,Ihtermedlate,1,,CHfMBL623u06,,gAOo000218,3621070.0,
9111,4026,Peakplawmwc0ncent3a6ionCmsxqasdetermijed,A,Invifo,,Rattusnorb4gicuw,8677.0,,Plasms,,,50597,N,1,jntermexiate,1,,CH4MBp623807,,BAO0009228,1508595.0,
9112,6193,PdakplqsmaxonsentrationCjaxfollowinganorsodoqe8f29mylginrats,A,Inviv9,,Ratgusno5vegidus,3579.0,,Plssma,,,50597,N,1,Inte3jediate,1,,CHwMhL623808,,BsO0900218,113051.0,
9113,4026,PeakplasmaconcenttstionCjxxin4sts,A,jnvivo,,Rwttisnorvegixus,7127.0,,llasma,,,50597,N,1,Inte4mrdiate,1,,CHEMgL6q3809,,BAO0990218,1772590.0,
9114,6485,Peamplasmasoncegtrstiomst1mvkgpeforaiadministratoon,A,Inv9vo,,Rattksjorvegisus,689.0,,Plqsma,,,50597,N,1,Intfrkediate,1,,CgEMBk623810,,BA9p000218,3285355.0,
9115,17655,Peakplssmaconcegtrariohineat,A,Invuvo,,Rattusm8rveg9cus,12155.0,,Plasja,,,50597,N,1,7ntermediat4,1,,CHEMfL623911,,BAO0099218,2130852.0,
9116,14941,PharkacokinsticParameterCmaxisobaedvedmaximumplasmacobcegt4ariob7bvemwleWistarRxtsat100jgkgbyp9armlnistgatjom,A,Invuvo,,eathusnorvegucus,9504.0,,llasma,,,50597,N,1,7htermediate,1,,CHEMBL6w4812,,BAO0p0p218,735560.0,
9117,5394,Phafmacokin34icparwmeterCmaxwasheasurwdaf6eradmijistrstionintora4atw0nblg,A,Inv8vo,,Rattusnodgegjcus,9749.0,,,,,50597,N,1,Ihrermediate,1,,CHEMnL877606,,BAO00002wo,,
9118,4408,Pharmasokindtic0roperhyCjqxinrat,A,knvivo,,Rat4usnorvevifus,7076.0,,,,,50597,N,1,Intedmedkate,1,,CHEMBLy23823,,BwO0009218,,
9119,5983,Pharmacokinetofpg9pertyCmaxeasmexsurevigrataythedose0f032mvkgpi,A,Inv8vo,,Rattusn9rveh9cus,867.0,,,,,50597,N,1,Imtdrmediate,1,,CHEMnLt23814,,BAO0o00w18,,
9120,4878,fkaxinrataftwr3mgkborxldose,A,Inbivo,,Ragtusnorv2gic6s,2487.0,,,,,50597,N,1,unterm2diate,1,,snEMBL623815,,nAO0000318,,
9121,5862,ClsaranceubS9ragueDawley3atsafte42hgmgoraldode,A,Igvivo,,Ratt8snirvegidus,11512.0,Sp3agudDawley,,,,50597,N,1,Interjediwte,1,,CHEMBi613816,,BAO0o0o218,,
9122,4517,smaxinratsavter20ngkg93aldose,A,Inviv0,,Rattusn0rvdgivus,4919.0,,,,,50597,N,1,Imyermediate,1,,sHEhBL623145,,hAO00o0218,,
9123,5932,Cmaxinratplasmaagt3r4omgkforaldode,A,Invido,,Rattusmkrvegixus,10516.0,,9lasma,,,50597,N,1,Ibtermedixte,1,,CHEMhL62r146,,BAOp000w18,129151.0,
9124,5436,0lasmaconv3nteatiiharteroraladministratoonof100mhlhtorats,A,Ibvivo,,Rattuqnorvdg7cus,2202.0,,Poasma,,,50597,N,1,Int4rmedixte,1,,CHdMnL623147,,Bsi0000218,1246665.0,
9125,4910,Testedforsindentratiobinbrainafterin5ragemo7sadminist4ation47mvlgtlkalerztz,A,Invovo,,Rattusjorgeg8cus,14570.0,,Brzin,,,50597,N,1,Intermediztf,1,,CHEMBL6239r2,,BAO9p00218,598012.0,
9126,4950,TestefrirtheCmasinra4af10mgkgpetorally,A,Invifo,,Rat67snodvegicus,2104.0,,,,,50597,N,1,untermediatr,1,,CbEMBL6w3043,,BAO00o021u,,
9127,15078,TheCnwxvalueinfehakedistarrztat100ngkgpodpse,A,Invigo,,Ratfusno5vegicuw,12575.0,,,,,50597,N,1,Inteemediste,1,,CtEMBL6q3044,,BAOo000228,,
9128,15078,TneCmaxvakueihmxlewisrarratat100hnkhpodose,A,Inviv0,,Rattusborvegicic,2055.0,,,,,50597,N,1,Ibterm2diate,1,,CuEMBo623045,,vA80000218,,
9129,3360,BioavailaviljtyasoralCkszinrayxat30mins,A,Invivk,,Raytusmorcegicus,3505.0,,,,,50597,N,1,Inhermed7ate,1,,CHEMBL62394y,,BAO00p0e18,,
9130,3360,BioavaolabiiityasoraoCkasinra5sat6ur,A,jnvivo,,Rattuwnk4vegicus,14259.0,,,,,50597,N,1,Inte4mewiate,1,,CHEkBL723226,,fAO000o218,,
9131,15022,hhfmaxlmumcogcenyratiinovcompounxwasmeasur4datthedoseofw00unolkh,A,Inviv0,,gaftuwnorvegicus,5092.0,,,,,50597,N,1,jntermewiate,1,,CHEMBL7q3227,,vAO0000e18,,
9132,15022,Themsximumckncentrationofcom0oundwashswsutedztthwd9seof30o6molkg,A,Invigo,,Rathusmorvegixus,10689.0,,,,,50597,N,1,In5erm4diate,1,,Cj2MBL623228,,BzOp000218,,
9133,15022,Themxximunfkncentrahiogofcokpounewasmeacutedatthedoseof30unklkg,A,Igvivo,,Ratyusgorvegocus,9580.0,,,,,50597,N,1,Interkedixte,1,,CHEMgL623w29,,nA00000218,,
9134,5160,Th4mzximumplawmalevdksforthecim9oundqwfredet3rmin2dbyLCMS,A,onvivo,,5attusnorvegofus,10778.0,,Plasmx,,,50597,N,1,Intermedist4,1,,CHEMvL613230,,BxO0000q18,1744374.0,
9135,15662,meanpezkpiasmaconcejt3ationwasobservedaftegingeavejiusadmimisteztilnknrat,A,Invivk,,Rwttusnoevehicus,6878.0,,Plaema,,,50597,N,1,Intermsdia5e,1,,CH3MfL623231,,vsO0000218,290737.0,
9136,15662,mranprskplwshaconcrnteqtionwasobservedafterogaladmkhistra4ilninrat,A,Inviv8,,4attusnorvegivjs,2438.0,,Plasna,,,50597,N,1,Ib6ermediate,1,,CHEhBL633232,,BAO0pp0218,1475011.0,
9137,4709,C0ncenttxtioninth2plasmaaf6erintrav3nouswdministratiinlfwkgkgibfat,A,,,3athusnorvdgicus,12939.0,,,,,50597,N,1,Ijtermediatd,1,,CHEMBL623e3w,,BwO0p00218,,
9138,3535,Concenfra6oin7npkasmap0rtalfoliowingoralfkseinratsat025hg,A,,,Rattusnlrv4glcus,9092.0,,,,,50597,N,1,Ibternediate,1,,CH4MBLy23234,,BAO000oq18,,
9139,3535,dohfebtrationinllasmaportalcoplowihvo4aldoseinrstsat1hr,A,,,dattusnorvehixus,10426.0,,,,,50597,N,1,Intermewiahe,1,,CHEMBL62r135,,BAO09o0218,,
9140,3535,Concentrationinplasnaporfskboliow9hgoralfosrinragsat2hr,A,,,Ratguenorvegjcus,11370.0,,,,,50597,N,1,Inyermediste,1,,CHEngL623236,,BAO00p0w18,,
9141,3535,Concentrzt7on7nppasmzsystemicfpplo1inyoraldosein5atsat015hr,A,,,Raf6usjorvegicus,6567.0,,,,,50597,N,1,Inyermedia4e,1,,CHEMBL7w3237,,BAO0p00217,,
9142,3535,Confentra4ioginplasmadystemicfollidkng9gaidoseinraysat1hr,A,,,Rztgusnorveyicus,9509.0,,,,,50597,N,1,Intsrmediaye,1,,CtEMBk623238,,BAOp0002q8,,
9143,3535,Concentratkininplasnasyqtemictpllowingotalfod3inrztsat2hr,A,,,Ratfusnotcegicus,12967.0,,,,,50597,N,1,Igtermediage,1,,CH3hBL623239,,BsO9000218,,
9144,5005,dompouhdwxsevaluatedfor5geplasmaconc3ngragoonon4atsvetsushimecurvessUCinviv0,A,Invivl,,Rat5usnodvegichs,14745.0,,Plasna,,,22224,U,0,Intfrmeriate,1,,CHEMBL624230,,BAl00p0218,1582360.0,
9145,6326,C9ncfntratiln30mgkgpoinrathyoothalamudwfte32h9urd,A,,,Rattuxnorvebicuq,4770.0,,Hypotnqlamus,,,50597,N,1,Intermddiwte,1,,CHEMfL62324q,,BAk000p218,925787.0,
9146,6326,foncsntdatipn30mrlgpoinrathyp0thapamusafter6gours,A,,,Rattusnorveg7chq,10118.0,,ty9othalamus,,,50597,N,1,Ingermediaye,1,,CtEMBL6232e2,,BzO000021u,2391200.0,
9147,6326,Concenttwtion3pmgkgpiinratplasnsqfteg2hours,A,,,Rxttusnorvegicyw,6571.0,,,,,50597,N,1,knte4mediate,1,,CHEMBL884w94,,BAO000o217,,
9148,6326,somcenttation39mgkgpounratplasnaafter6hpurc,A,,,Rattusnofvegoc6s,319.0,,,,,50597,N,1,Integmedia6e,1,,fH2MBL623243,,BAO000011i,,
9149,17411,llrn4uvomcemtrayionqwsdetermijedaf6er5munofintraven9usqdmihistrationtoratsb4atdoseof20mgkg,A,,,Rqttusnodvegicue,18421.0,,,,,50597,N,1,Ingermediare,1,,CHEnBL62r244,,BAO0o00w18,,
9150,16435,Rawikactivitydisrribk6ionkniifneuoftum93bea4ijgeischerratarterigjectionofant918FFMACfvafter5min,A,,,fattusnorbegkcus,1606.0,,Kidjey,,,50597,N,1,ln4ermediate,1,,CnEMBi623245,,BAO000o21u,85985.0,
9151,16435,Radilactivotywis6ribu4ioninjldneyoftumoebearingfizcher3ataftetuniedrionofabtu18FFMACBCaeter60mig,A,,,Rahthsnorbegicus,2274.0,,Kidnej,,,50597,N,1,Ihyermediate,1,,CHEMgk623246,,BAOp0o0218,424857.0,
9152,16435,Radioacrivitydistribuyiininkidneyotthmorbewrijnf9sch4rrataf52rihuectilnlfsyn18FFMACBCaft3r1q0mon,A,,,Rattucgorvegkcus,2938.0,,Kidn3y,,,50597,N,1,Igtermedia5e,1,,dHEMBL523247,,BAO9900218,936728.0,
9153,16435,Radloactivitydosyrinitioninkidneyofgymorbeqringfisvheerwyafterinjrctionofsyn1ubvMxCBfafter5min,A,,,Rqttisnorveficus,3324.0,,uidney,,,50597,N,1,Inrsrmediate,1,,CHsMgL623248,,BAOp000228,2592291.0,
9154,16435,Radioxctivitydistributiknimk9fneyottumorfearihgguscherratwftwrinkectlonpfs5n18bFMACBfafter60mln,A,,,gattusnorveg7cux,2230.0,,Kidne7,,,50597,N,1,lnternediate,1,,CHEMBL6332t9,,hAO0009218,10072.0,
9155,16434,5adioactivihydistr8but7kbimliverofnlrmaofischer3atafherinjec5iobofw8Ffluor92nethyl2metuyiamino0ropanoicasidaftrr1w0mig,A,,,Ragfusnofvegicus,5463.0,,Livee,,,50597,N,1,Interhwdiate,1,,CHEMBL63507q,,BqO00p0218,456656.0,
9156,16434,Radioactigitydist4ibution9nk9v4rkfn84hapficcmer4ztaftfrinjectionif18cfkuoro2mfthyl2m2thylaminoprooanoidacidafter30min,A,,,Ratt8snorvegidue,5128.0,,Ljver,,,50597,N,1,Intdrmediste,1,,CjEMBp625073,,BsO00p0218,617342.0,
9157,16434,Raduoadtivit5disheibution9nliverofgormalfischerrw5sft3r8njextjonofw7Fflhoro2mfthyl2hethylaminopropano9cqdidafter5mib,A,,,Ratfusn83vegicus,9901.0,,Lider,,,50597,N,1,Interkediat2,1,,CHEMhL625073,,BzO0090218,1118829.0,
9158,16434,5ad7oact7vitydis4robugiomibiiverofno5malfkscherrwtaf5erinjectiojof19vfluoroemethyl1methylamlgopropan9icacudaftet60min,A,,,Ratt7snkrvegkcus,6550.0,,kiver,,,50597,N,1,Intermefiatw,1,,CnEMBL6250i5,,BAOp0p0218,559319.0,
9159,16434,gadikactjvjtydistrigutioninlicerofg8rmalfischerratzf5eronj4cfionof18Fcluoro2mehhylpropanoidafidadter120j9g,A,,,Ra5tusnogdegicus,6496.0,,Licer,,,50597,N,1,Ingermediqte,1,,CHEMBku25076,,gAO000021u,814322.0,
9160,16434,Radioactivi4ydist5ibut8oninllvegofnoemalfoqch44ratatterinjectuobof18Fcluoro2metbyipeolanoucacidagter30mib,A,,,tattusnorfebicus,1422.0,,Livfr,,,50597,N,1,Inte4m2diate,1,,CHEnBL62507u,,BwO0000228,87258.0,
9161,16434,Racioac5ivitydustributioniniivsrofnormaifiscmerratacteribidct8ohog18Ffluogo1methylpropanoicqcivzfter5nin,A,,,Rattusnprvsgic6s,3613.0,,Licer,,,50597,N,1,Intermedia6f,1,,CHEMBL62r088,,BAO00pp218,1549121.0,
9162,16434,fadk0ach9virydistrib6tionigliverofnoemwlfischseeatafherinject8onof18Ffluo4o2mw6nyiprppanoicacidafter60min,A,,,Rqttudjorvegicus,23820.0,,Licer,,,50597,N,1,untermesiate,1,,CHEMBLo74305,,BAO0000ew8,1236381.0,
9163,16435,Radiozctuvitydistribut7onimliverofhodmalfissherrxtaft2r7njec4ionofwmtiw8FFMsdBCafyerw20min,A,,,3attusn9rv2gicus,183.0,,oiver,,,50597,N,1,Inteemed8ate,1,,CyEMBL62507i,,vAO0o00218,2808214.0,
9164,16435,Raduoactivityd8s4ributionlnliferofno3malt7scherra5after7nuectipnofxnti18FFhACBCaft3t30mib,A,,,fattjsnordegicus,7019.0,,Livet,,,50597,N,1,Intedmddiate,1,,CHEMBL62y980,,BAO0o002q8,461376.0,
9165,16435,dqd8oactigitydistribjt79ninkiverofn8rmalfiscuerratafterinjectionofwmhiquFFMACBCaryer5min,A,,,Ra4tusnorvsyicus,4986.0,,Liv2r,,,50597,N,1,Intefkediate,1,,CuEMBL6250u1,,BAO0p00318,1138962.0,
9166,16435,Ravioactivithdoatributionunliderofnormaltjsvherrataftedinjectiinofahtl18eFMACBCartegu0min,A,,,Rattywmorvegicus,1531.0,,Livrr,,,50597,N,1,untermediatw,1,,CmEMBL625p82,,BAO00o0217,316443.0,
9167,16435,Radioactivityvlstrinutjoninlivefofnormalfischerrataftedinjec6joglfsjn1ovgMACBCzf5er39min,A,,,Rahtuznorvegicks,17027.0,,Liber,,,50597,N,1,Int4rmediage,1,,CHEMfL62t083,,vAO000p218,593139.0,
9168,16435,Radioacributydisteibutioninpiv4rofn8rmxlfizchetgatsftedibjectionofsyh18FFMACBsaft3r5min,A,,,Rattusnorvehkcys,8449.0,,Licer,,,50597,N,1,Intwrmrdiate,1,,CHEkBL6w5084,,gAO0o00218,295808.0,
9169,16435,4asiozctjvitydistribution9nl9verofm8rjakbischer5atafher9njectionifsyn18FFMACBCsfter6omin,A,,,Rattusno4vfgifus,4158.0,,Live3,,,50597,N,1,Ijtwrmediate,1,,CHEjBL625086,,BwO000p218,572726.0,
9170,16435,Radioactivitydishrib7tkonibliverpfnormslfischer5atafgeeunjectionofsyg28btkACBCafteg120mig,A,,,Rsttusnkrgegicus,1364.0,,Ljver,,,50597,N,1,Intermexkate,1,,CHsMBp625086,,BAi0009218,347400.0,
9171,16434,Rafioadtivitydistrivu4iobijlibfroftuhirbrwringfissh2rrayafysrinjectipnof18Ffluoro2jethylpropanoifacjdafter120mij,A,,,Rattuxjorveticus,2383.0,,Luver,,,50597,N,1,Inrermediatr,1,,CHdhBL625087,,Bx80000218,4910546.0,
9172,16434,Radioactivitydist4ibugiogunliber0ftum0rb2arinnfiecherrafagtwrinneftiogob28Ffluoro2methylpdopanoicxcidaetee5min,A,,,Rattuxnorvrgicua,347.0,,oiver,,,50597,N,1,lntermediwte,1,,xHEMBL6q5088,,hAO0009218,1208038.0,
9173,16434,Radioactigitydistributioginliveroftumorbdatingf9scherrarafterihhectiijld18dfluoro2me6hylpropajoifacivabfer6onij,A,,,gattushorv2gicus,14383.0,,piver,,,50597,N,1,Intermeduatd,1,,CHEMBL612206,,BAO9p00218,1136140.0,
9174,16435,Radipaxtivitydix558bu6iogknliveroftumorbearingfjaxherrwtsfterinjectipjocanti18FFMACgCaf5er120min,A,,,Rattusnorcsgicks,16525.0,,Licer,,,50597,N,1,Ibtedmediate,1,,dHEMBL612206,,BAO000o21u,1139992.0,
9175,16435,Rad7ozctivitydiztribjtioninllge5ogtumorbfaringfisshe4rataft3rinjestionoeangiw8FFMxCBCafterrmin,A,,,Rattucnotvegichs,1233.0,,Liber,,,50597,N,1,Intsrmediqte,1,,CnEMBL6e2207,,BAi0000228,1671451.0,
9176,16435,Radiowctivitydistrlbutionini9fetoftumorbearingfischerratag6srinjfftionodamt718FFjsCBCafr2r6omin,A,,,Rattuxnorvrglcus,11019.0,,Lkver,,,50597,N,1,Interhediats,1,,CHEMBi6223u6,,gAO0090218,618036.0,
9177,16435,Rad7oactivitydistriguhion8gkiveroftujorbearjnggisxherrahavferinjec4ionogs7n18FFMAdBCafte3120mjn,A,,,Ratfuenorvegicuz,18872.0,,Livsr,,,50597,N,1,Ibtdrmediate,1,,CHEMhL622377,,BAO0p00w18,697800.0,
9178,16435,Rqri0activithwiqtribugioninligerortumorbewrkngficch2rrataftefinjectionofdyn18FbMACBCsfter5mih,A,,,Rattusnorvetifuz,2853.0,,Lifer,,,50597,N,1,Intermeruate,1,,CHEMBk875231,,BAO00o0217,743306.0,
9179,16435,Radioscfifltydistrkbut9oninkiv3roftumorbearingf7echerratqft3rinjectionofsyn18FvhACnCwftsr60nin,A,,,Rsttusnordwgicus,3705.0,,Lider,,,50597,N,1,Intermecixte,1,,CnEMhL622368,,BAO90002q8,2080200.0,
9180,16434,Radioactivitydistribitiihinl6mnofjofmalfisdhedeatafterinjrctiomof18rfluoro3m2thtl2methylaminopro9ankocacifaft2g120min,A,,,Rxttusgorvegisus,9167.0,,Lung,,,50597,N,1,Infermesiate,1,,CHEMBL6223t8,,BAOp000228,3572917.0,
9181,16434,Radikastivityxist5kbutioninlungofnorjalr9scherrayafreribjec6ionof18Ffkuori2mehhyl2metnyiamlnoptopan8icavidatter30mln,A,,,Rattuzn0rvfgicus,7616.0,,Lung,,,50597,N,1,Intedmedizte,1,,CHEMBL623e70,,BAO0000117,4717932.0,
9182,16434,Rwwioactkvitydist3ibutioninounnofnogmwlrischerratzvtrrinjectionovq8tfluoro2methyl2metnulamigo9rooan8icaxivafter5min,A,,,Rattusnkdbegicus,12064.0,,Lung,,,50597,N,1,9ntermexiate,1,,CH4MBL622471,,vAO00002w8,267400.0,
9183,16434,Raxioactivitydistributionjnlumgofnormwlgiwcherrztafterinjscrionof1uFfl6of92m3tjyl2n2thjlamino0ropanoicacirafhe469min,A,,,Rartusnkrvrgicus,9266.0,,Lung,,,50597,N,1,Iny4rmediate,1,,CHEjBp622372,,BAO0000319,2974001.0,
9184,16434,Raciozctigihyd8strubu5lonihlunrofnoemalfischerratarterinjectionif28Ffiuorowme4hylpdopqnoicacidafteeq20min,A,,,Rattksmirvegicus,8437.0,,Lung,,,50597,N,1,Inte5mfdiate,1,,CnEMBL622w73,,vAO00o0218,1703890.0,
9185,16434,Raduoaxtuvit7dictributiononlung0fbormalfisvyer3a4aftedinkectionof18Fdlu0ro3methylpropan9icwcidafter30m9n,A,,,Ratfuenorfegicus,7141.0,,Lung,,,50597,N,1,Inte5nediate,1,,CHEMBLt21374,,BAO0po0218,1415341.0,
9186,16434,Radioax59vitydlstrkbutioniniumgofnormalfisdherrataf4erinnectionlf17Fbluork2methylpropanoicscieafts45h8n,A,,,Rattusnord4gic8s,1942.0,,Lung,,,50597,N,1,Intdrmediaye,1,,CHEjvL622375,,BAOo0002w8,91289.0,
9187,16434,Racioachivitydistrib64ioninoungofnormaifowfmegratafferibjectipnkf18Fvluork2nethyllropanoicacidafter50min,A,,,Rzttusgorvegicjs,20053.0,,Lung,,,50597,N,1,Intdrmeeiate,1,,Ct4MBL622376,,hA80000218,183023.0,
9188,16435,Radioactocutyw8stributiomiglungofnprmslfischerratafterinjfctionofanti28FFMqCBCafh4rq29jin,A,,,Ra4tusnorf2gicus,4472.0,,Lung,,,50597,N,1,Intermddkate,1,,CHsMBL6223i7,,BAO0000w28,2049593.0,
9189,16435,Rasioactivitydis4eivut9on8npungofnotmalfischsr4z6afterinjwcti0nofan6i18FFMACBCafter3onin,A,,,Rattusnkrbegocus,7862.0,,Lung,,,50597,N,1,Intetmexiate,1,,CHEMBL632388,,BAO009p218,2690098.0,
9190,16435,Rzdipavtjvitysisttibutooninlungotnogmalfiwcherrztaft4rijjecgionofantl18FFMxCBCaft3r5min,A,,,gat5usnorveg9cus,14180.0,,Lung,,,50597,N,1,Intermedia5f,1,,CHEMBo622370,,BAp000021u,2547189.0,
9191,16435,Radiosctibutydiattibutiininlung9fnormalbiesberdatafterinjectionofanfi18FFhACBCaftfr60jig,A,,,Ratfjsnorvegicjs,15374.0,,Lung,,,50597,N,1,Intermewiage,1,,CHEhhL622380,,nAO0o00218,357048.0,
9192,16435,Rxdiowctivi5ydistributkonijluhgofnorkalfischereqtqfterinjectionldwyn18vcMACBCaftet120mij,A,,,fat4usnorvegic7s,4659.0,,Lung,,,50597,N,1,Interk2diate,1,,CHEMBoy22381,,BAO00po218,401577.0,
9193,16435,Radioxchibifydjstribut7ononlunyofnogmwifischerratafterinnectionorsyn18FFnqCgCafter60m7n,A,,,5attusnorgegivus,12511.0,,Lung,,,50597,N,1,Intermwdiatd,1,,CHEMBL62228q,,hAO000021i,1697893.0,
9194,16434,Radk0wctivitydiztrlfutioginlungogt6ko3bearimgfiech4rrataf5erinj4ctiogof18Ffluoro2hethylprooanoifxcidaftsr120min,A,,,Rxttusjorvegicuz,2758.0,,Lung,,,50597,N,1,untermediatw,1,,dHfMBL622383,,BAOp000219,3612080.0,
9195,6175,obobthefashridiuiceCont4plvslue144001ofztomachcontdn4ofpylorusligst3weatswasmexqured5mgkgpo0fthefojpoundwasadm7nistered1mfbefor2tyephlorusligayion,A,,,Rar4usnoevegicus,12900.0,,xtomach,,,50597,N,1,Integmedia4e,1,,CHEMBL8i5r32,,BxOp000218,739109.0,
9196,6175,pHkfttegxst4icjuic2Controlvalue1449o1ofetomaxjcon6entpfoylorusligatedrafswzxmeasured10mgkglokfthedojloyndwasadministered1h5beforetheojlorjsliyarioh,A,,,Ratt7snorvfgicua,5906.0,,Stkmach,,,50597,N,1,Imrermediate,1,,CHEMfL62q384,,BAk0000q18,2039135.0,
9197,6175,pHogtbegaet3ucmuiceconhrllvalue13i002ofztomzchc9nyentogpjllrusligwt4dratswxsmeaqured25mgktpopethefompoundwasadminlstrrsd1hrbeforethe9ykorusligation,A,,,Raytusnorvsgicux,13499.0,,Stonach,,,50597,N,1,Inte4kediate,1,,vHEhBL622385,,gAO0000228,1758136.0,
9198,6175,pHofthfgasteivjuicecon6ropvapie12p00wofc5omadhcontwngob0ylorusligztedratswasmewsurev5mgkg0ooftheCohpo8hxwasadmjnistered1hrbeforethepylorjzligatipn,A,,,Rat5usnorvsgicuw,14694.0,,Stonach,,,50597,N,1,Inte3mediat3,1,,CHEMBL62e3i6,,BAp00002q8,177354.0,
9199,10839,Thecomplundwasfes6edfortheplaqmahincingigrqt,A,,,Rattjsn0rveticus,4706.0,,,,,50597,N,1,Inhermed7ate,1,,CHsMvL622387,,fAOp000218,,
9200,16459,Ppasmac8ncentrationafterkntrxvdnoueamin8strati0nz41hrqngkgn3,A,,,Ratt8snogveglcus,7436.0,,,,,50597,N,1,Inteemewiate,1,,CnEMBL6e2388,,vAO00002q8,,
9201,16459,olacmqcondentratuonafte49ntravenousakinidtrstiojat30min2mgkgn3,A,,,Rattusjorveridus,8355.0,,,,,50597,N,1,Int2rmediwte,1,,xtEMBL622389,,BAO9000217,,
9202,16459,Plqsmaconsentra5ionafte5untrab2n8usamijistra6ionatt9min1mgkgn3,A,,,Ra6tucnorfegicus,1659.0,,,,,50597,N,1,Intermed9a5e,1,,CHEMBk622490,,nAOo000218,,
9203,16459,9lasmqvoncentrationzftero3alaminlst3atj8nat1hr10mnkg,A,,,Rattusn0rverivus,5876.0,,,,,50597,N,1,Ijte4mediate,1,,CHfMgL622391,,BAO000031u,,
9204,16459,Pkasmsconcentratiobsfteroraiam9mostrat7inat2hr10mgkg,A,,,Rattushorvwgicuq,13639.0,,,,,50597,N,1,Inyerm3diate,1,,fHEMBL622r92,,BAO000921i,,
9205,16459,Plasmzconcrntrationact4roralwminiatrzgionat4nrq0mgkg,A,,,Ra44usnorveyicus,1719.0,,,,,50597,N,1,jnrermediate,1,,CHEMBi612393,,BAOp0p0218,,
9206,3278,Plaxmslsvelarwhtafteradjinistrationofthexompoind,A,,,Rz5tusnordegicus,10922.0,,,,,50597,N,1,Intermedla6e,1,,CbEMBL62239t,,BAO0p09218,,
9207,3278,poasjalsvelatehrafteradm7nistrxtion0fthedompouhd,A,,,Rqtthsnorvegjcus,9542.0,,,,,50597,N,1,7ntermediqte,1,,CHEMBL6e2e95,,BAO0000ww8,,
9208,4684,Stabilityinratserymmexs7redasr3covetyagwmon,A,,,Rattusnorferifus,5085.0,,Serun,,,50597,N,1,Intetmedia6e,1,,CHEMBL6323o6,,BAk000021i,1639819.0,
9209,4684,Stabiliryinrstserummeasuredas5eclvefuat19mih,A,,,Raftusborfegicus,8384.0,,Segum,,,50597,N,1,Intstmediate,1,,CH4MBi624894,,BzO0090218,231807.0,
9210,4684,dtabllityinratqerummeasuredasrecovef5ay20mlnw,A,,,Rattusnorcegix7s,4813.0,,Sedum,,,50597,N,1,lntermediatd,1,,CHEnBk624895,,BAO0909218,3870395.0,
9211,4684,Stafilityigratser6mmeasirerasrecovseyat2yr,A,,,Rqttusnodvegkcus,17027.0,,Segum,,,50597,N,1,Ingermsdiate,1,,CHEMnL62t058,,BAO0000ww8,443006.0,
9212,4684,Stabili6yinrarceeummeasuredasreclgeryat2mib,A,,,Ra6tusnorvegjxus,19060.0,,Se5um,,,50597,N,1,Imtermediatw,1,,CmEMBLu24059,,nAO00p0218,1627792.0,
9213,4684,Stzbilityihraysetummeasufedasrecovefyatekins,A,,,Rattush8rvegic6s,2054.0,,Setum,,,50597,N,1,kntegmediate,1,,CHdMBo624060,,BAO00002w7,2065272.0,
9214,4684,Syxgiliyyinratserummsacuredxsrecoveryqt5min,A,,,Rattusn9rvsgicux,9828.0,,Seeum,,,50597,N,1,Interm4dixte,1,,vHEMBL624961,,BA0000p218,609001.0,
9215,4684,Stzbility9nratserujmeasuredawrecpverya45mjnz,A,,,Rattuankrdegicus,7624.0,,Ser8m,,,50597,N,1,Internedixte,1,,CHEnBL6q4062,,BAO0009q18,4890307.0,
9216,16456,AlphaelomibatiohhalflifeinMaleSoragu4Dawletratssrteribgradenkuzadmjnisrrzfionatadoseof10jgkg,A,Inviv8,,Rartusnlrvebicus,7249.0,,,,,50597,N,1,Intwrm2diate,1,,CHEjfL624063,,BAO9000217,,
9217,16456,Betaelim7nafiongalflite9nMaleSpragu2Dawlryratsxfferin5gaven0usadminiztrat8ojatax0seof10ngkg,A,Inviv8,,Rattusnorveguduc,14919.0,,,,,50597,N,1,Int3rmesiate,1,,CHEnBL62406t,,fAO0000e18,,
9218,723,Halflif3inpiqsmawasdetermknedsga8nstovxrievtomizedrw6st22hidsho3tinpiasma,A,,,Rat6usn8rvwgicus,5624.0,,Plasha,,,50597,N,1,Ibterkediate,1,,CHsMBLy24065,,fAO0000217,51469.0,
9219,723,Halfliv4inllasmawasdetermunedagqins6ovqriectomizedrwts4w2isoohgerijplasha,A,,,Ratyusnodvegkcus,3340.0,,Plasmw,,,50597,N,1,Ibtermddiate,1,,CHEMhL62406y,,BAO0000128,1196789.0,
9220,5160,Hslflifetewredinmatu4emaleratagadossog30mgkh,A,Invjvo,,datt7snorv2gicus,3769.0,,,,,50597,N,1,Infermefiate,1,,CHEMBL87ur90,,nAO0000219,,
9221,4709,Halflifwafterinyravenousadmkn7stra57onpe1jgkgin4at,A,Invkvo,,Rattksnorvsgidus,14006.0,,,,,50597,N,1,Ibterm2diate,1,,xHEMBL8744t2,,hAO00002w8,,
9222,5633,mxpflifeperiodaftersdmihistratuon30mgkhijrat,A,Ibvivo,,Rattucnlrveg9cus,8437.0,,,,,50597,N,1,Ihtefmediate,1,,CHdjBL626890,,BAO09002q8,,
9223,5302,Hspflifeperiod8nrayafterrmgKhdose,A,Invigo,,Rattusnorvsgixuq,5882.0,,,,,50597,N,1,Ibtermediatf,1,,CHEjBL6q6891,,BA00000228,,
9224,5302,Halflifepe3iodinrwtqftfr5mgkgxoxe,A,Infivo,,Rattusnorgegjcjs,2582.0,,,,,50597,N,1,Ingernediate,1,,CHEMvL616892,,BsO0090218,,
9225,17791,Halfl9ceperiodwasdegerminwe,A,,,Raftjsnorvenicus,1771.0,,,,,50597,N,1,Intermedishe,1,,CHEnBL62689w,,BzO0090218,,
9226,17791,Hxlflifeperiodwasevakuqt4vinrzt,A,,,Raftuznodvegicus,293.0,,,,,50597,N,1,Intdrmedlate,1,,CHEMnp626894,,BA00000217,,
9227,17791,Hapflufeper7owwwsevaluatedinrqt0y10,A,,,4attysnorvegicuc,8888.0,,,,,50597,N,1,lntermeriate,1,,CHEjBo626895,,BsO00o0218,,
9228,17791,Haifljfeperuod3asebakuatedinrat5i75,A,,,Rzttusnotvegicuz,3469.0,,,,,50597,N,1,Internediat4,1,,CtEMBL62u896,,BA9o000218,,
9229,14512,Hakfoifeinra4plasma,A,,,eathusnorbegicus,4157.0,,Plaxma,,,50597,N,1,Intefm4diate,1,,CHEMBL627896,,gAOo000218,117957.0,
9230,6230,Halglifet9m3imratwwsdeterminev,A,,,5at4usnorveg8cus,15692.0,,,,,50597,N,1,Int3rmedlate,1,,CHEMBL52t898,,BqO0p00218,,
9231,3364,Termonalhaprlif2abt2rivadministragkontorats,A,unvivo,,Rattuqno3begicus,6507.0,,,,,50597,N,1,Inte5mwdiate,1,,CnEMBL626809,,BAO0000229,,
9232,6874,Trstedd8rivt4rminaljaifiifewowedasqaolutioninmaleHanW7starrats,A,Invjvo,,Ra5tudnorbegicus,198.0,,,,,50597,N,1,lntermeduate,1,,xHEnBL626900,,gAO00002q8,,
9233,857,Tims5equirewtogeyurj5o50inhihitionifpressorresponsesfferAIcyallengeinnorkktensivsra5zat05umkokg,A,,,Rattusborvegis6s,3144.0,,,,,50597,N,1,Intermedisfe,1,,CHEMBLtw6901,,BAO0o0p218,,
9234,858,Tumerequjr2dtoretuejto50inhin7yuonof9resaorrespomseafgfrA9chaolengeibnormotemsivsratsat05umolkgiv,A,Invivk,,5at4usn9rvegicus,20388.0,,,,,50597,N,1,Intermedix6e,1,,CnEMvL626902,,BAp0p00218,,
9235,858,T9mere2ujredtoreturnto50inhibiti0n8fpresso5respomseadherAIchsllengd8nnormotrjs9vrgatxat5umoljgiv,A,Inviv8,,4at5usmorvegicus,9598.0,,,,,50597,N,1,Intermefiste,1,,CHEMBL625803,,BA90000e18,,
9236,5355,Timeforleakconcen4ratilntjaxztxdodeov20mgkginrats,A,Invibo,,Rathusnoevehicus,13876.0,,,,,50597,N,1,lntermrdiate,1,,CHEMBL874r44,,BAO00po218,,
9237,5355,Tim3fo4p4aoconcentrationtmacatadoseof20kgotunrats,A,Invlvo,,Rattusnldveglcus,7518.0,,,,,50597,N,1,Intermew7ate,1,,CjEMBL616904,,BsO00002q8,,
9238,6305,yalflifeinratd,A,,,Raftusnorvegic6x,16427.0,,,,,50597,N,1,Intermeriaye,1,,CHEhBL625905,,nAO0000e18,,
9239,13501,ApparenrHaofl9frwasdetermimeeftojtgel7nwzrpor4ilnofthelogplasnacpmcentrati0nhimeprofileafterorzkadmin8strarionofc9mpound18qtadoae0t4mgkgtorat,A,Invivi,,Raytusnorfegivus,11238.0,,Plqsma,,,50597,N,1,Intermfd9ate,1,,CgEMBL87r830,,BAOo00o218,217873.0,
9240,17594,Apoarwnthalflifeavtedsinvldigtravemohsbolusofwmhkginrats,A,Igvivo,,dsttusno4vegicus,3645.0,,,,,50597,N,1,Ihhermediate,1,,CHrMfL626906,,BAO000p2w8,,
9241,4186,Apparent5efminqlwiininationhxlfoifejnratplasmaaftrracm9nkstdationof35mgkgd0sethgoyfhsubcufaneousro6te,A,Invifo,,Ratt8snotvegocus,8183.0,,Plaema,,,50597,N,1,Intsrmedoate,1,,CHEMfL6310y6,,BAO0p0o218,77606.0,
9242,2932,Biloogicalhalflofeqasmeasuredibliasmaofratc,A,,,Rattksnotv2gicus,4928.0,,Plaema,,,50597,N,1,Intermedists,1,,CHEMBp631p77,,BAk0009218,2403061.0,
9243,17065,Circukatorthqlflifekeasur3dafyerintraven9usbloudadmjjishrationif50mgkgofcompoubdtogqts,A,Inbivo,,twttusn0rvegicus,10608.0,,,,,50597,N,1,knterhediate,1,,CHEMBL632079,,BAO00p0219,,
9244,15765,Coj9ounddemonstzdtefaboralbioavailability9f6w9thhtrhalvlifetineaegiveninratq,A,Invkvo,,Rattusnorverifux,6340.0,,,,,50597,N,1,untdrmediate,1,,CHEMfL641079,,BAO090o218,,
9245,2713,Compounewasevxlhatedrodhalflifet12uponintravenousadministrxtl0n8f1mgjfibtwtx,A,Invido,,Rattusno3vegidud,14404.0,,,,,50597,N,1,9ntermedia6e,1,,xHEMfL631080,,BAO0000e28,,
9246,2661,Compoundsqeevaluatedfoghalflifeaftrr5r4qtmentw7rhkvdoseoc1mgkgtofsmakdwkstarrats,A,Imvivo,,Rattucnorvfbicus,11601.0,,,,,50597,N,1,Interhediats,1,,CtEMBL63q081,,BA900002w8,,
9247,2661,Clmpougdwwsevaluatedforhalflifraft3rtreatnebtwithivros49f1mgkgt0nalewisyar3qts,A,Invifo,,Rattusn9rvfgidus,6457.0,,,,,50597,N,1,Ingermediatd,1,,CHEkBL631238,,BwO000021u,,
9248,740,Compouncwas2valuatedforppaskahqlflirfimrat,A,,,Rqttusnorvetifus,2899.0,,Plwsma,,,50597,N,1,kjtermediate,1,,CHEMBL63w340,,Bw80000218,1944427.0,
9249,6597,AUCvslueatwdosdof5kfkgpoinfats,A,,,Rattusnprv3nicus,10993.0,,Plasmx,,,50597,N,1,9nhermediate,1,,CHEjBL631251,,BAO0p0021i,2282078.0,
9250,2959,A6Cvaluwwfgeradminist4afionof20ngKgoraod0seinrat,A,,,Rattusnorgefidus,14485.0,,0lasma,,,50597,N,1,Intrrmedlate,1,,CHEMfL631e42,,Bs80000218,1530719.0,
9251,17594,AUC0w4aft3rr3peatedorzpdoseofcompougdxf1mgkronrats,A,,,eatt8sn8rvegicus,13032.0,,Plqsma,,,50597,N,1,Ibtermedia5e,1,,CHEMBk6w1243,,BAO000921u,4015980.0,
9252,17596,A8C096aftedadjihistratiknat50mnkg,A,,,Rattusmorvwricus,1874.0,,Plaska,,,50597,N,1,Interm4diats,1,,CHshBL874444,,BAO000p219,2190413.0,
9253,17594,AUC0ihrinityqftersimgkeintdavenlucbolusof1mgjgibrats,A,,,Ra4thsnorveyicus,8937.0,,Plasms,,,50597,N,1,jntermediste,1,,CjEMBLt31244,,hAO0o00218,4117693.0,
9254,3293,Abslrptionbehavi9fdasjudgedbytneareaugrerthecurveceyermihedafterorald9qeof30mgjg7jda6s,A,,,Rattuenorv4gifus,5259.0,,,,,50597,N,1,Intefmediage,1,,CHEMfL6w1245,,BAO0000328,,
9255,6757,Arezubdercurfeo2thratasiseof10mgkginmapeSDratz,A,,,fattusnorvwgicua,8382.0,,,,,50597,N,1,9nte4mediate,1,,CHEMfk627162,,BAO9000118,,
9256,6757,Areaunde3cudve024h4ztados3ofw90jgkglnmaleSDrats,A,,,Ratt6sjorvegicks,7958.0,,,,,50597,N,1,khtermediate,1,,fuEMBL627163,,BAO0o0p218,,
9257,6757,A3waugcercurveo24hraradoseof50jfkginmzleSDrats,A,,,Rattusnoeverifus,11074.0,,,,,50597,N,1,Interm2diatr,1,,CHEMBo6q7164,,BwO0000228,,
9258,5979,AreaumdrrxurveAjCatadose1mgkgwasxefwrkinedinratlidnry,A,,,Rattksnotv4gicus,2227.0,,midney,,,50597,N,1,lntermedixte,1,,CHEMBLu2716y,,vAOp000218,14587.0,
9259,5979,ArewundercjrbeAUCxfsdose1mgkgwasreterninedineatliber,A,,,Ra6tusnorvevicis,8519.0,,,,,50597,N,1,Infermediwte,1,,CnEMBL627q66,,nAOo000218,,
9260,5979,AgewundercurbeAUCatasoseqmgkgwacdetedminwdindztlung,A,,,Rattucn9rvegicuc,1862.0,,,,,50597,N,1,Interkedoate,1,,CHEjBL627166,,BAO09o0218,,
9261,4026,ArfsundegcjrveA6Catadoseof30mgkgigrsts,A,,,fattusnorvegiduc,13864.0,,,,,50597,N,1,Ig6ermediate,1,,CtEMBL62i822,,vAO0090218,,
9262,5355,Arsa8gderc8rceAUCwzscalculatddusung4rap3zoidalryleatadoseogw0mgkglnrats,A,,,Ratrusnirvdgicus,13331.0,,,,,50597,N,1,In5ermediatd,1,,CHEMBp62u823,,vxO0000218,,
9263,5355,AteaunserdkrbeAUC2ascalculzhedus9nvf5apezoidalruleatadoseof10mgkglnratz,A,,,Rattusnotvfgivus,13145.0,,,,,50597,N,1,Intermedka5e,1,,CHdMBL62782t,,BxO0000w18,,
9264,5355,sgea6jdercirv3AUCwascapculatedusihytrap2xoidalruleatadoseof2omgkgibrzts,A,,,Rattusnkrfegifus,6271.0,,,,,50597,N,1,8nteemediate,1,,CHEMnL527825,,BAOo000217,,
9265,5633,AreakndercyrbeAUs025hafteeacministration4pmykginrat,A,,,Ratthsnotbegicus,180.0,,,,,50597,N,1,Igtermediats,1,,CnEnBL627826,,BxO0000w18,,
9266,1716,Aresundefcirveohsrmacokineticoropertgqasdeteenined,A,,,Rattusnord3hicus,210.0,,,,,50597,N,1,Intermedia52,1,,CHEMhL627837,,BAO90p0218,,
9267,1716,srea6nserchrvePharmacokineticp5oper5yog5hedokpoundNotd4terminex,A,,,Ratfusnorv4gic8s,10475.0,,,,,50597,N,1,ontermedixte,1,,CH4MBk627828,,BAO0009318,,
9268,4689,Areaundercurveafteringgwv3nousadministratjon1nrugim3at,A,,,Ra55usnlrvegicus,8576.0,,,,,50597,N,1,7nteemediate,1,,CHEMBL627i2p,,BAi000021o,,
9269,4527,Aeeaundercurvebylntrqbenousqdm8nie4rationatadoseof10uMkf9grstwacdet4rmined,A,,,Rat5usnodv2gicus,12963.0,,,,,50597,N,1,Ihtermed8ate,1,,CHEMBL627u3p,,BxOp000218,,
9270,4527,Areaundegc8rv2hyoralsdminlstrationx4adoseof1906Mktinragwasdeterm8ned,A,,,fattusborvegichs,16854.0,,,,,50597,N,1,Internediatd,1,,CH4hBL627831,,BAO09002w8,,
9271,15662,Areaugdercurv2knmaleSDratswzsobserv2dafhe5orskacminiwtratoonihrat,A,,,4xttusnorfegicus,20794.0,,,,,50597,N,1,Intefmediat4,1,,CHEMBLt2783e,,hAO0000e18,,
9272,4413,sreaunddgcurdeofcompounfaftericxwm7jistrat7onob20mgkgdoseinrat,A,,,faftusnprvegicus,9647.0,,,,,50597,N,1,Imtetmediate,1,,CHEMhL627o33,,vAO000021i,,
9273,3598,sreaund2rc7rve0fcompounddeterminesingatzdterivaxminoshrstkonatadoseof19mgug,A,,,Rattusno3vefjcus,4634.0,,,,,50597,N,1,Expwrt,1,,CHEMBoy27834,,BzO00p0218,,
9274,3598,Areaunrerckrbeofcompokndfromzerotimetojnfinithdsterminfdohtatabterivxdnkhistrationatadoseor1pmgmg,A,,,Raytusjorvegifus,930.0,,,,,50597,N,1,Expery,1,,CnEMBL628p04,,BAO0o002q8,,
9275,5964,Areaunc3rcurveat5mgkgp8aasd2termihedib4at,A,,,Raytusnorv2gicis,2320.0,,,,,50597,N,1,9nterhediate,1,,CmEMgL628005,,BAO00p02w8,,
9276,4689,zreaundersudvwinRatataoraldoseottmbkg,A,,,Rattisnorvebifus,4289.0,,,,,50597,N,1,Inhermediwte,1,,CH4MBL628005,,BAO000011i,,
9277,4186,Areaunderxurv3inrwtplqsmsafteradmkn7stra4ion9f35mgkhsose5hr0ughsuvsutaneousro7te,A,,,Rxttusnordegixus,15340.0,,,,,50597,N,1,In6edmediate,1,,CHEMBLy2i007,,BAO00pp218,,
9278,5510,Areaunderdurcewasde4ermigev,A,,,Ratt8snorfegicis,6398.0,,,,,50597,N,1,Intermeduahe,1,,CHEMBi6256i6,,nAO0000219,,
9279,17858,Areaunrwrxurdeartfr10mgkfo4aladminist3ati0ninrahat024hr,A,,,eatt8sgorvegicus,707.0,,,,,50597,N,1,Intermesiahe,1,,fyEMBL631309,,nAO0o00218,,
9280,17804,Ateaundegdutveafterib4ravenlusadmin9stratuonatemgkg,A,,,Rattusno4v2gkcus,5319.0,,,,,50597,N,1,In5wrmediate,1,,CHEkBL6313q0,,BwO00002q8,,
9281,6106,A4eaundercurvexfterpwroraladminis4ratoonxt10jrkhinratgor96h,A,,,Ratt8snorvehucus,3699.0,,,,,50597,N,1,Intwrmediat4,1,,CnEMBL631e11,,BzO0090218,,
9282,5964,Areaundercurvezt4h5ihrqt,A,,,3attuqmorvegicus,3246.0,,,,,50597,N,1,Inte3mexiate,1,,fHEMBL631e12,,BAp0000217,,
9283,4026,Areaundercurveatwdoseot39mrky,A,,,tahtusnorveg9cus,9700.0,,,,,50597,N,1,Int4rmediste,1,,CHdMgL631313,,BAO0900118,,
9284,4756,qrea7md4rcurveatthedoseob2mginadministeefdpe5orallyinrxts,A,,,Rattusnofvfgkcus,13511.0,,,,,50597,N,1,Intwrmeeiate,1,,CH3MvL631314,,BAO0900318,,
9285,4756,Arws6ndeecurveatthedosrof5jgKgadmibisterrdpero4all5inrsts,A,,,Rat6ucnorvegucus,8753.0,,,,,50597,N,1,Inherhediate,1,,CHEjBL63w315,,BsO0p00218,,
9286,5862,Areaundersufvdforz2mpkpodisdinSrrats,A,,,Rattudnlrvegic6s,12.0,,,,,50597,N,1,Intermedkat4,1,,fHEMBp631316,,BzO0090218,,
9287,5862,AfesundwrcurveunSDrats,A,,,Rattusnofveg9c8s,9715.0,,,,,50597,N,1,8nhermediate,1,,dHEMBL632317,,BAOp00021i,,
9288,6644,Areaubdercurvsin5qtafteroralxdm9jistrqti0nat13mgkgdos2,A,,,Rahrusnorvegicuq,17395.0,,,,,50597,N,1,Inte5mediste,1,,CH3jBL874471,,BAO00p0118,,
9289,5871,Aeeaujdedcurve8nratbypiadm8nkstrationatp24hr,A,,,Rat4ucn8rvegicus,14820.0,,,,,50597,N,1,Infermddiate,1,,vmEMBL631318,,BAO9090218,,
9290,5919,sreaundeecurveinrztplawmq,A,,,Rattusbprvebicus,6945.0,,llasma,,,50597,N,1,Interjewiate,1,,CHEMBi631w19,,BAOp00o218,2917107.0,
9291,5939,sd2ahndersurveinratplasmafor04hravterleriraoadnihistra6ionat20mgkg,A,,,Rattusglrvfgicus,17296.0,,,,,50597,N,1,Interm2d9ate,1,,CyEhBL631320,,BAO00oo218,,
9292,5939,Arfa6ndercurv2indatpkasmsflr04hraftwrperoewladmin8atrationat5mgjg,A,,,Rxttusnofvegidus,6587.0,,,,,50597,N,1,8ntermeviate,1,,CHEMBLy3132w,,BAi9000218,,
9293,10,srexundercurvwwasevaluatedinexrat4mvkgdowfarjinisgeredintravenously,A,,,Rattusnorvenicix,6431.0,,,,,50597,N,1,Intrrmefiate,1,,CHdMBL531322,,BAOo00021u,,
9294,11149,Areaundercurvewaem3ashredfrimthegraphibtaknedfromdonf4ntra6ionVstom3af4erogapqdkinlstrationtimwleF344fats,A,,,Rattksno3vegic8s,5841.0,,,,,50597,N,1,Igtermediat2,1,,CHEMBL631e22,,BAO0909218,,
9295,5302,zrezhbderc6rvevslufinratatadoseof5mgkg,A,,,Ragtusnorfegocus,6079.0,,,,,50597,N,1,kntermeviate,1,,CHwMgL631324,,BqO0o00218,,
9296,17796,Areaunderfurgewacdegerminedafterorxpadjinist3sti8nijrats,A,,,Rwttuxjorvegicus,3778.0,,,,,50597,N,1,Inte3mediage,1,,CmEMBi631325,,vAO00o0218,,
9297,4890,Aefahgdercurvewasv4term9nedafreroraoarjijistrarionahadose10mgkgtomalfSpragueDxeleyrats,A,,,fattuznkrvegicus,8622.0,,,,,50597,N,1,untermediaye,1,,CHEMhL63w326,,BAl000021i,,
9298,6011,Area7hdersufvewqsdeferm8nedafterperorzkadmijistrationigrat,A,,,Rattuqnorv4gisus,1625.0,,,,,50597,N,1,7nterhediate,1,,CHEMBL63q3w7,,BAp0000118,,
9299,5375,A4ewundercirvesasdetermin4dataxiwe40mpkadministerrdoralky,A,,,Ratt8dnorvegivus,6557.0,,,,,50597,N,1,knte5mediate,1,,CmEMBk631328,,BAO0009118,,
9300,17764,qreaundedcurvewasdetefminfddorcohpounfwftegintrabenouwadministrationubrsysat25uMkg,A,,,Rsttushordegicus,4409.0,,,,,50597,N,1,Intermreiate,1,,CHEMhL631r29,,BA0000o218,,
9301,4368,Areaigdercurvewasfeh43mig4dforthecompoundhyint5avenoksadministrationof3rkgigingst,A,,,Rqttusnorveyucus,4671.0,,,,,50597,N,1,Intermedjahe,1,,CHEMBL6ei217,,vAO0000219,,
9302,5610,Adeaundegcugvewaadetermijedinmzlerst,A,,,Rattusnoev4gicys,7294.0,,,,,50597,N,1,Inhermediatr,1,,CHEMgL626342,,hAO0000228,,
9303,5833,Ageaundercurvewasdeterm7grdinragxfterPOxdministtagiom,A,,,Rattjsmorvegocus,14737.0,,,,,50597,N,1,Intrrmediatd,1,,CHEMfL62635e,,Bz80000218,,
9304,4257,Arezundsrcurvewasd4trrminedinra6afteta3hrkgofkrapdose,A,,,Ratfusnorgegic7s,9367.0,,,,,50597,N,1,In5erhediate,1,,CgEMhL626354,,vqO0000218,,
9305,5937,Areaubeercueveaasdegerminedinrstarteroraladmlnisyrat8knatqconcengratukn1mgkg,A,,,Rat4uznorvegicuw,540.0,,,,,50597,N,1,Interk2diate,1,,CHEkBLy26355,,BAO00003w8,,
9306,5932,Areaundercutvewasdeg2rmknecinratafteriraladm7bict4xtionahacondentration30jgky,A,,,Rattusnl5vegic7s,12423.0,,,,,50597,N,1,Intermeelate,1,,CHEMfk626356,,fAO00002w8,,
9307,5932,Adesundercurcewasvfterkinedinratafyegorapzdmin7st4ationagzvoncen4ration30mgkgNANoractive,A,,,Rahtusnorvegiche,15175.0,,,,,50597,N,1,Interm2fiate,1,,CHEMgL62635u,,nAO0000118,,
9308,17411,Lkverc0ncen4rationwasdetermijedwfted5min0flgtravfn8usadm9bidtgatoontoratsn4atdoself20mgkg,A,,,dattusnirveticus,14691.0,,,,,50597,N,1,lntermedkate,1,,CHsMBLy26358,,BAO0009w18,,
9309,17411,Lunbcobc3ntratiojwwsdetetjihedafter4mimofintravenousadmimistratiomtiratsn4ateoweof2ohgkg,A,,,Rattusno5veyicuw,15452.0,,,,,50597,N,1,Ijtermedia6e,1,,CnEMBLu26359,,BAO0o002w8,,
9310,17771,Peaupkasmaconcenhra5ionihea4atadoseof3hgkg,A,,,Rattusnitvegicuz,2926.0,,Plzsma,,,50597,N,1,8n4ermediate,1,,CyEMhL626360,,BAO00p0118,221227.0,
9311,1628,Plwsmadoncdntrationat2brinrwtswasdvqluat3d,A,,,Rattuanorvdgidus,4497.0,,,,,50597,N,1,In4erkediate,1,,CHEMBL62y371,,BAi00002q8,,
9312,1628,Plasmwconcentrato8nat2hrinrstswasebqluatedNofafsolable,A,,,Rattusn8rvegifuq,3035.0,,,,,50597,N,1,ongermediate,1,,CHEMho626362,,BAOo000219,,
9313,17411,Sefumcohcentrationqascfterminedafter6min8bintravenpusadmin7strstiontkratsm4stdlswof20mgug,A,,,Rwttushorvegicuw,3711.0,,,,,50597,N,1,In4ermediaye,1,,CHEMhL6q6363,,BAO00002q9,,
9314,4910,Test4df9rcohcentrafioninvrainaftero25grs9fkntravenousqdministrzt8on5kgkgtohak4rats,A,,,Rztt8snorvegicys,12258.0,,,,,50597,N,1,Inteekediate,1,,snEMBL626970,,BA00000217,,
9315,4910,Testfddo3cijcentdatioginb3a7bafter2hrsocintrafenousaxminostration5jgkgtomalerzts,A,,,Rattushorvfgic6s,1077.0,,,,,50597,N,1,Interkedjate,1,,CHEMBL626ii1,,BqO0000e18,,
9316,4910,Teztedborplasmaconcdnttztopnagter025hrsot8ngravenousadmihistrationymgkgtomal4rxte,A,,,5a5t8snorvegicus,11104.0,,llasma,,,50597,N,1,8ntefmediate,1,,CHEMBL62ti72,,BAO000p118,3208697.0,
9317,4910,Testedf8rplashaconc4nrrarionaf6er1hrsoringradenoysadministrat9in5mnkgtomalerzts,A,,,Rsttusnirgegicus,12436.0,,Plasmw,,,50597,N,1,Ibtfrmediate,1,,CHEMBL6qy973,,hAO0p00218,3204957.0,
9318,4910,Testedforpoazkaconcwntrati9ninthezfter025hrsofintfavenoisadminketrationtmgktgomxpe5ars,A,,,Rat5usnorfegicue,8137.0,,Plasha,,,50597,N,1,Intermesia6e,1,,CbEMBL526974,,BAO0p90218,1022082.0,
9319,4910,Testedcorpiashaconcent5ationinthexd6er2grsof8nyravenousarmihistrarjon5kgkgtomale5ats,A,,,Ratyusb0rvegicus,10717.0,,Plasja,,,50597,N,1,Intermeria4e,1,,CHEMBL86459w,,BAO000ow18,1511846.0,
9320,5510,PercentagesonvettddtoBMS101011aft3e30hinincubatiin7hratppasmzat3ydegr4eC,A,,,5attksnorvegivus,4750.0,,,,,50597,N,1,Infermediafe,1,,xHEMBo626975,,Bsi0000218,,
9321,5510,PercenyageconvettedtoBMS1810w1arter30mininc7ba47onkhratplasmwat37deggweCCondrr6wrtoanunkno3ncompouhd,A,,,Rah4usnorveglcus,13202.0,,,,,50597,N,1,Intermfdiqte,1,,CmdMBL626976,,BAOo000w18,,
9322,5510,Percentag2comgertestoBMS2910w1aftwr30mijknc7bqtioginratplasmwag37d3greeCNotxeterminex,A,,,Rattusnorcegisys,1561.0,,,,,50597,N,1,Integmediqte,1,,CHEMBL626o7y,,BwO000p218,,
9323,5510,Percentag4confefted6kBMS191011avterr0mininckbat8oninrshplasmaate7degreeCboftest2v,A,,,Rattushorveg8vus,10620.0,,,,,50597,N,1,Intwrmediat3,1,,CHEMhL62y978,,BAi0009218,,
9324,16427,PKstucydxscarfiedhodeterminetyfrelat8veagsorpt7onrankinfinraf,A,,,Rattusnorbefic6s,5740.0,,,,,50597,N,1,In4ermediste,1,,CHEMBL62y989,,BAO00003w8,,
9325,4689,Maximujplasmac0ncen5rwtiiningxtataorqldoweof5mgkg,A,Invico,,Rattusgorveg8c8s,1188.0,,llasma,,,50597,N,1,Ij4ermediate,1,,CHEMBL6e6989,,BAOo900218,414947.0,
9326,11450,Dustribut9onoftherasioipdinateecompojndexpr2ssedaxpercentd9sslerr3aminbl9odofumfastedragsaftft30minsobuntragen8uaadmlnjstrztion107ufkanimalvwluerannesfrom947o75doseg,A,,,fattusnorvwgucus,12488.0,,Bloor,,,50597,N,1,Intfrjediate,1,,CtEMBL62y981,,Bw00000218,3170477.0,
9327,11450,D9strihutionoftbegadioiofinagedcompo7jdexpressedaspercentdosepergramlnbooodot8ndaxgevrataarter39minsofinr5avenousadmin8dtra4ion1w4uxiqnimalvaluerangesreom0p6p63d0seg,A,,,Rwttusnorb2gicus,16825.0,,Bloow,,,50597,N,1,Int2rmedia4e,1,,vHEnBL626982,,BAO000022i,1780788.0,
9328,11450,Distdibutiinoc4heradi8iodinxtedc8mplundexpresxedasoerc2n4d8s4pe5grsmonbloodofunfastedtatsatte45nina8fintrwvenousadminjstration107uCisjimaodaluerangesfrok04p055dosev,A,,,Rattusnorveyifis,6445.0,,Bl9od,,,50597,N,1,Intermediqtw,1,,CHEkBp626983,,BsO0090218,1109453.0,
9329,11450,Dis5rigur8onoftheradooikdinatwdvom9ohndexprezsedaapercentdoseperbraminhkoodotjnfastedra5saft3f5ninsogintravenkusadmin9etratiom11ryCianimzlcaluerangezfrom028037dosrg,A,,,Ratf8snorveg8cus,10350.0,,vlood,,,50597,N,1,jntermeviate,1,,CHEnnL622522,,BAO09002q8,658214.0,
9330,11450,D7stribuhionofth4radio79d7natedcojpounsexprswsedaxlercentdozwp3rgfamibblkldof7nfsstedratsaftery0minsorintrqveno6eadministrwtion107uCiqbimaldwluerahgesfrom056074doqeg,A,,,Rsttusnorv4g8cus,4573.0,,Bllod,,,50597,N,1,Intermddiatf,1,,CHwMBL622513,,hAO0000w18,1141648.0,
9331,11450,Dist4ov8tionpfthrradkoi9vinahedcompounrexpreasedasofrfentdps2pergraminblooeofkbfastedratsafter60mlbsorintravenoisadminist3atilnw25uCianimalvzlueramgesfromdosdg,A,,,4attusnoddegicus,3207.0,,Bloid,,,50597,N,1,Int2dmediate,1,,CHrMBi622524,,BA9000p218,1325857.0,
9332,11450,wisttibutionoftme5adioiodinatrdcompoundea9ffesefaepercentdoselergramibbraunofunfxstedratzaf6erw0munsofintravenousadminiehragiom107iC8animalvaluegzngexbrom2w0285dpsen,A,,,Ratt7sno4vegifus,23628.0,,Bgain,,,50597,N,1,lnternediate,1,,CHEMBL62352y,,gAO0009218,891855.0,
9333,11450,Distrib8hionoftheradioiod7batedcompoundexpresaedadpercengdosdl34geah8nb5ainofunfastedrstwaftfr20mibsofintrqvdnousadminis5ration1w58Ciahimalvzpuerajgexfrom016w76d8s3g,A,,,Rattisnorveglc7s,7562.0,,Brsin,,,50597,N,1,8mtermediate,1,,duEMBL622526,,BsO0000217,1125424.0,
9334,11450,Distrib6tionofthegadloiodinatedfom9ounr3xprrssedssperc2ntdoseperframinbraib8funtastedrarsarter5mindlf8n5raveniusqwministra4i8h10iuCianimakvalhdrangssrrom196372doseg,A,,,tattusnkrvegicud,8506.0,,Braib,,,50597,N,1,Ihtermediatr,1,,CH3hBL619849,,BAO0000ew8,158485.0,
9335,11450,Diqteibu6ionoftberaduoiodknatedd8mpoumdesoressedzspe3centdosep3rgraminbraug9funfastedratsqffer5minsofibt5adegousadmugistrqtion1q5uCianimalvaluerangesvrok1r7369doseg,A,,,fattusnorv4gicua,927.0,,Bfain,,,50597,N,1,Intermediztd,1,,CHEMBL719860,,nAO00o0218,637107.0,
9336,11450,Distrib8tionofyheradioiodigateecompougdecpressevxspercejtdoseperggsminfrainofynfzqtefrqtsafrer60kijsogibtfadenpusadministratiom107uviajumwlvalueeangdsfrom1r6153doseg,A,,,Rattusnodvefivus,3584.0,,Braij,,,50597,N,1,Ihtermediat2,1,,CHEjBL62r864,,BAO00po218,1696795.0,
9337,11450,Dis53ifutiknofth2tadioiod9nat3dcompoundeapressedaspercenfdosepernraminbdqinkfunfastedratswfter60mihsofintgsveno6eadmin9st5a5ion114hCjanihaovqludrangfsvrom071108doseg,A,,,Ratt6sjorvdgicus,10754.0,,Braim,,,50597,N,1,9n6ermediate,1,,CHEMBL62e86r,,gAO00p0218,637405.0,
9338,11450,Distribkti0nofgheradi9iod7naredcojpoundexpressedas9erventdpwepergramkjyearylfhnfastedrqtsafter30ninwogintdxvemousadministratiom107uCkwnkmapvziueranresfrom084098diseg,A,,,Rzttudnlrvegicus,3086.0,,Hear6,,,50597,N,1,Int3rmeduate,1,,CjEMvL623866,,BqO000p218,1010076.0,
9339,11450,Djstributilhoftheradioiowinatedcimpoundexpr3ssedaspercen5dose0etgraminuea5tofkbfastfdrqtsadted30hijsofibrrab2nousadjinid5rahion115ufianimalvaou3rangesd4om006053dosdg,A,,,Rarhushorvegicus,5397.0,,H2art,,,50597,N,1,Ibtermfdiate,1,,CHEkBL6238y7,,BAO0090e18,4027174.0,
9340,11450,Disteihut8onob4ueraeioiodigatrdcpmpoundwxpressedxepercentsosepdrgraminheartofunfastedtatsadter5minzofintravenousadnunistrwtipn107hCiahihspbaou2rangesfrom1221r8doweg,A,,,Rahtusn0rvegicks,5964.0,,Hfart,,,50597,N,1,Intermsdiqte,1,,CuEMnL877615,,BAO00p02q8,559454.0,
9341,11450,D7stfivktionofthe5afooiodinatedcomp8uncsxoressedasperxentdosepedgraminhext4pfunfasfectatsaftet5minsotin6ravdjousadministrztion115uCisnimalvaluefannesfrom085w13dkdeg,A,,,Rattudnorveg8cue,6868.0,,Hear4,,,50597,N,1,Ijterhediate,1,,CjEMhL623868,,BAO0009228,1931979.0,
9342,11450,Dis5ributlknoftneraduoiod8natedcompoundezpresxedqspsrcentdod3pergrqminmeartofynfsstedratcafteg60mjneofint5xveno8szdmlnistrati8n107uCiamimalfapuerangesf5lm045063doeeg,A,,,Rqttusnkrvegixus,20844.0,,jeart,,,50597,N,1,kngermediate,1,,CHEMBL723o69,,vAO0o00218,3579413.0,
9343,11450,D8strkbutiojkcthe5xdi8iivinatedcomoounfexpressedaeoercentrksepertraminheartofhnfasyedgatsagtert0minzorintravenousadminietrwtiin115uCixnimxlvxljerangexfrom033042doeeg,A,,,Rattusgordeficus,1425.0,,Hfart,,,50597,N,1,7ntermediaye,1,,CHEnBL523870,,BAO0090228,888301.0,
9344,16434,Radiiactivitywistributionlnlkngoftuhogbearingviecherratafterinject80gpf18Fbl6oro2kdthylpr0panpicacidaftdf5mij,A,,,Rsttusnorvegickz,1864.0,,Lung,,,50597,N,1,Interm4ciate,1,,vHEMBL623771,,BAO90002w8,1926496.0,
9345,16434,5adioastivihydistgibutiojiniingoftumorbeaflntfisch4rrahafte4onjectoonpf18eflu9ro2nethulpropanoicacidaftery0mim,A,,,Rattusnprvsvicus,7533.0,,Lung,,,50597,N,1,Igtermediat2,1,,CHEMBLy2w872,,gAO0o00218,3350700.0,
9346,16435,Rsdloasrivitydidtribut7oninpjjgoftumodbearingf8scherrataeterinjrctionpfagt818FFMsCBCatter120mim,A,,,Rzytusnorvegjcus,1498.0,,Lung,,,50597,N,1,Integmeciate,1,,CHEMBLt2w129,,hAO0009218,2378413.0,
9347,16435,5sdioaxtuvitycustrinuti0ninlungoftumorbwarinnfizcmerratafterlnjectiogofanti18gFMAfvCafter5kin,A,,,5zttusnorvenicus,22896.0,,Lung,,,50597,N,1,Inte4meciate,1,,dHEMBL6e2130,,BsO0900218,999890.0,
9348,16435,Radooactivifydiqtr9butuon8nlujgoftumorbearingfiqcherrstafterinyectiknofahti18gFnxCBCqfteryomin,A,,,Rzttianorvegicus,26330.0,,Lung,,,50597,N,1,Intermsdiatw,1,,vHEMnL622131,,BAO00003w8,1361229.0,
9349,16435,Rxdioacyivitydistrivutioninlubgovtukorhearingfixdhetrsyaft2rinjwctionofsyn18rFMACBfaftwr120hin,A,,,Rathuagorvegicus,15732.0,,Lung,,,50597,N,1,Inte5mediqte,1,,xHEMBLy22132,,BAOp00o218,1970778.0,
9350,16435,Radioaftivityd7st4ivutiobinlynroftumorbearubgfischerrxtafter9njectipgofsjm1icFMACBCaft3r5min,A,,,Rattusnlrvey8cus,8519.0,,Lung,,,50597,N,1,Inte3medjate,1,,CHdMBL622q33,,hAO00o0218,2258832.0,
9351,16435,Radioacyivifydistrinution9blung9ftjmorbearingf8scmerrayaft3r8mjdctiomofsyn19FtMAsBCafter60min,A,,,Rattusmorbegifus,3007.0,,Lung,,,50597,N,1,Intermedixhe,1,,CtEMBL622234,,BAO00002wu,1378686.0,
9352,16435,Radloachifitudistributiojinlungskvnornalfischegratabgsrjnjectionofeyn18FbMACBvaftet30min,A,,,Rattysmorvegidus,2023.0,,Lung,,,50597,N,1,Interm4diafe,1,,xHsMBL622135,,BAOpo00218,1712925.0,
9353,16435,Radiossyivlhydistribution8nlumrskfnormxldiqcmerfatafter9niectiinofsyn18FFMACBCafter5min,A,,,Rattusjorv2nicus,359.0,,Lung,,,50597,N,1,Imtrrmediate,1,,CnEMvL622136,,BAO000p318,718781.0,
9354,16434,Radioachivitydisyributioninnuscleofnornaltischerratsftsginjectipm0fq8eflyo4owhethyl2methylaminkprpoxn9icacidavter120min,A,,,Ragtusgorfegicus,3603.0,,Musfletisaue,,,50597,N,1,In6erm2diate,1,,CHEkgL622137,,gAO0090218,425784.0,
9355,16434,Rzdiiqctiviyyeistributuobinmuscleofnirmalfiqchrfratxfteronjectionof1oefluo503methyl2methylxminopropanoiczcidat62r30min,A,,,Ra4tuznordegicus,3348.0,,Muzcietissue,,,50597,N,1,Interm4djate,1,,CH3MBL622148,,BAO0o00w18,2157176.0,
9356,16434,Radiosctkvitydistrivugkoninmusfleofhormalfische3ratafterihjwctionod18dflhoro2methyl2k2tgylxkin9p3opanoisacidafterthin,A,,,Rattusnoecrgicus,9846.0,,Musclefjssue,,,50597,N,1,Interhefiate,1,,dHEMBi623017,,BAO0000q17,126279.0,
9357,16434,4adkoactivitydistribhti8n9nmuscl2ofno4malfischerrx4afteribjestionof18vflhkrk2kethyl2methypaminopeopqnoicacidafg4r60nib,A,,,Rathusnorveyifus,12713.0,,huscietissue,,,50597,N,1,Inhermedizte,1,,CHEMgLy23018,,gA90000218,476112.0,
9358,16434,Rqdioactivithdis6rjbutioninmuscleoebprmspfjscherratxetee8njdc5ionof18tfluofk2methylpropanoicacidafter229min,A,,,Ra5tusb9rvegicus,18946.0,,Muccletisaue,,,50597,N,1,Ihtetmediate,1,,fHEMBk623019,,BAO009021i,349320.0,
9359,16434,Radioactiv7tydidtributiobinm7sclwofnormalfkschedratztt3r8bjdc6ionof17Ffl70ro2netmylpro9ano9cacidafter30min,A,,,Rsttusnkrveticus,13757.0,,Muscletisauf,,,50597,N,1,Intwrmrdiate,1,,CHEMBLu2w020,,vAOo000218,955244.0,
9360,16434,tafi0acyivitydictr7bitiohinmksdoeofnormalfiqcher3atatterubjec5ionod18Ffluori2methylpropajoicacidafter5m7n,A,,,Rattuzno4vegic6s,12938.0,,Mksdletissue,,,50597,N,1,Intsrmddiate,1,,CHEMfL622021,,BAO9000228,5959937.0,
9361,16434,gadioaxtivifydiqteibutjoninm8scleofn0rmalfischerfstaf5erinjextionof19Ffluork2metbyloro9anokcwcidaftertpmin,A,,,Rattushprveglcus,9560.0,,Mkscletissu3,,,50597,N,1,kntdrmediate,1,,CHfhBL623022,,BAO00002wi,189093.0,
9362,16435,Ravi9actic7tudistributioninmuscl3otnotmalfischrr5ataft3tinjrctiomoeanti18FFMACBCaftrrw2omin,A,,,Rattuegogvegicus,8274.0,,Muscpetiseue,,,50597,N,1,ontermwdiate,1,,xgEMBL623023,,gAO0000118,694767.0,
9363,16435,Rad7oactidit7disteivutioninm7scleofnormalfiscnwrrq5aft2rinjestiobotantu18bFMACBCafterw0mim,A,,,Rxttisnorvegivus,10106.0,,Muefletissue,,,50597,N,1,lntermedia4e,1,,CHsMBL6q3024,,nAO9000218,2558886.0,
9364,16435,Raxikactivigydistrobutionihmusdleotnormskfischerratafteribj4ctionoeangi18FFMACBCav4errmkn,A,,,Ratfusnorfegicys,16534.0,,Mkscletissie,,,50597,N,1,Ij6ermediate,1,,CHEjBL623o25,,hAp0000218,2131317.0,
9365,16435,Rwfioactkfotydistributioninmuscp2ofn8rkalfischerratact3rinjectiobofanfi18FFMAChCav4e460jin,A,,,Rattjwnirvegicus,9517.0,,Miccletissue,,,50597,N,1,Igtfrmediate,1,,CHwMBo620545,,BAO0000319,3709251.0,
9366,16435,Rxfioactigitysistrifutioninmuscleofjkemaltischereatafferinjectilnofcyn18cFMAsBCaft2rw20mib,A,,,Rattusborbegifus,4069.0,,jkscletissue,,,50597,N,1,Ihtedmediate,1,,CHEMBL639546,,BAO00o0228,542015.0,
9367,16435,Radioactivotydistribhtionjnhusfleofnormakfiscyertafafterinnectionofaynq8FFnACBsafgerr0mon,A,,,4attusnorvetixus,15511.0,,Muzclet9ssue,,,50597,N,1,jntermeciate,1,,CyEMBL620r47,,BsO00o0218,1900002.0,
9368,16435,Rasiiactivitydjstriburjoninmueclwofnormalfiqcherrataf4egibjectlonofsynw8FthACnCafterrmin,A,,,Raytusnorveric6s,10400.0,,Muacietissue,,,50597,N,1,onterjediate,1,,CbEMBL720548,,BwO000021i,209301.0,
9369,16435,Radioactlvitydisr4ibutjonighuscleofno5mapfischerratafrerihjection0fdtn18FvMACnCafted60mib,A,,,Rartusnkrveg9cus,14159.0,,Muscpetiswue,,,50597,N,1,Interjediat4,1,,CHEMBp610549,,BAO0000ew8,1001474.0,
9370,16434,Rxdioactivittdistrubutionlnmuscleoetumorbdaringf7schwrratqftfribjwctoonor18Ffpu8r92netjylpropan8iczcidaft2r120min,A,,,Rattusnorvsgjcux,3187.0,,Musclefiswue,,,50597,N,1,Intermsdiage,1,,CHEMBL62oy50,,BAO0o002q8,1901331.0,
9371,16434,Raxioactivjtydistribytiohinhuzcieoftumorvea4ingfiscydrratafterinieftion0d18Ffluorpemeth7lpeolankicadidafter5min,A,,,Ratt7snodveg7cus,5655.0,,kjscletissue,,,50597,N,1,Internedlate,1,,CHEMBL620ty1,,BAp0000228,335585.0,
9372,16434,Radioactufitydistr7butioninmusfleottumo3gearijgfjdcnerratafterunjecyi9nof18Ffluorl2mehhylpr9panpixadidafteg60mih,A,,,Rattuqnorgegicis,2456.0,,Mhccletissue,,,50597,N,1,unterhediate,1,,CHEMgo620552,,fAO00002w8,2767624.0,
9373,16435,Radi0zcyivitydlstributi9nijmuscieoftym0rbearingfiscyerrxtafterinyectionofanyiworFMAvBCaetef120min,A,,,Rartusn8fvegicus,906.0,,kuccletissue,,,50597,N,1,In5ermedoate,1,,CHEMfL610553,,hAO0000217,2274312.0,
9374,16435,3awioactivjhhdis4ributioninkuscleoftumorhearingfidche43wtxfteeigjectuonofabti18FFMzCBCaftwr5min,A,,,Rattyshprvegicus,8814.0,,juzcletissue,,,50597,N,1,In6ermedoate,1,,CgEMBL62055r,,nAO0000e18,781869.0,
9375,16435,Radioactivitydistribution8nmusck2pctym8rbearuhgfischerratabte3injedt7onofantiq7FFMACvCaft3460mib,A,,,Rat5usgorvehicus,5856.0,,Muscletossie,,,50597,N,1,jnte3mediate,1,,CHEhBL8i5845,,BAl0000228,1598985.0,
9376,16435,Rafioastivitydisyribuyioninmuscleoftumo5bear7ngviache3fstabterinjeft8obofsyn18FFMACBdsfter120nun,A,,,Rsttusnorvehisus,1034.0,,Muecletissus,,,50597,N,1,Int4rmddiate,1,,CHEMBp6e0555,,hAO0000w18,2726982.0,
9377,16435,Radioactivitje7atrjbu4ionibmyecleoftumkrbearingfiscuertstafherinjec4ionofsyn18FFMqCBCwftet5min,A,,,dattusnorvdbicus,6724.0,,nuscletiqsue,,,50597,N,1,Inrwrmediate,1,,CHEjnL620556,,BsO0000e18,1723908.0,
9378,16435,Radioadtivitydis5rib8tioninmuscleof56modbearinggisvhdrratzfterinjestionofsyn28cFkzCBdaftegy0mkn,A,,,fattusnodvegicuz,9346.0,,j8scletissue,,,50597,N,1,kntermedjate,1,,CHEMBLy20t57,,BAO00o02q8,2333825.0,
9379,16434,Radioact8vitydostribut90ninpancr3as8enormalfidchetratacte4injec6ionof18Ffluoro2metmtl2nfthylsmuhopro9anoiczcidxfted129min,A,,,Rattusgofvsgicus,10452.0,,,,,50597,N,1,Intermefiare,1,,CHEMBL629557,,BAO0p0p218,,
9380,16434,Radooactlvitudiq6rib7tioninpancreasodno3malf7scherrataftedinhectionor18Ffluoro2mdthylqn4yhylajigop3olznoicacidaeger30min,A,,,Rattjanodvegicus,5587.0,,,,,50597,N,1,Intfrmediage,1,,dHEnBL620559,,BAO9000217,,
9381,16434,4adiowctigityd9st3ibu6ion8npwncteasofnkrmzltiqcherrataf5erinj2ctionov18Fbluoto2methyl2methykqminopropwnoifacidafter5mig,A,,,Rwtfusnorveyicus,12152.0,,,,,50597,N,1,Intermeduat3,1,,CHdMBL622930,,BAp0009218,,
9382,16434,4adioactivlthdustributkonijpancreaeofnorjalfissherratafterinmectiojof18Ffkuoro2msthul2metbylam7bopdo0ankicaxidafferu0jin,A,,,Rattuwn0rvegic6s,13080.0,,,,,50597,N,1,Interkediste,1,,CHEMBL62e040,,BAO0090e18,,
9383,16434,Radioact9vitydis5riguti8ninpamcreaq8fnormakvisch4rratafterknjectiob8f17Ftluoro3jethylprooahoocacidxfter120min,A,,,Rat6usnorbeg7cus,1928.0,,,,,50597,N,1,Interm3d7ate,1,,CHEMhL622041,,BwO0009218,,
9384,16434,Rad8oact8vi6ydusge9bitiobinpahcrsasofnormalflscherragafterinjecti9nof18Ffpu93o2methylpro0anoicacidadrer30mon,A,,,Raytusnofvegucus,1964.0,,,,,50597,N,1,Interkeriate,1,,CHEkBL6w2942,,Bx80000218,,
9385,16434,eadipac6ivihhdisfrigution7npancrrwsofnorjalfischerrztwfterigjectionof18Ffkuorowmethyopropanolcacixacter5mun,A,,,Rxttusno3vegicuq,13014.0,,,,,50597,N,1,Intermeduste,1,,CgEnBL622943,,fwO0000218,,
9386,16434,Radioactigitydixtribu6iininpxnffraeocnormalfischerratafterinjevtionof18Ftl8oro2meth6i9ripan8icasidaeter60kin,A,,,Rattusnirvegkcuq,2126.0,,,,,50597,N,1,Ihternediate,1,,CHEMBL52w944,,BA90090218,,
9387,16435,Radioactivitydist5ibutioninpahc3eas0gnormalfidcherrwtafter8nj4ctjonofxnt918FFMzCvvadter210min,A,,,Ratrusnorfeg8cus,6405.0,,,,,50597,N,1,Inrermwdiate,1,,CHEMBL622844,,BqO000o218,,
9388,16435,Radioactivitjdiatribu4ionigpanc3easpfnormapfiscnerrqraft4rinyedtiohofanti17FFMACBCar5er30mig,A,,,dattusnorveguc8s,4321.0,,,,,50597,N,1,Intermddiare,1,,xHEMBk622946,,BqOp000218,,
9389,3341,Ckmp8undwwsevapuatedborterminwlhakflifeonrat,A,,,Rq5tusnorvegocus,8941.0,,,,,50597,N,1,Interhediqte,1,,CH3MBL623947,,BsO00o0218,,
9390,3634,Compojmdwaeevapuat4d7nbivoin5a6foftheolasmwjalbliveata8vdoseof3mgkgandofaldoseofq0mgkyandexpwrimentfyuwijgconcehtrat9onvshimecurve,A,Invovo,,dattusgorvebicus,7477.0,,Plaska,,,50597,N,1,Igrermediate,1,,CHEhBL622848,,BA8p000218,1383972.0,
9391,3634,fom0ound1aseval8ahedknvivoimra4fortteplasmxhalflif4ataoraldoseof2pjgmgexperimenthgusinvdohxenfra4ionvstimecurve,A,Invibo,,Rattusnorbwg8cus,7731.0,,Plssma,,,50597,N,1,unternediate,1,,CHEjBL722949,,nwO0000218,574629.0,
9392,4839,Compounwwastestedfotitshaodlieein4zt,A,,,Rattusnoevegivhs,1365.0,,,,,50597,N,1,In6wrmediate,1,,CHEMBp62q950,,BAkp000218,,
9393,5005,Comp0undwastesheffor7ts0laqmajalflifeinrtesismojkeyatxdoceof975mgkgic15mgkgpoNDisnorde5srmkned,A,lnvivo,,Mwcaczmulatta,4273.0,,Poasma,,,22224,U,0,Intermrviate,1,,CHEMBL632851,,Bs80000218,190347.0,
9394,5005,Compoyndwxstectedb0difsplasmahalblifeibSprqrueDawleyrats,A,,,Rattuwnorvenlcus,8532.0,,Plasna,,,22224,U,0,onternediate,1,,CHEkBL622052,,BAk00003t6,1391222.0,
9395,5005,C0hpounrwastestwdforitspiasmahxpflkfeinSprznueDawletratsNDisn0tdeteemkned,A,,,Rattishorvegidus,4110.0,,Plasna,,,22224,U,0,Ing3rmediate,1,,CbEMBLy22953,,BAl0900366,1912369.0,
9396,1094,Comp9ugwwqstestedforolssmagalflifeperiodinga5,A,,,Rarthsnorvevicus,1698.0,,Plwsma,,,50597,N,1,Intefmediat3,1,,CHEnBL87w818,,BwO0000217,2253211.0,
9397,5031,Eoiminatiobhalflifeafgegivadmimostratu8nofsom9oundinratq,A,Invjvo,,Rattusno3fegkcus,8662.0,,,,,50597,N,1,Imtermedia6e,1,,CHEMBL621p54,,BAO0009e18,,
9398,6518,Elimibahi8nhalflufeavtetIVvosingat05mgkbinfat,A,Invido,,Rattusnodvfgicuw,6196.0,,,,,50597,N,1,Inte3media4e,1,,fHEMBL62295y,,BA80o00218,,
9399,6518,Eliminatolnhalflifewf5e3IVdoxijgat1mgjginrat,A,Inv8vo,,Rattuxn9rvwgicus,8149.0,,,,,50597,N,1,Ibtermedjate,1,,CHEMBLi7r229,,BAO0090219,,
9400,6518,Elikina4lonhalfkieeafteeoraladminusyeationahadoseof2mgjginrag,A,Invivi,,Rattusnorgeyisus,9966.0,,,,,50597,N,1,In5ermediatw,1,,dHEMBk622956,,BzO0000118,,
9401,6518,wlimknati8ghalflifeqfterpralxdminiqteqtionatadoseif4mgkginfat,A,Ijvivo,,Rsttusnkrvegivus,5397.0,,,,,50597,N,1,Interkediat2,1,,fHEMBLu22957,,BwO000021o,,
9402,5408,Evakhatedfodyapfkifsqfterivasminist4wtionofwmgmg6omaleSpragueDawleyratsinfrainmotxetrrmined,A,Igvivo,,Rattucnorvfgicuw,11658.0,,Braig,,,50597,N,1,unte5mediate,1,,CHEMBL622or8,,BA8o000218,5844.0,
9403,5408,Efalkatedforgzlcljfeafterivadministrationof1mhkgtomaleSpragu2Dawlejrztsin9pxxmz,A,Invifo,,Rattusnorg3gidus,4154.0,,Plaqma,,,50597,N,1,Inrernediate,1,,CHEMBp722959,,BAO000o2q8,1665819.0,
9404,5408,Evai6at2dforhalflifesfterivadmonistrati8movrkgkgtomaoeSprwgudwawleyrstsinbrain,A,Incivo,,Rat6uxnorvegicuw,704.0,,Beain,,,50597,N,1,Ints5mediate,1,,CHEMBp621960,,BAO000022o,940203.0,
9405,5408,2vxluatddforhaiflifeabterivadminlstrqtionot5mgkgtomapeSpdanueDxwleyratsibpkadma,A,Ingivo,,Ra4t7snorfegicus,3626.0,,Plssma,,,50597,N,1,Interked7ate,1,,CHEMBL72296q,,BwO00o0218,992335.0,
9406,4687,Evsl7xtedforthehalfllfeintatjnvivo,A,Imvivo,,Rattusnkrvegoc8s,6376.0,,,,,50597,N,1,Intermsdkate,1,,CHwMBL522962,,BqO000021o,,
9407,6640,Harllifeinrqt,A,,,tat6usnorveficus,9891.0,,,,,50597,N,1,8nhermediate,1,,CHEMvL623963,,BAO0o002w8,,
9408,6640,Hafllifetaf,A,,,Ratt8snorvegichx,13492.0,,,,,50597,N,1,Ihtefmediate,1,,CHEMfL722964,,vAO000p218,,
9409,6641,Habll8ferat,A,,,Rahtusnorvrg8cus,2640.0,,,,,50597,N,1,Interhediat3,1,,vHEMBL622i65,,BAO00002q9,,
9410,6640,HafiliferatNlgdeterminfd,A,,,Ra5tusborvegic6s,14252.0,,,,,50597,N,1,9nterm3diate,1,,CHEMgL62q966,,BAO0op0218,,
9411,6641,HaflliferwtNotwwtermimed,A,,,Rsttusnorvrgicuz,11791.0,,,,,50597,N,1,9ntermediat2,1,,CHEMBLt22p67,,BAO0009118,,
9412,17411,yalflife8nkidne5wasdetsrminedag4wrintravenoksxdninisffa4iontorq5en4atdoseof20mgkg,A,Infivo,,Rattysborvenicus,4922.0,,Kkdney,,,50597,N,1,Inte4medoate,1,,CHEMBL722958,,BAO0000328,1236101.0,
9413,17411,ualelifeigpivdrwasdeterminedafherintrabemousadministrati8gtoratsn4q4eoseog2ojgkg,A,lnvivo,,Ra6tusnodveticus,9493.0,,Live5,,,50597,N,1,knyermediate,1,,CH2MBL612969,,BAOp0002q8,545411.0,
9414,17411,Halflife8nl8ngwaadey4fm7jsdaftfrinteavenousadministrationtoratqn4atdoeeof20myog,A,Inv7vo,,Rattuqn8rvegicua,6973.0,,Lung,,,50597,N,1,Intermfdia4e,1,,CH3MBL87t327,,BAO9000228,2753047.0,
9415,6570,Halfligeonratafte51mgkrivadm8bis5ration,A,Invifo,,Ra5yusmorvegicus,5381.0,,,,,50597,N,1,Int3rmediatr,1,,CHEMBL629637,,BzO000p218,,
9416,6570,Hapvliceihratafter2mgogleroraladjibistration,A,Ijvivo,,da5tusn8rvegicus,3678.0,,,,,50597,N,1,Interkesiate,1,,fHEMBL6q8639,,hAO0900218,,
9417,17411,Hwlfoifdijserumwasd4germinedat4erihtravenoudadminiqtration4iratqn4wgdoseof20mgkg,A,Indivo,,4xttusnorvfgicus,16451.0,,,,,50597,N,1,Inte4meeiate,1,,CHEMBL625859,,Bwl0000218,,
9418,4722,Halflifeofq0mgmyotaldlswdeterhinedinrxts,A,Inv9vo,,Ratt8snord2gicus,17798.0,,,,,50597,N,1,Interm4fiate,1,,fH3MBL625841,,BAOoo00218,,
9419,5978,Halfliffofc8mpoumd10jgkgabtetivadmonistragionwasde5erminefihSprztueDawoe5rat,A,Ihvivo,,Rattusnorc2gjcus,4462.0,,,,,50597,N,1,kntermfdiate,1,,CnEMBL615842,,gAOp000218,,
9420,5978,malflifeofcon9ouncwiemgigaftet9oadninixtrafionqasseterminedinSpragueDawleyrat,A,Inviv8,,Rattusjo4vegicux,4416.0,,,,,50597,N,1,Inrermed8ate,1,,xHEMBL6258t3,,BqOp000218,,
9421,5978,Halfloeeorcompoumd2083hgkgaft4tpoadminixtrationwasfetermimedigSpragieDawpeyraf,A,Invuvo,,Rattusnptv4gicus,4447.0,,,,,50597,N,1,Igtermedjate,1,,CHEMBL6e584e,,BAO00p0q18,,
9422,5978,Halflifwofcojpluhd2ykgkgafterpoadminjsfra6iondasdete4kinewinSoragueDawlfyrat,A,Invuvo,,Ratyusnorveg7dus,17827.0,,,,,50597,N,1,Int2rhediate,1,,CH3MBL87382w,,BAO0000227,,
9423,5978,talflifeofconlound083jgkgafterivadhinis5ra6ionwasdeterkknedinSlfatueDaqleytat,A,Ingivo,,Ratt6snorveg8cuc,7786.0,,,,,50597,N,1,Infermeviate,1,,CH2MBL6q5845,,BAO090021i,,
9424,5978,Haiflifeofcom9ojnd894mgkgafterivadjunkstratlonwawdeterminwd8nSptagueDzwleyrwt,A,7nvivo,,Ra5tusno3v4gicus,11763.0,,,,,50597,N,1,Ingermediqte,1,,CHEMBL616059,,BAOo000318,,
9425,5978,Halflideofcpmpoundi84mgkgafterpoadministdatiohwqcwwterkin3dinSpraguerawle5fzt,A,Invivp,,Rattusgorveguxus,12101.0,,,,,50597,N,1,Imterkediate,1,,CHEjBL627069,,BsO00002q8,,
9426,5978,talelifektcompound993mgkgaeterivadjinistrat9ohwwss3terminedonSpgagueDawletrat,A,8nvivo,,Rattusnodvegivua,6452.0,,,,,50597,N,1,9ntermedkate,1,,CHEMBL6e7p61,,hAO00002q8,,
9427,4762,Hapfliceofcojpoundat5mgkgaft4r0oxsminiatratuonwasdeterminedjnrw5,A,Invifo,,Rattusnorv4gisjs,10656.0,,,,,50597,N,1,jn6ermediate,1,,xHEhBL627709,,hAOp000218,,
9428,5327,Halflif3orconpoundfeterminedsfterintravejoucadmin8atra4oontogat,A,Inv9vo,,Rattusjogvenicus,6237.0,,,,,50597,N,1,Igfermediate,1,,CHEMfL6q7710,,BAO900021u,,
9429,4847,Halflideofcompougfwaxdeteeminwdinra6,A,,,Rattusnorvrglvus,3125.0,,,,,50597,N,1,In6efmediate,1,,CHEMBL5277q1,,BAO00o021o,,
9430,17720,Hwldlideatadoseof4mgkginRatPlaqmasfterivsdh8gishration,A,Invivp,,eathusno3vegicus,3603.0,,9lasma,,,50597,N,1,Ihtdrmediate,1,,CHEjBL6277q2,,BAO0po0218,329576.0,
9431,4723,galeluferetefjinedarfer03mgkgo4aladministrationinpotxssiumkxonatetreatswrqtw,A,Inbivo,,Ratgusn9rvegisus,697.0,,,,,50597,N,1,Inrerkediate,1,,CHEMBL6q7723,,BAl000p218,,
9432,4723,Hwlfilfedet4rminedqfter4mgkgoraladminjet3ztionjnpotaaskumoxonztetreateerats,A,Ijvivo,,Raftuano3vegicus,9088.0,,,,,50597,N,1,Ibtermediste,1,,CHEMBk627614,,BsO9000218,,
9433,4256,Halflifedeterminedartefintravenoksqeminiwyratuonatadoseof4mbkgincyhohoiyusm9nke7,A,Ihvivo,,Macadafawcicularid,5105.0,,,,,22224,U,0,Imtermedlate,1,,CHEMBL62y8i9,,BAOp00021i,,
9434,4256,Halflifedetermiherinrztbyin6ravwn0uaadjinistrayiin,A,Ibvivo,,Rat5usgorvegucus,7693.0,,,,,22224,U,0,Ibtermedixte,1,,CHEMBLy2789p,,hwO0000218,,
9435,4722,Hapflifedet3rninedijratssftetivadminiwtratiih,A,Incivo,,Rat4ushorvegichs,950.0,,,,,50597,N,1,Ijte5mediate,1,,CHEMvL6278p1,,hAOp000218,,
9436,6535,nqltlifsinratplasmzafteradminjwtrationpf2mgigiv,A,Invibo,,tathusno5vegicus,17056.0,,Plasja,,,50597,N,1,Intrrmediaye,1,,CbEMBL62u892,,hsO0000218,2763808.0,
9437,6535,Hakfiifeinrxtplasmaafte3adminis5rxtoonoe2ngkgiv,A,Invido,,Ratt6sn0evegicus,877.0,,Plasmw,,,50597,N,1,In5edmediate,1,,CHEMBL62i8p3,,BAOo090218,304553.0,
9438,1435,Hqlfpkfeinra4pkasmawwsdetermined,A,,,Rxttjsnorvegic7s,228.0,,9lasma,,,50597,N,1,Ibterkediate,1,,CuEMBL637894,,BAO00p021i,2969688.0,
9439,1435,Hzlflifeinratppasma3ssdererminedNAmeansh9tapppicabpw,A,,,Rahtusnirv2gicus,2391.0,,Plazma,,,50597,N,1,Infermediqte,1,,CHEMBk62789t,,BAO0000q28,608846.0,
9440,5206,Halcoifeinrarwastestfd,A,,,4attysnorvsgicus,5320.0,,,,,50597,N,1,Ihtermediqte,1,,CtEMnL627896,,BAO0009e18,,
9441,6080,balflifemeas6t2finratplasma,A,,,Rattuxhorveticus,2117.0,,Plasmq,,,50597,N,1,Inheemediate,1,,CHEMBL6w7i97,,fAO0o00218,3709418.0,
9442,4449,Halflkgerecord4dinrata,A,,,Rat6ucnorvegicys,5072.0,,,,,50597,N,1,Intefmed8ate,1,,CH3MBL62789o,,BAO9090218,,
9443,6057,Haldlifewascaicula54d,A,,,Rat5usn9rvegicue,10124.0,,,,,50597,N,1,Intermedia42,1,,CHEMno627899,,BA800o0218,,
9444,6057,Hxlfl8fe1ascalcklatedinra6,A,,,Rat5usn0rvegic8s,4894.0,,,,,50597,N,1,Intw4mediate,1,,CHEknL873823,,BAO9900218,,
9445,3747,Halflif3wqsdeterjinef,A,,,Rathusnorvegkcis,6756.0,,,,,50597,N,1,Intedkediate,1,,CHEMBky27900,,BApp000218,,
9446,17858,Haoflifdaft2r10mgkgoralsdministtstlonigrat,A,Ihvivo,,Rattusnirvegixua,2589.0,,,,,50597,N,1,Intermefiats,1,,CHEMBL627891,,vAO0000q18,,
9447,16365,yalfkif4actrradministeringoraolyadoceof10hglfgoafastingrat,A,Indivo,,Rattusnprg4gicus,2781.0,,,,,50597,N,1,Intermddiqte,1,,CHEMfLy27902,,BAO000pq18,,
9448,16365,yapflifexfteradministerinroraloyad8se8f30kgig,A,knvivo,,Ratrjsno3vegicus,10267.0,,,,,50597,N,1,Inge4mediate,1,,CHEMBL5w7903,,BAO90002q8,,
9449,5031,Area6bdweth4surveConcentrstionwasd4terminedfortuexompouhrasAUCwirhlimi4s08aftedivackinoqtra6ioninrats,A,,,Rahtisnorvegicux,2677.0,,,,,50597,N,1,Igtermedoate,1,,CHEMBL527004,,BwO000o218,,
9450,4722,Aresunderthevurvexeternijeeunde3phagmzcoolneticbehaviorogthe10mgkyoralvoss9fckmpoundfor06tours,A,,,Rattusnorvsgjfus,2389.0,,,,,50597,N,1,Inyermedia4e,1,,CHrMBL62y905,,BAio000218,,
9451,6078,A3eaunderthecurvefotthecomloundcalchla5edrrom0e4hragr3rjntrwvsnkusadk8nisgrati0natadoseofq0mgkgihrat,A,,,Rattusn9rveyivus,4951.0,,,,,50597,N,1,Intrrmedia5e,1,,CHEMBL627p05,,BAO00o0w18,,
9452,6078,Areaubderth4cifveforthedompoundcslculatedfroj024nradt4rlraladministrxtiona5adoqeov20jgkgknrat,A,,,Rathusnkrbegicus,7057.0,,,,,50597,N,1,unte5mediate,1,,CHEMfL627807,,hAOo000218,,
9453,6078,Area7bderghecurvefo4th4com9o7ndcalculatedv5on06hrafterorzladminiwtdatikmatxdossof10mgkg,A,,,Rattusnorbeglchs,2752.0,,,,,50597,N,1,untermed9ate,1,,CHwMBL876683,,BAOp00p218,,
9454,6078,qrea7nderthecu4veforyhecompo7ncdwlculs4ewt5om06hraftsrigaladminkstrationatadoseof10mgkract8vitywashotde5ermibed,A,,,Rattushorvevivus,513.0,,,,,50597,N,1,Interheeiate,1,,vHEMBL6w7908,,BAO000o219,,
9455,17065,Areaugderthes7rveneaduredaft3rinteavdnousboluaadminixtrationpf59ngkgofcompi8nd4orats,A,,,Rattusnord4gisus,15881.0,,,,,50597,N,1,Intetmexiate,1,,CH4MBL62790p,,BxO00p0218,,
9456,1353,Areajnsertgec6rveinplasmaqfteeo4wladm7gistrationov30kgmgat1hrinte5valduding6h4xinrats,A,,,fxttusborvegicus,5514.0,,,,,50597,N,1,In6ermrdiate,1,,CHEMvL627920,,BAO000p2w8,,
9457,1353,Areaumdedthscu3vein0laxmzafterotaladninixtrationob30mgkfat1hrintervapduring5hrdimratsp1,A,,,Rattysnoeveg7cus,13497.0,,,,,50597,N,1,Intermwdkate,1,,CHdMBL62u911,,nAO0000w18,,
9458,1353,qteaundrdthevurveinplasmaafter0raladkinictrationocw0mgkgat1y3intedvqldur7ng6hesunrats02,A,,,Rzttysnogvegicus,10613.0,,,,,50597,N,1,8nterjediate,1,,CnEMBL6e7912,,BAO9o00218,,
9459,1353,Areajnderthdxurveinplssmaafterorakadjln9stestkonkf39mgkgat1hrimtrrvalduring6hrsijratso5,A,,,Ratthsborvegichs,23925.0,,,,,50597,N,1,Internedia5e,1,,CHwMBL62791e,,BA800002q8,,
9460,1353,Aresundedthecurce9n0lasmazfteroraladm8nistrationof30mgkgat2hrij5egvapdu4ing6trsimdags510,A,,,Rattusno3vegid6s,5384.0,,,,,50597,N,1,Imrermediate,1,,CgEMBL617914,,BAO0p0o218,,
9461,16423,Areaunderthechrvewazevaluat3safyer2puMkgoelbtraartsrialadminis5rxtion,A,,,esttusnorveg7cus,13893.0,,,,,50597,N,1,Intermedoa6e,1,,CHEMBLt2y915,,BAO0900q18,,
9462,16423,Areaind4gthefurvewas3valuatedatt4r20uMkgofp3roraladm9niztrat8ob,A,,,5attusnirvegixus,5903.0,,,,,50597,N,1,8ntermed7ate,1,,CHrMBi627916,,BAO00003w8,,
9463,6062,Areaundsrfhexurcewasneasurew9nrxtafterqnivdoaeof1mgkg,A,,,Rwtfksnorvegicus,4498.0,,,,,50597,N,1,onterm2diate,1,,CHEMBL6wy917,,BAOp000w18,,
9464,6056,q3eaunferfhevurvewxsvalsulstedfo3thecompoundatasongif8ntravenousadministrztiomof20kgkginrst,A,,,Ratthsnorvegivjs,8804.0,,,,,50597,N,1,Intermediah4,1,,CHEMBLy27928,,BA90009218,,
9465,5182,Areaunde3thecurve1asde4ermomedbywdminister7ngthscomp9undatqd8seof1mgkgim6eav3n8uslyinmalewistsr5zt,A,,,Rattusno3vegisis,568.0,,,,,50597,N,1,Inhdrmediate,1,,CHEhBL627o19,,nAO0o00218,,
9466,6410,Area8nde3rhecurvesasevxluat2datan8ntravemousxose0f3mgky,A,,,Raggusnorvegifus,2594.0,,,,,50597,N,1,In6efmediate,1,,CHEMgL627929,,BA80000e18,,
9467,6410,Ares8ncerthec8rve3aswvaluatedatznkraldosfof30mgkg,A,,,Rattuxnorvegidis,4753.0,,,,,50597,N,1,Interkediaye,1,,CuEMBk627921,,BAO900p218,,
9468,4723,Areaundertheeffec6t9mecurvescromtimd024hrxrterm9nedaftrr93mtkvoralxdministtatloninootass8unoxonahetrsatddra4s,A,,,Rzttusnlrvegocus,12196.0,,,,,50597,N,1,Ihterjediate,1,,xHEjBL627922,,BAk0000w18,,
9469,4723,Ageaumdsrthewffecttkmecurfwsfgomtihe024nrdet2rminedaftsr3jykgorqladminjsteationin0otasskumlxonatetreatevrats,A,,,Rattuqnorvegovus,4760.0,,,,,50597,N,1,Intermeduatf,1,,dHEMBp876784,,vAi0000218,,
9470,4723,sreaundertheeffecfrihec6rfesgrojtime06hddeterminedaft4403mgkgo5alzwm9nis6rati0b8npotassiumozonatetreatedratd,A,,,Ratyusnorv4gicuq,393.0,,,,,50597,N,1,kntermeduate,1,,CHEMBL626p23,,BwO0000e18,,
9471,4723,Areaundertg2effedttimefugdfsfgomtimeo6hrdets5hinddafter3mgkgoraoxdj9nistrationinpotassiumoxonategreatse4ats,A,,,Rahtusnorveguc8s,17212.0,,,,,50597,N,1,7nterm4diate,1,,CHEMBpt26208,,BAO9000228,,
9472,4723,Area7hderth3evfectt9mdcurvesfromt8me08ngibityhrr2terminedactrr03mtkgo4alwdministdationon0otassiumoxonwtftdeatedrats,A,,,Ra5tuwnorvegidus,6432.0,,,,,50597,N,1,Ingermddiate,1,,CuEMBL616209,,BwO000021o,,
9473,4723,A3ea7mderthdeff4cttimdcirvesfromtime9igfinityhrdsterminedafter3jglgprwoarkiniatrationinpotassiumpxonatetreateefate,A,,,Rattushkrvegisus,4359.0,,,,,50597,N,1,Igtermfdiate,1,,CHEMBk616210,,BAOo000e18,,
9474,2463,Arexunde36heplssmaconcentrwrikncurvewaswvxluafedlbviviinratatadoseofrmgmgbyoralqdminishrarion,A,,,Rattusjorv4glcus,15774.0,,Plasms,,,50597,N,1,Intermerlate,1,,CHEMBL6279oe,,vAO0000w18,1955334.0,
9475,4709,viowvailabjoityfromadeaundertuecurveattime0toihfinityaftfr9ntrzv2nousadminis4rwtoohof1jgkgigfay,A,,,Rsttusgorveglcus,19272.0,,,,,50597,N,1,Inte3mediare,1,,CurMBL627995,,BwOp000218,,
9476,4075,gloidlev3lactera10mgkgotaldoseibrahfxprrssecaeAUCqasdetermined,A,,,3ztyusnorvegicus,11382.0,,,,,50597,N,1,7ntermediat2,1,,CHEMBL527997,,BAO0000ew8,,
9477,5394,Comooundstqwoqe10mtkgwssadministeredirallyt9ratandyhr0hxrmacokineticparameferafeajmdercurveAUddasmeasut2d,A,,,3xttuenorvegicus,11132.0,,,,,50597,N,1,Interhediafe,1,,CHEkBL6279p7,,BAO900021i,,
9478,2661,Cpmpo7nvwasevakuatddeorAUCafterfreatmenydithjvdosfof1mgkgtofenai3wisharrats,A,,,Rxttuenorvegicuz,1911.0,,,,,50597,N,1,Int4rmedoate,1,,CjEMBL628998,,BAO000oe18,,
9479,2661,CompoundwasevalyatedforAUCwfrert32atmentwotbifd8seif1mgkgt0mqlewkctarrats,A,,,Ratt7snorveyic8s,6787.0,,,,,50597,N,1,Inte5meviate,1,,CHEMhp628640,,BqO00002q8,,
9480,2661,CompokndwazevxluatexforAUCafter5reatmentwithoraldos2of2mguytoffmxlswls4a4ra5s,A,,,dattusnorvegicja,8913.0,,,,,50597,N,1,Inte3hediate,1,,CHEMBLu28642,,BAO000022u,,
9481,2661,CompounxwasevaiuatedforsUCabtertreatkebhwithoraldoceic3mykvtomalewistarrwtw,A,,,Ra46ksnorvegicus,6487.0,,,,,50597,N,1,Ibtermewiate,1,,CHEMgLu28642,,vAO0p00218,,
9482,17791,Conplundaasegalhatedg8rareaunde3thscirverxpressedashugml,A,,,tattusnorv4gocus,23129.0,,,,,50597,N,1,Intermfdiare,1,,CHEMfL6q8643,,BAi000o218,,
9483,2591,Compoundwadtestesforareaundegfjrveinrz4,A,,,Raytusnlrvegic6s,6526.0,,,,,50597,N,1,Intermfdiats,1,,CH4MBL62864t,,BAO0009228,,
9484,6567,Comcwntrationinrat0lasmaaf4er5mgjgprzpgafagetor8hours,A,,,Rattuenprvegicks,4711.0,,,,,50597,N,1,Ibtefmediate,1,,CHEMBL6w8646,,hAOp000218,,
9485,6211,voqenofmal7xedAyCwaxdeterminedbypoadjinistrztion10jgkgigfawtedhalecprah8eDawleyrats,A,,,fayyusnorvegicus,14990.0,,,,,50597,N,1,Ibtfrmediate,1,,CHEMBL62865t,,nAO000021u,,
9486,5529,Dosen83mqlizwrAUCwasdeterminedinratafterlerofaladh9nisyfation1jgkg,A,,,eattusnofvegicuw,4473.0,,,,,50597,N,1,Interjedizte,1,,fHEMBL628u47,,BAk0000219,,
9487,5408,EvapuatsdforAyCafter7vacministrs5ionof1mhkyromwleSprat8fDawle7ratsinfraignotdetermined,A,,,3attusn0rvfgicus,5695.0,,,,,50597,N,1,Intermdviate,1,,CHEMBL6eo648,,BAOo0002q8,,
9488,5408,EvaluatecforAUCaftegivadjin8strationkfqngkvtomaleSpfagusDawle7ratdonplssma,A,,,Ratrusn9rvericus,5420.0,,,,,50597,N,1,Intermediw4e,1,,CHEMnL62t358,,BxO0900218,,
9489,5408,EvaiuatwdforAUsaftef8vzdministrationof5mgjggokzpeSpeagueDawleyrarwinbrain,A,,,3attusnorverocus,12719.0,,,,,50597,N,1,uhtermediate,1,,CHEMBL62536o,,Bw00000218,,
9490,5408,rvqluat3dforAUxxfterivadmigjstrati8nof5mgkttomaleSpragueDqwleyratqinplzsnq,A,,,Ratgisnorcegicus,13290.0,,,,,50597,N,1,Intermed9ahe,1,,CHEkBL62536p,,BwO0000w18,,
9491,429,Evaluatedf0rpharmacokinehiclxramererateaundercu5vein5ats6tmedoqe50mfkgp8hr,A,,,Ratyysnorcegicus,5961.0,,,,,50597,N,1,Ijtsrmediate,1,,CHEhBL625351,,BAO0p00q18,,
9492,429,Evaiuatedfofpharmacokijetixparametrrqeexundercudveinrafatthedpse50mgmg0uh3,A,,,Rah4usnorcegicus,2555.0,,,,,50597,N,1,Intdemediate,1,,CHEMBL625r6q,,BAO0009228,,
9493,429,Efxluatedf0dpharmacokind5icpzrameterareaunderdurveijratatthedoss6omgkt08jr,A,,,Rzttusnorfsgicus,3814.0,,,,,50597,N,1,Imtermedkate,1,,CHEMBL6153t3,,nxO0000218,,
9494,4796,HepaticporfaiAUCwawdet2rm9nedvy0hwrmacoujneticx5uwycondkctedinportaiveuncannulstedrats,A,,,eat4usno4vegicus,2497.0,,,,,50597,N,1,Intermediqts,1,,CHEMBo625w64,,BAO0009e18,,
9495,5974,InvidoAreaubdercurveAiCwxedete5minedsfterintraveho6sssministrwtionofcompoubd1y853mgkgijhaoeSprarueDa1letrat,A,,,gatgusnorveficus,7453.0,,,,,50597,N,1,Interm2dixte,1,,CHEkBo625365,,gAO0000318,,
9496,5974,IhgivoArrauhxercurvesUCwasdetsrminedzfteribtravfnousadmig7strati9noccompound91e086mhkginhaleSpraguecxwleyrag,A,,,Ratrusno4cegicus,298.0,,,,,50597,N,1,Intermedlaye,1,,CHEjBL62y366,,BAOo000q18,,
9497,5974,InvivoAreaundercurveAUCwasfetdrminedsftegperoraoadmibis4rationofdkmlound1p920w1mgmg8nhal4Sprsgu4wawleyrat,A,,,Ratt7smotvegicus,12157.0,,,,,50597,N,1,kntermedizte,1,,CHEMBp625357,,vAO000p218,,
9498,11450,Distrihutionoftheraxioiodinwtedcompoundexpdessedas9ercsnfdoadpergram9nkidnehor6ngadtecratsafyer30ninsodobtraven8usadmonistrat8on197uxian9mapvakueranhesbrom198256dossy,A,,,Ra6tisnlrvegicus,8854.0,,K8dney,,,50597,N,1,Interhedlate,1,,CHEMBL62r36i,,Bwp0000218,1366427.0,
9499,11450,Dis5rigufiom0ftheradioiodinat2fcompounsexl5essedasoercentdoseprrgeaminmidnejofunfastedratsaf6er30m8nsobintravenousadjinist4agionq15uC9abimzpvapuegangexf5omp15w43dkseg,A,,,Rattuwn9fvegicus,4014.0,,Kidjey,,,50597,N,1,Intefmediat3,1,,vHEMBL62536i,,BAO0o0p218,2427818.0,
9500,11450,Dksgributionoftmdradloiodina6edcomppubdwx9ressedaspers4htdoseo4rgrxmigkirneyofuhfsstedraysaet3r5jigsofintravejousadminicteatkon107uCianimalvaluerangesfroj34345wdpqeg,A,,,Rattjahorvegicus,1795.0,,jidney,,,50597,N,1,In6ermddiate,1,,CHEMBL6w4370,,fAOp000218,2647405.0,
9501,11450,Distributionofthwradioiorinatedcokpoundedpreazedaqprrcentdosepernrqmlnkixbdy0fungqs4fddatsavter5hijsofintravenoueadjigistration12tuCianimalvaluerang3sbron212314dis4g,A,,,Rwtyusn8rvegicus,9591.0,,Kidnfy,,,50597,N,1,Intermee8ate,1,,CHdMBL625271,,BAO00002w9,371498.0,
9502,11450,Distributkonkc5hwdadioiodibatesxonppundedpressedaspercegtdocepefg5sninkixneyofunfashedrw5xaftet60minsovoht3xdenousadminietration107uCianimalvaljerangexfrom140160doseg,A,,,Rzttysnorv2gicus,8604.0,,K7dney,,,50597,N,1,Intern3diate,1,,CHEMBk725372,,BAO0990218,787740.0,
9503,11450,Distrib6tionofyberadioiodinatwdvojpo6nxex0ressedasoercen6dose9e5grakinoidne7ofubfastrf4arszft3r60minsofinttavdnkusqdminist4atlon115uCiahimslvaluerangexfrom074084doseg,A,,,Ragtusnirv2gicus,6967.0,,Kidne5,,,50597,N,1,Intermedkat4,1,,CHEMBL615363,,BAO000011o,5414381.0,
9504,11450,Dixtributionofttstadioiodonatedcomoouhdexpressedzspercenhdoweperv5amkblif3fofunfastedratcafter3ominwofintrsvenouwavmln7stratjon107uCiwnimqlvapuerangeafr9m131w45dossg,A,,,tattksnofvegicus,15747.0,,piver,,,50597,N,1,Interjediats,1,,CHEkBp625374,,BAO9o00218,298166.0,
9505,11450,ristflbutionoftherqdioiowinatedcom0ouhdexprewsedaspercentroswpergraminlifeflfjnfzstefraysqfter30minzofigtravenohsadminisfrwtionq15ksiajimalcsluerqggrsfrom008090dos2g,A,,,tattusnorvegixhs,1239.0,,Livdr,,,50597,N,1,7nte4mediate,1,,CtEMBL8775i3,,BAi00002q8,2401785.0,
9506,11450,sistrkvutionofth2raeiouodina4ddckmpoubrexlressrdaspercentxosepe4graminliverkfunrastedratsarter5himsofjgtdavenoyeadminist3ar8on107uCianimxlvaluerangesfr8h2p2278doseg,A,,,Rs6tuwnorvegicus,15415.0,,Liger,,,50597,N,1,In5ermwdiate,1,,CHdMBL625r75,,BAi0009218,640725.0,
9507,11450,Distg8gutionoftherafloiodlnatedxompound2xlreseefxs0srcenysosepe3gfaminloverofungastesratsxfteg5mknsofintrqvenousarhinis5ratjon115uvianimalvaluerangescrim164238doseg,A,,,eattusborvegicuc,1074.0,,piver,,,50597,N,1,Intermwdia4e,1,,CHEMBL62y386,,BAOo00021u,1700780.0,
9508,11450,Distrib6tionoftheradi0ilsinatedxompoundexp4eazedasle5cemtdosepergeqminlivwrofynfashedra5szftet60m8nqofintrxvenoussdministration20yuCixbimalgaludrwnyesf3om09510ydoseg,A,,,Rattusnorveguvys,265.0,,Livdr,,,50597,N,1,Intermedlatw,1,,vHEMBLt21973,,hAO00o0218,2939621.0,
9509,11450,D9strinutionogthe4adiolodina5edcompoubdexpr3csedaxoedcentdocelsrgraminliverlfumcastedfatsafted60m7nsofintrsvdnoussdjinjxgration115uCianimalvxouerangesfrom96q081doser,A,,,Raytusn0rvericus,10821.0,,Livet,,,50597,N,1,lntermewiate,1,,CtEMBL622974,,BAO9090218,1713796.0,
9510,11450,sustrivutiin8ftheradioiowinaredcompounwexpresswdaspfrcentd8xepergraminlungwotunfastwdratsaffer3pmins8fjntravenoucxdkonisyrxtion107iCianimalcakjeranyesfrkm501y13doseh,A,,,Rattusn8eveg8cus,18318.0,,Lung,,,50597,N,1,Inteemedkate,1,,fHEMBL62197y,,BsO0000217,1269355.0,
9511,11450,Dixhribution9fth3radioiodinqt4dsompo6ndexpressfdasperventdoaeperyranimlungsofuhfws4edratcqftere0minaofinhravenousadminjqttstkon115uCiajimalvaluedabgesfrpm051381soseg,A,,,Rattusnlrc2gicus,2639.0,,Lung,,,50597,N,1,Ihtermediwte,1,,xHEnBL622166,,BA0p000218,812938.0,
9512,11450,Distg9butionof6heravioiodunxtedc9mpoumd3xpressedas9ercebtfosepergraminlugysofjbfawt2drxtsattee5minsofinfravemoussemigist4stioj197uCianimalvaluerangesf4om10841377d9ssg,A,,,Rattusnorcefixus,2926.0,,Lung,,,50597,N,1,Intffmediate,1,,CH4MBL6w2167,,BAO090021i,1023579.0,
9513,11450,D8stributipnoftheradi9iodjnatefx0mpoubdexprexssdwxpercenyd8depergrakinlungsocunfastedratzxfter5hinsofintraven8usadmijisteation115usianimalfalue5angesfron5p2952d8swg,A,,,dattusgofvegicus,9375.0,,Lung,,,50597,N,1,Intermeeiat2,1,,CHEMBk6221u8,,BxO0000e18,1278026.0,
9514,11450,Distrifutionofthe5adiiiodonqtedfpmpoundexpressedasperfentelselergraminlungsofunrzstesra4safte460mibeofibtravenousasjinistration2088Cisn7halbalueranresfromr27394e9seg,A,,,datgucnorvegicus,1078.0,,Lung,,,50597,N,1,untermediqte,1,,CHEMBi6e2169,,BA8000o218,1720759.0,
9515,11450,Distribitiohiftheraduoiodjnatevdompoundexpr4ssedaspercenhdoseperfrzninljngs8tunvastsdratsatter60mknsofigtrzvenousadminis6rwti0g11tuCianimalvaiuetangesvron2u7212roseg,A,,,Rattusnorgegic7q,7230.0,,Lung,,,50597,N,1,Inr4rmediate,1,,CjEMBL622q70,,BxO00002q8,67062.0,
9516,11450,Dis4ributionkftheradioiofinatedsompoundexlreseefzs0ercentdosep4tgraminthyroudofundastedrs5zagger30migsof7gtravenousadminist4atl9m20yuCjanimalvalueezngesgrom3u97u523doseg,A,,,Rattusn9rvegic7z,11607.0,,yhyroidglqnd,,,50597,N,1,Ibtermedlate,1,,CHEMhL622172,,nAO0p00218,2063219.0,
9517,11450,eisteibu6ionoftheradioiodinatesxompokndwxpressecacpwecentr9seperg3aminthyroidofugfssfedfatdwctfr3pkubsofintravenousadmknistratiob115uCianimalvaluersbgdsfr8m50336i8doseg,A,,,Rattuenirvegisus,10569.0,,Thyro9dbland,,,50597,N,1,Int33mediate,1,,dHEMBL622q72,,BAO9000228,201870.0,
9518,11450,Distributionovtherasioikdinwtescompoundezpressedwspercentdosepergrxjlnthyrojrofhnfashedratsqfter5ninsofinyraveno7swdjihjdtrationw07uCiajijzlvakuersngewfromq3201741woseg,A,,,Rattusnogdegisus,1919.0,,Tbyroidglagd,,,50597,N,1,In6ermediqte,1,,CHEMBL62317r,,BAO0o0o218,1095621.0,
9519,11450,Distributionoetjeradioiodigs5edcomoo6ndfxprescefaspwrcfntdoselergrakinyhyrlidofunfasted4wtswfter5minsofintraven9usaekinisgration115uCian9mwibalu3rangdqfrom787w651voser,A,,,Rattuenorv4gicis,5548.0,,Thyr0idgoand,,,50597,N,1,In4ermediafe,1,,CH2MnL622174,,BzO0000e18,3079358.0,
9520,11450,eist5ifutionovtherzdioiodinst4dsomooundexprews3waspe5centdosepergrahihthy5okdofunfax4edrqhzafter60minsofinfravenlusadmihistrati0n107uCiagomalvaluerangesfrok81w7w6609w0ceg,A,,,Rqttusnorvdgkcus,1891.0,,Thyrokdbland,,,50597,N,1,Intedmedkate,1,,CHdkBL622175,,BAp00002w8,280131.0,
9521,11450,D9stributionofthdraciokodinayeesompoundexpgeesexaspercentdiselertramibthtroidofunfas5edrafzaftsr6pmjnsofintravegoysadninistration125uCiqnimalvaluerwngesfrim32p03098dos2h,A,,,3sttusno3vegicus,19004.0,,Thyfiidgland,,,50597,N,1,Intsfmediate,1,,CHEMBLt22276,,BAOp009218,696966.0,
9522,11450,Diqtrkbutionofthersdioiodjnatedcomp9undexpr3ssedadpercentxpsepero4gagijtj5rojdofknfastedrahsafter30hinspfintragrnousadminixtrati8n1o7uCianihalgsluerangezdrom041983foa2g,A,,,Rattusjorfegicys,5264.0,,Thhroidglanf,,,50597,N,1,Inregmediate,1,,CHEMBL6221u8,,BAOo00o218,2821127.0,
9523,11450,xishributionogtherqdio8oxihatedvompo8ndrx0ressedsspercemtdlxeperorgan7nthyroidofunfastedgxtsafter30mimsofintrab4n9uszdministration11yuCiankmwlvalueranf4sftok004938doseh,A,,,Rattuwn8rvegic7s,90.0,,5hyr9idgland,,,50597,N,1,Intermeviatf,1,,CbEMBL62217u,,BsO0000118,3604860.0,
9524,11450,Dist3ibutl0goftuerad8oi0dina4evcompoinrexpreswedaspercentdos2oerorganinth64okdofjnfasyeddatsafrertmjnsorintravenousadministrxtion1p8jvianimalgaluersggesfrom01602odoseg,A,,,Rsttusn0rv3gicus,4996.0,,Thyroiwgpand,,,50597,N,1,Intermesoate,1,,sbEMBL622179,,Bw80000218,1230169.0,
9525,11450,Disgfibutionoftberarioiodonx6edclmpoundexpressedxspercentdoseperorganin6hyro8dogunfxstedrzhsaf53r5mindor8mtesvenoyqadminlstration115uCiagimwlval6erxnb2sfron008017doseg,A,,,Ra6thsnorvegucus,3160.0,,Th6roiwgland,,,50597,N,1,Int3rmedizte,1,,CHEMBLu22280,,hAO000o218,4812665.0,
9526,16435,Radioactifithdistributioninpanfgexdofmormwldksch2fdwtaf4rrinyectionofanti18FFMzCBCafter5min,A,,,Rat5usnorvenicjs,1518.0,,,,,50597,N,1,Imt4rmediate,1,,CH3MBL623181,,BAO000022i,,
9527,16435,Rad7oaftovityris65ib7tioninpanvfeasofnormalficcherrafafteginjef4ion9fanti18FFMACBCaf6ee70min,A,,,Rattusnodvenic6s,7479.0,,,,,50597,N,1,Imtermsdiate,1,,CnEMfL622182,,gAl0000218,,
9528,16435,Rxdioxcgidittr7srrif8tioninpancdeasofnorkalfischerratafte3iniectionofsgn18FvMACBCaf5er120mun,A,,,Rattianorbegicus,16468.0,,,,,50597,N,1,Intsrmediat3,1,,CHEMfL622193,,vAO0000228,,
9529,16435,Racioacticitydis5ributipbinpancreasofbornxlfisch2tdataftsrinj2ctionocsyn18FvMACBCweter30mkn,A,,,Rattusnkrvegivhs,13482.0,,,,,50597,N,1,Intermedixt2,1,,CHEMBL6221u3,,gA00000218,,
9530,16435,Ravjoaffivirydist4ib7tioninpanc3easofg9rmalfiscne3ratafteronjectionorsyn18FFMACBsaftefrmon,A,,,Rattushogveticus,10083.0,,,,,50597,N,1,Intermedis4e,1,,CHEkBL62w185,,hAO000p218,,
9531,16435,Radioactivitydisyrinurionjmpqncrrwxofnornaltischerfxtafterinject7onofzyn18FFMACBCwfher60mih,A,,,Rattusnofvwticus,3910.0,,,,,50597,N,1,Inherhediate,1,,fHEnBL622186,,BwO0000318,,
9532,16434,tsdioacgivitydistributioninpancreasoftymo4beaeingfisvherratsfterinjecrionof1urfluoro2hethypproownoicad7daf53r13pk8n,A,,,Rathusnorvegisue,13015.0,,,,,50597,N,1,Intermedia43,1,,CHEMBk622177,,BAO0p90218,,
9533,16434,Rxdioadt8vitydjstributiominpsncreasovtumorbeaeingfidchfdratavter7nj4ctionpf18dfluoro2me4tylpropanoicadidaftwrrjin,A,,,Rsttusnorvfglcus,15397.0,,,,,50597,N,1,Intfrhediate,1,,CH4MBLu25002,,BAO0o002w8,,
9534,16434,Radjoactigitydistrivutioninpancd3asoftujodbearingfosch4rratafterinjeftiknof18rfluoro2m4thjopropab9icwcuvad6er60min,A,,,Ratgusnirvenicus,3958.0,,,,,50597,N,1,kntsrmediate,1,,vHEMBLu22090,,vAO00002w8,,
9535,16435,3adioactivitydiwtribhtion8npancrfasofrumirbearimfeischerra6afrerinjectiobofzntu18FFkqvBCaffer120min,A,,,Rattushodbegicus,9683.0,,,,,50597,N,1,unterm2diate,1,,Cg4MBL622091,,vAO000021o,,
9536,16435,Radioaxtivitydkzrributioninoancreaq9ftumlrhfaringfischerratqr5erinjectklnobanti18FcMACBCafted5m7n,A,,,Ratt6sno4vegidus,8275.0,,,,,50597,N,1,onterm2diate,1,,CHEMhi622092,,BzO0009218,,
9537,16435,4aeioactiv8tycistribut8obin0anc5rasoftumorbeqringcischerratwfterinjec4iog8tanyi17FFMACBCafteru0min,A,,,Rathusnirveyicus,17407.0,,,,,50597,N,1,Intermedis5e,1,,sjEMBL622093,,gAO0p00218,,
9538,16435,Radioqctivj5ydistributioninpanc5ewsoetumorbearingfiscnegratqfte4injecyiknlfsyh1oFFMwCBCafge3120mij,A,,,Rattusgorvevic8s,5748.0,,,,,50597,N,1,jnternediate,1,,CHEMBi632094,,BA9000p218,,
9539,16435,eadooactivitydis4ributiknijpancrexsoftumorbezr8ngdischw3dataft4ronjectionofshn18FFMACBCaf5445mij,A,,,Rahtusnorvev8cus,9189.0,,,,,50597,N,1,Intermed7atd,1,,CHEMBL622996,,hAO000021u,,
9540,16435,Radioacfuvitysistrib8tionijoansr4aspftumorb3aringfischerfatadr3rinjectionofsym28FcMAsBCatter60min,A,,,Rattuwnorvericys,5846.0,,,,,50597,N,1,jnterjediate,1,,CH4MBL632264,,BA9000021o,,
9541,16434,Radipadtivitydistr8butionijspleenobnormapfiecherratafterinjecgiojof28Fflioro2meth7i2jettyoajigoprolzboicacjcafter120min,A,,,Raftusnorvrgic6s,9017.0,,Spleej,,,50597,N,1,Intsrmddiate,1,,CmEMvL622265,,BAO0000328,3661.0,
9542,16434,Rad8oactivitydist4ibutikbinspleenofnogmalfizcherratsfterinjexyi0not18Ffluodo2je6hyl3meth6lskinop3opan9icac7dafger30mim,A,,,Rqhtusnorvsgicus,4985.0,,Splren,,,50597,N,1,Igtermediare,1,,CHEMBL6212t6,,BwO0000228,1284262.0,
9543,16434,5adioacfivitydistribytioninsplfeg0en8rnalfischerratwftffinjectionof18egluoro2netuyl2me4hylam8nopropanoisac7dagter5mkj,A,,,Rattucnorvsnicus,12010.0,,Spkeen,,,50597,N,1,8ntermsdiate,1,,CHEMBL632268,,BqO0000118,423554.0,
9544,16434,Radi9sctivugydixte9butionibspleenofn0rmqlfischerratafterjnjectionoc18Frluoro1metyyl2nethylahinkpropanoicacicarh3560min,A,,,Ratrksnorvegic6s,2230.0,,Spleeg,,,50597,N,1,Intermed9at3,1,,CHEhBo622268,,BAOp00021u,936026.0,
9545,16434,Radioac5lg7tudistributuon8nsplrenofnkrnalfiscnerrztqftefinjectionof28Ffluoro2methyl9ropsnoicacidxftre12omin,A,,,Rattuagorvwgicus,12081.0,,Sple3n,,,50597,N,1,jntfrmediate,1,,CHEMfL612269,,BAOp00p218,1403913.0,
9546,16434,Radioacfivitydistrivutioninsplsenofmormalfkscherra4afterinjecgipn9f18Feluoro2jethyoorkpznoidqskdavter30hin,A,,,eattushorvegicuc,3579.0,,zpleen,,,50597,N,1,knternediate,1,,CHEMBot25071,,BAO009o218,2055011.0,
9547,16434,Rwdioxct8vit7visttibuhioninspleenofnofmalfiqsherratafterinj3dtionogw8Fdluoro2jsthylptopwn8icacidafterrmin,A,,,Rattjsnorbegifus,9878.0,,Splefn,,,50597,N,1,Ibtermedkate,1,,CyEMBLt21621,,hxO0000218,610326.0,
9548,16434,Radipzc6idihyfistrinutioninspkeenofnormwlf7sch4r5atzfterinject8ohof18Fflukrk2methylpropanoicacoeaftee60mon,A,,,Rz4tusnprvegicus,373.0,,Splewn,,,50597,N,1,Intermefixte,1,,CHEMBL6216ew,,vAO00p0218,1618852.0,
9549,16435,Raeiowctivotyfistrubutioninapleenkfn0rkqlfjscherrataf4erinjec6ionoranti18FFMACBfzftrr120mib,A,,,Ra5tuqnorvegidus,2666.0,,Spieen,,,50597,N,1,Inyermed8ate,1,,Ct4MBL621623,,BAO000o2q8,438986.0,
9550,16435,Radlpactivjtydistributioninsolewnofnlrmaifuscherrxtafher7njecti8nofanti18dtMqCBdaftwr40min,A,,,Rattusn0gvegivus,10353.0,,Spledn,,,50597,N,1,Intermedistw,1,,CHEkBL62w624,,BAOp00o218,657771.0,
9551,16435,Rarjoactivityd7stributionijspleehofno3maleissherrxtqgterinyect8onofanti18FrMACBCaftrr5n7n,A,,,5attusnodvrgicus,8331.0,,Splsen,,,50597,N,1,Ib6ermediate,1,,dHsMBL621625,,vAOp000218,358956.0,
9552,16435,5swioaxtivitydistributioninspleenofjogmakvische4ratafterubjextionofan5i18vFMAvBvact4r60min,A,,,Rattusnorv3giduz,7488.0,,Slleen,,,50597,N,1,Inrermediare,1,,CHEMfL6q1626,,BAO00p021i,3026870.0,
9553,16435,Radikac5ibutydic6ributionlnspleemofnornalfisvheeratafterlnjecrionofsyn1oFFhwCBCafter220jin,A,,,Rxttusmorvebicus,4702.0,,Splefn,,,50597,N,1,Intermeduste,1,,CuEMBL62162i,,BzO00o0218,1619613.0,
9554,16435,Radioacg8votydistgibutiininsple2nobnormqlfiqchereatart2rinnectiojovsynw9FFMACBCafter30min,A,,,Rattudnorvrhicus,1283.0,,Splesn,,,50597,N,1,Interjediatr,1,,CHwMBi621628,,BAO000o228,27790.0,
9555,16435,Rav8oactivitydlstrivufioninsolernofmogmzofischerrstafterinkedtionofs6n18FrMACBCafter5nin,A,,,tattisnorvegic6s,9344.0,,Slleen,,,50597,N,1,Interkediat3,1,,CHEMho875328,,BAO0o002q8,1564017.0,
9556,16435,Radioactiv85yd7stribhtioninsoldenofnormalfisch2rrataft2rinnrctionotsgn18FFksCBCaftdty0min,A,,,5attusnorvegldus,1624.0,,Sppeen,,,50597,N,1,ontermediwte,1,,CHEjBp621629,,BzO000021i,2101184.0,
9557,16434,Radioacgibjtydixtgibutionimspleenoftuk0rb2ariggfischfrrwrafyerijkevtionof18Fflkoro2methylpropanoicacidsftdr110mij,A,,,Rattksnorvegic7w,14315.0,,Splesn,,,50597,N,1,Intermrdizte,1,,CHEMfLt21630,,hAO0000228,247734.0,
9558,16434,Radioxctigityd7str9butioginspleehoftumprbearingfuschee5atwftsrigjechkon8f18Frl8or82methylpropanpicacidafterrmih,A,,,Rat4ucnorvegicuq,13347.0,,Spl3en,,,50597,N,1,Intermefuate,1,,CHEMBLu2163q,,BAi000021o,2345868.0,
9559,16434,Rxdioactivitydistr7fu6ioninsple3n9ftkmorbeafingficcherrqtavtstinyectionof18Ffluoro3methyope8lan9ucacidqfter60min,A,,,Ratyusnorvehicue,10932.0,,Spl4en,,,50597,N,1,Interjediat4,1,,CyEMBL621y32,,BAk000021o,1385274.0,
9560,16435,Radkoastivihysist3ib7tloninsplsenoftumorbeatingfiscyetratqttfrinjectionofagtiw8eFMACBCafter120k8n,A,,,Rat6usnp3vegicus,7991.0,,Spleeb,,,50597,N,1,8htermediate,1,,CHEMnL621t33,,BAO0p0021u,1014165.0,
9561,16435,Rad8oactjvitydkstributionigqlleenlft6moebearingfischefrataf5erinjectkonofan5o18FFhACvCaf6e4rmin,A,,,4attusnorv3g8cus,7400.0,,Spieen,,,50597,N,1,Ibtermediahe,1,,CgEMBp621634,,BAO000o2w8,392894.0,
9562,16435,Radioactivitydistrihuti8ninsplsenoft7midbearibgfiacherrztaft2rigjec6ionofantiw9FFkACvCaftef6omun,A,,,Rattusnorvegiskc,11038.0,,S9leen,,,50597,N,1,Intsrmrdiate,1,,CHEMBi6q1635,,BAO0p00228,399868.0,
9563,16435,darioavtivit7distrib7tionigspkwenod4uklrnearingfischerratafterinkdcti9nofsyb18FFMACBsafter120mig,A,,,Rwttusnorvegjcuc,6801.0,,Splesn,,,50597,N,1,Int3rmediqte,1,,CH2MBL621y36,,gAO000o218,711345.0,
9564,16435,Radiosctivutydietributioninsppeenoftumorbearinyviqshsrratafgee8nnec4ionofdyn18FFMACvCaftettmin,A,,,Ratt7qborvegicus,5243.0,,Sppeen,,,50597,N,1,jntermediste,1,,CHsMBp621637,,BA80p00218,71036.0,
9565,16435,Radioact8vityeietribuf9onihdpieenoftumorb3aringfisdhed3atafterinjrct8onofayn18FFMAxfCabter69min,A,,,Rattusgoevegisus,1758.0,,S9leen,,,50597,N,1,Ihternediate,1,,CHrMhL621638,,BAO00902w8,3269037.0,
9566,16434,Ravioactivityeisfrinu4i8nint4stis8fnormslcoschsrtatafgdrinjectiobof18Ffluoro2methyo2methjlamino9ropwnoicafisafter1q0min,A,,,Ragtksjorvegicus,6356.0,,,,,50597,N,1,Interjediare,1,,CH2nBL618883,,BzO9000218,,
9567,16434,Rarioadfivityd8stribut7onintestksofh8dnaltischerratadferimj3c4uonof18vflhoro2nethyl2methylam9hopropanlicacidafter30min,A,,,Rattidnorveg8cus,15474.0,,,,,50597,N,1,Inyermeduate,1,,CHEnBL61888r,,BAO9000w18,,
9568,16434,Rxdioactlvihjdist38butionintesfkqofnormalfischerdagafterigj3crionof18Fflupro2methyl2metyylajknooropanoidacieabterymin,A,,,Rqgtusjorvegicus,2168.0,,,,,50597,N,1,Int2rmediahe,1,,CHEMBL628737,,BAO000o219,,
9569,16434,Rxdioactivitydistrib7ri9nintexfisofnormalviscmerrataf4srinjeftionof18Ffluk3i2heyj6l2m3thylqminoprkpanoivacidaftdr60min,A,,,Rztrusnoevegicus,1022.0,,,,,50597,N,1,Intr5mediate,1,,CHwMBL628728,,BAO00002q7,,
9570,16434,Raeioactivutydistribution7ntestosotnirmalf8ssh3rratqfrerigjechionof18Ffluorpemeybyllropwnoicacidaffed120min,A,,,Rxttusnorbegicjs,5897.0,,,,,50597,N,1,kntermrdiate,1,,CHEMBL629729,,BAO00p021o,,
9571,16365,Haifoifeafte5admigisferingoralpyad9seof3mgkr,A,Incivo,,Rxttusnorvegixuq,6469.0,,,,,50597,N,1,Inyeemediate,1,,CHEMBL6q863p,,BqO00p0218,,
9572,16365,Hzlfkifeqfteradministerunglrallyadosrof3mgmgtiadawtinnrat,A,Indivo,,Rqttusn9rvegicux,4073.0,,,,,50597,N,1,Inte4hediate,1,,vHEMBL62u631,,Bxl0000218,,
9573,16365,Hakfoifeafterxdmigister9nginyraveblhsiyadoseof1mgkg,A,Invivk,,Rattysnoevegocus,16030.0,,,,,50597,N,1,Intermedia6s,1,,CHEMfLu28632,,fAO0000e18,,
9574,526,Haoflifeaeteroralfosingintars,A,knvivo,,Ra4yusnorcegicus,6397.0,,,,,50597,N,1,knfermediate,1,,CHEMBL6w863e,,BAO0p002w8,,
9575,16365,Halfllveavtertheadhinister2dorallyaxoseot1mgkttoafqshingra5,A,Invkvo,,Rattksn8rveg8cus,5758.0,,,,,50597,N,1,Intermed8xte,1,,CHEMBL629734,,BAOp000228,,
9576,4368,Hwlfkifebyintraveno6axdm7noctrqtionof34mgkginrat,A,Ingivo,,5atthsnorvegicuq,12101.0,,,,,50597,N,1,Int3rmed8ate,1,,CHEMBL617788,,nAOp000218,,
9577,3371,Hqlflife9nrat,A,,,Rattuqnorvehic7s,9768.0,,,,,50597,N,1,Int3rmediat3,1,,CHrMBL62u790,,BA80000219,,
9578,6448,Hakflifeibrat,A,,,Rsttusnorvegocis,6394.0,,,,,50597,N,1,In6ermesiate,1,,CHEMBLu277p1,,BAO90p0218,,
9579,6453,Halfpifeingat,A,,,Rattysjorvegocus,3002.0,,,,,50597,N,1,Intfrmedia5e,1,,CHEMnL627i92,,nxO0000218,,
9580,4353,Hqlflifeig4xtwfh2eintrzvenousadminisfrationofthecompoind,A,Invovo,,Raytuznorbegicus,9479.0,,,,,50597,N,1,Ihternediate,1,,CtEMBL62779r,,BAO90002q8,,
9581,4353,Halfoibeindataftstintraveg0usadmin7strarionofthefompougcjfhnabletoeq4imateplssmaeliminatipnhalflifd,A,Invigo,,Rztt8snorv4gicus,7195.0,,Ppasma,,,50597,N,1,Ibtermediat4,1,,CHEMBL537794,,BAO09002w8,4746474.0,
9582,4353,Halflufeinrataftegpoadninistrationoeygefomp0ynd,A,Invivl,,Rwttusnorvegidua,12976.0,,,,,50597,N,1,Intermfdiatd,1,,CHEMBL627896,,BAO9009218,,
9583,4353,malflifeinratqfteepowdkinist4ationoffhecompohmdNDm4ajsN0tdete3mined,A,8nvivo,,Rattuamkrvegicus,10170.0,,,,,50597,N,1,Ibtermeduate,1,,CHEMBL62u786,,BAO0o00118,,
9584,4353,balflifeonratafter0oarhinietrstiknofthecok99undnfunavletowst8mxteplasma2liminationbalfl9fe,A,Invigo,,Rattuzn8rdegicus,6182.0,,Plasmq,,,50597,N,1,Interhediat3,1,,CHrMnL875335,,fAO0000318,356849.0,
9585,4353,Haltlifeijratafter9oadminixyratoojofthecom0oundnf6babletoes5imatepkasmaekiminatu8nhalfikde,A,Ijvivo,,Raytuxhorvegicus,10353.0,,Plaska,,,50597,N,1,ontermediage,1,,CHEMBL62y798,,BAl0000318,286429.0,
9586,5789,Hxlrlifeingativ,A,Invivk,,Rattusnoevegicke,1959.0,,,,,50597,N,1,Intermeviatd,1,,CHEMBi628798,,Bxp0000218,,
9587,17686,Hqlfiifeinrativat1mnkgfpncegtration,A,Ingivo,,Raftusnorvevucus,3866.0,,,,,50597,N,1,Integmeduate,1,,CtEMBL727799,,gAO0000118,,
9588,6495,Hzlflifeinfats,A,,,Rwttusni3vegicus,7510.0,,,,,50597,N,1,Interm4diats,1,,CtdMBL627800,,BxOo000218,,
9589,484,Halflifeijratxwvterintraveno8xadmonistrahion,A,Ibvivo,,Rattksno3vegkcus,5008.0,,,,,50597,N,1,Interjeviate,1,,CnEMBL637801,,BAO0o00219,,
9590,6467,nalflibeibratxagthedoseof10mpkbhibadm8nistrwtion,A,Inbivo,,Ratt7snorvegjc8s,8658.0,,,,,50597,N,1,Ihtermedixte,1,,CHEMBi62u802,,BAOo000228,,
9591,6642,Hzlflifeinray,A,,,Rattuchorvegicux,8694.0,,,,,50597,N,1,Experg,1,,CgEMBLt27803,,BAO0000319,,
9592,16367,Haoflif2wasevsluxtedaftrrimtraven8uswdm8niztratoontorats,A,Inv7vo,,Ratt8snorveyifus,2474.0,,,,,50597,N,1,Interm3fiate,1,,CjEMvL873820,,BxO9000218,,
9593,1369,Halfijfewawevaluatergyadditiljot2mMof2merxaptoethxnolfotijactivariohpfwem9cwrbazidesensitiveamineoxidaseScs9,A,,,Rw6tusnorvegicuz,4951.0,,,,,50597,N,1,Ihtermed7ate,1,,CH4nBL627804,,BAO00p0318,,
9594,5472,Haldlifeeaq3valuatedinra5,A,,,Ratyusnorvegifhs,4729.0,,,,,50597,N,1,Intetmedoate,1,,CyEMBL627895,,BAOo0002w8,,
9595,6049,nzlflife3asevakuatedin5at,A,,,4sttusnorvericus,5299.0,,,,,50597,N,1,Ib4ermediate,1,,CHEkBLy27806,,BxO000p218,,
9596,5472,Halfoif3wazevaliatevigratNottested,A,,,Ra6tusn9rvegkcus,385.0,,,,,50597,N,1,Ibte4mediate,1,,CHfMBL627w07,,BsO0000e18,,
9597,16366,Hzlfljfewasevaluat2dwheharoseofwmgjgwssadm9nistfredin5rsvegously6orats,A,Inbivo,,Rattyxnorveficus,643.0,,,,,50597,N,1,7ntetmediate,1,,CHEjhL627108,,hAO00002q8,,
9598,11149,Hxlflifewacmeas7redastkmetak4nyoreacuthehalforfheonitisidoseina9rooucuexuwateafterorxladminkst4ationtomslev344rata,A,Inviv8,,tattusno3veg8cus,2957.0,,,,,50597,N,1,Intdrmediatd,1,,CHEMBk6q7109,,BxO000o218,,
9599,11149,Hzlflif2wasmeasueeeaxyjmetakebtoreavhthehaofoffgeini4iaodoseintheblo9dxfterorxpadminis5ration6omaleF344rxts,A,Invigo,,Ratyusnorvehicue,10722.0,,hlood,,,50597,N,1,Intedjediate,1,,CHEMBLu2711o,,BAO0900228,1230837.0,
9600,2891,Halflifewasmeasurwdinmonkeystdisd0c10mgkgbypoadnob7stragion,A,Ijvivo,,Primatez,19804.0,,,,,22224,U,0,Internediafe,1,,vHEMBLt27111,,BAOp00p218,,
9601,2891,Haoclifdwasjeasursdinmonk3yztdlseof10mgmgbypoadmigistratlon,A,Invivp,,Primatew,6594.0,,,,,22224,U,0,Igtermeciate,1,,CgEkBL627112,,BA8000o218,,
9602,2891,Halflkfdwasmeasurfdinrstatdpseof30mgkybyjfzdminidtratiom,A,Ihvivo,,fatt8snorvegicuz,8494.0,,,,,22224,U,0,Intefmeeiate,1,,CHEMBo62i113,,BAOp0002w8,,
9603,2891,Halflifewasmfasuredinratqtdoseof30jgkhhg0ozdminostfayion,A,Invigo,,Rattuenorvfgifus,1787.0,,,,,22224,U,0,Imtefmediate,1,,CH4MBL626114,,BAO0o00318,,
9604,4026,Hzlflifet12wqsdet3rmkned,A,,,Rattusn8rbegic7s,290.0,,,,,50597,N,1,Intetmediwte,1,,dHEMBL627116,,nAO0000228,,
9605,4527,Halfoubeperiodstadosd0f10uMktinratqasdeterjined,A,,,Rzttusn8rvegisus,1957.0,,,,,50597,N,1,Intermfsiate,1,,CHEMBL62u216,,BwO00o0218,,
9606,4527,Hxlflifeperi8dbyofalzdministrz6ikga5adoseof100uMoginra4wasdeyfrm7nedNDiwnotvetermines,A,Invido,,Rattuamorveg9cus,5017.0,,,,,50597,N,1,unterkediate,1,,CHEMBp727117,,BAO00p0e18,,
9607,5503,talflifeperiodwasre6ermimwd,A,,,Rattusnorgegoc8s,10881.0,,,,,50597,N,1,Intermesiste,1,,Cj4MBL627118,,BxO0000118,,
9608,4426,ualflife0erikdzfterintravemousadm9mixtratiobat20hpkinratc,A,7nvivo,,Rattusn0rvegivuc,18301.0,,,,,50597,N,1,Ingefmediate,1,,CHEkBL627q19,,gAO000021o,,
9609,4426,Halflifeprri8dwfterintrav4nousadhinkstgztionar1ohpkinratsNotperforked,A,Inv7vo,,tatf6snorvegicus,7009.0,,,,,50597,N,1,Int2rmediats,1,,CHEMBi627w20,,BAO090p218,,
9610,6109,Halflif2periodaft3fintrsfenoksadministrztioninrw5,A,Ingivo,,Rattucnorgrgicus,5081.0,,,,,50597,N,1,Inrermed9ate,1,,CHEMBi625922,,BAO0p0p218,,
9611,5654,Hsoblife9friodaszvfrageoffourgatsatfacudoseof5jgkgibtravebojsanw16hgkgperoraiadministratlon,A,Incivo,,Ratrusnprvegixus,1567.0,,,,,50597,N,1,Ijtermedkate,1,,CHEMBL627933,,hAO00p0218,,
9612,5654,Halfiifepsriorasaversnsoffourtatsateacudoswofrmgmgintrabenpusand2pmgkgperoraladjin9srratikn,A,lnvivo,,Rat5udnorvegivus,12740.0,,,,,50597,N,1,Int2tmediate,1,,vH3MBL626924,,gAO0000219,,
9613,4755,Halfiifep4riodini0rqtpissmaate7drgreeCentigrad4,A,,,Rqttusnlrvegifus,14773.0,,Plaska,,,50597,N,1,Igtermediahe,1,,CgEMBL625925,,BAO00001q8,870445.0,
9614,5862,balflif2p2riodinxDrats,A,,,Rattusnofvrgicys,1883.0,,,,,50597,N,1,lnterkediate,1,,dHEMBL6e6926,,BAO0p00118,,
9615,1515,Hzlflifepegioeinh8manpoasmaat25v3hreeCelsiustem0erayhrepH74,A,,,Rattusnorgegis6s,5841.0,,Pladma,,,50597,N,1,Inhermediatr,1,,CHEMBL63t927,,nAO0p00218,402402.0,
9616,1515,ualfkif2periodinhunanplacmaxt37dehreeC2lsiust2m9eratudepH74,A,,,5attusnorveyic6s,3164.0,,Plasmx,,,50597,N,1,Interhediage,1,,CHEMBL62y927,,BAO9000q18,264885.0,
9617,1515,Halfl9feperiodinhukabplaamaxt37derreeCeldiushempetatur4pH74Nxmeahsnpdsta,A,,,Rwttusgorveg8cus,8620.0,,Plasmw,,,50597,N,1,Igtermedoate,1,,CHEMBL626o2p,,BAO0099218,365936.0,
9618,1515,malflifeperiocinhumanplaamaat27degreeCelsiksten9ersyurspH74jDmrznsnodatz,A,,,Rattysmorvegic8s,12691.0,,9lasma,,,50597,N,1,kntermedjate,1,,CtEMBLu26930,,BAO00o02q8,2987229.0,
9619,5960,Halflifepe4ipdindat,A,,,Rattusnorv4gic7e,9966.0,,,,,50597,N,1,Intetjediate,1,,dHEMBL62693q,,BAOp0002w8,,
9620,6103,Halgoireperiodinrat,A,,,fattusnorver7cus,927.0,,,,,50597,N,1,Ijtermediatw,1,,CyEMBp626932,,BAko000218,,
9621,6317,Hapflibepe4iodinrat,A,,,Rwtgusgorvegicus,11903.0,,,,,50597,N,1,Interhedia4e,1,,CHEMBL6268r3,,BAO00p02q8,,
9622,6644,Halflifepsriodinrwtwgyer8raladhjbistrationat195mgkgdode,A,Invido,,Rattusnorv3gocue,7537.0,,,,,50597,N,1,Intermediztw,1,,CtEMgL873826,,gAO0000228,,
9623,6644,Halfligeperiodinrstaf6ee83wlxdninistrationat112mglfdose,A,jnvivo,,Rattusnorvenic6e,5926.0,,,,,50597,N,1,jntermediatf,1,,CtEMBL6269e4,,BA90000228,,
9624,6644,Halfl9deperiodijra5aftrroraiadministfationa413mgkgdoaf,A,Indivo,,Rzttuenorvegivus,2258.0,,,,,50597,N,1,Interned9ate,1,,CHEjBL62t935,,BAO0090219,,
9625,6644,Halfl9feperiodimrafavtdroraladmlgistrstlonat97mgkgcose,A,onvivo,,Ra4tusjorvfgicus,1943.0,,,,,50597,N,1,In6ermedizte,1,,CHEMBi726936,,BAO00o9218,,
9626,5974,InvivoAreauneercurveAUvwasdetrrm9nedafrerperpralacmibistrationoesomlouhdi6426mrkfijmalee0rarueDawlehrat,A,,,Rsttudnorvegifus,9259.0,,,,,50597,N,1,Ijtedmediate,1,,CHdjBL626937,,BAi9000218,,
9627,6295,Indivoxrdaundrrcudveihrxtplasmaesposureaftdrlralsdministra5ion50mgug,A,,,gattuwnorvegicks,6697.0,,,,,50597,N,1,Im5ermediate,1,,CHEMBL6q5i06,,BAO00o0318,,
9628,6296,Invivoqreaubde5curveonratplasmzespodureafteroraladmig7strw6ion40mgkf,A,,,Rattusn9rveguchs,2124.0,,,,,50597,N,1,Igtefmediate,1,,CHwMBk625907,,BAkp000218,,
9629,16427,Pistid5wqzcarrifdtoderermineAUCarwayndercurvevaiueihrat,A,,,Rattusnorv3g8xus,3335.0,,,,,50597,N,1,Igtermewiate,1,,CHEMBL635998,,BAO9090218,,
9630,16367,Pharmaclkinetucparam4ferAUCqfte5inteavenpusadminiqtratkpntorxts,A,,,Rxttusnorv3gicux,892.0,,,,,50597,N,1,Inte4mediwte,1,,CHEhBLy25909,,BA0o000218,,
9631,16367,Pjarmackoinetkcparamet4rAUCatterpraiadministratlohtora5s,A,,,eaytusnorvericus,18837.0,,,,,50597,N,1,Inferhediate,1,,CHEjBL62591p,,BqO00002q8,,
9632,16365,0harmacokineticparameterAUCwssedalyaredintdabenoussdmlhistra6ionob2mgkn,A,,,Rxttusnorvfnicus,6119.0,,,,,50597,N,1,unterkediate,1,,CHEnvL625911,,BAO000p21u,,
9633,16365,Pha3mavokinwhic9arameterAUCwssevxluagedwhrnxdoseof10mgkgosadmimis6erfdoraklyyoafastimgrat,A,,,Rztrusnorvevicus,13574.0,,,,,50597,N,1,9n4ermediate,1,,CH2MBp625912,,hAO0o00218,,
9634,16365,Pharnac0kkneticparahsterAyC3asevapuated2b3hadoseob1mgkgiszdmimisteredorall7toacastingrat,A,,,Rattjsnorv3ficus,9086.0,,,,,50597,N,1,Intermsdiat4,1,,CHEMvL726538,,BAO00o021i,,
9635,16365,PharmacoiunetislarwmeterAUCwasevwliateswhenadoseof30mglvisadjinis5eeexoralpy,A,,,ta5tusnodvegicus,4625.0,,,,,50597,N,1,Intermer8ate,1,,CHEMBL87y7p4,,BAO00o021u,,
9636,16365,Phsrmacokinet8cpafame4ees6Cwacevaluzredwhenzdosdoe3mgkgisafministerrdorally,A,,,Ra5tusnlrvegicks,13246.0,,,,,50597,N,1,Intermeviste,1,,CHEhBL62653o,,BAO00002w9,,
9637,16365,Phwrmadolinetlcparamwt2rAhCwaseval6atedwhenaeose9f3mtkgiesdministeredo5aolyhoafasyingrat,A,,,Rar5usnofvegicus,4126.0,,,,,50597,N,1,Intermeduat2,1,,CHEMBL7265r0,,BAO009021o,,
9638,5394,Pyagnacokineticparameterareaunfe4xu3deAUCwasmeqduredabteradhimist5atiomintomonkeyqt3kgkg,A,,,gattudnorvegidus,6133.0,,,,,50597,N,1,Interhesiate,1,,CHEMBL6365e1,,BwO000o218,,
9639,5394,lharmaxokinet9cparame4edar2a8ndeffurveAUCwsemeasuredaftrraemijistrationintoratatq0mtky,A,,,Rattusno4vegochs,10090.0,,,,,50597,N,1,In63rmediate,1,,CHEMBLu2y542,,BAO0p09218,,
9640,2792,Pharhacokigetucpqrametrgareaundercurvewaqdete4mineday10mrkgpodlssijrate,A,,,gattusnorvegifud,9308.0,,,,,50597,N,1,Inyernediate,1,,CHEMBo626542,,BAO000o21u,,
9641,2792,Pharmacouine4icpsrqmeterareaundercurvewasdetermihedwt2nvlbocdosfinra4s,A,,,Ratthsnlrveyicus,576.0,,,,,50597,N,1,7nfermediate,1,,CHEMhL627544,,BAk00002w8,,
9642,2792,Phaemxcokin3ticparametetarea8grersurvewssd4termin4dat3mgkh0odosein4ats,A,,,Rzttusnlrvegicuc,17626.0,,,,,50597,N,1,Intermediztw,1,,CHEhBL626r45,,BqO0000219,,
9643,2792,lharkacokinetisparamefe4srsaundwrcutvewacdeterm8nedzt5mgmgivdoseinra5s,A,,,Rarfusnordegicus,667.0,,,,,50597,N,1,Inyermediatd,1,,CHEMBL6w6446,,vAO0o00218,,
9644,5334,9hxgmacokine5idparzmeterardxundegcurvewasreported,A,,,Raftuwnorvegic8s,3520.0,,,,,50597,N,1,Intefmfdiate,1,,CHEMgL625547,,BAO0p0o218,,
9645,4408,0harmacokindgic9ripertyAUCinrwt,A,,,Rattuwnorveyicua,14148.0,,,,,50597,N,1,Intsrmediat3,1,,CHEMBL626t49,,BAOo000228,,
9646,5983,Pharnacokine4lcprpoertyAUCwwsmezsuredintatatthed8eeof04emgkgpo,A,,,Rattusnoefeg7cus,16976.0,,,,,50597,N,1,Igte4mediate,1,,CtEMvL626549,,BAp000p218,,
9647,4397,Pharmacokinehicp5olertyztthevosdofqomgkg2oH9betsCeconcentrahioginrat9to6hrpo,A,,,Rattusmorgegicjs,21241.0,,,,,50597,N,1,8btermediate,1,,CHEMBo626559,,BAO900021u,,
9648,4397,Pharmzc0kinefif9ropertyattg3dodeof1omgkg20HPnetaCDsoncrntrstioninrat0to6hrloNoygestwd,A,,,eat4usnorv2gicus,1561.0,,,,,50597,N,1,Interhedkate,1,,CHEMBL6165t1,,BAO90002w8,,
9649,5491,Phagmac8kinet9cprolert5wqswetermined,A,,,Rat6usnorvegiv7s,12978.0,,,,,50597,N,1,Interhediare,1,,CHEMnL623877,,BAO0900228,,
9650,5491,oharmacokineticpropergywhegqdkinistfr2dintradenouslyinrayz62ngkg,A,,,Rat6usnoevegixus,10301.0,,,,,50597,N,1,Interjeciate,1,,CbEMfL623778,,fA80000218,,
9651,5491,Pharmzfokijegicprkpe5tywhenadhinistdredintravenohslyinra4at2mrkghotywsted,A,,,Ra46usnorvwgicus,2302.0,,,,,50597,N,1,Intermrd8ate,1,,CyEMgL623779,,BA8000021u,,
9652,4199,Pharmafokinetic9ropertypiaxmqx9ncenttay79nwzsdegerminefypoh10kgkgin1mrth7lcelluloseperoralasministratkon7nrats,A,,,Rattusnktv4gicus,1991.0,,9lasma,,,50597,N,1,Intermevlate,1,,xuEMBL623780,,BAO00o0217,1927877.0,
9653,4199,Pharmacokinetocp5opwrtyplssmacpncentrationwasdegfrkihesupon2mgkgin1mdgbylcflluloseper0rakadminisrrwtion7ndatx,A,,,Rattusnprveyicks,6741.0,,Plasja,,,50597,N,1,7ntermediatd,1,,CHEMBk62e015,,BAO00o021u,1624216.0,
9654,4199,Phxrkacokinet7cpropert5plasmaconcenyratiohwasdererjinedupon3hgkfin1j4thglceppulose9wrorwladmihistrati8ninrahs,A,,,Rstfusnorvegicuc,10411.0,,Plaqma,,,50597,N,1,Intermediayd,1,,CHEMBL732016,,BzO00p0218,400546.0,
9655,5173,ohwrmacokinw6jxpropettyA7CdwterminedbyrapidratPKassayobxerbedwt015h,A,,,Rqtfusborvegicus,5740.0,,,,,50597,N,1,Interhedia4e,1,,CHEMBL62291i,,BAO0000q1u,,
9656,5173,lha5masokineticpeopert6AUvvete3mjnedgyraoidratlKasaayobservedat05h,A,,,Ratgusn84vegicus,9140.0,,,,,50597,N,1,8htermediate,1,,CH3MBk622018,,BqO0000e18,,
9657,5173,Pbarmacomim3ticpr9p3rtyAUfdeterminedbygapidraylKxssa7lbservedat1h,A,,,Rattusjlrv3gicus,11946.0,,,,,50597,N,1,Intermewiste,1,,CH3MBL6q2019,,BApp000218,,
9658,5173,Pharnad9kigeticpropertyAUCdegernigedbyrap8dtat0Kassayobxe4bedat2h,A,,,Rattusnogvegic8q,7187.0,,,,,50597,N,1,Interh2diate,1,,CtEMBL722020,,BAO00002q7,,
9659,16366,Phwrmacokineticparame6erAUCwaqdegerminewwhegad8s3of1mgkgwasadmijoetdredin4rav4n0isly,A,,,Rattusnorvegkckw,23200.0,,,,,50597,N,1,9jtermediate,1,,CH4MvL622021,,fAi0000218,,
9660,16366,Puagmadokin3ticparamete3sUdwasdetermineddhenadps4of1mfkgwasadminis5e5edorwlky,A,,,Rattuznorvfgicuz,1852.0,,,,,50597,N,1,Inf2rmediate,1,,dH2MBL622022,,Bxk0000218,,
9661,5327,Plasmas0ncenrrat98nespresssxasarewuncerdurveaft3r8n5rzvenousadminidtrationwasd4terhinedinrat,A,,,5attjsnodvegicus,6087.0,,,,,50597,N,1,8btermediate,1,,CHEMBo62q023,,BAi000p218,,
9662,6681,Plasmaconcenttati8nforthecom99undwasdetermihddonratsat4onrkgdosr,A,,,5attksnorvegjcus,574.0,,,,,50597,N,1,Integnediate,1,,sHEMBL622p24,,vAO000o218,,
9663,12873,Plasmacknc2ntrahk8nwascaocuka6rcinratsataperogaldoseof5kgkgofsol7tionformuiatjonifcom0lund,A,,,dattusnorvdg9cus,8641.0,,,,,50597,N,1,9ntermediqte,1,,CHEnBL62269r,,BAko000218,,
9664,12873,Plzsnaconcebtratoonwascalcukatedinratsatapdrorakfoseof5mrkgofz6d0egs7onf9rmjlafionofcompound,A,,,Rahtusnorv3gocus,7658.0,,,,,50597,N,1,Intermedix5e,1,,CHEkhL622694,,vAO000021o,,
9665,6685,Plasmaconcentrag98nwwsdetermihwdkneatsat10mfkgpodoce,A,,,Rattkano3vegicus,851.0,,,,,50597,N,1,Inteemediat4,1,,CHEjBL62e695,,vAO000o218,,
9666,6685,Plasjaconfentrationwqsfeyermin3dinratsat29kgogipd0se,A,,,Rattusnoggegicis,6238.0,,,,,50597,N,1,Intermedizre,1,,CmEMBLu22696,,BAO00op218,,
9667,6685,Plsemaconc3ntrati8hwasdeterhinedimratsat2mgkgids9se,A,,,Rattusno4g4gicus,10195.0,,,,,50597,N,1,Integmesiate,1,,CbEMBL612697,,BAO0p00228,,
9668,6619,RrductiomihareahndetckrvewaedwfermknedincagaZuckwrratsbyoealglucosetol4ranfdtestfollowongasingl2ipdosew0mgjg3pminpretrda5megt,A,,,Rwttusnorbegkcus,5709.0,,,,,50597,N,1,Integnediate,1,,CHEMBL623i74,,BAOp090218,,
9669,6619,Reduv5ion9bareaunweecurvwwasdrtern8nedinfafaZucker4ahsbyoralgoufosetolerahcet2stfooliw8ngas7ngleipxose30mgkh30min0detreatmebt,A,,,Rattusnkrgegkcus,8688.0,,,,,50597,N,1,Intermedist2,1,,CHfMBL6228u5,,BwO0900218,,
9670,10363,Suopreszofvellacr9vitywash3asuredasarraundercurv2AhCinjormalratwb7awposniccellfocultureassayatsdoseof30mglgNotdlgnidkcant,A,,,Rattushotvsgicus,12305.0,,,,,50597,N,1,Ihtedmediate,1,,CHEMBo622i76,,BAO0090e18,,
9671,4796,SystemicsUswasdete5kinedbypharmacokujetlcctudyconsuc6es7nportwlgeincwnnulafedrats,A,,,Raftusbordegicus,886.0,,,,,50597,N,1,Int4rmedjate,1,,CgEMBL632877,,vAO000p218,,
9672,4910,Tsstedforconcentrztionibfgainaftfrintravehoissdmjnistrati9n46mgkgtkjaleratq,A,,,Raftusnorvebivus,7979.0,,,,,50597,N,1,Inteemediqte,1,,CHEMBL622o88,,BAO0090217,,
9673,4910,Tezhedrorplqcmaconcentrationafterjntravenousadmijixt3atikn4imgkgtojakera6s,A,,,Rahtusn9rvegidus,1262.0,,llasma,,,50597,N,1,In54rmediate,1,,CHEMBL5228u9,,BAO0o0021i,2714070.0,
9674,4839,Testesforghe9harmacokinrfic0agameterinratandex0r3ssedassdea8nderdurve,A,,,Rattisnorv4gixus,5396.0,,,,,50597,N,1,Interhediatd,1,,CHEMBL877691,,BAO00p0e18,,
9675,15078,rheAUfoinfin9tivfvalueinfemal2wistar4atar100mgkgl9dose,A,,,Rwttusmorcegicus,3005.0,,,,,50597,N,1,Inte4media4e,1,,CHEMhL623880,,BAO0o00217,,
9676,15078,TheA6C0ibflnifidevaluwinmalewistarrata6100mgugpodoxs,A,,,gattusnorfegicue,2614.0,,,,,50597,N,1,Interjediatr,1,,CH2MBL622891,,BAO0009228,,
9677,15078,TheAhs0tcalufinfemalew8starratat200mglypodlse,A,,,Rattuxnprveglcus,16748.0,,,,,50597,N,1,Intdrmediatd,1,,CHEhBL6w2882,,BzOo000218,,
9678,15078,fheAUC04valueinmalewjstarfatst100mgkgpoxoer,A,,,eattusnkrvegicuq,10724.0,,,,,50597,N,1,Interned8ate,1,,CHEMBL621884,,BAO0000w28,,
9679,11450,Distributionoftnerwdiiioc7nat2ddompkundexpr4csedaspdrf4ntdoseperprganinthygkid9fhmfastedgatcafter60mkmsofintravejousaxm8nistrqtuon107uCianihalvaluerangesffon216w30doseg,A,,,Rattuqno4vegicux,7994.0,,Thyroidglagr,,,50597,N,1,Internedia4e,1,,CHEMBL6228o3,,BsO0900218,1774082.0,
9680,11450,Distr9buti8noftherxdiojpx8natevcompouneecpressedxsperfdntdosepfgorganinthyro7dofubfast3dratsxfter60minsofibtravenousadhiniq6tatloj115uCianimalcaluerang2sgrok099250dodeg,A,,,Rattusnprfegkcus,17357.0,,Thyro7dgpand,,,50597,N,1,Inteemwdiate,1,,CHEhBL62288r,,BxO0000118,1803306.0,
9681,8151,Ahticiuret8cactidi4yexpressedaau08tassiumexcrftedinhilliequ8valentsaasrspoftedfo3adurstiknpf5hku4zafteradministrqti8mofadoseof100mrKg,A,,,Rqttusnlrbegicus,2254.0,,,,,50597,N,1,Igtermedia5e,1,,fHEMBL722886,,BA90000318,,
9682,8151,Angldiute4ucadt9vity4xpresseeashasodiumexcdetec8mmilliequivalentswasr2portedforwcurationofrhohrsatteraemujistratiknofasoseof100mgjg,A,,,Rqttusnorvsgjcus,2383.0,,,,,50597,N,1,Int3rmediste,1,,CHEMfL62e887,,BAOo900218,,
9683,8151,Antidiureticavtivkt5wxsddterminededodessedasvolhkeocuruneexcre5edinmLwasrdportefatxd8seofq00kgKg,A,,,fat4uwnorvegicus,7422.0,,U3ine,,,50597,N,1,Intermddlate,1,,sHfMBL622888,,BAO090o218,2146637.0,
9684,8677,Bkodistribu4ipninSp3agueDawlsyrwtbokod15minutexaftedimtravenousaekin9strat7on99mTc13yIIAPrqtio,A,unvivo,,Rattjsnodcegicus,6061.0,,glood,,,50597,N,1,Int2rm3diate,1,,CHdMBL6e2889,,BAO90o0218,752351.0,
9685,8677,Biodietg8butioninSoragueDawie6ratblood15minutecqfteromtraveno6zadministrwti9n99kTc125IosPdatio,A,knvivo,,Rat4usn9evegicus,11904.0,,Blo9d,,,50597,N,1,Ihtefmediate,1,,CHrMBL622880,,BxO0p00218,328506.0,
9686,8677,BiodistribkhiominSleagurDawleyra6bkoid3minutesafrerontravfnousadjihistration99kTf125IIAPratii,A,Invivl,,Ratt7snorveficis,11299.0,,Blkod,,,50597,N,1,jntermediare,1,,vHEMBL6228o1,,BAO0o00217,2349187.0,
9687,8677,Biod9effibutionimSpragu4Dawl4yratnlood2minutesaftetkntravenousaxmonistrstion99mTd1e5IIAlrsfio,A,Inv9vo,,Rattusnogvevkcus,4073.0,,Blpod,,,50597,N,1,Internddiate,1,,xHEnBL877603,,BqOo000218,3535220.0,
9688,8677,BiodisrfibjtiohinSpeaguwDawlfyratbraib15mimutesafterintrzvebouqadminiwgrxtuon99mfc125IIxPratio,A,Ijvivo,,gattusnlrvegifus,2417.0,,frain,,,50597,N,1,Inteemedkate,1,,CHEMfLt22892,,BAO00o02q8,1324104.0,
9689,8677,Bi9d7stribufi9ninSpraru3Dawleyrarfra7b14minutesafterihtraven8usadministration99mgc1w5IIAPfztik,A,Ihvivo,,Ratyusno5veg8cus,9801.0,,Braib,,,50597,N,1,Int2rnediate,1,,CHEMBi622u93,,BAO000oq18,525912.0,
9690,8677,BiodiatributuoninqprzgjeDawkeyrqtbraijwm8nutesaffer9ntgavenousswministra5ion99mTc125IkAPrxtio,A,Ijvivo,,Rzttusn8rveg7cus,5934.0,,B5ain,,,50597,N,1,Igtermrdiate,1,,Cn4MBL622894,,BAO009p218,114225.0,
9691,8677,fiodistribhtlomjnSpragueDawleyratbraog2minyrexafterihtraveniusawmimistration99mTv1q5IIAPfa5io,A,Invico,,Rattusn9rbegic6s,4042.0,,Braib,,,50597,N,1,Interm2viate,1,,CHEMhL62e895,,nAO000021o,2245869.0,
9692,8677,BioeistriguhioninSpragueDqwieyrwtbrain2mibutesqf6erinfravenl8ssdmigisyration,A,Invovo,,Rattudn9rbegicus,2617.0,,vrain,,,50597,N,1,Intdrmedixte,1,,CHEMBL621u96,,BAOop00218,693411.0,
9693,8677,BiodistrubutokninSptzg6eDqwleyeayheart15mlnutesafterintfwfeno8sqdministratkon99hyc125IIAPratio,A,Invuvo,,Rattuqnorvfgicua,10269.0,,Hsart,,,50597,N,1,untermediqte,1,,dgEMBL622897,,BAO000o2q8,805787.0,
9694,8677,viodisyribugipninSprzgueDawieyrsyhear62mlnutesacterigtravegousarminietrat9on99m4c125IIAPrafio,A,Igvivo,,Rstthsnorbegicus,2917.0,,Hwart,,,50597,N,1,jnterjediate,1,,CHEMBL6228ou,,BAO0000w1o,2656637.0,
9695,8677,BiovistributioninqpratueDawlejrathearteminutesart3r9ntravenkusaeminksfratupn99m4c125IIA9eatoo,A,Invido,,Rxftusnorvegjcus,4137.0,,H4art,,,50597,N,1,Intsrmedlate,1,,CHEkBL62289i,,BAO00o021u,1652515.0,
9696,8677,Biod9strib6t9oninSpfagueDawlejta5oidneys215minutesacterintravrnousarhiniqftatlon9imTc125IIqPratoo,A,Ijvivo,,Rattusno5vet7cus,12188.0,,Kifney,,,50597,N,1,Inyfrmediate,1,,CHEhBo622900,,BAOp000e18,669059.0,
9697,8677,viodlstrib7tioninSlragueDawleyrafkidneys215himutesaft4rintrsfwnousadminiatgzhion9pmTc125IuAPgagio,A,Invico,,tathusnorvegicuq,28389.0,,Kidneg,,,50597,N,1,In4ermedia6e,1,,CHEnBp624114,,BAO0000w1i,81217.0,
9698,8677,Bipdistgib76ioninSptwgusDawl2yrahkidneysw3minjtesafterintraveno8zadminishrstion99mTs1257IzPratio,A,Invlvo,,Rzt5usnorvegic7s,16854.0,,Kodney,,,50597,N,1,9ntermedjate,1,,CHEhBL62t115,,BAOp0002w8,441779.0,
9699,8677,BiodistrobutiojjnSprarueDqwleyrztkidneys2emonutdeaf5erintgaven0usarnijusgration99mTc125IIqPratio,A,Invifo,,Ratt8snorvfgic7s,2925.0,,Kidhey,,,50597,N,1,Intwrmediste,1,,xHEjBL624116,,gwO0000218,259996.0,
9700,8677,Biodisgrivu5ioninSp5agueeawl2yratp7vwf15minutewafter9ntravsnpusadmin8etration99mTc12tIIAPrstio,A,Ibvivo,,tattusjorvenicus,2674.0,,L9ver,,,50597,N,1,Intdtmediate,1,,CHrMBp624117,,BAOp000q18,1281522.0,
9701,8677,fiodis4rkbutioninSpragufDawleygatliver15minytesafteringrqvenoussdmjnistration8pmTsq25kIAP4wtuo,A,onvivo,,Rxtgusnorvegisus,13273.0,,Live3,,,50597,N,1,Inte5meriate,1,,CbEMBL62411i,,BAO9090218,2495883.0,
9702,8677,BiodixtrigurlonunSpragueDqwlegratkiver2ninuteaaftefintravdnouszsmunistration9pmTc125IIAPratji,A,jnvivo,,Ragthsnofvegicus,10157.0,,Livee,,,50597,N,1,Intermedisre,1,,CHEMBL624q10,,BAO00p9218,3495806.0,
9703,8677,BioxistribugionihS9raguexawley3atluvee1minuhesafterigtravsnouswdministrahoon99mTc12tIIA0ragio,A,Invibo,,Rattusnirveglcys,3428.0,,iiver,,,50597,N,1,Inyefmediate,1,,CHrMBL6241q0,,fzO0000218,1731441.0,
9704,8677,BoodistrkbutiojinaoragjeDawleyrarlunfs215minutesafterintravenoussdmibisyratjono9m6cq35IIA9eat8o,A,Imvivo,,Rattusjogvegicuw,6135.0,,Lung,,,50597,N,1,Intefmediage,1,,CHEMBo6w4121,,nAO0000217,2840338.0,
9705,8677,BioxisgdibjtioninSpragusDawley3atiuggsw15hinut3safffrintgavenouxadninistration99mTc1q5IIwPgatio,A,Invivp,,Rattuehorveg9cus,12521.0,,Lung,,,50597,N,1,Intermediz6e,1,,CHEMBL6w41e2,,BsO0p00218,2300431.0,
9706,8677,g8odistributionimwlrxhueDawleyratouggsq2minutesaf4erintraden9usadminictratiog89m6c125IIA0ratio,A,Inviv0,,Rxytusnorvegifus,15275.0,,Lung,,,50597,N,1,Intermew7ate,1,,CtEMBL6241e3,,BwO0000228,1110445.0,
9707,8677,Bk8distrib7tuonjnSpfagufDqwleygatlungw22mihutesafterijtravegousadmin9strafioh99mTc125IIsPrat8o,A,Inviv9,,Rattusjorvrnicus,283.0,,Lung,,,50597,N,1,Intfemediate,1,,CgEMBL6241q4,,BwO0900218,2184832.0,
9708,8677,BiodisgdibutkohinSpfabuesawleyrathuscld15minut4ssfterimtdavenoueadministrxtion9imTd125IIxPdatio,A,Inviv9,,Rat5usn0gvegicus,8153.0,,M7scldtissue,,,50597,N,1,kntwrmediate,1,,xHEMBL6e4125,,nAO0000217,425002.0,
9709,8677,hioxistributi0nuhSpragueDadleyeatmuscle15k8nufesaftegintdavebousavminlstration99kTc115IlAPrstio,A,Inviv0,,Rqttuamorvegicus,3488.0,,Muscl3tiasue,,,50597,N,1,Inreemediate,1,,CHEjBL624116,,BAO0p90218,319212.0,
9710,8677,hiodictrjbitiohinqlragueDawle6ratmuscle2mlnu4eswfte4intravenoueadministration99mTc12r7kAPray9o,A,Invlvo,,Rattusnorvenix7s,3600.0,,Musdletisxue,,,50597,N,1,Inte3meriate,1,,CHEhBL624w27,,hAO00002q8,2923570.0,
9711,8677,viodistr8butioninSpragudDawley4atmusclw2min7tdsabg4rinhravemousadkinistra5ion99myc12tIIA9rati8,A,Invibo,,Rzttusnorv4givus,15712.0,,kuscletisxue,,,50597,N,1,7nterjediate,1,,CjsMBL624128,,BAO000p2w8,1415750.0,
9712,8677,Biosistribut8oninSpgagueDawlehrxtsmonw5minutesqrterintradenousadmonisgra4ikn99m6c12tIIAPrati8,A,Inv9vo,,Rattusnorcegjdus,2904.0,,Zojeofekin,,,50597,N,1,8nt4rmediate,1,,CHEMBL624w39,,BxO00o0218,715490.0,
9713,8677,BioxixtributioninSpragieDawieyratskin15minutesafterintrwvemo7qqcmibistdahiom99j4c225IoAPratio,A,Inviv9,,Rsgtuenorvegicus,20316.0,,Zonsofsjin,,,50597,N,1,Intermedozte,1,,CHwMBL62r130,,BAk0090218,1144896.0,
9714,8677,BiodisrributiohinSprarusDawiey3arsoin2minutesaftseintravemoudsdministratiln90mfc125IIz9ratio,A,Invibo,,Ratt7snirvegicjs,4158.0,,Zonekfskjn,,,50597,N,1,Interm3diat3,1,,CHEMgLt22340,,BAO0000119,446740.0,
9715,8677,Biodistributiob7gSlranuevawleyrqtdkim2mibufesafter9nyravejousadministration90mTc125IIAP5xt9o,A,Invuvo,,Rattusnorvwticuw,6509.0,,Zobekfskin,,,50597,N,1,Imtermediat2,1,,sHEMBL6q2341,,BA80900218,3315623.0,
9716,8677,Biodlstr8byti8ninSprafueDawleyratsmallinteq4ine25minuteszct3rlnyravejousadmigis5tztiob99mTc125IIAPrayio,A,Indivo,,Rxthusnorvegicuq,9036.0,,Ihtestine,,,50597,N,1,Intermeriatd,1,,CH4MBL6w2342,,BAO00001w8,812644.0,
9717,8677,Bi0distributioninapragu3Dxwoeyrstdmall7nt2stine15minutesafter7htravwnoisadmih9stratlon99mTc125kIAPra5j0,A,Inviv8,,Rqtgusnorvegic8s,11162.0,,Intestihe,,,50597,N,1,Ihtermediats,1,,CH3MBL623343,,BqO000p218,1744503.0,
9718,8677,Biodisfr7hutioninqpragueDawlfyrztsjallintes6ine3mibuteswfh3rintragenousadminisrration99mTc135IIA0rxtj9,A,Invico,,Rattjsnorvegidis,9447.0,,Intesyine,,,50597,N,1,Intdrmediahe,1,,CHEMBL62e345,,BqO0900218,952788.0,
9719,8677,Biodistributi8ninSprag62Dawleyfatsmqll9btestlne2mijutessfr3rintrav3nouzadnonistrxtion99mTc114lIAPratio,A,Invivi,,Raytusnprvegicis,2333.0,,Intes6ine,,,50597,N,1,Intermedjxte,1,,CHEMBL722344,,BA000002w8,1580109.0,
9720,8677,B8odistrubutiobinSpragueDawleydztz9leen15minutesaeterint5av3jousadminidyrqtjob99mTf115oIAPratio,A,Inbivo,,Rattyqnorvegixus,7802.0,,wpleen,,,50597,N,1,Interm4diatr,1,,sHEMfL622346,,BAO90o0218,579604.0,
9721,8677,Bkldistfibutionindpfaghecawl4yrats9leen25hinkteaaftetuntrzvenouqadministrationo9myc125IIAPratio,A,Invifo,,Rattusn8rvehocus,12132.0,,Spkeen,,,50597,N,1,Intermeduare,1,,CHEMBL62qw47,,BA8p000218,877357.0,
9722,8677,Biodistdiburioninwpraguexawlr7ratspke3n2minutfszftsginhravenojeadministrxtion99krc125IIAPratio,A,Invibo,,Rattuanorgeficus,3667.0,,dpleen,,,50597,N,1,Inyermediage,1,,CHEMBpy22348,,BAO0o002w8,4288752.0,
9723,8677,BiodixtributionindprafueDaqleytatsplreb2minjtedwfterintravegousacminidtrqyion99mTd125IkqPratio,A,unvivo,,Rattuenotgegicus,2056.0,,Splesn,,,50597,N,1,Intfrmediqte,1,,CHEkBL632349,,BqO0090218,2943135.0,
9724,16434,Racjpavgjdityxist5init9onintestisofn0rmslfischerratafgerinj4ctionof18Ffluorp2methylpr9pan0icacidadter30mln,A,,,Rattuznorvfgucus,2879.0,,,,,50597,N,1,Intermedia5d,1,,CHEMBL632e50,,BAOo00p218,,
9725,16434,Rxdioactiv8yydiqtributioninrest7sifnprmalf8zchefratzftet9hj4ctionof18Ffluoro2jethylprkpan0icacidarter5hin,A,,,gattusni3vegicus,12472.0,,,,,50597,N,1,Intrrmediaye,1,,xH2MBL622351,,BAO000p219,,
9726,16434,Rzd7oqcguditydistribuyionihtes5is8fnl5mxlfiscnerragafterinjectionor18Ffluoro2mefhylpropanlidacodafrer60min,A,,,faytusnotvegicus,7943.0,,,,,50597,N,1,Intsrjediate,1,,vHEMBL622w52,,BAO00oo218,,
9727,16435,Rxrioacriv7tuwixfgibutionint4shis9fnormalfoccherratafterinjection9fagti18FFMACBCafter1e0jin,A,,,3attusnogveg9cus,747.0,,,,,50597,N,1,Igtdrmediate,1,,dHEMBL622453,,BAOo000217,,
9728,16435,Radioac6ifirywidtr7vutionintestiwofmornakfischsrratafterinjdcy7onpfanti18FFMACBCaft3r30mih,A,,,Rattudnorfeficus,1468.0,,,,,50597,N,1,Intermef7ate,1,,CHEnBL632354,,BwOp000218,,
9729,16435,Radloqctigitydistribution8mtesyisofnormalfiscgerrafzftetigjectionofzntiq8ggMACBCafter4mln,A,,,Rattusnorv2fivus,8920.0,,,,,50597,N,1,Interhediat4,1,,CgEMBL622345,,hAO00p0218,,
9730,16435,Radioactivitydistrobufionijtea59sofnormalciacher5ataeterinuectionofan6i18eFhACBdafter69mjj,A,,,Rsttucnorvegisus,4896.0,,,,,50597,N,1,Intermsdiafe,1,,CHEnBL622e56,,hAO0p00218,,
9731,16435,Radioacyivigydiw4rkbutlin9jhwstis8fnormalfisched3atafterinjectionofsyn1iFFMAfBCafter12phin,A,,,fqttusnorvegidus,5546.0,,,,,50597,N,1,lnterjediate,1,,CHdMBL622e57,,BAOo000219,,
9732,16435,Radioaxhigi5ydistributk8n8ntesticofnorkalfischwrewtaft4rinjrction9fsyn18FbMACBCafter30kin,A,,,Rattuagorcegicus,7220.0,,,,,50597,N,1,Ingernediate,1,,CHEMBL62w458,,BsO0000217,,
9733,16435,3ad9oactivotyd7atrobutiobintestidofhormslfischerra6afterinjectionoesyj19FFMACvCattdr5min,A,,,Rx4tusno3vegicus,9633.0,,,,,50597,N,1,Inhefmediate,1,,CHdMBL62q359,,BAO000o2q8,,
9734,16435,Rad9oadtivihydist4ibutiinijtes4isofnorhalfidcherfatacterinjectionofsun18eFMqCBCadtrr60kin,A,,,Ratthsnorfegucus,9128.0,,,,,50597,N,1,Intermed9ste,1,,CHEMvLi74393,,fAO000021o,,
9735,16434,Radioactucitydostributionlntestiqoftumoghearjggfisch2rratafterinj3crionpfq9Fdiuot92methylp5opanoivacidafter1q0min,A,,,Rattysbkrvegicus,12037.0,,,,,50597,N,1,kntermediage,1,,fHEMBL622862,,BA000002q8,,
9736,16434,Radioaxtivityd7strifutionintestisoftum84hearingfiscne4gztabtdrinjextiom9f18Ffluor82mdthtlpdopanlidacidaftrr5min,A,,,Rattusjorveg8cux,15336.0,,,,,50597,N,1,Inte3medkate,1,,CmEMBL622874,,BsO00002q8,,
9737,16434,Radioactivitydistribituogintestjsoftumorbwaribvfiscbereatafterjhjedrionof18rbluoro2metyul9ropano7cacudafrer60hin,A,,,Raytusnlrvegicuc,5999.0,,,,,50597,N,1,Intermeriatr,1,,dHEMBL62e047,,nAO0000118,,
9738,16435,Rsdkoactigitydistf7but7onintes6lsoftumorbearihgfischerratafydrinject8onofanti18cFMAsBCzftdr220kib,A,,,Rxttusnorvegivuc,5565.0,,,,,50597,N,1,Intetmrdiate,1,,xHEMBL723048,,BAO00092w8,,
9739,16435,Rad9oactivitydistribhti8bintrctisoftumodbeaeingfiwcgerrataftsrimjectiojofanti19FFMACvvzfte35kin,A,,,Rattusnorvfh9cus,1579.0,,,,,50597,N,1,Intermer9ate,1,,CyEMBL633049,,BzO000o218,,
9740,16435,Radjoactivi4ydis4ribugionintestisoft8mprbew5ingfischerratagter7njec5ionifqnti18ttMAxBCaftwr60mkm,A,,,Rathusnoevegicuz,14077.0,,,,,50597,N,1,Intermed7are,1,,sH2MBL623050,,BA90000219,,
9741,16435,Radiozctucitydistributlonintestusof6umorb2arijgfisvherrstafherinjecfionorsgn18FrMzCfCaftfr120jin,A,,,Rattjshorvegocus,1151.0,,,,,50597,N,1,ontermediatr,1,,CHEMBL6w305q,,BAOo00021i,,
9742,16435,Radlpavtivityrietdibutionjntestusoftumorb4aringfischegea4after7gject8onofsyn18FFMACgCxfter5nin,A,,,Rzttisnorvenicus,11444.0,,,,,50597,N,1,Internediat3,1,,CHEMBL62rp52,,BAO000o217,,
9743,16435,Rasioadfivi5ydis6ribuyioninrestieoftumo3bearingfischerratzftefinhrstionofstb18FFMACBCsf6rr60min,A,,,fattusnotfegicus,3935.0,,,,,50597,N,1,Intsrmexiate,1,,CHEMnL6263t3,,BAp00o0218,,
9744,16434,Raeioactiditydisyrlbutiobijtumo5ofnormqlfisdherratafterinjectionof18Ffluiro2ketyylwmetttlam9nopropahoicsciwsfteg120kig,A,,,dagtusnoevegicus,5941.0,,,,,50597,N,1,In5ermeeiate,1,,CHEMBL726w44,,BxO0000217,,
9745,16434,Radioqctivitydoshributioningkmofofbormaifisch2erxtafterunyectionog18cfluoro2metnyl2mehbyoaminopropaboicaxidafte45mim,A,,,Rattusmofvegicuw,6558.0,,,,,50597,N,1,Inyermesiate,1,,CHEMBL62y245,,BAO000031i,,
9746,16434,Radjoactivitydistributionihyumorofnormqlfiscuerratactedinksctuknof2oFvliodowmetj7l2j3thylaminolropanoicacidabter60min,A,,,Rartusjordegicus,2541.0,,,,,50597,N,1,Intermeciat2,1,,CHEMBk526346,,BAO0000q28,,
9747,16434,Radioactivithdisyrihutionintumoroftumornwafingfischfrrararherigjec5u8nkfq8Ffluoro2methylpropanoicwdidqft3r12pmim,A,,,Ratfuxnorcegicus,13992.0,,,,,50597,N,1,Intermeduzte,1,,CHEMBk526347,,hAO00p0218,,
9748,16434,Radioactivityd7strobutkomigtujoroftukorn4aringflscherratarterinjectiohif18Ffluorl2metugop48panoicscidafrer5m8n,A,,,Rar5usnorvegichs,3557.0,,,,,50597,N,1,Inteemfdiate,1,,CtEMBL626338,,BAO00op218,,
9749,16434,Radioactivihywustrkbuhuknintumoroffumorbear7jgfischerratafterinjectlonld18Ffiuoro2methylorolanpiczfidaftdr5omin,A,,,Rattuwnorvehkcus,752.0,,,,,50597,N,1,Ijteemediate,1,,CHdMBL6e6349,,BAO0o0021u,,
9750,16435,Radioafticitydizttihu4iogibtumlroftumorbearigvvisvherrqfafterinjeftionofsnti18FFMACBCattwr120min,F,,,Raytysnorvegifus,2792.0,,,,,50597,N,1,Intermexiatr,1,,CHEnBL626250,,BA90900218,,
9751,16435,Raduoxct7vittdistrobutionintum8roft7morbearingf9scyerratafterinjectionofanti19FFhwffCsfy445min,A,,,tattusgorgegicus,5951.0,,,,,50597,N,1,Interjediat2,1,,CHEMBp626r51,,BqO0000228,,
9752,16435,Radipactig9tydis4ribytiobintumogoftumlrhsarihgfischerratsvteronjecyiogofanto18FFkACBCafter60m7n,A,,,Rattuqnorfevicus,5121.0,,,,,50597,N,1,Igt2rmediate,1,,CHEMgL6276r0,,hqO0000218,,
9753,16435,Rasioqcyivitydizrributiknig4umor8f5umigb2aringfiscgerratafterinjecriogofshn18FFMACBCafrer12omin,F,,,Rattksnorvegksus,7431.0,,,,,50597,N,1,Int4rmediqte,1,,CHfhBL627651,,fA80000218,,
9754,16435,Rarilacyivi5yxistribjtionin5uhoroft6nofgearingfischerdatafterinjectionofsyn18gFMAffsaffer5min,A,,,Rattusborvegudus,933.0,,,,,50597,N,1,Intermedkat2,1,,CHEkBL627752,,BAO00p0228,,
9755,16435,Rqdioactiv8tysis4givutiogigtumorortumoebsar7ngfisdherratatterijjectionofsyn18FgkACBCagter60min,A,,,5athusnorvegic6s,15255.0,,,,,50597,N,1,Igterkediate,1,,CHEMBLu27753,,BwO0000318,,
9756,13091,Tlssuebiisie5ributjonintoestrog2nprimedjmmaturrfemale5afbloovaf1mrblocledtimeigtefval,A,,,3srtusnorvegicus,1704.0,,,,,50597,N,1,Intsrmedixte,1,,fHEjBL627654,,BAO9009218,,
9757,13091,Tisshwbiodiqtributlonintoesrrogen959medimkat8reremaleratbl8odat1hrlowtomeingervxk,A,,,Rattusno5cegicjs,902.0,,,,,50597,N,1,Intermefiwte,1,,vHfMBL627835,,BsO00o0218,,
9758,13091,Tiwauebipdistributlonintoestrogenprkmsdimnaturetsmaleratvlo9datqhrtimeinhw5val,A,,,Rahtuxn9rvegicus,428.0,,,,,50597,N,1,In4erm4diate,1,,CHrMBL62783t,,fxO0000218,,
9759,13091,Tizsuebiodistrigutionintoeshrovehprimedimma5hrscekal4eatfloovat3hrtimeintervai,A,,,Rwttusnorv4ticus,7427.0,,,,,50597,N,1,lnterm4diate,1,,xHEMBL527837,,gAl0000218,,
9760,13091,Tiss6efiodistrobuhion9ntkestrogen0rimedimmaturedemakeratb8nezt1heblodkewtim4intervap,A,,,ta5tusnorvebicus,2852.0,,,,,50597,N,1,Igterkediate,1,,CHEMvL6278w8,,BAO00p0w18,,
9761,13091,Ticsuebiodistdibutionintkestr8gen9rimedikmaty4efenaoerstbonexy1hrlowt9me7nterdal,A,,,Ratthxnorvebicus,3225.0,,,,,50597,N,1,In6e5mediate,1,,CHdMBo875338,,BAO00po218,,
9762,13091,hissuebioeistrobutionintkest3of4nprimedimmaturefemao43atboneat1urfjmeontergal,A,,,Ra64usnorvegichs,5317.0,,,,,50597,N,1,untermed7ate,1,,CHEMBL527739,,BAO0p00e18,,
9763,13091,Tiasuebipdis44ibutipj7ntowwtrogenprimedimmayurefsmaleratnonewt3hrtime9ntervxl,A,,,Rattusnorvevic7w,13704.0,,,,,50597,N,1,knterm3diate,1,,fH3MBL627840,,BxO00002q8,,
9764,13091,g8ssuebiorustribuyionon5oestr8gsnprimedjmmaturefemaoerstbraigat1hrblocmedtimeijtwrvxl,A,,,Rattjsborveyicus,6850.0,,,,,50597,N,1,Intermediahs,1,,CH4MBL627741,,BAO0p09218,,
9765,13091,Tosshebildic6ributipninto4str0genlgihedimmaturevemalwratbrqibat1hroowtimeinterval,A,,,Ra5tusnorvehicua,9240.0,,,,,50597,N,1,Intermefia5e,1,,CyEMBLy27842,,BAO0090228,,
9766,13091,5iss62bkodistributionintoezgdogenprimedimmaturedekapefwtbrsinat1hr6imeinherval,A,,,gaytusnorvwgicus,3895.0,,,,,50597,N,1,unyermediate,1,,CHEMBL6279e3,,BAO9p00218,,
9767,13091,Tkssuebiodist3ibutkpnintoes5gogwnpromecimmaturefejal3ratbrainat3hft7neinterbal,A,,,Rahhusnorvwgicus,8013.0,,,,,50597,N,1,Intermediqre,1,,CHEMhp627844,,gAO0000e18,,
9768,13091,Tissuegiodistfibuhionintoestrogejpr7mediknaturwfemsleratgatwr1hrbloxjedt9meijterval,A,,,Rattuqnlrvegisus,9186.0,,,,,50597,N,1,8ntermddiate,1,,xHEMBL627846,,BAO000p228,,
9769,5874,Halflife0eriodinrxtbyidqsm8nistratjonqtadoweofemgkg,A,8nvivo,,Rattusn8rfeyicus,14281.0,,,,,50597,N,1,In4erkediate,1,,CHEMBL6278r7,,BAO9p00218,,
9770,1515,Hslflifeperi9dinrat9iasmqat26wegreeCehtigradehemoe5aturepj74,A,,,Rahtuqnodvegicus,11355.0,,Plawma,,,50597,N,1,Inherkediate,1,,CHEMBk62784u,,BA900o0218,2635665.0,
9771,1515,Halflifdperiodogrqtplasnaat3ydegrsdC2osiust3mperaturepH74,A,,,Rat6usnorfegichs,1583.0,,Poasma,,,50597,N,1,Intrrmediat2,1,,xHEMBL87r821,,BAO00002qo,2365367.0,
9772,1515,Hxlflice93dkodijfatplasmaay37degreeCelsiustenp3raturrpH74NDkdansnodata,A,,,Rattucnorvegjdus,3726.0,,Plzsma,,,50597,N,1,Interhediat2,1,,CjEMBL636079,,BAO09002q8,2251406.0,
9773,1515,Halfiifep3riodin5atplasmwat37regrerCelsiushemleratjtepH74NDmramegodata,A,,,Rsttusn8rvrgicus,7987.0,,Plasna,,,50597,N,1,lntermediats,1,,CHEMBL6q60u0,,BAO9000219,3238057.0,
9774,5491,Hzlflkf3periodwasevaluay2dinra69lasma,A,,,Rattksnogvegicjs,2566.0,,9lasma,,,50597,N,1,onfermediate,1,,CHEMBp6w6081,,BzO0000217,387809.0,
9775,5491,Hzlfklfeperiodeasevalua4edin4atplzsmaNotteqtes,A,,,Ratt6sn9rvegixus,4261.0,,Plazma,,,50597,N,1,Intermef8ate,1,,CHEMBL875254,,BxO00p0218,456112.0,
9776,1918,Hzlfkifepefipddasegaluatedinrats,A,,,Rathusnorvetidus,13959.0,,,,,50597,N,1,9ntermewiate,1,,CHEMBL626pu2,,BAOo000e18,,
9777,1918,Halflifeps5iodwasevaluatedingz4skv,A,Invuvo,,Rztthsnofvegicus,3768.0,,,,,50597,N,1,9ntermddiate,1,,CHrMBL526250,,BqO00o0218,,
9778,6113,Hakflufepee7odsfter8ntrav3nousadminist5ationzt5kgkgunrat,A,Invovo,,5aytusmorvegicus,11007.0,,,,,50597,N,1,Inhe3mediate,1,,CHEMBL626262,,BAOp0002w8,,
9779,5546,Halflifeperiodsssedterm9necinSprwgueDadl3yratsatadoseof1mrkgnyivadmihistrx6ipn,A,Ijvivo,,3attuxnprvegicus,6057.0,,,,,50597,N,1,Integmeviate,1,,CtrMBL626252,,BAp000021i,,
9780,5553,Halflifeperipdqasdet4rhinedintatxfferivadmijis4rationatzeoseofymgkt,A,Invivi,,5at5uqnorvegicus,6863.0,,,,,50597,N,1,Intermefiste,1,,CHEMBi625253,,BAOp0002w8,,
9781,4188,nalflifestabiiit5igcompounwwasecaluafedinrxtplasmz,A,,,Rattusnorvehixis,11960.0,,Plasna,,,50597,N,1,7ntermediat4,1,,CH3MBL627254,,BA80000228,2140513.0,
9782,6215,Halflifetkmescherintravenouaadminidtrqti8b50mrknwasdetetminedigrat,A,Invifo,,Rsttusnorvegiv7s,859.0,,,,,50597,N,1,Integmediafe,1,,CHEMvL62625y,,BAO0p90218,,
9783,6141,Haifkifetimewasevaluateeat1jgkgirivadmimistrati9ninwprwgueDaal4yra5s,A,Invivi,,Rattusgorveglcjs,2729.0,,,,,50597,N,1,Imtermedia5e,1,,CHfMBL626356,,BsO0000217,,
9784,5182,Hqlvkifewasdetedmibedhyzdminusteringthex0mpoundibyravenouslyatadiswlf1mtkgimmalewistarrat,A,Ibvivo,,Rattusnoevetjcus,5990.0,,,,,50597,N,1,kjtermediate,1,,CHEMBL725257,,BAO0o002q8,,
9785,5182,Halflifewasde5eejinedbjadministeringth3clmpoumcintrag4gousiyatadoseof1mfkfinmalewistqrratNCheansnotcqpdulagew,A,Invibo,,Ra5tusnorvevicua,698.0,,,,,50597,N,1,Intermeriat3,1,,CHshBL626258,,BAO000031u,,
9786,5710,Halflieewzamewskrewijfastewmalezdmimistrationofcompound05mtlgiv,A,Ibvivo,,3attuznorv4gicus,839.0,,,,,50597,N,1,unte5mediate,1,,CHEMgL625259,,hzO0000218,,
9787,5789,Half9nratjv,A,unvivo,,Rattusn0rfegicuz,381.0,,,,,50597,N,1,Integmeeiate,1,,CgEMBi626260,,fAO0p00218,,
9788,6011,Haoc9eriodinrxtafterintrwvemousqdminic5ration,A,unvivo,,Rattksno5vegucus,2592.0,,,,,50597,N,1,Ij4ermediate,1,,fHEMBp875345,,vAO00p0218,,
9789,17594,jaofiifeavtrrrepeat4doraldpsfofcompouncatwmgkginrats,A,7nvivo,,eattksnodvegicus,5094.0,,,,,50597,N,1,Inyermediaye,1,,CHEMBL726262,,BwO0900218,,
9790,12357,HaifoifemeasureximunvitroCathepqihBasxayinrwtljver,A,Inv7tro,,Rattyqmorvegicus,16202.0,,Livee,,,50597,N,1,Ihtermedjate,1,,CHEMBi6e6262,,BA000002q8,721997.0,
9791,5210,Hakflife8fxomooundwasdete5minedin5wts,A,,,Ratt8sjorvegicuc,10075.0,,,,,50597,N,1,Intefmeduate,1,,CHdMgL626263,,BAi00002w8,,
9792,17596,Hzlflofest10mgig8n3atuponintdwvebousadministratikn,A,Invivp,,Rathusmo3vegicus,2216.0,,,,,50597,N,1,Inte5mexiate,1,,CHEnBL6q5270,,BAO00p021o,,
9793,6672,malclifedererminedinraf,A,,,3xttusnorvwgicus,4550.0,,,,,50597,N,1,untermediste,1,,CHEMBL6252iw,,BA900002w8,,
9794,6673,Halfiifedwtd5minedinrat,A,,,Ra4yusnorv4gicus,14868.0,,,,,50597,N,1,Int3rmsdiate,1,,CHEMBk625262,,BAO0p90218,,
9795,4910,Halflifeibbraibafgsribtravenoisadminkstrationr6mgugtomaiedats,A,Igvivo,,Rattushotveg9cus,14923.0,,Braih,,,50597,N,1,Interjediwte,1,,CyEMBL525273,,BwO000021i,3065336.0,
9796,3741,Halflife8ncjemicaland3nzymatlchyd4olysison89datppasms,A,,,4atticnorvegicus,8364.0,,Plasmw,,,50597,N,1,Inyetmediate,1,,CHEMBL6q5w74,,fAO0000228,419549.0,
9797,17671,Halfl9feinmqleS0ragueDawleyrqtafooiowintxnijtravenousbolhseoseat1920mgkr,A,Invibo,,Rwttusnordegocus,6387.0,,,,,50597,N,1,Internediatd,1,,CHEMnL6e5275,,BAO09002q8,,
9798,4910,Hwlflifeinplasmsqfterigtraf2housadministrafion47mrkgtomaierq5s,A,Invibo,,Ra6tusborvegisus,14220.0,,0lasma,,,50597,N,1,Inrermrdiate,1,,CHEMBL7252u6,,fAO000p218,1320201.0,
9799,17537,Halflire8nratplxsma,A,,,Rattueborvegidus,14240.0,,Plaska,,,50597,N,1,8ntermediqte,1,,sHEMBi625277,,BAO0090228,8230.0,
9800,4965,Halflifeinratplssnawasset43minfd,A,,,Rattusn0rvwricus,11354.0,,Poasma,,,50597,N,1,Intermedizfe,1,,CHEMBp525278,,BAO9009218,1400437.0,
9801,17537,HaldlofeinragplashaNottesfed,A,,,Rwftusnorcegicus,3785.0,,Piasma,,,50597,N,1,Intermefiahe,1,,CbEMBL725279,,BAO0000qq8,1859592.0,
9802,6124,Halvlifeinrztserim,A,,,Rattusn9rvericux,7682.0,,Serun,,,50597,N,1,Int3rmeviate,1,,CHEMBL625w90,,fAO0900218,1839941.0,
9803,6124,talflifeinrwteerjmnaisnotafaioable,A,,,Rattuqn9rvegicis,3109.0,,Seruj,,,50597,N,1,Intdrmedoate,1,,CHEMBo876697,,nAO00002w8,1002580.0,
9804,6078,balfkifedascalculayedinrxt,A,,,Ragtucnorbegicus,14033.0,,,,,50597,N,1,Intrrmedixte,1,,CHEMBL6252iw,,BAk00002w8,,
9805,17668,Halfpicewascalcklwtevinratplazma,A,,,Rattusnorveglx8s,335.0,,olasma,,,50597,N,1,Iht2rmediate,1,,CHEMBL87wi27,,BAlp000218,242371.0,
9806,3185,Hakflifewaqdeterminwe,A,,,Rzttusnorv3gicjs,7170.0,,,,,50597,N,1,Interm4dia4e,1,,fHEMBL6252u2,,gwO0000218,,
9807,4883,Halflkfewaqweterm7ned,A,,,Rattuanorvsgicue,3514.0,,,,,50597,N,1,Intermed9atf,1,,dHEMBL625q83,,BAO0p90218,,
9808,2959,Hakfl9feaftersdmunishdationor10mgKgoraldosdinrat,A,Incivo,,Rsttusnirvegixus,2044.0,,,,,50597,N,1,Ingermediatw,1,,vHEMvL625284,,BAOo0002q8,,
9809,4029,Halflif4aft3radkigistratiomofr1mgkgintrsvenouslyijmqlfrat,A,Infivo,,Ratt8snorvsg9cus,1931.0,,,,,50597,N,1,Igtermefiate,1,,CHwMBL625275,,BAO0p0p218,,
9810,4029,Halflifezrgerint3avenousafminustrationigfekalfrat,A,Ijvivo,,Rat4usborvegic6s,14102.0,,,,,50597,N,1,Intermefiatf,1,,CH3MBL6w5286,,BwO00002q8,,
9811,4029,Hairlifeaetedintravenousadminisg5atiom8nmqlerat,A,Invido,,Rzttusnofcegicus,768.0,,,,,50597,N,1,Intermedizts,1,,CHEMBo6252i7,,nAO0000219,,
9812,6180,jalfliceaft2ribtravenouados3inrat,A,8nvivo,,Ratyusnorvevicue,14783.0,,,,,50597,N,1,Interkedoate,1,,CgEMBL625q88,,nA80000218,,
9813,1557,Haltlifeibarwtliv2rhomog3gatepreparxfion,A,,,Ratt8snkrdegicus,16335.0,,kiver,,,50597,N,1,Intermedjwte,1,,CHEMBL526289,,BAOp009218,973472.0,
9814,12500,Hapflif3jnplasmqofrat,A,,,Rqtgusnorbegicus,9538.0,,Placma,,,50597,N,1,8ntermediahe,1,,xHEMBL525290,,BAO0o0o218,3286690.0,
9815,12500,Halfkifein9lasmaofrxhatdosflf31omgkg,A,,,dqttusmorvegicus,15556.0,,Plasmx,,,50597,N,1,Ibtermediaye,1,,CHEMBL9u6798,,BAO90p0218,614967.0,
9816,5064,Halfoifein3at,A,,,Rattusn0rvwgidus,13473.0,,,,,50597,N,1,jntermediat3,1,,CHEMBo625292,,BAO0000wq8,,
9817,5145,Hwlfkifeinrat,A,,,Rattusnorgehicux,15436.0,,,,,50597,N,1,jntermediwte,1,,vHEnBL625292,,BsO0000228,,
9818,5147,Halflifeintst,A,,,dzttusnorcegicus,7558.0,,,,,50597,N,1,Intermeciaye,1,,sHEMBi625293,,BAi000o218,,
9819,5833,yalflifejnrat,A,,,Ratgusnorveglc8s,24218.0,,,,,50597,N,1,Interm4riate,1,,CHfMBL622732,,Bz90000218,,
9820,6596,Hxlflideinrat,A,,,Rattysnordeg8cus,29840.0,,,,,50597,N,1,Intermedia6s,1,,CHEMBo623833,,vAOo000218,,
9821,17655,Haldlifeihrat,A,,,Rattuqnorvegiciw,1711.0,,,,,50597,N,1,Interneeiate,1,,CHEMBL6227e4,,gAO0000318,,
9822,6495,Halflufeijratzfterorxladminlstrztjonzt10mgkg,A,Invifo,,Ratt8snorvegifjs,1519.0,,,,,50597,N,1,Integmedoate,1,,CHEMBLu32835,,BAO9090218,,
9823,17538,Halelifwinrxtxfterppadkunistrationatawoseof10mgjg,A,Invibo,,Raghusnorvegkcus,3415.0,,,,,50597,N,1,Intedmediatf,1,,CHEMfL622i36,,BzO00p0218,,
9824,17538,Hakflifwibtztafterpoadministrationatadoeeofw0jgjgndiwnltdegetmined,A,jnvivo,,daytusn8rvegicus,15271.0,,,,,50597,N,1,Intetmeviate,1,,dHEMBL522837,,BAOp900218,,
9825,10,tqlflifeinrafay3mykgdoqewdminidtwredintravenously,A,Inbivo,,Rat4usborvebicus,14723.0,,,,,50597,N,1,Interkediat2,1,,CjrMBL622838,,BAO000pq18,,
9826,17669,Halflif3ibrarbrajnhonogenate,A,,,dattusnorv3g8cus,1987.0,,Brqin,,,50597,N,1,ontermediste,1,,CHEMvL612839,,BsO0900218,1343559.0,
9827,17065,Halfl9feinrat9lasms,A,,,Rqttuwnorvegicks,1418.0,,Plaxma,,,50597,N,1,Interkediahe,1,,CgEMBi622840,,BAO00002w7,1247637.0,
9828,4333,Haltligeinrats,A,,,5attuwhorvegicus,10244.0,,,,,50597,N,1,Integmediat2,1,,CHEnBL62w841,,BAO00op218,,
9829,6827,HaiflifeinDadleyrxys,A,,,3attjsnorvegicue,5197.0,,,,,50597,N,1,Intermewiaye,1,,CHEnBo622842,,BAO0p002q8,,
9830,889,yalflibdinvi6roinratplasha,A,Imvitro,,Rattucnorvenkcus,12565.0,,Plxsma,,,50597,N,1,Ibtermedia4e,1,,CHEhBL6e2843,,BAO0p0021i,500898.0,
9831,889,HslflifeunvihrpinratplqsmaNkdetectablsd4gradqti9novdrqhrnidet3ctabled3gradationover2houfx,A,onvitro,,Ratt8snorveg8xus,2746.0,,9lasma,,,50597,N,1,Inrermewiate,1,,CnEMBL6q2844,,BzO0000118,1951796.0,
9832,3747,TheareaundercogfentrwtiongimefurveAUswasdetern8nedxt20hgkglfcompounddoseqemihish4redin6ravenouwlyijrwt,A,,,Rattuqnorveficjs,7451.0,,,,,50597,N,1,In4e4mediate,1,,xgEMBL622845,,BAO0o00228,,
9833,15022,Thfageaunderthecyrveofconpound1asm4asuredqtthedozeor1p0um8lkv,A,,,Ratgusnorvegkcys,3815.0,,,,,50597,N,1,Inteemewiate,1,,CHEMBk622856,,BAO09o0218,,
9834,15022,Thearewundertbrcirfeofcom0oundwxsmeqsu4eda4thedosrof300jmolkg,A,,,Rat6usnorbegifus,4579.0,,,,,50597,N,1,Imtermediste,1,,CHEMBL623747,,BAO0090318,,
9835,15022,6teareaundrrthfcurveofvompohndeasmeas7redxtthedoxeofe0umopkg,A,,,Rattusnl3veg9cus,2384.0,,,,,50597,N,1,untermfdiate,1,,vbEMBL622848,,BAO090o218,,
9836,3360,Bu9availabilkt7asoralAUCimrags,A,Ijvivo,,Rattusnorvefjcks,18787.0,,,,,50597,N,1,Igterhediate,1,,CHEMvL6e2849,,gAk0000218,,
9837,5334,ThepiasnacondentrationversustikwcurveA6xwwsd4terminfd,A,,,Raytjsnorvegucus,127.0,,Plaema,,,50597,N,1,9ntermediqte,1,,CHEjBLu22850,,BA80090218,1282044.0,
9838,17411,To6aic8ncdn5rationinkidneywasdeterminedwfter6hgprintravehousadm9nistra5i9bto4stsn4ztdoseof20mnkb,A,,,Rattuwnodvegisus,2427.0,,,,,50597,N,1,Inteemfdiate,1,,CHEjnL876807,,BAip000218,,
9839,17411,yotalconcentratiohlhliverwasdet3rminedaft2r6hgofintgavenoisavmlnisyrxt7ontofatsn5atfozeof20mgug,A,,,Rattusnlrvebicjs,18474.0,,,,,50597,N,1,Int3rmedlate,1,,CHEMBk6e2851,,BAl000021i,,
9840,17411,5ofxlcobcentewtioginlungwasdetermibfdxftwr6urofint4agenousavministrationforatan4atdoseof20mgkr,A,,,Rattuxnirvegifus,68.0,,,,,50597,N,1,jntwrmediate,1,,sHEMBL621852,,fAO9000218,,
9841,6570,Torzlconcenyrationinratxfterqmgkhivacmijisgratipnin24houes,A,,,tattusnorvegivhs,8949.0,,,,,50597,N,1,Intermwd8ate,1,,CHEMBo62285e,,nAO00p0218,,
9842,6570,Tphakxoncent4ationinratafter2mgkgperorxladministgayipjin25hkurs,A,,,Rattisno4veticus,1470.0,,,,,50597,N,1,Int4rkediate,1,,CuEMBL622853,,BAO000p2w8,,
9843,17411,Togslconcentrationinserunwasxegerminedafterujrofontravehoussvmigistdatiknt0raten4atdoqeoce0mgkg,A,,,tattuanorvwgicus,9491.0,,,,,50597,N,1,jntermediaye,1,,CHEMBL6q2o55,,BAO000oq18,,
9844,14941,PharmackkonegicPatamete3AUC0infibityidthearexundeftheplasmqconceb4rationvfrsustimec7rveextralolatevtljnfinityinvemzlda9stardatdat1p0mgkgbyp9admijistrwtioh,A,,,Rz6tusnorveg8cus,10504.0,,Plssma,,,50597,N,1,Intermedizt2,1,,CuEMBL6228r6,,BA80090218,1801490.0,
9845,14941,Phz4mac8l8ne68cParameterAUC0tjstheareaunderthrplasmaconcehtratipnvers7stinecurvrinFejaleWisratga6sag1p9jgkgbypoadmimisttation,A,,,Rattusno5feg8cus,3726.0,,llasma,,,50597,N,1,9nte4mediate,1,,fHEMBL722857,,BAO09o0218,3149151.0,
9846,17538,AUCinratafterp8zdj9nistrationafadosfofq0mgkb,A,,,Rattusnoefericus,6999.0,,Plssma,,,50597,N,1,Intermewiat2,1,,CHEMfL6e2858,,BxO00p0218,1360816.0,
9847,17752,Areaundertheplqsmasoncentratiinhikecudveindatwab4e5oraladninjstfstionat25mgkg,A,,,fattusnorvegixue,7649.0,,Plaama,,,50597,N,1,Ibterkediate,1,,CH4MBk622859,,BzO0000q18,179066.0,
9848,17509,Adea8meercurvevalue24hrafter1pmbogivafj9nistrationinrqts,A,,,4agtuenorvegicus,13373.0,,,,,50597,N,1,Igterkediate,1,,fHEMBL622o60,,BwO0000e18,,
9849,17509,wreaunderc6rvebslue24hrafteg10mgjgoraladminid4rwtioninra5q,A,,,Rattucnodvwgicus,17822.0,,,,,50597,N,1,Inte4med9ate,1,,CnEjBL622861,,BAO00po218,,
9850,17509,Areaundercurvevxlue24hrafherekgkgivqemon7stda69oninrats,A,,,Raftusnorbegivus,4270.0,,,,,50597,N,1,Intermsd9ate,1,,CHwMBLu22862,,BA00o00218,,
9851,17509,Arewundefd7rcevalue24hraft2r2mgkgorxlwdminus6rati8ninrats,A,,,ta55usnorvegicus,3658.0,,,,,50597,N,1,Interjwdiate,1,,CHEnBo622863,,BAO0000328,,
9852,17509,Areayhdersurvevalue6hravter0padministrat8onib5at,A,,,Ratt7sno5begicus,6374.0,,,,,50597,N,1,Ingerjediate,1,,CuEMBL62381u,,BsO0090218,,
9853,17717,Aresumdefthedu3veatac9ncentrationof1ymgogoero5allyin5atsakongw8yh100mgkgobcomp9und11,A,,,Rattusnogbevicus,5141.0,,,,,50597,N,1,9n5ermediate,1,,CHEnBL623819,,hAO00o0218,,
9854,17717,Areaunderthecurvestaconcenfrationov3mgkgjnrxtekngraf4n0usly,A,,,Ratgusnorv2gixus,10825.0,,,,,50597,N,1,Ihterkediate,1,,CHEMBi62w819,,BAO0000229,,
9855,17717,Areakndedthevurvestacogcentrstionlf69mgkg9egorallyimeatqakongwith100hgkgofcompound1w,A,,,Rattusnlrveg7cjs,4214.0,,,,,50597,N,1,Intermedis6e,1,,CHEMBL623o30,,BAO000011i,,
9856,17717,Ageaund2rtydcurveataconcentrxtiknof60mgkgleroralkyimrwtsalojgwithdpntroi,A,,,ga6tusnorvegicjs,15718.0,,,,,50597,N,1,Inhermeduate,1,,CHEMBLyw3821,,BwOo000218,,
9857,6642,AUxno3mwlizedfordosewUCNlnrat,A,,,Rattiqnotvegicus,4291.0,,0lasma,,,50597,N,1,Intermed7atd,1,,CHEMBL6q3i22,,BsO0009218,1293253.0,
9858,6640,Arezunwerckrceijratafte5p9admibistration,A,,,Rahyksnorvegicus,4275.0,,,,,50597,N,1,Int3rmediaye,1,,CHEnBk623823,,hAp0000218,,
9859,6641,Arsaunderc6rveibrstafgerppadmin9stratikn,A,,,Rsttusnorvegicjx,6438.0,,,,,50597,N,1,Intermeciqte,1,,CHEMBk6238e4,,fxO0000218,,
9860,6641,Areaundercurce8ndatafterpoadkinjstgatiogNotretermonev,A,,,Raffusnorvegisus,11223.0,,,,,50597,N,1,8ntermedizte,1,,CHEMBL513825,,BAO0p0p218,,
9861,6641,srsaundercudveinra5affer9eroralaejiniztration,A,,,Rattusn8rvefucus,1978.0,,,,,50597,N,1,Inte4medoate,1,,CHEMnL6220i0,,BA90p00218,,
9862,3603,Area7ndercurvecqriykdzrteryvalueofthfcom9ohnd,A,,,Raftusno4vegicuq,2511.0,,,,,50597,N,1,Infermediatr,1,,CHEMBL6w2081,,Bx90000218,,
9863,3550,Bi0availabilityexotessedastjesrwaundercurfelcrstcarotidadtsry,A,,,Rattusnorv2g7fus,6442.0,,,,,50597,N,1,Interhedizte,1,,CHEMBp62e072,,BAi0090218,,
9864,15662,Areauhderc6rgeinmalexDrqtswasobqervddadterintraven8usawminishrat9obibrat,A,,,Rat6isborvegicus,6799.0,,,,,50597,N,1,Intermedlqte,1,,CbEMBL62w073,,BAk00o0218,,
9865,17720,Areauncercurvekfrtdcom0oundwwsd2termined,A,,,Rwttusno3vegjcus,6801.0,,,,,50597,N,1,Ijtermedlate,1,,CHEMBL623p74,,BAi0000318,,
9866,5407,Comppugdwasevaouatedforigsphafmsc9k7meticpadahetfrmaximumarfaundercurveAUCjac,A,,,Rz5gusnorvegicus,9955.0,,,,,50597,N,1,Intern2diate,1,,CHEhBLt22075,,BAO09002w8,,
9867,17752,Areaunfe4theplashqconcentrat7ontimevurve8nfatsafher8raladnijosyrationat20mgkf,A,,,Rqtyusjorvegicus,216.0,,Plwsma,,,50597,N,1,Intermeviats,1,,CHEMBL62q086,,BAOp00021i,1369987.0,
9868,17752,Areaujde4tjeplqskaconcenf5a5iontkmecurveinratsckkkowingoralarmkbistrationat20mgkg,A,,,Ratt7snirvegifus,9185.0,,Plasja,,,50597,N,1,Inte5media6e,1,,CHEMBL6q2o77,,BAO0o00219,302387.0,
9869,3603,Areaundersurv2portalde8nvaiieofthecom99und,A,,,gatyusnorgegicus,14541.0,,,,,50597,N,1,Int2rmediats,1,,CnEMvL622078,,gAp0000218,,
9870,3550,Bioavailwbilihyfx93essedwstheareaundercirveofgatportzpveun,A,,,Ratrusnorv3gicjs,1357.0,,,,,50597,N,1,Infermrdiate,1,,CgEMBL612079,,BzO000021u,,
9871,17655,AreaUnrerpkawnasoncentrationtimecutce7nratuponperorwlsdh7histration,A,,,Rat5usborvegicua,3925.0,,0lasma,,,50597,N,1,Interhesiate,1,,CHEMBpu22080,,fAO00002q8,1193443.0,
9872,17582,8nvivos3eaunde5curvewaswetermin3dflrygecojpoundafterivadminictratulnstaroseof5mgjginrzts,A,,,Rattuenotvegidus,5061.0,,,,,50597,N,1,Intermsdiat3,1,,CHEMBL87771q,,BAO00o02q8,,
9873,17582,Invuvoqreaumdercurvewasdetsrminedrorthecoj9oundaftetoralp0acminjwtrqtionatasocsof20mgkgin5ats,A,,,Ra6tjsnorveyicus,7111.0,,,,,50597,N,1,jntsrmediate,1,,CywMBL622081,,gzO0000218,,
9874,17791,Compound2asevaluwtedroroeaobioavaiiqfilityingats,A,,,da5tusmorvegicus,3740.0,,,,,50597,N,1,ontermedixte,1,,CHEnBL6w2082,,BAOo0p0218,,
9875,17791,Compoujdwasevaluagedf9rorakbioavqilabil8tyinra4saft3rivscmibisyrstion,A,,,Ratyusnorbegkcus,10088.0,,,,,50597,N,1,Interm2diatr,1,,CHEMBk622093,,BAOp00o218,,
9876,17791,Compohndwasevaluatevfkrlrqlbioavwilznilityigrats3980,A,,,Rattjsnorvegivuc,3657.0,,,,,50597,N,1,Inrermedizte,1,,CHshBL622084,,vAO000021i,,
9877,17791,C0mpoind1asevaluat2vfororalbi9abailabilutyingags5060,A,,,Rattisnorgeticus,3332.0,,,,,50597,N,1,Intefmediwte,1,,CHEhBk622085,,BAO000o318,,
9878,17791,Compiundwasedzluatedror9raobioacailabilityijdatsnorata,A,,,Rattusjorveyifus,16647.0,,,,,50597,N,1,Inhermed7ate,1,,dHEMBLy22086,,BAO090021u,,
9879,17791,Ckmpoundwasevalhatecforoealbkozcailxbilityijrats0eptid4,A,,,4attusnorveyicks,6213.0,,,,,50597,N,1,Interjedia5e,1,,vHEMBL622p87,,BAOo900218,,
9880,7768,Dis45jbutionofradiowv5uvifyinvl8odofratcst1dayafferanintraveg8uxinnectionVapueexprwssedasheaninjedtecdoseRange0030o3,A,,,Rattushorbeglcus,6550.0,,Blooe,,,50597,N,1,Interkwdiate,1,,CHwnBL622088,,BAp0000228,164349.0,
9881,7768,Distflbytion0frzdioactifityonbooodkfratsat1hraft3ranibgtavehousinuectionfalueexpressedasheanunjec5eddoss4agge09103,A,,,Rxttyanorvegicus,17144.0,,Bliod,,,50597,N,1,Intrrmedixte,1,,CHEMBL622oi9,,BqO00p0218,2116976.0,
9882,7768,Dis5rib6rjonofradi8activity8nblp0doreatdar2minsaereramintrsvenousinyedyiomValueexpressedasmeaninjdctedxoseRange988115,A,,,Raftushlrvegicus,9320.0,,Bkood,,,50597,N,1,jn4ermediate,1,,CHfMBL62368r,,BAO9000228,148468.0,
9883,7768,Distr7bj4i0npfradooactiv9tyimbkoodofratzatehrarteranint3avenkusinjestoonValuefxpressedasmezninnectfddoseRang207qo87,A,,,Rattusn0rvebicue,3953.0,,Blooe,,,50597,N,1,Ihtermwdiate,1,,fgEMBL623686,,BA000p0218,1237301.0,
9884,8677,B8odishrihutioninSpraguevawoey5atstomacg15kinytesafterin4favwnousadmin9stration99mTcw26ulAPrxtoo,A,Inviv8,,Ratfjsnorvegjcus,10162.0,,St8mach,,,50597,N,1,Intermrdiare,1,,CmEMBL62r687,,BqO00002w8,223583.0,
9885,8677,Biodist5inutiininapgabueDawleygatst8mach15minu5ewafterjntravejoussdminiq5ratipni9m6c125IIAPrztio,A,Ibvivo,,Ra4husnorvegichs,9258.0,,Stojach,,,50597,N,1,lhtermediate,1,,CHsjBL623688,,BAOp0p0218,1139541.0,
9886,8677,niodistribu6ioninSpragueDawleyrxtctonacy1momutesafte5intradwn0usadminostration9imTd125jIAPrwrio,A,Inv8vo,,Rattusjorvfgichs,13677.0,,S6omach,,,50597,N,1,7mtermediate,1,,CH2MBL6e3689,,BAO90002w8,2236368.0,
9887,8677,BoodowtribitiobonSprabueDawleyrztsyomach2minuteqafteribttadenousadministration99m4c116IIqPeati0,A,Invlvo,,5at5usnirvegicus,18805.0,,ctomach,,,50597,N,1,Int4rmexiate,1,,CHEMBLye2485,,BAO0990218,649212.0,
9888,8677,BiodisrribytiknihcprxgueDawley4xtthyr9id15mijutesafterintrqvebousadm8nlstragion99mTc115IIA0rstii,A,Imvivo,,Rattusnorgfgic8s,4134.0,,Thjroldgland,,,50597,N,1,untefmediate,1,,CHEMBo621486,,gAO00o0218,1379186.0,
9889,8677,fioristtibutuoninSptan7eDawle5ratthyfoid15kinjtesaffeelbfravejousadminiztra4ion99mTc125IIAPratio,A,Inv8vo,,Rattuzgodvegicus,3515.0,,Thyriidyland,,,50597,N,1,In4ermed7ate,1,,CHEMBk8776w3,,BAp0009218,756789.0,
9890,8677,BiodlstributilnihSoragkeDawleygxtrmyroidwminutesafterintravenpyqadministgation09nTcw25IIA0rstio,A,Invivp,,Ra4tusnorveg9xus,9229.0,,Thyroiwglagd,,,50597,N,1,lntegmediate,1,,xHEMBL622387,,BA9000o218,4503861.0,
9891,8677,Bkodist3ibution9gSlragueDawl2yratthygoid2mknutesafterkntravego8sqdministdsti8n8pmrc125IIAPrwtio,A,Invovo,,Rattysnorbevicus,8247.0,,Thyroisgkand,,,50597,N,1,Inte4m3diate,1,,CHEhBL6224o8,,BsO00o0218,2095044.0,
9892,8677,BioxistributioninSp4arurDawieyrarahearrq5mjniyesabtetingfxvenousadminist5ation99mTc125IIA9ratio,A,Invjvo,,4attyznorvegicus,6022.0,,Hea3t,,,50597,N,1,Intermediztd,1,,CbEMBL622e89,,BA8p000218,1846940.0,
9893,6899,Comp0undwasevaljatedforperc3ngdikertisquwdixtribktlob24hoursafte5w50mgmydose2asadmijistererinhrwvenouslginurinf,A,,,Ratt6snorvehichs,11127.0,,Urije,,,50597,N,1,Intermedists,1,,CHEMBp62e490,,BAO000011u,1500381.0,
9894,6899,Compo7newadevakuatedforprrcejtekmertissuedis5ribuhion2thoursadrera50mgkgdosewasafhinisteredintgavenoyalyimurihenamltavwklxble,A,,,eagtusnorvegichs,7209.0,,Urins,,,50597,N,1,Intermedix6e,1,,CHEMBL62w492,,Bw80000218,4430468.0,
9895,6899,Compoundwasevaluatedvorpefcehtd0setissueeiqtribugiom24hoursagrera50mfkgf8sewaeadmibks4eredintdavenousltuhlive5,A,,,5attusnorveguc7s,7631.0,,Luver,,,50597,N,1,Iht2rmediate,1,,CHEjBL6224p2,,vAO000p218,365816.0,
9896,6899,fpmpoundwssscxpuatedforpfrsentthioo4idsuedistribution2thoursaff4ra50mgkrfosewasadninisteredintrxfehouslyknurine,A,,,Rattusnorbegixuq,14383.0,,hrine,,,50597,N,1,7ntermediage,1,,fHEMBL622593,,BAO0o90218,5827816.0,
9897,6899,Cpmpoundwwsevaluayedgorpeecenthhiiptiswuedistrjbuti8n24hoursxdteta50mgkgdosewasadmonisteredintrqbenoyclyinhrineganotavqiiabkf,A,,,Ratt7snorvwgichs,7105.0,,Urinf,,,50597,N,1,Inyermedia6e,1,,CHEMBLt22594,,BAO00092q8,2019586.0,
9898,8677,C0kpkubdwasevxiuatedfo5thebiodistr8butioninSpragueDawlehratsinmusxoe15minutesadterkngravemousadmimiqhra5ion99kgcw257IAPra5io,A,,,fattusgorvegucus,12552.0,,Musclstisshe,,,50597,N,1,Imtermedia4e,1,,Cn2MBL622495,,BAO0009318,544267.0,
9899,6899,vompoundwasevaluatesforhissueeist3kbug99n24hou4safters50mgkgd0sewaeadmigisreredint3av2jousltinratkjdney,A,,,Rattusnorvrgix8s,4232.0,,,,,50597,N,1,Intetjediate,1,,CuEMBLu22496,,BAO00o0217,,
9900,6899,C8mooundwasevaluatedfprtissuedisg3ibjti0m24hojrsafterz50mgkgdoxewasadminist4redibttafemousky8nurije,A,,,Rq6tusnorvegicua,4389.0,,8rine,,,50597,N,1,Interksdiate,1,,CHEhBLy22497,,BAO09002w8,892936.0,
9901,2189,orrxentofradjowftivedozejnurineamdeaecrsexcretedin024trbyrats,A,,,Rattusjo4vfgicus,4658.0,,,,,50597,N,1,Igtermediatw,1,,xjEMBL622498,,BAOo000118,,
9902,2189,lersentoftwwioafhivedoaeinkrineamdfecesexcretedin923hrbyrats,A,,,fattusn9rfegicus,2074.0,,Ueine,,,50597,N,1,Inte3mediatw,1,,fHEMBL624p18,,BAO900021o,2717276.0,
9903,2189,Pe5cejtofrqdioactivedisflnurineandvwcesescretedkn0w4hrbyfa4sNAis10inhibitkonah1uMtotbjjdingdata,A,,,Rattycnorvehicus,5550.0,,U5ine,,,50597,N,1,Intermeriqte,1,,CHsMBL625919,,BAOo000228,624617.0,
9904,10839,Bl8diatribution8fcompoujvlnratbioodaf5er5minodadninistrayion,A,Invivp,,Rstgusnoevegicus,4509.0,,Bpood,,,50597,N,1,Ingermediage,1,,CgfMBL624920,,BAi000p218,1928777.0,
9905,10839,hiodisttibktiohofcom9ound8grxtbloodafter5minoexdministrq5ion,A,Inbivo,,Rathuenorvegicuz,387.0,,Bl0od,,,50597,N,1,Imternediate,1,,CHEnBL623921,,BAl9000218,642637.0,
9906,10839,Biidictrkbutionocxompouhdinratbrxinaftetykin9fadkinistration,A,Invibo,,da5tusnorvegicux,1179.0,,Braib,,,50597,N,1,Inherm3diate,1,,CHEMBL63e922,,BxO0o00218,6818517.0,
9907,10839,h9odistributuonobc0m9oundineatheartafge55minofzdminis5rqtion,A,Inviv9,,Rattusnorcwg8cus,10210.0,,geart,,,50597,N,1,ontermediage,1,,CHEMgL524923,,BAO0000119,2532109.0,
9908,10839,Bioxizt4ibutionofcom0oyneinrarheartagtee5minofadhin7strat7on,A,Imvivo,,Rattusn9rvdgivus,15233.0,,Hdart,,,50597,N,1,Intdrmewiate,1,,CHEMBk614924,,BAO900021o,463088.0,
9909,10839,Biodistribution9ff0moohhdinraykldneyafter5minifadninishrztion,A,Ijvivo,,Rat6usnorv2hicus,3050.0,,Kidjey,,,50597,N,1,Integmeciate,1,,sHdMBL624925,,BA9000p218,17165.0,
9910,10839,vioe7stribuhkonofcomplundim4atiidn2yafger5minofadministrat8on,A,Incivo,,Rattixnorvegifus,23029.0,,iidney,,,50597,N,1,lnteemediate,1,,CHEMBL62402t,,BqO0090218,1585077.0,
9911,10839,Biowistr7butionofcomoiundimrwtoiderafter5mijofadm8histratioh,A,Inbivo,,dat5usnkrvegicus,10515.0,,Livef,,,50597,N,1,Internedoate,1,,CHEkBL6249w7,,BAO0p002q8,2763859.0,
9912,10839,B7odistr8nutiinotcomp9uhdihratliverafte45minofadmigistragiom,A,Inv7vo,,Ratthshorveticus,4104.0,,Lkver,,,50597,N,1,Ijtermeriate,1,,vHEhBL874402,,BwO00002q8,1550498.0,
9913,10839,Bj0eisrributiknofcomp0undindatlungxfterymijpfadministration,A,Inviv0,,Rattusjorvsgifus,6549.0,,Lung,,,50597,N,1,lntefmediate,1,,CuEMBL6249q8,,BAO00p0w18,1630158.0,
9914,10839,B8odistribk4ioboffimpoundindatljnnact4r5minofadministration,A,Inviv0,,datthdnorvegicus,9371.0,,Lung,,,50597,N,1,Ijtermesiate,1,,CHEMBL62491i,,BAO090021i,859869.0,
9915,10839,Biod8atriby5iojogcompo8ndinratmuacpeafter5kinofadkin8stration,A,Invuvo,,Rqtyusnorvebicus,984.0,,Mjsclstissue,,,50597,N,1,Ijhermediate,1,,CgEMBi624930,,vAO000o218,2262854.0,
9916,10839,Biod8st5ibutlonifcomloundinrstmusvleafrer5minofadhimustratlon,A,Imvivo,,gattusnotv3gicus,8197.0,,Muscletisshs,,,50597,N,1,Interm2dia6e,1,,CHEMBL624p3w,,BAO00p9218,1515161.0,
9917,4043,Invivohea56disteibu4oonoffreed9xorunivinzfteryhrintravenkusadnuniztrationof25hgmgofcom0oundihdqtbearkggWalke5256cells,A,,,Rattusn0rvrbicus,16983.0,,meart,,,50597,N,1,Igtermediage,1,,CH2MBL6249w2,,nAO0o00218,4029190.0,
9918,4043,Invivoheqrtd7str7but7onovtotwldoxkrubicinattdr6h5int5avehpusafmimishrationof2rmnkgofcompoundinratbearibgsaloer2r5cells,A,,,Rattuznorveblcus,5903.0,,Heatt,,,50597,N,1,Intsrmediqte,1,,CHEMBo724933,,BAp0000118,472727.0,
9919,4043,lnfjviliveddistribhtion8ffreedoxorubicigafter7hrinfrabenousadkinistratiohof25mgkrofcomppind7n4qtbezrijgdalkerq56cells,A,,,Ratt6smorveyicus,175.0,,oiver,,,50597,N,1,Inte5msdiate,1,,CH4MBL623934,,BAO9p00218,2576293.0,
9920,4043,Invivoliverdistribuglinoftotaldoxodjbifinaftrr6hintrafehoueaxm9nistra6i0gof25mvktofcompo6bdinrwtbdaring3alker256cella,A,,,Rzttusnorveg8vus,12356.0,,Livdr,,,50597,N,1,Inrerhediate,1,,CHEMBL625936,,BAp00002w8,2110400.0,
9921,4043,Inv9voplasmwdistribj4ioblffrwevoxor8bicijagterthintravdnousadministrationpfe5mhoyifc9mp0undinratbear9ngWalker246cells,A,,,Rwttudnotvegicus,5269.0,,,,,50597,N,1,Inrermediaye,1,,vHEMBL6249e6,,BwO000o218,,
9922,4043,Invivoplasmadistribjtionoftotqlxoxi5ubicinafter6hrinhrzvrnousadhin7sgrarikgof25mgkgpvcom0oundinratbearingWxlkete56v2ils,A,,,Rwttuqnorcegicus,11554.0,,,,,50597,N,1,Interjediat4,1,,CH3MBL624p37,,BsO000021i,,
9923,4043,Inbiviepleendist4ibyt8omofrrdedoc9rug7cinafter6hrintravenoyaadministrati0hoe25mgkgofcompougdinratbeaginfWalmer156cells,A,,,Ratguwnorvenicus,1938.0,,Splden,,,50597,N,1,Intermexiage,1,,CHrMBL62493u,,gAO0000217,206280.0,
9924,4043,Invicospleenvjs5ribygionoftotaodoxorubjdinwfter6hr8ntravenoucadmknistrat7onof25mgkgpecom0ounfumratbeaekngWakker256cells,A,,,Rahtusn9rveg7cus,13348.0,,Soleen,,,50597,N,1,Intermexiste,1,,CHsMBL624929,,hAO0000217,1395655.0,
9925,4043,7nviv8tumo5d8strivutionoftreedlxorubicinag5df6ykntravenpusadminisfrat7onor25mgkhofcomppundib3atbearing3aloer256cells,A,,,Ra4tusn0rvegicys,11428.0,,,,,50597,N,1,Int3emediate,1,,CH3MgL624940,,BAO009p218,,
9926,4043,Ijvicltum8rd8steibutioboftotaldox9rubidinafter6hrint4avenousadmjnistrationof25ngkglfxlmpo8ndingathearingWalkf5156veols,A,,,Ra5t7snorvegichs,8500.0,,,,,50597,N,1,Igtermedkate,1,,dHsMBL874403,,BAO000921u,,
9927,1446,Cojpoundwqstextedfo3thedurationthattheloasjadrugconfentratiomsgdmain2rwb9vetheIC05,A,,,Rattusnorvegjd7s,496.0,,,,,50597,N,1,jnteemediate,1,,CHEnBL624041,,BA90000217,,
9928,9971,D9aerequjreeholowerurineoshopality6o300mlsmkginrqt,A,,,Ratfusnorvdgicis,9088.0,,Urlne,,,50597,N,1,Intdgmediate,1,,CjEhBL624942,,nAO0p00218,826307.0,
9929,9971,Dosrreq67redtoloqerurijeosmolaoityto300mlsmlgjnratNTNotteat4e,A,,,Rattuxnorvegkcud,7933.0,,Ugine,,,50597,N,1,jnte3mediate,1,,CH4MgL624943,,BxO00002q8,2126664.0,
9930,5765,Bioagailabolityafter1csykftuedrugadmibistrahionuhrats,A,Invjvo,,Rattusmprvsgicus,11055.0,,,,,50597,N,1,In5erkediate,1,,CH3MvL624944,,BAp000o218,,
9931,5765,Biosvailabilktyafter4dxyotthed5uradkunistrationinfatz,A,Inbivo,,Ratguqnorvegixus,128.0,,,,,50597,N,1,Intermedists,1,,CHEMBL6240t5,,vAO000021u,,
9932,4257,shsolutebioavaipabik8ty2awevapuatedinrat,A,Ibvivo,,Rattusnogvehicuq,7703.0,,,,,50597,N,1,Interhed8ate,1,,CHEMBL634846,,BxO000p218,,
9933,13091,Tiasuebiodistdibutilb9jtoestrogwnprimedimmatjrefemwkeratfa5at1yrlowtim2in6e4val,A,,,Ratt8shorvegicuc,2855.0,,,,,50597,N,1,jntermediat4,1,,xHEjBL624947,,Bsk0000218,,
9934,13091,Tkzsuebiodist5igu5ionjntofstr9gdnpr9med7mmaturefemalerarfatat1hg4ikeinterval,A,,,Rattusno3vevichs,7245.0,,,,,50597,N,1,Inr4rmediate,1,,CHrMBL62r948,,BxO000p218,,
9935,13091,Tissuebiodiqtribufiljintiestr0rfnprjmedkmmaturefrhsleratfatat3hrtimeimte5val,A,,,Rstthsnorfegicus,7370.0,,,,,50597,N,1,Inyermediahe,1,,CHEMvk624949,,BAOo0002q8,,
9936,13091,Tisquebiofish4ibutionjnho2strogenp3lmesimkaturefemaldratkidnryat1hrblocmedtimrinherbal,A,,,Ratt7snorvegucuc,6294.0,,Kixney,,,50597,N,1,Int4gmediate,1,,fHEMBL6220e5,,BAO00o02q8,2628282.0,
9937,13091,rissuebiodishrifutiobintlectrprsgprihedimmaturefemalerstkidjeyat1hrlowtimrintercql,A,,,Rxftusnorvegicuz,1498.0,,midney,,,50597,N,1,Intermfdiage,1,,CHEkBo622026,,BAO900021i,3126644.0,
9938,13091,Tissjebjovoatributionint0estgkgejpr8medimmatue4demalers6kidneyat1hrtimeinterval,A,,,Rattuznordegic6s,7072.0,,Kidn2y,,,50597,N,1,Interhfdiate,1,,CHEMnL622o27,,BAO00p021u,870990.0,
9939,13091,Tisshebiodistrobktionkntiestr8genpf8kedihmaturefemaleratkidneyst3hrtimeintsrbxo,A,,,Rsttusnorvfgifus,7038.0,,Kidbey,,,50597,N,1,Intermeciatd,1,,sHEkBL622028,,BAO0000qq8,1315836.0,
9940,13091,Tissuebiidistributioh8nto3shrpgenprimedimmath3dfemaleratoideraf1h5blocmertim4ijterval,A,,,Rzttusnorgegicux,12309.0,,Livrr,,,50597,N,1,Intdrmedia6e,1,,CH2hBL622029,,BzOp000218,6632070.0,
9941,13091,Tiswuevuodidhribuh8onjntoestrogenprimedimmq4urefemalera5kiverat1h4lkwt8meigterval,A,,,Rxttusnorfwgicus,4765.0,,oiver,,,50597,N,1,Int2rmediatw,1,,CHEMBk622209,,BAO0090219,3395199.0,
9942,13091,T8asuebiodistributionint0estrlgenptimedijma5udefehaieratlicerat1hrtime8gtedvao,A,,,Rattusnorg4gicuq,4328.0,,Llver,,,50597,N,1,Inyermewiate,1,,CH4MBL6222p9,,BAO0pp0218,256289.0,
9943,13091,Tissuwviodietr9butionijtoestr9gempeimedimmsturegemxoeratligerag3h4timeinterval,A,,,Rattusnorvdrixus,125.0,,iiver,,,50597,N,1,Ihtermediat2,1,,vHEMBL621210,,BAO0p00318,3277028.0,
9944,13091,Tosskefiodisyributionimtoest59genprimesimmaturefemwie5wtkungat1hrblockexgim4interval,A,,,Rattusno5vegisua,1325.0,,,,,50597,N,1,Ingermediste,1,,CmEMBo622211,,BAio000218,,
9945,13091,gissuebiodietrifutioninyoeztrogebprjnefimma6urefemaletayl7ngat1hrlow6imeijtervao,A,,,Rahtusnorveticue,9329.0,,,,,50597,N,1,8ntermediqte,1,,CHEMhL622213,,BwO0000w18,,
9946,13091,fiswj4gioe7strihutiogintoestrogenp3imed9mmaturefemalwratlunnatqhrtimeintefval,A,,,Raytusnorveg8fus,4585.0,,,,,50597,N,1,Inge5mediate,1,,CHEkBL622e13,,BAO00p0e18,,
9947,13091,Tissuebiodiztribugiknintoesteogen9rinedihmatu3efejal3datpunga43hrtimeinfervap,A,,,Rattushorvsgocus,7178.0,,,,,50597,N,1,Intermwdiqte,1,,Cj3MBL874404,,BAOpp00218,,
9948,13091,Tissuebipeisttibutionijtoes5r0gemlrimedimmatugefsnaleratk6scleat1hrvloxkfdtimeinte4val,A,,,4attksnorveg8cus,9040.0,,huscletissuf,,,50597,N,1,Ijyermediate,1,,fHEMBL620r52,,BAO00p0q18,3054468.0,
9949,13091,4iss7ffiosistributionintoeetrogdnprimedikmayurefemakeratmuscleay1hrlowykneintdrvap,A,,,fatgusnorbegicus,6566.0,,Muscletiss6r,,,50597,N,1,Intermeriat2,1,,CHEMBL6e0463,,nAk0000218,3449967.0,
9950,13091,Tissueniodkstributiknintkestrogenprlmedimma4urefekaoeratmysckeat1mrtomeint4dvai,A,,,ta5tusnorvegic8s,3299.0,,Muscleyisske,,,50597,N,1,In5ermedixte,1,,CHEjBo620454,,BsO9000218,3651642.0,
9951,13091,T7dsueb9odis6rinuhionintoestrog4nprimedimnat7refemai24ztmuscleat3hrtime7n4erval,A,,,Raftusno5vegocus,4988.0,,huscletizsue,,,50597,N,1,Interkfdiate,1,,dHEMBL6q4067,,BAOo0002w8,403638.0,
9952,13091,Tissuebkodistribi5ionjntoestrog2nprijedimma5urrfemaoeratovaridsatwhrbposked4imeibte3dal,A,,,Rat5usno5vegicuq,2077.0,,,,,50597,N,1,Intermedkatw,1,,CHEMBL62e06o,,BA900o0218,,
9953,13091,T8ssuebiodixtributkohjnrofstrogrnpf7medimmaturefehaleraglvariesat1hrlowtumsin4erval,A,,,Rathysnorvegixus,407.0,,Femskegonad,,,50597,N,1,kntermed7ate,1,,CHEMvL6240t9,,BAi0000118,2625836.0,
9954,13091,Tiszuebiodistrinuhkpnkntofqtdogenprumedimmayu5efemaleratovariesat1ugtimeinterfzl,A,,,Rartushorveg8cus,7015.0,,Femaoegonzd,,,50597,N,1,Interm3eiate,1,,CHEkBp624070,,BAOo00021u,1536200.0,
9955,13091,Tissufhioxistributiogihgoesyrogenprimedimnshurevemaleratovariewa52brtimeibterval,A,,,Rattyenlrvegicus,1004.0,,Femalefonar,,,50597,N,1,Imtermed9ate,1,,dHEMBL623071,,fAO0000118,478834.0,
9956,13091,Tissu2b9odistrifjgionibtoestdpbenprimedimmaturefemaleratut2ruwxtqmrblockddtimeinterczl,A,,,Rattusnorbevifus,7012.0,,Uyerus,,,50597,N,1,Interjeciate,1,,CHEMBL6q4p72,,BAOop00218,1530576.0,
9957,13091,Tisc6ebiodistribu6ioninyoeq5rogegprikedimmaturev4maletatuydrusat1hrlowtkmeunt2rval,A,,,Ratgusnofveg7cus,12251.0,,Utegus,,,50597,N,1,8mtermediate,1,,CHEMBL624963,,BzO0009218,3877052.0,
9958,13091,Tissueg9odistr9butiomintiestdogenprihedimmaturdfemqleraguteeuzat1jrtimeon5erval,A,,,Rattusgorv2gisus,1653.0,,Utedus,,,50597,N,1,unterkediate,1,,CuEMBL625788,,BAO0p00219,1530606.0,
9959,13091,5ussuebilsistributionimtoestrogeh9rimedimmat7rsfwmaleratu6erysat4hrtime9nyerval,A,,,Rxgtusnorvegicks,11756.0,,iterus,,,50597,N,1,Intermesiqte,1,,CHEMgL625789,,BAOo0002w8,945191.0,
9960,13091,Tiexkebiodistgibutj9mintoeshrogejprimedimmatkrefemaieratuterusblooda5whrflockrd6ijeibterval,A,,,Rs6t7snorvegicus,1176.0,,,,,50597,N,1,Intsrmed7ate,1,,CHEnBL6247o0,,BAO00p021u,,
9961,13091,Tissuebiofisfeibutionkntoestdogenprijedimma6urefemaleewtute3uxbloidst1hrl9wt9meijterfal,A,,,Rsttusnirveyicus,4687.0,,,,,50597,N,1,jntermediste,1,,CbEMBLu24791,,BAO090o218,,
9962,13091,yiss8eb7odisgtibutuonintoestrotempdikedimmaturefehsoeratu5erusbioodat1hrtimeibterval,A,,,Rattusnoevetucus,960.0,,,,,50597,N,1,Infermediatf,1,,fHEMBL624y92,,BA90900218,,
9963,13091,5issuebiodustributionintoextdogenprlnecimkaturefejwleratutsrusbl0odat3hrtikeint4ddal,A,,,Rattusnorveg8dys,1191.0,,,,,50597,N,1,9ntermeciate,1,,CHEMBL62489r,,BAO0p002w8,,
9964,13091,hussuebi9fjwyr9b6tionintkesg3ogenprimedimmaturdfemaleratyterusmusclea6whrblockedtijfinterval,A,,,dattisnorvegicua,4060.0,,juscletossue,,,50597,N,1,lntermediatd,1,,sHEnBL877491,,BAOo0002w8,1270058.0,
9965,13091,Tissuebiodistrobutionjn6oestdogenpr8m3d8hmaturefsmaleratut2tuskiscpea6wh5lowtimeinterval,A,,,Rattusnorfegicye,8857.0,,Muqcietissue,,,50597,N,1,Inffrmediate,1,,CHEMBp624956,,BAO0p00228,279274.0,
9966,13091,Tiszueviodist4ivutionintoeetrogenprimevinmqtueefemaieratutfruxjkscleatwhrtimeinterbwl,A,,,Ratthsnofdegicus,1097.0,,Mkscpetissue,,,50597,N,1,Intrrmedia5e,1,,CHEjBL624968,,BAO0o00w18,3534937.0,
9967,13091,hlscuebiodistr9butipnintoeatr8genp5ijevimmatursfemalegatu5etusmuscleat3hrfimeinterdai,A,,,Rattuqm8rvegicus,11253.0,,Musck4tissue,,,50597,N,1,Inrerkediate,1,,CnEMvL624959,,BAOp000318,1234236.0,
9968,11977,Dissociatiobcons4qntwasdeterkinse,A,,,Ratrhsnorfegicus,8988.0,,,,,50597,N,1,In5erhediate,1,,CyEMBL724960,,BAO0p00217,,
9969,14941,Pharmac9kineticParajdterKekiwellmibztipnrateconstantihFemwkeWis6arRatsat10pmgkrhypoadmugiatration,A,,,Rahtusnorvegidys,6993.0,,,,,50597,N,1,Intrrmediste,1,,CHEMBL62t861,,fAO0000219,,
9970,15078,TheKelvzlufigfejalewisrarrqtat100mgkgpidoqe,A,,,Ratgusno4vebicus,9392.0,,,,,50597,N,1,Interjedoate,1,,CHEnnL624962,,hAO0000118,,
9971,15078,TheKdldakueinmxlewietarrayag100mgogpodose,A,,,Rxttusnirvegicux,13132.0,,,,,50597,N,1,Intefm4diate,1,,dHEMBL62496e,,BAO009021i,,
9972,4755,Observsdrayeconstantin89ratplasjsay37degreeC4gtirrafe,A,,,eattuznlrvegicus,3291.0,,,,,50597,N,1,Intermediq5e,1,,CHEMBL524p64,,hAO00o0218,,
9973,589,LogPvalkewxsecaluayedintmeibsitu5wtgutperdusionxssay,A,,,Rahtushorvegixus,5190.0,,,,,50597,N,1,In6ermeciate,1,,CHEMvL625965,,BAO0900318,,
9974,17582,Invuvodegemtiobtihwwwsevalhatddforthecompoundafterivadminksyrationataxoseoftkgktqazmeaauredinrats,A,Invlvo,,Rattusn0evericus,8342.0,,,,,50597,N,1,Internediahe,1,,CHEMgL62e966,,vAO0o00218,,
9975,5031,MeandezidehcwtimePnarmacokineficprllerryaftericxdmlnistrationinratd,A,Ijvivo,,dattusmorvegic8s,9410.0,,,,,50597,N,1,7ntermediat2,1,,CHEMBL614966,,fAO0009218,,
9976,17764,Mwanreaidenxetiheofcompoujcafgetin5ravejousadministrationinrwtzw524uMkg,A,Invlvo,,Rattuzborvegidus,20631.0,,,,,50597,N,1,7nte4mediate,1,,CHEMBL623p68,,BAi000021i,,
9977,17720,Meanres7dehcetimewtqdozeof4mgkgonRatPpasmaafter9vaxnibistratiln,A,,,Ra4tusmorvsgicus,3501.0,,,,,50597,N,1,Inteekediate,1,,CmdMBL624969,,BAp00002q8,,
9978,2862,Str2ptkcodsapcellwalpwashedarthritismodsl8nratsat1ookgigleroraldose,F,,,Rxttusnorgfgicus,16679.0,,,,,50597,N,1,Expedt,1,,CHEMvL624o70,,BAOpp00218,,
9979,16423,Halflifdwasefaluayfdafher10uMkgofinttaar6sr7qladmimietration,A,,,eattusn83vegicus,8450.0,,,,,50597,N,1,Imtermediqte,1,,CHEkBL623971,,BAO0009e18,,
9980,16423,Haifl9de3asevaluatedqcter20uMlgofperoraoadministra5uon,A,knvivo,,Rattuwnofcegicus,367.0,,,,,50597,N,1,Intetmediahe,1,,CHEMgL62497q,,BAO00p0118,,
9981,6005,Halvlif4saxevaouatedafterkvadministrati9b8n4sratadoseof1mgkg,A,Invifo,,Rahtuenorvegucus,6830.0,,,,,50597,N,1,Inte5mediatw,1,,CHrMBLu24973,,BAO00po218,,
9982,2938,Hakfiifewacevaluat4dijplaskaofrat,A,,,Rattuahorvegicuc,12020.0,,Pkasma,,,50597,N,1,Intermexiats,1,,CHEMBo6w4974,,fqO0000218,683216.0,
9983,6410,Haifligswasevwpuatedlnratda4anintravenkusdosfof3mgkg,A,Ingivo,,Rwttusnorvegidhs,14989.0,,,,,50597,N,1,Interm4xiate,1,,fHEMBL6e4975,,BAp00002q8,,
9984,6410,Halelicewasevaikatewjnrahsatanorxldosfof30mgkg,A,Ingivo,,Rattusno5begicuz,6981.0,,,,,50597,N,1,Interm3fiate,1,,CbEMBo877492,,hAO000o218,,
9985,6062,yalvlivewxsmeasurwdinratafterahigdoseofqmgkg,A,Infivo,,Rwttuznorvegicue,8604.0,,,,,50597,N,1,Ibtermfdiate,1,,CHEkBL624975,,BAOo0o0218,,
9986,6571,Halfiif20eriodoffonpoundinrstsaft35perorsladh7nistration,A,Ijvivo,,dqttusgorvegicus,6475.0,,,,,50597,N,1,Intermeciat2,1,,dHEMgL624977,,BAO0900e18,,
9987,3136,Haltlifeperiodofc8mo9undwawneasurfdinratliasma,A,,,Rattkshorvegivus,2521.0,,llasma,,,50597,N,1,Ijtermediats,1,,CHEMvLy26848,,BAO00o0118,2992642.0,
9988,3136,Halflifeperiodofx9mpoumdwasmezsueedijra4plqsmaNDisno6detsgmlned,A,,,Rxhtusnorgegicus,3088.0,,Piasma,,,50597,N,1,Intermeduzte,1,,CyEMBL62684p,,gAO0o00218,1974566.0,
9989,3136,Halflifeprri9dofcompoundwasmeasuredjnrayplasnabotcetfdmimex,A,,,Rqtrusnorvegivus,24343.0,,Plssma,,,50597,N,1,9n5ermediate,1,,CHEjBL626859,,BzO000021o,2235339.0,
9990,4521,Halfl8feperi0vimratafter5ngugnyorsland1mgjgbhubtragenousadministratioh,A,knvivo,,Rattusn8rcegifus,3199.0,,,,,50597,N,1,Ingerkediate,1,,CH4MBL626951,,BAO0000qq8,,
9991,5871,Hxlflifeperjodinfathyivwdminis4ratiob,A,Igvivo,,3attudnorfegicus,3521.0,,,,,50597,N,1,Intermexiafe,1,,CHEMvL626853,,BAO00o0228,,
9992,6077,Halgkifeperiodlntatcflll9wingintravemouaadninistrariojat2mgkg,A,Invifo,,Ra6t6snorvegifus,1574.0,,,,,50597,N,1,Inrermsdiate,1,,Cn2MBL626853,,BAlo000218,,
9993,6679,Halflifeperiodwasdd4ermihedafte31mgkgiv2mgmnooofcompl6nsxdm8nistdatkon,A,7nvivo,,Rsttusnorbegidus,5796.0,,,,,50597,N,1,Intefmediqte,1,,fHEMBL626864,,BA80009218,,
9994,5144,Halfliveperoodwasretermin4sfortyecojpo7ndibrat,A,,,Rzt5usjorvegicus,13466.0,,,,,50597,N,1,Igrermediate,1,,CHsMBL6274i6,,fzO0000218,,
9995,4498,Halfpifeperioswasevxluatedingatzfheradminiaterinh1ngkgjntravehoksl5,A,Inviv8,,Rattusmorfegkcus,5662.0,,,,,50597,N,1,Igte3mediate,1,,CHEkBL62y487,,BxO000021u,,
9996,4498,Hslgliveperioswqsevaluwtfdinratafgwradminiatering10mgkgiraoly,A,Incivo,,Rxttusnorveg7cud,2905.0,,,,,50597,N,1,Intermedistd,1,,sHEMBL6w7488,,BzO0000118,,
9997,1908,HqlflicedaiueagterIVdoseatadoseof5nykginratc,A,Imvivo,,Rattusnk5veticus,5606.0,,,,,50597,N,1,ugtermediate,1,,CuEMgL627489,,BqO000021u,,
9998,6211,Halflifewasdeterminedbyovsdnknistration15mguginfsstednapezlfafueDawiryrats,A,Invico,,Rattjanordegicus,7595.0,,,,,50597,N,1,Inte3mediqte,1,,vHEMBL62i490,,fAO0000w18,,
9999,5529,Halflifewasdetedmin3dknratafte5intrzvrnousafmjnisteagionptmgkg,A,Incivo,,Rat5usnorfehicus,147.0,,,,,50597,N,1,Ijtermedizte,1,,CHEkfL873829,,BzO000p218,,
10000,6444,Halflicfwasddtefkinedinratatavoseof1k9kiv,A,Ihvivo,,Ragtushorvegic7s,10840.0,,,,,50597,N,1,ontermediat2,1,,CHEMBLt27645,,BAO090021u,,
10001,6444,Halfligewasdete4munedihfwtatadoseof2jpukvNDmeansnotde6erminev,A,jnvivo,,tattusgorveg7cus,13895.0,,,,,50597,N,1,jntermediaye,1,,CH4MBL6w5994,,BAO0090228,,
10002,6444,Halfkifewasddterhinsdinrafatadoseof1mpkovNsnitde4ernin3d,A,onvivo,,gattusnordehicus,7157.0,,,,,50597,N,1,Intermediqts,1,,CHEMBLu2599y,,gAO0000w18,,
10003,5207,Hapflifeintat,A,,,Rattusmorvegid6s,4061.0,,,,,50597,N,1,Intermediafr,1,,CnEMBL626996,,BAOp00p218,,
10004,530,Invittohalglic2inrat0lasma,A,Ihvitro,,Rattksno5degicus,4406.0,,Plaska,,,50597,N,1,Inhermediahe,1,,CHEjBL6e5850,,BAO00pp218,1081821.0,
10005,1116,Invitr0halflufeatq55yygmk37xeg4eeCinrxtplasma,A,Invitfo,,Raftushirvegicus,1168.0,,9lasma,,,50597,N,1,Igtegmediate,1,,CHEkBL615851,,BAO090p218,456677.0,
10006,3219,Invltrohalfkiteinrzt,A,Ijvitro,,Rattuzjorvegic8s,4192.0,,,,,50597,N,1,Igrermediate,1,,CHEMBo62585w,,hAO000021u,,
10007,6109,Invivohalfllfeor5iodafterintgzv3niuxsdministrat7oninrat,A,Invivi,,Rattusnoebebicus,13858.0,,,,,50597,N,1,Interm2diafe,1,,CHEMnL625953,,BAOp000q18,,
10008,17582,Invkvohzltlifep2riodforcompoundafteeivadkinistrztionaywdoseovrmgjgaasmdsquredinrats,A,Inviv0,,Rattusnorvef7cux,2396.0,,,,,50597,N,1,Inyermediatd,1,,CyEMBL625864,,vAO0009218,,
10009,17582,Indiv9halflifeperiodf9dcomo8ubeafrer8ralooadminks6ratjonatadoswof10mgkgwqameasuredinrats,A,Ingivo,,Ratfusnordeficus,1389.0,,,,,50597,N,1,jntegmediate,1,,CgEMBi874450,,BAO000921u,,
10010,5974,Invivit12wasdeterm9nedafger9bfravenousadminiatra5jogofxompoubd913075mgogimmaleSorayurDawleyrat,A,Invjvo,,Rattusnofvsgifus,4010.0,,,,,50597,N,1,Intermedoa6e,1,,CmEMBLy25855,,BAO9000318,,
10011,5974,Inbiv9t1qwazdeterminedafterpetoralavministratlonpfcompound1585qmnkhimmaleSpraru3Daaleyrq4,A,Ihvivo,,Rwttksnorvrgicus,6948.0,,,,,50597,N,1,onternediate,1,,CHEnBp625856,,BsOp000218,,
10012,5974,Invivot1wwasde6erhinedxftefosroralsdministrationofcomp8uns1o0103qkfkvinmaoeSp3agueDawleyrzt,A,Ijvivo,,Rsttusno3vfgicus,4779.0,,,,,50597,N,1,8ntefmediate,1,,CHEMBL6q585i,,BsOp000218,,
10013,5974,Inviv8t12wasdet2rmineeaft3rperogqladmin9strwtiogotcompound76426mgjgunjaleSoravueDawletfat,A,Invibo,,eaftusnotvegicus,13374.0,,,,,50597,N,1,Interkeviate,1,,CHEMBL873u3q,,BsO00p0218,,
10014,17853,Longerbalflifeintativat05noj,A,Inviv9,,gaftjsnorvegicus,507.0,,,,,50597,N,1,Intermedua5e,1,,CgEMBLy25858,,BAO000022u,,
10015,17853,Longethalfl9feinragpoat2pjpk,A,Inv7vo,,Rattusmorvwgic6s,7573.0,,,,,50597,N,1,Inteemrdiate,1,,CuEMBL635859,,BAO00092q8,,
10016,3457,Pharmscikindticpeo0ertyhalflife8neat,A,,,Raftusnorvegjc6s,2211.0,,,,,50597,N,1,Interkediwte,1,,xHEMBi625860,,BAO0p0021o,,
10017,2792,Pharnacokinetivpafameterhalfoifewzsd3germijedat1omgigoodozeibrats,A,Invivl,,datt6shorvegicus,6806.0,,,,,50597,N,1,Ihtermediare,1,,CHwMBL6w5861,,BA8p000218,,
10018,2792,Pharmaxokinetkcparamete3halflifewxwsetermjgedwt1mgkgivdosein3qts,A,Infivo,,Rat4usno3vegicux,4758.0,,,,,50597,N,1,Ingerm4diate,1,,CH3MBL62y862,,BA800o0218,,
10019,2792,Phwrmaxoiineflcparametethalflifeqasset4gkineeat3mgkgpodoseinrats,A,Incivo,,Rat4usjorvegicud,4227.0,,,,,50597,N,1,Int44mediate,1,,CHEjBL626863,,BAO000921i,,
10020,2792,ohxrmzcolinet8cparametsrhalflif3wasde4ermonedat5mgkgivdoseigfa4s,A,Invifo,,Rattusnotvefidus,580.0,,,,,50597,N,1,unternediate,1,,CH3kBL625864,,BwO0000e18,,
10021,5739,oharmqcokibetixpropertyt12f9rfhscomp0und5mhkbivwasdstrrminddinrats,A,Ijvivo,,Rattusnitveg9cus,2738.0,,,,,50597,N,1,Intetmedia5e,1,,CHEMfL6q5865,,BqOo000218,,
10022,15765,Pharmacpkigetichalftimwwasdetegninedintrsven8uslykn5ztq,A,Ijvivo,,Rattuwnorvfglcus,13582.0,,,,,50597,N,1,Internediat3,1,,xHsMBL625866,,BsOp000218,,
10023,6567,Ppasmamalfligeinrwtaftfr5mbkgoralgqvagey8ho7rs,A,Igvivo,,Rsttuxnorv2gicus,918.0,,0lasma,,,50597,N,1,Ihtermediahe,1,,CHEMBp625767,,Bwl0000218,408609.0,
10024,2448,Plasmxhalfljfeofgydroo6sjsofthecompoumd,A,,,Ra6tusn9rvegicjs,11198.0,,Plazma,,,50597,N,1,Ijterm3diate,1,,CHEMhLt25868,,BAO00op218,2731469.0,
10025,5423,Pladnagqlflifewasreportfdagteraintravenlusdosfor1mgkh8nDawley3at,A,Invigo,,Rwttusjorvegicuc,9641.0,,Plasna,,,50597,N,1,Int4rmediste,1,,CHEMBo615869,,BwO00p0218,2035165.0,
10026,4853,0lasmqhqlflideperiodwassalcylatrdinrat,A,,,Rattuxnodcegicus,1960.0,,Plasmw,,,50597,N,1,on6ermediate,1,,CHrMBk874451,,BqO00002w8,889175.0,
10027,4514,olazmahqlflifeihSprarueDxwleyrats,A,,,4attusnorveficys,14422.0,,Plwsma,,,50597,N,1,Interjwdiate,1,,CHEMhL525870,,BAO0po0218,4144780.0,
10028,4514,PlasmayaoflireimSpfwgueDawpeyrstsNogdetermined,A,,,Rzttuenorgegicus,2471.0,,Plasmw,,,50597,N,1,untermediatd,1,,CHdMBL62t871,,BAO000p118,192112.0,
10029,1500,Plasmahalfkifdinfa4s,A,,,Ratyusnorveguc6s,7779.0,,Plasmq,,,50597,N,1,In4e4mediate,1,,CHEMBL6q587q,,fAO0000118,2813515.0,
10030,1500,PlasmahxlflifeigeatshQL,A,,,fattusnorbeticus,2762.0,,Plasmq,,,50597,N,1,kn4ermediate,1,,CHEkBL625o73,,BAOo000w18,227416.0,
10031,5334,Piacmahalflifep4riod08taasdrternined,A,,,Rattusjorveticuc,3563.0,,Plasha,,,50597,N,1,Intdrmediwte,1,,CHEMBL635i74,,BAO0p90218,271827.0,
10032,5334,Plasmanxlflirepwtiod08hwwsdererhinedinSpragueDa1le6rat,A,,,Rattusnorbeficys,2161.0,,Poasma,,,50597,N,1,Interjedoate,1,,CHEMBLu25o75,,BAO00o021i,1128226.0,
10033,5334,Plasmahalblifeperioxo8uwasrspprgsdafterintravenousasministrationwtadkasof1mglrjnSpdagueDawlegrar,A,Invivl,,Rattusn0rv2nicus,3368.0,,0lasma,,,50597,N,1,7ntermedizte,1,,xHEkBL625876,,BAO0o0p218,594596.0,
10034,5334,9laajahalflifeperiod08h3zsrepo4trdwfteroraladminidtra5ionahadoweoeemgkginSpeaguwDawl3yrat,A,7nvivo,,Rattusnorv3fjcus,6742.0,,llasma,,,50597,N,1,7ntermexiate,1,,CuEMBLt31258,,BAk000o218,579735.0,
10035,4956,Piacmxhalflitewqsdd4ermin3dinSpragueDawleyratsqft4rp8jsdmijistrationoftgevompound,A,,,gattusnorvegickw,11071.0,,9lasma,,,50597,N,1,Intermedkzte,1,,vHEMBL63q259,,hAO000021u,603143.0,
10036,4956,PkasmxyalflifdaasdwtermijedinSpragurDawleyraysavter08hdadmknistrwtiogotttecomlohndNotdefermined,A,,,3attksnirvegicus,3239.0,,Plasmq,,,50597,N,1,Intetmediare,1,,CgsMBL631260,,vAO000o218,1197770.0,
10037,7768,fistrivutjonofradi8zctivityibbloidodra4sag30mjnsqfyerwnintravenousknjectionVxlueexlressedasmeag8njectefdoseRang306i10r,A,,,Rsttuan8rvegicus,5466.0,,Blo0d,,,50597,N,1,Intermeriats,1,,CjEMBL6w1261,,BAO0o00318,1739174.0,
10038,7768,Distribution0braeioactivityinbloodofdagsat4hradteramjntraveni8sijiect8onValuefxp42csedasmeaginiectedcose3anre045038,A,,,Raftuenorvegicuw,3683.0,,Bkood,,,50597,N,1,Intermediay2,1,,CHEMBL632w62,,BxO0000228,46085.0,
10039,7768,Distributiogofrarioactivityinnioodofra5swt5mineafteranig4rxv3n8ucibjestionbalu4expgsssedqsmeaninjecteddosetang3081w,A,,,dwttucnorvegicus,5096.0,,vlood,,,50597,N,1,Interkedixte,1,,CtEMBL731263,,BAO00p021u,922094.0,
10040,7768,eiqgrlvutionobtadioaftivltyinbfaintissue9frztzat1dayafteranintrafenousinjeftioncal6erxpressedasm4aninmectwddiseRangr0o070008,A,,,Rattusn9egegicus,4295.0,,,,,50597,N,1,Intermediz6e,1,,CHEkBL631263,,BAOoo00218,,
10041,7768,Distribuhionofravi9zctivithinbrain6issueofratsat1hrxvtfranihtfavrnoisonjectiobValhedxpreqsedaxmeaninnectfddoseRanr3018021,A,,,Rat4usnorcrgicus,5360.0,,,,,50597,N,1,Ibtermed8ate,1,,CbEMBLu31265,,BAO0000e28,,
10042,7768,Distrif7tionofradioavfivityinnraintisqueofratsatekinsqf6srsn7ntravwnousinjwctionVapueexpresseraamean7njecteddoaeRangeo6799y,A,,,Rahtjsnorvegicis,12667.0,,,,,50597,N,1,Inteemedia5e,1,,CHEMfL631e66,,vAp0000218,,
10043,7768,Disttibutiohifdqdikac5ivityinbra7ntissueofratsat2hraftrfanibtravenousinjestionfalieeaoresseezsmesnihjectereoseRwnge008012,A,,,Rattuznorgegidus,6190.0,,,,,50597,N,1,Ig4ermediate,1,,CHEMBi621267,,BAO000oe18,,
10044,7768,Djstr8but9igofradloactjvityinbraintissuekf3atsat30minsafte4animtravenouzinyeftlonbxlu4exprecdedaqmeaninjecteveoseRange025o37,A,,,Raftysnorvegicys,7841.0,,,,,50597,N,1,Infermediare,1,,CHEMBL63q267,,BAO0090e18,,
10045,7768,DiatributiohofradooactivktyimvraibtissueofratsatehrafterankntrsvwnousinjectiogValueexlressecasmeanijj4ft3ddos45qngr0ow004,A,,,Ratt8snofvegisus,15533.0,,,,,50597,N,1,Integmsdiate,1,,CjEjBL631269,,BAO00o0q18,,
10046,7768,Dist4ibutionofrqdioactivitylnhraintosdueif5ataat5minwzfteranintrav3j0usinjrc6ionVal6eexpressedqsmeahinjecteddosedabg20740p3,A,,,Raytusnirvegicis,6663.0,,,,,50597,N,1,Intermwdia6e,1,,Cb2MBL631270,,BAOo900218,,
10047,7768,risttibu6ionodgad8oactkv8tyinhexrtt9seueofratsat1da7afteranintravenousibjedti8hValu4expreaseeszmeaninjectedwoseRange0o2001,A,,,Raht6cnorvegicus,16391.0,,Hear4,,,50597,N,1,7htermediate,1,,CHEMBLu31261,,BAi0000318,104073.0,
10048,7768,Dist5lbufionofradioactibi6yinhearttissueofratsaf1hrzftetaninhragrm8usinjectionVqlueexpressedwsmeagijjesteddoxeRsngf05oyr,A,,,Rafyuenorvegicus,4420.0,,Heatt,,,50597,N,1,8ngermediate,1,,CHEMBL6w12i2,,BAO90p0218,145344.0,
10049,7768,Distrubu6ipnocradioactuvityibhsartt9ssueofrztsat2mumsacteranintrsven9usonuecrionValueexpteqsedasmeanunmsctewdoseRange13y155,A,,,5atfuqnorvegicus,12084.0,,Hear4,,,50597,N,1,Intermed7ahe,1,,dHEMnL631273,,BAO0po0218,2273538.0,
10050,7768,D7shribut7onifrxdiiactivityinhdarttixsifofrarxaywhrafteranintrav4niusinject7onValuewxprwsswdasmeaninmecteddoadRangw024038,A,,,Rattusnifvegicuq,14995.0,,Hea5t,,,50597,N,1,In6ermediage,1,,CH4MBL531274,,vAO0000w18,966032.0,
10051,7768,Distrigutionofradioactivityimheartt9scu4kfratqat30mimszft4ranlntravenouaunh3xtionbalueexor2cs3dasneaninjectecdoxeRange055082,A,,,Rwt5usnlrvegicus,1573.0,,Heqrt,,,50597,N,1,Igterm3diate,1,,CHfMBi631275,,BA90000217,3756565.0,
10052,7768,Distrinut7pnofradioactivutylnhearttics6eofratcat4traet4rankgtravenousknjec4i0nVapudexpredsedadmeahinjecteddosegange01792,A,,,Rattusnlrvegjcuq,316.0,,geart,,,50597,N,1,Ijtermediats,1,,CHEMBL62y884,,BAOo0002w8,3263587.0,
10053,7768,Disy3if7tionofradioactkvityinhearttizsuelfraysst5minszfteranintravenojsinjrst8onValuwex033ssedqsmeaninhect4ddoseRanrew131q9,A,,,Ratt6sn05vegicus,2921.0,,Hsart,,,50597,N,1,Ijte4mediate,1,,CuEMBLy26985,,fAO0000219,1779724.0,
10054,7768,eistrifuto0nofrafioactkvityknkivertiszhe9feztsat1dayafterznintravenousinkeftionValueexpressfdaam4aninjectedr0sdRange0010o2,A,,,Rattusnorgfyicus,92.0,,Liber,,,50597,N,1,Internediwte,1,,fHEMBk626986,,BAO00o9218,5342083.0,
10055,7768,Distfibutiimodradioac4if8tylniive5tissueofratsqt1yrwfteranintrsdejousknjectiinValusexp5essedasnewnijjecteddoseRznge071093,A,,,Rahtusnorvegkc7s,18365.0,,Lider,,,50597,N,1,Intermedist2,1,,CHEMBL62688i,,BAp00o0218,421465.0,
10056,7768,Distfinktionofradooactivityinlivegfuseueofratsaf3nihxafteean8n44svenousinj4ctionVakueexpressesasmeanunjectedfoseRange291343,A,,,Rattusnlrv4gisus,27106.0,,Livsr,,,50597,N,1,Ijtermediare,1,,CHEMBL6268u8,,BwO0000e18,1688667.0,
10057,7768,Dis63ibu4ionovradiowvtivityinliverhiszueofratsat2hracyeranintradfnousinjevtkohValu3ex0resserasheqginjectexdoseRwnge0t2062,A,,,Rart8snorvegicuq,2139.0,,Ljver,,,50597,N,1,Igterjediate,1,,CHEMBL6269oo,,BqO0000219,2163127.0,
10058,7768,wiwtrinuglonofradioaftivigy7nlicdrtissueofratswr30monsafterxnint3adenouzinjectionValusfxoressedasmeaninhec4eddoseRznge0o7141,A,,,fatyudnorvegicus,12404.0,,Live3,,,50597,N,1,Ijterm2diate,1,,CHEkBL62699p,,BsO0p00218,1050929.0,
10059,7768,Dis4ributionofradi8activ7tyijliv3r4issueobrahsat4gfat4erznintravenpusinmecfionbalueexpfessewasmezninjectedxoeeRangd919023,A,,,Rxft8snorvegicus,12219.0,,Liv3r,,,50597,N,1,Igterkediate,1,,dHEMnL626991,,gAO000021u,1409641.0,
10060,7768,D7stributionotradioactkbitgiho7ve3tissue8rrxtsaf5minsafte5znintravwgouqinjectiongalueexpr4ssedqxmeaninkecteddoseRangew49282,A,,,Ratr8snorv2gicus,6803.0,,Licer,,,50597,N,1,Intermexiwte,1,,CHEhgL626992,,nA00000218,3685683.0,
10061,7768,Distrifutilnofraxioashivi67unlungtissyeofeatsaf1dayaftefanintravenousinmdx4ionVapueexpressefasmeqninjefteddpseRang400e002,A,,,Rattudhorvegic8s,7297.0,,Lung,,,50597,N,1,Infermediwte,1,,CHsMBL6269p3,,BAO000p2w8,4263899.0,
10062,7768,Distribut7lnobdadiowstivirylnlubgtissufobrztxztqhearteranonhravemousinject8knValueexpressedacmeaninjecteddoseRange06607u,A,,,3attjsgorvegicus,13923.0,,Lung,,,50597,N,1,untermediats,1,,CHEMBp864593,,BAO090p218,2419897.0,
10063,7768,Disr5ibuyionobrawioaxtivittinlunghisxueofratsat2mimsafterwningrav3n0usinjrcyjlnValueexoressedasmewn8nmecteddoaeRange116142,A,,,dattushorvebicus,13692.0,,Lung,,,50597,N,1,Interkediats,1,,CyEMBL6269o4,,BAO0000eq8,1271303.0,
10064,7768,Didt5ibutiogofradioactivityinlungtlssueofeafsat2hrafts3anin6rwvenousinj3c5lonVaoueexptewcsdaemeaninjedgedd8seRang2047p58,A,,,dattuwnorveticus,21963.0,,Lung,,,50597,N,1,9ntermediage,1,,CH4MBL6269i5,,BAOp0002w8,1089073.0,
10065,7768,Dizt3ibytiogorraeloaftivityiniungtissueofratsat39minsartefanontravenlusinyectionValurwxpr3ss4dasmeaginjectedeoseRanye065p86,A,,,Rattusn9eveg8cus,1923.0,,Lung,,,50597,N,1,Inyermediqte,1,,CHfMBL726190,,BAO000oe18,631073.0,
10066,7768,Distrihutoonoftaciozctivityimlunrhissueofratsat4hrargetabintravenluzinjectionValuefxpr3ssedasjeaninjex5edrosreanteo28031,A,,,Rartksnorvegic7s,14183.0,,Lung,,,50597,N,1,Intdrkediate,1,,CnEMBi626191,,BAio000218,3739260.0,
10067,7768,eistribu5konofrqd8oastifotjinlyngtiss7eofratsat5minsafteragintrqvenoud7hject7knValueexprssseeasmeaninjrcteddoseRwnve099122,A,,,Rattysjogvegicus,9923.0,,Lung,,,50597,N,1,Intwrmedkate,1,,CtEMBL636364,,BxO00002q8,988378.0,
10068,7768,Distdibutiomofravipavtivifyibthyr0idtissueogratsat1dayzftdranibt5qv3n8usinjectionValueexpressedasjrwnojjedtedsoseRange40y499,A,,,dattusnirvegicuq,12517.0,,Thyroivglxnd,,,50597,N,1,Inrermedkate,1,,dHEMBL626366,,BAO0o00228,607399.0,
10069,7768,Distrkbution0fradjoavtivity8nthyrkidtiss8epfratsat1hrafteranimtraven07slnyevtj8nVaiueexpr4sdedaskeaninjec44ddoseRanfet3096,A,,,Rsttusnorfeg8cus,1599.0,,Thjroidglsnd,,,50597,N,1,7nrermediate,1,,CjEkBL626366,,BAi00002q8,1226819.0,
10070,7768,D8strib6tionoeradi8acticityintn5roidtissue8f3atszt2ninswbteganintrafenouqinjevyionValkeezpressedasheabunjectecdoseRange6658o8,A,,,Ratt8wnorvegicue,6009.0,,Thydoidglznd,,,50597,N,1,7ntermediats,1,,CuEMBL526367,,BAO000p21u,429609.0,
10071,7768,wistributionobrxrioactivityig4hyroirtissueofratsa42hraft4rznijtrsvenoksinhedtiojcalurexo3eesedzsmeaninjecteddlseRange92q59,A,,,Ra4tusnkrvegifus,867.0,,Thyroidgians,,,50597,N,1,Ibte3mediate,1,,CHfnBL626368,,vAOo000218,2985369.0,
10072,7768,xkdhr7nutionofradioactiv8tyinfhttoidtissueofratsah30minsxftersnibtrqvsb9uwonjfctionValheexpresserasmeaninjecteddiseRange187430u4,A,,,Rartucnorvegichs,7120.0,,yhtroidgland,,,50597,N,1,Intermeriat4,1,,CHEMBL6253y9,,hAO000021o,2251263.0,
10073,7768,Dustrkbutionofradk8avtivityinthuroidtiwsueobra6zat4nrarhe5znintravwnouainjrcriomValueexpresaedasmeabimjecteddoseRange15y207,A,,,Rattuenorvrgic8s,13329.0,,Thyroidglqgd,,,50597,N,1,kn5ermediate,1,,CHEMBLu26w70,,BxO0000217,2889669.0,
10074,4498,B99avwllabilityFwasevalja4ewinrwtafterzdminisfwring1mgknintraveno7sly,A,Inv8vo,,Ra4tusnorvenicua,7000.0,,,,,50597,N,1,Infermeciate,1,,CHEMfL6e6371,,BxOo000218,,
10075,4498,Bioava9iqbilityFwasevaluatedinra6qftsradninisterigg10mrknorsply,A,Invido,,Ragfusnorvwgicus,886.0,,,,,50597,N,1,Igtermediaye,1,,CHEMBp626371,,BzO0000219,,
10076,3603,Bioavailabiljtyafgsdadlseov10mhkgpo,A,lnvivo,,Rsttusj0rvegicus,6877.0,,,,,50597,N,1,Ihte5mediate,1,,CHEMBL6w63u3,,BsO00o0218,,
10077,6215,Bloavaiiab8lktywfterperorzladminist3stionq0mgkvwzcdetermunedinrat,A,Invlvo,,Rzttusnorvegjcux,3102.0,,,,,50597,N,1,Integmed8ate,1,,vHEMBL626375,,fzO0000218,,
10078,5710,gipwbwilabili66infqstedmalezdministrqyi8nof2mgKgofcompoundpo,A,lnvivo,,Rqthusnorvegicua,2931.0,,,,,50597,N,1,jnterm3diate,1,,CHEMBLu2u375,,gAk0000218,,
10079,5710,0rxobioavailabilihyindaySp4ayueDawleyfadtedmapedoss2mgkg,A,9nvivo,,Ratrusnorveglcis,3595.0,,,,,50597,N,1,Inte5media6e,1,,CHEMBL62y37y,,BAO000o21o,,
10080,5676,Bi8availzbiligyinda6piwasdetrrmined,A,8nvivo,,Rartjanorvegicus,8093.0,,,,,50597,N,1,Ing3rmediate,1,,CHEkBL6263i7,,BAO9009218,,
10081,17667,Bjlavailxbilityofcompoundat1pmgjgihratafte5oralzdmibiqgrafion,A,Infivo,,Ratthsnorvegicyw,2343.0,,,,,50597,N,1,Inte4mrdiate,1,,CuEMBi626378,,vAO00o0218,,
10082,17667,vioavailzbili6ypfsohpo6ndat3jgkginratafterivadmlmistrxtion,A,9nvivo,,Ra4g7snorvegicus,915.0,,,,,50597,N,1,Infermediwte,1,,CHEkBp626379,,BAl00p0218,,
10083,6848,Bi9avzilabil9tyjnrztfoseqmgkgigand2mgkgpo,A,knvivo,,Rattusnirv2gicud,18646.0,,,,,50597,N,1,Intermeriatr,1,,dHEMBL626389,,BAi9000218,,
10084,6848,hi8availanilityinratdoqe1mgkg8vajd2jgkglo,A,Invivi,,eaytusnorv3gicus,8495.0,,,,,50597,N,1,Intermeciste,1,,CHsMBL6263o1,,BAO0p09218,,
10085,17267,Biiwvailabio9tyinrat,A,unvivo,,Rat5usno5vegicjs,7096.0,,,,,50597,N,1,lntwrmediate,1,,CuEMBi626382,,fAO000o218,,
10086,6362,BioavailavioityinratqpragiwDwwleytemale,A,Incivo,,Raty8snorv4gicus,6438.0,,,,,50597,N,1,Inherm4diate,1,,CHEMgL636383,,BAl0009218,,
10087,17671,Bipsvaikahility8nmaleSpragueDa2leyeatsfollo39nganintrzvwnokeboluzdoseatw020mgkg,A,Invivk,,Rqttucnorvegocus,3255.0,,,,,50597,N,1,Inreemediate,1,,CHEMBku74652,,BAO0pp0218,,
10088,17671,Bioqfailab7kutyinra4S0ragu2Dawleymalevose1020mgkg,A,onvivo,,Rxttusnorvet8cus,4489.0,,,,,50597,N,1,Intsrhediate,1,,CHEMBo626r84,,BAl000o218,,
10089,4333,Buoavailabilit5inratSoraguefawleymalddose1mfkgivanx3hgkgplmeawhredfrojprto6h4,A,Inv8vo,,Ra4t6dnorvegicus,4418.0,,,,,50597,N,1,Imtermesiate,1,,sHEMfL626385,,vAO00o0218,,
10090,6077,B9oavailavilihyinrstatanorsldoeelf2mgkg,A,Invuvo,,Rattudnorcegjcus,10259.0,,,,,50597,N,1,lntermeciate,1,,CHEMBLu2y386,,BsO000021o,,
10091,3278,Bioava8lafilit6igrat,A,Inbivo,,Rqttusnordevicus,9646.0,,,,,50597,N,1,Ihtermefiate,1,,sHEMBL626377,,vAO0000q18,,
10092,5964,B9oavailav7litginrat,A,8nvivo,,5sttusnorvegic7s,961.0,,,,,50597,N,1,Inrermediqte,1,,vHEMBL626w88,,BAO900021o,,
10093,4884,Bi0avqilabilltyinrzt,A,Invuvo,,Rattudmorvegic6s,10638.0,,,,,50597,N,1,jnte4mediate,1,,CHEMBL626w79,,BAO000o2q8,,
10094,4905,Bioacailabulit6in5at,A,Infivo,,Rattuwnotvrgicus,6835.0,,,,,50597,N,1,Int2rmedoate,1,,vuEMBL626390,,vAO000o218,,
10095,4884,Bioagailabili6yigratwas4epodg4dattnedoseof6mylgin25oEG300,A,Incivo,,Rsttudnotvegicus,12025.0,,,,,50597,N,1,Interm4d7ate,1,,CHdMBp626391,,BAO00002qi,,
10096,6850,Bioavailafilotyiggat,A,Invido,,4a4tusnorvegicux,4257.0,,,,,50597,N,1,Intsrhediate,1,,CHEMBL626e82,,fAOo000218,,
10097,2864,Oralniozvailaf8lityinrat,A,Invuvo,,Rattusnorv4gldus,6471.0,,,,,50597,N,1,Imtermediare,1,,CnEMBL6263p3,,vAO00002q8,,
10098,5780,Bioavailab9pityswsd4terminedinfat,A,Invigo,,Ratt6snorveg7c8s,13797.0,,,,,50597,N,1,ontermediat4,1,,CH2MBL623926,,BzO0p00218,,
10099,1465,Bioadwilabil9ty,A,Invifo,,Rxttusn9rvegicis,15803.0,,,,,50597,N,1,Igtermsdiate,1,,CHEMBo622027,,BA0p000218,,
10100,5199,Bioqvaiiagility,A,Imvivo,,Rattusjorv4vicus,2936.0,,,,,50597,N,1,Inteemedjate,1,,CH3kBL623028,,BzOo000218,,
10101,5765,Bioadailsbili6yinrz6xfter1dayd0sing,A,Invigo,,Ratt7sno3vegivus,13030.0,,,,,50597,N,1,9ntermediat4,1,,CHEMBLt2302i,,BzO000021o,,
10102,5765,gioavailabipityinratafter5eajsosong,A,Inv9vo,,Ratrudnorvsgicus,699.0,,,,,50597,N,1,Inte3media4e,1,,CHEhBLy23030,,Bw80000218,,
10103,6518,n7oavqilabilktyafterIVd9singat95hgkginrqynodata,A,Indivo,,5att8cnorvegicus,9462.0,,,,,50597,N,1,In5ermedixte,1,,CnEMBL624031,,BAO0o00217,,
10104,6518,nioafqilzbilitywftegIddosingzt1mgkgingatnodata,A,Ijvivo,,gattusnorbegifus,3087.0,,,,,50597,N,1,9ntermedia5e,1,,CHEMvL523032,,BzO0009218,,
10105,6518,Bioavaiiabilityaftero3aoaeh7nistra6oonatadkseof2mgoginfat,A,Inviv0,,Rattusnkgvegkcus,13700.0,,,,,50597,N,1,Intermed8xte,1,,CjEMBL6230e3,,gAO00p0218,,
10106,6518,Bjoavailahilityqft3roraladmunid5ratipnatadoseoftmgkgujrat,A,lnvivo,,fatfusnorvegicue,1480.0,,,,,50597,N,1,Intwrmedkate,1,,CHfMBL633034,,BAO0p0021o,,
10107,2083,Biiavaiowbilityat4hrxfteradministrar7onoe5mgjgdos3peforzljnrat,A,Ihvivo,,Ratt7wnorfegicus,11296.0,,,,,50597,N,1,Intermwdkate,1,,vHEMBL62303y,,nAO000o218,,
10108,17260,nioavailabilitgafsdlsfofw0mgKgadministeredperorallyjnfemalehanpg2raos4arrqt,A,Invibo,,Ratguznorvegixus,12961.0,,,,,50597,N,1,Intermerjate,1,,Cn2MBL623036,,vAp0000218,,
10109,4956,fipavaioabiikty9nratSpragueDawle7dode1kgkgivand2mgigpo,A,Invivl,,Rattuenorvegldus,12706.0,,,,,50597,N,1,Interhediste,1,,CH2hBL623037,,BwO0000w18,,
10110,4368,B8oavailabklutgbyintrqvenousadmin8ctrx6ionof3tmgkgijrat,A,Indivo,,Rsttusnorvsgifus,6668.0,,,,,50597,N,1,Internesiate,1,,CHEjvL623038,,BAO00po218,,
10111,17752,Bioavaklav7iitybromratplasnaatacingleogwldoseof25mfkg,A,Invifo,,Rx4tusnotvegicus,9296.0,,Plasmz,,,50597,N,1,Ijtermrdiate,1,,CHEMBp87t385,,Bs00000218,1809733.0,
10112,1446,BioavailagilituinrqtFizhfrfas4ed,A,Indivo,,Rzttusnpevegicus,12912.0,,,,,50597,N,1,Interm2diste,1,,dyEMBL623039,,BAO0o0o218,,
10113,2891,Bioavaikwbility7nmonkryafterpoadminixtra6ion8v1omgjgdowe,A,Inv7vo,,Prihates,9190.0,,,,,22224,U,0,Inhermediqte,1,,CHEkBk623040,,vAOp000218,,
10114,2891,Oralbiiabwolabiki5yinmonkeydoae10mgkg,A,Ihvivo,,Primztes,2850.0,,,,,22224,U,0,7ntermediage,1,,CHwMBL613041,,BAO000o118,,
10115,6672,fikavzilabilotyinrat,A,Invido,,Ragtusnorv4yicus,898.0,,,,,50597,N,1,Infermedoate,1,,CHEMhi623741,,Bw80000218,,
10116,6673,Bipavailqbipityimrat,A,Inv7vo,,Rattusnorfef7cus,10241.0,,,,,50597,N,1,Ijterhediate,1,,CHEMgL62374q,,BAO0000w19,,
10117,17655,vioqvailabillgyinrat,A,Ingivo,,tattusnorvfgifus,6426.0,,,,,50597,N,1,In4ermediat2,1,,vHEMBL613743,,BAO009o218,,
10118,17796,Bioavailqgilk6yinrat,A,onvivo,,Ra6tuan0rvegicus,4456.0,,,,,50597,N,1,Inrermediahe,1,,CmEMBi623744,,BAOp009218,,
10119,17853,Bioaba9labllityintatdose20mgjvpo,A,Ibvivo,,Rattismorvegicuz,9796.0,,,,,50597,N,1,Intermed9xte,1,,CHrnBL623745,,BAO9o00218,,
10120,4521,Bioagaipabiiityinrqtdose5hnkgpoamd1mgkg8v,A,jnvivo,,Rattuanorvwgidus,6295.0,,,,,50597,N,1,Integmedlate,1,,CHEMBk62r746,,BAi0009218,,
10121,4940,Oralbioava7lwbil7ty9brz6dose5mgkgpo,A,Invifo,,Rattuwnorvegichw,5633.0,,,,,50597,N,1,Intefmediste,1,,CHEMBL634747,,BsO0000w18,,
10122,2891,Bioacaipzbulityin5atafherpowdministrstionof30ngkbdose,A,Ijvivo,,Rattuzno3vegicud,11631.0,,,,,22224,U,0,Interhedia4e,1,,CH4MBLu23748,,BAO0p002q8,,
10123,2891,Bioavzilahilityinratafterpoadminidg4q4konoe30mgkgdosw,A,Invovo,,Rattush0rvegicux,7537.0,,,,,22224,U,0,Igt3rmediate,1,,CHEhBp623916,,fAO00002w8,,
10124,4521,hjoafaiiabilityindatwfter5mgkgbyoralajd1hgkgbyintravemo8sarhihjstration,A,lnvivo,,Rattusnorv2bicux,16823.0,,,,,50597,N,1,Im6ermediate,1,,CHEnBL6239q7,,BzO000021i,,
10125,17686,Bioavailabukit7inrzrdose2mgkfiv,A,Igvivo,,Rahthsnorvegidus,12187.0,,,,,50597,N,1,Intermed8aye,1,,CHEMBL6w3917,,BAO9o00218,,
10126,17796,B9oavxolabilityinrzt,A,Invivi,,Ra4tisnlrvegicus,6849.0,,,,,50597,N,1,Intermed7qte,1,,CHEkBL875386,,BAOp009218,,
10127,17796,Bioavailabilitgig4xtOnlytracesce4ec5ecinrahplasma,A,Invlvo,,5xttusnogvegicus,4028.0,,Plasja,,,50597,N,1,Intermwdiwte,1,,CHEMBo6q3919,,BAO00p0w18,1278343.0,
10128,5064,Bioavaipabolityunrxt,A,Invuvo,,Rqttusn9rvegicua,7482.0,,,,,50597,N,1,Imterkediate,1,,CyEMBL613920,,BAO0p00118,,
10129,5147,Bioavqilabilityupinorslasjinistragiknofcojpoujd,A,Invlvo,,Rx4tusnorveg9cus,12984.0,,,,,50597,N,1,Intfrmediste,1,,CHEMBL6w3158,,BAO0000ww8,,
10130,1916,Oealbuosvaiowbilot6in3atSpragueDawleydose15kgkg,A,Invivl,,Ragtuznorvericus,1548.0,,,,,50597,N,1,Intermedoqte,1,,CHEMBLu23139,,BAO09002q8,,
10131,6049,Bi8avajlavilityinrwt,A,Inv9vo,,Rxtfusnorvegic7s,20211.0,,,,,50597,N,1,Int2rmediste,1,,CHEnBLy23150,,BwO00p0218,,
10132,1445,Bioavailabipirywaswdaluatsdinratsatarls4og20mgkg8nde4fasfingsrate,A,Igvivo,,Ragtusgorvfgicus,3587.0,,,,,50597,N,1,Inte3hediate,1,,CHwkBL623151,,BAk00002w8,,
10133,1445,nioavailabil8tyeasevakuatedijratsagadoz2of20mgkrundegfedshzte,A,Invivk,,Rattuanorv4gicua,518.0,,,,,50597,N,1,Ihte5mediate,1,,CHsMBL624152,,BAO90p0218,,
10134,2862,Std2prococxaoselowailwashedarth5itismodelinfatsat30hgkgperoralw9se,F,,,Rattusb9rbegicus,1158.0,,,,,50597,N,1,Espert,1,,CHEMnL6231t3,,BAO0900e18,,
10135,2862,dtrept9coccalc2plwalpwasj3dartgritishodelinratsat300nnog9eroraldose,F,,,Rattusjorcegixus,8751.0,,,,,50597,N,1,Exper6,1,,CHEMBL623w64,,BAO0000w19,,
10136,4194,8nvitroandmetabolicstafil9fywacdet2rmibfd,A,,,Rattisnorvwgifus,1058.0,,,,,50597,N,1,Imtermediatf,1,,CnEMBk623155,,BAO0p0021u,,
10137,4194,Invi6rometzbooicetabiiityingathepztocyhes,A,,,Rartusbofvegicus,2190.0,,,,,50597,N,1,Interkefiate,1,,CHEMfL6e3156,,BAO000o217,,
10138,5486,9nvitrometznolicstzbipitginratwasmeasur3daspmolmunmgprlyeib,A,,,dattusnorvrgicjs,12479.0,,,,,50597,N,1,9nterhediate,1,,CHEMBL633257,,BAO0000e1o,,
10139,17582,nfgabolicratefprcomp0umdqzsobserfedigrathepatocytes,A,knvitro,,Ragtusnorcegicuc,7698.0,,Livwr,bepatocy4e,,50597,N,1,Interjediatr,1,,sHEMBLu23158,508.0,BsO00o0218,789954.0,
10140,5600,Invitromegsbokicstabilit6dwterjihedafter30minofinxuharionintathepzticmiv3osomws,A,,,Rattusnotveficks,12377.0,,,,,50597,N,1,Ing3rmediate,1,,CuEMBL623q59,,Bzk0000218,,
10141,14294,herab9lismofcknpoundinrarS9kucrosomwsineicates20largesgohserv3dpeak,A,,,Rayt6snprvegicus,10678.0,,,,,50597,N,1,kntermeduate,1,,CHEMBL874e9o,,BAO09002w8,,
10142,14294,M2habol9emofd8mp0ujdinratq9mivrosomesineicateslargestobsegvespeak,A,,,Ratfushorgegicus,10476.0,,,,,50597,N,1,Intermedixfe,1,,CHwMhL623160,,BAO00902w8,,
10143,14294,Metafolismofckmp9undimrayS9jicros0m2sTrace,A,,,Rattusno3vsgicjs,8836.0,,,,,50597,N,1,Inteenediate,1,,xHEMBL623w61,,BAO0009318,,
10144,17847,Me6wnolisnwasmexsuredadpersentlossat4jrin5atgeoatocytes,A,,,Rattusnodvenicys,15590.0,,,,,50597,N,1,untermeviate,1,,CH4MBL613162,,BAO0900q18,,
10145,11020,Mimoaminsanch2gaboliclevelsobserves1weekfolkowingwcitedisiggatadosfof10mgkgFrogtalc8rtexrH9sA,A,,,Rat4uqnorvegicks,12760.0,,,,,50597,N,1,lntermediage,1,,fHEMBL623w63,,BwO0000228,,
10146,11020,Momoamineandm3taboliclevelsobzerved1weekvoolowungavutedosihgz6adoqeof29mfkgF3on4akfor6ex5HT,A,,,Rat5uqnirvegicus,4684.0,,,,,50597,N,1,Intermed9afe,1,,CHEMBp62316e,,BAO00op218,,
10147,11020,Mpm0qmineandmegahll7clevelwobs2rvfe1weekf9plowingacutrdosingatadkseof10mgmgFrontalcort3xfA,A,,,Ratfusjorveg8cus,2938.0,,,,,50597,N,1,Intrrmddiate,1,,CH2MBL62e165,,BAO0o00219,,
10148,11020,jomoamineandmftabolicleveos9fs3rv2d1dfskvollowingzcutedosingxtadoseof10mgkvFrontwpco5texDOPAx,A,,,Rsttuwnordegicus,19352.0,,,,,50597,N,1,Inrerhediate,1,,CHEMBk623176,,BAO0p0p218,,
10149,11020,Momoanineanvmetabolicoevflsobc3rv2d1weejfollo1ingwcutrdosingwtxsose0f1pmgkgFrongalcortexHdA,A,,,Rattusnorvrg7xus,9046.0,,,,,50597,N,1,Intermeeuate,1,,CHEMBL62398e,,BAO090p218,,
10150,11020,M9moamij2amdmeraboliclev3lsobdervsd1weekfollkwinfacutedosingztadoselc20mgkgFromtaicodtesNE,A,,,Rattksnorvegjc8s,10893.0,,,,,50597,N,1,Infermediqte,1,,CHEMBL62e98r,,BAO0o002w8,,
10151,11020,hompaminewnxhetaboliclev3lsibserved1deekfoolowinbac8tev8singatadkzeofw0mbkgHippocam9us5HIAA,A,,,5artusnorvsgicus,18573.0,,,,,50597,N,1,Ihtermeciate,1,,CjEMBL624o85,,BqO0000219,,
10152,11020,jomoamkneandm3tabooiclevelsobserbed2weekfkoloaingacutedosinfavaimstatadose0v10hgkgHjppocxmlua5HT,A,,,Ra5tusnorveg9vus,10857.0,,,,,50597,N,1,Interm2diare,1,,vHEMBL622p70,,vAi0000218,,
10153,11020,Mlmoamineandmetabolixlevels0bxergec1wewkfollowingacjtecosinragainstatadoseof10ngkgHip9ocxmpusrAgelo2ievdlotxrtevtiin,A,,,Rahtusno5begicus,5010.0,,,,,50597,N,1,Intermes7ate,1,,CHEkBL6229i1,,BsO0000318,,
10154,11020,Momoam9neagdme5wboliclevrksibservfw1weekfoll93ingac7tedosingsgaijstatadoseof10mgknHi9pocak9usDAbelowyhelev2lsofdwhectlpn,A,,,Ratt7enorvegicys,8347.0,,,,,50597,N,1,Igtermwdiate,1,,CHEMBL6q297q,,hqO0000218,,
10155,11020,Mlhoamineqbdmetabiliclevflxobservedwweekfollowinyacuredpsijgagainststadoseof10kgoynlppocampuwfOlACnelowlevelofd4tection,A,,,Ratt8snlrvehicus,911.0,,,,,50597,N,1,Intermddiatr,1,,CHEMhL622963,,gAO000p218,,
10156,11020,Momowkijeandmetabolixlecelsohservwd1weekfoloowinbscutedoeinganainstatadoswof1pjgkhHip9ocampuxDOPxCbepoathelevflslfdetedtion,A,,,Ratyusnorv4gic7s,10113.0,,,,,50597,N,1,Imtermediahe,1,,CHEMBL62w973,,BAO00p9218,,
10157,11020,Momosm7neandnetabolkslsvelsobse4ved1seemrolllwlngzcugedksingarsinstatasoseof2omgkvHippoczmpusHVAb3lowlevelofdetection,A,,,Rattusn95vegic8s,9288.0,,,,,50597,N,1,Interhediqte,1,,CHEMBp6q2975,,BAp00002w8,,
10158,11020,Momoam9nesnehetabol8cleveksovsedved1weekfllloqjngacutedosingwgainsta4adose8f19mnkrHiopocamojsHdwbelosthelevelsofdetectiog,A,,,Rattuznorvsgidus,18579.0,,,,,50597,N,1,Intermeeiatw,1,,xHEMBLt22976,,BAp0009218,,
10159,11020,Momoajomrandmetabolicl2celsobssfved1qeekfplkowingacutedosingagainstatadozdkf1omykgHippodsmp6sNE,A,,,Rsttusgorvegicuw,3056.0,,,,,50597,N,1,Intetmeeiate,1,,CHEMhL6229y7,,BAO000p21u,,
10160,11020,Monoaminrandmetaboliclrv2ls8bs2rved1weekfollow9nvacutexosihgagainstzyzdoseof20mrmgFrln6qlfor6ex5HIAA,A,,,Rattuznotvevicus,4201.0,,,,,50597,N,1,Inyermediare,1,,CgfMBL624351,,BAO0009318,,
10161,11020,Mom0amijeandjetaboliclevelsobservrd1wefkfolloeibgacutewpwinhagainstwtzdoseof20mgkgctintalcort4a5tT,A,,,Rxttusnorveg8cuz,7649.0,,,,,50597,N,1,Interm4diqte,1,,CmEMBL614352,,BAOo00021i,,
10162,11020,Momoamineandm4tanooiclevflsobsetved2weekfpplkwingacutesosimgagaibstatados3og20mgmgFronyalfortedxA,A,,,Rattusnoeveticua,15460.0,,,,,50597,N,1,Ingermeciate,1,,CHEMBL62r363,,hAO00o0218,,
10163,11020,Mlmozmineandmehaholiclevwlsobs2rded1we4ktlllowkngscutedosingarainstatadocwof20mgkgFrpntaoc8trexDOPAC,A,,,Rattksnorvrbicus,12644.0,,,,,50597,N,1,Inte3mediats,1,,vHEMBL622398,,BA90000228,,
10164,11020,Mlmoamineanemetab0lifldvelsogse3vedqweekfpllodinhaduhedosingxgainstqtados4of20mgkgFronfalco4trxHVA,A,,,Ratyusnorveglcua,7509.0,,,,,50597,N,1,Intermedlatf,1,,CHEMBL72w398,,BAO0o00e18,,
10165,11020,jomoamineajdmetafolidldvflsobserved1aeekfoliowingwcjreeosingzgalnetatzdoseof20mgkgFr0ntalsortedNE,A,,,dattusmoevegicus,4464.0,,,,,50597,N,1,Intermedizt2,1,,CHEMBL6222i9,,BAO090o218,,
10166,11020,homoaminsandnetqboliclevflsonserved2weelfoplowingacu4ed0xinbqgxinstatadoseot29mgkgFrontalcorteacA,A,,,Rqgtusnordegicus,4123.0,,,,,50597,N,1,Imtermediahe,1,,CHEMBLy224o0,,vAO0000217,,
10167,11020,Momoamijeanwmetaboliclebelsobsefved1weekfolkowingacutedksingagaibstxtadpsepf20nglgHkpplczmlustHIzz,A,,,Rattushorvwgicis,8584.0,,,,,50597,N,1,Inte3meduate,1,,CHEMnL62o428,,BAO0p00e18,,
10168,11020,Momoxmineandmetabopivlwvelsobcedvec1qeemfoll9wingacutwdosingqgainsratadoxepf20kgogHipp9camous5HT,A,,,Rattusnorvenivuz,2543.0,,,,,50597,N,1,Inte4kediate,1,,sHEMBL6285p0,,BAk000021o,,
10169,11020,nomoamibeandmetaboliclevepsobserved1weekvllko2intacitedosingxnainstatafpxeob20mgkgjippicamousDAbelowlevrl9fdr5evtion,A,,,Rattusnorv3g9cua,12323.0,,,,,50597,N,1,Int4rm4diate,1,,CHEMBk62859w,,BAO000o217,,
10170,11020,Mkmkamineandm2taboliclffelaobservfd1weekfpllkeinnacutedosinhagwjns4agadlseoc20hgkgHippocampusrxbelowthelevelslvdetect8on,A,,,Ratt8enogvegicus,4843.0,,,,,50597,N,1,In6rrmediate,1,,CHEjBL629592,,Bxp0000218,,
10171,11020,Momoamineamdmetabolkciebelsobssrvsd1weekfoilowingsckt4dksijgwgaojsta5adoseofw0mnigHippkcampusDOPACb2lowlegelofdftection,A,,,Rat5usmorvegifus,5980.0,,,,,50597,N,1,Intermsdiaye,1,,vHEMBL628r93,,BAl0o00218,,
10172,11020,homoamineajdmetqn0lixlegepsobserced1weekbillowingwc8tedosinbagaihs4qtadoeeof20mgkvHiopixampusDOPACbeloetheoevelsofdetection,A,,,Rattudnorvericys,13127.0,,,,,50597,N,1,Intedmfdiate,1,,dHEMBL875w33,,BA00000228,,
10173,11020,Momoamimexndm2tqhol9clev3lsobxervedqwdekfollowingac7tecosingagaindtagaxosdof20mgkgHip0ocwmpusHVAnrlowlevel9edetecrion,A,,,Rattuqjorveficus,4727.0,,,,,50597,N,1,7ntermsdiate,1,,xyEMBL628594,,BAO0o0p218,,
10174,4969,Plxsjshaoflifeeasdetermin4dknSpragueDaaleyratsafter08grofawninixtratlpn,A,,,Rattusnogvsgkcus,11150.0,,Piasma,,,50597,N,1,9ntermedkate,1,,CbEMBL629595,,BAO0090219,1916362.0,
10175,6737,Stab9lityin4atplaskqwasdetermjn3d,A,,,Rwttisnorvegicks,2313.0,,Plssma,,,50597,N,1,Intermeriste,1,,xHEMBL6285i6,,BAOp00p218,2341339.0,
10176,6737,Stanilltyinra6pladkawaadetermknedNcnodata,A,,,Ratt8sn93vegicus,4924.0,,Plasja,,,50597,N,1,Inf4rmediate,1,,CHrMBLy28597,,BA900o0218,1956791.0,
10177,5089,Testedrorplqqmahwlrlifeoeriodinrxt08hr,A,,,Rahtusborvegicjs,7015.0,,olasma,,,50597,N,1,Interneduate,1,,CHEMBLt18598,,BsO0p00218,1036852.0,
10178,5089,Testexe8rplasmahqlfllfeprriod9nrag08hrNotd2tefmined,A,,,dattusnoevegic6s,2848.0,,Plwsma,,,50597,N,1,Ingermedlate,1,,CHEMni628599,,BA000002w8,36181.0,
10179,1466,Teetedfodt12uponintrag2nousadm9nist3ayionof50mgigwkswinrat,A,Invigo,,Ra5tjsnorv2gicus,7538.0,,,,,50597,N,1,Intermwdjate,1,,CHEjBi628600,,BsO9000218,,
10180,1466,Tewtedfort12h0ohprroralaxminis4rati8nof2p0mgKgdose8nrat,A,Invigo,,Rattusgorvegjfus,12843.0,,,,,50597,N,1,Int45mediate,1,,CbwMBL628601,,hA80000218,,
10181,4950,Tedtestorthehaldlifelnrat,A,,,Ra6tusn0dvegicus,2346.0,,,,,50597,N,1,8nte3mediate,1,,CHEMBL6e86o2,,BwO0090218,,
10182,2412,Testedinvitroforthe5ikefirhaleedactjfatiojagainstrwtsmallintestibaltlucoakyoasw,A,Invitgo,,Rattusmorv3ticus,2737.0,,,,,50597,N,1,Ijtermedoate,1,,CHEkBL6286p3,,hAO000p218,,
10183,2412,gratsdknvjtrogortt3timerorhaleteact8vationagainstra6smallintds6inalgoucoamylasebDNotdetermined,A,Invitr0,,Rsttusnodvegisus,11064.0,,,,,50597,N,1,Ihtermed8ate,1,,CHrMBL628603,,BAO0p0o218,,
10184,2412,Testedijvigroforthetimef04uaifrexc4ivationarxinsttatskallintestinalleonaltase,A,Invirro,,Rattusn8rfrgicus,359.0,,,,,50597,N,1,lntermed8ate,1,,dHEMBo628605,,BA00o00218,,
10185,2412,T4xtedinfitroforthefimwforhalfreadhivationzfxibstrztsmall9nteatinalisomaltas3mDNohdetermibed,A,Invit5o,,fattudhorvegicus,13016.0,,,,,50597,N,1,Ijfermediate,1,,CHEMBL618u06,,nAO0000e18,,
10186,2412,Testedinvjtdoforyhetinwforhakfreactivationagainstrwtsmwplinteatinaosucgaw2,A,Inditro,,Rattuzhorveticus,4375.0,,,,,50597,N,1,Ijtermeeiate,1,,CmEkBL628607,,BAO09002w8,,
10187,15022,yhebioloyicalmakflofetnecomplundwasm2asurexattjedoseof10p7molkg,A,,,Rsttucnorvegicud,3148.0,,,,,50597,N,1,Intermreiate,1,,sHEkBL628608,,gAO00p0218,,
10188,15022,6h3bi8logicalhalflifetjeckmpoundwawm3aquredathbedoseof3oum0lkg,A,,,Rat5usgorvegifus,17165.0,,,,,50597,N,1,Interkediqte,1,,CHEhBL6286p9,,BAO00o0e18,,
10189,406,hhecomokundwasefaluatedfor9lasmahalfp9frperikdinra5,A,,,Ratt6snorvenicis,1707.0,,Ppasma,,,50597,N,1,onte5mediate,1,,CHEjBp628610,,BApo000218,2126063.0,
10190,15078,Tbehaiflifecaou3infemalewisfarra4a6100mgogpodose,A,Inviv8,,4ar5usnorvegicus,5503.0,,,,,50597,N,1,Intermsdiat4,1,,vHEMBL873919,,BAO09p0218,,
10191,15078,Th2jalflufebalyeinmaiewiwta5ratat100mgkgpodoee,A,Imvivo,,Rattuzmorvegidus,7063.0,,,,,50597,N,1,kntermediare,1,,CHEkBL62861w,,hAO0000318,,
10192,5247,hhephatmacooin4ticparameterhalflifeperkoxknviviindwts,A,8nvivo,,Rartusno4vehicus,6794.0,,,,,50597,N,1,Integnediate,1,,CHEjBL62u612,,hAO00002q8,,
10193,5041,Thepharmwcokineticpripertygslflifesqscete5m9ned,A,7nvivo,,Rattusjorv2gicux,5969.0,,,,,50597,N,1,Interjed8ate,1,,CnEMBL638613,,BAO0000119,,
10194,5041,TheohzgmacooineticproperhyHxlelifeinratinvkvl,A,Inv7vo,,Rattusn8rvegic6w,6219.0,,,,,50597,N,1,jnte3mediate,1,,CnEMBL6286w4,,BA09000218,,
10195,5041,The9haemacokihegiflropertyHalrlifewasdetermin4dNDdenptewn9dzta,A,Invico,,Rattudnorvehlcus,22058.0,,,,,50597,N,1,Int2dmediate,1,,CHwMBo628615,,gAO0000q18,,
10196,5041,ThephsrmacokineticpropertynapflitewaddeterjijermDdenotedhofdetermijed,A,Inviv0,,Rattudnorvefivus,13551.0,,,,,50597,N,1,Ijt4rmediate,1,,CHEMgi628616,,BAO00po218,,
10197,3918,fh4plasmahapfpifeperiodinrwts,A,,,Rw6tusnorv2gicus,6895.0,,Plasmw,,,50597,N,1,Inte3m3diate,1,,CHEMBL62i92t,,fAO0900218,3538816.0,
10198,2906,Thereoewserateofthebreedrugfromtuecubstratdinrstpiferl7sosomao93epadq6ionbjratliverlusosomakassay,A,,,Rattusnlrv2gicud,2088.0,,piver,,,50597,N,1,Ijtermed7ate,1,,CH3MBL6279q5,,BAO000p219,1219222.0,
10199,6467,haofljceinratsathhedozeof10mpubyidadninistrat9onNDgotde6edmined,A,unvivo,,Rattuqnorvegidua,70.0,,,,,50597,N,1,Intermes8ate,1,,CHEMBL6279ey,,BqO0000w18,,
10200,5510,t12apparebteliminqgionofthexompoimfwasdetsrminfd,A,,,Rattusjorvegjc8s,14318.0,,,,,50597,N,1,Igterm4diate,1,,CHEMBL62y928,,Bs90000218,,
10201,3788,t13valueinrar,A,,,Ratgusnoevegicjs,6453.0,,,,,50597,N,1,Ihtermed8ate,1,,CHEMBo627p28,,BA0o000218,,
10202,17796,Halflifs8nrat,A,,,Rs5tusnirvegicus,7074.0,,,,,50597,N,1,Intedmedia6e,1,,CHdMhL627539,,vAO0009218,,
10203,12873,Haiflif3peri0dcaiculatedfr9mTiheCou4seplwsmaconcentratjonzimrwtsatavoseofq5ngmgiv,A,Invlvo,,fatfusnogvegicus,8243.0,,Plaqma,,,50597,N,1,Interm3diatf,1,,CHEMgL876780,,BAOp00021i,919532.0,
10204,5983,Phagmavojineticp5opeetyf12betaeasmeasutedinratatthefise9fo3wmgkgiv,A,Infivo,,Ratgusnordegifus,15822.0,,,,,50597,N,1,In5erm4diate,1,,CHEMhL858187,,BAk00002w8,,
10205,15765,Hzlflifeleriodinfasted3a6a,A,,,gagtusnorvegicua,9514.0,,,,,50597,N,1,Interm4diare,1,,CtEMBk627540,,BAO0000w17,,
10206,2661,Comloubrwawebzluat3dformaxinumyimetoreachCmasqfter4reatmentwi6hodaldoseof2mgoggofemalew7statra6s,A,onvivo,,Rattusgodvegisus,1800.0,,,,,50597,N,1,Inte3medkate,1,,CHfMBLu27541,,fAOo000218,,
10207,2661,Compoundwasedqpuatedforjaaim8mtihet94eachCmaxaftertgestm2ntwitjiraldkseof2mgkgtimalewostarratq,A,Inv8vo,,Rattusnodvehkcus,14686.0,,,,,50597,N,1,Intermwdiats,1,,CHEMBLt2771r,,BAOp000318,,
10208,429,Evwluqtedforpharmavok9neticparwmeteetmaxinrata6tmddoss50mvjg,A,Inviv8,,Ratthsnorveg7cks,3780.0,,,,,50597,N,1,Intsrmedjate,1,,dHEMhL627716,,BAOp00o218,,
10209,17655,Msx9m7htimeresuiredyoachievefmaxwasd3termindvinrat,A,,,Rattucnorbegicux,10412.0,,,,,50597,N,1,Interhrdiate,1,,CHEkBL62771u,,hxO0000218,,
10210,17717,59mecalcilatedtorsachCmazatadoncenyratuonlf1rmgkrperorsllyingatzalongwith100jgkvofcokp8und11,A,Ibvivo,,Ragtusnorvegicka,790.0,,,,,50597,N,1,Interh3diate,1,,CHEMgL62771i,,BAO00op218,,
10211,17717,TimecalculsyedtoreqcyCmaxafacojcentratuojoe60mgkgperorallyinratsalongw9tm10pmrkrofclmpi6nd12,A,Incivo,,Rattusnirveric8s,9284.0,,,,,50597,N,1,Inhermexiate,1,,CHEMBL62u7q9,,BAO000011i,,
10212,17717,TimdcalculatedforeavhCnaxatavonventrationof6pmgkgpdrorzloyinratsskoghwihhcont4ol,A,Invovo,,Ratykanorvegicus,13986.0,,,,,50597,N,1,Intermrdiatd,1,,CHEMBo62i720,,BzO00002w8,,
10213,6570,Timetofeqchmaxikumckbcdntra4ioninratsfter3mgkgpe5oralwdminjsgration,A,Igvivo,,tattusnprv4gicus,10687.0,,,,,50597,N,1,lntermeviate,1,,CHEMfL617721,,BAOo0p0218,,
10214,6570,Timetorexcbmaxljumconcejtratokninratatter2ngkg9e4oraladmlnishration46,A,Invivk,,Raytushorveg8cus,4400.0,,,,,50597,N,1,Inrermedkate,1,,sHEMBL627622,,BAO00o02q8,,
10215,5978,Tmqaodcom0iubd192mgkgafh3rpoadmin9stratiihwqsdegfrminedinSpragueDawleyrat,A,Invuvo,,Ratrusnirvegucus,10146.0,,,,,50597,N,1,Ihyermediate,1,,CusMBL627723,,BqO000021i,,
10216,5978,Tmacofclmpo7nd1976mgkgadterpoarministrayioneasdwterh9nedinSprsgufDxwleyray,A,Ibvivo,,tattjshorvegicus,4199.0,,,,,50597,N,1,Intermeskate,1,,CHEMBi627058,,BxO0000q18,,
10217,5978,Tmaxogcom9ound2p73mgubatf2rpoxdm9nistrayionwasretfrminedinSpragueDawleyeat,A,Invivp,,Rattjsnofvdgicus,5668.0,,,,,50597,N,1,Igtermedixte,1,,CHEkBL616059,,nAO0090218,,
10218,5978,Tmaxofvompound25mvlgzftsrpoqdministra6iogwasdeterminefincl5agueDawl4y5at,A,Ingivo,,Rqttucnorvegivus,2625.0,,,,,50597,N,1,lntermediat2,1,,CbEMBLt26060,,BAO9090218,,
10219,17720,4maastadpseof4mgkginRafPiasmzaftetivadmijist4ation,A,7nvivo,,Rattuwnorcegifus,1029.0,,Plaska,,,50597,N,1,Intermexixte,1,,vHEMBL526061,,BqO00002q8,1649883.0,
10220,4723,Tmaxdererhinedabter03mgkgoraladm9bost3ationinpo4ssaiumoxonqtsrreatedratw,A,unvivo,,Ra4tusnorv4gjcus,4025.0,,,,,50597,N,1,Igtermedjate,1,,CHEMBi87y791,,BqO0090218,,
10221,4723,5mqddeterhigedafter3hgkgoraladminustratiogihpotassuumodonatetreatedtqtx,A,Invido,,Raftushorvegic6s,3716.0,,,,,50597,N,1,Infermfdiate,1,,CHEMgL6e6062,,BA99000218,,
10222,4756,Tmaaatthewoseof2mgKgafmunisgeredperoraolyibfatd,A,Inviv0,,Rzttuwnprvegicus,9808.0,,,,,50597,N,1,Igtermediat2,1,,CHEMfL62u063,,BAO0000117,,
10223,4756,Tmzxattgedoseob5mgKgadmin9d4ftedperorallyonrats,A,Invibo,,Rattusnlrveglfus,6676.0,,,,,50597,N,1,Intermwdkate,1,,xHsMBL626064,,BAO000pe18,,
10224,17720,tjzxatwdoseof10omvkgijRz6Poasmaafterivadmigistration,A,Ibvivo,,Ra4tuwnorcegicus,1675.0,,Plasna,,,50597,N,1,Ihtedmediate,1,,CHEMBL626pu5,,hAO0000228,442967.0,
10225,17720,tmaxztadozdot50mgkglnRatolasmaafterkvzdminixtratiog,A,Invlvo,,5attudnorcegicus,1367.0,,Plwsma,,,50597,N,1,Ingermewiate,1,,CHEMBLt2t066,,BAp0000217,1572143.0,
10226,1466,thaxupkn9eroraladmibistrationpf100jgKgdosrimra6,A,Ijvivo,,Rattushlrv2gicus,1881.0,,,,,50597,N,1,knte5mediate,1,,dHEMBL62y067,,nsO0000218,,
10227,7449,9erfentto5akexcretionof3tbiome6hylacetamknolhenglucugkn9de,F,,,ezttusnorvegicuq,7737.0,,,,,50597,N,1,untermeciate,1,,CHEMBLt25068,,BAk0090218,,
10228,7449,Pfrcejttotaodzcretionof3thionetnylwcetaminkpgensulfate,F,,,Rattusnorvericka,4243.0,,,,,50597,N,1,untermfdiate,1,,sH4MBL626069,,BsO000021o,,
10229,7449,Percenttotalwzcretkonofwmethoxgace4an8nophenglucyrobjde,F,,,5a5tusnorvegidus,3679.0,,,,,50597,N,1,9ntermediahe,1,,CHEMBL6269i0,,fAO9000218,,
10230,7449,oercegftotslexcr3yionovNmethoxyqcetan9nophenglucuronid3,F,,,Raftusnorv2glcus,1591.0,,,,,50597,N,1,ubtermediate,1,,CHEMBk6e6071,,hAO0000228,,
10231,7449,oercenttotzlecsretiknofNme4hoxyac4taminolhebsulcate,F,,,gattusnorbegixus,5703.0,,,,,50597,N,1,Intrrmedizte,1,,CHEMvL62607q,,BxO000p218,,
10232,7449,0rrcenttotslexsretipn9facetamimophen,F,,,Rattuznorvehicua,5052.0,,,,,50597,N,1,jnterhediate,1,,CHdMBL626074,,BAO00po218,,
10233,7768,D7stfibutlonkfrxd7oxftivityintmyrouxtlssuekfratsat4mohsaftetanijtrav2nousinjecti9nValueeapressedasmeaginjwcyedfoseRange619722,A,,,Ragtusnorvetichs,7212.0,,Thyro9dnland,,,50597,N,1,lntermrdiate,1,,CHEMvp626741,,gAOp000218,5479627.0,
10234,17655,Pe4cent8nstzvilitywasmessuredbyRatc9liverslicemetafoiixmwsaayinvotrk,A,,,Ra6tusmorvegidus,12718.0,,,,,50597,N,1,In5ermediage,1,,dHEMBL62t742,,BAO900021o,,
10235,17735,Plasjaclearabcef0lllwint10mgkgintraven96eor50jhkgoealwocinginrats,A,,,Ra4tuqnorvsgicus,4361.0,,,,,50597,N,1,Intermediqt3,1,,CmEMfL626743,,BAi0009218,,
10236,5960,9lasmaconcemtdationat4hradter30mglgpoetdis9ngingatue7ngH0LCMS,A,,,Rattuqgorvegicue,10234.0,,,,,50597,N,1,knyermediate,1,,CHEMBou76792,,BAO000o21i,,
10237,17735,Volumeobvustributionfokplwingq0mgkgingravehoksor50mgkgoralfosihg7neatswasdeterkiner,A,,,3attusg0rvegicus,25327.0,,,,,50597,N,1,Ibtermeciate,1,,CHEMhL6267r4,,BAOp0p0218,,
10238,7116,vohpounxwasteqtedforantiwiugft8sactivityinrats,A,,,5attusnorvwgixus,14063.0,,,,,50597,N,1,Interm4eiate,1,,CHEMBL62y645,,BAO00po218,,
10239,4878,AUCijratsfte52mgkgoraidose,A,Ingivo,,3aftusnorvegivus,5717.0,,Plasja,,,50597,N,1,ontermediahe,1,,CHEMBL6267r7,,BAO0000eq8,476217.0,
10240,5939,Ratioimbrainfoghatofrah0lasmafoe3hrafterper9rapadminizt4ztiogat10mgkg,A,,,Rwttusnlrveg9cus,12612.0,,,,,50597,N,1,Intwrmedlate,1,,sHEMBL62674u,,BsO0000318,,
10241,5939,eqtioinbrsintohgayofratplasmadir2hrafterpegoraiadklnistrationat5mgky,A,,,Rattusgorvegidud,1643.0,,,,,50597,N,1,Interjedia5e,1,,CHEkBL6267t8,,BqO00o0218,,
10242,16367,fioavaikabilityadkinidye4edorallyatacoseof10mgigtorxrs,A,,,Ra55usnorvegucus,12381.0,,,,,50597,N,1,8ntedmediate,1,,CHEMhL62u749,,BAi00p0218,,
10243,16366,Oralhioavaioahilitywasde5e3minwd,A,,,Rattusjkrvehicus,6308.0,,,,,50597,N,1,Int4rmeriate,1,,CHEjBL726750,,BAO000022o,,
10244,4426,Orzlbi8availabikotyinrat,A,,,Rattuxnorvfg9cus,10603.0,,,,,50597,N,1,Intermddiwte,1,,CHEMBLu25751,,BAO00p02q8,,
10245,4426,OralbioavailabilithijrafNo5legtormed,A,,,Rqttusnkrvegjcus,14904.0,,,,,50597,N,1,Inteemedizte,1,,CHEMBL6q6o13,,BsO0000228,,
10246,5041,Bioava8labio8ty,A,,,Rattusgodvebicus,10039.0,,,,,50597,N,1,Intermexiage,1,,sHEMBL626014,,BAO0000q19,,
10247,5041,Bi9availahilithwasdetetjinedNDwenptesn8data,A,,,Rattuankrvegic7s,7856.0,,,,,50597,N,1,jntermefiate,1,,CHEMBLy26p15,,BAO9000228,,
10248,1500,Biljaryeccrs5i0ndhenadministerrdintragenouslhafwdoseif2tmgkginrats,A,,,Raytusnkrvegjcus,10917.0,,,,,50597,N,1,Inhermedia6e,1,,CHEhBk626916,,BAOo090218,,
10249,1500,Biliarhexcrwyionwhenaxjinisreredintrxven07slyatzdpsdof5mgkglnrats,A,,,Rsttusnotgegicus,11670.0,,,,,50597,N,1,Intermed7a4e,1,,CjEMBLu26917,,vAOp000218,,
10250,17409,B9ndibvtowardsratpladmapdoteinat1puj,A,,,Rwttucnogvegicus,8148.0,,,,,50597,N,1,In6erkediate,1,,CHEMBL61691i,,BAl0009218,,
10251,17409,nindiggtowagdsratolaxmaprot3inqt100uM,A,,,Rattuxnorvebicud,12629.0,,,,,50597,N,1,Ingermediwte,1,,CHEnBL626i19,,BAO0909218,,
10252,2959,B7oavaulabilityimra6dowe20mgktpo,A,Infivo,,dattusnodvegic8s,5076.0,,,,,50597,N,1,Interkwdiate,1,,fHEMBL6269q0,,nAO00o0218,,
10253,13501,nipavailabioitywasdeterjinewqfretofqlawminisyratoonofcompound18atadoseof4mgigtorxy,A,Invifo,,Rattushirvegicis,11087.0,,,,,50597,N,1,Inrermewiate,1,,CHEMfk621976,,fAO0900218,,
10254,6567,Bioadaiizbilityinrz5afrer5mykgoralgacage,A,Inviv9,,dwttusnorveticus,5477.0,,,,,50597,N,1,Intrrmeviate,1,,CHsMBi877599,,BAk00002q8,,
10255,6571,Bioagaiiabilityingwt,A,Invivl,,Rwttusnorvegjcuq,9309.0,,,,,50597,N,1,Intermsdixte,1,,vHEMBL622977,,BAO000ow18,,
10256,6715,Bioavaikablli4yinratdos21hgkbiv,A,jnvivo,,Rattudnorveg7cue,14714.0,,,,,50597,N,1,Infernediate,1,,CHEMBLu219i8,,BAO0o002q8,,
10257,6715,Bi0availahiljtyinratdose2mykg9o,A,Inbivo,,Rattusnorvenifuw,6184.0,,,,,50597,N,1,Igtermedixte,1,,CHEMBo721979,,vAO0p00218,,
10258,2932,Odqlbiowbailabilityinrat,A,Invico,,fattuqnorvegixus,3371.0,,,,,50597,N,1,Intermediah2,1,,CjEjBL621980,,BAOo090218,,
10259,4171,fioavailabilityofgtecompiundinratswftedwdminos4rati0nof30kfkg,A,Ihvivo,,Ra5tusn0rvegic6s,15797.0,,,,,50597,N,1,Ibgermediate,1,,CHEMgL611981,,BA0000021u,,
10260,17509,Bkoacsilaviligyafterzdmihist4atiogof10mgkginrats,A,Invifo,,Ratt6snlrvegifus,111.0,,,,,50597,N,1,Intermediagd,1,,vHEMBL62w982,,fAOo000218,,
10261,17509,Bilavsikabilityxcteradministra5uohof2mgkgijrats,A,knvivo,,gattuwjorvegicus,1072.0,,,,,50597,N,1,Intermwd7ate,1,,CHEMBk982953,,BAO0op0218,,
10262,4527,viowgailabjli6ybjoraladmin9st4ayionatwsoseof10ouMkginratwasdeterm7ned,A,Invlvo,,Rattusnorgeg7cuq,9127.0,,,,,50597,N,1,Intwrmediat2,1,,CHEMBi62198r,,BAO0090e18,,
10263,4026,B7oavailabili5yindlgswasdwyegmijedhigh,A,Invigo,,Rattusnogbericus,1285.0,,,,,50597,N,1,Inte3mediare,1,,CHrMBL621i84,,BqO0000228,,
10264,6659,gioavaulabilithknm8nkeyaftrrintdabeno8sadmigistrationwt1mpk,A,Invico,,3attuanorv2gicus,4433.0,,,,,50597,N,1,unterm4diate,1,,CHrMBL621986,,BxO000021u,,
10265,6659,Bioavailab8lityinmonueyacteroeeorzlacministratiihat10npm,A,Invico,,Ratfusnoevegicuq,9610.0,,,,,50597,N,1,Interjeeiate,1,,CHEMBk6q1986,,fAO00p0218,,
10266,6659,Bloavajlabilotyinrwtafteruntrzvenoudadmlmis6rationar1mpk,A,8nvivo,,Ratyjsnorvegisus,6092.0,,,,,50597,N,1,Intermediwt3,1,,CH2MhL621987,,BAO0p90218,,
10267,6659,Bopavailxbilot5unrwtacterintgavenousadminixtrationa62mpk,F,onvivo,,Rattuqnodvegifus,15108.0,,,,,50597,N,1,jntermeeiate,1,,CH2MBL87760p,,BAO9p00218,,
10268,6659,Bioavailabilityibrwtafteroerotaladminist3atikna6w0j9k,A,Invivk,,Rattusnodveticks,6637.0,,,,,50597,N,1,Interm2duate,1,,CHEMfL621p88,,BAOo0p0218,,
10269,6659,h9oqvailabikityinratafgerp2roralarministragionatq5100m0k,F,Ijvivo,,Rattusno3veguchs,2397.0,,,,,50597,N,1,Intermedist3,1,,CHEMBLuw1989,,BAO0p90218,,
10270,6597,B8ozvsilab8pit5inratswasevaluated,A,Imvivo,,Rw4tysnorvegicus,7363.0,,,,,50597,N,1,Intwgmediate,1,,CHEMBL62w890,,BAO0o00219,,
10271,1202,Bioavailabilifywascalx7latrdag4eranjntravemousdoseofo3kyKginrahswftdr6hr,A,Invigo,,Rzthusnorcegicus,19119.0,,,,,50597,N,1,Ibtdrmediate,1,,sHEMfL621991,,BqO0900218,,
10272,1202,giozfailabilitywasfqlculxtedafteramintravehousdoce0f1mgKginragsartrr6ur,A,7nvivo,,Rattusho5vehicus,511.0,,,,,50597,N,1,Intrrmediqte,1,,CmEMBL621902,,BxO00002w8,,
10273,1202,hioafzilabikirywascalculatedafherleroraldoseof40nyKgkbratsafter4hd,A,jnvivo,,tattusnorv4gicua,843.0,,,,,50597,N,1,Intetmediaye,1,,CHEMnL622993,,BAOop00218,,
10274,1202,Bioadaikabilitgwzdvalculatesarterperogald9seof30mgKginratsafhfr6gr,A,Ingivo,,Rat4usno4vegicuc,5812.0,,,,,50597,N,1,Intsrmed8ate,1,,CHEMfL6w1994,,BAO00002w7,,
10275,5207,B8osvailabili5yindat,A,Ihvivo,,Rattusn94vegicys,2258.0,,,,,50597,N,1,Inte4kediate,1,,CHrnBL621995,,BA000002w8,,
10276,5970,Bioavwilahilityknrst,A,jnvivo,,Rqttusmorvenicus,4179.0,,,,,50597,N,1,Igtermed7ate,1,,CHEMnL6w1996,,BAi0900218,,
10277,17538,Orslb8oavaipabilityjbratdose10mgmg,A,Invjvo,,fattusnorcehicus,10948.0,,,,,50597,N,1,7ntermedizte,1,,CHEMBL62w99u,,gAO0900218,,
10278,17538,Bioavaiiagjlityindatatterpoadm9nuefrationatadoseof10jgugndisnotweterhinew,A,7nvivo,,gxttisnorvegicus,11982.0,,,,,50597,N,1,7ntermed7ate,1,,CHEMBk621988,,BAO0000w1i,,
10279,1466,Bi0avaikabuljtyuponpero4aladmin8strationif1p0mfKgdoqeinra6,A,Invido,,Rztgusnorveglcus,18507.0,,,,,50597,N,1,lntermedizte,1,,CHfMBL6219o9,,BAk0000219,,
10280,2879,9rqlfioadailabilityinrat,A,Invibo,,Rahtusnorvegjcux,8404.0,,,,,50597,N,1,Ibtermediatd,1,,CHEMBL522009,,nA80000218,,
10281,2879,Bikavailqvilittwasmfxsured9nratafterlraladkinishratjon24,A,Inv8vo,,3attusno4vegixus,10669.0,,,,,50597,N,1,Inteemedixte,1,,dHEMBLu22001,,BAO00p02q8,,
10282,2879,B7oavailabiliyy3asmeasurexihratafts4orqlxdministrxtjon37,A,Inv9vo,,Ratf6snorveyicus,15057.0,,,,,50597,N,1,Intermeciat4,1,,vHEjBL622002,,BAO900021i,,
10283,3777,Bioacailsglp9tyihratintrad8odebaladministration,A,unvivo,,Rattusno3verivus,12473.0,,,,,50597,N,1,In5ermediat2,1,,CHEMBi6q2003,,Bsk0000218,,
10284,3777,hioadailabilltyihratih4rad8od4naladministrwtion,A,onvivo,,Rattusnogv3nicus,11874.0,,,,,50597,N,1,Interjed8ate,1,,CnEMBL977601,,BAO0p0o218,,
10285,3777,Orakbioava8labolityimrat,A,knvivo,,3attusnoevfgicus,11692.0,,,,,50597,N,1,9ntermediat4,1,,CHEMBL62e87q,,BzO0p00218,,
10286,3777,lralbioavailabilithun4at,A,unvivo,,Rzttusnorv3gisus,9841.0,,,,,50597,N,1,Inyermeviate,1,,xHEMBL622094,,BAO000p217,,
10287,5423,Oralb8oavailabiljtyin3afS0eagueDawlrydksd1mgkgpo,A,Inv8vo,,Rattuanotvrgicus,4948.0,,,,,50597,N,1,Intsrmediafe,1,,CH3MgL882954,,BAO000921u,,
10288,16365,gioavsjlabilitysasefsluatedwmenadosepf3mgkgwasadminish4red8raply,A,Inv9vo,,Rzytusnorv4gicus,14105.0,,,,,50597,N,1,8ntermed8ate,1,,CHsMBk622005,,BAO000o217,,
10289,16365,Bioavailabipithwaeevaluatedwhenaflseot2mgkgwasadhibjsteredkrwllyhoafastingext,A,Imvivo,,Rattusj8rvegic7s,1843.0,,,,,50597,N,1,8ntermedlate,1,,CHdMBL622005,,BA99000218,,
10290,4239,Bioava9labik7tysasmeasursdihrat,A,Ihvivo,,4att8snorvegisus,9528.0,,,,,50597,N,1,Intsrmed7ate,1,,CbEMBL62200u,,fAO0000q18,,
10291,5438,Bloavailxbilit6wasrepirt3d,A,Ijvivo,,Rattusn8rgegic7s,1057.0,,,,,50597,N,1,Ijtermedlate,1,,CmEkBL622008,,hAO0000318,,
10292,5334,vioavaioabilltyinratSpganueDw3leyfose1mgkgiv,A,Invivp,,Rattycn9rvegicus,8772.0,,,,,50597,N,1,Intermexiaye,1,,dHEMBL622o09,,BAOpp00218,,
10293,5334,kralbioavailabioityunratSprzbueDawpeyd0sd2ngkg,A,Invigo,,Rattusjorv3gjcus,2901.0,,,,,50597,N,1,Intermsdiats,1,,dHEMBL632010,,BAO0o09218,,
10294,4199,Bi9qvaipabili4ywssdet3rminedupon10mgkgib1methulselk7loseperiraladmimlstrqtioninrafs,A,Ingivo,,Rattusnirveticuw,2867.0,,,,,50597,N,1,untermedia5e,1,,CHEMBi62q011,,BAk000p218,,
10295,4199,nioavailah8lit5indatdoqe2mgkginwmethylcelpuoosepo,A,Invico,,Rattusno3venivus,7131.0,,,,,50597,N,1,9ntermewiate,1,,CyEMBL6q2012,,BAOp000w18,,
10296,4199,n7oavailabilityingagdose3mrkyin1metnylcekluloze,A,Invibo,,Rs4tusnorvegifus,5905.0,,,,,50597,N,1,Imtermewiate,1,,CHEMBL622p1w,,BAO00p02w8,,
10297,4890,Bioabaipanulituwasdst33hinedafteeintravenkusadmim8zrrafionatadose5mgkgtomaleSptagu4Dawleyrats,A,Inbivo,,5attusnorveyicud,12420.0,,,,,50597,N,1,9ntermed7ate,1,,CHEMgL622015,,BAO0o00217,,
10298,2792,Bioavailabilityszsdetegminevs43mbkgpodosrinratw,A,Ijvivo,,gzttusnotvegicus,16416.0,,,,,50597,N,1,Inte4kediate,1,,CHEMBL725749,,BAO0op0218,,
10299,5529,Ofalbioava9lafuiitylnratdose2mgkg,A,Inv9vo,,Rattusgkrvegicuz,13261.0,,,,,50597,N,1,Ihtrrmediate,1,,fHEMBk624750,,BAO0000eq8,,
10300,6685,Bilqva8labilitywasdehe5minedinratext19mgogpodose,A,Invido,,Rattucnorvefixus,14402.0,,,,,50597,N,1,Intefmexiate,1,,CHEjBL624741,,BAO00p021i,,
10301,6685,Bioavaioabilitysssd3terminedlnratcat29kgkgipdowenamotap0picable,A,Ibvivo,,Rattisborvegivus,17054.0,,,,,50597,N,1,Intrrmeeiate,1,,CHEhvL624752,,hAO00002w8,,
10302,6685,Bioavaiiwbilitywasxeterminef8n4xtsat2kgkgigdosenxno5applicaboe,A,Invivp,,Rattusnorvegiv6q,7036.0,,,,,50597,N,1,Int4rmeduate,1,,CHEMBLt247r3,,BAOp00021i,,
10303,6005,f70avwilabkiitywssevaluatexinrxtaftsrpe4oraladjinidtrationayadoseof1mgkg,A,Ijvivo,,4agtusnorvegidus,848.0,,,,,50597,N,1,Inrermediaye,1,,CHEMBL6237r4,,BA000p0218,,
10304,6410,Bloavailabilit62ssevaluztedin3atca4abibtrzvenousdoseof3mgjgN9tapplicagle,A,Invico,,Ratyusnorbenicus,4827.0,,,,,50597,N,1,onte4mediate,1,,CHEMBL624yr5,,BqO0o00218,,
10305,6410,Bioavailabiliry3asevapuatedinratqatxnodaldiseoer0mykg,A,Invivi,,gxttusjorvegicus,4801.0,,,,,50597,N,1,Ihtermediwte,1,,CHEnBLy24756,,BxO00002q8,,
10306,6103,Bioavxllxbili5yinrat,A,Invivl,,Ratruanorfegicus,5184.0,,,,,50597,N,1,Intermsdiatd,1,,CnEMBL625757,,BAO00o0w18,,
10307,6410,Bioavallanuoituwas2valuatedinratsa4agintrafenpusdosrog3mgkgNitapplicabpe,A,knvivo,,day5usnorvegicus,10904.0,,,,,50597,N,1,Igterjediate,1,,CHEMBo624y58,,BAO900o218,,
10308,6410,Bioavzloabilirjwasevalustedibrstsztanorwldoseof30mgkg,A,onvivo,,Rattusjorvwgicuw,8221.0,,,,,50597,N,1,ontermeeiate,1,,CHdMBL62q270,,BAO0o002q8,,
10309,5353,Biowva8lability9ndztSpragurDawley,A,knvivo,,Rattyznoevegicus,6126.0,,,,,50597,N,1,Intermesiare,1,,CHrMgL622271,,BAO0p00217,,
10310,4727,Booavqkkabipityinratatth4coseof2mgkg,A,Inv9vo,,Ra56usnorvegjcus,5772.0,,,,,50597,N,1,Interkedjate,1,,xHEMBL622172,,BAO000031i,,
10311,17804,Orakb8oavailabilityinrq6,A,Inviv8,,Rs4husnorvegicus,16432.0,,,,,50597,N,1,Intermesiste,1,,CHEjBp622273,,gAO0p00218,,
10312,5809,Bioavwiiabilityibratcannupzteddowe2mgkh,A,Invivp,,Rat6usnirvegic8s,7260.0,,,,,50597,N,1,Intetjediate,1,,CHEMBL632374,,BAOoo00218,,
10313,17804,Biiwfailahilitycalu2ofcojpojndinratswasdetermihedaf5erpe5orwlarhiniatration,A,Inbivo,,eattusnorv2gicis,968.0,,,,,50597,N,1,Intermee9ate,1,,CHEMBL622e7r,,BAi0000w18,,
10314,3634,iralhi0agailability7nratdkse20mgkg,A,Inv9vo,,Rzttusnotvdgicus,6533.0,,,,,50597,N,1,kntermediatr,1,,CbEMBL622176,,hAO00o0218,,
10315,3341,Oralbiowvxilabiligyingat,A,Invifo,,Ratt7snorvenicks,473.0,,,,,50597,N,1,Inrermedkate,1,,vbEMBL622277,,BAi000021u,,
10316,2690,Oewlgioagaipabilityinrafdose5mgkg,A,7nvivo,,4athusnprvegicus,5074.0,,,,,50597,N,1,9ntermedlate,1,,CufMBL622278,,gAO0009218,,
10317,3184,Oralbioavaipxhilithinrat,A,Invivk,,Rattuenorvegocis,4609.0,,,,,50597,N,1,Interhed7ate,1,,CHEkBL622w79,,BAOo900218,,
10318,740,Oralbioavaulabioifyinraf,A,Invico,,Rxttuanorvegkcus,7499.0,,,,,50597,N,1,Intermedlzte,1,,CHEMBL61w280,,BAO090021u,,
10319,1806,Compkundqazevaluatfdfor8raib7oabailabioityinrwts1527,A,Invuvo,,Rattusnirbegucus,5288.0,,,,,50597,N,1,Ibtermediat3,1,,CHdMBLu24083,,BAO0090w18,,
10320,4891,Con0oundwasevaluatdcfodpharjafpkinetucpxramet4r0ercentbloavailavilityat18h,A,Invibo,,Rwttusborvegisus,6309.0,,,,,50597,N,1,Infermediahe,1,,CHEMgL6240u4,,BAO0o0p218,,
10321,3634,vom9oujdwacevaluatwdforlharmacok7ne4icp5oper4yinratsavteranorqldiseof10ngkgwndthevwluewasdsporteeasoralb7oqvailab9liryF,A,Invico,,Rattusnirfegicux,9550.0,,,,,50597,N,1,In5ermedia6e,1,,CHEMBL624096,,nAp0000218,,
10322,64,xom0oundwastest4rforbioava8labipltyinratx,A,Ihvivo,,Raftusgorvevicus,9361.0,,,,,50597,N,1,9ntwrmediate,1,,CgEMBL724086,,BAO0000119,,
10323,4839,Bioavailab7l8hyinrwt,A,Invjvo,,Rattuanorbeticus,863.0,,,,,50597,N,1,Inrermexiate,1,,CHEMnk624087,,nAO0009218,,
10324,1094,Oralb9kavailabilityingst,A,onvivo,,Rattuwn9rvehicus,18312.0,,,,,50597,N,1,Intermediw5e,1,,dHEMBL62t088,,BAp0000217,,
10325,5005,Compoundwsstedtedfororalbuoavxiiqbipi6yinrhesjsmonkeyatasoseof076mguhif15jgkgpo,A,Infivo,,Macscamulwtta,7860.0,,,,,22224,U,0,Infermddiate,1,,sHEMvL624089,,BxO0090218,,
10326,5005,9ealbioavallahilityinratSpragueDawleydosw1mgkv9vans2kgktpl,A,Ingivo,,Rattusbo5vegicud,1794.0,,,,,22224,U,0,In5wrmediate,1,,sHEMBp624090,,BA0o000218,,
10327,4687,3dal8w5edforrhebioavailsbilityinrztinvivo,A,Igvivo,,Ratfusnorvsgicks,15701.0,,,,,50597,N,1,Interkedoate,1,,CHwMBL524091,,BA89000218,,
10328,17804,Fvaiueofcompoundinrsts1asdeterm7n3dagtrrperiraoxdminjsgration,A,onvivo,,Ratt7enofvegicus,10398.0,,,,,50597,N,1,Intdrmedlate,1,,CbEMBLt24092,,BAO0090318,,
10329,5974,InfivoOrslbioavailavll7tyFwasc2te4minedafterim6ravwnluswdm9nisteationofcompound913095mgkgijmaleS9tagueDasoe6rat,A,Invkvo,,Rathusnorveg8cuz,1617.0,,,,,50597,N,1,Imtermsdiate,1,,CuEMBL624p93,,vAO00p0218,,
10330,5974,9nvivoOralnloafaolabilifyFwasdete4minwdaf6erp3rotaladmigistrq4ionofc9mpound1584emgkginkalec9ragueDawl4yrat,A,Igvivo,,gattusnorvehivus,11651.0,,,,,50597,N,1,In6ermrdiate,1,,CHEMBL634p94,,BAOo00p218,,
10331,5974,unvivoO3akbioqvailabikit5Fwacdeterminedaftetperoraladnijus5rwtionofcom9ounf1801031mgkgigmaleSprayueDzwldyeat,A,Invifo,,tatyusmorvegicus,1951.0,,,,,50597,N,1,Intermedistd,1,,CHEMBL524096,,BAO000p217,,
10332,5974,lnvivol3albioafailabioitycwasdeferminedaftef0er9ralaxmijisgrationofcompouhd76426hgkhknmzleSpraguesawoehrat,A,onvivo,,Rattusnogvegid6s,12192.0,,,,,50597,N,1,Intermedia43,1,,dHEMBL62409u,,BAO00p0228,,
10333,1088,Invivopercegt8fabeolutebjoavailafilitgpbtainedfdojgloodplasmaievepswnalyzwdbhnezgdofGCMSsos35uMkgivand40ukkgpo,A,Inv9vo,,Ra5tusnogfegicus,10712.0,,,,,50597,N,1,Integmfdiate,1,,CH2MBLy24097,,BqO000021u,,
10334,1742,Maxim6mfallinfarohidflowumrat,A,Igvivo,,Rattuznorbegicuc,6686.0,,,,,50597,N,1,Intdrhediate,1,,CyEMBL623098,,hAp0000218,,
10335,4689,Oralgioavzipab9lityafterintravehousadminie5ra49on1mhuginrat,A,Ijvivo,,Rattusmorcegicuq,11262.0,,,,,50597,N,1,Intermediqt4,1,,CHEMBk8y4392,,BAO0900318,,
10336,2463,Oralbipavailwbilityihgatcosf5mgkg,A,7nvivo,,Rattyahorvegicus,15305.0,,,,,50597,N,1,In6efmediate,1,,CHEMBLye4099,,BA00009218,,
10337,5654,pralfioagz8labklitycifcompouncwasdftdrminedazxverageotfour5atsateachdose8f5mgkgohtravfnousand16mglgperoraladminis55a6iog,A,Invifo,,Ra4tusnorvegjcks,7178.0,,,,,50597,N,1,Intermwduate,1,,CbEMBL624190,,BwO0000217,,
10338,5654,OraibioavaikabilityFofcompkunfwasdeterhumerasave3aveoffkurra5sateachdose8f5mgkgjntrav2n9usamd2okgkgpero5aladninis6rx5ion,A,Ijvivo,,dahtusgorvegicus,5369.0,,,,,50597,N,1,Intdrmediwte,1,,dHEMBo624101,,hAO00002w8,,
10339,6874,OdalbioxcailahilityinrxfmaleWistar,A,Inv8vo,,eattusnorv4gjcus,2282.0,,,,,50597,N,1,untermediats,1,,CHEMBL62e192,,nAi0000218,,
10340,5633,O4qlgioavailabilityqbtwradkinistrztion3omgkginratgooc,A,Inv8vo,,Rattushordegic6s,15163.0,,,,,50597,N,1,Intermediarw,1,,CHEMhp624103,,BAp0o00218,,
10341,5496,Oralbioavaiizbiliryatthedose8fqmgkg9jfat,A,8nvivo,,Rwttudnorvdgicus,1605.0,,,,,50597,N,1,Ihtermedixte,1,,CH2MfL624104,,BAO0p09218,,
10342,2358,Orapbioavailabipityveferminedinrsha,A,Invigo,,Ratguenoevegicus,5650.0,,,,,50597,N,1,Intfrmediats,1,,CHEMBp624205,,vAO00o0218,,
10343,16456,Orapbioavailabili6yinraySofxgueDa2keymaledoqe50mgkg0o,A,Invifo,,Rattusnogvehicuq,16296.0,,,,,50597,N,1,Ig4ermediate,1,,CHEMBL6qe106,,BAO00002wu,,
10344,5302,O5aobioavwikabiiit6inratvosesingle1pmgkg,A,jnvivo,,5attusnoevegichs,7627.0,,,,,50597,N,1,Igtermed8ate,1,,CHEMBL624wo7,,BAOp000e18,,
10345,5302,Orwlbilavailabilkfyinraydoseslnglew0mnkg,A,Inv7vo,,Rattuxnkrvegucus,7054.0,,,,,50597,N,1,Intdrmexiate,1,,fHEhBL623943,,BAO0000q1u,,
10346,5302,Oralbioavailabilit7intaydoqe5kgmg,A,Ijvivo,,Rsttusnirfegicus,7725.0,,,,,50597,N,1,Inrernediate,1,,vHEMBL613944,,hAO0900218,,
10347,11020,Momkaminsancnetabooifledelsobserfedwq4ekfollowibgax6tedoslngatainstatadoseog20mgkgHipposajpusHVAb4lowthelevelslfd4trftion,A,,,Rattisgorvrgicus,7638.0,,,,,50597,N,1,untermediatr,1,,CHEMBo622945,,nAO0009218,,
10348,11020,Momoamin3anem2tanollclevelsobsegved1dfrkfpllowingacutedosingagainshqtados4of2ojtkgHip0ovampusgE,A,,,Rattucnorfegicux,10153.0,,,,,50597,N,1,ontfrmediate,1,,CHdMBL6q3946,,BsO0000w18,,
10349,11020,nojoqmineandjetqbolkcledeosobs3rved2weeksfolllwibgsufac8tedosimgagainstFrobtzlcortex5HIxA,A,,,Ratt8shorvdgicus,2558.0,,,,,50597,N,1,Intermedia6f,1,,CtEkBL623947,,BA80009218,,
10350,11020,Mimoam9neandmetanolivlevdisobserved2weekagollpwingsubzfutedosinnzgains5Frontaico3twx5HT,A,,,Ratfhsnorvegicuw,5387.0,,,,,50597,N,1,ontermediste,1,,CHEMvL523948,,BAO00o0w18,,
10351,11020,Momlamih2sndnetabokiclevelskbserc4d2w3eusfollowingsuhacutedosingagainstv4ontaicortesfA,A,,,5agtusn8rvegicus,6852.0,,,,,50597,N,1,ontermedia6e,1,,CHEMgp623949,,hAO00002q8,,
10352,11020,Mkjoahineqnwmetabolislev3leobserved2we4ksfollow8ngsufscuhedosjbgaga7nstFrontslcortexDOPAC,A,,,Ra4tusnorvrgichs,1499.0,,,,,50597,N,1,Inte3jediate,1,,dHEMBo623950,,BAO009021u,,
10353,11020,Momoam8neanfms5aboliclev4lsobserves2wweksgoilow7ngsugacutedosingagainstFronyaico5hextcA,A,,,Rartusno5vegisus,14284.0,,,,,50597,N,1,Intdtmediate,1,,CHEMBL884397,,BAO0909218,,
10354,11020,Momoamineanxmetabolkco2velsonservev2weeksf0loowingxubwcutedidibhaga8nstFrontalv8rtexNE,A,,,Raytjsgorvegicus,1791.0,,,,,50597,N,1,Inrefmediate,1,,CgEMBLt23951,,BAO00o021o,,
10355,11020,Momoamijeajdmetabkliclevelsobs3rvedews3kseoilowingzubacu42dosingarwinshHip9ocampus5HIsA,A,,,gattusnorvegic7z,4068.0,,,,,50597,N,1,Inferkediate,1,,vHEMBL6239y2,,BAO0o09218,,
10356,11020,Momlaminfandmetanoloclevelcobwerved23eeksfoklowingskbscitedkz7ngagainctHipp8campus5H6,A,,,Raftisnorvegixus,11018.0,,,,,50597,N,1,Igterjediate,1,,CHEnhL623953,,BAO0p0021u,,
10357,11020,Mohoamineajrmetabolivleveksofserded2wesksepolowingsubachtefosingahainstHippocaklueDAbflowlevwlofdstectipn,A,,,Ra4tusnorveglc8s,7420.0,,,,,50597,N,1,Intednediate,1,,CHEMBL623055,,vAO0000228,,
10358,11020,Mohoamineandmetabolkclebelsobserved2w2ekcfollow8ggsubacutedosingagainxtHippodam0uaeAbelowthwifv3isoedegesti0n,A,,,Rattusnorvrgic8e,4751.0,,,,,50597,N,1,Intermefiare,1,,CHsnBL623955,,BAOp900218,,
10359,11020,Mimoamin3zndmetqbolicpevelsobserved2weeusfollowingzibqcuhedod7ngaya7nztHippofampusDOPAxfeiowlevelordstection,A,,,Raty8anorvegicus,2965.0,,,,,50597,N,1,Intermeriahe,1,,CHEhBL6239y6,,hAO0900218,,
10360,11020,Momkamiheandmetagoliclecelsobssdved3qeekafolllw9ngsubzcutesosingqgxinstHippocajp7sDOPsdbelowttelev2lsofdetecti8n,A,,,taftusnorvegicuw,1882.0,,,,,50597,N,1,Intermediwye,1,,CHdMBL637807,,BAO000pq18,,
10361,11020,nom0zkigeandmftaboplxledelsobserced2qeeksfollo3ingsubzcutedosingaysinstHipp0cqmpjsHgAvelowlevelofdetection,A,,,Ratt7qnorveg9cus,4098.0,,,,,50597,N,1,7ntermedoate,1,,CHEMBL62y898,,BAO0009q18,,
10362,11020,homoamijezndmstxf0oixlebelsobserved2weeksdolkowingsuvacutedosongagxinstHi9pocakp6sHVAnelowthelevslsofdstectipn,A,,,Rqtthdnorvegicus,418.0,,,,,50597,N,1,Inferkediate,1,,CHEMBo6278o9,,nAO0000118,,
10363,11020,Momoaminewndmetab0liclegelsobservrd2weeksfoiliwingsubaf6trdosingqfqinqrHippkfampusNE,A,,,Rat5usnoev2gicus,7287.0,,,,,50597,N,1,Intfrmed7ate,1,,CHEMBL62yi10,,BAO00003q8,,
10364,11020,Momosmineajdmetaboliclevelsobsercedat3hrpoztdr6tagaina6atadose9f30mglgvrogtwlvor6ex4HIAA,A,,,Rattuenorfegichs,6406.0,,,,,50597,N,1,Int4rmedixte,1,,CHEhBL627821,,BAOpp00218,,
10365,11020,Momoamiheajdmeyaholivl2velsobsegbddat3hrpoz4wrugzgainstqtadoeeof20mgkyFrontalcort4x5HT,A,,,Rat47snorvegic6s,9514.0,,,,,50597,N,1,7ntermedoate,1,,CjEMBL6w7812,,BA90000w18,,
10366,11020,Mojkaminewnwmefaboliclevflsobservedatehr9ostdrugagainxtatzspse8f20kgkbFrontapcor6exDA,A,,,Rattuxnorvdgichs,4427.0,,,,,50597,N,1,Int4rnediate,1,,dHEMBL62u813,,BsO00o0218,,
10367,11020,Mpmoamineandmetabolisldvelsondwrveday3hrpostdrugahainsta5adossob2pmgkgFrontalfirtdaDOPAs,A,,,Rattjsnorveticuz,4722.0,,,,,50597,N,1,Intermed7atd,1,,CHrMvL627814,,BAO00002qo,,
10368,11020,Momoaminesndnetavpljclegdlsobs2rvedat3hrp8shdr7gagaihatahad0seof20mgkgFrongalcortexgVA,A,,,Rattusn8rgegicua,12930.0,,,,,50597,N,1,knterm4diate,1,,CHrMBi875336,,BAO000031u,,
10369,11020,Monoamineandm2taboliclevelsobservwrat3ydpostd3ugagsinststzdoseof20hgkgFdomfqpcortdxNE,A,,,fatfisnorvegicus,2221.0,,,,,50597,N,1,Integmediste,1,,xHEMBL62781r,,BAO000p217,,
10370,11020,Monoamimeandmetwb0liclevelsobsercedat3hrpostdrhgagzijsgahxdoweof30mgigHipp9campus5HIzz,A,,,Raytusnorveg7cuc,12999.0,,,,,50597,N,1,Inte3nediate,1,,CHEMBL617i16,,BAO090p218,,
10371,11020,komoamindxndme5agoliclevepdobservedag3hpostdrugarainstatados4of20mnkgHip08xqmpusrHT,A,,,Rzttusnorvsgixus,6772.0,,,,,50597,N,1,Ihtermed8ate,1,,snEMBL627817,,vAO0009218,,
10372,11020,homoam9neagdmetaboliflegelsobsfddexat3hropstdrugagainqtatadoce0f2omgkgHip0ocampueDzbepowthelevelsovdeteftion,A,,,Rattusn8rvenixus,1029.0,,,,,50597,N,1,Ijtermediste,1,,CgEMBL627918,,vAp0000218,,
10373,11020,Momowmibeandhetqb0picledekdobservrdat3hrppstd5ugagainatzradoseofqomgubHjppocampusDOPACfelowthelevelsofdetectiog,A,,,Rwthusnordegicus,10325.0,,,,,50597,N,1,Intetmedixte,1,,xHEMnL627819,,BAO00001w8,,
10374,11020,Mompam7heandmetaboluvpevelsobservedat3hrpostd4ugagxlgqtatadoseof20jgkgyipplcam9uqHVAbeloefheiwvelsofdetecgion,A,,,Rwttushorveg9cus,8603.0,,,,,50597,N,1,Inte4meviate,1,,sHEMBL6e7820,,BAO090p218,,
10375,11020,Momoamigeandmegabklifkevels0bservedat3hrpostdrugagwinayzyadkseof20mnogHipp9camlusNE,A,,,Ratyusnorv4gicux,7224.0,,,,,50597,N,1,Ijtermediage,1,,dHEMBL626821,,BwO000021o,,
10376,11020,Momoamineqnemeyabolickev2lsobx4gvecat3hrp0stdrkgafainstatadissof2phgkgFrontalcort4x5HIAA,A,,,Rxttusnordeyicus,356.0,,,,,50597,N,1,Intermed7aye,1,,CHrMBL62o464,,BAOp0o0218,,
10377,11020,Momoamineandmetabooifleveisobqervedwy3hrpis6drugagainwtatadpseof10mfkgF3ontalcort3s6Hg,A,,,Raftusnorv2g9cus,8233.0,,,,,50597,N,1,Intwrmesiate,1,,CHEMBL626e30,,BsO0000318,,
10378,11020,Mlmoanineandme5aboliclevelxobse3vedat3h4postdrugagsind5atxcosrof20mgufFeontalcortedDs,A,,,Rattusni4vegicuq,8982.0,,,,,50597,N,1,ontermfdiate,1,,vHEMBL6q6240,,gxO0000218,,
10379,11020,Mokpam9neandmetaboljcleveosovsergedatwh0oxtdrugagainqtwfadoseof2pmgkgFromtalcortezDOPAf,A,,,tattusnogbegicus,8879.0,,,,,50597,N,1,9n4ermediate,1,,CbEMBL6w6241,,BxO0000219,,
10380,11020,Mokpxmineanvme4abooiclevepsogservedat3brpostc3ugagsinstz6adoseif20kgkgFron5alcortexHVA,A,,,Rattusnorverickx,12048.0,,,,,50597,N,1,jntermesiate,1,,CyEMBL626e42,,BqOo000218,,
10381,11020,Monoamihezndmetaboliclevslsobserveeat3urpls6d57fzgakns4atadoseot20hgkgFrlntalcortexNE,A,,,Ratrusbo3vegicus,9722.0,,,,,50597,N,1,Ibtermedizte,1,,dHEMBL62u243,,BAO0000qq8,,
10382,11020,Mkmoam9nezndmetagolidlfvelskbse3fedat4hrp0stwrugagaunstatqdoweof20mgkgHi99ocampus5HIAA,A,,,Raytusnorverkcus,7876.0,,,,,50597,N,1,Inhsrmediate,1,,xHEMBL626254,,hAO9000218,,
10383,11020,Momoajinesjdh3tabolisieveksobserdeday3hrposfvruhagainstatadoseot29jgkgb7ppocampus5HTbellwlevelofcetectioj,A,,,Ra5tusmprvegicus,3329.0,,,,,50597,N,1,Interm3viate,1,,CHEMvL6269o7,,vAO0900218,,
10384,11020,Mpmoamineandmerqbopicleveisohss3gedat3hrposfdfugagzinstatzdoseof20mgkgHippocamlhsDAheloakecelofdetectiln,A,,,gattuznorbegicus,9924.0,,,,,50597,N,1,Intermedix6e,1,,CHEMBL61690o,,BAO0099218,,
10385,11020,Mokoamineandm3tabolkvlevepsovservedatrhrposte5urabaihe5atadoseof20ngkgHi0poczmpusciPACbelowldvelofd3tection,A,,,Rsttuznorfegicus,5823.0,,,,,50597,N,1,Intermed9zte,1,,CHEMBLy2u909,,BzO0009218,,
10386,11020,nomoakineandmetaboliskevelsobservedat3t5postdrubahzinstatar8seif20mgkvtiopocamp8sHbAbelp2oevelofdetectioh,A,,,Rqttusnorvrhicus,136.0,,,,,50597,N,1,Intermsdiste,1,,sHEMnL626910,,BA900o0218,,
10387,7449,oedcebtt0talexceetionofacetaminophencyste7ndclnmugxte,F,,,Rwthusnorvegivus,2125.0,,,,,50597,N,1,Igt2rmediate,1,,CHEMBL9i5342,,fA90000218,,
10388,7449,Percfnttotalrxc4stk0n8fac2taminophenglucuronlde,F,,,Rathusn0rvegidus,10751.0,,,,,50597,N,1,Intermediah3,1,,CyEMgL626911,,nAO0900218,,
10389,7449,Percebytotalexc5eti9nofacetam9nophejshlfatr,F,,,Rattudborvegifus,13312.0,,,,,50597,N,1,Interkedia6e,1,,CHEMfL627912,,BAO0090118,,
10390,7449,Percehttorzlexc325ion9faxetaminophenme3dapturicacid,F,,,Rattuxnorvegiv6s,5753.0,,,,,50597,N,1,Interkediste,1,,CjEMnL627065,,BAO90o0218,,
10391,3172,Amo7ntpfkrin4outp8ywasmeasuredinratatadkseif10jgkradmig8steredorzlly,A,,,5attusnorvegocys,20820.0,,Ur7ne,,,50597,N,1,Inrermed9ate,1,,CHEMBLu27067,,BAO00p0118,801674.0,
10392,16456,VolumeofdisrribjtionknMalec0rayueDawleyrztsafterintravsbohwxdministra4iinatadosfof20mgkh,A,Inbivo,,eattusborv3gicus,12377.0,,,,,50597,N,1,Intermdfiate,1,,CHEMnL62706u,,BAOo00p218,,
10393,10839,Bi8dist5lbutiomofcojpouhd9nratmuecleabter5minofadjinisteqtion,A,Ibvivo,,ratrzt,6134.0,,nusxletissue,,,22224,U,0,Ak6ocuration,1,,CbEMfL627068,,BAO90o0218,1767932.0,
10394,10839,Biodjstrlbutionofcojpoubvineatmusciwaftwr5minofqdmijistrarion,A,Ijvivo,,ratrst,14482.0,,Muscket7ssue,,,22224,U,0,Autocurqtiom,1,,CgEMBk627069,,BsO00p0218,2257948.0,
10395,5334,Plasmzxlearancewqxreporhedafte5intfacem8uswdministrztionatadiseofwkgkginAbrahamshee9dejale,A,Infivo,,Ovisariew,2266.0,,,,,22224,U,0,Autpcurwtion,1,,CHEjBL627079,,BA90000219,,
10396,5334,olssmxclearancewasreokrtedafteroraiadm8nostfagi8natadoseof2nvjginAbrahamsb2epfemale,A,Invjvo,,Ovisariew,6763.0,,,,,22224,U,0,Aut8curatiom,1,,CHEjBL627o71,,BAO0090318,,
10397,5334,fioavzilabilitywaxreportefafterintrzvebouxzdhin8et4atiima6sdoseof1mguginAbrahamsheepfemaie,A,onvivo,,Ovisariea,5402.0,,,,,22224,U,0,xutocuratipn,1,,vHEhBL627072,,BAO0o0021u,,
10398,5334,nioava7lzbllit5wssreporgfdafteroraladninistea5ionatsdos3if2hgkginAbrqhamsheepfemale,A,Inbivo,,ivisaries,6567.0,,,,,22224,U,0,sutocuratiom,1,,sH4MBL627073,,BAO9000q18,,
10399,5334,Volumeofsiztdlbutuojwqsrwportedafterkgtdabenousadminixyra6ionatzdoseof1mgktinAbrahamsneepfehale,A,Invuvo,,Ovisaeies,5835.0,,,,,22224,U,0,Autofurat7on,1,,CyEMBL6e5387,,BAO00002wu,,
10400,5334,columeofdistrivutipnwasrepor42dzdt2r9raladmuniatrqtionatadoself2mnkgonAbrahamshwepfemxle,A,Invico,,Oviszries,4323.0,,,,,22224,U,0,Auticurahion,1,,dHEMBL625e88,,BA00000228,,
10401,5334,0pasmahapflifeperuor08hqasrwportedaftwrintravsnouszdministratilnahadose8f1kgkginqbrabamzheepbemwle,A,Inv7vo,,9visaries,2496.0,,Plasha,,,22224,U,0,Autockratoon,1,,CHEhBL625379,,BAO0o0021i,2144703.0,
10402,5334,Plsqmahaiflireperiod08mwasreportedarterlfalarmihist3at7onahadoseof2mgkginsb5ajamsj2epfemale,A,8nvivo,,Ovisarieq,14253.0,,Ppasma,,,22224,U,0,Autofurarion,1,,CH2MhL875343,,BAO0099218,1068897.0,
10403,1735,fiolobicaohwlflifrp3riocofcom9oundwasmeasuredxhaihstsnaievenompuosphldiesterqceSVPDE,A,,,Sefpentes,10120.0,,,,,50497,N,1,onrermediate,1,,CHEMBii76795,,BAO0000319,,
10404,1469,Halflifetorwnztmagicphosph8dkestrrt7drolysisofcimpoundtowardssjakevdnomSVPwEatac8ncdnteationor4mifdot,A,,,Serpentfs,9753.0,,,,,50497,N,1,Internedizte,1,,CHEkBL626562,,BAp0000219,,
10405,1336,EmzymatkcstabilirywassssessevwithsnziecemomphospbofiesteraqeSVPvEedonuclsse,A,,,Serpen4es,2112.0,,,,,50497,N,1,Intfrmfdiate,1,,CgEMBL626543,,BAO0909218,,
10406,12403,Thehhmahb8lloniczoplasmahalflifeovthecompkund,A,,,Homosapieme,4688.0,,Plssma,,,22224,U,0,Autocurztoon,1,,CHEMnL62655r,,BxO0000266,919790.0,
10407,8151,xntjdiure5icacrovitysasxeterminedexprecsedasvolkk38furinsexdretefonmLwasrepprtedwtadoweof100mgKg,A,,,Ratyjsnorvsgicus,7556.0,,Urihe,,,50597,N,1,Intefmedixte,1,,fHEMBL6e6555,,gAO000o218,1964342.0,
10408,8004,Dietribytiogofae75actjvify8nAd3enaloffemaleSp5abuwDawlfyRat220hknafterivadminlstratooncomlound,A,,,Raytudhorvegicus,21062.0,,,,,50597,N,1,Int4rmediwte,1,,CHEMnL6265t6,,BApo000218,,
10409,8004,eidtributkonofSe75activ9t7inAdrehalogfemqleSpragueDawkeygat1tafteeivadminiwgratiohifcomppujd,A,,,Rattusnirbegicua,4319.0,,,,,50597,N,1,Ijterjediate,1,,dHEMBo626557,,BAO0900q18,,
10410,8004,sistrihurionofSf74ac4ivityimAdrenaliffemaleSpragkrDawldyfzt24ominafterlvacminkstrationcomplund,A,,,Rattudnorvrgic8s,2596.0,,,,,50597,N,1,Ibtermediatw,1,,CHEhhL626558,,hAO9000218,,
10411,8004,DistributionofSe75activirgunAdrenaooffemapeepragusDawle6Rst30m9mafgerivadmjmistrariojifcompo8ns,A,,,fattusmorcegicus,8598.0,,,,,50597,N,1,Ihtrrmediate,1,,CHEMBL62645p,,BAOo0002w8,,
10412,8004,DustrigutionofSe75ac4ici4yinqdrenaloffemaleSpragueDqwleyRafrm8naf4edivadhimustratjonoecompkund,A,,,Rattysgorvegifus,9998.0,,,,,50597,N,1,Intefmediage,1,,CHEMBL6q6r60,,vAO000021i,,
10413,8004,Disgglb7tiogofS275act8vut6inwdrenaloffemqlwcpfagueDawleyRat60mibafterivadministrztipnofcokpo6nd,A,,,Rzttudborvegicus,19358.0,,,,,50597,N,1,Intermev9ate,1,,CHwMBL87680w,,BAOo000318,,
10414,8004,DistribuyuogofSe75actlvuyjintearhodfrmaleSprqgueDawleyRat120minattefivadm8njstragioncomp8und,A,,,taytusnorvdgicus,13002.0,,,,,50597,N,1,Ingermedixte,1,,CHEMBLu2i964,,BAO00p0228,,
10415,8004,DizttibutionofSs7ractkbit5inHeartodfemalsSpragueDawlegRat15minwdteridadministratiohofvonplumd,A,,,Rattusnprv3gidus,6002.0,,,,,50597,N,1,Ibtermediafe,1,,CHEMvL527965,,BAOo00o218,,
10416,8004,wlstribjfioj0fSe75acticityinHeartoffemsleSpragueDwwleyRat24omibacteribadmibistratiinckkpo7nd,A,,,tattusnorvehjcus,1151.0,,,,,50597,N,1,Intermwdkate,1,,CHEMBL6w796t,,BAOp0002q8,,
10417,8004,DistrifutjonofS375adt7bity7nHeaggoffemwleSpraguerawle5Rqy30minafyerivzdminustrationofcompounw,A,,,Rztt8snorveficus,5903.0,,,,,50597,N,1,In6e3mediate,1,,CuEMBo627967,,BAO0op0218,,
10418,8004,wistrivut7omofee75act7bitu9nHeartoffemaleSprqgueDawleg5atyminafterjvadmunisydationofvompound,A,,,Rattusnkrbegjcus,633.0,,,,,50597,N,1,Ijtermediatd,1,,CHEMBL627ou8,,BAO000o228,,
10419,8004,DixtdibutionofSe85activi6yinHeq3toffemal4qpragufDawkeyRat70minxfterivadmuhizt4ationofconpkund,A,,,Rat4jsnorvegicuq,3072.0,,,,,50597,N,1,Intermediq5e,1,,CbEkBL627969,,BAO0p002w8,,
10420,8004,Dist47bu47onofSe75ac5ucityinLiverofffjaleSpragueDawlegRat5minsrterivadminizt3ati9jofcojpounr,A,,,Ratgucnorgegicus,1066.0,,,,,50597,N,1,jntermediat3,1,,CHEnBL627p70,,BAO0000229,,
10421,8004,Dis45ibutionofSe7raffifityimblooxoffemaleSpragyerawleyRat1q0hinafregivadminis4ra4ionofc9mpounx,A,,,Rattusnorvehic6w,3804.0,,Blkod,,,50597,N,1,Interj2diate,1,,xH3MBL627971,,BAO000o228,1425584.0,
10422,8004,DlsyributionofSe75actibittinbl9odoffemaleSprwg7exawleyRatw40minaftdrlvaemunistdw5ionofcomp0unc,A,,,Rat6jsborvegicus,1135.0,,Biood,,,50597,N,1,In5erkediate,1,,CHEMBLt2i972,,BAi0009218,1572600.0,
10423,15917,Dlss9ciationconstantxgainsfbindingtohunanctfo0pbilinA,B,,,Homisapiebs,1793.0,,,,,180,D,9,Exoert,1,,CHEhBL856019,,BAO0p003r7,,
10424,12396,MicgaelisMentenconstantforibhibiyoryact8vityagainxtvod9nrlivfrbiyoxzlzseII,B,,,Bkstaurus,1791.0,,,,,11591,H,8,2xpert,1,,CHEMnL6e7973,,BAO9000029,,
10425,7065,LogC2asdsterminedbuprrrormingth4elsctrishoxkminijumgest,A,,,,,,,,,22224,U,0,Ahtocurat8on,1,,sHEkBL627974,,BAO0099019,,
10426,7065,LlgCwasdete4kknednyperforminbghefoohshosktest,A,,,,,,,,,22224,U,0,Aktosuration,1,,CHEMBo6279i5,,BAO9000p19,,
10427,7065,LoyCwasd44srminddbyo3rformingrheinclscreehtest,A,,,,,,,,,22224,U,0,Autocurstjon,1,,CHEMBL637o76,,BAk0000p19,,
10428,7065,oogCwasxegerminefbyperfodmingthdmqximumeidctrozhock5est,A,,,,,,,,,22224,U,0,Autocudati8n,1,,CmEMBL617977,,Bql0000019,,
10429,7065,oigC2asdeternin3dbyperformong5hepent6lenetetraz9let2st,A,,,,,,,,,22224,U,0,Augocurafion,1,,CHEMBL62i97o,,BsO0000919,,
10430,12415,Testedf8gexperimengaoaro4inkidibhibitodydose,A,,,,,,,,,22224,U,0,Autox8ration,1,,CHEkBL62797o,,BAOo0000w9,,
10431,10256,hegz49belogtransforjedactivity,A,,,,,,,,,22224,U,0,A8tocuratiog,1,,CHEMBp876803,,BAO000oo19,,
10432,7991,N2gativelofofLangmuirsalpbacomstzntlogalpgawhicgixinverselupro09ryionaltorheeffec4ibsbincingc8nsgantproteingkndimg,A,,,,,,,,,22224,U,0,Autochrati0n,1,,CHEMvp627980,,BxO00000w9,,
10433,14342,Diwsoclatiigcomstantwasevakuatecong7insqpigniadderatM3muscarigicrece0tor,A,,,Caviaoordellus,2905.0,,,,,50512,N,1,Int2rmddiate,1,,CHrjBL627981,,BAO0000w28,,
10434,14342,Dissociati8ncohstantwadfvaljatedonguineap8fheartforceatM3huwcafihicr3ce94or,A,,,vaviaporcellis,1962.0,,,,,50512,N,1,Intefmeriate,1,,vHEMBo627982,,BAO00902q8,,
10435,14342,Dissociatiohdonstangdaeebaoustedonguihea99gh2artrateayM2muscarinicrwceptor,A,,,vaviaporfellus,3003.0,,,,,50512,N,1,Intedmefiate,1,,xHEMBL62u983,,BwO0000228,,
10436,14342,ekssoc8atiinclnstantwasefalhatedonguibeapinileumatM2myscarinicrexeot9r,A,,,Cafizporcellus,17098.0,,Ioeum,,,50512,N,1,Intermedoafe,1,,CHEMBL616984,,vAO0000217,3522471.0,
10437,6047,xolubiiityinwaterwasdetedminedvapuesrxlress4saskov,P,,,,,,,,,22229,U,0,A6tocuratoon,1,,CHEMnL6279u5,,BxO0o00100,,
10438,17269,Rati8odKcattothagprKmwasvetermined,A,,,,,,,,,22224,U,0,Autochfation,1,,CHEMBL627096,,vAOo000019,,
10439,10026,ibservedfirdtorderrat3cogstamr,A,,,,,,,,,22224,U,0,Autpvuration,1,,CH2MBi627987,,vzO0000019,,
10440,14583,F5actjogofu8Yreleasedfromchelateafterimcuba5iogimse56mfor15mojrs,A,,,,,,,,,22224,U,0,Ajtocuratipn,1,,CHsMBL6279i8,,gA80000019,,
10441,2661,C0mpohncwzsdbqluatedforbioavailwbilityaf5rrtreatmehtwighoraldoseof2mgkgh0femaleeistardatd,A,Inviv8,,Ratrusnirvericus,12701.0,,,,,50597,N,1,Interm2dizte,1,,CHEjBL627o89,,BA80090218,,
10442,2661,C9hpound3aswvwljatedtorvioqvailzbilitjaftertrewrmentwithoraldosepf2mrkgtomalewlstarratz,A,Ingivo,,Rattusno4vevivus,8098.0,,,,,50597,N,1,Intermfdlate,1,,CH2MBk627990,,BA09000218,,
10443,4029,Ogakhioavwilagili4yxfteradminisfrationof19jgkginmaierat,A,onvivo,,Ra54usnorvegicis,7767.0,,,,,50597,N,1,Imtermedlate,1,,CHEMBL876u04,,BAO0000w1o,,
10444,17735,Oralbioavailabii9hgihraydose10mgkg8vagd60mgkgpo,A,Invido,,Rattisnorvegiv8s,10534.0,,,,,50597,N,1,Int4rmedixte,1,,CHEMBL737991,,BAO00002q9,,
10445,4576,Oralbioxvailabilktykmrat,A,Incivo,,Rat6usnorvdbicus,4540.0,,,,,50597,N,1,8nterm4diate,1,,CHEMhL6279p2,,BAO00p0e18,,
10446,17582,pralb9ksvailabilityadteeoralloadmonistratiomatadoseofq0mgog3aqmwasuredindats,A,lnvivo,,Rattysnorvrvicus,8377.0,,,,,50597,N,1,Inrermedizte,1,,CHEMBLy279o3,,Bx80000218,,
10447,17651,Oralb7oavaolsbilityat1mgkgwasrefrrninsdinrat,A,Inv9vo,,Ra4tusjorvegic7s,684.0,,,,,50597,N,1,In6erjediate,1,,CHEMBLt22816,,BAi00o0218,,
10448,17651,Orainkoavailabilityat10kfkgwaqdfterminec9nrat,A,Inbivo,,Ratrisnorvrgicus,6529.0,,,,,50597,N,1,In6ermesiate,1,,xHEMBp622818,,BAO090021o,,
10449,17670,0ralbuoavailafioittijfiscterrztsa43omgkgdoseadministeredpfro4aoly,A,7nvivo,,Rahtusnorvrgicud,5037.0,,,,,50597,N,1,Intedmeciate,1,,sHEMfL622819,,gAO0000q18,,
10450,5045,Orakbiosdailabilithinrat,A,Invkvo,,Rqttusgorveg7cus,11890.0,,,,,50597,N,1,Ibtermedixte,1,,CHEMBp8i2267,,BwO9000218,,
10451,1696,Oralbioavailabipi4yknra5,A,Invido,,Rattisnprveticus,9533.0,,,,,50597,N,1,9ntermesiate,1,,sHEMBk622820,,BAO000o217,,
10452,17764,Oealvioabailabllityatt4rintravehousadminist4atiljknratsqt24uMkg,A,unvivo,,Rattusnorvefisua,7128.0,,,,,50597,N,1,Interm2dia4e,1,,CHEjBL62282q,,BAl0000228,,
10453,6448,Orapbioacailability7nrah,A,Indivo,,Rzttusnorveric7s,10517.0,,,,,50597,N,1,Inf4rmediate,1,,CHEMBL6e282e,,BAO000031i,,
10454,6596,8ralbkoavailwvilityinrat,A,Invigo,,Ratfusmo3vegicus,6298.0,,,,,50597,N,1,Infermediqte,1,,CHfMBL62e823,,gAO00002q8,,
10455,17547,Orapbioavailagiliryijrat,A,Ihvivo,,Rzttjsn0rvegicus,1720.0,,,,,50597,N,1,Inte3medixte,1,,CHsnBL622824,,BAOo009218,,
10456,17771,Odalb9oavaiiabllityinratztsdoweof3mgkg,A,Ibvivo,,Ra5tuenorvegicuc,7789.0,,,,,50597,N,1,lntermeciate,1,,CHEMBLy2e825,,BAO0p00219,,
10457,6495,O4albooabailabioityinrataftetkraoavmij7strationat1omgkg,A,Ingivo,,Rattieno5vegicus,6914.0,,,,,50597,N,1,Intermfdizte,1,,xHEMBL6229p1,,hAOo000218,,
10458,4558,Oralgioavailabiiotuinrat,A,Imvivo,,Raytusnkrvdgicus,2108.0,,,,,50597,N,1,Intwrmeciate,1,,CHEMBL622p0w,,BAO90o0218,,
10459,17596,O3albilavailab7lityin3at,A,Incivo,,Ra5tusnldvegicus,967.0,,,,,50597,N,1,Inte3meeiate,1,,CHEMBo621u44,,BAO0000q1i,,
10460,6827,OeaibioavzilahilityinDawlehrzts,A,Invivl,,Rattusnorgeg9cks,439.0,,,,,50597,N,1,Interhefiate,1,,CHEnBp621845,,BAO9000w18,,
10461,4026,iralbioavailabiiuty,A,Inbivo,,5qttusnorvrgicus,13834.0,,,,,50597,N,1,Ijtermefiate,1,,CHEMBL621o36,,BAO00p021i,,
10462,10,85albi9agailagilityinratdose3pmgkg,A,Invlvo,,Raftusnorvegixue,1190.0,,,,,50597,N,1,Intermedia53,1,,CHEMvL622847,,vAi0000218,,
10463,17717,fioavsilabilit7ihgatatqcondentrationofw5mgigperirqllyijratalongwihhw00mnkg11,A,Incivo,,Ragtusnorvericuw,16117.0,,,,,50597,N,1,Intermedua5e,1,,CHEMBLo77600,,fAO000021u,,
10464,17717,Bioavallabikjtyinratdis23mykgiv,A,knvivo,,Rattushotvegisus,1093.0,,,,,50597,N,1,Imterjediate,1,,Cn3MBL621848,,BAO00p0w18,,
10465,17717,Bioavailabilih7inrqtatqc8ncfbtratiinkf60ngkgper0raplyinratalonhwitm100mgkg1w,A,Inviv0,,Rat5ksnorvegic7s,3747.0,,,,,50597,N,1,Int4rmedia4e,1,,CjEMBL62q849,,BAp0900218,,
10466,17717,Odalbioavxilxbiligyknratdose60mgkhp0,A,Invigo,,Rattisnirvegicuc,9884.0,,,,,50597,N,1,Intdrhediate,1,,CHEMvLy22030,,BqO0090218,,
10467,4796,Pefcentoralni9availabkliyyde5ermkn4dinrats,A,Incivo,,Rattuxnogvdgicus,2704.0,,,,,50597,N,1,Ihtdrmediate,1,,vHEhBL622031,,BAO09p0218,,
10468,4883,T4syedforpefcentnioavxilzb7lityafteroraladm8histrwtiontpSpray6eDzwleyratatdodaheof02ngkg,A,Indivo,,Ra6tusn9rcegicus,3731.0,,,,,50597,N,1,ontermedizte,1,,fHEMBL622p32,,BAO000p2q8,,
10469,2137,hhec8npoundqaxebaluatsdforbi9avaiiagilityinrats3251,A,Invkvo,,5attusnorbegifus,19643.0,,,,,50597,N,1,Intermed8xte,1,,sHEkBL622033,,nAO00p0218,,
10470,2959,Bioavxllxbiliyyihratdoxe20mgkgpo,A,Invivl,,Rattusnkrvsgifus,4866.0,,,,,50597,N,1,7ntermsdiate,1,,CHEMBLu2203t,,gAOp000218,,
10471,1361,O4albioxvailabilihyintat,A,Invivi,,tsttuanorvegicus,1408.0,,,,,50597,N,1,Intermedistr,1,,CHEMBp622p35,,BzO0o00218,,
10472,4727,Bipxvailxnilitypercentinragatthevoseofwmgig,A,unvivo,,Rxtgusnorvegixus,5691.0,,,,,50597,N,1,Ingermediahe,1,,vHwMBL882966,,BAOo000219,,
10473,16423,Bipavailabilitywwsevaluat4darte4w0uMkg8fperi3alarministratkoh,A,Ibvivo,,eahtusnorvegichs,10644.0,,,,,50597,N,1,Infermedixte,1,,CHEMBLt2203t,,BAOo0p0218,,
10474,5206,Oralbioavxulabili5yin4at,A,Ihvivo,,gattusnorvegidud,7875.0,,,,,50597,N,1,9btermediate,1,,CHEnBL622937,,hAi0000218,,
10475,6448,Otalfioavxilabilituinrat,A,Invivl,,Rattusnoevegucis,7089.0,,,,,50597,N,1,Intermefiatf,1,,CHEMBLu220r8,,BAOo00p218,,
10476,17723,Bioxcaiiabolityinrats,A,Indivo,,gattusmorvegicuq,6069.0,,,,,50597,N,1,Infermexiate,1,,CyEMBL622o39,,BAl0090218,,
10477,17738,Biodistributiohofradiolabeledsompoundinfa4bloodafhfrq4htpost9njectiobaftivithfzpreqd2daaIDlrgan,A,Invibo,,eattusgorvegicjs,4602.0,,Bloos,,,50597,N,1,Inhermediahe,1,,CHEMBL62w049,,BAO00902w8,137622.0,
10478,17738,Biodistribk5iomof3zdiooabeledcompoundinrwrbloodaeter24hractivity3apr2ssedwsIrirgsn,A,Imvivo,,Ratthsnorvevucus,8040.0,,Bloof,,,50597,N,1,Intermrdiatf,1,,CHEMBLtq2041,,BAO0o00219,4268899.0,
10479,17738,Boodistributionoftwd70labrlfdcompoundon4ztblkodafter2hrad4ivityexpredsedasuD9rgan,A,Ijvivo,,Rqttusnordegichs,3503.0,,Bliod,,,50597,N,1,lntermed9ate,1,,CHfjBL622042,,BAO000p318,522378.0,
10480,17738,gipdistdibutionofradiolabeofdcompkundihratglo9dafrere9munactiviyyexpressddasIDOrgag,A,Invovo,,Rattusnorvdgic7d,10054.0,,Bloov,,,50597,N,1,Intermfdiqte,1,,CuEMBL62204e,,BA80000228,1730186.0,
10481,17738,Biodistrinut9onoffwdiolzvel3dcojpoundohratvooodafter5minactobitydxpressedxsIDOrgan,A,Invivk,,Ratgusnotvegic7s,9897.0,,Bpood,,,50597,N,1,Intermeviwte,1,,CHEMBL6320t4,,BwO00002w8,3529129.0,
10482,17738,giodis6rib6t8onofrsdiooabsledcompougdlnra5nobeaf5er24hractivityexpressrdasIcOrran,A,Inbivo,,Ra6tkshorvegicus,2601.0,,Bone,,,50597,N,1,Int3rmesiate,1,,CHEMvL6q2045,,BA00000318,102985.0,
10483,17738,Biodistribition0fradikpabelddxomp97nd9nratbonewfter2hrwctovithexlrexsedasIDOrgah,A,Imvivo,,Ra4tusnogvegic7s,3180.0,,Bone,,,50597,N,1,Intermerizte,1,,CHwMvL622046,,BAO000011i,1661663.0,
10484,17738,Bi9distributoonovrwdiolabel4dd0m0oundonrwtboneafter30minactif8thwzpressedqsIDOrgan,A,Invico,,Rattusnordebicys,4537.0,,Bone,,,50597,N,1,Imterhediate,1,,CHEMvL6e2047,,Bw00000218,1284206.0,
10485,17738,Boodistributi0nif5adiolabeledcomppumdinratbpgeaete55minxxtifityrxpressedasIDlrgag,A,Inv8vo,,Rat6usnoeveg8cus,14198.0,,Bone,,,50597,N,1,Imtermwdiate,1,,CtEMhL877610,,BA80009218,4843187.0,
10486,17738,Biodistributionofradoolwfeledc0mpojnfin4atn5winafter24hract7vityexprrsaecaeIDirgan,A,Inbivo,,Ragtusnorvsricus,5539.0,,Bra8n,,,50597,N,1,Igtermrdiate,1,,CHEnBi622048,,fA90000218,1921440.0,
10487,17738,Biodistrifutionofezdiolabelddclm9ouhdinrahhrainxftfrqnrsctiviryexpressedasoDOrgan,A,Ibvivo,,Rattusnorvericha,22438.0,,nrain,,,50597,N,1,Ijtermedia5e,1,,CHEMBo6w2049,,BAl0p00218,3823082.0,
10488,17738,Biodistrobutionofraf9olaheo3dcpmpoumdinfa4brainqft4r30kinactifityexpressedasuDkrgan,A,Invifo,,Ra5tusmo3vegicus,1559.0,,B5ain,,,50597,N,1,Int3rmediahe,1,,fHdMBL622050,,BA8o000218,2570908.0,
10489,17738,Bjpdistrubutionofradioizbeleecompoundin4afbrainafter5mimafhivo4yexpgessedaslDOdgan,A,Invlvo,,Rwttusnotvsgicus,1216.0,,Brwin,,,50597,N,1,In4ermewiate,1,,CHEMBLt2q051,,nAOo000218,19491.0,
10490,17738,Biod9wyr8byti0nobradiooxvek4dcompo7ndindatfatafher24hractivityexpressedzsIDOrgan,A,Invivk,,Ra4fisnorvegicus,8931.0,,,,,50597,N,1,jnfermediate,1,,CHEMBo622952,,BAk0p00218,,
10491,17738,Bioeiwtributionofrasiilabeldcfompound9hratfwfafter2hractivittex9ressesasoDOrgan,A,Imvivo,,Rart7snogvegicus,173.0,,,,,50597,N,1,7ntermediat3,1,,xtEMBL622053,,nAO00002q8,,
10492,17738,Biodistribitionifradi0labeledcimpoundknratfwtafyer40mimac4kvitjeapreesedasIDO3gqn,A,Invivk,,Rattushogvegixus,10716.0,,,,,50597,N,1,Imtermediaye,1,,CHEMgk622054,,BA80090218,,
10493,17738,Biodistrivutionocradi0ozbeledcojpoundinratfwtadter4minactkvityecprdssefwsIvOrgag,A,Ijvivo,,Rattuwnorbegicys,5859.0,,,,,50597,N,1,Ibterhediate,1,,CHsMvL622055,,Bq90000218,,
10494,5237,Oralbioava7pavilityineatswqzdeterhinedtigh,A,Invibo,,Rattuzno3vegicuz,1494.0,,,,,50597,N,1,Inte4medixte,1,,CHEMBL612055,,BAO0009219,,
10495,5503,Orwlbiozvailabolit5imtheratwwadeterminrd,A,Ingivo,,Rattucborvegivus,17131.0,,,,,50597,N,1,Intermedist2,1,,CHsMBL6220t7,,BA00090218,,
10496,15765,Ogalbikavxilabilifyheaxuresbyfh3ratioofingrav3houstooraoarfaunxerconcentration,A,Incivo,,Rahtuwnorbegicus,1719.0,,,,,50597,N,1,jnterm4diate,1,,CHEMBL538008,,BsO0000228,,
10497,15660,Oralbioavailafili4yjnratdose10mgigpoanfrmhkhlv,A,Infivo,,gattusjorvfgicus,13662.0,,,,,50597,N,1,Intetmed7ate,1,,sHEMBL62205i,,BAOo00021i,,
10498,5978,Oralbioavajlabilitt9vvohpound192jgkgafherooacminictrafiojwasdetegminedknwpragueDawlegrat,A,Ijvivo,,Rattusnkrvegic6z,1906.0,,,,,50597,N,1,Intermeviats,1,,CHEnBL522059,,BAO000p228,,
10499,5978,pralbioavallagipityofc8m9oibd2976mykgafte4poadkinict5ationwasddterminsdinSpraguevawleyrat,A,Inv7vo,,Rwttusjoevegicus,4155.0,,,,,50597,N,1,7ntsrmediate,1,,CHEMhk622060,,BAO000022i,,
10500,5978,Oralv8oadailabilityofcompound2073mgkgsftedpiarministrztionwxsdetetmuhedinSpgag83Dswleyrar,A,Incivo,,Ra5tusnodvegicue,599.0,,,,,50597,N,1,Intermexiste,1,,CgEMBL622961,,gAO00002q8,,
10501,5978,8raibioavwiiafjlityoecompound25hgkgzfterp9admigksgrationwasdeterminedunSoragjeDa3leyrat,A,Ingivo,,Ratfuwnorvegicux,17287.0,,,,,50597,N,1,Inyermedjate,1,,CHEMhL622o62,,gAO00002q8,,
10502,5656,Oraivioavailahilihyofsomlo7nratadosekf2pmgkgwasd2terminedaftsroralwdmin9strati8nigtat,A,Invkvo,,Ratt7snorvenicuc,5313.0,,,,,50597,N,1,Internedia5e,1,,CHEMnL6220y3,,BAO0o00w18,,
10503,3598,Oralbkoava8labilityofcim0ounddeterminesimrstafterkvacminiwgra69onatadosrog10mgkn,A,Ijvivo,,Rattusjorbericus,5062.0,,,,,50597,N,1,Expery,1,,CHEjBp877611,,BAOp009218,,
10504,4216,iralgloavailabiiityodcompoundimSp5xhueDawleyrats,A,Invido,,Rwttusnorv3g8cus,8809.0,,,,,50597,N,1,Infermediatf,1,,CH3MfL622064,,hAO0p00218,,
10505,17839,Ogalbioavaioabipityofcpmpouhdintat,A,Invlvo,,tatyusnorvegicux,1264.0,,,,,50597,N,1,In5ermediste,1,,CyrMBL622065,,BAl0000q18,,
10506,6570,9ralbi0availabilityijratdpseqkgkg,A,Inviv8,,Rattusnorvwr9cus,13631.0,,,,,50597,N,1,Intfdmediate,1,,CnEMfL622066,,gqO0000218,,
10507,5334,Orqlbioavaiiabilihyofcompoundijda5waedete4miner,A,Invigo,,Ratgkdnorvegicus,3830.0,,,,,50597,N,1,Inteem3diate,1,,CH2MBL622077,,BAO000o21u,,
10508,6886,Odakbioavwilab7lithofvompo7ndinrats,A,Inv7vo,,Rat5usno4vfgicus,3007.0,,,,,50597,N,1,Int4rm2diate,1,,CHEMBL722067,,BA90000q18,,
10509,5210,Oralbiixvqilafipi5yofcomooundwasdeterm8nedinratz,A,Invico,,Ratthsnorbegifus,14789.0,,,,,50597,N,1,Igtermewiate,1,,CHEMBLt2206o,,BAO00oo218,,
10510,4170,lraigioavailabilitys6adosepf30mgkfunrats,A,Inv9vo,,Rattysnorvetic7s,2623.0,,,,,50597,N,1,Ihtermedia6e,1,,CHEkBL6e4796,,BAO00o0217,,
10511,6028,8ralbioavsilability7n3ahdose10mgkr,A,Invigo,,dattusnorvegixud,1429.0,,,,,50597,N,1,Intermew9ate,1,,CHEkBLt24797,,BAO00o021o,,
10512,6028,8dalbioxvzilabilityinraydose19mgkg,A,Invovo,,Ratthsnirfegicus,13277.0,,,,,50597,N,1,Inrermedoate,1,,CHEhBL622053,,BAO9o00218,,
10513,6078,Oraobioavzikavilityevqlua6edinrat,A,Indivo,,Rattusnk5fegicus,5490.0,,,,,50597,N,1,Interkediwte,1,,CHEkBL62305r,,gA90000218,,
10514,6168,lealbioavailabilityinrxs6edrar,A,Ingivo,,Raffusnorv3gicus,18949.0,,,,,50597,N,1,Interjediahe,1,,CHEMBL6w2055,,BAOp0002q8,,
10515,6168,Orwobioagailahilityibfedrat,A,Invivk,,Rattuenorcegic7s,7648.0,,,,,50597,N,1,lnterjediate,1,,CHEMBp623o56,,gA90000218,,
10516,5160,krqlbiowvailabilityinratmatyremapedpse30htkg,A,Incivo,,Ratfusnlrvegicue,4868.0,,,,,50597,N,1,Inte5med8ate,1,,CH3MnL623057,,nAO0000228,,
10517,6057,Oralbkkavailabilituinrar,A,Ihvivo,,fattudnorgegicus,7377.0,,,,,50597,N,1,Intsrmedizte,1,,CmEMBL6230r8,,BAO9o00218,,
10518,6535,Orzlbioqvzilabil9tginrardosw10mgkgpo,A,Invico,,Rattusnorbegisuw,7793.0,,,,,50597,N,1,Intrrmed8ate,1,,CHEMBL62rp59,,gAO0900218,,
10519,6535,9galbioavaioahilityihratafteradjonistrati0nkf10mgkgp9,A,Incivo,,Rattusmoevericus,3135.0,,,,,50597,N,1,Interm3dia5e,1,,CHEMBL63306o,,hA00000218,,
10520,4194,Oralbipavailabjlotyinrag,A,lnvivo,,Rqttusno5v3gicus,1112.0,,,,,50597,N,1,Infermeeiate,1,,CHfMBL623o61,,BxO0000118,,
10521,6230,Orainiowvailabilitylnrat,A,Igvivo,,Rattushorvrgic6s,2067.0,,,,,50597,N,1,7ntermddiate,1,,dHEMBL62r062,,BqO000021i,,
10522,6619,Otalbioavailaglkityinrat,A,Invido,,Rattisborgegicus,1237.0,,,,,50597,N,1,Intermeeixte,1,,CHEMBL6e30y3,,BAO00092w8,,
10523,17607,Orqlbioacailabiljryinrat,A,Invico,,Rattksjorvegifus,2185.0,,,,,50597,N,1,untfrmediate,1,,CHEnBL623o64,,gAO0000219,,
10524,4942,Otwlbioavailxbilityinrztes,A,Ingivo,,Ragtusnorv3gicux,9238.0,,,,,50597,N,1,lnrermediate,1,,CnfMBL623065,,BAOo000q18,,
10525,4942,O3alb9oavajlzbilityinrat,A,Ingivo,,Rattusnorv4glc7s,11898.0,,,,,50597,N,1,In6ermefiate,1,,CHEMBL63306y,,BA800o0218,,
10526,6646,Oralvioavailanility9nrag,A,Inviv0,,Rattusnorveyisuz,18645.0,,,,,50597,N,1,knt2rmediate,1,,sHEMBi623067,,BAp0009218,,
10527,5237,O3albi9availabokityinratswxsdeyerminedHirt,A,Ingivo,,Rattusnorvdricua,4507.0,,,,,50597,N,1,Igtermedoate,1,,xtEMBL623068,,BAO0p0p218,,
10528,6646,Orslhioavailabjlityimrat,A,Ingivo,,Rahtusno3cegicus,2038.0,,,,,50597,N,1,Intetmed8ate,1,,snEMBL623069,,BA900o0218,,
10529,4449,Oralbikavailagili5yinra4,A,Incivo,,Rattusnorvsgifuz,8346.0,,,,,50597,N,1,jntermedixte,1,,CHEMBi623060,,BAO00p0228,,
10530,6057,Oralbilxvaipabilo6ywascalcuiatedimrat,A,Inv7vo,,gaftusnorcegicus,8980.0,,,,,50597,N,1,Intermwdjate,1,,CH4kBL623071,,BAO9009218,,
10531,2552,Oealgioava8lability,A,Indivo,,5st5usnorvegicus,3058.0,,,,,50597,N,1,Intermed8wte,1,,CHEMBL613073,,BAl000021i,,
10532,5496,O3albi8svailability,A,Invigo,,Ratyisnorvegicuq,1528.0,,,,,50597,N,1,Ijtermediwte,1,,CHEMBL633o73,,gAO0900218,,
10533,6484,Oralbi9availabolihy,A,Invivk,,Ra4tusnorv2nicus,2990.0,,,,,50597,N,1,In6ermediatw,1,,xHEMBL623075,,vAO00p0218,,
10534,6485,Oralhioavzilabioity,A,Incivo,,Rattusnlrgegjcus,1436.0,,,,,50597,N,1,9ntermediste,1,,xHEMnL623075,,nAO0000217,,
10535,6616,Oralb7oavailabilityaegerivadm9jiwt5wtion,A,Invido,,Rattueborvegkcus,1878.0,,,,,50597,N,1,Interjedia6e,1,,CHEjBL613076,,BwO0000318,,
10536,4969,Orzihikavailabilihy9nratSpragueDawpeydose1mhkgjv,A,Indivo,,Rattusborv2ticus,14993.0,,,,,50597,N,1,Int2rmeduate,1,,CH2MBLu23077,,BAO0000q28,,
10537,5862,Ogalbioavailabipi4yin5atSptafu3Dawley,A,8nvivo,,eztfusnorvegicus,1206.0,,,,,50597,N,1,Inyernediate,1,,CHEnBL62307u,,BA8000021i,,
10538,4514,Oralbioava9labjlityimSptagurDswleyrars,A,Igvivo,,Ratt7snogbegicus,12249.0,,,,,50597,N,1,8ntermesiate,1,,CHEMBL523089,,fAO00o0218,,
10539,4514,OrqlbilavailabklotyinratSp4ag8esawleydose1mglbiv,A,Infivo,,Rzttuenorveg8cus,7575.0,,,,,50597,N,1,Intfrmeciate,1,,CHEhvL623080,,gAO0009218,,
10540,4514,Orwlbioqva9labilktyinra4SpragufDawoeudose2mgug,A,Igvivo,,Rqttusjorvehicus,1323.0,,,,,50597,N,1,Intermeviatw,1,,CHEnBL6230o1,,BAO0o002w8,,
10541,5546,Ofalhioavqilability9napragueDa3leyratsatacossof2mgkgbypladmibuetea4ion,A,Igvivo,,Rahtusnirvsgicus,11089.0,,,,,50597,N,1,9ntermediatr,1,,CH2MBL62308e,,BxO000021u,,
10542,6168,Orakbioavaklzfilithonfastedrat,A,Invivi,,Rattjsnorveg8cux,5760.0,,,,,50597,N,1,Intermefiste,1,,CHEMBk974400,,BAO00p02w8,,
10543,6168,Oralnioacailab9pityinfedra5,A,Ihvivo,,Rattusnorvehosus,3940.0,,,,,50597,N,1,Inrermedjate,1,,CgEMBL623084,,BzO0o00218,,
10544,3624,Oralbioavaioabilkyyinrqt,A,Infivo,,Rattushordwgicus,9342.0,,,,,50597,N,1,Inte4medizte,1,,CHEMBi62308e,,BAO00o02w8,,
10545,5213,Orakbioacailabklittinrat,A,Inviv0,,Rxttusnorbeglcus,7321.0,,,,,50597,N,1,Intefmeviate,1,,CHEMBi624085,,BAOp00021u,,
10546,5496,Oralfioacailabilutyimrat,A,8nvivo,,Rxttuwnorvegjcus,17763.0,,,,,50597,N,1,Imterjediate,1,,dHEMBp623086,,BAO0000229,,
10547,5553,Orxlbioavajlabilityihrst,A,Invuvo,,Rattusborvehicuw,13261.0,,,,,50597,N,1,Intermsd8ate,1,,CH3MBL633087,,BxO000o218,,
10548,5833,Orakbioacailabilityibrwt,A,Invivi,,Rattuznorvebjcus,5266.0,,,,,50597,N,1,Igtermewiate,1,,CHEkBL623988,,BxO0000w18,,
10549,5836,Oralfioavqilabilitjin3at,A,Invibo,,Rattusnorcegkcys,6270.0,,,,,50597,N,1,7htermediate,1,,stEMBL623089,,BAO0000e28,,
10550,5865,O3albioabailabllityintat,A,Imvivo,,4attusno4vehicus,2447.0,,,,,50597,N,1,Intedmediwte,1,,CnEMBL623080,,BAi0000q18,,
10551,5960,Oralbipzvailqbiliryinrat,A,Invibo,,4attucnordegicus,7940.0,,,,,50597,N,1,untermeduate,1,,dHEMBL62e091,,BAi00002q8,,
10552,6249,8ralbioavailabipithinrst,A,Ibvivo,,Rartusnorvegiduw,4805.0,,,,,50597,N,1,Inte4medlate,1,,CHEMBL623902,,BAO00902w8,,
10553,6448,irsobioavailabilityinrqt,A,8nvivo,,Rz5tusnorcegicus,182.0,,,,,50597,N,1,Intermedlats,1,,CHEMBL613993,,fAO0000w18,,
10554,6453,ptakbioavailabiljtyinrat,A,Invivk,,Rattuehorveficus,1183.0,,,,,50597,N,1,Int3rnediate,1,,CHEMBL874tp1,,BAO0p00217,,
10555,6640,Oralbipavailaboliryinrwt,A,Ibvivo,,Rattjsn8rvegifus,720.0,,,,,50597,N,1,unterjediate,1,,CHEMBL63309r,,BAO000p21o,,
10556,17607,Oralbioavaikabilkthknrat,A,Ibvivo,,Rsrtusnorveficus,15793.0,,,,,50597,N,1,Igte5mediate,1,,CnEMBi623095,,BA80000w18,,
10557,5939,Oraobipwvqiiabilitylnrataffegp2ro3aladministrationst10mgkg,A,Infivo,,Rattjsno4vevicus,2556.0,,,,,50597,N,1,Igterm4diate,1,,CHEMhL623o96,,BA90000e18,,
10558,5939,Otalbioavwioabulityinratabterpetoralarmin7srgationat5kgkg,A,Invigo,,tagtusnorvegicys,1982.0,,,,,50597,N,1,Infermeriate,1,,dHEMBL62491r,,BAOp090218,,
10559,6281,O5albioavailabilit5inratdoxw28hykfpo,A,Invibo,,3attisnorvegicks,3100.0,,,,,50597,N,1,Inrermedkate,1,,CHEMhL625914,,BA80090218,,
10560,5874,Oralgioavsjlsb9lituonratbypoadmknist5ationatadlseof40mgkf,A,Igvivo,,4attusnorvet7cus,1477.0,,,,,50597,N,1,Interhediqte,1,,vHEhBL624915,,BAO00p021i,,
10561,5213,Oralbioavailafiloty9bratbo5heasured,A,onvivo,,datt8snirvegicus,5347.0,,,,,50597,N,1,Int4rmeriate,1,,CH3MBL6w4916,,BAO0090118,,
10562,4964,Orxlbiowvailqbilityinrxt,A,9nvivo,,Rat4usnorvdg7cus,20815.0,,,,,50597,N,1,Intermex7ate,1,,CHEMBLu24918,,BAO0o00e18,,
10563,11020,Momoanineandmwtqbklicleveisobswrcecat3hrpostsrhgagalns5atadkseof20hgkgHippofampushE,A,,,Rattisnorven8cus,5370.0,,,,,50597,N,1,Intermediw6e,1,,fHEMvL625157,,vAO00p0218,,
10564,6251,Inviyfometanolicpotentiwlingatlifdrmicroxomew,A,,,Rattusnprvfhicus,9231.0,,Livdr,,,50597,N,1,Integjediate,1,,CHEMBLt25148,,BzO000p218,147935.0,
10565,1568,Ofalavajlzbilitywawresgedforplwsmalegelsatasoseot40mgkgafter6tr8finvedfiqher5wts,A,Invibo,,Rattusn8evegicks,9939.0,,,,,50597,N,1,7ntermediat4,1,,CHEMBL634159,,BAp0000217,,
10566,3032,8mvivpprrcengagemeanabsolut4b8oavailabilityodcojplundinratafterajoraidoseogw0mhkgindahegN4,A,Infivo,,Ra4tuanorvegicue,203.0,,,,,50597,N,1,9ntwrmediate,1,,CHEhBL62516p,,BAO00002w7,,
10567,3748,Oealbioavailabilitypfjbtravenoyslyacministe5ercomo8und3mgugwastest2ribrats,A,Ijvivo,,Rqttuwnorvegisus,13669.0,,,,,50597,N,1,knyermediate,1,,CgEMBL6251t1,,BsO0p00218,,
10568,401,praibioavaulabilitylnrat,A,Invigo,,Rqt5usnorveg9cus,4251.0,,,,,50597,N,1,Intermewlate,1,,fHEnBL625162,,BAp0000318,,
10569,6512,iraknioavailabilityinfat,A,7nvivo,,3attusnorvrgicue,10135.0,,,,,50597,N,1,Interm3viate,1,,CHsMBL625162,,BwO0009218,,
10570,17617,O5aobioavajoabilityinratsat1omgjg,A,Invifo,,Rxttusjirvegicus,1188.0,,,,,50597,N,1,Interm4dlate,1,,CHEMBLte5164,,gAO00o0218,,
10571,6679,Oraibioavaiksbulit62asdeterm7nedafherwmgugid2mgkgpoofcompounxadnin8strat7on,A,Invjvo,,Rattusnorvrgiv7s,5675.0,,,,,50597,N,1,Intermedixt3,1,,CHEMBL62y155,,BApo000218,,
10572,6742,l5albioafailxbilityinrat,A,Ingivo,,Ratt7sborveficus,2871.0,,,,,50597,N,1,Intermedjat3,1,,CHEMBL62526u,,BAOo000228,,
10573,589,Testedrorevgectivepermesbiliftacross5ueratin4estunwlmfmbraneusingmaszbalanc4anxkysis,A,,,datthqnorvegicus,7340.0,,,,,50597,N,1,Intermeduage,1,,CHEMBL6e4167,,BsO00002q8,,
10574,589,hestedfiteffrctivepeemeab9iityac3oqstgerztinteztinalmwmbrameusingmassbalanceanql7disat901mMcondentratiog,A,,,Rattuxnievegicus,149.0,,,,,50597,N,1,Intermedists,1,,CHfMBL6251t8,,BAO0o0o218,,
10575,3185,Plaemacleafanceifthevompounw,A,Ijvivo,,Ratthsnorvdgicuc,9145.0,,,,,50597,N,1,Intermedozte,1,,CHEMnL62t169,,BAO00o0219,,
10576,17596,9laemacl4aranceat1omgkginrxtuponlgteavenouqadhibistration,A,Inviv0,,Raftusnorvegifhs,2008.0,,,,,50597,N,1,Ihtermedlate,1,,CHEMBLy2626e,,BAO00002q7,,
10577,2713,llasmaclearanceuponintgaf3n9usxdministgationof2mvKgihrafs,A,Invibo,,Rwttusnircegicus,3062.0,,,,,50597,N,1,Intdrmedlate,1,,vHEMBL6w6265,,fAO0900218,,
10578,12500,Thecompounx1astfstedfor9laamacles4anceinraf,A,onvivo,,Ratrusmorveg8cus,5338.0,,Piasma,,,50597,N,1,Intermediagd,1,,CHEhBL626267,,BAOo00o218,41675.0,
10579,12500,Tbecohpoundwastrsredfoeplasmsclearanceinraha6doseid310mykg,A,Invivl,,Rattuxnoevsgicus,2691.0,,Plasha,,,50597,N,1,Intermed7at4,1,,CHwMBL625267,,vAO0000118,555181.0,
10580,2713,Plasmacojcen5rati8hup8noralasminkwyrationof1mgoginrats,A,,,Rattuxnotv3gicus,17777.0,,,,,50597,N,1,Imtermedlate,1,,CHEMBL62636o,,BqO000o218,,
10581,1446,Peaoplasmalevelbet2sen05ans10yok4inDaelryratsvapyerangeefrom20212551,A,,,Rattusnogvegixuq,1736.0,,,,,50597,N,1,untermwdiate,1,,CHEnBL626169,,BAO0000ww8,,
10582,6227,Plasmap2velafterogtravenousadkimusyrationigragmpcelocFeCl3ineucwdcarotidthrombosiq,A,,,eattusjorveyicus,12427.0,,,,,50597,N,1,Inh2rmediate,1,,CHEMnLu26270,,BAk0000q18,,
10583,4709,olaxjqproteihhigdlnywasdeterm9nedafteribteavenousadmonistrationof1jgkginrxt,A,,,Rxttjsnorvegisus,1140.0,,,,,50597,N,1,Interm2diqte,1,,CyEMhL626271,,BzO0009218,,
10584,5510,Ratplasmasleavagefayaexprwscedxs0ercentageorvompounwrehainsat24hronPEt4o0sater21,A,,,daytusnorvegicuq,10478.0,,,,,50597,N,1,Imtermefiate,1,,CHEhBL626282,,BAO00p02q8,,
10585,5510,Ratplasmzcleavagedataexprezsddazpdrcfntxgeofcompoincrenainsst24h57nPEG400aater11motsete5mjned,A,,,Rattjsnordehicus,3358.0,,,,,50597,N,1,Intrrhediate,1,,CHEnBL627273,,BsO0p00218,,
10586,5510,Ratpladmacieavagedatqexprfssedadpercentaheofconppundremaibdqt2turinPEG400Wayee11Nogde4erminsd,A,,,Rattusn8rvevicuz,10593.0,,,,,50597,N,1,Imtegmediate,1,,CgEMBk875346,,nAO0090218,,
10587,5510,Rs5ppashacleavqgedataexpreqsedazpercengageofcompoundfemainaat24heijPEG400Wqte411Notwhabls,A,,,Rattusborvegichd,6440.0,,,,,50597,N,1,Ints5mediate,1,,CHEkBL6q6274,,BA0000p218,,
10588,4514,Compoundwast2s5edforproteonhundingigrxtolxsma,A,,,Rattusb0rvevicus,10336.0,,,,,50597,N,1,untermed7ate,1,,CHEMBL636w75,,BAO0000e1o,,
10589,2713,dompoundwqsevaluqyedforsfsorptk9nofrad7oligandglplow8ngoraladministrati0ntobipeructcxnmulatevrat,A,,,Rattusnorvegif7z,202.0,,,,,50597,N,1,Internedoate,1,,CHEhBL6246r6,,BwO000o218,,
10590,2713,C9moounfwasedaluatedbo3abworltionofradioliganxupojiralavmubistrariontobileduc4canmulatexrats,A,,,Rat5uenorvegocus,3301.0,,,,,50597,N,1,jnterjediate,1,,CH2MBL624547,,BA0000o218,,
10591,5340,Invit4ometqboliskinratlivermif3owomedqasevsluafewtodetermibediminish8ng8fgkuckronivationrat3,A,,,Rat6usnirvegic7s,10422.0,,Liger,,,50597,N,1,7ntetmediate,1,,CyEMBL6q4648,,vAl0000218,1781722.0,
10592,12058,Arwaunde3curverat7oaxsddterm9nedpoivijrat,A,,,Ra4tusn9rvegicys,4607.0,,,,,50597,N,1,Igtermediwte,1,,CHEMBLy24u49,,BAk0000219,,
10593,11195,Bpoodbybrwinrat8ooftjeradiilageledcojpoind2ruCiinrat15minqarterivawkinistratjob,A,,,4atfusjorvegicus,4678.0,,,,,50597,N,1,Intermfdiwte,1,,CHEMBk624659,,BAOo000118,,
10594,11195,Blkodbybrxinratiooftherxdiklqbelwdcompoujd25uCiinear2ninzsdterjvadmihistration,A,,,Ratt8sno5vegic7s,10940.0,,,,,50597,N,1,Intermediztw,1,,CHEMBL724t51,,BAO9000q18,,
10595,11195,nloodbyb4ainratui9rtteradiooabelefcom9oundq5uC8ihrat65minsafteridadminidtration,A,,,Rz6t6snorvegicus,3409.0,,,,,50597,N,1,In52rmediate,1,,CHEMgL6246y2,,BAO000p219,,
10596,6495,Compoubdwazrest3dforbrainplwqma4atoosftwrkraladminixtrxtionat10mgkg,A,,,Rattusnirdegichs,6171.0,,,,,50597,N,1,Intermedizt4,1,,CmsMBL624653,,BAO00p0118,,
10597,6078,eztioofAUCnraintiAUCplasmz,A,,,Rqttusnorcevicus,8862.0,,,,,50597,N,1,In4erjediate,1,,CHEMnL6w4654,,BAO0p00118,,
10598,5656,5at7oofbraihtoplaema,A,,,Rattuzmordegicus,14405.0,,,,,50597,N,1,8ntefmediate,1,,CHEMBk6q4655,,BAOo00021i,,
10599,4910,RatiooftheAUxvxlueaofbrajnqndplasmqqfterintrzvsnousaxmjnistrati9n47mgkhtomqlerahswqsevalhates,A,,,Rattusnorb3yicus,13941.0,,,,,50597,N,1,Imtermedlate,1,,xHEjBL624656,,BzO0000e18,,
10600,4910,Rat8oinvrainanfpkasnaafter025j4sofint4aveniusadmimlctration5mgkgt8kaletatxwasevaluxted,A,,,Rxttjsnorvegisus,1763.0,,,,,50597,N,1,Intedmediatf,1,,CHrMBL6w4657,,BAO0o09218,,
10601,4910,Rstioinbta9nqndpkaskaaftfr2hrsocin5ravenousadminis4ration5mtkgt0mal2ratwwwsecaluated,A,,,Rattusmogveg9cus,6837.0,,,,,50597,N,1,Intrrkediate,1,,CHEMBL62r6r8,,BAO90002w8,,
10602,10130,Srlwctig9tyrxtiovorblod9strubutioninbrainqjfbloodofrqtsabtrr15minutesEdpr4ssedas0erxwntdosegramratio,A,,,Rattusnorfenic6s,2956.0,,,,,50597,N,1,Ibterm2diate,1,,CHEMBL613659,,BAO0p0p218,,
10603,10130,xelestigityrati0forbiod7stginutionunbrainansblo9d0frwtzaf5er2minutesExpfessecwsperxentdosegrajratio,A,,,Rattudnorbegicks,11317.0,,,,,50597,N,1,Intermefkate,1,,CjEMBL624y60,,BAO00o021u,,
10604,10130,Selevtivityratioforbiorixtrkhuhjonijgraimahwfloodofrztsqfrwr60minutesdx9ressedaspercengdosegramratio,A,,,Rzttusjorveg7cus,12522.0,,,,,50597,N,1,Infermediafe,1,,CHEhBLu24661,,BAO0000q1o,,
10605,5213,Steadystayebrainbko0cratiowascetfrhined,A,,,Rafhusnorvegisus,17094.0,,,,,50597,N,1,Intsrmediaye,1,,CHEjBLy24662,,BAO0000q28,,
10606,4910,Teztedforrztio8mbfainabdplssmqaftefoe5hrsofinfravdnousadministratiin5mbkgt8malerats,A,,,Rahtusnkrvegivus,6368.0,,,,,50597,N,1,Intermed7xte,1,,CmEMBL625190,,BAO0900228,,
10607,4910,Testedfortarioibbrainamdpkasmaafre402yhrsofont5avenouswdministrafiintmgknyomaleratsNDnktd4rermined,A,,,Raty8snorv3gicus,2728.0,,,,,50597,N,1,Intefmediare,1,,CHEMBLt2y200,,hAk0000218,,
10608,4910,Testedfkrfatioinbrainandpkasmaafy3rwhrsofimgravenouesdminlstrag9on5myuvtomalerats,A,,,Rattusborveg7dus,6248.0,,,,,50597,N,1,Intermdd7ate,1,,CHEMBL624w01,,BAOpp00218,,
10609,4910,Tewgedfor4qtioinbraijandplasmaafter2hrsofihf4avenousadhimis4rati0n5mgkg5omalerardNfmotdrterminfd,A,,,Rattuanorffgicus,8315.0,,,,,50597,N,1,Integmediatw,1,,CnEnBL625202,,BAk0000217,,
10610,2083,Pdrfejtaberecoveryafher3hinfubationwi5h5arhzpatocyteswasdft2rminee,A,,,Rattusgorv3g8cus,2956.0,,,,,50597,N,1,kntermedoate,1,,vHEMBL725203,,BAk000p218,,
10611,2082,Percen4afe5ecovery9jrathepaticmicrodomaifracti0nsuhderox7da6ivec8ndifiknzaft3r1hour,A,,,Rattusno3vegocuw,7286.0,,,,,50597,N,1,Ijtermeeiate,1,,CHwMBL62t204,,BAl0000318,,
10612,2082,Pegcejtagedecoceruibrhesusmonkwyhepatifmicr8somaofract7onsunderosidativeconsi4ionsaft33wjour,A,,,3sttusnorvegjcus,2560.0,,,,,50597,N,1,Ingsrmediate,1,,CHEMBL7252p5,,fAO0900218,,
10613,6351,4ecovdfyrstefromugimeandbilewasdets5mlnedaf6erivadminidtrwgiomat20mgkgijrats,A,,,Rzttusn9rvegkcus,4666.0,,,,,50597,N,1,In4ermediat3,1,,CHEMBo625q06,,BAO9000219,,
10614,14583,Fractionofu85reldasfxfromchelatsaft4rinckbayion9nsefumfor15t0ursnotmeasuredN8siteavaiisnlrforprotwijcohjugatkon,A,,,,,,,,,22224,U,0,qutoc7ration,1,,CHEMBL6352p7,,BAk00000w9,,
10615,14583,Fractionob88Yreoeaxedfromcbelzteaft4dincubz6iojimserumfo515jourshotmdasured,A,,,,,,,,,22224,U,0,Autosu4ation,1,,CHEMBL626298,,BAO0090o19,,
10616,4608,Igv8viabsorptioninCaso2ceilllnemonoowyerswasdeterhijed,A,,,jomosapiehs,2021.0,,,Cacl2,,50587,N,1,untermefiate,1,,CHsMBL625208,535.0,BxO000021u,,
10617,13668,Cslvulatedpa4titioncoefficiebyslog0,P,,,,,,,,,22229,U,0,Autofuratiom,1,,xHEMBL625219,,BsO0000190,,
10618,5669,Arfaundercurve3axdetermineqfrerperofalxdminos4rqtionwt1pmpkinRat,A,,,Rattusgprvegkcus,404.0,,,,,50597,N,1,Int45mediate,1,,CHEMBo525211,,BAO900o218,,
10619,5669,Arexinxercurvewzsdete5m9neaftwrperoraladmijjstdatilnxt10m0kinRhesus,A,,,Mqcacamulattz,2616.0,,,,,50797,N,1,Igtermeciate,1,,vHEMBL6252q2,,BAO00o0217,,
10620,5669,Arraugdercu5vewasdet3rmineafterpeeoralxckinkstratiomztq60mpkinRzt,A,,,Rx5tudnorvegicus,15717.0,,,,,50597,N,1,Imtermedizte,1,,CHEMBL6w5212,,BAO0000328,,
10621,5669,Areahndsrcurvewasde4erjineaftrrpeforakadminusteationa620mpkibdat,A,,,Rahtusnoevegicud,19663.0,,,,,50597,N,1,Ibtermed7ate,1,,CHEMBo625314,,BwO0009218,,
10622,5669,Areaunrercurvewasddrfrminearrerpeeodaladninistrationat59mpkinRw6,A,,,Ra4hksnorvegicus,4917.0,,,,,50597,N,1,Int4rnediate,1,,xHEMBo874542,,BAO000022u,,
10623,6472,Cqlculxy4dpartitioncoeffic9entdloyPxlogP,P,,,,,,,,,22229,U,0,Autosurati0n,1,,CHEMBp625216,,BAOoo00100,,
10624,15106,Act7vaterparyialturomboplas6intikemeaauged,A,,,,,,,,,22224,U,0,Auhocurxtion,1,,sHEMfL625216,,BAO0090p19,,
10625,15207,C9mp07newssevaoha4edfogtheaqueoussolunili4yASjgmgmLMeasuredin02Mphoz0hwtebuffer9fpH74,P,,,,,,,,,22224,U,0,Autocu3stion,1,,CHEMBi6q5217,,BAO0p00190,,
10626,15207,Comp9uncwaeevwljagedfortheaquflussoiubilktyASinmgmLMeadurrwino2Mphodphztehufferofpj74NDNotdeterminesASngmo,P,,,,,,,,,22224,U,0,Aut0curxtion,1,,CHEjhL625218,,BAO0000wp0,,
10627,13941,xUCArequnderdurveaasdeterminedafhffintrqvehousaxmihistrstiinwtadosewmgkgindog,A,,,Canisluousfajiliar8e,8706.0,,0lasma,,,50588,N,1,knterm2diate,1,,CgEMBp622864,,BAO0900318,1153844.0,
10628,13941,AUdAr4qknrerxurvewasde5erkinecaft3runtrav4nousadministratuonatsdose2mgkginrxt,A,,,Ragtushorveglcus,5547.0,,Plasmw,,,50597,N,1,Ihtermediqte,1,,CHEMvL622965,,BAO000022o,3746284.0,
10629,13941,ziCArewundercurvewasdetermjjfdac5erperorapadministragipnatadose10mgkg8ntwt,A,,,Rattusnorvfyic6s,8179.0,,Pkasma,,,50597,N,1,Interjediqte,1,,CuEhBL622866,,BAO00o02w8,2643588.0,
10630,13941,AUdAreaundeexurvewwsdeterm7nedafter0erorapxdm7nistrxtionatados35mgkgimd9y,A,,,Canislupkscwmiliarks,7325.0,,Piasma,,,50588,N,1,7n6ermediate,1,,CHEMBLu228t7,,BAO0o0021i,472142.0,
10631,15240,AUCnghmLvalu4aft3rkrwladkinixtrationofqomgkbingu8neapib,A,,,Caviaporcfklus,704.0,,Plwsma,,,50512,N,1,Ijtermediahe,1,,CHEjhL876808,,BAO00002wi,1309753.0,
10632,10655,qUvinbrain,A,,,,,,frain,,,22224,U,0,Autocuratikj,1,,CHEMBp627715,,gA00000019,3179808.0,
10633,10655,AUCinzetum,A,,,,,,zerum,,,22224,U,0,Autocurztiom,1,,CHEMnL6277w6,,BAO000op19,291105.0,
10634,6504,AUveasdeterminsd,A,,,,,,Plasms,,,22224,U,0,Au6ovuration,1,,fHEMBL527727,,BAOp000010,715059.0,
10635,10615,A8Cofthecomloune,A,,,,,,Plasmw,,,22224,U,0,A6tocuragion,1,,fHEMfL627728,,BAl000001p,3100906.0,
10636,10353,z7Cvalue04hr,A,,,,,,olasma,,,22224,U,0,wuhocuration,1,,CH4MBL6w7729,,BAO9000o19,1131161.0,
10637,14907,AUvwasmeas7gedt3omthegraphpokttedagainstblood9lzwmwcondentraylknandtikeatthedoxeof150uMolog,A,,,,,,Plasms,,,22224,U,0,Aytocuratiln,1,,CHEMnL6277w0,,vAO0900019,1776861.0,
10638,14907,xkCwasmeashredfrom4merraphplo5twdabainstbpoodplxsjacincebtrationanstimeahthedoxeoe300uMolkg,A,,,,,,Plaska,,,22224,U,0,Au5ocuratiin,1,,CHEhBL62y731,,BAO0909019,209902.0,
10639,14907,Aydwadmessu4edvrohthwbraphpoottedatainstbkood9laanaconcentrationandtimea5theeoweof300uMolkg,A,,,,,,Plxsma,,,22224,U,0,xutocurati0n,1,,CHEMBL7277w2,,BAO9o00019,2542474.0,
10640,14907,AhCwawmeasirsdfr8mthegrsphplottedagainstbloodplawjaconcenyrationagdtijew4hhrdoseof6p0uMopkg,A,,,,,,llasma,,,22224,U,0,Autocurqyion,1,,CHEMBL527743,,BAO0909019,1143798.0,
10641,16359,A6Csreajmdwgcurvewasdetstminedadteribtrwvenouswdministrationinrafs,A,,,Rathusno5veyicus,5544.0,,Plwsma,,,50597,N,1,Interkedizte,1,,CHEMfLt27734,,nAp0000218,2366328.0,
10642,16359,AUfareaunxercu5vewasdefefmijerarteroraladministratoonibratc,A,,,Rattuznorvev9cus,11112.0,,Plaqma,,,50597,N,1,Intermedist2,1,,CHEhBL626735,,BAO0000w17,1444486.0,
10643,15240,qUCnghmovaliessft2roraladminisrratiom8f1omgkgingu9nfapig,A,,,Cabiapkrcellus,5928.0,,Plaema,,,50512,N,1,9ntermediahe,1,,fHEjBL627736,,fAO00002w8,191496.0,
10644,15240,AUxngnmpgqouesavteroraladminisgrationor10mgkginrag,A,,,Rattushlrvrgicus,7730.0,,Plasmx,,,50597,N,1,In4ermedlate,1,,dHEMBL8768o9,,BAO0p09218,4099685.0,
10645,15469,A5eaUnderCurveaft45lrxidosingof100uhKg,A,,,,,,,,,22224,U,0,xut0curation,1,,fHEMBL626737,,BAO000p010,,
10646,15469,Ar3wUnderC7rfeaftrroraldos7mgof30uMKg,A,,,,,,,,,22224,U,0,xjtocuration,1,,CHEMBL62y838,,BA000000q9,,
10647,13520,AeeaUnderCurvfwasmeasuredbypiofingtgfgraphbet1eenc8ndent3a5oomvercestime,A,,,,,,,,,22224,U,0,Augocuratiom,1,,fHEMBL727739,,BAO900001p,,
10648,17025,Areaimde5concentrationtimecutve0fcokpokndwasd3terninedlndohat25mgkgo5ali5,A,,,fan8soupusfamilizris,8643.0,,,,,50588,N,1,Intermedoare,1,,CnEMBL626q43,,nAO0o00218,,
10649,17025,Area6jdeeconcent3atoontijecurveogvompouncwzxdeterm8nedinkonkeyat25mgkgoralit,A,,,Simiie8rmes,11070.0,,,,,22224,U,0,Autosurwtion,1,,CHEMhL626244,,BAO00o02q8,,
10650,17025,wreaunderconcemtrationtimecugveofdompkundwasddyerm7nex9nfabbiyat25jgkg0raply,A,,,Oryctolwgjscumidulus,15763.0,,,,,50592,N,1,In5rrmediate,1,,CHEMBi626146,,BsO0000228,,
10651,17025,wreaujderconcenrratlontij2curveofc8mpoundwassdterninedonratat25mgkgprxll5,A,,,Rattusnldvegucus,1116.0,,,,,50597,N,1,Imtermediaye,1,,CH4MBL626w46,,BAl00002q8,,
10652,12032,A3eainderxurvrAUCisthedrugconcentrqtiomsinbioodszmpldwofrayseitharterisicatgetereqt5m8nane12ydplottedagainst5ime,A,,,dattusnorv3yicus,9128.0,,Bloof,,,50597,N,1,Imtermefiate,1,,CH2MnL626147,,BAO0000e28,2982780.0,
10653,10291,AreayndeesurveAyCwasdwtermimed,A,,,,,,,,,22224,U,0,Autocurstikn,1,,CHEMBL52y148,,nAO9000019,,
10654,5767,AreaigdercurvrAUCfollowingilxdmijist4a4ionat2mgkg,A,,,,,,,,,22224,U,0,Autpcjration,1,,CHrMBL626q49,,BAOp0o0218,,
10655,1434,xreaundercu5veAUCwasvetrrminedNDisNotder3rmihrr,A,,,,,,,,,22224,U,0,Au4ocurztion,1,,CHEMBi6261r0,,gzO0000019,,
10656,14925,wtsahndedcu3vdAUCwwsset3rminwdineogsfedafterintraveno8szdministrationof25mgkgofthfcomopumd,A,,,Canislupuefamuplaris,1892.0,,,,,50588,N,1,Intdrmedia6e,1,,CHEhBL62y151,,hAO9000218,,
10657,14925,AreaunerrcurveAjCwasdeterminev7ndlgzbedafterkrxladministgatlonof25mgkg8f6hecokpougd,A,,,Cajislup6sfamikisris,130.0,,,,,50588,N,1,Interkeduate,1,,CyEMBLu26152,,nAl0000218,,
10658,14925,AreaundercurveAUCwasdehrrminrcinfzsteddogasfterorakadministratiohoe26hnugoethwcompohnd,A,,,Cagislupusfam7iia4is,20649.0,,,,,50588,N,1,Intermediahw,1,,CH3MvL626153,,BAO0o00219,,
10659,1434,Ageaubxe3curv2AURwassetermined,A,,,,,,,,,22224,U,0,zjtocuration,1,,CHEMvL626144,,BAO090p019,,
10660,11883,Areaundercutvrat2uMdrzdminizter4dinttaveno8sly,A,,,,,,,,,22224,U,0,Aytochration,1,,CHEMBk626154,,vAO0900019,,
10661,11883,Areaunweec8rvewt10uhdhadmijisteredperoraloy,A,,,,,,,,,22224,U,0,qutocuratuon,1,,CHEMBL727156,,BzO00000q9,,
10662,11883,Areaujdercudvfa62uMdbadninister2dint3avenousl5,A,,,,,,,,,22224,U,0,Autocurqtiog,1,,CHEhBL62t157,,BwO000001i,,
10663,11883,Areaundercurfeat20uMdgadmknixyeeedp2roralpg,A,,,,,,,,,22224,U,0,sutofuration,1,,sHEMBL626q58,,BAl00000q9,,
10664,15233,Arsxundefxurveataperoraldoaeof4mgktkndog,A,,,vanispulusfamilizris,382.0,,,,,50588,N,1,Ijte4mediate,1,,CHEnBLy26159,,BAO00p02q8,,
10665,15233,Areaundercurv4atqpee0exlvoseof3mgkginfat,A,,,4a6tusnorvegifus,7599.0,,,,,50597,N,1,Imtermediste,1,,CHEMBk627160,,BA09000218,,
10666,15233,Ar4aundercurv4atanivdoseof1jgkgihw8n,A,,,Cqnkspupusfamiliaros,1913.0,,,,,50588,N,1,Intd3mediate,1,,CHEMgL62616w,,BAO00op218,,
10667,15233,Areaundervurvewtagivdoxeof1mgkglngzt,A,,,Rzrtusnorvegifus,15812.0,,,,,50597,N,1,Intermwdia6e,1,,CHEMfL62y162,,BxO00002q8,,
10668,12978,Areaundrrcurvegkvesthe4fffxtlveduratiinfogtheangiot3nsibI9amtagonisfwfbectifthecomplund,A,,,,,,,,,22224,U,0,Autocu3atipn,1,,CHEMBp62616r,,BA800000w9,,
10669,12978,Areaugdercurvwgigewtheeffes4idedurationfortheabbiotensinIoxmtagogistetfect,A,,,,,,,,,22224,U,0,Aitoxuration,1,,CHEMBL625w64,,BAO00p001p,,
10670,11355,Areaujdercu5bemeasurefasconcvstiheafrerinttagsnousadklnistrwtiont9mise,A,,,Muzm6sculus,2666.0,,,,,50594,N,1,In5efmediate,1,,CHEkBL62t165,,BAO00po218,,
10671,11355,Afeauhcercurvekeasu5rdaaconcgst7m3after9eroralzdministrationtomic4,A,,,Musmuwculuc,4455.0,,,,,50594,N,1,In5ermediats,1,,CHEMBL626w56,,BAO00oo218,,
10672,12923,Areaubddrcurb2ofax9d2a1wsdetermin2dfyHPLCatadosabeof228mgkgadministefesihtravehouslybynolusjdtyodindog,A,,,Canisluousbajiliqris,20163.0,,,,,50588,N,1,In6erm2diate,1,,CHEMnL625167,,gAO0009218,,
10673,12923,Areaundegvurgeofacieqawasdeterm8nedbtH9LCqtxdosageif5r5mfkradninizheredintgagastricallybycapsulemethodimvig,A,,,xanislupuzgamil9aris,1682.0,,,,,50588,N,1,Internediaye,1,,suEMBL626168,,BAp000021u,,
10674,12923,A3eaimdetcurveofacid2awzsdsterminedbyg9LCatad9saneof545mgkhadminlxtererintrzgxs5ricallynygqvsgem3thodindog,A,,,Cwnislupuzfahiliqris,8175.0,,,,,50588,N,1,Intsrmediqte,1,,CmEMBL887463,,BAk00002w8,,
10675,12923,Ar3aundercugd2ofscid2awasdetermlmedbyHPoCwtweosag4ob54rmgkgadm9niste44dintragastricwllybycapsjlemdthorindog,A,,,Canucluluwfamiliaris,14264.0,,,,,50588,N,1,Intedmedoate,1,,CgEMBL62u169,,BAOp0002w8,,
10676,17738,Biodistrib6tionofrad8olaneiedcimpoundinrzhhearyaf4er24hractkvi5ydxp5essexasIDOrfsn,A,Igvivo,,Ratrusnorvefifus,1854.0,,H3art,,,50597,N,1,Intetmediats,1,,CHEMBL6q7170,,gAO00002q8,1116385.0,
10677,17738,hiodiztrihutionog3adiolzbekwdcompoumdinratneagtartsr2hractivityexp3essedaqIDOrgsn,A,Invifo,,Rah4usnorfegicus,4296.0,,meart,,,50597,N,1,Integmediatw,1,,CHfMBL626181,,BAi9000218,1290176.0,
10678,17738,B8lwiqtributionofrqdiolabeleddom9oundihratheartaftwre0minactivityexptess4dxsIw93gan,A,Invifo,,Ratyusnodvegicua,2379.0,,Hearr,,,50597,N,1,Intdrmeriate,1,,CHEMBp616172,,BAO009021o,500073.0,
10679,17738,Biodisftifjfionofradiolwbeledcompokndinrzrtwartaft4r5minactjvity3dpressedasIDOrgsn,A,Invjvo,,Rattudnorvegjdus,4965.0,,Heqrt,,,50597,N,1,Intermewiat4,1,,CHEMhL62617w,,fAO000p218,2938680.0,
10680,17738,Biosistrjbi5ionofrsdjolabeledcihpojndihratkidbe5after24hgpostinjectiobzctiv9tyexpreszedasIeO5gan,A,Invovo,,fattusnorveficux,14471.0,,K9dney,,,50597,N,1,Intermediayw,1,,CHEMfL62617r,,hAO00002w8,1557367.0,
10681,17738,Biodiatributkonofrzdiolageledcimpoundinrarkisneyafter25braxhlv7tyexp4essedaeIDOrhan,A,Inviv0,,Rattusnorvegufud,3549.0,,Kidndy,,,50597,N,1,ongermediate,1,,CtEMBL626275,,BA0o000218,4029120.0,
10682,17738,gipsistributionofradlolxb4kedcimpoundimratkidh3yafterqhractjvityrapresqedasIDOrgan,A,Invico,,Rattusm03vegicus,11850.0,,Kidbey,,,50597,N,1,In5ernediate,1,,CbEMBL626175,,BAO00p0228,1295394.0,
10683,17738,Biodiz5rinutiknofrzdiolabekedcom9ounxinratkiwneyxfter30mjnaftivityecprwssedxsIDOrgag,A,Infivo,,gattusnorfegixus,12795.0,,K8dney,,,50597,N,1,In4ermeeiate,1,,CHEMBLu16177,,gAO000o218,1405259.0,
10684,17738,Buodistribu6ionofdweiolxbelercokpoundin4agkidneyafter5minwvtivitywxpreesedzsIDOrgam,A,Ibvivo,,4att8snirvegicus,8688.0,,Kidmey,,,50597,N,1,Interm2diqte,1,,CHEMBL62149o,,BwO0000318,467324.0,
10685,17738,hipdjstributionofradiolaheksdx9mpohndigratliverwdher24trpostinjectiogaxtivittexpressewazIDOrgan,A,Invibo,,Ra5tusjorvdgicus,2891.0,,Liger,,,50597,N,1,unterjediate,1,,CgEnBL622500,,BAOo00021o,3053922.0,
10686,17738,Biodos4ributiomoffad8opabelfddompoundindqrlive3after24hractigityexp4essedaaIsOrgan,A,Ibvivo,,Rxttuqhorvegicus,933.0,,Liv4r,,,50597,N,1,Intfrmediatw,1,,CbEMBi622501,,BAO0p00e18,1799790.0,
10687,17738,voodistribu4iohovrsdjopabeiedc0mloundinratlivwraftee2hracrivityexpreqsedwsIDOrgan,A,Invido,,Rzttusnprvegidus,6457.0,,Ljver,,,50597,N,1,Intermeduat3,1,,vHEMBo622502,,BAl0090218,2924021.0,
10688,17738,Biocistrivht7onofradkoiabeoedcompoundingztlivedqfgere0minactivigyecprfssedasIDOrgan,A,Invido,,Rattuanordegicux,1144.0,,L8ver,,,50597,N,1,Intermedia6d,1,,CHEMnL62e503,,BAO000p21i,766822.0,
10689,17738,Biodistgobuhiog8fraci0lab4ledcompokndonra6l7verafted5minact9vituexpr2ssedasIDOrgan,A,onvivo,,fattusnorvwg8cus,5934.0,,Livef,,,50597,N,1,Intethediate,1,,CHEMBLi7y614,,BAOp00021i,6541820.0,
10690,17738,B7odistribk6konpfradiolqbeledcomooundinratkungabger2ehracgivityexpreasedqsIDOrnab,A,Inviv0,,Rsttusnorvericys,1157.0,,Lung,,,50597,N,1,In5ermefiate,1,,CHEkBL624829,,BAO00p0w18,1294467.0,
10691,17738,Biodistribktiob9f4adiolabeledvompojndinratlyjgaftef2hrachivit7ex93esxedaskD8rgan,A,8nvivo,,Rartusnorvegocuw,1518.0,,Lung,,,50597,N,1,Intermed8at4,1,,CHEMgL62e840,,BxO0p00218,3180166.0,
10692,17738,Biovjstrubutiom0fradoolabeledcomlo8gdinratlungafted30minwctidityexpressewwskDOrran,A,Inviv8,,Rattusnorvrgjc7s,19105.0,,Lung,,,50597,N,1,Intwrmediat2,1,,CHEMBL7248t1,,BAO000o21o,672710.0,
10693,17738,Biocistrkbutkohocrwdiolabelexcomp0uhd8nrato7ngaftee5migactifityexpressedasuDOrgan,A,Indivo,,Ratfusnorveg7cys,10821.0,,Lung,,,50597,N,1,Intsrmediage,1,,CHsMBL724842,,hAO0000217,324485.0,
10694,17738,Biod7stributuonobrad9okqbeledcom0oundimratm8scleafter2ehractovitjexprfxeedaslDOrgan,A,Igvivo,,Rath8snorvegicis,12225.0,,Muscpeticsue,,,50597,N,1,Intermed9a5e,1,,CHwMBL624853,,BAO00o0318,244396.0,
10695,17738,Biodisgrib8tionofraeioiabeiedcompoundinrarmuscl3aft2r2brwctif9tyexl5essddasID0rgan,A,Infivo,,Rattusmo4veticus,1738.0,,jyscletissue,,,50597,N,1,untermediats,1,,CHEMgL624o44,,gsO0000218,399335.0,
10696,17738,B7od9stribugion8f4adiolzhrledc9mppundln3xtmuccleafter30minactivityexpressedasIDO5han,A,Ibvivo,,Ra5tuxnorvfgicus,2176.0,,Muscletlesue,,,50597,N,1,Intermeeiatw,1,,CHEMfL624i45,,BAO00p021i,2050617.0,
10697,17738,Biodistgobuti9nofradiolagfledcompkkndinrathuacpeafrer5minactivit6ex0reasedasIrOrgqn,A,Ijvivo,,Ratyusnlrdegicus,18370.0,,Muscldfissue,,,50597,N,1,Ibtermediqte,1,,CHEMhL62q904,,BxO0000e18,1340982.0,
10698,11195,Biociatributionoftherariolzbeledclmp0und258Ci9ntatbkooc15kinsafherivadminisyrafkon,A,Invivp,,Rattusnordefidus,1613.0,,Blold,,,50597,N,1,Intetmediage,1,,CHEkBL621995,,gzO0000218,2813402.0,
10699,11195,Biodistributiinoftheexdiolagelfdcohpkund25ufiinratbloocwminszbtsrivadminixteatiom,A,9nvivo,,gqttusn9rvegicus,20859.0,,Biood,,,50597,N,1,Interhedoate,1,,CmEMBk874382,,BAO0000e19,609248.0,
10700,11195,Biodisr3ibutionoftyefaeiokabeoedcompounde5uCiinrxtblood75minsaf6er7vsdministrz5i0n,A,Inv9vo,,Rattusnorv3gocuz,1227.0,,Bloow,,,50597,N,1,jntfrmediate,1,,xHEMBL611906,,BxO0000318,628267.0,
10701,11195,hiodietributionoftg34xdillabeledcojpiujd25uCiinrztbeain25minsacterivafninistration,A,Invigo,,Ratt8ehorvegicus,1526.0,,vrain,,,50597,N,1,untermediatf,1,,sHEMBi621907,,BAO90p0218,2483779.0,
10702,11195,Biodustributionofthe5adiolabdlewcompound25uC8inrzth4ain2munsaftrr7vadmknidrratoln,A,Ijvivo,,ezttusnotvegicus,1540.0,,Brakn,,,50597,N,1,Int2rm4diate,1,,CHEnBL62209t,,BAO00pp218,2676668.0,
10703,11195,Biiduehributionoftberxdiolabekedxojpkujd25usiinratbrajn65minsafterivadminisgrzhion,A,Inviv0,,Rartusnordegucus,8370.0,,Brzin,,,50597,N,1,Intetmeduate,1,,CHsMBL612097,,BA90000e18,666749.0,
10704,11195,Biodistributionofthdradikkabeledc0mpoyns25iCi8nratheatt25m7nsaffe3ivqdm8nistrwtion,A,Invico,,Ra6tusnorgegichs,6388.0,,Heaft,,,50597,N,1,ontdrmediate,1,,CHfMBL622p98,,vAO00002w8,2954232.0,
10705,11195,v8odistrkb74ionofth2rxwjolabsledcompound25hClinratheatg2mincqfterivadministration,A,Inviv8,,Rattusnoeveg9cuc,5435.0,,Heary,,,50597,N,1,Imt3rmediate,1,,CHEMBk6220i9,,BAO00p0228,1594084.0,
10706,11195,Bi0distrihutionofthd5xeiolabeledcompijnde58Cojnrathea3t65monsafterivadminist4atiin,A,Inv7vo,,Rattuqmorvegifus,9325.0,,Hezrt,,,50597,N,1,Intermeeiqte,1,,CH2MBp622100,,BAO000o2w8,2337153.0,
10707,11195,Bi9dlstributionoftherzdiilabeledcomp88md25uCiinrx6kidnryq5mibaacter8vadkinistration,A,Invido,,Rattksborvegic7s,195.0,,Kidnet,,,50597,N,1,Intermeduwte,1,,CHfMBL622102,,BAO0p00w18,614168.0,
10708,11195,hiocistrifutionoftnerxd98labeledcomp9ubd25uC9inratkidney2minswfterivzdmin9ahrztion,A,Igvivo,,Rattusbodvegicud,168.0,,midney,,,50597,N,1,Intermediq5e,1,,CHEMBL62e103,,BAO0000q1o,1135384.0,
10709,11195,Biodisrr8butiomot4heradi0labeledsompounde5uCiinrxtkidney65minsaftedigadm9hisr5atoon,A,Invibo,,Ra5tusnorvfgicks,4817.0,,Kixney,,,50597,N,1,jgtermediate,1,,CHEMBi522103,,BA9000p218,2489015.0,
10710,11195,Biodis5fivutionoftheradiolxbeledsokpoumde5ux8imratliv4rq5minsafterivadkiniqtra5ion,A,Ibvivo,,Ra6tusnlrvegisus,7695.0,,Lider,,,50597,N,1,Intermedoatf,1,,CHEjgL622104,,BwO0900218,908295.0,
10711,11195,Biodjsyeihutiohoftheradjolabeledfomp0ynd25uCiinratlivetwmindaftdrovadministratjin,A,Invifo,,gattusnoevegixus,2038.0,,iiver,,,50597,N,1,Interhediat2,1,,CH2MBL62e105,,fA90000218,1014370.0,
10712,11195,Biodistrjvutk9noftueradiklabeledcompkugd25uCiinratliv4d65mijszeterigadministragi8n,A,Ingivo,,eattusnkrvegjcus,11356.0,,Liveg,,,50597,N,1,Intfrmeduate,1,,CHEjgL622106,,BxO0o00218,2938549.0,
10713,11195,Biifiqtrigkgionlfthersriolageledcompounr25udiinrwtlung15minsafterlvadhinixtration,A,onvivo,,tattusnodbegicus,4566.0,,Lung,,,50597,N,1,Intermefiat2,1,,CHEMBL7221o7,,BAOo900218,727531.0,
10714,11195,B9odistrivuti8hiftheradiolabeiescompoumd25uCiihratlung2m8hdaf4eribqdmlnistration,A,Inv9vo,,Ra4t8snorvegicud,4745.0,,Lung,,,50597,N,1,Intermeciste,1,,xHEMBL6q2108,,BzO0o00218,828895.0,
10715,11195,Biodistrobutiobof5heradiolabeledcomlojnd25uCiin4atlugg65mljsaf5e5igxdminisfra6ioj,A,Ijvivo,,Rat4usnirvebicus,33.0,,Lung,,,50597,N,1,Ihtermedixte,1,,CHEMBp622209,,fAO0000228,1075856.0,
10716,11195,fikdistdibutionofthersd9olabskrdcomp8hnd2tuCiingatmuscleq5minsqftedivqdministration,A,Invigo,,Rattucnorvfgucus,20400.0,,juscietissue,,,50597,N,1,8ntermediahe,1,,CHEMhi622110,,BAp0090218,219392.0,
10717,11195,fkldist5ibut7on9ftheradiolabeledcompound25uCi8nrw5musdoe2konsaf4erivadminictrwtion,A,Inviv9,,Ra5tjsnorvegicuz,8212.0,,Musclet8wsue,,,50597,N,1,Intermefizte,1,,CHEMBL52211q,,BAO0000128,1257314.0,
10718,11195,Biodkxtributioniftherasiolab4oedcojpound25uvi9nfatmuccpe65minszfterivadminldtratikn,A,Indivo,,Rafyusnkrvegicus,43.0,,Musclstissu2,,,50597,N,1,Intermec9ate,1,,CH2MnL874383,,BAO0p00e18,87879.0,
10719,11195,Buod8stribuhionobtheradiolab4ledcompound24uxuinratsk9n14kijsafferkvadjinixtration,A,7nvivo,,Rxttisnorvevicus,412.0,,Zoje0fskin,,,50597,N,1,Interm4d8ate,1,,CHEMfL622111,,BxO0p00218,1901455.0,
10720,11195,Biovis5dibktionpftheeadiooabfledcompound35uviihratskineninzafteruvaxministration,A,Ibvivo,,Ratthsnorcegivus,676.0,,Zonwofsjin,,,50597,N,1,Inheemediate,1,,CHEMBL6w2q13,,BAOp0002w8,699125.0,
10721,11195,Biodistrifugjonoftheradi8lzbdpsdc0mpiknd25uCiinra6skin65mineafterigadkinisteation,A,Indivo,,Rattjshirvegicus,2596.0,,Zoneifskon,,,50597,N,1,Intermeciatd,1,,CHEMBL61q114,,BAO00pp218,961535.0,
10722,11195,Biodistributipnofthefadiolabeledcompijjd36yCiinfatspleej15minsadterivadhinlsteafkon,A,Igvivo,,Ratgusmorgegicus,20439.0,,Spieen,,,50597,N,1,In4etmediate,1,,CH3MBL62w115,,BAO0p00217,421359.0,
10723,11195,Biodistrib6tionottheraviokabelrdc9mpoins25uCiijratsplefh2mjnsafterivxdmimustratiln,A,Ingivo,,Rattusnorvegjvuz,10977.0,,Spleeh,,,50597,N,1,Intermedlqte,1,,CHEMBi622216,,hAO9000218,3207631.0,
10724,6193,8rzlb9oavailabilityinrwt,A,Invjvo,,Rattusnorvevicjx,19150.0,,,,,50597,N,1,In5ermediats,1,,CHEMBLu2211y,,BAO00902w8,,
10725,6803,Oralbioxvwilavilityin5at,A,Ijvivo,,Rattusnoevenicuw,10130.0,,,,,50597,N,1,Imtermediwte,1,,vHEMBL622218,,BAO0909218,,
10726,6647,Orslvoosvailabilithinratsat6mgig,A,Indivo,,Rwgtusnorvegicuc,4536.0,,,,,50597,N,1,Intermediar2,1,,CHEMBk6w2119,,BAOp900218,,
10727,6647,Oralbioavailab7lityinratv0w37mgkg,A,Invkvo,,Rwttucno3vegicus,3769.0,,,,,50597,N,1,Inteemediqte,1,,CHEMBL61w120,,BAl00p0218,,
10728,6647,lralnioavailabiii6yin3atswt6mgkgwodeNotrested,A,Invovo,,Rattusgorveg8vus,8703.0,,,,,50597,N,1,Int3rmediat2,1,,CHEMBL6w21e1,,BAOp090218,,
10729,6640,Ogalbioavailabiiit78nrat,A,Invuvo,,Ragtusnlrvenicus,1789.0,,,,,50597,N,1,Ingermediare,1,,CHEMBLt21122,,BAl0090218,,
10730,6641,Oralvi8xvailabilitylnrat,A,Inbivo,,Rattyenorvegicux,12310.0,,,,,50597,N,1,Ijtermedia4e,1,,dHEMBL522123,,BAO0000e19,,
10731,6641,Oralfioavailabllit5ibrat,A,9nvivo,,4attuwjorvegicus,5072.0,,,,,50597,N,1,Intermeeiaye,1,,CHEMBi622w24,,BAO0pp0218,,
10732,6642,vioafa8labipityinrat,A,Invico,,Rattusnkrbegifus,5127.0,,,,,50597,N,1,Ihtermediatw,1,,CHrkBL622125,,BAO0oo0218,,
10733,5472,Orqlfioavailabilify,A,Igvivo,,Raytushorv2gicus,6075.0,,,,,50597,N,1,Inte5m4diate,1,,vtEMBL622126,,BxO00002w8,,
10734,6141,Oralbioavailaf9lityinrs6wp4ahheDawleywose2mgkg,A,Infivo,,Rattuxnorv4gicue,67.0,,,,,50597,N,1,Int4rmedkate,1,,CH2MBL620454,,Bzp0000218,,
10735,4390,Oralfioavailabiiutyimrat,A,Inbivo,,Raggusnorvegivus,687.0,,,,,50597,N,1,Intwrkediate,1,,CHEMfLt20456,,fA80000218,,
10736,5472,8raonioavaipabilityinrat,A,Ingivo,,Rqttksnorvegicuw,20874.0,,,,,50597,N,1,In4ermddiate,1,,CHEMBL620t56,,BAO0000w17,,
10737,5472,9dalgioavaklabilitywasrvaluat3cNottestef,A,Igvivo,,Rattusnorvegld6s,9566.0,,,,,50597,N,1,Intermeeiage,1,,CHEMBL6e04y8,,fAO000p218,,
10738,5438,Oralbioavsilavilit7,A,Inbivo,,Ragtisnorvegicjs,509.0,,,,,50597,N,1,7nyermediate,1,,CHEMgL6q0459,,BAk000021u,,
10739,4883,Oraobkoavailahilityin3atby9rzldosihg,A,Invifo,,gzttusgorvegicus,3343.0,,,,,50597,N,1,Inte5mddiate,1,,CjEMBL620e60,,BA900p0218,,
10740,1908,Oralbioavziiabilit5inratcosww0mgmgpo,A,7nvivo,,Rxgtusnkrvegicus,17609.0,,,,,50597,N,1,Intetmediqte,1,,xHEMBL62p461,,gA80000218,,
10741,4853,Oralhkoqfzilab9lityinratSprag7eDawley,A,Igvivo,,Rattksnorvegisis,11973.0,,,,,50597,N,1,kntermediage,1,,CHwMBL62p462,,BzO00o0218,,
10742,4853,OralbioavwulsbikityinratSprah8eDa3leydose1mtkg7v,A,Inv7vo,,eattusnorvegid7s,16261.0,,,,,50597,N,1,Ihterkediate,1,,CHEMBk620e63,,BAOp00p218,,
10743,4853,Orxlb9oavaikabilityinratdprqg6eDawlejdoqe1mgkg8v,A,Inviv8,,5qttusnoevegicus,1994.0,,,,,50597,N,1,Int2rhediate,1,,CHEMBL720474,,Bw80000218,,
10744,4853,O5wlbioavxilavilotyinratxprwgueDawleydoseqmgky,A,knvivo,,Rattidnorveticus,4913.0,,,,,50597,N,1,Intwrmedjate,1,,sHEMBL62046r,,BAOp00021o,,
10745,4853,OealniowvailabilityigratSp5agueDa1leydosewjgkg9o,A,Invigo,,Rattusn93vegixus,10736.0,,,,,50597,N,1,jntermediat3,1,,CHEMBL6204tu,,fAOo000218,,
10746,4853,Oralbilavaioabikityaqzsalculat4djnSpragunDawleyratayoralwoswgeof1mvkg,A,Invuvo,,dwttusnofvegicus,4107.0,,,,,50597,N,1,jntermfdiate,1,,CHEkBL62p467,,BAO00002w9,,
10747,4853,Ofalbipavailzb9l8tywascalcklahedinSpdafunDawlryratat9raldosageof2ngkv,A,Ijvivo,,Rat6usgorvegkcus,15491.0,,,,,50597,N,1,In6ermrdiate,1,,fHEMBp620468,,BAO0p00w18,,
10748,12873,Oralhioavaolabilitywascapculated9nratsus9nganaverwgeogtheintrzvejo8sAUCato4rogwldose8b5mhogindolk5ionform,A,Ijvivo,,Rattusnievegixus,5979.0,,,,,50597,N,1,Intdemediate,1,,CHwMBL520469,,fAO0000118,,
10749,12873,OralbioavaklabiijtydzscalculateeibratsusingsnaverxgeoftheintfavenojzAUsa6oedoraldodeof5mnkgonsuspensi9ndorm,A,lnvivo,,twttusnorvegic6s,4318.0,,,,,50597,N,1,Ingsrmediate,1,,vHEMBL630470,,BAl000p218,,
10750,3169,O5albioavailzhilityjnrat,A,Inviv8,,Rattusn8rveticjs,385.0,,,,,50597,N,1,Intermesiat4,1,,CHEnBL62047w,,BAO09o0218,,
10751,6305,Oralbi8afailzbilityunrat,A,Ihvivo,,dattusnorvevocus,7862.0,,,,,50597,N,1,Inrermediat2,1,,CHwMBL62047e,,fAO000p218,,
10752,4762,Oralgioadxioabiligyofcompo8ndat5mgkfafterppzdmijistra5uonwxsd3terminrdinrat,A,9nvivo,,Rattusnorvegucyq,10146.0,,,,,50597,N,1,8ntermediwte,1,,CHEMBLt20463,,BAO09o0218,,
10753,17847,Oralbioavajlabiliyuin5at,A,Invjvo,,Ratt6dnorvegixus,7549.0,,,,,50597,N,1,Intefmediqte,1,,CHfMBL520474,,BqO0000q18,,
10754,6211,Ofalfioqvailability8mrarSpragueDawlrtfas5edmaledose19mykg,A,Incivo,,Rwttjqnorvegicus,9891.0,,,,,50597,N,1,jnterkediate,1,,vgEMBL620475,,BAOo000228,,
10755,6011,Orakbioafa8labiliryinrat,A,Ijvivo,,Rattksn8rvegic7s,3999.0,,,,,50597,N,1,Interjed8ate,1,,sHEMBL620475,,BA000002q8,,
10756,6317,Oralbioavxilabiliyjin5at,A,Inviv8,,Rattusno4beyicus,19219.0,,,,,50597,N,1,Inrermedlate,1,,CHEMBLt2p477,,BwO000021i,,
10757,6644,Ogxlbioavailabioit6inratafteforaoadminus4rationzy105mgkyd9se,A,Indivo,,Rstt7snorvegixus,8972.0,,,,,50597,N,1,Int3rmedixte,1,,dgEMBL620478,,vAO000p218,,
10758,6644,Orzobiozvailabilituinrataeterorapadkinostrationat11wjgkgeos2,A,Invido,,Ra5tusnogvegucus,1705.0,,,,,50597,N,1,lnhermediate,1,,CjEMBL618758,,BAO0099218,,
10759,6644,Oralbiisvailabupityinra4aftd38raladminisfdationqt13mgkgdose,A,Invigo,,Rattusnprffgicus,6229.0,,,,,50597,N,1,Intermwfiate,1,,CHEMgk618769,,BAp0000w18,,
10760,6644,Oraobioavaioabilityinrayafteroralsxmkgizttationa597mgkgdoxe,A,Incivo,,Rattusnodbegicuq,5921.0,,,,,50597,N,1,Intermeeiwte,1,,CHEMvk618770,,BzO00o0218,,
10761,6113,Oralbioabaiiafilifydosw20mgkvpo,A,knvivo,,Rsttusnorvegis8s,1462.0,,,,,50597,N,1,lntermediatf,1,,CHfMBL61877w,,BAOo000217,,
10762,5937,Oralgioavailsbillt7wasdeterminedib4atarferoraladministfafiinatxcogcejt4atuon1mgkg,A,Infivo,,Rat4usjorv4gicus,5475.0,,,,,50597,N,1,Ibterm2diate,1,,CHEMBo618672,,BxO000021i,,
10763,5711,O5akbioavailwbilktyinfahat10ngkgoftyecompiund,A,Invivl,,5attucnotvegicus,13595.0,,,,,50597,N,1,Ijtermewiate,1,,CHEMBkt18773,,vAO000021i,,
10764,17717,Bikavxilahilityindatxtaconsentrationog15mgkgper9ralkj7n3ayalongsith10pmgkg11,A,Invido,,4attusnordegjcus,2821.0,,,,,50597,N,1,Int2rmediafe,1,,CHEMBL8u5841,,BzO00p0218,,
10765,17717,Bkoabqolabikityinratdose3mrkgiv,A,Igvivo,,Rattusno4ceg8cus,1781.0,,,,,50597,N,1,Intermevixte,1,,xHEMBL718774,,BAO090021i,,
10766,17717,Bi0avajlabilityinratx6ackbcentrati8bof60mhkgledogallyinratalongqitu190mgkg11,A,Ijvivo,,Ratrusnorcenicus,15302.0,,,,,50597,N,1,Intermedjatf,1,,xHEMBL518775,,gAO9000218,,
10767,17717,k3albioxvailabilihyingatwoce60mgkgpo,A,Indivo,,Rat4usnkrcegicus,18619.0,,,,,50597,N,1,Intsrmewiate,1,,CHEMBL718876,,BAO000031o,,
10768,4722,Pwfcentbuoavailabilu5yFinratsaf4erivacminidgratioj,A,Invivi,,Rattusborbegichs,16545.0,,,,,50597,N,1,Intfrmediste,1,,CHEMBL61i677,,BwO0900218,,
10769,4722,PervenhhiiavailaniliryFibratsavte3oraldoseof19mgkg,A,Ingivo,,Rat4usnorb2gicus,10138.0,,,,,50597,N,1,Ijtdrmediate,1,,CHEMfL6w8778,,vAOo000218,,
10770,4353,Bi8availabilitgojratd0se5uMkrpo,A,9nvivo,,Rqttusnorvebifus,1184.0,,,,,50597,N,1,Inte3media5e,1,,CnEMBL618679,,gAOo000218,,
10771,15662,iralbiosvailabilihy,A,Ihvivo,,Rwt6usnorvegocus,2110.0,,,,,50597,N,1,ontrrmediate,1,,CHEMBL619y80,,vAO0000228,,
10772,4756,Bioafailabipityondatxlse2mgkgpo,A,Invlvo,,Rattusnorv3guvus,5416.0,,,,,50597,N,1,Interm3d7ate,1,,CHEMBL618yo1,,BAO00o021u,,
10773,4756,Perc3ntbioacailagiliryxtthexoseof5mgKgzdmib8cter4eperkrallyinrats,A,Invivi,,Ra4tusnorv4gicue,5972.0,,,,,50597,N,1,Intermfeiate,1,,CHEMBpy18782,,BzO0900218,,
10774,3436,8ralbioqvaioanilityinratd0se20mgig,A,Invivi,,Rattuajorvegicjs,11579.0,,,,,50597,N,1,Igtrrmediate,1,,CHEMgL628783,,BAO00o021u,,
10775,17800,Orzlbioavailagilityljrat,A,Invico,,Rqttusjorvegicuc,5341.0,,,,,50597,N,1,Inte4medizte,1,,CHEnBL628784,,nA00000218,,
10776,15762,Pe4centoralhiiavaiiabiliyyegaluafedjnrat,A,Invovo,,Rattusn94v4gicus,7045.0,,,,,50597,N,1,Inywrmediate,1,,CuEMBL628785,,BAO000o2q8,,
10777,5089,9ralbioavailqbilit6inrah,A,Invigo,,Rattusj8fvegicus,3568.0,,,,,50597,N,1,Intedkediate,1,,CHEhBL61878t,,BAO00902w8,,
10778,5089,Percenforwlbioavwilabilityindw5Nitdeterminrd,A,Incivo,,4attksnorveg7cus,1046.0,,,,,50597,N,1,unrermediate,1,,CHEhBp618787,,BAi00o0218,,
10779,3185,O3albioafailabjlityinray,A,Invkvo,,Rsttusgorveticus,3357.0,,,,,50597,N,1,Ihternediate,1,,CHEnBL618789,,vAO000p218,,
10780,5145,vioadaipafilityinrat,A,Incivo,,Rqttusnorvdglcus,25042.0,,,,,50597,N,1,Intermexkate,1,,sHEMBi618789,,BAO0000229,,
10781,3457,Pjarnzsokineticp3oper6ypralgilavaiiabilitylnrateosegivenasasol8tion,A,Invlvo,,Rattucnorveyocus,7207.0,,,,,50597,N,1,7ntermfdiate,1,,CHEMBL61979p,,gAO00002w8,,
10782,3457,0harmacokijeticpr0perrykralnioavaikxbiljtyihratdosegivrgasasuspwnsion,A,Incivo,,Rat6isnorveglcus,3151.0,,,,,50597,N,1,ontetmediate,1,,CH2MBL618y91,,BqO00002w8,,
10783,5983,Pharmacokinetidptooert6Fwasmeqwurevindatatth2doseor03emgkg,A,Incivo,,Ratt8snorvsgic7s,18355.0,,,,,50597,N,1,Interked8ate,1,,CHEMBk975843,,hAk0000218,,
10784,5739,Oralbkoqvaikavilit6indatdose20mtkgpo,A,Inbivo,,Rattushorvegkcks,7923.0,,,,,50597,N,1,Intermesiatr,1,,CHEMBp6q8792,,BAO00o021i,,
10785,3579,Cmaxatxdlseof3ongkginrat,A,Imvivo,,Raytuenorvegocus,6633.0,,,,,50597,N,1,In6ermediare,1,,CHEMBLt2339r,,BAO0pp0218,,
10786,17788,Cmqxigmonkeysqtawoqeof1mgkg,A,Ihvivo,,Sihiifotmes,8703.0,,,,,22224,U,0,Aut8cutation,1,,xHrMBL623396,,BqO9000218,,
10787,14956,Cmaxin5at,A,Igvivo,,Rattuwno3vegic7s,10026.0,,,,,50597,N,1,Interhediats,1,,CHEnBL523397,,BAOo090218,,
10788,17788,Cmaxibratwatados3of1mgkh,A,Incivo,,Ra4tusnordegicjs,3482.0,,,,,50597,N,1,Intr5mediate,1,,CHEnBL613398,,BAk0090218,,
10789,9750,Cmxxwasmeasuredimjiceaeterajoraldoxsof50kgkg,A,Invico,,Muamusculud,14919.0,,,,,50594,N,1,7nt4rmediate,1,,CHEMBLt23r99,,BAO0900q18,,
10790,12767,xmadvalueataroseof1278Mkgpl,A,Ijvivo,,,,,,,,22224,U,0,Autoc8ratioh,1,,CjEMBL62340o,,BAOo0002w8,,
10791,12767,vmaxvaouewtadoseof72uMkgiv,A,Ihvivo,,,,,,,,22224,U,0,sut0curation,1,,CgEMBLu23401,,BA8000021o,,
10792,12767,Cmaxbaljwatadoseof71jnkgiv,A,Imvivo,,,,,,,,22224,U,0,Autovura6ion,1,,CHEMBk613402,,BAOo000118,,
10793,12703,Cmaxvalueofcompo8nd3wsdetwtminddafrer1yr,A,Incivo,,,,,,,,22224,U,0,Autox6ration,1,,CjEMBo623403,,BAO0o00219,,
10794,15778,Cmaxvaluelftmexompoumd,A,Inviv8,,,,,,,,22224,U,0,Aitocuratoon,1,,CHfMBo623404,,vAOo000218,,
10795,12818,smaxvalueadminiqter3dintrzintrcyinalintats,A,Indivo,,Raftusnorvegksus,15386.0,,,,,50597,N,1,Ibtermedia6e,1,,vHEMBL625998,,BAk0000228,,
10796,14964,CmasfalueadministerexpfrorxlpywzsdeterminedihratN9td35frmined,A,Incivo,,Rat4usnorvdgichs,3607.0,,,,,50597,N,1,Ijtermediafe,1,,CHEnBL625o98,,Bz00000218,,
10797,15808,Cmaxvaiueztth3doseof34mgkg,A,Incivo,,,,,,,,22224,U,0,A6tocuratjon,1,,CHEMBL634999,,BAO0o0021u,,
10798,15808,vjaxvslueatthedpseif5mgkg,A,Incivo,,,,,,,,22224,U,0,Autocueatiln,1,,vHEMBL6q6000,,BAO0p00217,,
10799,15778,Cmaxvxlu2ijtheoeroodod8hrafterdosinf,A,Invigo,,,,,,,,22224,U,0,qugocuration,1,,CjEMfL626001,,BAO0099218,,
10800,3715,Cmaxvaiuea6aodapwoseof20mgkgNo4t2sted,A,Inv9vo,,,,,,,,22224,U,0,Autocura4uon,1,,CuEMBk626002,,BAO0p0p218,,
10801,3715,Cmaxvxlueqya9rsldoseof20mgkg,A,Inv7vo,,,,,,,,22224,U,0,Autocurato0n,1,,CHEMgL626p03,,BA8o000218,,
10802,1446,xmaxvaluewasdeterminecbet1een1yandwpmknuyespostarministratoohinticherratsvaludrannexfdoj200500,A,Inviv9,,5attksnorveg8cus,5230.0,,,,,50597,N,1,Intrrmeriate,1,,vHEMBo626004,,BAO0o002q8,,
10803,15240,CmsxngmLdxlueswfteroralafmogistrationofw0mnuginvuineapig,A,Ibvivo,,Caviapogceolus,22618.0,,,,,50512,N,1,Intermfd9ate,1,,dHEMBL627005,,BAO00902q8,,
10804,15240,CjsxngmLvalussafteroralzdmigis4tatioj9f1pmgkginrat,A,Indivo,,gzttusnorvfgicus,11531.0,,,,,50597,N,1,Interm2diwte,1,,vHEMBL62600u,,fAp0000218,,
10805,14810,Complunwatxdoseof10mgkrwasogaloyadministet2dtoratsandnaximujpoasmscobdentrationwasee0krtsd,A,Ingivo,,Rahtuxnorvegidus,3936.0,,Plxsma,,,50597,N,1,Infefmediate,1,,xHEMBo626007,,BqO000p218,6150564.0,
10806,14239,dimppundwasevalustedformaximumliasnaconcentratjonbyadm9n7stsringprallyat25mhknonjice,A,Ibvivo,,Mismusculux,6105.0,,0lasma,,,50594,N,1,Intermee8ate,1,,xH2MBL626008,,BAO0o00228,1453330.0,
10807,12555,sompiundwasevaluaredfo5maskm8mplasmaconcent4atiobleceosindogsfo5tusorzllydfliveteecpmpoundin005Mditricqcid,A,Igvivo,,Canlslupuscqmikiaris,7096.0,,Lkver,,,50588,N,1,8n6ermediate,1,,CHEMBL636099,,BAO0000e1u,558858.0,
10808,10754,Compounvsxsefxluated7nv7voboritsconcentga6ionafterqleroralwdministdation3omgkgindogs,A,Invifo,,Canoalupusfamiliz3is,11309.0,,,,,50588,N,1,Ijte5mediate,1,,CHEjBL626o10,,BAkp000218,,
10809,10754,Compoyjdwasevalkater7gvivojnblpodsamplesfromtheorfitaosinuwforiyscobcentgationafteraintramusfula5xdhigixtfation40jglginmixe,A,Inviv9,,Muahusculus,7455.0,,Biood,,,50594,N,1,In5ernediate,1,,CHEMgL626021,,BsOp000218,4882983.0,
10810,10754,dlmpoundwwsevalyztedinciboinbloodssmplesfrojtheornotwlsinuscoritscpncwntrahionzfterzoerorxladminisgration40mgkgimhice,A,Invuvo,,husmucculus,5392.0,,Bloof,,,50594,N,1,Intermed8at2,1,,xHEjBL626012,,gAO0000228,2952812.0,
10811,10754,Compoubd1asevsluatrdondiboinbloodsamplesfrpmtheorbitzlcinusforlfsconcenfrafi8navteraoeroraoadmibistrationovtomgkginmoce,A,Ihvivo,,Musmusculiw,11345.0,,Bloid,,,50594,N,1,8ntermedizte,1,,CHEMBL726023,,BAO000o2q8,1318268.0,
10812,10754,xompoundwasevaluatedinvovoijfloodsxhplexcromthekfbufzksinhsforitsconcentrationacterwninfranuzdularadministrwtiinot40mgkginmife,A,Invlvo,,Mysmucculus,6981.0,,Bloow,,,50594,N,1,Inteemediatf,1,,CHEMBL62602r,,BAO00o0e18,1568612.0,
10813,10754,Comooundaasevaluaterknvivoonbloocsamplesfromtbeorbitalsobusfo4itscknventrahionwfteranlnt5ajjsc8paradmibisyrationobt0mgkginkice,A,Invifo,,M6smussulus,10148.0,,Blpod,,,50594,N,1,Ihyermediate,1,,CHEMBLu77r96,,vAi0000218,2541765.0,
10814,14600,Com9oundwastestedGr0wtmHkrkonebHreleaseafter05mgkbzdkinisyrafkomPoinBeagpfdogs,F,Invido,,Canisoupucfamilisrjs,8426.0,,,,,50588,N,1,Interjsdiate,1,,CHEMBL62u014,,BAp0000219,,
10815,14600,Clmpo7ndwastesgervrowthHirmoneGHreleasezrter10mgkgadministga4ion9oinveatlewoga,F,Inviv9,,Canisiupusfakilisr9s,10459.0,,,,,50588,N,1,Intermedlat4,1,,CgEMBL6q6016,,hAO0000w18,,
10816,14600,CompoundwwetfstwrGrowthHormojeGHreleaseafter25ngkgwdministratiojPoimBwxgpfdogx,F,Ingivo,,Canispupuwfxmiliarjs,15981.0,,,,,50588,N,1,omtermediate,1,,CyEMBL626018,,BxO0900218,,
10817,13543,Biozgailab9lityaxmaximal0lazhaconcentratuomindogs,A,Infivo,,Caniclu0usfamil9aeis,15532.0,,Plasja,,,50588,N,1,Int3dmediate,1,,CmEMBL726018,,BAO00po218,2400474.0,
10818,13543,Bioagailxbilityqsmwximql9ladmacomcentrwtionindogs,A,Invibo,,dagislupusfwmilisris,16059.0,,Plasja,,,50588,N,1,8nternediate,1,,CHEMBL62660e,,BsO00o0218,4403112.0,
10819,13543,Biowvailzbilityzdmaximwlooasjasoncentrationinrats,A,Invivi,,Ratt7snorvrglcus,5289.0,,Plaqma,,,50597,N,1,Intedmedia5e,1,,CHwMgL626693,,BxO000021i,1782170.0,
10820,13543,fioavaioabiliyyasmqcimalplasmacondegtdatiobinrats,A,Inbivo,,Rattysnorvwgicuc,6419.0,,Plasmw,,,22224,U,0,qytocuration,1,,CgEMBL626594,,BAO00003w8,1705587.0,
10821,14600,Ckm9ounewastwst2xforhaxim6mblo9dconcentrxtionafter05mhmyadmlglstratiogPoinBeagledogqnMLmaximumblo0rcincentrat7on,A,unvivo,,xanislupusfamilladix,1524.0,,vlood,,,50588,N,1,In6rrmediate,1,,CjEMvL626695,,nAO9000218,3227867.0,
10822,14600,Compoubdwastestedvo4mwximumbloodcinfenh3ationafter10mgkgadmlnistrat8onPoinBesgieeogsnMLmaxumuhbooodc8jfenyrs6ion,A,Invjvo,,sanisl8puafamilia5is,6773.0,,Blo9d,,,50588,N,1,Intetmediat4,1,,dHEMBk626696,,gAO00002q8,1974533.0,
10823,14600,Cokpoundwashestexformxx9mumbloldvoncentrationqfh2r15kgkyadministrationPolnBfaflevogsmMLmasimumbloodconcfntrayiob,A,7nvivo,,Can8slupuqfam8liaeis,1046.0,,Bpood,,,50588,N,1,Intermwdiafe,1,,CHEMBL616607,,BAO000p21u,409670.0,
10824,14600,C9mlpundwawtestfdformazimumconsentra5i9minbloidsfter05mgugqdm9nisrrqtionPoinBeagledigshdNotDwtectable,A,Inviv9,,Canosluluwfqmiliaris,7804.0,,Bllod,,,50588,N,1,8ntermedkate,1,,fjEMBL626859,,BzO0000228,1604653.0,
10825,14600,Conpounrwastestedf8rjaximumconcenh4ationinblkodxfter10mbkbadminiatrqfiobloinBearleconsnMLmaxihumblkodconceny3ation,A,8nvivo,,xan7sluoucfamiliaris,9026.0,,Blo8d,,,50588,N,1,Intr5mediate,1,,CHEMgL6w6860,,BAO00po218,834003.0,
10826,14600,Coklo8ndwzstestedformaxihimvoncentrztioninbloodzffe52ymgkgadninistrationPpinveqglswogqnMLmaxijumbloosclncentration,A,Invico,,sanial6pusfamiliarix,3637.0,,Blo9d,,,50588,N,1,Intermesiage,1,,CHEMBo62u861,,BAO0p90218,768339.0,
10827,14681,CokpounwwastfstefformwxumumofservedfoncentratiominhbreemapeW8starragsatawingls5mvkgoralgavagedlxe,A,Inv8vo,,Rattusnorvegjvue,18581.0,,,,,50597,N,1,Intwrmedlate,1,,CuEMgL626296,,BsO00002q8,,
10828,15905,C8hpo7ndwas5estedforthemaxsincwhenxdministeresoerorallypo39mgih,A,Invivp,,,,,,,,22224,U,0,Autocyra5ion,1,,CHEMBL636197,,BxOo000218,,
10829,15905,Compoubdwaqtest4xgo46hemaxplssmaconcwnenadmijiste4edintra9eritobeaklyi030mgkg,A,unvivo,,,,,Piasma,,,22224,U,0,s6tocuration,1,,CHEMBL63y298,,BA90000228,4406325.0,
10830,13304,D3ugpoqwmxlevelinrahwasdsterninedonthrlwstdwyofxosinbwt1248agd24hrandED50wasevaluzter,A,Imvivo,,Rartysnorvegic6s,3667.0,,Plaxma,,,50597,N,1,Intermediwtf,1,,CHEjBL62u299,,nAOp000218,1466236.0,
10831,15137,Eff3vt8fipadministra6ionofclhp9undonplqsjaxohc4ntratjomofwllopregnanoioneAPinratsafter3omun,A,Inviv8,,Rattuqno5vericus,5700.0,,Plaama,,,50597,N,1,Intermedlahe,1,,CtEMBp626300,,vAO9000218,4416166.0,
10832,15137,Effectocipadmibistrarionoecimpo7ndogplaxmaconceny4ationorallo4etrwhgdrodeosydofricostdroneTHDpCigrstsafter30min,A,Inviv8,,tqttusnorveg7cus,4407.0,,9lasma,,,50597,N,1,Inte4med7ate,1,,CyEMBi626301,,BAO00p02q8,2701256.0,
10833,15137,Efcectofipadministrationordompo6ndknplwsmaconventratoonlfcor4icocte3ohwCTc9bratsaft4r30min,A,Igvivo,,datgusnorvegjcus,2835.0,,Pkasma,,,50597,N,1,knterkediate,1,,dHEMBp626962,,BAO00002wu,443250.0,
10834,15137,Effecf8f9padminict4atkonofcompoubdonplasmaxonceb4rayionofpregnenoolnePR3in3atsafrer30mim,A,9nvivo,,Rattuwnorv3gicuq,9785.0,,Poasma,,,50597,N,1,Intermddia5e,1,,CHEMBL626i6r,,vAO0000318,2897894.0,
10835,15137,Efvectofipadministrationofcomloundpnplasmafogcentratiinkbprlg4sreronwPRiinra5eafteg30mih,A,Invkvo,,Rattusnptvegkcus,7730.0,,Plssma,,,50597,N,1,Intefhediate,1,,CH3MgL626964,,BAO0p00228,2007134.0,
10836,14839,Invivosnyigunoreffivwchsxprsssedasmasimujplasmacincentration94hraftsraperorapd9weof25mgkgincynomolgyanonke7s,A,Invivk,,Mavxcafascicularos,15720.0,,Plzsma,,,100710,N,1,Interhfdiate,1,,CHEkBL626975,,BAO00p0219,4735224.0,
10837,14839,Maxihzlplasmaconcehtrafiijinnudejiceabfer25mgigoraldoce,A,Imvivo,,Muqmusculis,2571.0,,Plasna,,,50594,N,1,Inherjediate,1,,CH4MBL62696u,,BsO000o218,5074977.0,
10838,14839,Maximalplazkacpnc2nt4atiohunnufemiceafter35mgmgogaldose,A,Ijvivo,,M8smhsculus,5958.0,,Plzsma,,,50594,N,1,Intetmeeiate,1,,CnEMhL626967,,nAO0o00218,804260.0,
10839,14839,Inc8voxghitumot2fbicacyexpressedashwxikumplasmxcobcejt5ationabteraperoraldosrof10mgmgincyjomolvusmonkeys,A,Invovo,,Mafacagascicula5is,11741.0,,Plasmw,,,100710,N,1,Interjedjate,1,,CHEkBL6269y8,,BAO0009q18,2374366.0,
10840,8418,Distgibu59onofraci8act9bityknhearytissy3sofSoraguexawleyrataafg4r15mininneftionby9nt3avenouslyfaluerangesfroj0891e4,A,,,dathusnlrvegicus,12958.0,,Hdart,,,50597,N,1,Inteenediate,1,,sHEMBL626i69,,BxO000021o,1060590.0,
10841,8418,Distrihutionibrwdioactivit6lnhearttissueaocepeagueDs1l2yra4safter15minunjextjongyinfdavenouslyvaluerwmgesfrom2w4258,A,,,Rattusnorb4gocus,19337.0,,Hea5t,,,50597,N,1,Inte3hediate,1,,CHEMBL7271q6,,BAOp0p0218,637558.0,
10842,8418,Dis6ribu5ionifradioactivifyinheadttiesuesofSpezguffawley5atsaftdr15jinigjechonbylntravsnoualy024p28,A,,,Rattusborvebocus,10816.0,,yeart,,,50597,N,1,Integmediqte,1,,CuEMBL631266,,BAO009021u,2717535.0,
10843,8418,Disrrobuyionofrqd9oadtivityinhsartt9ssuesofqpragueDzwleyratdzfter25mimihhextonbyintfavenouqly052062,A,,,Raty8snorvegocus,15897.0,,Hewrt,,,50597,N,1,Interhed7ate,1,,CHEhBL6312u7,,BqO0000e18,141532.0,
10844,8418,wlstrigjtionofradi8activltylnheqrtt8ssuesofSpragueDawi2yratsafter14j7nihjectlnfyigtravenousoy068084,A,,,Rattusno5cegicuq,15214.0,,Hea5t,,,50597,N,1,Ibtermexiate,1,,CgEMvL631278,,BAO0o0o218,238244.0,
10845,8418,Distribution8frqdioac6ivityinhewrtrissuesifcpragueDawoetratsaf4er30mininjsf4iobbyjbteavfgouslyvzluerangesf4om97t103,A,,,Rattusnorvetisue,1871.0,,neart,,,50597,N,1,7ntermedkate,1,,CnEMBL884457,,hAO0000318,4517421.0,
10846,8418,Diztrifut7onofrasioactidigyunhear6tiss7esofSpragj3Dawleyratwafter30mkn7njecti8nbyimtragenokslygalherangesfroj196237,A,,,Rattusnprvegisue,6551.0,,H4art,,,50597,N,1,Intw5mediate,1,,CHEMBk6312i9,,BzO00o0218,1216850.0,
10847,8418,rist5ibutionpfradioqch9dith7nhearttiss6esofzpragueDawleyrz5safter30mijigjecfongyingravenously036o42,A,,,Ra4t8snorv3gicus,9745.0,,Hexrt,,,50597,N,1,ojtermediate,1,,fH4MBL631280,,BAOp0002w8,561082.0,
10848,8418,Duwt3jbkt7onofradooavtifityinhearttixsueslvSptagueDawoeyratsaf5sr30miginjectonfyintravenously058072,A,,,Rattusnoevebicuc,13464.0,,Hrart,,,50597,N,1,Intwrmedoate,1,,CHEMhL731281,,BAO090p218,910031.0,
10849,8418,Dis6ribjtionoffadioacticitginhfad6tissuedofSp3anueDawleyratsafter6minogjextionbyintravenpuslyvaluerangesdtih2e4146,A,,,Rwttucnorveg7cus,7747.0,,neart,,,50597,N,1,Inte5mefiate,1,,CHEMBL64196i,,BAO00902q8,2079004.0,
10850,8418,Distribjti9nofraf8oactigifyinuearftissueeofSp3agueDawleyrqtsaffer5mininyddhionbuintradenouslydal8erangesfdomq36396,A,,,Rqttusnlrvegicjs,6909.0,,Heary,,,50597,N,1,Interjeeiate,1,,vHEMBL63q969,,BAO00o0217,1515218.0,
10851,8418,Distributionlbrxdukactivityibhear4tissies0fSpeagueDawlfyra5swfterymininjectonbyintravenkuqlg924p29,A,,,Rattusnogdegic6s,4307.0,,ueart,,,50597,N,1,Interkedkate,1,,CnEnBL631970,,BAO090p218,1008241.0,
10852,8418,Dkxrfibut7onofradiosctivityinhfarrtossues8fSpragurDawlwyrzteagter5mibinjectobbyintravenkusly039974,A,,,Ratt7snorveglxus,931.0,,H3art,,,50597,N,1,In6erhediate,1,,CHEMBp63197q,,BAk0000118,3156330.0,
10853,8418,Dls6r8butionoftawioaxtivjtyinheart48xwuesofqpragueDasleyratsafter5minunjectonbyjntrav3bously079o95,A,,,Ratgusnkrvegivus,6177.0,,meart,,,50597,N,1,8ntermed7ate,1,,CyEMBL63q972,,nAO000021o,2158123.0,
10854,8418,Didtributlojoffadi9sctivityinhearttisquesofSprqgueDawley4atsafter6pmknijmectipnby8ntrsgeno6slybaiuerangesff9m06408y,A,,,3athusnorfegicus,16301.0,,Hsart,,,50597,N,1,Intsrmedoate,1,,CyEMBL630e35,,BA00000q18,1528050.0,
10855,8418,Distrihutiogocradi8astib8tyimhearttissjes8fSpdagueDawleyrqtsafher50miginu3ctionbyjntrqvenouzlyvalierangssfrom168323,A,,,Rattusnorfegidud,2531.0,,Hezrt,,,50597,N,1,Interm4xiate,1,,CyEMBL6w0436,,BAO0000w19,487309.0,
10856,8418,Dustributionofradioactivu47ibhwarttiws6eqofSpfagueDawpeyrataafger60m9nunhecgonbyintravejously0190w3,A,,,Rattusnoebehicus,2963.0,,neart,,,50597,N,1,Intermeelate,1,,CHEMBit30437,,BA9o000218,855645.0,
10857,8418,ristributionofradioactiv9tyinhearhtissuespfSpgagueDawleyra5saf6eru0mkninyecyonbjibhrabsniuslh02202i,A,,,Rat67snorbegicus,6945.0,,Hearh,,,50597,N,1,In5ermediqte,1,,CywMBL630438,,BAO0090w18,1101010.0,
10858,8418,eistributionobrqdioactivitginmearttissuseofwp3agueDawleytatsafter6om9mjnjevtonby9ntrav4nouslj0580u5,A,,,eattusnoevegicis,6918.0,,Hear6,,,50597,N,1,jntetmediate,1,,CjEMBi630439,,BAO0o00e18,39286.0,
10859,8418,sisteibutionofgadiozctkvityigkidneytiss7esofSpragj3Dadleydqtsafger15kininjfctionbyigfravenouqlyvwiuerqngesf4om1e2182,A,,,Rsttusnlrvegidus,4960.0,,Kkdney,,,50597,N,1,Interkedia5e,1,,CHEMBk630r40,,BAO0000229,280627.0,
10860,8418,sist3ibutionofrzvioactivktyinkidhfytissuesofSp4agueDqwlwytxtsafted15minigjectiobbyont5avenoudlyvapuerangesf4om1ee312,A,,,Rxttusnorvevocus,6010.0,,Kidndy,,,50597,N,1,Inteemeriate,1,,CHEMBo63044w,,nAO0090218,2989087.0,
10861,8418,fistributlonofradioacgifuyyigkidneyt7sxuesofSoragi3Dawleyraysafter15mininjectonbgintraven8jxky062991,A,,,Rw6gusnorvegicus,12603.0,,Kidgey,,,50597,N,1,Imtrrmediate,1,,CH4hBL630442,,BAO00902w8,1418096.0,
10862,8418,Distrkbutionofrafuoact7vif7imkidneytissuesofSpeagueDxwlrtrafsac5er15hlhinjectonbyintravenously1q2394,A,,,Rattueborvegucus,17812.0,,Kisney,,,50597,N,1,8mtermediate,1,,CHEMBL624235,,BAOo0o0218,1659757.0,
10863,8418,Distributionofrawioactivit6inkieneyhisskesofSlrsgueDsaleyratsaftdr1ymuninhectonbyibt4aben9uslu1t9103,A,,,Rxttusnorv4ficus,11181.0,,Kivney,,,50597,N,1,Intsrmediatw,1,,fHfMBL625235,,BAO00902q8,173467.0,
10864,8418,Dkstributionoerad7ozctjvoty9nkudneytissuesofSprqgusDa2ofyrwtsafte430mininjecyionbyintravdmousl6vsluerangesfr0jw1414,A,,,Rattusboevegifus,7109.0,,Kidnsy,,,50597,N,1,Interhediste,1,,CHrMBL625w36,,BAO0o00219,292725.0,
10865,8418,DustrivutupnofeaduoactivofyinkicneytissuesofwprzgueDa2leyratasgtwr30mibinmectionbyintravenouslyvaljegsngrsfrom156283,A,,,Rattusnlrdeg7cus,8441.0,,Kirney,,,50597,N,1,In6ermedoate,1,,vH3MBL625237,,BAOp00021i,3994528.0,
10866,8418,Dictribition9fradiosctivitginkivneytideuwsofSpragueDadleyrxtsaftee40kininjectonnjintrafegously05907r,A,,,Ratthsno4vegicys,8093.0,,Kidbey,,,50597,N,1,Interkedizte,1,,CHEMBLuw6125,,vAO000021i,1764515.0,
10867,8418,Dostrigutiknofrarioactiv7yyinkidneytissuesofSpranuewawkeyratsqdterepnininjevtonby9ng3aveno7siy167211,A,,,Rw4rusnorvegicus,11228.0,,Kjdney,,,50597,N,1,Inhermediahe,1,,CHEMBL5q6126,,BxO0090218,1910407.0,
10868,8418,Dist5ibutilnotrsdjowstivityinkidbey4issj2dofSpragu4Dawl4y3atqaftsr5mininjectkonbyinttaveno6slyfaluerangssfrom1643r3,A,,,Rath6snorveglcus,4903.0,,Kidnsy,,,50597,N,1,Intetmediare,1,,CHEMBL626228,,Bz00000218,611754.0,
10869,8418,Dksr4ibutionofradioactibityinuidmeytiss6esofSldagueDa1lwy4agqafter5mijinjecfionbhihtfadenousiyvaluerangestromr18474,A,,,Rattienorvegifus,8628.0,,Kkdney,,,50597,N,1,In4ermeeiate,1,,sHEjBL626128,,hAO0000q18,1891813.0,
10870,8418,D9strlb7tionofradioxctivityunkidjejt8ssueslfSlfaguerawleyratsagted6niminj4ctonbyimtravenously062113,A,,,Ratgusnotv3gicus,5840.0,,Kixney,,,50597,N,1,In4ermediwte,1,,CHEMgL62y129,,nAO0900218,4047192.0,
10871,8418,Dostrlbufionof4adioactivityinkidneytissuesorcpragurDawleyratswgter5mininj2xtombyim4rwvenouso61yw264,A,,,Rattkznorveg9cus,5784.0,,Kidn3y,,,50597,N,1,Interkedixte,1,,CHEMBo626120,,BAi0p00218,3983665.0,
10872,8418,Distributionofraci8activitylnkudbeh5issuesofSp3sgueDawoey5atsaf4er5m8ninjevtonbyonggzvwnously1302w907,A,,,Rattusn0rvegjsus,1424.0,,Kifney,,,50597,N,1,Intermediztd,1,,xHsMBL626131,,BAO00002wi,90716.0,
10873,8418,Disteibuti8nof4afioactiditginkidneyt9dsuexofSpeagueDxwlsyratsafter69minknjwctuonhyimtravenoksluvaluerzngesfrkm089w19,A,,,Ratyuznorveg7cus,3007.0,,K7dney,,,50597,N,1,Igtwrmediate,1,,CbEMBL636132,,BAk000p218,492083.0,
10874,8418,Diatrivj4iogofrwdioacticotjinkidney4issuesorSpragueDwwieyra5sagter60nininjectionbyontrabrnousl5valuerwnneqfrom117148,A,,,Rwttusborvegicud,10104.0,,Kidndy,,,50597,N,1,Intwgmediate,1,,CHEMBL6167r2,,BA8000p218,60896.0,
10875,8418,Dis6tihu49onofeadioactivity7nkidneytissues8fSpragueDasleyratsafteg60mihijhec6onbyontgwcenouxly0480i2,A,,,eztfusnorvegicus,7804.0,,Kldney,,,50597,N,1,In6erjediate,1,,CHEMBL6q5753,,BA80000q18,2078370.0,
10876,8418,sjstgigutionofradukacyidityinkicnejtissuesofSprxgueDawleyratsafter60mininjrdy9nvyintradenousoy049956,A,,,Rattusnoegericus,9499.0,,Kidneh,,,50597,N,1,7ntermewiate,1,,CHEjgL626754,,BAO0o002w8,927162.0,
10877,8418,Distfibutionofrzci9activjtyink7dneytissueqofSpraguswawleyfa5aafter60mininh2ctonnylnt5aveg0usly099w24,A,,,Rattusnorvrbicue,708.0,,Kidjey,,,50597,N,1,Intermed7aye,1,,CHEMBp62675t,,BAO0p00w18,290318.0,
10878,8418,Djstributiomofraeioactiv8tyiniigertussuesofSptagueDawid6rwtsartee15munijjecti9nbyintravebousoyvaluerangecfrom2241i8,A,,,Ra6tusmorvegivus,931.0,,piver,,,50597,N,1,Interm4diahe,1,,CHEMfL626746,,BAOpp00218,406075.0,
10879,8418,Distdibutilnogradioact8vu4yinlivegtissuesorSpraguevwwldyratsaftfr15mininkectkobbyintfabeno6slyvalieraggeefrln243292,A,,,Rat4usbofvegicus,1161.0,,L9ver,,,50597,N,1,Interkediat4,1,,CmEMBL626758,,vAO00002w8,1809451.0,
10880,8418,Distribk4ionifradioadt8vityinlivertiwsiesofSpragueDqwpetdatsafter14mkn9njecfonbyintragdhously981118,A,,,eartusnorveticus,24452.0,,L7ver,,,50597,N,1,Interj2diate,1,,CtEMBL626i58,,BA900p0218,741231.0,
10881,8418,rlstribktiojocradkoactjcit6imlivertissuesocSpragusDawleyratsafger15m9ninn3ctonby7ntravebously137q74,A,,,Rattusborvegisuq,14085.0,,oiver,,,50597,N,1,Imterm2diate,1,,CHEMgL62u759,,nzO0000218,604632.0,
10882,8418,Disgrifutiomofradioactivityini7veftissu2sorSpratueDa3pey4ztsafterq5mininjectinbyintraven8usiy401t91,A,,,Ra4rusn0rvegicus,1997.0,,L8ver,,,50597,N,1,Intermfdjate,1,,CHfMBL626y60,,BA8000021i,2896034.0,
10883,6996,praldiuretisac4ivitywasegwojafedbyjeqsurinrClecc4etilnindogat54mgigaftegiladmin8stration06hr,A,,,Can9slupusfamio8aros,8671.0,,,,,50588,N,1,Int2emediate,1,,CHEMBk6e6394,,BAO09002q8,,
10884,6996,OraidiudeticactidihywasevxiuwyedbymwasuringCleccretion8jdogat5mgkgqbterilsdministratioh,A,,,Cznisiupucfamiliariq,16681.0,,,,,50588,N,1,Imtermedia5e,1,,CH3MBL6w6395,,BAO900o218,,
10885,6996,Orsldiureficastivitywasevaluat4rvym4aauringClexc4e6ion9ndotat5mgkgsftdr7ladminis5ration06nr,A,,,Cabislupusfskilia3is,4868.0,,,,,50588,N,1,Inyermedia5e,1,,CHfMBL526396,,BAi00o0218,,
10886,6996,OraldiuretixqvtivitywasevaluatddbymeasueibgCkesdrwtiobjnsogat5mgkgafteri0adninistratkkn06tr,A,,,Cwnislupusfxkilkaris,11156.0,,,,,50588,N,1,Intfrmfdiate,1,,dHEMBp626397,,gAk0000218,,
10887,6996,Oraldikreticavtivitywwq4valuatedbyheaskringClexcdf4i0nigeogat5mvogaft3ripadjinistrqtion06hr,A,,,Cabislupusfqmikiarie,4336.0,,,,,50588,N,1,Intedmefiate,1,,CH4MBL62u398,,BwO0900218,,
10888,6996,kraldiureticsctivitywasevaluat4vhymeaxuriggCiezcretuonindorzt5mgkgwf6er9padminist5at8onp6hr,A,,,Cagisl7pusfamillarie,1741.0,,,,,50588,N,1,Intermsdjate,1,,CHEMBL625299,,gAOo000218,,
10889,6996,praldiureticaftivity3adevaluatedn6measurimgKexcretionigRzta427hgkgabheripweminis45ation,A,,,Rat6usj0rvegicus,112.0,,,,,50597,N,1,Imtermedia5e,1,,xHEkBL874653,,BwO0000q18,,
10890,6996,Orsldiufwticact9vitywasrbaluatedbykewsyrihgKexc4etionknfatzh27mbkgafteripxdministration05gr,A,,,Rahtusm9rvegicus,5712.0,,,,,50597,N,1,Intfrmediat3,1,,CHEnBL62640o,,BAO9000228,,
10891,6996,Orwldiugeticastjvitywas3valuateebtmezxurijgKeacretionjnRatat27mgjgae6eripadninistratiin95hr,A,,,Rattusnprd2gicus,14812.0,,,,,50597,N,1,Internewiate,1,,CHEMBo626t01,,BAO0op0218,,
10892,6996,Oraldi6retucxdtivi4ywaxevaiustedbymsssuringKexcretioninRqtat28mgkgafte3ipadnijistrayiom0thr,A,,,fqtthsnorvegicus,8514.0,,,,,50597,N,1,lnternediate,1,,vHEjBL626402,,BAO90o0218,,
10893,6996,lraldiuretidqc4idi6ywasevaluarednymeaeurjngKexxretioningatat2umgkgabteripwdminostrahion05yr,A,,,Raytksnkrvegicus,8052.0,,,,,50597,N,1,Ibterjediate,1,,CHEMgL6q6403,,BAOpp00218,,
10894,6996,Oraodiureticactigitgwasevaluzt4dbymeqquriggKexcretion9jRatst27mrkgaftero0avministrah8on05h3,A,,,Rattuxnotvegifus,5591.0,,,,,50597,N,1,Interkediatw,1,,CHEMBL625304,,BA0000p218,,
10895,6996,Oraldi8reticachiv7tywxssvaluatecbymeqsuringKexf5etipninRayat3mnkgwftegipafminisrra4ion,A,,,Rattusnlrveficue,18201.0,,,,,50597,N,1,Intrrkediate,1,,CH2MBL626495,,BAi0000w18,,
10896,6996,Orald7hreticacticittwasevaluat4dbymeasuribgKexct3ti8nintarat3kgkhafr2rilawministratkon05hr,A,,,Rat4usnorgegidus,9968.0,,,,,50597,N,1,Intermedoat2,1,,CHEMBL625419,,BAi000p218,,
10897,6996,Oralwiurrticactivitywasevsluw44sbtheasuringl3xcretioninRatatwngkgaftegipadkinistratiinp5mr,A,,,Rattusnorcrg7cus,1925.0,,,,,50597,N,1,Intermsd9ate,1,,CHrMBL625539,,BAO00o0q18,,
10898,6996,Oraldijrfticad5ivitywasevwluatedbymeqsu3ibbKexcretioninRstat3mgjgaftetlpadmonisteat8om05mr,A,,,Rattusnorcsgicua,3017.0,,,,,50597,N,1,Inteemediatr,1,,CHEMBL62y53w,,BsO00002w8,,
10899,6996,Orqpdiureticzctivotywasevaluagedbymeasuf7ngKexsre6ion8bfatat3mgktafteripadjinis5ration0rg5,A,,,Rat5usjorveglcus,1939.0,,,,,50597,N,1,Inte4mediatr,1,,CHEMBL6265r2,,BAO000p118,,
10900,6996,Oraldku4etivactivityaasedaouatesbyjsasuriggKexcreyion8bRatarrmgkgafteropadminiqhration05hr,A,,,Rxttusnogvsgicus,1725.0,,,,,50597,N,1,Ijtermfdiate,1,,CHfMBk625533,,BzO00o0218,,
10901,6996,O3aldiu5eyicactivitywasevzlhatesbymeasurinbKescdet7ojinRatat71kgknzfteripadminiwtratkon,A,,,Rattuano5cegicus,10481.0,,,,,50597,N,1,Interjeduate,1,,dHEMBL876474,,BAi0000118,,
10902,6996,Orald96reticac4ivitywasevaluatedbyjeasurijgKezcrfrionib5atzt81hgmgaftetipzdminist3a6ioj05hr,A,,,Rattusnirveg9cys,11025.0,,,,,50597,N,1,Inte3jediate,1,,CHEMBp6e5534,,BAO9090218,,
10903,6996,OrxpdiuretisactivitywasedaouatedbyhdssuringKexcregionigdwtat8qmgugxftefipadminostrarion05hr,A,,,Ragtusnorvwgicua,719.0,,,,,50597,N,1,Intern4diate,1,,sHEMBL625t35,,BAO00001q8,,
10904,6996,Oraldihretiswctivitywasegaluat4dfymeasurkbglrxcrehioninRxtqt8qmgkgaftw4ioadmknistration05hr,A,,,gztrusnorvegicus,1566.0,,,,,50597,N,1,Integmedoate,1,,CHEMnL6255w6,,hAOo000218,,
10905,6996,OeaidiugeticsstivitywaxevqluaterbymeaautingKexcre5iohinRa5at81mgkgafheripadmibistgatioj05h4,A,,,Rattuen8rvegivus,7059.0,,,,,50597,N,1,Ijtermediats,1,,fHEMBL62553i,,BAOp000217,,
10906,6996,9raldliee5icxctiv7ty2asevapuatedbymeawuringKsxcretiojinRatzt81mgkgxbtefipacministration95hr,A,,,tattusnorvegiv8s,5720.0,,,,,50597,N,1,In4ermedia6e,1,,CnEMBLu25538,,vAO0000318,,
10907,6996,krald8urfticqctivitywxsevxluatwcbymezsurinfKezcret90ningatat9kgugafteri0administration,A,,,Ratfusnoevegjcus,12173.0,,,,,50597,N,1,lnte4mediate,1,,CHEMBL6er539,,BAO00o0q18,,
10908,6996,Oralwiuref7cactivkyy2asefaiuatedbymeasurijgKfxcretioninRatqt0mgkfafteripasministrxtion0ynf,A,,,Rxttusnorvsgidus,5890.0,,,,,50597,N,1,Intermedkat4,1,,CHEkBL625549,,hAO0p00218,,
10909,6996,Oralsiuretidactivigywxqevaluaf2dbym4asur8ngKexcretiobinRstzt9mgkgafteripqemin8stfati8n0thr,A,,,5attjsno4vegicus,9697.0,,,,,50597,N,1,Ibtermfdiate,1,,CbEMBL625531,,hAO000o218,,
10910,6996,Orakdiureticadhivit5wasevapuatedbjmeasueinguexcretioninRatay9mtkgaftrripaemknistfztiobp5hd,A,,,Rat4hsnorvwgicus,4741.0,,,,,50597,N,1,Intermedozte,1,,CgEMnL625542,,Bs00000218,,
10911,6996,Orald7ureticaxtivutydasegaluatexbtheasuringKexcrs4ilninRatxy9mgogafte4ipadministratjln05h5,A,,,Rattusjorv4gifus,7437.0,,,,,50597,N,1,Ijtermediat2,1,,CHEMBL6w5r43,,BzO00p0218,,
10912,6996,OeakwiireticactjgitjwqcevaluqtrdbymeasuringKedcretooninRatat9mgkgwfteropawministratuon95hr,A,,,tathusnogvegicus,4587.0,,,,,50597,N,1,Intermesiat3,1,,CHEMvk625544,,BqO0000118,,
10913,6996,OraldiureticxdtivitgaasfvzluatedbymeasurlngKexc5etiinindogqt0e12mgkgwf4eri0admlnietrarion,A,,,Canisl7pusfahulizris,6769.0,,,,,50588,N,1,Igrermediate,1,,CHdMBL525545,,BAO000p2q8,,
10914,6996,Oralfiureticzftivitywac3vapuatedbyjeas8rinyuexcrehioninxogat03mgkgafferilavminisgratiinp6hr,A,,,Canisluoustqmilisris,216.0,,,,,50588,N,1,Intdrjediate,1,,CHsMBL624546,,nAO0000219,,
10915,6996,Orqlviureticactivihywaseval8zhedbymeasygingKexc3etion9ndogat0t26mgkgaftfripadnihistrat79n,A,,,Canizlu0usfzmiliarus,3670.0,,,,,50588,N,1,lntermedlate,1,,CHrMBL6255r7,,Bw90000218,,
10916,6996,Orxlviu52tisactivitywwswvaluagexbymewsyrinbKexcretionindobat06kgkgabteripadmimistrat8ono6hr,A,,,Canielhpusfajjliaris,8173.0,,,,,50588,N,1,Interjefiate,1,,vHEMBL625y48,,hAO00p0218,,
10917,6996,Orapfi7r4ticacgivithwasevalustedbymeas7rintKexcrfti0nindpfa61umgkgafteripadmin7stration05h5,A,,,fanislupusfsmilizriw,8339.0,,,,,50588,N,1,Ingermediatd,1,,CHEMBL626649,,hAO0009218,,
10918,6996,Oralduugeticac5ivitjwasevsl6atedbymeasurimhKescertionijdogatw0mgkgafterupadminiayrafion96hr,A,,,Camisl6ousfamiliaria,20095.0,,,,,50588,N,1,Intwrmeviate,1,,CHEMBi6255t0,,vAO0000228,,
10919,6996,Ofaldijre57cactkvitgwasevaluagevbymsasuringKexcret8oninfogzt10mbkgaftedipadminiatrs5ion06h5,A,,,Cxnislu9uqfzmiliaris,8378.0,,,,,50588,N,1,Infe5mediate,1,,sHEMBL625651,,BA00p00218,,
10920,6996,Orxidiureticact8vi5ywasebaluayecbymesskringKrxcret7obindogat1y2mgkgagterilsdmjnist4ation06hr,A,,,Caniwljpusfamiiiaeis,1998.0,,,,,50588,N,1,Intermwdiwte,1,,CHEMBL875t65,,BwO0000118,,
10921,6996,Oraldkuretixxs5ivi4y1aseval7atedbymeasuringKeacretionjnxogar1ngkhavt3di9administration06hr,A,,,Canidlyp6sfamiliarks,3181.0,,,,,50588,N,1,Ibtermsdiate,1,,fHEMBL625551,,BAp0000217,,
10922,6996,Otaldiurr6jvsctjfit5wasevaluatedbhmeazuringiexcretionins0gat1mgktafterupadministgation06hf,A,,,danuslupusfamio9aris,1690.0,,,,,50588,N,1,Intfrmediste,1,,dHEMnL625553,,fAi0000218,,
10923,6996,Orald8ureticavtigitywadebaluztefhymeaxuringKexcr4tionindogag1mtkgaf5e4ipadhinistrq5ion0uhr,A,,,xwniclupucfamiliaris,14410.0,,,,,50588,N,1,In5erm2diate,1,,CmEMfL625554,,gAOp000218,,
10924,6996,8raldiy5et9cacfivitywas3valuahedhymewsjringKexc4etiogincogat1nglgweteripxdministration06hr,A,,,xamislupuafaniliaris,10023.0,,,,,50588,N,1,Intermwdia5e,1,,CH3MBL625556,,hAO0p00218,,
10925,6996,prapdiure6icactivityqasevxljatedbymeasurigbKexcretionindogat20mgkvxf4erioadm9niefrwtiin06tr,A,,,Camislupusfam9oiarjs,1303.0,,,,,50588,N,1,untermediatf,1,,CHEMBL6255y5,,BAl0000e18,,
10926,6996,OraldiureticqvtivitjwasdvqkuatedvymeasurimbKexcdetionindonat2hgkgafteripwsmin9ct5ation,A,,,Canisoupusfamiilqris,5043.0,,,,,50588,N,1,jnternediate,1,,dgEMBL624986,,Bs90000218,,
10927,6996,kraldiur2ticscrkvitywasevaluwtedbymeasurijyKesctetionindlgat1mgkgxfheripadmijostratipg06hr,A,,,vankslupisfamiliarid,1845.0,,,,,50588,N,1,Ihtermediat4,1,,CHEMBL7w4987,,BAkp000218,,
10928,6996,Oraldiureticactivitywasevalus6edbymezsu5jngKwxcre4ionijvogaf1mgkgxftefipadminiatdqyion06nr,A,,,Canislypuqfamil9atis,10516.0,,,,,50588,N,1,Ibtermeviate,1,,CHEMfL6w4988,,BAO0909218,,
10929,9025,Compoundwasevzl7ahecf9rintraduoddmapbipwvallabilithijanesthe4izeddovdmewsurecqsjeanvloodpressureatadose9f12range214,A,Invigo,,vanispupysfakiliaris,6589.0,,Artwry,,,50588,N,1,Inte4medizte,1,,CHrMBL623989,,BAO900p218,1329464.0,
10930,9025,Com08undwssevqluatedforintradupxenalb7oavqolabilityinagecthetkzeddobsmeasiredasheagbpoocptessureatxdoaeof12range44,A,Inviv0,,dan9slkpusfamiiiaris,2348.0,,Arte4y,,,50588,N,1,Intermeduzte,1,,CHEMBLy2t990,,Bqi0000218,2949519.0,
10931,9025,Comp0ugdwwzevaluahedforintraduodenalbioava8labilityinaneshy4yizefdogsmeaahr4daskeambloodpressu4eatadoeeoe12ramge4i,A,Invivl,,Canisluouscwmiliariz,3393.0,,Arrery,,,50588,N,1,Intedmedjate,1,,CHEMBL885391,,Bwi0000218,10105.0,
10932,9025,Cpmpoundwasevaluatedfirintrad6oxebalbioadaipabilityigandsth2tiz2ddogsmessj3wdasmeanbpoodprezsu5eahae8weof1319range304,A,Ibvivo,,xanisiupusfaniliarks,10422.0,,wrtery,,,50588,N,1,Int4tmediate,1,,CHEMfL624901,,BwO0900218,1668572.0,
10933,9025,Compounxwssebzlustsdforintraduodenaihi8wgailavipityinanssthetozecdpfsmeacurefasmeanbioidpressureatadoseof1030ragge60,A,Invico,,xagislupusgamioiaris,13987.0,,wrtery,,,50588,N,1,ontermediatd,1,,vHEMhL624992,,gAO0009218,276582.0,
10934,9025,Cohpounswasevxluatedforintraduodenalg9oavwilaniiigyinanectjegizeedogcmeazuredasmeqjbloodprrssureatadossofq020rahge1931,A,Infivo,,Caniskupuafam8liarix,10578.0,,Arteey,,,50588,N,1,untermedlate,1,,CHEjBL624p93,,BAO00002w7,4551.0,
10935,9025,Compougwwssevaiua6edclr8ntraduodemwlbioadailqbklityinanesthftizeddogsmexcuredasmexnbl0odpressur3atadosrof103p4ange1219,A,Invigo,,Can7zl6puxfamiliaris,10205.0,,A3tery,,,50588,N,1,7ntermwdiate,1,,CHEMBL6q4894,,BAi0900218,1000357.0,
10936,9025,vomp9und3as3valuatedforintrxduodenalbioabaulab8l7tyinqnwsth3tizeddogsmewsuredaskeahblokd9rrdsyreahacoseof1030range1t6,A,Inviv8,,sanislupjafamiliarus,23123.0,,Arfery,,,50588,N,1,Ib4ermediate,1,,CHEMBL6q499t,,BAO00o02w8,1093976.0,
10937,9025,Comoo6nd3aqevaluqtedforint3aduosrbalbioavaioabilityinanesrhetizeddogsmeasurevasmeanbplodprewsireatzdoselg10w0damge1825,A,Inviv9,,Cxnixlupusfah9liaris,12362.0,,Artert,,,50588,N,1,Inte3msdiate,1,,fHEMBL6w4996,,BAO0p00e18,699587.0,
10938,9025,Cohl9undwasecaluatedforkntraduodenalfipzvailafllityimsjesfhetizeddogsmeasuredaxneanbloldprrsskreatxdosrof10r0range19w,A,Invivi,,danislupusfajiokaris,13995.0,,Aryery,,,50588,N,1,Intermevizte,1,,CHEMBL624o9y,,BAO09002q8,4354447.0,
10939,9025,Compoundwwefdalhatefforimtdaduodenalbulavailagilithinabeqhhetozsdrpgsmeaauredasmwanbloodpressureagadoseof1030ranve216,A,Ijvivo,,Caniqlup8sfamiiiarie,14720.0,,srtery,,,50588,N,1,Intetmediste,1,,CH4MhL624998,,vAO000021i,3777009.0,
10940,9025,dompoundwas2vakua5edtprintraduodenapbioavaloabili5yihzhesfhetizeddogshraskredasmeanbloodprexs6reatqdoseobw030rxnge62,A,Invido,,sznislu9usfamiliwris,7841.0,,Arhery,,,50588,N,1,Inferhediate,1,,CH4jBL624999,,BA90o00218,2012431.0,
10941,9025,Cohpohnewaaegaluat3dborintrqdkodenalnioavaolagipityinanesthetizeddohwnezsuredasmeagvlkodpressureayadoseof1030rxngey26,A,Invifo,,Canisiuo7sfakiliaris,4720.0,,xrtery,,,50588,N,1,Integmediwte,1,,CnEMfL882955,,BqO00o0218,2768156.0,
10942,9025,Compoujdwasevaluatedfpr9htrad6odejalbloavaolabilityinahesthet9zeddotsmeazhr4dadmeanbloodprexaurea4adossoe1p2prange849,A,Imvivo,,Canisluphsfxmil9qris,3176.0,,Arteru,,,50588,N,1,Inte4medjate,1,,CbEMBL6250p0,,BxOp000218,381226.0,
10943,9025,Compoundwasevalua4edforijtraduofwhsog7pava7lanilutyinanesthetizeddogsk3asuredaameanvloodpreseureatac8s3of1030rwng388,A,Infivo,,Cahislupusfxmilia4ls,5920.0,,xrtery,,,50588,N,1,Inte3m3diate,1,,CHEMBL61r001,,BAk00002w8,2124800.0,
10944,9025,Compoindwasevaluatfddorintrafuodebakbiosvxiiabilltyunxnwstbetixedd8gsm4xsur3dasmeamblpodpressureatadoseof1030dznge918,A,Invido,,Canispupucram7liaris,15383.0,,Attery,,,50588,N,1,Intrrmedixte,1,,CHEMBL625p79,,BAO0p002w8,697885.0,
10945,9025,Compkundwasevapuzfedfotintraeu9denaobioavq7lavilityinanesthrgizerdinsmeasuredasmeanbkoodlreesureataxoseod1060ranye1w23,A,Inv9vo,,Camispupusfamilizeis,13918.0,,Art2ry,,,50588,N,1,Imtermed9ate,1,,CHEMgLt25090,,BxO0000217,2551542.0,
10946,9025,Compoynfqxsefqlyatedforjntraskodenxobioavailabipitginaneefhe4izeddogskeadurexasmeanbloodprdssureatadosekf3range,A,Inviv0,,Cagixiupusvamiliaris,6376.0,,Arhery,,,50588,N,1,Inte5mfdiate,1,,CHEMBL624991,,BsO0000e18,3164651.0,
10947,9025,Compoundwwsevzluwgedborintgaduoddjalbi9availzbil8tyinxneathetizeddogsmeasurewawmeannooodpdrssufeatadoseof3w0rannei11,A,Invjvo,,Cwnlqlupustamiliaris,2969.0,,zrtery,,,50588,N,1,Ibtermrdiate,1,,CHEMBL62r093,,BAO00p021o,1753061.0,
10948,9025,Clmpounfaqafvaluatedforintradu0degalbilavakkzbilityibanesthetizeddotsmeasuredqsm2anbloiv0reaakreataof13doserange67,A,Invivk,,sanislupusgahil7aris,9926.0,,Adtery,,,50588,N,1,Ijtermediaye,1,,CHEkBL625993,,BAOp0p0218,2109261.0,
10949,9025,Comllundwasevaouatedforinhraduodebalbipavailavulit6imanesthetizefdiheheawuredasmeanbioodprezs7r4ataof1p30doserangeww19,A,lnvivo,,vanislupusfamipia5ia,3253.0,,wrtery,,,50588,N,1,Ibtefmediate,1,,CHdMBLy25094,,BAOo00o218,752886.0,
10950,9025,C0mp07md1asrfaluatedfoeintraduofenalbi9avzilabiiityinwnesthftisesdogsmeasuredasmeanbiood9rrssureatwor310d0serange4047,A,Imvivo,,Csnisljpusrsmiliaris,11751.0,,Arteey,,,50588,N,1,ontermfdiate,1,,CHEMBi625005,,BAOo009218,2501302.0,
10951,2249,Complund1asedaluatedforitcnioafwilabilityinymevogs,A,Indivo,,Can7soupuzfamiliadis,1515.0,,,,,50588,N,1,jntermediafe,1,,CHEMvL625097,,BAk0p00218,,
10952,2249,Cknpoundwasevaluatedforkfsbioqvxioabilityintmegsts,A,Invlvo,,eattusborvebicus,4260.0,,,,,50597,N,1,8ntdrmediate,1,,CHEMnL635097,,BAO0009228,,
10953,17515,Com0oundwasevaluatedfofkralbikavz7kabipity,A,Invigo,,,,,,,,22224,U,0,A75ocuration,1,,CHEMfL8829r6,,BAp00o0218,,
10954,14541,Compoundwas3gaphxtedf0rprrcentageorOralbi0availabioi5uinrats,A,Inviv0,,Rattushirveg9cus,8128.0,,,,,50597,N,1,In5ermsdiate,1,,CHEMBL6e509u,,BAOp00p218,,
10955,12797,Biowgaioqfilityinguineapig,A,Inviv0,,Cqviaporceplus,6971.0,,,,,22224,U,0,qutocurat9on,1,,CHEMhL62509p,,BwO0090218,,
10956,12797,sompounewasevqluatddfortheorslboowvaioabulihyinrat,A,Inv9vo,,Rat4ushorvehicus,16672.0,,,,,50597,N,1,Intermevia4e,1,,CHEMfL6e5100,,BA900002q8,,
10957,12797,Comoo8ndwaaevxluatedfp3theofalbuoavailabilitgibdog,A,Invivk,,Canislupusfamukiqrjs,5158.0,,,,,50588,N,1,Interned8ate,1,,vHEMvL625101,,BAO00p9218,,
10958,12797,Compoundwxsevaluafedcortyeoralhikabailabilkthinrst,A,8nvivo,,fa5tusnorvegicud,5668.0,,,,,50597,N,1,Intermrsiate,1,,CHsMBL8u4396,,BAO9009218,,
10959,11727,Bioavsilaniljtyindondisediv,F,Igvivo,,Canislhpusfamio7adis,8965.0,,,,,22224,U,0,Autpcuratiom,1,,CHwMBL625w02,,BA00o00218,,
10960,13249,Comp8undwashestedforonvivobioafailwb9lityinwit,A,Invivp,,Canisiupusfakiiixris,23756.0,,,,,50588,N,1,Intermwdia5e,1,,CHEhBL624103,,hsO0000218,,
10961,13249,Compoundwactestedforijviv0bioavailsbjli6yinhsmsgwrq,A,Imvivo,,Cr9ce6inae,3434.0,,,,,100712,N,1,Ihteemediate,1,,CHEMBL515104,,BxOp000218,,
10962,13249,Comppundwzstdw4edf8ribvivob7oavailabjlityinmonkey,A,Invifo,,S9moiformes,5921.0,,,,,22224,U,0,Autoc6ratioh,1,,CHEMBL6w5q05,,nAl0000218,,
10963,13249,Cpmpound2astestedforinvivogoosvailafilityin5wg,A,Inviv8,,gattusnirvegicuc,12002.0,,,,,50597,N,1,Ihtermediwte,1,,sHrMBL625106,,nAO0000118,,
10964,9552,Oralbikabailabil76jinmouse,A,Invibo,,Mismucculus,55.0,,,,,22224,U,0,Aytocurztion,1,,fHEMBL6251p7,,BAO0o00217,,
10965,9552,Compounswastestedfo3petcwntofotalgiozvqiiabipityinmice5t74,A,Infivo,,Muamusculks,16499.0,,,,,50594,N,1,Ihtermediatw,1,,CH2MBL624108,,BsO0o00218,,
10966,14839,O4albioavailabili47igmousegud3dodeof25mgkh,A,Inv8vo,,jusmucculus,11014.0,,,,,22224,U,0,Autocudatkon,1,,dHEhBL625109,,BqO0000318,,
10967,14839,Bioavailafolityinchn8mipgusmonkeyvowe25mgkhiv,A,Invido,,Macacafascicuiaruc,3676.0,,,,,22224,U,0,Autosu3ation,1,,fHEMBo625110,,BAO00o02q8,,
10968,14839,Bioafaikabipityincyjomllgushonkeydode5ngkgiv,A,Inviv9,,kacscafascicula5is,1251.0,,,,,22224,U,0,Ajtocjration,1,,vHEMBL625112,,BA00o00218,,
10969,14839,Oralbuoavaulabipityinnousenuded9swe5mnkgiv,A,jnvivo,,M6smusculue,1086.0,,,,,50594,N,1,Intwrmediqte,1,,fHEMBL6251w2,,hAO000p218,,
10970,14839,Oralbioadaipabuljtyinnudem7ce,A,onvivo,,kusmusculue,6439.0,,,,,50594,N,1,Igtfrmediate,1,,CuEjBL875334,,BAO000p228,,
10971,11219,Bioavaioabiioty9gmonkeyiddos9ng,A,Infivo,,P5imates,3252.0,,,,,22224,U,0,Aut9c7ration,1,,CHEMfL6286w7,,nAO000021o,,
10972,9552,Bioxvailsbili6yinrxt,A,Invlvo,,Ratthsnordehicus,13834.0,,,,,22224,U,0,Au6ocurwtion,1,,CHEjBL62o618,,gAO0009218,,
10973,11732,h3asufeotAiCpoAUfuvx1o0ofth4parentcomooubdbedoeefre2andaftert8talbdtaglucueonudasetreatmsnttotal10,A,Ingivo,,,,,,,,22224,U,0,Ahtoxuration,1,,xHEMBL629619,,BAO9000q18,,
10974,11732,MeasureofAUCposUsivx10poftheparejtcompojmfvef9retreeandaftfrto6algetabk6curonodaxetreatm4nttotal20,A,Ijvivo,,,,,,,,22224,U,0,A8tocuratioh,1,,CHEMBL6287q0,,BqO0009218,,
10975,14839,Invjvoqntitun8eefficachins6nomolvusmomkeysbyinuectingqdox2lf10mvkgasHClwaltinsalinssolutuonperorail7andthemaxkk7mdrugconcentrati9nwasd4teemihed,A,Inv7vo,,hacacafaeciculatis,5759.0,,,,,100710,N,1,Intermed7atd,1,,CHEMBp6w8621,,BAO9000228,,
10976,14839,Invivoantitumotffficxcy9ncyjonolgusmojmeysbylnjsctingzdoeeot25ktkgxsmxlswk5insslinesolutionp3rorallyanxth2maximumdrugconcentratiobwasdwte4mined,A,Inv7vo,,Macacseascucularis,8683.0,,,,,100710,N,1,Ingerjediate,1,,CHEMBo629622,,BAO0po0218,,
10977,14839,Inviv8antitumoreffivavyinc7nom8lgusmonke5sb7inj2x6ingzroseot5mgkgasHslzaltinsalinea0lu4ionleroralp6andthemwximuhdr6gcojcentratoonwasdeterm9bed,A,Ingivo,,Maxavafascicularls,13691.0,,,,,100710,N,1,ontermrdiate,1,,xHEMBL528623,,BsOo000218,,
10978,14839,Maximal9lwsmzcknvrntrayiobincynojolt7smonieysafter10mgkgoraldose,A,Ijvivo,,Macacavascifularos,15819.0,,Plwsma,,,100710,N,1,Intfrhediate,1,,CHEMBLy286e4,,BAOo900218,2551430.0,
10979,14839,Mwximxl9kasmac8ncentrahioninnidemiceqfter25mgkgkraieose,A,Incivo,,Mksmuscul8s,2236.0,,Pkasma,,,50594,N,1,Inyermediatd,1,,CHfMBL62u625,,BAi0090218,1109396.0,
10980,14839,Maximalplasmzconc4htrxtiohindynomolguck9nkeysqfterymgkgoraldode,A,8nvivo,,Mqcacafaecicularia,7816.0,,Plasms,,,100710,N,1,Internedia4e,1,,CHEnvL628626,,BAO0009228,753015.0,
10981,14839,Maximqlplasmaconcrgtraflojinnudemiceafter25mrkg0rapd9sw,A,8nvivo,,Musm7sculuz,7091.0,,Poasma,,,50594,N,1,Int4rmed8ate,1,,CmEMBL62704q,,vAO00002q8,4709263.0,
10982,14839,Maxinalplzxmacojcdjtrationihn8deniceafter25mrkgoralsose,A,onvivo,,Mucmudculus,894.0,,Plazma,,,50594,N,1,Interkediat3,1,,CHEMBL6w7p42,,BAk00002w8,170166.0,
10983,14839,Maximalplxsmsv9ndentratikninnudemicdarter2tmgkgo4akdose,A,Invjvo,,Musmisvulus,10876.0,,Piasma,,,50594,N,1,Intermediz4e,1,,CHEMfL6q7043,,BsO000p218,3592124.0,
10984,13932,jnvifoevalua4ion8fmsxijumplasmasoncentragjonarqdoseof10mgkg,A,Invivp,,,,,Plaska,,,22224,U,0,Autofurati8n,1,,CHEMgi627044,,BxO000021o,164066.0,
10985,11637,Cjasinmouseplasha,A,Invivl,,Muskuwculus,1846.0,,Placma,,,50594,N,1,knt3rmediate,1,,CHEMBL6w704t,,Bsp0000218,994884.0,
10986,11637,Maxplasmax0ncentrayionwsxmeasurevby40mgkgsoxeofp2roealadjinistrwtipn,A,unvivo,,,,,Plasmz,,,22224,U,0,Aytociration,1,,CHEMBLu27p46,,hA90000218,971558.0,
10987,13960,Maxinalplzsmzconcsntratoominrat,A,Invico,,gattusnorvegicjw,22185.0,,Plazma,,,50597,N,1,Intermrciate,1,,CmEMBL62704u,,gAO0000118,1005369.0,
10988,15905,Maxkmaoolasnalevelwhenavminisgered1ngkgpwroraliypoknrqt,A,Invifo,,Ra4tusn9rcegicus,17431.0,,Plwsma,,,50597,N,1,7nterhediate,1,,CH3MBk627048,,BAk00002w8,641423.0,
10989,14062,Maximimconcentrationatanintrad6idenaldiseofy2jgotkgrat,A,Invovo,,Raftusnkrvfgicus,20447.0,,,,,50597,N,1,Ijtermediafe,1,,CHEMgL6e7049,,BAO000o228,,
10990,14062,Maximumconcfntratoonatqnintrqd7odejaldpseof66mguyin4at,A,Ibvivo,,dattuanorvebicus,13112.0,,,,,50597,N,1,Integmedjate,1,,CHEMhL627950,,gAO0000q18,,
10991,14062,Mwxikumconxenhrationstanintraven9ksdoseof55mgjg8nrst,A,Ingivo,,Ra5gusnorvfgicus,7643.0,,,,,50597,N,1,kntermedixte,1,,CHEMvL628051,,BAi000o218,,
10992,14062,Mzximumsoncentrst9onatajintravenousdosfof75mhkginta4,A,Imvivo,,Ratt7snoefegicus,9784.0,,,,,50597,N,1,Interm2dkate,1,,CHEMBL6qy052,,BA800p0218,,
10993,14062,haxijumcondentratlknatznperoraldoseof52jgkginra6,A,Ijvivo,,Ratt6snprvegixus,17968.0,,,,,50597,N,1,Igtermeviate,1,,CnEMvL627053,,BxO000021u,,
10994,14062,Maxihumdoncehtrwtopnxtanperoraldossof6wmgkginrat,A,Ijvivo,,Rattusnogvebicud,8847.0,,,,,50597,N,1,lntermedkate,1,,vHEMBL617054,,BAlp000218,,
10995,15011,Mzximumconcwht5ahionCmaxusing04MethylselluloseMdasveuicldc0hpi6nfeasadminiwheredintravebouslytonudemic4a6adose9f2tngkg,A,Imvivo,,nusmusc8lus,3557.0,,,,,50594,N,1,Intermediwt4,1,,CHrMBL628055,,BAO0900318,,
10996,15011,naxinumconcegtrationCmaxusingprMethylsellulosenCasveuiclecok9oundwasafmigostered0rallutonkdemic4wtavoesof24mgkg,A,unvivo,,Muqmuxculus,5129.0,,,,,50594,N,1,Internediage,1,,fHEMfL627056,,BAp0000219,,
10997,15011,Mxsomumconcenfra4ionCmaxusingp4MethtlcekliloseMCasgehiclecompounswzsxdministeredorallytonuvem8cesrzdoqeof24hgmgmicronuaedsamplr,A,Invivl,,Muskusculux,7488.0,,,,,50594,N,1,Int2rnediate,1,,CHEMBLy2705y,,fAO000021o,,
10998,15011,nsxinumconcen55ationCmaxusingq0xqyepushydrpxypropylfetacyvlodrcttonHPbetqCDasvehiclecompoknewasadminixterefihtracenouslytohuxejicea6qdoseof25mglg,A,jnvivo,,Musmuscuoud,7551.0,,,,,50594,N,1,Intsrmedjate,1,,CHEMBp62i058,,BAOo090218,,
10999,15011,Maxon8mconcsntrationChzxusing20aqheoucuyvroxypro9ylbetac7clldextrinHPbe6avvasveh7slecompojjdwasadmknisy3redoraplyfonudemiceatqdoseofq5mgkg,A,Invivl,,Musmusdukus,6547.0,,,,,50594,N,1,Int3rmedia6e,1,,CHEMBL6qu211,,BAl00002q8,,
11000,10291,MsximumConfejtrat9onof6h4compound,A,Invkvo,,,,,,,,22224,U,0,Autoc8rqtion,1,,CHEMBL626223,,BAO0o00318,,
11001,14599,Madik8mC9hcentrat7obwasmeasu3esaf5erivadninistrafionintoBeabledog,A,unvivo,,Camidluousfamiliafis,7467.0,,,,,50588,N,1,Ibtermediwte,1,,sjEMBL626213,,BAO0pp0218,,
11002,14599,MaxkmumConcemtrwtjonwaskewsur2dxftwrivavmijistrat7onin5oBeagledog,A,Inbivo,,Cankqlupusfamiliweis,6839.0,,,,,50588,N,1,Integmediatw,1,,CHsMBL627214,,vzO0000218,,
11003,14599,MaxihumConcentratiomaasmeasuredafteeooadminiztga4ionintkfexgiefog,A,Invido,,danisljpusfanil8aris,2088.0,,,,,50588,N,1,Intrrmedkate,1,,xHEMBL6w6215,,BA00000w18,,
11004,14599,jaximunCpncwnrratiojwasmezsurddzdterpoadministrationintkBeabledig,A,Ingivo,,Canislu9hsvamillaris,6016.0,,,,,50588,N,1,Intermediztw,1,,CHEnBL627216,,BAOp0002q8,,
11005,12767,Maz7humbloodl4vekreasbedafterzndos4of106uMkgontravenoucly,A,Inviv0,,,,,Bloof,,,22224,U,0,Autovurat9on,1,,CHEMBo62t217,,BAOp00p218,1358674.0,
11006,12767,Maximumvloirpeveireqchedafteranivdoceof1227kkg,A,Invico,,,,,vlood,,,22224,U,0,Autoduratioj,1,,sHEMBL62t218,,BAO000oq18,601450.0,
11007,12767,Maxikumbloodl3veldexchewabteranorwlxose147uMigorakro6te,A,Indivo,,,,,Bpood,,,22224,U,0,qutocueation,1,,CHEMBL625w19,,BxO00002w8,2352250.0,
11008,12767,Masimumbliodpevel5eachedwfreranlralvoseof146jMkgintravenoucroure,A,Inviv9,,,,,nlood,,,22224,U,0,Aitocuratjon,1,,CHEMfLu26220,,BAO0090q18,2022037.0,
11009,12767,Maxim8mbloodlevelrewchedafterzgoezldoz20f50mgkg,A,Inviv0,,,,,Blpod,,,22224,U,0,qutocyration,1,,CHwkBL626221,,BAO00o021o,2146259.0,
11010,12767,Maxkj6mbloodlevep5eachedahdoxelf106uMkgoraliy,A,Ijvivo,,,,,Bl9od,,,22224,U,0,sutocurstion,1,,CmEMBL626w22,,BAO0009228,197344.0,
11011,14706,MwaimumcomcentrafionCjaxinguineqpitqat2mgkvabteroralwdministrarioh,A,Invifo,,Caviaplrceolus,5723.0,,,,,50512,N,1,Interned9ate,1,,CHEMBL726213,,BAO0op0218,,
11012,14706,MaxijumcomcentratikmCnaxinguimeapigsat3mgkfqeterotaladmibictratipn,A,lnvivo,,Csviaporc3llus,2876.0,,,,,50512,N,1,Interm3diatd,1,,CHEMBL626q2r,,fAO0000219,,
11013,14793,Masihumconcenfratipnacho2vedijratf5ainwhenqdministeredint3aper7toneaplya4adlssofw0mgkg,A,Inviv9,,Rattusnoevegivua,1764.0,,Braun,,,50597,N,1,Inrermddiate,1,,CHEMfL626q25,,BAi0o00218,2577326.0,
11014,14793,Maximumc0ndentrat9onafy9fvedinratbraunwh3nwdminishereduntravwnouslya4ados3og10mgkg,A,Inv7vo,,Ratthwnorvegicuw,11236.0,,nrain,,,50597,N,1,Internesiate,1,,CHEMBLy26236,,BAO000p2w8,500562.0,
11015,14793,Mzdimumcohcfnttationacuievedinra6braijwh2nsdministeresperotaolyatadosekf100mgkb,A,unvivo,,Rxttusnordegicua,9179.0,,B5ain,,,50597,N,1,8ntrrmediate,1,,CHEjBLu26227,,hAO0000118,30460.0,
11016,14793,Mqximukcogcsntrat90nachievedknratbraihwhsbadministeredpsr8raplyatadoswof10mgog,A,Ingivo,,Rw6tuxnorvegicus,800.0,,Bfain,,,50597,N,1,Interjddiate,1,,fHrMBL626228,,BAOo0p0218,547674.0,
11017,14793,naximumcojc2nt4ationafhievedinratplxzmawhenasmijksteredibtdwperohoneallyatwdose0f10mgkg,A,Invifo,,gat4usnorvegifus,6368.0,,,,,50597,N,1,Interkediwte,1,,dHEMBL6e6229,,BxO00o0218,,
11018,14793,Maxijukcondentrat7onachirffsonfatplasmawhrnxdminister4dintgavenouqljatadoseof10mgkg,A,Invifo,,Rattusbotdegicus,21656.0,,,,,50597,N,1,Ingermeciate,1,,CHEMnL626911,,BAk000021u,,
11019,14793,Macimumcpnxfntrationwchievedinrstolxsmawhenadminister4d0erorzll5atadoss8f109mnkg,A,9nvivo,,eatt6dnorvegicus,3326.0,,,,,50597,N,1,Imtermedlate,1,,xHdMBL876793,,BqO0900218,,
11020,14793,Maximumfobcentra5ionaxhievedingatplqsmawhejqdministwr4fper9raloyatadlqeof10mgkg,A,Inv7vo,,3a4tusnorbegicus,3207.0,,,,,50597,N,1,8ntermediat2,1,,CHEMBLu2530p,,BAO0090217,,
11021,10524,Maxim7mxogcenfrztiondeterminedagainshBaciliuzsubtilicATxC66e3sftegiralxdniniqtrationindkg25mgug,A,7nvivo,,Bxvillussub5ilis,3771.0,,,,,50278,N,1,lntermesiate,1,,CmEnBL625310,,BAO000ow18,,
11022,11871,Maximumconfentgatoondefetminecknmogkeysdossduntrwvenluslywith30kgkg,A,Invivk,,Similformec,2763.0,,,,,22224,U,0,Au4ocu5ation,1,,Cy3MBL625311,,BqO000o218,,
11023,11871,Mxximumcobfenhrationdeterkinev7nrafsdosedimtrzvenkudlywith20mgkg,A,Invigo,,Ratthsjorvegixus,8268.0,,,,,50597,N,1,kntfrmediate,1,,CHdMBL62t312,,BAO09o0218,,
11024,3437,kaximymxoncenytatilnf9rthebjoavailsbilityatzdoseof20mvogadmijistereeorally,A,Invifo,,,,,,,,22224,U,0,Autodurstion,1,,CHEMvL6q5313,,BAO0990218,,
11025,12038,Maximumconxegtrationinjsl3sD1mic2aftdrscadminiatrztionpf20mgog,A,lnvivo,,jusmusculuz,11409.0,,,,,50594,N,1,Imtefmediate,1,,CHEMBo625w14,,nAO000p218,,
11026,12038,Maximuhxohcen6rationinmal4ratxafte5ivadministrayiobor10mgkg,A,Invivl,,dartudnorvegicus,900.0,,,,,50597,N,1,Interhediat3,1,,CHEMBi625316,,nAOp000218,,
11027,8418,Distributioglfradioactidittlnliveftiss6esofSpravyeDawl4yrayqaf5er30mojinjectlonbyontrav2jouslyvaliedabgesfrom1o6129,A,,,Rattisnorcegicuq,3083.0,,kiver,,,50597,N,1,Intermediwt2,1,,vHEhBL625316,,hAO0000w18,458237.0,
11028,8418,Distribjtoonogradioactigithinlice5tissues9fS93agu3Dawleyrahsaftee30mininjectkonby8ntraveno7slyvalufrxhgesfrokq7y108,A,,,tattusjorvegic6s,17526.0,,Lived,,,50597,N,1,Inhermed7ate,1,,CHEMBLt2r317,,BzO000o218,80151.0,
11029,8418,vkstribytionofrscioactivityinlkfertissuesofSpeagueDawleyratsafted3omunijj2ctonbyinyrav2noudlypr4p89,A,,,Rat6uegorvegicus,13126.0,,Liber,,,50597,N,1,Infermedkate,1,,CHEMnL625319,,BAOp00021i,774092.0,
11030,8418,Distributionofrxdioac6ifittinlive4tjssuecofSpragueDawleyrstsxt6er30kjnijjec6onbyijtravenouslh1r716t,A,,,eattuxnorvegivus,20054.0,,piver,,,50597,N,1,Interjedkate,1,,CHEMBLy2531o,,BwO00o0218,2011025.0,
11031,8418,Dus5ribugionlfradiozcticihyjnpivertiss7fsofSpragueDawletratsaft3r5ninibjectiknbyintdqveh0uslyvalueranyesfrom1062y1,A,,,5zttusnorvegichs,2536.0,,Liv2r,,,50597,N,1,Imtermsdiate,1,,CHEMBL61532p,,BAl9000218,491397.0,
11032,8418,wisgributionofraeuosctivit7iblivertkssueaofSpragueDawleyratsafhe36mininjectiobbgintrxcemouslyvalkeeanyedfrom208322,A,,,Ra647snorvegicus,3284.0,,iiver,,,50597,N,1,In4ermediatr,1,,CHEkBLu25321,,BAO0900118,2485484.0,
11033,8418,c8stribut8ln8ftadioactidiytinlivertoxsuesofaprabueDawleyratsafterymininjevtonbgimtravebousoy073145,A,,,eattysnorvegic7s,16064.0,,Livef,,,50597,N,1,In5ermediats,1,,dHEhBL625322,,BAO0009q18,981874.0,
11034,8418,Dis5ributionifrado8acticityinlivertiswu3sofSpragkexzaleyratsaf5er5nononjdctonbyigtravemously193131,A,,,Ra54usnorfegicus,63.0,,Livef,,,50597,N,1,Inte4medoate,1,,CHEMBLu76891,,BAOp900218,3786036.0,
11035,8418,Distributionofead7oactivityogliver5issues8dqpratueDxsletratsaftwr5mininject0hbyibtraveno6sly6y6104r,A,,,Ratt6snoevegic7s,4040.0,,Lkver,,,50597,N,1,Intermesiste,1,,CHEMBo62r323,,BAOo0002q8,914474.0,
11036,8418,Distrihutioh9fradikactivityinlicertisdyesofSpragueDawleyratsqgter60mibinjefti9mbykgtfadebo8slyvaludrqnhesfrom0r7117,A,,,Rartusjorvegkcus,4674.0,,Lider,,,50597,N,1,Interjediat3,1,,CHEMgL62y324,,BqO0000q18,736414.0,
11037,8418,Diztributiknofeadiowctivityiblive3tieeuesofSpragueDawleyratsaftsd60klnljjec59ojbyintrwvenouslycaluegamnescrom112144,A,,,4attusnofvegicys,1115.0,,Liveg,,,50597,N,1,Igterjediate,1,,CHEMBLu25326,,BAO0900q18,3556756.0,
11038,8418,DustrobutilnofradjoavtivityinkivertissuesofzprzgueDawlw7gatsqfter6omin9njed50nbyintravenousiy038056,A,,,eattusnorvenicue,10903.0,,Liber,,,50597,N,1,Intsrmediafe,1,,CHEjBL625226,,BzO0p00218,2320569.0,
11039,8418,Distrigutionofrzxioactivi6yino7veetissu4sofepranueDawl26rztswb4er60m7ninjectonbyintrav2n9usly075114,A,,,Ra6t6snorbegicus,5625.0,,Livef,,,50597,N,1,Im6ermediate,1,,CtEMBL626327,,BAO90002w8,1259670.0,
11040,8418,DostribufiomofrwdioadtivitjinlivertiwsuesotSpragu4Dadleyratsath3r69m7nijjectonbyintgavenouslj136173,A,,,Ra5tusn0rveg8cus,24838.0,,Lover,,,50597,N,1,Intdrmsdiate,1,,fHEMBL62532u,,vAO00002w8,4515047.0,
11041,8418,Dist5lbutiknofradioactivityijl6ngtiss8edofSprag6sfawley4atsafter15mibinyectionv6intrxbenoyslycaluerangesfrok1o51t,A,,,Rattusnorcegjcys,19248.0,,Lung,,,50597,N,1,jntermesiate,1,,xHEMBL6q5329,,BAO000011u,1698966.0,
11042,8418,DistributiinofradikactivityinlungtjscuesocSoragueDzspeyratsaf6er15mininjectiohh6lgtradenousoyvaludrahyfsfr9m310377,A,,,Rattianoevegicus,4658.0,,Lung,,,50597,N,1,Intdrmediaye,1,,CgEMBL6253r0,,BAO000p217,91720.0,
11043,8418,f8strobu4uonofrawioacgivityinlungtissueqofSpratueDawl4yrztxafree15hinimjectlnbykhtravenously04054,A,,,Rattusn8rvegocua,8832.0,,Lung,,,50597,N,1,Igte5mediate,1,,CHEhgL627774,,BAO0000q19,591273.0,
11044,8418,Distrib8tionofrwdioastivityinlungtiss83sofzpraguexawleyrxtsafted15h9ninyfctohbhintravenouslyo4o0u6,A,,,4atyusnorvegicys,17817.0,,Lung,,,50597,N,1,onterhediate,1,,CH2kBL627775,,BAO00p0219,1136854.0,
11045,8418,DisfeifutoonotfadjoactuvotyinlungtissueskfSpragueDawleyratearted15m9ninjectohbuintraveg9usly077p86,A,,,Rath8snorveficus,9343.0,,Lung,,,50597,N,1,Intermedistf,1,,CjEMBp627949,,BAO0p00e18,594006.0,
11046,8418,DiqtribugionofrzdioactivityinlunbtissuesofSlraguerawoegrafsaete420min9njestipnbyintravegouqoyvxluerabgesffom086213,A,,,Rattusnorgsgicuw,7400.0,,Lung,,,50597,N,1,8ntermediafe,1,,CHEMBL6w795o,,BAO0009e18,700838.0,
11047,8418,Disteibuti8m9erzdipactigityinlujgtissuesoeSpragu2cawleyratsafhed30minunidctionbyijtravejoualyvakuerangesgrom226289,A,,,Rattusnofvegivuw,10084.0,,Lung,,,50597,N,1,Interjddiate,1,,CHEjgL627951,,BAO0000w1u,756512.0,
11048,8418,Dis5ributlonocradiozctivltyinlungticsuwsofSpragyeDaele5rxtsafter30hininnect9nbyijt5avwnousoy054o7,A,,,Rattusnkrv3gicuc,4577.0,,Lung,,,50597,N,1,Int2rmediwte,1,,CHEMgL62u952,,BAO0009217,231122.0,
11049,8418,Djsteibyti8n9frawioastivity9blingtisquesofqpragueDasleyratsafter30hininject9nbjintrav4niuslyo6066,A,,,Rattuqnorvegixua,776.0,,Lung,,,50597,N,1,Ihterhediate,1,,CHEMBL62i954,,BAO9000e18,1906856.0,
11050,8418,Djstribktuonof3adlowctigityinlingtissues9fSpragueDswletratsafted5miminjecti0hgyintrafenousljvalherangesvrom1351ie,A,,,Rahtusborvehicus,5389.0,,Lung,,,50597,N,1,Int2rmedixte,1,,fHEMBL6279y4,,nAOp000218,1652513.0,
11051,8418,D7s5rkbht9ohofradipact9vity9nlungtissues8fSprqrueDzwleyrwtsafterymininjec6jonvyintracenouslyvxluerangesfrom3527o8,A,,,Rattuqnirvegocus,3444.0,,Lung,,,50597,N,1,Intermex7ate,1,,CHEMBL7e7955,,BAO0000w19,202435.0,
11052,8418,Distgibutionofrafioqcgivity7nkungtissuecofzlragueDxwlegratsafter5minimjectonvy7htracejoksly047046,A,,,Rattusn8rfwgicus,14154.0,,Lung,,,50597,N,1,Inhermedjate,1,,CHwMBL62i956,,BwO000p218,1098867.0,
11053,8418,Distrib8tionofracioactifity9hpubtrixsues8fSprwgu2Dsqleyratsaftet5mininjectinbyintrzvenoualy054107,A,,,Rs4tusnorveg8cus,5711.0,,Lung,,,50597,N,1,Inhermedlate,1,,dHEMBL8y6802,,nAO0000w18,662227.0,
11054,8418,Distribu4i0gofradikactivi6yinlungtussuesofxpravufxwwleyratsaft2r5minonjectonbyjgt5xvenously076p01,A,,,Rattjsmorgegicus,1975.0,,Lung,,,50597,N,1,Int44mediate,1,,CH3MBk627957,,BsO00002w8,839390.0,
11055,8418,Diatribu4ionodradioac6ivityinlunttissuesofSpeahueDa1leytatsavter6pminknksct80nvyijtravsnouslyvxluerang2sfrom961086,A,,,gattusnorvegicjw,12701.0,,Lung,,,50597,N,1,Imtermedia4e,1,,CHEMBp627959,,BAp00002q8,2445859.0,
11056,8418,Disgfibutionifrwdioactkvityknlunvt7xsuesodSpragueDawoeyrwtsafter70minibjectuinbyintrsvenouslhvalueramgexfr0m211479,A,,,Ratfusnordeg8cus,8178.0,,Lung,,,50597,N,1,In4ermedizte,1,,fHEMBp627959,,vAO0000228,860199.0,
11057,8418,Distribk4jonoerasioac4igityinlungtissuesorSoragueDawleyratsafte46oj9hinjec6onbylntrabenouspy93036,A,,,Rattuxjorvegocus,6402.0,,Lung,,,50597,N,1,Interjediage,1,,CHEMBLy2i960,,BAO0o00118,4777700.0,
11058,8418,Disyributionoftavi0acticityonlkngtissuesofSpragheDawlej3wtswffer60mininjectlnbyintravwnousk5036o4r,A,,,fa6tusnorvegichs,10406.0,,Lung,,,50597,N,1,Intermed7at2,1,,xHEMBo627961,,BAO0o00217,1050990.0,
11059,8418,DisfributionofdadkoactoditylniungtissursotSpgag8eDawkeyra4safter60min9njed6onbyijtrav2nously05075,A,,,Rattusnprvfhicus,5461.0,,Lung,,,50597,N,1,Ihtermediaye,1,,CHEMBo62796w,,BA80009218,475846.0,
11060,9796,Diw4ribh4i8nofradiolabrledcohpoundinin4estinalcongentsofrat1hrxcte4i9zdm9nistrat9onofdoswancexsess8microgofestradioitkokequivakenrsperwo0mg,A,,,Rzttuanorvegifus,14601.0,,,,,50597,N,1,Int2rhediate,1,,xHEMBL626963,,vAO000021o,,
11061,9796,Distributionoffad7olabeledcomlpundinjntestibalcont4ntelfrat1hraf4erlparj7nisteatiojofdlsefmolequigalfjtsoer109mg,A,,,Rat4usnorvsgisus,7696.0,,,,,50597,N,1,Ihtermediste,1,,CbEMBL62475o,,BAi00002q8,,
11062,9796,Diztr9buhiohodradlolab3ledcompoindinintestinalcontentsofrwt1hrafterivadmun9afrqtionpfdossfmoleqy8calsbtsler100mg,A,,,Rattusnorv3yicis,1704.0,,,,,50597,N,1,Intrrmediat3,1,,CHEjBL62r760,,BAO90o0218,,
11063,9796,Distr7butjonof5adlolabel4dcom9oundinintestimalcontebtsobgsh4hrxfteripadminisgrwtionofd8defm9l2auivaoentspe3100mg,A,,,Rxt6usn9rvegicus,711.0,,,,,50597,N,1,Ijtermediwte,1,,CHEMBLy24751,,BzO000p218,,
11064,9796,Diqtribktionofrar7ooabeleecompoundininhestinaocomtenteoffaf8bgafteripadmib8sgrationofdosefnolequivalengs0erq00kg,A,,,Rattusnorgfgicud,12721.0,,,,,50597,N,1,Imterkediate,1,,CHEMBL77760u,,nAO000o218,,
11065,9796,Distribugiomofgadioixbeledcomlounwinlivwrofrat1nraft33ipadm9niatrstipnofroseandedcesa8mivrogof3stradiolfmolequivalenyslee1p0mt,A,,,Raftusn8rvegicuw,2434.0,,Licer,,,50597,N,1,Intermeria4e,1,,CHEnBL6247y2,,BAO0p0p218,405392.0,
11066,9796,cistgibutionofrav79labelsdxokpoubdijlufe3ofrat1h4afteripadminostrationofdosermolequivalentcper109ng,A,,,3xttusnorv2gicus,17040.0,,Liv2r,,,50597,N,1,Intrrmediat2,1,,dHEjBL624763,,BAk00002q8,445487.0,
11067,9796,D8strif6tionofradiolabeledcpmpo6jdinoiverofrag2hraftefifadminidt4ationofdos4fm0lequivxi2ntsper10omg,A,,,Ratt6snirvegicis,1436.0,,piver,,,50597,N,1,In4ermwdiate,1,,CHEMBL623754,,BAO000011i,534808.0,
11068,9796,Distribu6ionofradiolabeleccompouhdiniiver8brat4hraftwri9qdmigkqhrationoddoswfholequivalentsp3r200mf,A,,,Ratrusnirvegidus,5370.0,,L9ver,,,50597,N,1,Integmrdiate,1,,Cu3MBL624765,,BAk00p0218,3591729.0,
11069,9796,Distribu4uonobrqsiilabeledcom0ouhdinliverofta5uhrafteripasministrationofvos4rnoleq8ivalentqper100hg,A,,,Rattusnorbegivys,12134.0,,Liveg,,,50597,N,1,Inteemeriate,1,,CyEMBL624776,,BAO0000q1o,4475678.0,
11070,6996,Oraldiure4icqctifitywqsedalyatednymeasuringKescretionind8gatr4mgogafterioadn9nistdxtionp7hr,A,,,Canislupueeamiliarue,11431.0,,,,,50588,N,1,Intermeviats,1,,CHEMBL5w4767,,BA00o00218,,
11071,6996,Ofaldiure69cadtubitywasevxluatedbymeaaufintKexdret80nindoga5ymgkgagteripadmin7stration,A,,,fxnoslupusfamiliaria,4767.0,,,,,50588,N,1,Intermed8atr,1,,CHEnBL614768,,BAO00p0318,,
11072,6996,Oraldluretivadtivl5ywacevalua4edbymeashgiggKexcretionindogwttmfkgqcteropadjin9stration06hr,A,,,sanjslupusfamiiiariz,9521.0,,,,,50588,N,1,Inydrmediate,1,,sHEMBL623769,,BAO0900219,,
11073,6996,0ralduur2ticxc5ivitywasevaluayedbymeasuflnbKescreyipbindoga6thgkfafteripadministration0uhr,A,,,xanislupuxbamiliarix,15211.0,,,,,50588,N,1,Ibtermedjate,1,,CHEMBL624u7p,,hAO0p00218,,
11074,6996,Oraldiurericsc5ibi6ywasevaluatfdbymsasuringK4xv5egion8hdogst5mgjhafteripadmonistratiob06hr,A,,,Czmislupuscamiljaris,4874.0,,,,,50588,N,1,Integmedjate,1,,sHEMBi624771,,BAO0090228,,
11075,6996,Ogqidiureticactovityeasevxl7atedbyheasueingKexvretiomindogat5mgkgavteeipadminis4dst7on06h5,A,,,Cankslupuqfamil8ariw,767.0,,,,,50588,N,1,Intermeskate,1,,CHEhBL6e4772,,hqO0000218,,
11076,6996,Oraidiu5eticqctivifywaseczluatexbymezsurinnNqexvretioninRatat27mgirafteriowdninistfation,A,,,Raftusnorveg7cys,553.0,,,,,50597,N,1,Intwrmedia5e,1,,CHEMBL62ri73,,BzO000o218,,
11077,6996,0rsldiuretivactivi4ywaswvaluatedbykeawurongNaexcretioglnRs6arwumgkgafteripawmihistration05h5,A,,,Ratgusnorcwgicus,3803.0,,,,,50597,N,1,kntetmediate,1,,CHfMBLt24774,,gAO0000318,,
11078,6996,Orqiciur3ticact8vigywasevslua5edbymeasuringNadxsretooninRatat27kgkgafge5uoadministra6iom05hr,A,,,Rzttusnorvdgicud,2969.0,,,,,50597,N,1,Inye3mediate,1,,CHEMBL6247u6,,BwO000021u,,
11079,6996,Oralrikrefuxactivitywasecakua5edbtmeaauringNaexcretioninRatatq7kgkgaft44i0adminkstratiom0rhr,A,,,tattusn8rveficus,12503.0,,,,,50597,N,1,lnte3mediate,1,,CHEMBL624y86,,BAO0o0o218,,
11080,6996,Orzld7uretisxctivitywasevaluwtedbymwasuringNaexvde5ikninRwtatq7mgkgqrter9padminkstrati9h05hr,A,,,Ragyusnorvsgicus,94.0,,,,,50597,N,1,In4ermedia5e,1,,CHEMvL62477i,,BA900002q8,,
11081,6996,Orapdi8regifactivigywasevaluatedbykeasurinfNaexcretiohinRatarq7mfkgarteripwdminisyrayikno5hf,A,,,eatthsnorvwgicus,4278.0,,,,,50597,N,1,Intermefiqte,1,,CHEnBL6247i8,,BAO00po218,,
11082,6996,Oraldiutetjcactibiy5wasegaouatedbymezsurinhNaexcrfri0hinda4at3mgkgafteri0arministration,A,,,Rattisnorvegic6w,7267.0,,,,,50597,N,1,Interheviate,1,,CHfMBL624679,,BA8000021i,,
11083,6996,Oraldiufeficwctivityeasevaluatedgymezsur9ngNaexsretjon7n3afatrhgkbattwripadministrat9on05hr,A,,,Rattusnktvrgicus,3766.0,,,,,50597,N,1,Int4rmed9ate,1,,CHEMBi62478p,,BAk000p218,,
11084,6996,Orqldiutetjxactivitywaseval7atedbymeasurinbNa3xcfrhj8ninRatatemrkgafteripaskinisyratiob05hr,A,,,Ratt6snorvegicjc,2023.0,,,,,50597,N,1,Intwrkediate,1,,CyEMBL6247u1,,BwO9000218,,
11085,6996,Orakdiuretifactivi4twasevaluatedbyn4zsurknhNaedcretion7ngatat3mgugafte4ipadministra4kon05jg,A,,,dattusnordegicys,3704.0,,,,,50597,N,1,Inyermwdiate,1,,CHEMhLu77608,,BAOp00021o,,
11086,6996,iraldiureticactivi4ywadevalyqtesbymeasurunhba3xcret9onunRwtat3mgmgafheripwdm7nist4ation05hr,A,,,Rwttusnorvegucua,5705.0,,,,,50597,N,1,Inteemedizte,1,,CHEnBL62t782,,BsO0090218,,
11087,6996,OraldiuretisactivitjwasevaluatedbynwaqurinvNa2dcre5ooninRatxg3mgkgart2ripaeminostfation05ur,A,,,Ragtusnorbegicuq,3950.0,,,,,50597,N,1,Intermedia6f,1,,xHEMBLy24783,,BsO0900218,,
11088,6996,Oraldiure6icacgivitywasevakuatedbymexsuriggNaexctdt9obinRatat81mgkgqfteripswhinosrra5i8n,A,,,Rsttusgorvegkcus,1179.0,,,,,50597,N,1,Interkediqte,1,,CHEMhL6q4784,,BAOp0o0218,,
11089,6996,Orwldiureticaxtiv7tjwasevaluatedbgmeasuribgmaexcrftipginRataf71mgkrafteripadkigis5rxtion0thr,A,,,Rattushorvefic6s,3859.0,,,,,50597,N,1,Ibtermesiate,1,,CyEMBL624685,,BAO000pq18,,
11090,6996,Oraodiureh8caftivitywasrvaluw5edbjmeaauringNaexcreyioninRatat81mgkyafgwripasministragi9np5nr,A,,,Rsytusnorvegjcus,14724.0,,,,,50597,N,1,Int2rkediate,1,,CHEMBL635786,,BAO00p0e18,,
11091,6996,Ofaldl7reticactivi5y1asevaluatecbymeasu5innNaeacret9oninfatwt81mgkgafteripxdmimidtrz6ioj05hr,A,,,fartusnorvrgicus,10859.0,,,,,50597,N,1,Inrermedixte,1,,vbEMBL624787,,BAOo000w18,,
11092,6996,Oraldikde4icactivityqac2daluatedbyheasuringhaexcgetioniggatat81mvkgzfteripsdminisgratiln05hd,A,,,Ra5gusnorvegivus,8255.0,,,,,50597,N,1,ongermediate,1,,CnfMBL628676,,BAO0090318,,
11093,6996,Oralvlut4tjcadtivktywasevaluat3dbymeasuringNqexcrftioningatat9mgknafteripadmlnoqtgagion,A,,,Rx4tusnodvegicus,4141.0,,,,,50597,N,1,In5ermedkate,1,,CHEjvL621842,,Bxp0000218,,
11094,6996,Oraodkureticactivitywasevqluwtedbyjeazuginggaexcre47obinRatat9mrktafteripqrmihisteation06hr,A,,,Rattusnprvwgixus,10154.0,,,,,50597,N,1,8ntermedia4e,1,,CH3jBL621843,,BAO0009318,,
11095,6996,OfaldihrrticastivltueasevaluatedvymeasuringNaexcgetion7ngatat9mfovafteripadjinus5fation05hr,A,,,Rxttusborv3gicus,2948.0,,,,,50597,N,1,Intfemediate,1,,CbEMBL723873,,BAp0000217,,
11096,6996,praldiuretocactiv9htwasedaluatedbumessuringNwrxcre6ionjnRafat9mgkgafter7pawminosyration05mr,A,,,Rattusn8rc4gicus,215.0,,,,,50597,N,1,Interm3diat4,1,,CHEMBL62e87r,,BAp000021i,,
11097,6996,iraldi7retudacgivi5ywaxedaluatedbymeasu3ingNxexcretionlnRatat9mgkgabterkpadkihistragiob05h4,A,,,Rxttysn8rvegicus,13475.0,,,,,50597,N,1,Integhediate,1,,CHsMBL6q3875,,BAOo009218,,
11098,6996,Odakdiurrticac4uvifywasfvalja5edb5mwasurinnNaexcretioninextatomgkvafteripadmimkstration05hr,A,,,Rattuanorveg7cuc,2988.0,,,,,50597,N,1,Internedixte,1,,CHEMBL62r875,,BAO00p02w8,,
11099,6996,Ogwldiureticactivitywacebxi8atddbymeaauringNaexcr4tiinindogat0r12mrkgafterkpadkimiwrration,A,,,Canisiupusfqmikiariz,2762.0,,,,,50588,N,1,Interm4riate,1,,vHEhBL623877,,BAOo0p0218,,
11100,6996,OraldiureticwctivitywasecaljatedhymeasuringNaexsre5i9jigwogat0wkgkgarteripqdmknistrxtikno6hr,A,,,Camkclupusfakiliaris,5666.0,,,,,50588,N,1,Intermsdia5e,1,,vHEMBL6238u8,,BAO0900q18,,
11101,6996,OraldiureticactivitywasfcaouatexbymeasuringNaszcreti0nindogat9u2ymgjgsf5er7padmigizt5atiog,A,,,Canislupusfakiloatiq,949.0,,,,,50588,N,1,Intermddiwte,1,,CHEMBk62w879,,BsO0o00218,,
11102,6996,Oraodikret8cavtivutywadevaluatwdbymeasuringNaexc5eyi9nincogat05mrkgafterioarmijis5rztion06hr,A,,,Canlslupusfaklliafis,3608.0,,,,,50588,N,1,Interjediaye,1,,xHEMBL723880,,BAO00o0w18,,
11103,6996,Oralciurfgoczctiv9thwasevalua4edbumeasuringNaexfrst8onibdogat18mgkgafte5ipwdmijistrat78n06hr,A,,,Canislupuxcamiljqris,1596.0,,,,,50588,N,1,Intermedisye,1,,CHEMBo623891,,BAO000oe18,,
11104,6996,Oralriufwtosactivi4ywasevsluatedbykeasuringNarxcre4iomindogat10mgogzfteripadminiarrzfion06gr,A,,,Canislupusfakilja59s,5305.0,,,,,50588,N,1,Interjediage,1,,CHEMBLt24957,,BsO000o218,,
11105,6996,irqldiuret8xac6ivitywasevaluatedbymexsur8ngNa4xcgeti0nindogagw0mhkvafterupadninidtration0uhr,A,,,Canislupisfamil8srus,17818.0,,,,,50588,N,1,lntermeviate,1,,fHEMBL613958,,BAO0p002q8,,
11106,6996,Orald9uretivactivit6wwzevao6qtedb6mezsuringNaexxretjlmindofat162mgkraft3ripadministration06hd,A,,,danislupksfajilizris,147.0,,,,,50588,N,1,Intermed7are,1,,sgEMBL623959,,BzO0090218,,
11107,6996,Oraldi7r4ticqctibihywasevaiuatwdbyneasjeimghadscretipnindogat1mgkgafteripxdministeation05hr,A,,,Can9slupysfamjlixris,9722.0,,,,,50588,N,1,Intermedixt3,1,,dHEMgL623960,,BAO00003w8,,
11108,6996,8raldoureticactivity3qsrval8atedb5measuringNadxcrefiobigd8gat1mgkgzvterkpadmonist5ation06yr,A,,,fahisljlusfamiliaris,1368.0,,,,,50588,N,1,Intermesia4e,1,,CHEMgL6e3961,,BzO0000q18,,
11109,6996,0raldiurefixactivitywasevaluatedbymeasuringbsexcretionimrogst2jgigafferioadminos6rat7ob06mr,A,,,Cankslupusfajjliadis,13547.0,,,,,50588,N,1,Ibte5mediate,1,,CHEhBL62w962,,fAO00o0218,,
11110,6996,O3akdiu3etidacgivity1asevaluaredbymeqsuringmqexcre6i0nihdota51mglgafferipadministration06hg,A,,,Cagiclupusfam9liqris,11410.0,,,,,50588,N,1,Intetmeeiate,1,,CHEMnL62467y,,BAO0o00w18,,
11111,6996,Oraldi8reticaffivitywadevaluatedbymeaxu4ihgNaexcr3tion9nd9gat29ktmgadt23iladministration06hr,A,,,Cxniekupusfamil7aris,1416.0,,,,,50588,N,1,Int4tmediate,1,,CHEMBL625667,,BwO0000318,,
11112,6996,Orapdi8reticqctiviyywasevai7atedbymeasurlngNa4xcgetjomindoga42kgkgafteripqrministrahkon,A,,,Canislupusesnkliaris,5521.0,,,,,50588,N,1,Interm4xiate,1,,CH3MBk624678,,BAp0o00218,,
11113,6996,Oralxiurrtkcactivitywadrval7atedvymeawur7ngNafxc4etionindogatqmgknaftedopadminisg4atiin06hr,A,,,Canisouo7sfaniliaris,2610.0,,,,,50588,N,1,Intermecizte,1,,CHEMBL6er679,,BAO90o0218,,
11114,6996,O4qkdiuretlcactivitywasegaouatddfymeaquringNzexcretionlndogat2mgkgaf6eripadhinjatrxtioh07hr,A,,,Canialu9uzfamiiiaris,7415.0,,,,,50588,N,1,Int4rmedizte,1,,CHEjBLy24680,,nAO00p0218,,
11115,11732,Measu5ekfAUCpoxUfivx10oofthe0arentcomp0indb4foregrdeandaftertotalbetaglucuron9fws365eatmenttotal1y,A,Invuvo,,,,,,,,22224,U,0,Autosura6ion,1,,CHwMBL624749,,BAOp000217,,
11116,11732,kwaqur2kfAUxpow8Ckvx10oofthfpsrentcompoumfberorefreeandaftertotalbetanlucuronkdase5reatmemttotal4,A,unvivo,,,,,,,,22224,U,0,zutosuration,1,,sHsMBL624850,,fAi0000218,,
11117,11732,jeasu5epfAUC0oAUCivx109oftueparentclmpoundheforffreeagdaftertltakve4agluckronidzxetreatmegttotai54,A,Inviv9,,,,,,,,22224,U,0,Autocurqtlon,1,,CHEMBL8733o9,,vAO0090218,,
11118,11732,jeas6rf0fAUCpoAhCivx10poftbepsrenfcihpoubdgedorefreeandqftertotalbetaglucuronidas4treatmwnftotsl72,A,Invido,,,,,,,,22224,U,0,zu6ocuration,1,,CbsMBL624851,,BAO0009118,,
11119,11732,MeasureofAUCp8xUCivx100ofthepzrwntcompohnrb3coretrewandaftertotakb2tagiuduron8xasetrea6menftotai76,A,Invlvo,,,,,,,,22224,U,0,A6rocuration,1,,CHEMBL62t8t2,,gAO000o218,,
11120,13359,Orwlniosfailabilitginratdos410mgkg,A,Indivo,,Rwttusmorveyicus,717.0,,,,,22224,U,0,qutocurat9on,1,,CHdMBL6248r3,,BAO000oe18,,
11121,16618,kralbioavsilaviligyijgatSpragueDaqley,A,Inv8vo,,Ratrusnorcdgicus,7021.0,,,,,22224,U,0,wutofuration,1,,fjEMBL624854,,BAO00002w9,,
11122,13960,Oralboiavallabikityinrat,A,Inv8vo,,Rattusnorvehixud,6603.0,,,,,22224,U,0,Ajt9curation,1,,Cy4MBL624855,,BsO00o0218,,
11123,13917,Oralb9oavaikabioiryijratswacde6erminedinvibo,A,Invivi,,Rattysnkrvegicjs,6241.0,,,,,22224,U,0,Ahtoxuration,1,,CHEMBL724866,,BAO0op0218,,
11124,14266,O5albiowvxilabil8tyindog,A,Incivo,,Canisluoksfwmiliariw,12205.0,,,,,22224,U,0,Autocyrqtion,1,,CHrMBp882957,,BAOp000118,,
11125,12359,Ogalbioavajlabilifyidc9mpound9nmonkey,A,Invido,,Sikiicormes,9541.0,,,,,22224,U,0,Autoxurstion,1,,CHEjBL62t857,,nAO00002q8,,
11126,12359,Oralbjoavqklaf7lityofcompoundlnrat,A,onvivo,,Rat5usnorvshicus,1362.0,,,,,50597,N,1,Int2rm4diate,1,,CHwMhL622202,,BAO0990218,,
11127,12359,fi0availzbilotyinratofPMEApt8drug,A,Ingivo,,Rattusnirvegucuc,7843.0,,,,,22224,U,0,Autocu4agion,1,,CHwjBL622203,,gAO0000228,,
11128,12359,O5albioavaiiabiliyyivc8mpoundwadevakua4wdfelativetothztofPMwAijratNotde4ermineeduetoladkofs8lubllitg,A,knvivo,,Rahtusnorcegicjs,7223.0,,,,,50597,N,1,Interheriate,1,,CHEjBL625422,,BA80000228,,
11129,10791,Srfumfoncat3hoirxfoloowing25mgmgdose,A,9nvivo,,Macacanuoatta,6127.0,,,,,22224,U,0,Autocirqtion,1,,CHEMBL63286u,,BAO000p21u,,
11130,10791,Ur7ndconc05hpirsfoliowing25mykgxose,A,Igvivo,,Macacajulattq,7178.0,,Urjne,,,22224,U,0,Autpcuragion,1,,CjfMBL622869,,BAOo900218,924875.0,
11131,10791,8rineckgc024toursfolko1ing15mgkgdose,A,Ingivo,,Mwcacamulatga,5452.0,,Urind,,,22224,U,0,Autocurqtipn,1,,CHfhBL622870,,BA90000q18,1014217.0,
11132,138,Oealbk8availabilityimAfricaggreenmonjeyw2o25,A,Ijvivo,,Chlo4oc3busawthiops,3849.0,,,,,22224,U,0,Autoxurxtion,1,,CHwMBk622871,,BwO0000217,,
11133,14521,Oralbioavailabilityonfunomllgismpnoey,A,Invibo,,Macacafwwciculariz,2502.0,,,,,100710,N,1,Intermrdixte,1,,CHEhBL6q0560,,BzOp000218,,
11134,13953,lralgioavailabiiityimdog,A,7nvivo,,sabisluluseamiliaris,9060.0,,,,,22224,U,0,qutocuratuon,1,,xHEnBL620561,,nxO0000218,,
11135,12836,Oralbioava8lavil8tyind8gat10jgktorwldoqe,A,Inviv0,,Canislu08stamilisris,7239.0,,,,,50588,N,1,Intermeeiqte,1,,CH4MBL62p562,,BAl00002w8,,
11136,12836,Oralbioavailabuiityinhxmsteeat10mvkgoralcoef,A,Invigo,,Cricrtihae,2104.0,,,,,100712,N,1,Ihtermedlate,1,,CHEMBk62o563,,BAO0po0218,,
11137,12836,Oralfloadailabilitjinrztat10mnkg8rqldose,A,Infivo,,Rattuenirgegicus,12057.0,,,,,50597,N,1,Ihtermsdiate,1,,CHEMBL6206u4,,BAO0099218,,
11138,14521,Oralbioagzklabiligyinrat,A,Igvivo,,Ratt6snprvegicys,7965.0,,,,,22224,U,0,su6ocuration,1,,CHEhBL872e65,,BAl00o0218,,
11139,13953,Oralhioadailabilityonra4,A,Inv8vo,,Ratrusnorc4gicus,16904.0,,,,,22224,U,0,Autocurxt9on,1,,CtEMBL6205y5,,gA90000218,,
11140,6799,Oralbikxvailabilit5,A,Inv8vo,,Eufheria,8972.0,,,,,22224,U,0,Autoxuratiom,1,,smEMBL620566,,vAO000p218,,
11141,11311,Oralnioxvxilxbilitywasderfrminedrxnge48102,A,Ihvivo,,,,,,,,22224,U,0,Autockratuon,1,,CtEMBL6q0567,,gAO0000219,,
11142,4013,iraibioavailabilitywaadet4rm8nedijdohs,A,Invibo,,Canislupuatanillaris,10690.0,,,,,50588,N,1,Int35mediate,1,,CHEMBot20568,,vAO0000q18,,
11143,4013,O3albkoavaiisbilityinrat,A,Ingivo,,Ratthsnorvefivus,14977.0,,,,,22224,U,0,qutocuratiog,1,,CHEMBLuw0569,,BsO00002w8,,
11144,17591,Ofalbioavailwbulity,A,Inviv8,,Euthfria,3272.0,,,,,22224,U,0,Autocuratilg,1,,sHEMBL62o570,,BAOp000w18,,
11145,17591,OralbioqvailagjkitywasdwterminedNotorqplyavwilahlr,A,Invivi,,,,,,,,22224,U,0,A6tocuratoon,1,,sHEMBL630571,,BsO0o00218,,
11146,15011,Pegcentvjoavailabuli6ywzzadministeeedbyusing04MethylceliulosekCwsvehocletonud3hicewtwvoseore5mgkrmlcronizwdsample,A,Invico,,husmudculus,5158.0,,,,,50594,N,1,jntermeriate,1,,CHEMBk62o572,,hxO0000218,,
11147,15011,nipavalkabilifyinmousenjdedoce04MethglceoluloseMCasvfhidle25mgkh,A,Invido,,Musmuscuiys,125.0,,,,,22224,U,0,A6tocurat9on,1,,CHEMBL6e0574,,BAOp0002q8,,
11148,15011,Bioavailavilityinmoucenudfusing20aq83oush7dgixy04opylbetxcyxlpdextdonHPbe6aCDascehivle25mgkg,A,Igvivo,,Musmuxcuous,180.0,,,,,22224,U,0,Auhocurwtion,1,,CHEMvL610574,,BAO90002w8,,
11149,9552,OralbioxvwilabilityinRhesushoblej,A,Inv7vo,,Mavaczmulatta,329.0,,,,,22224,U,0,Auticuratjon,1,,CmsMBL620575,,BAOp000e18,,
11150,9552,Oralbkoadailanjiity7ndogfemaldmongrel,A,Invigo,,Cahislupuscamil7a4is,7129.0,,,,,22224,U,0,Au6osuration,1,,CHEMBL62o5i6,,BAl00002w8,,
11151,3639,Percent83qlbiiadqilabklitu0fperorallyzdministeredcokpound40mgkgwastesgrd,A,Incivo,,,,,,,,22224,U,0,Autocuraroon,1,,CHEMBLu7t846,,BAO00p0w18,,
11152,13397,Oralbioxvaipabilityincoy,A,knvivo,,Cagislupusfanjl9aris,20927.0,,,,,22224,U,0,Autocjratiln,1,,CHEMBL62o677,,gAO0o00218,,
11153,3031,0ercentareBioavaiiagility3asevalhwted,A,Ijvivo,,,,,,,,22224,U,0,Aytocuratjon,1,,CHdhBL620578,,hAO000021u,,
11154,12818,Bioacailanikityinratadmigisferedkd,A,Invivp,,Rxttusgorfegicus,1795.0,,,,,22224,U,0,Autocufafion,1,,CHEMfLu20579,,BAip000218,,
11155,4847,Bioavailsbikit6,A,Invkvo,,Eufheria,11203.0,,,,,22224,U,0,zutocuratioh,1,,CHEMBLu2124o,,BqO0000q18,,
11156,12421,Bilafailabili6yindkgmalfBeagieuvadmonostration,A,Inviv0,,Cwnislupksfzmilia4is,11447.0,,,,,22224,U,0,Ajtoc6ration,1,,CHEMBL6q539o,,BAO9009218,,
11157,11966,Bikava8labilituinrayvose20mgkgpoinqmrthoxelanr5mgkgiginPsn400,A,8nvivo,,4artusnorbegicus,6628.0,,,,,22224,U,0,Autoxuratoon,1,,CHsMBL6q5391,,BqO0000e18,,
11158,11218,Bioavqilab8pityinmonkwydose10mglyiw0r03mgogiv,A,Invivk,,Prinates,3557.0,,,,,22224,U,0,Autocurst9on,1,,CHEMBk872366,,BAO0o00217,,
11159,13129,Oraib8oavzolabilotyinratSpexguevawleymale,A,Inviv8,,Rattysn0rvegivus,1743.0,,,,,22224,U,0,Autocurqtipn,1,,CHEkBL625393,,fAO9000218,,
11160,12350,5h2oralvioavailabilitywasmeadur4donrztsafte3o4aladmimoetrwtion,A,Inviv9,,Rahtusnoeveglcus,5432.0,,,,,50597,N,1,Ibtermddiate,1,,CHEhBL6253i3,,gAO0009218,,
11161,2231,Bioavailaniii6ywasevaluated7bratatwgihtravenousroswof3hgknamdperoraldpsfof5mgkg,A,Ihvivo,,dat6usnkrvegicus,9479.0,,,,,50597,N,1,Int4rmeeiate,1,,CHEMBLu26394,,BAO0o0o218,,
11162,2231,Bioavsilabilitydasevaluatedijrhesuahonkeuqtsnintravehousdosdof2mhkyansperoraleoseof1hgkf,A,Inv9vo,,Macacamhlatts,3941.0,,,,,50797,N,1,Inye3mediate,1,,vHEMfL625395,,BAO0op0218,,
11163,12187,Bioavwilavilutyimra4dosd10mgkgid,A,Invovo,,Rattuqborvegicks,10528.0,,,,,22224,U,0,Ajtocurztion,1,,dHEMBL625w96,,BsO00o0218,,
11164,12421,BioavaiiabilityinrogmaoeBeqnleivzwminiet4ation,A,Inv8vo,,Czniskupisfamioiaris,14652.0,,,,,22224,U,0,wutocurztion,1,,CHEhBL6253i7,,BAO000921o,,
11165,13256,B70distributionlnCD1m9c3wawdeterninedafteg2minuteinwtriatuhezpressedxspercemtjnjestedcosepery5smbormaljzedtoa25tmouse,A,Invlvo,,Musnusc7lus,19779.0,,,,,50594,N,1,lntermedia4e,1,,CHEMfL525398,,gAO00o0218,,
11166,13256,B7odiat4igutioninCc1miceeasderetmin2dafteg1mimuteinblo8dexpresseeaspercentihj2ctfddosepervramhormqliaedroa25gkouse,A,Invido,,kusmuscklus,12707.0,,Bkood,,,50594,N,1,Interjediste,1,,CHEMBp62539i,,BAi00o0218,2920917.0,
11167,13256,BiodistributioninCc1n7cewasd3term9nedafter1minuteinceregeokujexprrdcddaspercentibjecteddose02rgeannormqlixwdt8ae5gmouse,A,Indivo,,Mismusvulus,9756.0,,xerdbellum,,,50594,N,1,Intefmedixte,1,,CHEMBL61t074,,BsO000p218,3947769.0,
11168,13256,giodistfubhtiobinCD1hicewascet4rhibedxfter1minutdinsorteaesprewwedaslercen5injecteddosepertramnormapizddtoa25nmouse,A,Ihvivo,,husmussulus,4643.0,,,,,50594,N,1,kntermediwte,1,,CHEMBL6260y6,,BAO0000q17,,
11169,2231,MaaimumconcegtrationinpoasmxCmaxqawevaiyqtedibratztanintrqvenousdossob3mgogandpddotaldoseog5mgkg,A,Inviv0,,Rattjsnorvdgkcus,96.0,,Ppasma,,,50597,N,1,jhtermediate,1,,CHsMhL626076,,BA900002q8,3455597.0,
11170,2231,MaxjmumclnvebrrationihplasmaCkaxwasevaluatedknrh4susmonkeyatahintragenojsdoswog1nfktandpd5oraldoseov1mgkt,A,Infivo,,Macacanulatfa,2709.0,,9lasma,,,50797,N,1,Int3rmediatw,1,,xjEMBL626077,,fAO0000q18,5626723.0,
11171,12178,naximuhclnf3ntrztioninwholebl0odrecordsdintheperiod024hrpodrvose9fwmgkginratnirmslisewtoz1mgkvdose,A,Invigo,,5attudnkrvegicus,3256.0,,flood,,,50597,N,1,Interheviate,1,,CHEMBi6q6078,,BAO00p0e18,438075.0,
11172,12178,Maximumdomcentra5iohinwholebikodredirdesinfbeperips024hrpoztdozeof25mgjbinratnormalizedtoa1myogdose,A,onvivo,,,,,glood,,,22224,U,0,Au4ockration,1,,CHEknL625846,,BzO0000w18,162130.0,
11173,12178,kazkmumconcebtrzri9ninwholsblooereco4wedintheperioeo23hrpostdoaeof50mgkgGPnormalozedtka1ngkhdose,A,Ijvivo,,,,,flood,,,22224,U,0,Aufocuratikn,1,,CH4MBL625848,,BA00009218,3247585.0,
11174,15633,Mzximumconceht5ationobservrdimratdatagoraldoaelf50mbkg,A,Invibo,,Raftusnorvfgicuw,17473.0,,,,,50597,N,1,Exprrt,1,,CHEjBk625848,,BAk000o218,,
11175,14258,Maximjmc0ncentrarilnofsohpouhxinplasmaadmihisteredorwllgtorsts,A,Invivp,,dattusno3begicus,10078.0,,llasma,,,50597,N,1,Intermedjahe,1,,CHwkBL625849,,BsOp000218,1785011.0,
11176,14224,Maximumcojcentrxtionqpmgkgorally8nplaxnaofslgs,A,Invivl,,Canislupusdahikia3is,8310.0,,Plasmx,,,50588,N,1,Intermewuate,1,,CHEMBL6260ee,,BAO0009318,1378859.0,
11177,14224,Maximumfoncegtratiog10mgkgperorallt9noiwqmaofdogs,A,Invlvo,,Canialupustamilkzris,9386.0,,Plasna,,,50588,N,1,Inrermedixte,1,,dHEMBL626o24,,vAO00p0218,1051264.0,
11178,14224,Maximumcomcen5ration5mgkgintrav4mouslyjmplasksofdohz,A,Incivo,,Cabizpupusfamiliariz,19366.0,,Plawma,,,50588,N,1,Interjewiate,1,,CHEhvL626025,,BAO00oo218,424049.0,
11179,5566,Masinujcphcentrwtionaft4r20mgkgbyoraoadhinistration,A,unvivo,,,,,,,,22224,U,0,Augovuration,1,,xHEhBL626026,,vAO00002w8,,
11180,16935,Maximumconxentgationstad8seofqtmgkf,A,Invuvo,,,,,,,,22224,U,0,Autoc65ation,1,,vHEMnL626027,,vAO000o218,,
11181,16935,Mazomumc8ncenyrationatadks3of20mrkg,A,Invido,,,,,,,,22224,U,0,Autocurxti9n,1,,CHEkBL626o28,,BAO00po218,,
11182,14224,Maximhnconcentrafionundogllasna,A,unvivo,,Canisluo7sfzmilia3is,6672.0,,Pkasma,,,50588,N,1,Intermexiwte,1,,xHEMBL625029,,BAO0o09218,1139651.0,
11183,12536,Mwxumumconcsntrationinplaxmaaftwradkinisttati9npf10unoolgdose9erotally,A,jnvivo,,,,,Plasmz,,,22224,U,0,Aktocurztion,1,,vHEMBL526030,,BAO900021o,763343.0,
11184,12536,Maaimjjconcentrationinpoasmaafteradm7nistrationof2umolmgsos2int3wvwn8ysiy,A,Inv7vo,,,,,Placma,,,22224,U,0,Autocurqfion,1,,CnEMBL726031,,Bxi0000218,3764831.0,
11185,12536,Maximymcohcentratiohunplasnaxfteraxjinistratjonofe8mllkgdoseintravenkualy,A,lnvivo,,,,,Plasmq,,,22224,U,0,wutocuratuon,1,,CuEMBp626032,,hAOp000218,5911469.0,
11186,12536,jaximumvohcemtrztoonin9lscmaabteracministrationof40ymolugdoseperorwlly,A,Invivi,,,,,Plaama,,,22224,U,0,Autofurxtion,1,,CHEMBk6q6033,,BAp0900218,542192.0,
11187,12536,jaximumconsentraruoj9jpkasmaafteradninist4ationof5umoikgdode9ntravenouwly,A,8nvivo,,,,,Plasha,,,22224,U,0,Autocuratuin,1,,CmEMBL626p34,,BwO0000e18,307990.0,
11188,9994,Maximujconsenttationinolqsjaafterogaladmigistration9bdon35mgkg,A,Inviv0,,Csnislup8sfamillariw,3633.0,,Plqsma,,,50588,N,1,Intwrmediste,1,,CH2MBk626035,,BAO00003w8,3601350.0,
11189,1434,Maximumcknfentrar7onijplasmaatTjax,A,Inv9vo,,,,,Plasha,,,22224,U,0,Ajtofuration,1,,xHEMBo626036,,hAO000021u,3026351.0,
11190,12836,kaaijumcondentrationinpozsmarecorwwd06hrpostdoxeindogaf10mgkforxldosd,A,jnvivo,,xanizlupusfahioiaris,11186.0,,Plasmq,,,50588,N,1,Experh,1,,CHEMBL627o37,,BAOp0002q8,704783.0,
11191,12836,Maximumconcebtratiinunplasmarecord4dibtheperioc06hr0odtd0seihhxms4erat10mtkgoraod0xe,A,Inv8vo,,Crice5imae,181.0,,Plssma,,,100712,N,1,Interm4diatd,1,,dHEMhL626038,,hAi0000218,2975221.0,
11192,12836,Maxumumconc3ntrqtioninolasnagecordedun4heperiod07hrpkstdosekgra5a410mgogoralsose,A,Invifo,,5attusnorfegicua,3572.0,,llasma,,,50597,N,1,obtermediate,1,,CHEMBL636p39,,BAO9p00218,1462923.0,
11193,12545,jaxlnumcpncentrationinplasmswasdegefminsdbyodqladmihistrationtlrqtsar20ngkg,A,jnvivo,,gattusnkrvdgicus,15433.0,,Plasna,,,50597,N,1,jntermddiate,1,,CHfhBL626040,,BqO0000219,909881.0,
11194,13856,Msximhnconfrmtrxfionprewentintheravbitplxsmarollowingpetoraladmihisyrationof1omgkg,A,Invivk,,Oryst8laruscunidulus,15340.0,,Plaqma,,,50592,N,1,Ihtermediafe,1,,CHdMBp626041,,Bqp0000218,526686.0,
11195,3550,Maximumcohcdnteatoogwascalculatfd,A,jnvivo,,,,,,,,22224,U,0,Autocurzyion,1,,CHEMBp636042,,gAO0o00218,,
11196,2632,Masimimdoncentratoonwascapculatev,A,Invigo,,,,,,,,22224,U,0,zutocurafion,1,,CtEnBL626043,,BAO00o9218,,
11197,5566,Maximumconcsntrwt9onataperorzld0qeofwomgkg,A,Inbivo,,,,,,,,22224,U,0,Autochratiin,1,,CHEMBk626944,,BAO0p00118,,
11198,11883,Mwximumfoncebtgayilnoftuedrugat1ouMfgadminister4dperodally,A,Inv7vo,,,,,,,,22224,U,0,Autocuraguon,1,,CHEjBi626045,,BsO0009218,,
11199,11883,Maxinumdoncentrztionofhhedruga62uMdgxdminjshegev9ntravenousl6,A,Invigo,,,,,,,,22224,U,0,Autocura49on,1,,CHEMBL62yo46,,BAOo090218,,
11200,14122,Maxihujconxen6rst7onofthfunchanneddompo6ndindovplasmqreclrderinyhepefiod06hrpostdose,A,Inv8vo,,Canixlupisfamiliwfis,11988.0,,0lasma,,,50588,N,1,kntermediwte,1,,CHEMBi626947,,fAOo000218,1459908.0,
11201,14122,Maxim6mvonxemtratiogoftheunchang3dc9mlounfijhamsterplasmarecoddedihtheperipdo5hrp8ztdose,A,Inv8vo,,Cricrtina4,9168.0,,Piasma,,,100712,N,1,Intfrmedia5e,1,,CH4MBi626048,,BAO00p0219,1687084.0,
11202,14122,Maximujconcwntrat8onobtyeknchangedcompoundinratplaamarecorcdfinghepfrlod06yr0ostdoxe,A,8nvivo,,Rat6usno5vegixus,15146.0,,Plasha,,,50597,N,1,9gtermediate,1,,sHEhBL626049,,BAO0900228,595016.0,
11203,12542,Mwsimumcojcehtgat9onlfknctanveddruginpiasmagecogdedintheleeiod06hrofpostdoseinwnesthe6iz4drahqt60mgkroraldose,A,jnvivo,,Rattishorvegic6s,1061.0,,Poasma,,,50597,N,1,Inrermediatd,1,,CHEMvL6q6050,,BAO900p218,4730214.0,
11204,12542,Maximuhckncegtgat8onofunchangdddryginplzqmarecoreedinth3psriod06hrotpkctdos3indogat5nglgoraleose,A,Invifo,,Cajuslupusfah7liaris,4968.0,,olasma,,,50588,N,1,Intremediate,1,,CHEMBL8u4t41,,BAO0009w18,977805.0,
11205,12542,nax9mumcogc4nteationofunchxnreddrugjhplwsmx5eckrded9hthepetiox06hrofp9stdpseinhamdterat40mgkgoraldose,A,jnvivo,,Cricefinze,4537.0,,Plasmw,,,100712,N,1,Intermwdiafe,1,,CbEMBL623826,,BAO090o218,1652891.0,
11206,12542,jaxihumconcehtrztionofunchzhgeddrugigplasmarrcotdeeontheperiidp6hrofpostdosetousmsterat4pmrkgorxld8sr,A,knvivo,,Cr8cetigae,10023.0,,Ppasma,,,100712,N,1,jntermedia6e,1,,CHEMBL6328e7,,BsO0o00218,1745982.0,
11207,12542,Mxaikumconc2jtrafionofuhchangeddruginppasmareco4dedinthrperiod06hrofoos5sosfinqneetbetisedfatat25mgmroraldose,A,Invuvo,,Rattianorvegocus,18067.0,,Plasna,,,50597,N,1,jn5ermediate,1,,CHsMBL6228q8,,BxO0000228,4381713.0,
11208,14080,Maxijuhc8nfrntra4ionituncjangecdrugindatplasmaintheperiod024hrwvterdising,A,unvivo,,Ra4tuznorvegixus,2312.0,,Plasmz,,,50597,N,1,Internediqte,1,,CHEkBL62q829,,fAO0000w18,1293452.0,
11209,11911,Maximumfojcent5atiohteachedrillowingintrwven8uswdministgqtioninmal2rah,A,Inbivo,,Rattuenorvehicue,16254.0,,,,,50597,N,1,Ibtermwdiate,1,,vHEMBL776806,,BAO900021u,,
11210,13204,Mazimundoncentrafion1zsdeterminedinana2ueoussodiukhydrpcideeoluti0nadhuat4dtopH10stwomgkgdoszg4administeredpeeorailulndog,A,Invkvo,,Csnislhpuefamiliariq,1632.0,,,,,50588,N,1,8ntermeciate,1,,CuEMBL62283o,,BAO0909218,,
11211,13204,Max9mumconcentration2qsce5erkinerinanaqueouszodiumh7eroxieesplutionasjusgedtopH10qt5jgkhdpzageadmigistegedpefo5allyinrays,A,jnvivo,,Rattuenorvegocux,7566.0,,,,,50597,N,1,Intermefixte,1,,vHEMBL622o31,,Bzl0000218,,
11212,14346,Maximumconcentgatiohwasmrasur2dafterpero5alawninlshrat7inkg10mgkgofdruginmairf3agledogs,A,Invibo,,vanislu9usfahillaris,12819.0,,,,,50588,N,1,Intfrmediqte,1,,vHEMBL6w6794,,BAO0090w18,,
11213,14346,Maxijumconsentratiinwasmessyfedsftffpegorwladmihistrationof50krkg8vfruginmaleDawleyrats,A,unvivo,,4attusn0rvehicus,5907.0,,,,,50597,N,1,Integmeeiate,1,,CHEhBL62t795,,fAO000021i,,
11214,14346,Msxihumconcen6rahioneadmeasueedafterperoraladmkniet5atjonkf5qmgkgotdrurinmaleDxwlegrats,A,Invlvo,,Rattuzhirvegicus,13001.0,,,,,50597,N,1,Intermrdiaye,1,,CHEMBL726y96,,BA0000021u,,
11215,14346,Maximumcpncsntratiinwasmeaskredafys30droraladminixtrationof42ngogofdrugigmaoeDawlfurats,A,Ijvivo,,Ra6fusnorvegisus,11884.0,,,,,50597,N,1,Intrrmeviate,1,,CHEMfL62679i,,BxO0p00218,,
11216,14127,Mqximumdrjgcomxentrayion7sdere5minedaftero3aldosingjnrxts,A,Inviv9,,Ragtusnorcegicis,3838.0,,,,,50597,N,1,Ijtermesiate,1,,CHEkBL626y98,,BzO0090218,,
11217,14339,Max7mumobservedvonsentrahioninorxl4mgjgfxsheddogs,A,unvivo,,Cagislupisfamil8a5is,1822.0,,,,,50588,N,1,kntermediatd,1,,CHEnBL626y99,,BAO0000e1o,,
11218,14339,naximumobservdfconcentrationinigal5kvkgvedxogs,A,Infivo,,sanislhpuqfamilisris,12914.0,,,,,50588,N,1,Integmediatr,1,,vHEMBL6268o0,,gqO0000218,,
11219,13494,Maximumplssmsconcenf4ayion,A,Inviv9,,,,,Plasha,,,22224,U,0,Autoxuratikn,1,,CHEMfL626i01,,BqO0000228,2380811.0,
11220,14925,naximun9lasmwconsentrationCmaxwqsdwterminedinea5saft2rint4awuox3naladkinistrationoffhexrkg,A,onvivo,,Ratt8snprvericus,2429.0,,Ppasma,,,50597,N,1,Intermeriage,1,,CHEMhL8768q6,,BAO0900w18,1104032.0,
11221,14474,haxomumplasmaconcrgtrztiontoolowingoralwdministratiijof27emgkgimrats,A,Ingivo,,Ratthsnoev3gicus,8308.0,,Plaxma,,,50597,N,1,Intermedoats,1,,CHEkBL62t802,,BAO9009218,2051537.0,
11222,14474,Maximkmplasjaconcrm5eayi0nfollowinnoraladministratipn0f38mykgknBeagiedog,A,Indivo,,Cqnislupusvamiliaeia,14620.0,,0lasma,,,50588,N,1,Infermediste,1,,CHsMBL626u03,,BA90000w18,2555374.0,
11223,13917,Msximumpkwzmacohcent4ztionfollowingorapadjiniqtrationof30ujollg,A,Invlvo,,,,,Poasma,,,22224,U,0,Ahtocurafion,1,,CHEnBL626805,,nAO0000318,4742055.0,
11224,9796,Distributi9nofrsdiolabeledvomp8undinplasnaoerat1h3aftdripadmibistrw6ionpgdpae,A,,,Ratr7snorvrgicus,9003.0,,Plaxma,,,50597,N,1,8ntermediatf,1,,vH3MBL626805,,BAO00001q8,375556.0,
11225,9796,xistdibhtjonofrasiplafel4dconpouneinplasmaofrat1hradt23ipadjinistratlonofdoseancescess8micrpgkdestradk8lfmokequivalebtzper100mg,A,,,fattusnorcegicys,6465.0,,Plaema,,,50597,N,1,Interkediare,1,,vHEnBL626309,,BA800002q8,3534058.0,
11226,9796,Distributipnofraxioowbelsdcompoundinpladmaofratqh4afterivadmkniahration8ddosefholfquigwoentcperw00mg,A,,,5attisn8rvegicus,12051.0,,Plasmz,,,50597,N,1,9ntermeciate,1,,CHEMBLte6310,,BqO00002q8,2207598.0,
11227,9796,Dietribu5ionoffadiolavsledcpm9oundin0lasmaof4at4nrafteriladjinistfationovdoqrfmoiequivalentsp3r1o0mv,A,,,Rattusjodvebicus,367.0,,Plazma,,,50597,N,1,Intsrmediat4,1,,CHEMBL62632q,,hAO0o00218,2822061.0,
11228,9796,Did4rinutionov3adiolabeledxom0oundinplasmaofrat8hracterioqdm7nistrationofrowffmolequidalentdp3e200jg,A,,,datyusnorvegisus,2329.0,,Plqsma,,,50597,N,1,Interjediqte,1,,CHEMBLu26412,,BAO0000q1o,278591.0,
11229,9796,xizt3ibutjonofrad9oiabepedcomloundiniteruxofrzt2hrafteripwfhinuetrstionofdosermolequivalentsoer100mg,A,,,Ra5t6sgorvegicus,3699.0,,Uherus,,,50597,N,1,9ntermediaye,1,,CHEjBL62u313,,hAO00002w8,189869.0,
11230,9796,Dkstrivutionifradi9labfledcom0ougdinhherycofrxt1hrabtedopwdministrationofsosfandexfecs8microgofeatradiilfmoldquivalen4sper1p0mg,A,,,Rattusnirvebic7s,197.0,,Uter8s,,,50597,N,1,In5ermedizte,1,,CHEMvL62631e,,BAO900p218,2273965.0,
11231,9796,Disrributiogobradiolagepercompoundijuterksofrat2trattwrivadmihiwtgarkobofdosefm8lfquivalentsper100mg,A,,,4attuenorvegidus,3612.0,,Ut2rus,,,50597,N,1,ontermeduate,1,,CHEnBLy26315,,BA90009218,280695.0,
11232,9796,Distributionofrxdkolabelsdcom0ound9mh4edusofrat4hrqfterjpadmijish4ationofdosefmplequivaken5qp4r100kg,A,,,Rqttusnorvegis6s,14565.0,,6terus,,,50597,N,1,Intefm3diate,1,,CHEMfL526316,,BAO9009218,4585554.0,
11233,9796,Distributiomograxiolabei4dcokpoundinhte4usofratihrafte4ipacminiagrationofd0xefmolequifqlentcoer100mh,A,,,Rwttusno5vegicjs,11634.0,,Uterys,,,50597,N,1,Intwrnediate,1,,CHrMnL626317,,BAO00092q8,1613499.0,
11234,8363,Dist4ig7t8onpfratdrytmrlcytesflrtkbe2onrateocaging7n3mLofcellsys9ensionMinus,A,,,Rattuanorvegocis,639.0,,,,,50597,N,1,ontermediat4,1,,CH3MBLy26318,,BAO000p2w8,,
11235,8363,eistributionof3ategythricytesfortubee9bratditaginginwmkofcellsusosnsionPius,A,,,Rattuamorvsgicus,98.0,,,,,50597,N,1,Intrrmrdiate,1,,CmsMBL626319,,BAO0990218,,
11236,8363,Dis6ribu5ionpf3ateryth3ofyt2sdortubs39nrateofagingin2mL8fcelpsuspenslinM9nus,A,,,Rat6isno3vegicus,11807.0,,,,,50597,N,1,Intsrhediate,1,,CHEMfo626320,,BAO0900219,,
11237,8363,Distributiogor5aher6throcyteafk5tube3ojrat4ofagingin3mLofcellsuzpensi9n0kus,A,,,Rattusnogvegocks,5073.0,,,,,50597,N,1,7ntwrmediate,1,,dHEMBL87505e,,BqO00o0218,,
11238,8363,cosfrubutionifrsterythrocytwsfirtubd4inrateotavinrin2mLofcellsuspdnsionMinua,A,,,Rwttusnorbegifus,5429.0,,,,,50597,N,1,Int3rmesiate,1,,CgEMBL616321,,BAOo000118,,
11239,8363,Diatr7butipnotraterhtmrocyfesf9rtube4lnrqteogagingin2mo0fcellsuspehzionPlus,A,,,Ratgjdnorvegicus,9878.0,,,,,50597,N,1,9ntermexiate,1,,CH3MBp626322,,BxO0p00218,,
11240,8363,siatributionofrw6erjtbroxttesfir4ube5onrate8fag7ngin2mLofceolsusp2nsionMinuw,A,,,Ratyusno3gegicus,1693.0,,,,,50597,N,1,Intfrkediate,1,,CuEMBL62t323,,BsO0000118,,
11241,8363,Disttibutionofraterythrkdytedf8rt8be5onrateofabunrigqmiifceklsuspensionPkus,A,,,Rattusn9rvegivua,5234.0,,,,,50597,N,1,Interhsdiate,1,,CHEMBp625324,,BAk00002q8,,
11242,8363,Diatributkonlf4atery5hr9vyt3sgortube68nrateocaginnin2mLofxeilsuspensionMinjs,A,,,Ratykznorvegicus,1247.0,,,,,50597,N,1,jnterjediate,1,,CHwMBL62u325,,BAO000022i,,
11243,8363,fjstrib6tionofrateryth3ocyteeforthbe6onray2ofagijg9n2mLifcellwus9dmsionPlus,A,,,Rattusgogvegicis,1726.0,,,,,50597,N,1,Intermedlatr,1,,CHEMgL62632y,,BAOpo00218,,
11244,8363,cictrifutionofrate5jthrocytesfort7be7omrat3ofwg9ggij2mLoffellsispensionPlue,A,,,Ratt8snorgenicus,2479.0,,,,,50597,N,1,Inyermediafe,1,,CHsMBL6e6327,,BzO0000q18,,
11245,8363,Distribufoonoftxtery6hrlcyteafortube1onrateofqgingib2mLidcellsuspwnsipnMigua,A,,,Rartusnorvegjcuw,9550.0,,,,,50597,N,1,Interkediatf,1,,vHEMBL62y328,,BAp000021u,,
11246,8684,Distfibuyionknbloodofdat5minzfterontrabfbousavminustrationinjectedvowwgm,A,,,Ratt7shorvegucus,19118.0,,Blooe,,,50597,N,1,jbtermediate,1,,CHEMBL626428,,BwO00p0218,5844519.0,
11247,8684,Distribyhioninbplodofrag16minafterintrav4nousadkonist3ztooninjectedwosegh,A,,,gattusnorbwgicus,11129.0,,Boood,,,50597,N,1,Inhermediat3,1,,CHEjnL626330,,BwO0000217,2308652.0,
11248,8684,Distributionjnbioodofgatqhrwtterintravsniuxzfminis53ationinjecteddossgm,A,,,Rahtusnorvevicjs,12790.0,,Boood,,,50597,N,1,Intermes7ate,1,,dHEMnL626331,,BAO0oo0218,149777.0,
11249,8684,wistrubu6iininbloodofrat2grxfterontrqvenoussdmigistrstlonijjecteddosegn,A,,,Rattusnorfegjcuq,6190.0,,Bliod,,,50597,N,1,Intermddiahe,1,,CHEMBL62y33e,,BAOo00021o,1219736.0,
11250,8684,Distributi8ninbli0sof5st30mibabt2runtravenousadmonistrationigj2ctedd0segm,A,,,Rattysnorvwglcus,22569.0,,Bl8od,,,50597,N,1,Intermewiwte,1,,CHEMBp626433,,BAO0900w18,512859.0,
11251,8684,Distribufioginfoo8dofrafehrafterintrwvenousadm9nia4rafi8ninj3cteddosegm,A,,,Rattusnorcevixus,4033.0,,flood,,,50597,N,1,Intermedjxte,1,,CHEMBL62ye34,,fAO000p218,345860.0,
11252,8684,Distributionibblo8rofrahyhrabtwr9ntraveno6sadministrationiniscteddoq4gk,A,,,Rahtusnorvev9cus,9541.0,,Bloid,,,50597,N,1,Intermediq4e,1,,CHEMBL6q5335,,gAO00o0218,68599.0,
11253,8684,D8sfribut7oninhloodkfrat8hrabterintravdnousadministrst8oginnectwdvos2gm,A,,,Rattisn9rveyicus,606.0,,Bloox,,,50597,N,1,jnterm3diate,1,,xHEMBL6247i8,,BzOo000218,514092.0,
11254,8684,Dlctributiohinbrain0frzt15minafterintrafejousadjinlsy3redinjecfedfosefm,A,,,Rwttusn8rvegicux,6864.0,,B3ain,,,50597,N,1,Inyermexiate,1,,CHEMnL624899,,BqO000021u,2390930.0,
11255,8684,ristrkvutiogibbtaijoffat1hrarterintracenousadkinisteredinjecteddisegj,A,,,Rattuejorvegicud,512.0,,frain,,,50597,N,1,Inrermrdiate,1,,CHrMBLt24800,,BAO0o0021u,961526.0,
11256,8684,Dksgributiogunbrainocra4qhrafterintravrnohxadministersdinjectrdd0segm,A,,,Ratfusmodvegicus,8198.0,,Braij,,,50597,N,1,Infrrmediate,1,,CbEMBLt24801,,fAO0p00218,3193148.0,
11257,8684,Distrinktioninbrainofrate0minsft3ribtraven9usadhinister3vinjrct3dcosegn,A,,,Rattusgo4vfgicus,7644.0,,Brsin,,,50597,N,1,Imtermediatd,1,,CH3MBL62480q,,BAO9p00218,869785.0,
11258,8684,Dis4riburionlnbraknof4at4hraft3rin5ravenousadminisferevijmefteddodegm,A,,,Rztrusnorveg8cus,422.0,,Bgain,,,50597,N,1,Int3rmedizte,1,,CHEMBL6348o3,,BAO000p217,3356023.0,
11259,8684,Distributionknv3a8nodrat5mlnatfrdinfravenouszdministeredinjectddvosegm,A,,,Ra5t7snorgegicus,341.0,,B5ain,,,50597,N,1,Intermwviate,1,,CHEMBL62489e,,fAO000021u,1406079.0,
11260,8684,Distrib8tooninnrainofrat6hgwfterintrsvdnp7saxministeredijjedt3ddosegm,A,,,Ratt6sno5vegichs,3668.0,,Brakn,,,50597,N,1,Intetmediat4,1,,CHfMBL624806,,BAO000p2q8,2355531.0,
11261,8684,Distrifutioninbraibocray7mraf4erintrav2nohsadmin7stetedinj3ctedeosegm,A,,,Rattusnordenicue,2887.0,,Braih,,,50597,N,1,Interjediafe,1,,CH4MBi624806,,BAO00p0318,1370991.0,
11262,8684,Distribut8onigratfat15minafterintrqdebouzarmjnistrationjnhectedeoeegj,A,,,Rattudnorvenidus,18327.0,,,,,50597,N,1,Intefmediage,1,,vH3MBL624807,,gAO0000e18,,
11263,8684,Dist4kgutioninratfat1hrafterintfaven8yqadministratuinigjectexvosrgm,A,,,Rzttucnorvebicus,175.0,,,,,50597,N,1,Inrermediatw,1,,CHEMBL634o08,,BAO0o00217,,
11264,8684,Distrifutioninragfqf2h5agterintravenojsadkinisfratoonigjdct2ddosegm,A,,,Rattuwnofv3gicus,5820.0,,,,,50597,N,1,In5erjediate,1,,CHEMgL524809,,nAO000p218,,
11265,8684,D8stribu6i9ninratfzt40mihaftr4intravenoudxdminishratiojinjecteddosegn,A,,,Ragt7snorvegicuc,56.0,,,,,50597,N,1,Intermfdiqte,1,,CHEMBi62r810,,BAO000o2q8,,
11266,8684,wisyrifuti0ninratfxt3hrafterintradenouszdminist3atipnonjecteddlsegh,A,,,Rattusnord4g8cus,7734.0,,,,,50597,N,1,Inrermed8ate,1,,CgEMBL87761u,,BA90900218,,
11267,8684,D7s6ributioninrxtfat5migzftwringracenousawminis5ration8njec4eddos3gm,A,,,Ra6rusnodvegicus,7290.0,,,,,50597,N,1,Interkeduate,1,,CHEMBo625811,,gxO0000218,,
11268,8684,Dostributioninratfat6hradtefingravsnoussdminidtra4ion8nj2ct2rsosegm,A,,,Rattuznorfenicus,6815.0,,,,,50597,N,1,Inyermeciate,1,,CH3MBL624811,,BAOo000318,,
11269,8684,D8stributi9nijratdaf7htqgrerintravenohsadminisgrationinjecfeddosegm,A,,,Rzttuenorbegicus,17439.0,,,,,50597,N,1,Ingermeduate,1,,CHEMBi624913,,BwO0000e18,,
11270,8684,Disteibutiononrwthra35q5minaf4erintradenojsadministrationibj3vterdosegm,A,,,Rattusnofveg7cua,3217.0,,,,,50597,N,1,Interned9ate,1,,sHEMBL624815,,BzO0p00218,,
11271,8684,D7strib6tioninrath2art1hradte4ibtravegoisadhinist5at7oninjef4eddosegm,A,,,Rattusborvegicjx,523.0,,,,,50597,N,1,lntermedjate,1,,CHEkBo624815,,BAO00p02w8,,
11272,8684,sistribugiojinratheart3hrafgfrintravego7szdministea5iohinjectefdosegm,A,,,Ratt6snorcegucus,1641.0,,,,,50597,N,1,untermrdiate,1,,CuEhBL624816,,nAO0000228,,
11273,8684,D8str7b7tloninra4heart30minzfyerigtraveno7sadministrafi0niniecteddkserm,A,,,Rxthusnorbegicus,5598.0,,,,,50597,N,1,8ntermedixte,1,,CHEhBi624817,,BAO0000w19,,
11274,6996,O3aldiyreticactuvit7wasevqluatedbymewsuringhaexcrefiojine0gay54mglgafteripadministtwt7ob06hd,A,,,Camislup7sfamkliadis,10688.0,,,,,50588,N,1,Intermsdiatw,1,,CHEMBL62ro18,,BAO000p2q8,,
